UUID,Date,Sentiment_score,Lsa_summary
629f61da-d2f3-4933-a5dc-3838b4100cd7,2023-12-17T04:00:00.000+08:00,4,"Eli Lilly (LLY) Rises Yet Lags Behind Market: Some Facts Worth Knowing. Eli Lilly (LLY) closed the most recent trading day at $572, moving +0.31% from the previous trading session. Meanwhile, the Dow gained 0.87%, and the Nasdaq, a tech-heavy index, added 1.26%."
72d93d69-9205-4f4a-8a8b-08f16f74bb5b,2023-12-16T20:00:00.000+08:00,3,"Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry. It's a mammoth market and one that looks to be heating up with a growing number of large healthcare companies showing interest in the space. Below, I'll look at some of the top names in the weight-loss market today, and others you may not have realized could be potential rivals in the future."
37e26e65-5ae5-4755-9cb9-f62659be2581,2023-12-16T19:00:00.000+08:00,4,"3 Cancer-Focused Biotechs That Appear Promising Bets for 2024. Oncology treatments have been at the forefront this year, with biotech companies looking to capitalize on advancements in technology in this challenging but lucrative space. This has put the spotlight on companies with a solid portfolio of cancer treatments and/or a promising pipeline."
f75608ea-b808-4be9-80e0-5944f3d0ff13,2023-12-16T18:00:00.000+08:00,2,"Below is Validea's guru fundamental report for ELI LILLY AND CO (LLY). Of the 22 guru strategies we follow, LLY rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. This multi-factor model seeks low volatility stocks that also have strong momentum and high net payout yields."
fa8b3939-23f5-4864-b516-1497056336c2,2023-12-16T16:00:00.000+08:00,1,"Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?. The Invesco Pharmaceuticals ETF (PJP) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market."
dd9978f8-80f3-4e31-a1f8-217cd9113522,2023-12-16T08:00:00.000+08:00,2,"SOFTS-Arabica, robusta coffee ease off peaks, raw sugar consolidates. Updates prices"
d7162927-37c2-4392-a64c-9966c2a177af,2023-12-16T08:00:00.000+08:00,3,"2 Unstoppable Growth Stocks to Buy in 2024. Growth stocks have done well this year, but heading into 2024, many of them could start to lose steam, especially amid rising valuations. Yet, some businesses still look poised for much more growth in the years ahead, and are likely to continue rising in value next year, regardless of their high prices tags."
e1f79566-cb04-4b05-a28b-91e2f6d2177c,2020-06-11T09:40:14.000+08:00,4,Lilly's Chief Scientist Says Co's COVID-19 Treatment Could be Authorized for Use by September
1e8727d6-838c-4609-b5e5-cae086084f63,2020-06-11T09:40:14.000+08:00,5,Lilly's Chief Scientist Says Co's COVID-19 Treatment Could be Authorized for Use by September
624c50ee-9359-483a-9fc6-a22153cecba4,2020-06-10T19:40:33.000+08:00,5,"Eli Lilly Shares Spike To Session High, Up 1.7%, Following Report Co. Chief Scientist Has Said One Of Co.'s Antibodies Could Be Authorized As Coronavirus Treatment As Early As Sept."
19a4f0e2-078f-4a3f-a0e9-298ab6d8b510,2020-06-10T19:40:33.000+08:00,4,"Eli Lilly Shares Spike To Session High, Up 1.7%, Following Report Co. Chief Scientist Has Said One Of Co.'s Antibodies Could Be Authorized As Coronavirus Treatment As Early As Sept."
f83687bd-70fa-49c8-be54-999f4ab9497f,2020-06-09T13:49:09.000+08:00,2,Travel Stocks Lose Momentum In Pre-Market After Leading Yesterday's Sharp Rally
ca5db735-8a32-4876-8b38-193e236b9755,2020-06-09T13:49:09.000+08:00,3,Travel Stocks Lose Momentum In Pre-Market After Leading Yesterday's Sharp Rally
7253f349-03fd-4162-ab35-fc674fbcd412,2020-06-09T10:47:38.000+08:00,4,First Patient Dose Delivered For Lilly's Tirzepatide Cardiovascular Outcomes Trial
95af3434-87fb-45bc-a790-56b50660d124,2020-06-09T10:47:38.000+08:00,5,First Patient Dose Delivered For Lilly's Tirzepatide Cardiovascular Outcomes Trial
f8551b85-c84e-4b04-ac47-45498092340a,2020-06-08T11:18:03.000+08:00,4,"Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment, Doses First Patient"
5c197486-a380-4b7c-af56-7202e45e7c30,2020-06-08T11:18:03.000+08:00,4,"Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment, Doses First Patient"
d7ac087f-03cd-4a82-8924-e524f4c6fa80,2020-06-05T16:36:32.000+08:00,3,"Fauci: Need To 'Definitively Show' Treatments Are Effective, On Eli Lilly's Recent Human Trials"
0b7d4d5e-91db-4136-88d1-75ec84a6ddd1,2020-06-05T16:36:32.000+08:00,2,"Fauci: Need To 'Definitively Show' Treatments Are Effective, On Eli Lilly's Recent Human Trials"
48937aec-f65e-4f2c-b59f-faf969d61afd,2020-06-03T11:39:19.000+08:00,1,"The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study"
dbae739f-badd-4a11-a8ea-bb4139ef93d9,2020-06-03T11:39:19.000+08:00,4,"The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study"
aea9ea99-8e37-4a24-ab59-80df9f26e6b1,2020-06-03T08:00:00.000+08:00,3,EULAR —…—…: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent ...
8187f386-0e1c-40de-8d62-fddb1210d69a,2020-06-03T08:00:00.000+08:00,3,EULAR —…—…: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent ...
b9185c8e-cb48-45e9-8849-9d1489ebf128,2020-06-02T08:00:00.000+08:00,2,"AstraZeneca Ranked Most Inventive, Roche Most Innovative"
bf09f9b2-a50e-4060-b2d7-7e0b102479cb,2020-06-02T08:00:00.000+08:00,1,"AstraZeneca Ranked Most Inventive, Roche Most Innovative"
f5b86921-3ca0-46f0-8246-35c4eaeb5267,2020-06-01T19:40:17.000+08:00,4,Eli Lilly CEO Talks Coronavirus Treatment Progress: 'This Is An Important Bridge Therapy'
5b75b628-7cbc-4928-b166-b97630c8d9e1,2020-06-01T19:40:17.000+08:00,4,Eli Lilly CEO Talks Coronavirus Treatment Progress: 'This Is An Important Bridge Therapy'
1d048a1e-b0ca-4b42-9ea3-924a78a5a6a0,2020-06-01T10:49:07.000+08:00,5,Eli Lilly's Supplemental Biologics License Application for Taltz for the Treatment of Active Non-Radiographic Axial Spondyloarthritis Approved by the FDA
07e7ea0b-62b2-4f43-a87d-59f797920cbd,2020-06-01T10:49:07.000+08:00,5,Eli Lilly's Supplemental Biologics License Application for Taltz for the Treatment of Active Non-Radiographic Axial Spondyloarthritis Approved by the FDA
461cb1ca-f997-4854-8fd3-f4edb9b7b3d8,2020-06-01T10:31:40.000+08:00,3,Eli Lilly Doses Patients in its Phase 1 Coronavirus Antibody Treatment
b0ae92ee-624e-4c7d-8cd0-3596363e690e,2020-06-01T10:31:40.000+08:00,4,Eli Lilly Doses Patients in its Phase 1 Coronavirus Antibody Treatment
14accc72-81ac-4f98-a0ef-cca08a328248,2020-06-01T08:00:00.000+08:00,4,Lilly Begins World's First Study of a Potential COVID-–9 Antibody Treatment in Humans
42426eb0-911f-4361-9027-44006978ce41,2020-06-01T08:00:00.000+08:00,3,Lilly's Taltz® (ixekizumab) is the First IL-–7A Antagonist to Receive U.S. ...
723d57d6-11f9-407f-b66a-46a62e48c95e,2020-06-01T08:00:00.000+08:00,4,Lilly Begins World's First Study of a Potential COVID-–9 Antibody Treatment in Humans
bb89723a-4615-49c9-ab51-a5d348895bb9,2020-06-01T08:00:00.000+08:00,5,Lilly's Taltz® (ixekizumab) is the First IL-–7A Antagonist to Receive U.S. ...
69f8b20d-4f2d-4b59-b9db-aed43834917f,2020-05-31T08:00:00.000+08:00,4,Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma at ASCO
a5c9ab2e-f7e8-434f-8930-4460bf55527f,2020-05-31T08:00:00.000+08:00,3,Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® ...
385dca6e-dea0-458c-9896-b56ac6c3de78,2020-05-31T08:00:00.000+08:00,5,Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® ...
2ea05178-90f0-49d7-9f6d-54c816803749,2020-05-31T08:00:00.000+08:00,1,Bristol-Myers Deserves Better Than a Single-Digit Multiple
59c837a7-1a0d-4ba1-8ebd-8c7281e2e6d4,2020-05-31T08:00:00.000+08:00,4,Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma at ASCO
8e96b082-0931-430a-88e6-2e41915320b7,2020-05-31T08:00:00.000+08:00,4,Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® ...
249813de-1e59-4753-9052-f7d37e860e80,2020-05-31T08:00:00.000+08:00,5,Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® ...
d00c4ddc-513d-4ff3-8023-db8ff8ab436e,2020-05-31T08:00:00.000+08:00,1,Bristol-Myers Deserves Better Than a Single-Digit Multiple
41aa8ba4-b91c-4bf0-a0bc-6552b7c68d54,2020-05-29T08:00:00.000+08:00,4,Lilly Yesterday Received U.S. FDA Approval of TAUVID for Use in Patients Being Evaluated for Alzheimer's Disease
1255d6fb-ef38-4d8d-b691-397b50de6b2c,2020-05-29T08:00:00.000+08:00,3,Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic ...
9d3acd53-6e02-404e-8d37-87329bc97467,2020-05-29T08:00:00.000+08:00,2,"Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN"
b889f2e6-3575-41a3-8282-1799e9ac0b86,2020-05-29T08:00:00.000+08:00,5,Lilly Yesterday Received U.S. FDA Approval of TAUVID for Use in Patients Being Evaluated for Alzheimer's Disease
cd8f3d9f-9216-431b-aef0-c510860f7984,2020-05-29T08:00:00.000+08:00,3,Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic ...
16731e53-a3d6-4ef9-90ce-a7981311eead,2020-05-29T08:00:00.000+08:00,4,"Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN"
9a3d116f-b018-4d35-8714-9f30cf6f3106,2020-05-28T08:00:00.000+08:00,4,"Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector."
d4c2606a-cc41-47b0-b964-6be70b5fe873,2020-05-28T08:00:00.000+08:00,4,Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F –8 injection) for Use in ...
b059af77-d6a8-4ad6-864c-8e163582b673,2020-05-28T08:00:00.000+08:00,3,Thursday Morning Market Highlights
c301274b-7e0c-405e-ad26-01546fc747fe,2020-05-28T08:00:00.000+08:00,2,"3 Investing Facts About Required Minimum Distributions You Need to Know - May 28, 2020"
4196cc66-3e1c-4593-98bf-9ebc2f86396f,2020-05-28T08:00:00.000+08:00,4,"Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector."
11d1be7b-097b-4083-be1e-bcd9b6735b97,2020-05-28T08:00:00.000+08:00,5,Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F –8 injection) for Use in ...
58a0f49a-39cf-4d5c-ab02-9f2c6b995c2c,2020-05-28T08:00:00.000+08:00,2,Thursday Morning Market Highlights
54bc207b-14f1-4563-a2cb-2d51923538b8,2020-05-28T08:00:00.000+08:00,3,"3 Investing Facts About Required Minimum Distributions You Need to Know - May 28, 2020"
372bd925-27f7-456c-a534-509ff9471f2b,2020-05-27T08:00:00.000+08:00,3,"\"Trumpdesivir: Operation Warp Speed, \"\"Engage.\"\"\""
a8913caa-aa77-4576-8c7d-2f03ad6edff4,2020-05-27T08:00:00.000+08:00,4,"\"Trumpdesivir: Operation Warp Speed, \"\"Engage.\"\"\""
abdea272-b4a1-4a79-9dcd-4b2834dae124,2020-05-26T08:00:00.000+08:00,5,'List of external participants expected at Rose Garden event starting momentarily where @POTUS will announce @MedicareGov patients will be provided with new choices of Part D plans for insulin at no more than $35 for a month's supply.' -Steve Herman Tweet
29e035d9-c36d-4775-b0a2-9714418ea174,2020-05-26T08:00:00.000+08:00,4,"Eli Lilly Intend To File An IND, Initiate Clinical Trials In U.S. & China In Q2 2020 For Company's COVID-19 Neutralizing Antibodies"
46b8d421-6647-4317-81b2-e00b29d70818,2020-05-26T08:00:00.000+08:00,3,Boehringer Ingelheim And Lilly To Collaborate With Duke Clinical Research Institute On A Pragmatic Trial Examining Jardiance's Effects Following An Acute Myocardial Infarction
f65dbca4-7df2-455a-8747-b9af6308bb70,2020-05-26T08:00:00.000+08:00,4,Eli Lilly Announces Emgality 'significantly improved work productivity and reduced interictal burden' In Migraine Patients
f0978d2e-c4ed-4614-9b9b-253e223b5284,2020-05-26T08:00:00.000+08:00,2,Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model
51d64642-6e90-43d5-a389-b68e0654b346,2020-05-26T08:00:00.000+08:00,1,"GCIC Ltd. Buys Amazon.com Inc, Brookfield Asset Management Inc, Eli Lilly and Co, Sells Bank of ..."
884194d5-3903-464e-9b6d-0e3f740f7138,2020-05-26T08:00:00.000+08:00,4,CanSino Biologics' Covid-–9 Vaccine Shows Early Promise
d449243a-2a31-437d-8439-3b3d2d4cca9a,2020-05-26T08:00:00.000+08:00,5,Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi ...
ba977753-eb03-4574-8733-1883d611c734,2020-05-26T08:00:00.000+08:00,3,Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in ...
002124c4-126b-455c-8da1-f899016dbec5,2020-05-26T08:00:00.000+08:00,2,Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a ...
58a94271-263f-4171-a370-ecc6a80e6024,2020-05-26T08:00:00.000+08:00,1,'List of external participants expected at Rose Garden event starting momentarily where @POTUS will announce @MedicareGov patients will be provided with new choices of Part D plans for insulin at no more than $35 for a month's supply.' -Steve Herman Tweet
4b294ccd-fe45-409b-bcaf-36808e1bede4,2020-05-26T08:00:00.000+08:00,4,"Eli Lilly Intend To File An IND, Initiate Clinical Trials In U.S. & China In Q2 2020 For Company's COVID-19 Neutralizing Antibodies"
f9e4f638-d1b2-4bed-84d4-b6c10f7de5c2,2020-05-26T08:00:00.000+08:00,3,Boehringer Ingelheim And Lilly To Collaborate With Duke Clinical Research Institute On A Pragmatic Trial Examining Jardiance's Effects Following An Acute Myocardial Infarction
c41b3508-b1f5-460d-8783-ad4464d183dd,2020-05-26T08:00:00.000+08:00,4,Eli Lilly Announces Emgality 'significantly improved work productivity and reduced interictal burden' In Migraine Patients
de70c130-dccb-4de6-9fca-8412ca17a245,2020-05-26T08:00:00.000+08:00,2,Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model
a416ac14-5bd5-4f6e-b78c-d8bc12ec4de9,2020-05-26T08:00:00.000+08:00,1,"GCIC Ltd. Buys Amazon.com Inc, Brookfield Asset Management Inc, Eli Lilly and Co, Sells Bank of ..."
9329b1d4-746e-4a2c-b0de-30e3f477b737,2020-05-26T08:00:00.000+08:00,4,CanSino Biologics' Covid-–9 Vaccine Shows Early Promise
c07b21d3-f7cd-4195-b382-94fd9485d731,2020-05-26T08:00:00.000+08:00,3,Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi ...
b558f0ab-9670-4184-984c-45d161779666,2020-05-26T08:00:00.000+08:00,4,Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in ...
4a56525d-cc57-4f4b-ad42-c1448882b9da,2020-05-26T08:00:00.000+08:00,2,Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a ...
ff6283c1-47e3-4771-90a4-d795abe3b483,2020-05-23T08:00:00.000+08:00,1,Why Is Lilly (LLY) Down 5.5% Since Last Earnings Report?
e0246ff3-e68b-4451-8130-930bb7ea25e1,2020-05-23T08:00:00.000+08:00,2,Why Is Lilly (LLY) Down 5.5% Since Last Earnings Report?
1a90c91a-d87f-4ab2-9fac-1ac690d6af4e,2020-05-21T08:00:00.000+08:00,1,Clovis Oncology Needs a Savior
e046012c-0621-4163-9976-ade0d63fe132,2020-05-21T08:00:00.000+08:00,1,Clovis Oncology Needs a Savior
575f898c-e39e-4e73-95da-2238aff78e74,2020-05-20T08:00:00.000+08:00,3,J&J to Stop Sale of Talc-Based Baby Powder in North America
7ed81aed-6f8d-42be-94ba-12c99a4421e7,2020-05-20T08:00:00.000+08:00,4,J&J to Stop Sale of Talc-Based Baby Powder in North America
aaea577a-79b8-4339-8583-2f9ee065e1df,2020-05-19T08:00:00.000+08:00,2,"Eli Lilly Reports Results Of GERAS-US Study Showed Societal Cost Burden For Patients, Caregivers During Early Stages Of Alzheimer's Disease"
0536574a-de88-480a-90aa-4a5bb77867a5,2020-05-19T08:00:00.000+08:00,2,Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During ...
16ffa43e-11a5-4985-a5ce-3bbda0324404,2020-05-19T08:00:00.000+08:00,2,"Eli Lilly Reports Results Of GERAS-US Study Showed Societal Cost Burden For Patients, Caregivers During Early Stages Of Alzheimer's Disease"
3a7f19b5-b5b9-4f59-88e1-ab8eeb6fe826,2020-05-19T08:00:00.000+08:00,1,Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During ...
5830b7af-76d8-4ebf-a6a5-0df7f7da4f8b,2020-05-15T08:00:00.000+08:00,1,"Asahi Life Asset Management Co., Ltd. Buys Facebook Inc, Alibaba Group Holding, Amazon. ..."
f63f21c0-a2c4-4a8e-ab88-ca2876d072ac,2020-05-15T08:00:00.000+08:00,2,"UBP Investment Advisors SA Buys iShares Short Maturity Bond, iShares MSCI China ETF, Eli Lilly ..."
cfcc2750-4129-4c20-8c63-62e84b89680a,2020-05-15T08:00:00.000+08:00,3,"Asahi Life Asset Management Co., Ltd. Buys Facebook Inc, Alibaba Group Holding, Amazon. ..."
de466877-b867-4c59-8232-c3fee34c9fa0,2020-05-15T08:00:00.000+08:00,3,"UBP Investment Advisors SA Buys iShares Short Maturity Bond, iShares MSCI China ETF, Eli Lilly ..."
2a0a9e38-6697-4435-937d-7b9aa2ab43e6,2020-05-14T08:00:00.000+08:00,4,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger"
ad475160-0b3e-44b8-add4-816502d19fe6,2020-05-14T08:00:00.000+08:00,1,"Summit Global Investments Buys Amazon.com Inc, Clorox Co, Adobe Inc, Sells NVR Inc, TJX Inc, ..."
77318ef1-7a41-4930-9bf6-6b0fe10628d6,2020-05-14T08:00:00.000+08:00,2,"GCIC Ltd. Buys Brookfield Asset Management Inc, Eli Lilly and Co, Stryker Corp, Sells Bank of ..."
4c32b30c-e86e-4fc1-9838-29724ecec830,2020-05-14T08:00:00.000+08:00,3,"Tekla Capital Management LLC Buys Centene Corp, Moderna Inc, Eli Lilly and Co, Sells Anthem ..."
469fbd44-e2ab-4697-adb3-2a39a3a45e3f,2020-05-14T08:00:00.000+08:00,4,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger"
1af7858d-363d-411c-aa09-a1e05591a0d3,2020-05-14T08:00:00.000+08:00,1,"Summit Global Investments Buys Amazon.com Inc, Clorox Co, Adobe Inc, Sells NVR Inc, TJX Inc, ..."
db49c2f0-1d9b-48a3-9cac-d6b074509a49,2020-05-14T08:00:00.000+08:00,2,"GCIC Ltd. Buys Brookfield Asset Management Inc, Eli Lilly and Co, Stryker Corp, Sells Bank of ..."
39ddece2-d742-4200-b2b6-53fcb00dfe0c,2020-05-14T08:00:00.000+08:00,4,"Tekla Capital Management LLC Buys Centene Corp, Moderna Inc, Eli Lilly and Co, Sells Anthem ..."
e0c35aa9-945d-4dd9-8abd-b16f4d5096d9,2020-05-13T08:00:00.000+08:00,3,"AbbVie's Potential Is 'Underappreciated,' Says Morgan Stanley Analyst"
a0614b2a-70d3-4a12-95e3-3f4352740349,2020-05-13T08:00:00.000+08:00,2,"'6– Capital Llc Buys Spire Inc, McKesson Corp, Berry Global Group Inc, Sells Jazz ..."
dfc3dd7c-ec31-419a-8561-281108400683,2020-05-13T08:00:00.000+08:00,5,"AlphaCrest Capital Management LLC Buys AT&T Inc, Eli Lilly and Co, Apple Inc, Sells The ..."
c67e6f70-3ee1-4832-ba4c-8c95ac70ecf6,2020-05-13T08:00:00.000+08:00,4,"Pitcairn Co Buys Mastercard Inc, Eli Lilly and Co, Seagate Technology PLC, Sells IQ Hedge ..."
83da3ad3-1fa6-439e-ba80-1ba5098dd3cd,2020-05-13T08:00:00.000+08:00,4,"Skandinaviska Enskilda Banken AB (publ) Buys Align Technology Inc, Eli Lilly and Co, Alibaba ..."
be3adc7e-6300-45ef-bc53-05e5f9808ff8,2020-05-13T08:00:00.000+08:00,3,"AbbVie's Potential Is 'Underappreciated,' Says Morgan Stanley Analyst"
ca269ca7-9b98-4b7a-896a-af6eb272148a,2020-05-13T08:00:00.000+08:00,2,"'6– Capital Llc Buys Spire Inc, McKesson Corp, Berry Global Group Inc, Sells Jazz ..."
a363d54a-9e7b-4c92-aa25-7c727b1c967d,2020-05-13T08:00:00.000+08:00,5,"AlphaCrest Capital Management LLC Buys AT&T Inc, Eli Lilly and Co, Apple Inc, Sells The ..."
cbd468e7-c1f5-4f9c-9b22-3aed3cda5d19,2020-05-13T08:00:00.000+08:00,4,"Pitcairn Co Buys Mastercard Inc, Eli Lilly and Co, Seagate Technology PLC, Sells IQ Hedge ..."
566edbb7-b833-4d75-8f9a-d65b2613fc0d,2020-05-13T08:00:00.000+08:00,2,"Skandinaviska Enskilda Banken AB (publ) Buys Align Technology Inc, Eli Lilly and Co, Alibaba ..."
e9ac1655-e658-463a-879f-33a0968e2053,2020-05-12T08:00:00.000+08:00,3,"Oxford Financial Group Ltd Buys Intuitive Surgical Inc, Eli Lilly and Co, Vanguard Value, Sells ..."
a4f4b191-c72a-489e-8514-58fb59da4d60,2020-05-12T08:00:00.000+08:00,4,Smith Asset Management Group LP Buys Amazon. ...
9fe719f8-7ee0-4432-9ca8-8f7c9f3ce30f,2020-05-12T08:00:00.000+08:00,1,"Oxford Financial Group Ltd Buys Intuitive Surgical Inc, Eli Lilly and Co, Vanguard Value, Sells ..."
d453d96c-f530-41a5-b8b7-31d6567de798,2020-05-12T08:00:00.000+08:00,4,Smith Asset Management Group LP Buys Amazon. ...
2efdeafd-d393-4dd6-9ed2-b64f6a08b7db,2020-05-11T08:00:00.000+08:00,4,Why Eli Lilly's Stock Is Trading Higher Today
0a6ed6a1-b192-4ff7-9042-7af0e8623744,2020-05-11T08:00:00.000+08:00,5,Eli Lilly shares are trading higher amid strength in the healthcare sector. The company late Friday announced FDA approval for Retevmo in patients with advanced RET-driven lung and thyroid cancers.
80fd753b-5558-4d17-838d-60fe68463d05,2020-05-11T08:00:00.000+08:00,3,"Lilly Late Friday Announced Co. Received U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers"
394efff0-0982-4b10-be16-06effbede0d0,2020-05-11T08:00:00.000+08:00,2,LLY Stock Approaching Support: Here Are Two Option Trade Ideas
a3e6e0f8-e10a-4bb6-9724-2e1f94c101e0,2020-05-11T08:00:00.000+08:00,1,"Varma Mutual Pension Insurance Co Buys PowerShares QQQ Trust Ser –, iShares MSCI China ETF, ..."
a18693d0-addc-4402-b34a-0c8be1c274c3,2020-05-11T08:00:00.000+08:00,5,Health Care's Market-Beating Performance
231728c8-2dd4-41e1-8b92-d0433269c7a1,2020-05-11T08:00:00.000+08:00,4,Why Eli Lilly's Stock Is Trading Higher Today
57daf949-7347-4b7d-930a-8111ba7865b5,2020-05-11T08:00:00.000+08:00,3,Eli Lilly shares are trading higher amid strength in the healthcare sector. The company late Friday announced FDA approval for Retevmo in patients with advanced RET-driven lung and thyroid cancers.
66137bd8-5033-4c5d-b267-133cb8db2eb4,2020-05-11T08:00:00.000+08:00,4,"Lilly Late Friday Announced Co. Received U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers"
9a2b9899-877a-42e6-bc92-90c3d58670d5,2020-05-11T08:00:00.000+08:00,2,LLY Stock Approaching Support: Here Are Two Option Trade Ideas
9043d0fa-ebf9-4ebf-8e1e-310d309044e2,2020-05-11T08:00:00.000+08:00,4,"Varma Mutual Pension Insurance Co Buys PowerShares QQQ Trust Ser –, iShares MSCI China ETF, ..."
28692fd2-138f-4eb3-9969-3f1cde74788b,2020-05-11T08:00:00.000+08:00,5,Health Care's Market-Beating Performance
385fbfda-ba07-4bb6-8965-013fa577e8f2,2020-05-10T08:00:00.000+08:00,3,8 Monster Stock Market Predictions For The Week Of May 11
e5c82654-311a-4109-98af-e27f75ac7616,2020-05-10T08:00:00.000+08:00,2,8 Monster Stock Market Predictions For The Week Of May 11
fcfdd827-f268-4591-b514-7e7a6d62a83e,2020-05-09T08:00:00.000+08:00,1,Week In Review: Junshi Out-Licenses Ex-China Rights For COVID-19 Therapeutic To Lilly
9a815347-566f-431b-a0d8-728f921bb8da,2020-05-09T08:00:00.000+08:00,4,Week In Review: Junshi Out-Licenses Ex-China Rights For COVID-19 Therapeutic To Lilly
6cf51beb-5a66-415e-8035-450010d9cfb0,2020-05-08T08:00:00.000+08:00,5,Eli Lilly Press Release Highlights 'Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes'
e848f27a-2a12-434e-b855-0b9011fae266,2020-05-08T08:00:00.000+08:00,3,5 Biopharmas Where BofA Would Put Its Money To Work
37463995-3945-4d81-a028-c79e2b505a4d,2020-05-08T08:00:00.000+08:00,5,"Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically ..."
dfd37118-e55e-49de-a3fa-2705b32f6228,2020-05-08T08:00:00.000+08:00,2,"Radius' (RDUS) Q1 Earnings Miss Estimates, Sales Surpass"
78136897-6629-4ada-a5e6-59666fcc2f4a,2020-05-08T08:00:00.000+08:00,4,Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A–C and body ...
23d707b7-f2d9-430b-bcf9-f11ebc5e2c87,2020-05-08T08:00:00.000+08:00,5,"Sustainable Insight Capital Management, LLC Buys Apple Inc, Eli Lilly and Co, Truist Financial ..."
2fe465b9-09b0-467b-b870-0e1a78ac4e7f,2020-05-08T08:00:00.000+08:00,3,"Mastrapasqua Asset Management Inc Buys II-VI Inc, Ciena Corp, Skyworks Solutions Inc, Sells ..."
e07fae25-1ec4-462b-806a-644dabc14ffb,2020-05-08T08:00:00.000+08:00,2,"Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY"
bb3aa73e-7579-4e66-9b27-a647aeffd90c,2020-05-08T08:00:00.000+08:00,1,"OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates"
40a65209-0f11-489e-bfee-26e3745f2e14,2020-05-08T08:00:00.000+08:00,2,Globus Medical (GMED) Misses on Q1 Earnings and Revenues
73d0df75-98f8-4e73-b44e-395349286f80,2020-05-08T08:00:00.000+08:00,4,"Omnicell (OMCL) Q1 Earnings Top, Operating Margin Rises"
1e26bc93-ae03-4034-8aa3-826df0055b2a,2020-05-08T08:00:00.000+08:00,3,"Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top"
dda0e0f0-1e07-4137-ba32-86ed46cec12e,2020-05-08T08:00:00.000+08:00,1,DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results
2377c5c1-b554-4708-91a6-48986d7335c3,2020-05-08T08:00:00.000+08:00,2,Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates
e4b673cd-819f-4817-b8b4-3e926c9d04eb,2020-05-08T08:00:00.000+08:00,3,"Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook"
f8404b7a-5fa6-4169-bcdb-949be3e5234f,2020-05-08T08:00:00.000+08:00,2,"Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended"
c3de5621-7ee2-4692-88a4-57ab2f6fc5d6,2020-05-08T08:00:00.000+08:00,4,Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates
47825f4d-7bb5-49e2-929a-25a8765511bb,2020-05-08T08:00:00.000+08:00,4,Eli Lilly Press Release Highlights 'Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes'
9ae439fb-38f8-4e57-ad7d-efd1fa103624,2020-05-08T08:00:00.000+08:00,3,5 Biopharmas Where BofA Would Put Its Money To Work
13d98f4d-7a80-4bd9-9a6f-75f4282963f3,2020-05-08T08:00:00.000+08:00,5,"Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically ..."
7f29bbb8-2d29-4f5f-858b-b139d1909e18,2020-05-08T08:00:00.000+08:00,2,"Radius' (RDUS) Q1 Earnings Miss Estimates, Sales Surpass"
3bf1b968-64ce-4b00-a836-f5fd6633b62b,2020-05-08T08:00:00.000+08:00,4,Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A–C and body ...
b7e97d53-0a3a-41eb-a854-5375175527d8,2020-05-08T08:00:00.000+08:00,3,"Sustainable Insight Capital Management, LLC Buys Apple Inc, Eli Lilly and Co, Truist Financial ..."
0fce5543-a739-444e-a64b-d8e4fba4cb45,2020-05-08T08:00:00.000+08:00,1,"Mastrapasqua Asset Management Inc Buys II-VI Inc, Ciena Corp, Skyworks Solutions Inc, Sells ..."
ac1de9e5-e11c-4863-95a0-51aab36afe13,2020-05-08T08:00:00.000+08:00,2,"Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY"
aa07fecc-a233-4d2b-9ead-02637518e92c,2020-05-08T08:00:00.000+08:00,3,"OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates"
0d3ff15b-860a-41fb-86c6-d32607516f65,2020-05-08T08:00:00.000+08:00,4,Globus Medical (GMED) Misses on Q1 Earnings and Revenues
e6c0ab1f-8038-4db9-a4a3-6917ce952041,2020-05-08T08:00:00.000+08:00,2,"Omnicell (OMCL) Q1 Earnings Top, Operating Margin Rises"
4f91220e-84ae-42e7-b8d2-ff8ed8a2d915,2020-05-08T08:00:00.000+08:00,3,"Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top"
03418e8a-e805-482d-a073-4875e1ac29a9,2020-05-08T08:00:00.000+08:00,2,DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results
10bbfc6a-5b14-438a-8274-791a32ffb30c,2020-05-08T08:00:00.000+08:00,3,Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates
8bb2df14-eeb2-4175-88a0-3d8a72493120,2020-05-08T08:00:00.000+08:00,4,"Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook"
16996e98-2b61-4526-a72e-bdc9accfc425,2020-05-08T08:00:00.000+08:00,3,"Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended"
607db8dd-5c7e-4b55-98f2-3df1ea788c65,2020-05-08T08:00:00.000+08:00,5,Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates
fc3cd6fc-44ca-4af6-98f8-d500eb6479c1,2020-05-06T08:00:00.000+08:00,2,Tyvyt® (Sintilimab Injection) Combined with Gemzar® (Gemcitabine for Injection) and Platinum ...
48566d95-3d81-40eb-acc8-c12e42b3db28,2020-05-06T08:00:00.000+08:00,4,"Mengis Capital Management, Inc. Buys 'M Co, SPDR S&P 5……, Eli Lilly and Co, Sells ..."
048dd6c1-a665-419e-a4d1-f108879ae700,2020-05-06T08:00:00.000+08:00,3,"Jennison Associates Llc Buys Eli Lilly and Co, Uber Technologies Inc, Goldman Sachs Group Inc, ..."
7400ffe8-6540-4163-9b7b-91250909eb25,2020-05-06T08:00:00.000+08:00,1,"Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View"
2c7863fd-dd2a-4b5c-a71e-56d2da70c111,2020-05-06T08:00:00.000+08:00,4,"Pearl River Capital, LLC Buys American Electric Power Co Inc, Goldman Sachs Group Inc, ..."
ca30fe82-8cd7-41d8-8ff8-fb904848cfa6,2020-05-06T08:00:00.000+08:00,2,"CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate"
0ce2063a-77d6-44b6-809a-c816c8c8d031,2020-05-06T08:00:00.000+08:00,5,Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates
33e8337b-a07b-44c7-8b0a-432aaad3c6be,2020-05-06T08:00:00.000+08:00,3,DaVita (DVA) Earnings and Revenues Beat Estimates in Q1
062ea4d9-8c9f-4005-99e1-bb61eeec3cc0,2020-05-06T08:00:00.000+08:00,1,"Cardiovascular Systems (CSII) Reports Q3 Loss, Lower Margin"
dfde1bf5-8a72-4fca-b095-fcdcaab91533,2020-05-06T08:00:00.000+08:00,4,PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
132f05ca-347f-46ad-b2bd-8c24bdb34721,2020-05-06T08:00:00.000+08:00,4,"NN Investment Partners Holdings N.V. Buys Mastercard Inc, Apple Inc, The Estee Lauder Inc, ..."
6fe3c93f-90cf-432a-9819-96be7953d732,2020-05-06T08:00:00.000+08:00,2,Tyvyt® (Sintilimab Injection) Combined with Gemzar® (Gemcitabine for Injection) and Platinum ...
5a184a36-2644-4181-8ee5-6fdd546e3b85,2020-05-06T08:00:00.000+08:00,3,"Mengis Capital Management, Inc. Buys 'M Co, SPDR S&P 5……, Eli Lilly and Co, Sells ..."
d8508d2e-3288-47d7-a38d-c70721f1ab8e,2020-05-06T08:00:00.000+08:00,1,"Jennison Associates Llc Buys Eli Lilly and Co, Uber Technologies Inc, Goldman Sachs Group Inc, ..."
0a454181-b5b3-46c9-8399-01a1b7ead425,2020-05-06T08:00:00.000+08:00,1,"Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View"
effe4e60-26bc-4e28-8567-5105bc8efcd9,2020-05-06T08:00:00.000+08:00,2,"Pearl River Capital, LLC Buys American Electric Power Co Inc, Goldman Sachs Group Inc, ..."
3ad35e11-bb7f-438a-ba9e-acdffcee099f,2020-05-06T08:00:00.000+08:00,4,"CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate"
2e799701-9c99-47c3-8ca4-8e32d0701c7c,2020-05-06T08:00:00.000+08:00,5,Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates
e70e12b7-541a-4c35-87f9-3a36112ccf60,2020-05-06T08:00:00.000+08:00,3,DaVita (DVA) Earnings and Revenues Beat Estimates in Q1
b91aa3b0-81b1-41e0-878d-abac1778028f,2020-05-06T08:00:00.000+08:00,1,"Cardiovascular Systems (CSII) Reports Q3 Loss, Lower Margin"
f06f00f3-5537-46d2-9ce2-7533542c00f7,2020-05-06T08:00:00.000+08:00,4,PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
b0607e6d-5ac0-4367-891a-4213a4aa210b,2020-05-06T08:00:00.000+08:00,5,"NN Investment Partners Holdings N.V. Buys Mastercard Inc, Apple Inc, The Estee Lauder Inc, ..."
a68e303d-1d79-4860-b7c1-ad65a66f30a5,2020-05-05T08:00:00.000+08:00,3,Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session.
94a266d3-4a3f-4bb3-88f4-0c9447f0b3f0,2020-05-05T08:00:00.000+08:00,2,Lilly to Participate in UBS Virtual Global Healthcare Conference
e58cc262-3bca-40fa-89d8-b09886206962,2020-05-05T08:00:00.000+08:00,1,"The Vanguard Health Care Fund Exits CVS Health, Teva Pharmaceutical"
fb409e74-e19c-401c-921f-71b65fca3cfc,2020-05-05T08:00:00.000+08:00,2,"Highland Capital Management, Llc Buys Johnson & Johnson, Truist Financial Corp, Honeywell ..."
129b6af5-0ec4-4674-a68a-edfd8a9bf6f5,2020-05-05T08:00:00.000+08:00,3,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
0d54b17a-8efd-48e8-a7ee-a58d88c3651d,2020-05-05T08:00:00.000+08:00,4,"Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues"
e111b0ef-cb30-4d6b-9ae6-a40585e53591,2020-05-05T08:00:00.000+08:00,3,Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates
0b358823-9f92-4af7-b9f0-0ca5fc38200f,2020-05-05T08:00:00.000+08:00,2,"Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates"
05e56069-0220-4dce-939b-a6c6597c98d5,2020-05-05T08:00:00.000+08:00,4,"First Quadrant L P Buys UnitedHealth Group Inc, Eli Lilly and Co, Sanmina Corp, Sells Vanguard ..."
f2c1f448-3c1e-4b6d-9063-8b941be6ca38,2020-05-05T08:00:00.000+08:00,4,Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session.
8f8a6873-b455-4c88-a165-31798eb7728c,2020-05-05T08:00:00.000+08:00,3,Lilly to Participate in UBS Virtual Global Healthcare Conference
f5a0c9a0-8428-48d6-aead-b67d4b7722df,2020-05-05T08:00:00.000+08:00,2,"The Vanguard Health Care Fund Exits CVS Health, Teva Pharmaceutical"
332138e4-728f-4bad-95b1-e906006f4e63,2020-05-05T08:00:00.000+08:00,5,"Highland Capital Management, Llc Buys Johnson & Johnson, Truist Financial Corp, Honeywell ..."
64d4a415-6bfd-4e90-8c29-ea2b05fa6d4d,2020-05-05T08:00:00.000+08:00,2,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
fddf6d05-33a2-4993-b1f2-041710405988,2020-05-05T08:00:00.000+08:00,3,"Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues"
0eeccb5d-91d3-4e98-aabe-d7af3d586295,2020-05-05T08:00:00.000+08:00,4,Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates
4dc08216-eba9-419b-bb1a-b9d1522eba4e,2020-05-05T08:00:00.000+08:00,1,"Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates"
313c1540-8332-49a3-9ceb-ae9b370d7c51,2020-05-05T08:00:00.000+08:00,4,"First Quadrant L P Buys UnitedHealth Group Inc, Eli Lilly and Co, Sanmina Corp, Sells Vanguard ..."
58b98df5-8dcc-4d76-8eee-42003fe926a1,2020-05-04T08:00:00.000+08:00,4,Lilly And Junshi Biosciences To Co-Develop Antibody Therapies For The Prevention And Treatment Of COVID-19
ae031487-6dad-487e-94ab-5145b6603337,2020-05-04T08:00:00.000+08:00,5,Lilly Declares Second-Quarter —…—… Dividend
562923dd-a0f5-45e4-b07e-df5831b9a755,2020-05-04T08:00:00.000+08:00,3,"Cookson Peirce & Co Inc Buys Eli Lilly and Co, Vertex Pharmaceuticals Inc, Netflix Inc, ..."
9a3dd4fb-4e9e-41e7-aa4b-0fd716e79a2c,2020-05-04T08:00:00.000+08:00,2,"Hill-Rom's (HRC) Q2 Earnings Top Estimates, Margins Expand"
f041c49f-6f86-4b14-ac48-2acf3c689070,2020-05-04T08:00:00.000+08:00,1,Teleflex (TFX) Earnings and Revenues Beat Estimates in Q1
d7c876d0-a617-4302-ad33-2f75aa2ef306,2020-05-04T08:00:00.000+08:00,2,"Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down"
e5e77af7-c915-4a11-ac93-a3b79adec451,2020-05-04T08:00:00.000+08:00,3,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
18149272-6681-4311-b997-e5a8cd13b163,2020-05-04T08:00:00.000+08:00,4,Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment ...
1c836cc4-1608-4509-b9d9-8e0806fb323d,2020-05-04T08:00:00.000+08:00,5,Lilly And Junshi Biosciences To Co-Develop Antibody Therapies For The Prevention And Treatment Of COVID-19
df7cf466-eaed-4def-b7f0-2a19d78b32e3,2020-05-04T08:00:00.000+08:00,1,Lilly Declares Second-Quarter —…—… Dividend
d5498d42-c599-4235-9c0a-8162ea4ea36c,2020-05-04T08:00:00.000+08:00,2,"Cookson Peirce & Co Inc Buys Eli Lilly and Co, Vertex Pharmaceuticals Inc, Netflix Inc, ..."
8084d8b7-e365-4318-99e3-9b05ee76e0d2,2020-05-04T08:00:00.000+08:00,4,"Hill-Rom's (HRC) Q2 Earnings Top Estimates, Margins Expand"
5a83a7a2-32e9-494d-b702-8caacb2d0b0a,2020-05-04T08:00:00.000+08:00,3,Teleflex (TFX) Earnings and Revenues Beat Estimates in Q1
51f903b4-7c10-46c8-96eb-1ac56c27f6dd,2020-05-04T08:00:00.000+08:00,2,"Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down"
33086211-b167-4c4e-a584-11b6ce2932dd,2020-05-04T08:00:00.000+08:00,3,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
c58dfeb8-b752-42be-a652-0e06ab127121,2020-05-04T08:00:00.000+08:00,4,Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment ...
1c257faa-ae8a-493a-a659-88c2c5968c3c,2020-05-03T08:00:00.000+08:00,3,Shanghai Junshi Biosciences Says Entered Research Collaboration and License Agreement With Eli Lilly; Says Parties Will Collaborate in Research Relating to Sars-cov-2 Neutralizing Antibodies
f97872ef-e15c-4b8b-bab8-1a08e03bb087,2020-05-03T08:00:00.000+08:00,3,Shanghai Junshi Biosciences Says Entered Research Collaboration and License Agreement With Eli Lilly; Says Parties Will Collaborate in Research Relating to Sars-cov-2 Neutralizing Antibodies
a5299b1f-24b3-486e-8e87-6b873211e836,2020-05-01T08:00:00.000+08:00,2,"Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View"
28652225-77e0-4d94-b90c-f2b8dbc8d2d3,2020-05-01T08:00:00.000+08:00,5,"Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View"
7edeb6db-f753-439e-8099-0012a30aee98,2020-04-30T08:00:00.000+08:00,3,Lilly to Participate in Bank of America Securities Health Care Conference
49279789-fa61-4161-88bf-ecd91a2c09b7,2020-04-30T08:00:00.000+08:00,4,"Chartwell Investment Partners, Inc. Buys Allison Transmission Holdings Inc, Truist Financial ..."
93a05348-9a77-4b60-a31b-d33a8a8da7f1,2020-04-30T08:00:00.000+08:00,5,"Moody Lynn & Lieberson, Inc. Buys ishares Gold Trust, Eli Lilly and Co, ServiceNow Inc, ..."
80ee1874-c7c0-47ed-be4c-0687f96b0729,2020-04-30T08:00:00.000+08:00,4,"Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View"
1f89dfa3-b600-4ae0-bf7d-773cd37e862c,2020-04-30T08:00:00.000+08:00,5,Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat
27ac9d7a-25e0-46ca-a3d4-7b2930385eba,2020-04-30T08:00:00.000+08:00,1,United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
4ce11c87-df72-413e-9d9d-661cfbd060cf,2020-04-30T08:00:00.000+08:00,4,Lilly to Participate in Bank of America Securities Health Care Conference
63d05b79-5b93-49b0-b6c6-ef800ff6ad1b,2020-04-30T08:00:00.000+08:00,3,"Chartwell Investment Partners, Inc. Buys Allison Transmission Holdings Inc, Truist Financial ..."
39a97f72-5d79-4516-935c-6c5185472420,2020-04-30T08:00:00.000+08:00,4,"Moody Lynn & Lieberson, Inc. Buys ishares Gold Trust, Eli Lilly and Co, ServiceNow Inc, ..."
9b9a23c1-3961-4580-9250-da33f5092194,2020-04-30T08:00:00.000+08:00,2,"Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View"
8e3bb1d3-add5-4c01-ab09-24054271572e,2020-04-30T08:00:00.000+08:00,4,Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat
c7bc0665-6f0e-464a-8d13-68ebb603ca5e,2020-04-30T08:00:00.000+08:00,2,United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
f03e7bc2-e351-4726-9a4a-bb071cc109ee,2020-04-29T08:00:00.000+08:00,3,"Chronos Wealth Management, LLC Buys Illinois Tool Works Inc, Facebook Inc, iShares U.S. ..."
808e5824-e569-46a4-a09a-4473d968cf7d,2020-04-29T08:00:00.000+08:00,5,Bull of the Day: Eli Lilly (LLY)
1213f736-7544-4158-9cb2-83cf062bffc5,2020-04-29T08:00:00.000+08:00,4,"Chronos Wealth Management, LLC Buys Illinois Tool Works Inc, Facebook Inc, iShares U.S. ..."
b07fe5af-92d5-433e-944c-b0090a1702d5,2020-04-29T08:00:00.000+08:00,4,Bull of the Day: Eli Lilly (LLY)
d4bea2db-ac03-4c54-b9f1-8d6c16014105,2020-04-28T08:00:00.000+08:00,3,"Sym Financial Corporation Buys Vanguard Total World Stock Index, Schwab Short-Term U.S. ..."
d728f53e-9cf7-4bc4-b127-7e5b3664fbcf,2020-04-28T08:00:00.000+08:00,2,Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates
191170d1-b1c8-4835-a7b3-acd7a7935477,2020-04-28T08:00:00.000+08:00,4,Axsome Shares Jump —5% on Alzheimer's Study Results
28590109-7c52-4487-9165-c3438bd832bc,2020-04-28T08:00:00.000+08:00,5,Solid Rally Kicks Off Tech Week
56eb8b36-8e8a-4231-8429-8bd7118c2106,2020-04-28T08:00:00.000+08:00,4,"Sym Financial Corporation Buys Vanguard Total World Stock Index, Schwab Short-Term U.S. ..."
565703ac-0f8e-4141-b1ac-41a788c397d8,2020-04-28T08:00:00.000+08:00,5,Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates
7f7bb064-640c-476f-a266-1558eba7e4c2,2020-04-28T08:00:00.000+08:00,3,Axsome Shares Jump —5% on Alzheimer's Study Results
18684b55-d9dd-4140-a4e5-4be2fe6b10f3,2020-04-28T08:00:00.000+08:00,2,Solid Rally Kicks Off Tech Week
aabe4a90-4e63-421c-b090-7ecfe7ef7e07,2020-04-27T08:00:00.000+08:00,1,"Apple And Amazon Earnings, Fed Meeting Among Highlights In Busy Week Ahead"
dbd701eb-da71-485e-905b-f305baeb0638,2020-04-27T08:00:00.000+08:00,2,"Geneva Partners, LLC Buys Eli Lilly and Co, Netflix Inc, Veeva Systems Inc, Sells Vanguard High ..."
25cd8cb5-e31a-4e55-9fa4-9d4ff3a41d79,2020-04-27T08:00:00.000+08:00,3,"Huntington National Bank Buys Apple Inc, NVIDIA Corp, Fidelity Total Bond, Sells iShares Core ..."
984ef1a5-cb33-4739-8f9e-dfcf2ba3f269,2020-04-27T08:00:00.000+08:00,4,"Apple And Amazon Earnings, Fed Meeting Among Highlights In Busy Week Ahead"
2a0675fd-d5ad-4a3f-b868-2c24cf711420,2020-04-27T08:00:00.000+08:00,1,"Geneva Partners, LLC Buys Eli Lilly and Co, Netflix Inc, Veeva Systems Inc, Sells Vanguard High ..."
5956dc5d-ac18-499e-b0c4-b39de03d0dea,2020-04-27T08:00:00.000+08:00,3,"Huntington National Bank Buys Apple Inc, NVIDIA Corp, Fidelity Total Bond, Sells iShares Core ..."
04fc6038-85b9-4c80-aa03-3f31d3c0c8de,2020-04-24T08:00:00.000+08:00,4,"CFRA Maintains Hold on Eli Lilly, Raises Price Target to $167"
ddc20d3f-3dca-4a7f-800b-798b7e9f6b61,2020-04-24T08:00:00.000+08:00,5,Eli Lilly shares are trading higher after the company announced the NMPA has of China has accepted the supplemental NDA for Sintilimab in combination with ALIMTA and Platinum as first-line therapy in non-squamous non-small cell lung cancer.
e25760e5-5a48-410f-8417-471b449c4c82,2020-04-24T08:00:00.000+08:00,3,Stocks That Hit 52-Week Highs On Friday
c579158a-1921-46b4-b0a0-09b6769b1d8c,2020-04-24T08:00:00.000+08:00,4,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO"
5ba818fb-4827-4cfa-92ef-1f621f6c7b9e,2020-04-24T08:00:00.000+08:00,5,Eli Lilly Stock Joins IBD's Long-Term Leaders Portfolio
bf50cb9a-9e23-4c54-99d5-ffcfeefbb325,2020-04-24T08:00:00.000+08:00,4,"Thinking about trading options or stock in Eli Lilly, Square, Tesla, UnitedHealth Group, or ..."
d523108e-20e1-40bc-b356-46a56f24fd88,2020-04-24T08:00:00.000+08:00,5,Will Eli Lilly and Company Continue to Surge Higher?
9aeacb01-e00a-4aff-84ad-f0f8043e10ee,2020-04-24T08:00:00.000+08:00,3,"Company News for Apr 24, 2020"
80d1bec3-a1dc-4fcb-b53f-5542d25ecd59,2020-04-24T08:00:00.000+08:00,4,S&P 500 Stocks That Rose In The Crisis: It's A Market Of Stocks - Part 2
351b1f39-1fe8-40b4-a41f-59a85f9e8ffa,2020-04-24T08:00:00.000+08:00,4,"Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN"
1c71c0ec-646d-4805-a54e-363a8c4923dc,2020-04-24T08:00:00.000+08:00,4,"CFRA Maintains Hold on Eli Lilly, Raises Price Target to $167"
9411c6b3-04af-4243-b4d9-94f052b95e9a,2020-04-24T08:00:00.000+08:00,5,Eli Lilly shares are trading higher after the company announced the NMPA has of China has accepted the supplemental NDA for Sintilimab in combination with ALIMTA and Platinum as first-line therapy in non-squamous non-small cell lung cancer.
4640cd8c-4ecf-43a3-b49a-4b7246c1820c,2020-04-24T08:00:00.000+08:00,3,Stocks That Hit 52-Week Highs On Friday
21ea200e-41d1-4971-abd8-501c5fa1875d,2020-04-24T08:00:00.000+08:00,4,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO"
a76a4c77-4ad7-4917-8e6a-116d35e0b9ba,2020-04-24T08:00:00.000+08:00,5,Eli Lilly Stock Joins IBD's Long-Term Leaders Portfolio
060a4d2f-76b6-4aa5-b716-4c76fa7c7532,2020-04-24T08:00:00.000+08:00,4,"Thinking about trading options or stock in Eli Lilly, Square, Tesla, UnitedHealth Group, or ..."
1c7657df-2ed2-40b9-8410-d52f8545842f,2020-04-24T08:00:00.000+08:00,5,Will Eli Lilly and Company Continue to Surge Higher?
f41d7d0e-52e0-44b7-acaa-3d83e2c2cc00,2020-04-24T08:00:00.000+08:00,3,"Company News for Apr 24, 2020"
0ce26f77-aff3-4063-9a25-26fc8c63b869,2020-04-24T08:00:00.000+08:00,4,S&P 500 Stocks That Rose In The Crisis: It's A Market Of Stocks - Part 2
8a1d8bf2-7efc-4773-bf42-a2ffa48e169d,2020-04-24T08:00:00.000+08:00,4,"Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN"
18a925f7-c51b-420c-b63c-bf531e05bb81,2020-04-23T08:00:00.000+08:00,4,Mid-Afternoon Market Update: Sleep Number Surges On Strong Q1 Results; NETGEAR Shares Drop
32f24d65-5149-41c8-ae5d-19bbed897cc8,2020-04-23T08:00:00.000+08:00,2,Afternoon Market Stats in 5 Minutes
596c5193-eed1-4214-918d-8fde83555bf4,2020-04-23T08:00:00.000+08:00,3,Mid-Day Market Update: Crude Oil Jumps 31%; Invesco Shares Slide On Downbeat Earnings
1a427a9f-9428-4815-947b-961c2e4081e9,2020-04-23T08:00:00.000+08:00,5,Stocks That Hit 52-Week Highs On Thursday
22dac53f-82a5-42c0-aa98-9f3b4578c739,2020-04-23T08:00:00.000+08:00,5,Mid-Morning Market Update: Markets Open Higher; Eli Lilly Beats Q1 Views
39cc01a5-700b-4f0d-bb1b-87e06ccdf149,2020-04-23T08:00:00.000+08:00,5,Eli Lilly Kicks Off Earnings Day With A Beat And Investors Prepare For Intel After Close
f9c6f1f5-06f0-41d2-b610-52076ae57dbc,2020-04-23T08:00:00.000+08:00,4,"From Eli Lilly Earnings Conference Call: CFO Says Expecting Muted Impact From Unemployment In 2020, Sees A Bigger Impact In 2021"
954eea97-8403-4b8e-858f-90f4d84f075c,2020-04-23T08:00:00.000+08:00,3,Eli Lilly And Co shares are trading higher after the company reported better-than-expected Q1 EPS and sales results. The company also issued FY20 EPS and sales guidance above analyst estimates.
7f76b617-03d6-4831-a9c5-2e48d9b10ad9,2020-04-23T08:00:00.000+08:00,4,"The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt"
0347c7ff-3505-44cd-9b19-9ff5710f89e4,2020-04-23T08:00:00.000+08:00,4,"UPDATE: Eli Lilly FY20 Adj. EPS Guidance Raised, Widened From $6.70-$6.80 To $6.70-$6.90"
53fba134-1a09-44a2-95a0-3a21f3234891,2020-04-23T08:00:00.000+08:00,2,"Eli Lilly Sees FY20 Adj. EPS $6.70-$6.90 vs $6.73 Estimate, Sales $23.7B-$24.2B vs $23.84B Est."
6c923d39-f936-420b-b82e-c94a297fa7dd,2020-04-23T08:00:00.000+08:00,4,"Eli Lilly Q1 Adj. EPS $1.750 Beats $1.480 Estimate, Sales $5.860B Beat $5.510B Estimate"
ba307427-b971-4172-8aae-5f3706be9fc3,2020-04-23T08:00:00.000+08:00,3,"A Peek Into The Markets: US Stock Futures Flat Ahead Of Earnings, Economic Reports"
8129b957-61e0-46b0-80d2-2157807aaf06,2020-04-23T08:00:00.000+08:00,4,"8 Stocks To Watch For April 23, 2020"
43009d12-f564-41d3-8498-205ba7e661a9,2020-04-23T08:00:00.000+08:00,1,"Earnings Scheduled For April 23, 2020"
2e8933df-4cc9-4169-909b-93115e2242a3,2020-04-23T08:00:00.000+08:00,4,Innovent and Eli Lilly Announce NMPA Acceptance of a Supplemental New Drug Application for ...
82ef43d5-1ce0-469a-9ae6-0eb42efe86b0,2020-04-23T08:00:00.000+08:00,2,"Van Leeuwen & Company, LLC Buys UnitedHealth Group Inc, Microsoft Corp, SPDR S&P ..."
99f3fbb9-bd29-44a7-a72b-762b01e3ad1e,2020-04-23T08:00:00.000+08:00,5,Eli Lilly (LLY) Is Up 7.93% in One Week: What You Should Know
f50545a2-cb3f-4897-93d4-78cd7af854c8,2020-04-23T08:00:00.000+08:00,4,Eli Lilly (LLY) Surpasses Q1 Earnings and Revenue Estimates
b9ec1159-c611-4674-abab-6b911918610d,2020-04-23T08:00:00.000+08:00,3,Mid-Afternoon Market Update: Sleep Number Surges On Strong Q1 Results; NETGEAR Shares Drop
7c4ed4dd-7bbe-443b-b4e0-addb579ce175,2020-04-23T08:00:00.000+08:00,4,Afternoon Market Stats in 5 Minutes
85cacbdc-096e-406f-b9d8-ad370fbcdd29,2020-04-23T08:00:00.000+08:00,2,Mid-Day Market Update: Crude Oil Jumps 31%; Invesco Shares Slide On Downbeat Earnings
8e15083a-7f84-4186-854d-454a21b22173,2020-04-23T08:00:00.000+08:00,3,Stocks That Hit 52-Week Highs On Thursday
56558e64-a28a-4d68-90ac-1ac03794097f,2020-04-23T08:00:00.000+08:00,4,Mid-Morning Market Update: Markets Open Higher; Eli Lilly Beats Q1 Views
d2ed2401-8c02-45e8-b534-9c8b8b49fcd3,2020-04-23T08:00:00.000+08:00,5,Eli Lilly Kicks Off Earnings Day With A Beat And Investors Prepare For Intel After Close
e07d43d4-8ac1-4de6-b515-f785c03a7863,2020-04-23T08:00:00.000+08:00,4,"From Eli Lilly Earnings Conference Call: CFO Says Expecting Muted Impact From Unemployment In 2020, Sees A Bigger Impact In 2021"
44a6660f-5d71-4f8b-bda8-5e2288f6bab5,2020-04-23T08:00:00.000+08:00,5,Eli Lilly And Co shares are trading higher after the company reported better-than-expected Q1 EPS and sales results. The company also issued FY20 EPS and sales guidance above analyst estimates.
49d74e6b-d960-49f4-ab56-173739ac045d,2020-04-23T08:00:00.000+08:00,3,"The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt"
d54c99f7-4742-4280-bd91-0c3ee780997b,2020-04-23T08:00:00.000+08:00,4,"UPDATE: Eli Lilly FY20 Adj. EPS Guidance Raised, Widened From $6.70-$6.80 To $6.70-$6.90"
13949d0c-48d3-445e-b3bd-002df9c23e15,2020-04-23T08:00:00.000+08:00,4,"Eli Lilly Sees FY20 Adj. EPS $6.70-$6.90 vs $6.73 Estimate, Sales $23.7B-$24.2B vs $23.84B Est."
40f2e37b-220e-4000-84a4-1b973c6cd726,2020-04-23T08:00:00.000+08:00,4,"Eli Lilly Q1 Adj. EPS $1.750 Beats $1.480 Estimate, Sales $5.860B Beat $5.510B Estimate"
5f96c9cf-9c0a-468d-b5c7-9ed1fec03540,2020-04-23T08:00:00.000+08:00,3,"A Peek Into The Markets: US Stock Futures Flat Ahead Of Earnings, Economic Reports"
4cefabd7-7ad0-48cd-979c-102bf09304e2,2020-04-23T08:00:00.000+08:00,2,"8 Stocks To Watch For April 23, 2020"
38efd92b-1bc1-4f89-b9e2-752fa216eec6,2020-04-23T08:00:00.000+08:00,5,"Earnings Scheduled For April 23, 2020"
a7bf7fe1-98dc-4ac9-93a7-d824b0f4d4b4,2020-04-23T08:00:00.000+08:00,4,Innovent and Eli Lilly Announce NMPA Acceptance of a Supplemental New Drug Application for ...
e5ed01ce-610a-43d6-af15-41dd9e9830e3,2020-04-23T08:00:00.000+08:00,5,"Van Leeuwen & Company, LLC Buys UnitedHealth Group Inc, Microsoft Corp, SPDR S&P ..."
27529cfc-ea97-429f-aeb7-f7c7eefe303a,2020-04-23T08:00:00.000+08:00,4,Eli Lilly (LLY) Is Up 7.93% in One Week: What You Should Know
c3f0d7e0-62ab-41a4-af84-fe38571ebc59,2020-04-23T08:00:00.000+08:00,5,Eli Lilly (LLY) Surpasses Q1 Earnings and Revenue Estimates
6cfeb8d3-72b2-4283-8f05-33c4242b54e2,2020-04-22T08:00:00.000+08:00,3,"Dow Jones Futures: Coronavirus Stock Market Rally Powers Back; Apple, AMD, Tesla, Intel, Microsoft Near Buy Points, But Watch Out For This"
9f9387d1-ceb6-4365-b095-f8d8ce4497f4,2020-04-22T08:00:00.000+08:00,2,"Anderson Fisher Llc Buys Kulicke & Soffa Industries Inc, Bloomin Brands Inc, ..."
8da44ac7-5976-4ac6-86f1-9bf0291b0f40,2020-04-22T08:00:00.000+08:00,4,Chip Earnings To Continue With Intel Stock Near Buy Point; Domino's Due: Investing Action Plan
c442fc01-059c-4cea-a90e-5f99f5e22ee2,2020-04-22T08:00:00.000+08:00,3,"Railway Pension Investments Ltd Buys AbbVie Inc, Intel Corp, Eli Lilly and Co, Sells iShares ..."
dd33224a-bbd0-4da5-9fc6-70f8757b21a9,2020-04-22T08:00:00.000+08:00,2,"The Zacks Analyst Blog Highlights: Exxon Mobil, Oracle, Eli Lilly and Coke"
62257219-0192-4f36-9241-c24d9c3effc5,2020-04-22T08:00:00.000+08:00,5,Is a Surprise Coming for Lilly (LLY) This Earnings Season?
1dc7beec-52c8-455a-8122-5f8e872c6b49,2020-04-22T08:00:00.000+08:00,4,"Dow Jones Futures: Coronavirus Stock Market Rally Powers Back; Apple, AMD, Tesla, Intel, Microsoft Near Buy Points, But Watch Out For This"
1fad33ef-a548-4004-be28-1b0de9de6ddf,2020-04-22T08:00:00.000+08:00,4,"Anderson Fisher Llc Buys Kulicke & Soffa Industries Inc, Bloomin Brands Inc, ..."
b6168f78-0fee-4f74-8256-989662f00433,2020-04-22T08:00:00.000+08:00,3,Chip Earnings To Continue With Intel Stock Near Buy Point; Domino's Due: Investing Action Plan
4920e898-bda9-4f6c-a17c-6d1f68842c61,2020-04-22T08:00:00.000+08:00,2,"Railway Pension Investments Ltd Buys AbbVie Inc, Intel Corp, Eli Lilly and Co, Sells iShares ..."
5b722d2e-4f5c-4992-870d-a1670959ceb5,2020-04-22T08:00:00.000+08:00,1,"The Zacks Analyst Blog Highlights: Exxon Mobil, Oracle, Eli Lilly and Coke"
c5a00672-f8d9-4c8a-ad33-0787e1608e3c,2020-04-22T08:00:00.000+08:00,3,Is a Surprise Coming for Lilly (LLY) This Earnings Season?
4dc35400-676c-49a9-8f82-d1989254fc28,2020-04-21T08:00:00.000+08:00,2,"Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic."
242b2c64-ecf1-484f-aa10-9d9200bb7443,2020-04-21T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives"
242458b0-ba3c-4a26-a52e-83d5a7feba34,2020-04-21T08:00:00.000+08:00,3,"A Peek Into The Markets: US Stock Futures Fall Ahead Of Coca-Cola, Lockheed Martin Earnings"
910fd6b6-d2f0-4267-94a7-59a08a6c7b7c,2020-04-21T08:00:00.000+08:00,1,"UBS Downgrades Eli Lilly to Neutral, Raises Price Target to $158"
e1a7d4e8-3f52-4829-a312-a75c5d858edf,2020-04-21T08:00:00.000+08:00,4,"Cordatus Wealth Management LLC Buys Apple Inc, Eli Lilly and Co, Netflix Inc, Sells Danaher ..."
ff18d625-9b51-450d-8495-ea9d3a1fb409,2020-04-21T08:00:00.000+08:00,2,"VeraBank, N.A. Buys Vanguard High Dividend Yield, Exxon Mobil Corp, Chevron Corp, Sells Wells ..."
71fd6558-fe83-4062-806a-dd31208d1489,2020-04-21T08:00:00.000+08:00,4,Health Care Leading In New Highs
0108c99b-9efa-4134-8df8-754d64853559,2020-04-21T08:00:00.000+08:00,1,Stocks Drop as May Oil Contract Goes Negative
65ae6237-001b-4026-970f-5fbd8802d303,2020-04-21T08:00:00.000+08:00,3,"Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic."
b9f3714d-4feb-45a7-be75-567ecd700c62,2020-04-21T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives"
5d8dfaca-4996-4985-832c-ee45b432be8c,2020-04-21T08:00:00.000+08:00,2,"A Peek Into The Markets: US Stock Futures Fall Ahead Of Coca-Cola, Lockheed Martin Earnings"
cefa75b0-01f1-4838-b5e4-a2d5e7d2401c,2020-04-21T08:00:00.000+08:00,4,"UBS Downgrades Eli Lilly to Neutral, Raises Price Target to $158"
26263d08-96bb-45ae-b7dd-01a1565546cb,2020-04-21T08:00:00.000+08:00,3,"Cordatus Wealth Management LLC Buys Apple Inc, Eli Lilly and Co, Netflix Inc, Sells Danaher ..."
95737863-92a9-48bf-b1ce-afd457ca6190,2020-04-21T08:00:00.000+08:00,4,"VeraBank, N.A. Buys Vanguard High Dividend Yield, Exxon Mobil Corp, Chevron Corp, Sells Wells ..."
8f7f66ac-a205-4263-b649-2a5c846c5b99,2020-04-21T08:00:00.000+08:00,5,Health Care Leading In New Highs
0222185f-eec9-4903-8bdb-a9f5b8717dd6,2020-04-21T08:00:00.000+08:00,2,Stocks Drop as May Oil Contract Goes Negative
ce557aa7-6934-4c1b-a0cd-9b965822ece9,2020-04-20T08:00:00.000+08:00,3,Will Lower WarnerMedia Margins Hurt AT&T's (T) Q1 Earnings?
23743602-0b73-495c-a71a-8acb1246edff,2020-04-20T08:00:00.000+08:00,3,Will Communications Segment Buoy AT&T's (T) Q1 Earnings?
47b5ad66-10fb-4bdf-98b0-1a67cf47e1c8,2020-04-20T08:00:00.000+08:00,4,Ericsson (ERIC) to Report Q1 Earnings: What's in the Offing?
f1dcf6b1-8884-4c08-a806-7a14cc027587,2020-04-20T08:00:00.000+08:00,1,"Steigerwald, Gordon & Koch Inc. Buys Adobe Inc, The Walt Disney Co, ViacomCBS Inc, Sells T. ..."
c54a35b0-daf0-4c29-a777-ad78774addb4,2020-04-20T08:00:00.000+08:00,2,"The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly"
c416874b-84d1-4e4e-a790-9e2838540a75,2020-04-20T08:00:00.000+08:00,3,Will Lower WarnerMedia Margins Hurt AT&T's (T) Q1 Earnings?
40a76416-7990-4861-a6e0-9b9a1612d969,2020-04-20T08:00:00.000+08:00,3,Will Communications Segment Buoy AT&T's (T) Q1 Earnings?
96221d55-1a1d-4cc1-973f-dad93374963e,2020-04-20T08:00:00.000+08:00,4,Ericsson (ERIC) to Report Q1 Earnings: What's in the Offing?
020bae1f-fdd6-40f3-a99d-cf1835b5f78a,2020-04-20T08:00:00.000+08:00,1,"Steigerwald, Gordon & Koch Inc. Buys Adobe Inc, The Walt Disney Co, ViacomCBS Inc, Sells T. ..."
78adf5bd-185e-4035-8751-13c64c4e4468,2020-04-20T08:00:00.000+08:00,2,"The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly"
a14b49d4-975f-4c00-bb76-9db450be974b,2020-04-19T08:00:00.000+08:00,3,"The Week Ahead In Biotech (April 19-25): Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision"
d9a2316e-4767-43e2-9a93-86959e68353f,2020-04-19T08:00:00.000+08:00,3,"The Week Ahead In Biotech (April 19-25): Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision"
ba068034-f126-4f1f-ab4e-5c008f6fcf46,2020-04-17T08:00:00.000+08:00,4,Stocks That Hit 52-Week Highs On Friday
e7e832ae-a95a-41c7-a6f3-266045444830,2020-04-17T08:00:00.000+08:00,1,"Big Earnings Day As Honeywell, Procter & Gamble, Schlumberger Among Those Reporting"
dd05f906-196d-4279-9ec2-d96c22deb6b6,2020-04-17T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement"
af2c7494-fded-4abf-8071-30089fbbf14f,2020-04-17T08:00:00.000+08:00,3,Coronavirus Stocks Hitting New Highs This Week In Current Stock Market Rally Include Eli Lilly
f69ec60d-e649-4b2f-ab36-a72179978f3b,2020-04-17T08:00:00.000+08:00,2,"Netflix Stock Rallies Bullishly Ahead Of Earnings, But Is All The Good News Priced In?"
e7d8b788-6797-46ad-b79a-ae0313757474,2020-04-17T08:00:00.000+08:00,3,"Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts"
b2e42988-a67a-4c62-93e6-ad3a679bbf7f,2020-04-17T08:00:00.000+08:00,5,"Bremer Bank National Association Buys Xilinx Inc, iShares Cohen & Steers REIT, Eli Lilly ..."
51aad97f-5146-41d7-b4f7-e8f3b46fa102,2020-04-17T08:00:00.000+08:00,4,Buy 5 Top Medical Stocks on Coronavirus Drug Trial Results
08b959f1-c108-415a-ab5e-deb11dc9cf77,2020-04-17T08:00:00.000+08:00,5,Stocks That Hit 52-Week Highs On Friday
add8d597-e03d-4ff0-9099-f5d5d84f0782,2020-04-17T08:00:00.000+08:00,3,"Big Earnings Day As Honeywell, Procter & Gamble, Schlumberger Among Those Reporting"
21016b98-aeb6-4a6d-9e0e-fdabb2b83692,2020-04-17T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement"
3b083d4f-461b-49e0-b653-54e51bace706,2020-04-17T08:00:00.000+08:00,5,Coronavirus Stocks Hitting New Highs This Week In Current Stock Market Rally Include Eli Lilly
121dba6c-1c82-4dea-9ea2-8a4430ae194d,2020-04-17T08:00:00.000+08:00,2,"Netflix Stock Rallies Bullishly Ahead Of Earnings, But Is All The Good News Priced In?"
5a9ad7d6-cbb5-49c1-a454-04f3d055a1e5,2020-04-17T08:00:00.000+08:00,3,"Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts"
bb9861c1-769e-4bd2-8d20-135ab94f5c71,2020-04-17T08:00:00.000+08:00,4,"Bremer Bank National Association Buys Xilinx Inc, iShares Cohen & Steers REIT, Eli Lilly ..."
f83616aa-912e-4f64-b52f-c8b23a639156,2020-04-17T08:00:00.000+08:00,4,Buy 5 Top Medical Stocks on Coronavirus Drug Trial Results
c8b741ab-3515-4917-89f0-7c15c4278b73,2020-04-16T08:00:00.000+08:00,1,10 Stocks Hitting All-Time Highs Amid The COVID-19 Pandemic
374fed76-d772-4244-810e-a5348346885c,2020-04-16T08:00:00.000+08:00,4,Stocks That Hit 52-Week Highs On Thursday
dfb0fe08-8347-42c6-ac92-513c9ec0defc,2020-04-16T08:00:00.000+08:00,3,"The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant"
2aa75f7f-77b2-401c-8ab2-7d4b0d24103c,2020-04-16T08:00:00.000+08:00,2,"Eli Lilly Reports Non-Branded Versions Of Humalog KwikPen, Humalog Junior KwikPen Now Available For Order By US Pharmacies"
5fbfbeb6-efa2-4996-906a-3aefd4a74f25,2020-04-16T08:00:00.000+08:00,1,"Are These 5 Stocks Coronavirus-Proof? What Fortinet, Veeva, Eli Lilly Charts Say Now"
0de29d6b-1e3b-4aa6-b2c4-9a296c0d5057,2020-04-16T08:00:00.000+08:00,4,Eli Lilly Just Within Buy Range As Quarterly Report Nears
e8330ce4-983b-46c6-8f69-8f95682bd5ed,2020-04-16T08:00:00.000+08:00,4,Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?
66358f63-dd15-4b5b-be17-0f48d0a15edf,2020-04-16T08:00:00.000+08:00,3,"Roche Most Innovative, Astra Zeneca Most Inventive"
32b9b6eb-2f83-4575-956a-f5cc106b1f7c,2020-04-16T08:00:00.000+08:00,4,Lower-priced versions of Humalog® Mix75/—5™ KwikPen® and Humalog® Junior KwikPen® now ...
dcffb49d-7a8b-4c3f-bb92-dadc835b92da,2020-04-16T08:00:00.000+08:00,5,10 Stocks Hitting All-Time Highs Amid The COVID-19 Pandemic
0384ecbb-64f4-4b5f-afea-da58580d24de,2020-04-16T08:00:00.000+08:00,4,Stocks That Hit 52-Week Highs On Thursday
6ca9005e-1081-4458-8144-5154c95f7587,2020-04-16T08:00:00.000+08:00,4,"The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant"
bb902ccb-fe84-4233-8343-cc90e7db1865,2020-04-16T08:00:00.000+08:00,3,"Eli Lilly Reports Non-Branded Versions Of Humalog KwikPen, Humalog Junior KwikPen Now Available For Order By US Pharmacies"
85938a55-ec66-4c8a-a99a-408d685a1604,2020-04-16T08:00:00.000+08:00,2,"Are These 5 Stocks Coronavirus-Proof? What Fortinet, Veeva, Eli Lilly Charts Say Now"
82cf79c2-5f2c-4be1-8daf-060ba8ceebf4,2020-04-16T08:00:00.000+08:00,1,Eli Lilly Just Within Buy Range As Quarterly Report Nears
906da430-1602-4daa-9538-0a0e4ab5dbee,2020-04-16T08:00:00.000+08:00,5,Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?
dd3852d5-2e70-4878-b598-a8972754789e,2020-04-16T08:00:00.000+08:00,4,"Roche Most Innovative, Astra Zeneca Most Inventive"
879f76ee-2ec8-44d3-a716-50454d631a37,2020-04-16T08:00:00.000+08:00,3,Lower-priced versions of Humalog® Mix75/—5™ KwikPen® and Humalog® Junior KwikPen® now ...
f3ccf24c-b559-4a4f-92bb-56eed34b2687,2020-04-15T08:00:00.000+08:00,2,Every Member Of Trump's 'Great American Economic Revival' Industry Groups
c3989536-6567-40e4-9348-9f184c424eda,2020-04-15T08:00:00.000+08:00,5,"Cowen & Co. Maintains Outperform on Eli Lilly, Raises Price Target to $160"
1fc0d2ee-1dbd-4387-bf62-a6cf7e8cd9e5,2020-04-15T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US"
52ed04dd-8309-4583-9aad-c84ccad608a0,2020-04-15T08:00:00.000+08:00,4,AstraZeneca to Begin Calquence Study for Coronavirus Treatment
e2d29990-be22-4d89-a490-d46f52631b23,2020-04-15T08:00:00.000+08:00,5,Buy 5 Top Stocks Set to Beat on Q1 Earnings This Month
c21adfcc-d632-460d-b73d-8f181117af65,2020-04-15T08:00:00.000+08:00,3,Every Member Of Trump's 'Great American Economic Revival' Industry Groups
e8c5a64d-e7a0-42e7-bc75-c411a8439854,2020-04-15T08:00:00.000+08:00,4,"Cowen & Co. Maintains Outperform on Eli Lilly, Raises Price Target to $160"
96bc408b-695e-4f7b-aa96-74768d824948,2020-04-15T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US"
85a1b865-7bc4-4e3b-8e53-e485119482ba,2020-04-15T08:00:00.000+08:00,4,AstraZeneca to Begin Calquence Study for Coronavirus Treatment
a43e1c77-3eaf-491e-a8a8-0c10112d8a82,2020-04-15T08:00:00.000+08:00,5,Buy 5 Top Stocks Set to Beat on Q1 Earnings This Month
afecb248-62d3-459f-8a1f-dc6ed2363440,2020-04-14T08:00:00.000+08:00,3,Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.
7b28c185-fc3e-4511-b0f2-0b24e9e4a596,2020-04-14T08:00:00.000+08:00,4,Stocks That Hit 52-Week Highs On Tuesday
7aa5b26e-caf2-4c54-a7a8-5ff8d74f9f24,2020-04-14T08:00:00.000+08:00,5,"Dow Jones Futures: Coronavirus Stock Market Rally Soars As Two Wrongs Go Right; Amazon, Nvidia Lead New Breakouts"
bb531f7a-c715-4754-a00c-ef205fe868fc,2020-04-14T08:00:00.000+08:00,4,Indexes Near Session Highs As These Top Stocks Finally Clear Buy Points
8d0797b9-f622-46f0-946d-d0ea1aecb645,2020-04-14T08:00:00.000+08:00,5,"Six Surprising Stocks Making New Highs Today, One Especially"
36605909-2b16-4942-a5d5-7b6056db3924,2020-04-14T08:00:00.000+08:00,3,SNY vs. LLY: Which Stock Is the Better Value Option?
1398ac57-c273-4d6c-9c29-f2bc78ed6ff2,2020-04-14T08:00:00.000+08:00,4,"OneAscent Financial Services LLC Buys S&P Global Inc, Eli Lilly and Co, Brookfield ..."
8d5b6f5f-b654-49a6-896c-e4310b42fcd3,2020-04-14T08:00:00.000+08:00,2,"J&J (JNJ) Beats on Q1 Earnings, Cuts View on Coronavirus Impact"
db679564-654b-4ba4-9b47-534a86bba5e9,2020-04-14T08:00:00.000+08:00,5,Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.
cbecff0e-50a3-4dbe-b231-295802980398,2020-04-14T08:00:00.000+08:00,4,Stocks That Hit 52-Week Highs On Tuesday
7d144419-9688-4c30-adcf-5f38030229ee,2020-04-14T08:00:00.000+08:00,3,"Dow Jones Futures: Coronavirus Stock Market Rally Soars As Two Wrongs Go Right; Amazon, Nvidia Lead New Breakouts"
c6e7d64e-8be4-4c60-bcdf-1afef7332792,2020-04-14T08:00:00.000+08:00,4,Indexes Near Session Highs As These Top Stocks Finally Clear Buy Points
808be2f5-3392-45e2-b9a7-2afbba7845f7,2020-04-14T08:00:00.000+08:00,5,"Six Surprising Stocks Making New Highs Today, One Especially"
5f0df933-61ab-4532-a86e-289b6a6e9f6c,2020-04-14T08:00:00.000+08:00,2,SNY vs. LLY: Which Stock Is the Better Value Option?
1f314658-3c79-4490-8100-7a288f834f32,2020-04-14T08:00:00.000+08:00,4,"OneAscent Financial Services LLC Buys S&P Global Inc, Eli Lilly and Co, Brookfield ..."
d5eea007-040f-424f-852d-f22c96145eb2,2020-04-14T08:00:00.000+08:00,3,"J&J (JNJ) Beats on Q1 Earnings, Cuts View on Coronavirus Impact"
1c62bff4-37d1-4bc6-b460-098a4d3f7a03,2020-04-13T08:00:00.000+08:00,5,Lilly On Friday Anounced It Has Begun Clinical Testing of Therapies for Coronavirus
d1dbff81-e979-4734-90e4-fe3e1c26163f,2020-04-13T08:00:00.000+08:00,4,"Norman Fields, Gottscho Capital Management, LLC Buys Amazon.com Inc, Liberty Global PLC, D.R. ..."
f9f89718-21e4-4dfe-b918-533bca9182f8,2020-04-13T08:00:00.000+08:00,4,"Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo"
5f286c77-dc36-4002-992e-aab6ebc47cbf,2020-04-13T08:00:00.000+08:00,5,Lilly Announces Clinical Study Plans for Coronavirus Disease
32b86b3a-e1fc-4ac4-ada0-a9600bb51e8f,2020-04-13T08:00:00.000+08:00,3,Lilly On Friday Anounced It Has Begun Clinical Testing of Therapies for Coronavirus
06532db5-bed7-4bc1-8e43-4f7fce319aad,2020-04-13T08:00:00.000+08:00,4,"Norman Fields, Gottscho Capital Management, LLC Buys Amazon.com Inc, Liberty Global PLC, D.R. ..."
ba59dddf-fc9a-4b73-9f7a-a779cb1597cb,2020-04-13T08:00:00.000+08:00,4,"Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo"
3b4f30d3-ef2e-4c34-89f5-5f9f0bde06d8,2020-04-13T08:00:00.000+08:00,4,Lilly Announces Clinical Study Plans for Coronavirus Disease
373dde5d-c75d-4daf-aa7d-e650940a4e67,2020-04-12T08:00:00.000+08:00,5,This Trio of Strong Performers Is Predicted to Outperform
bf889341-38eb-400a-b17a-1f1af9f9f4a4,2020-04-12T08:00:00.000+08:00,3,This Trio of Strong Performers Is Predicted to Outperform
18a9d0b4-5cf7-4f36-adae-bd982d16dc8b,2020-04-11T08:00:00.000+08:00,2,"Benzinga's Bulls And Bears Of The Week: Apple, Disney, Intel And More"
cd0eb59e-8ad8-406c-9904-b448833566a0,2020-04-11T08:00:00.000+08:00,1,"Benzinga's Bulls And Bears Of The Week: Apple, Disney, Intel And More"
e12f28b3-5d40-448a-9e23-038312c16d18,2020-04-10T08:00:00.000+08:00,4,Lilly Begins Clinical Testing of Therapies for COVID-–9
c3cec752-0160-46c1-a360-0f68974c411a,2020-04-10T08:00:00.000+08:00,3,"Perkins Coie Trust Co Buys First Financial Corp, Truist Financial Corp, Vanguard Mid-Cap, Sells ..."
9d471d57-e8eb-4821-86b0-e0148b0c715c,2020-04-10T08:00:00.000+08:00,4,Lilly Begins Clinical Testing of Therapies for COVID-–9
b4df5eab-731b-4cb6-a5b9-63cef54dd101,2020-04-10T08:00:00.000+08:00,2,"Perkins Coie Trust Co Buys First Financial Corp, Truist Financial Corp, Vanguard Mid-Cap, Sells ..."
c0fdb7ea-c801-4f27-947c-3240a1ce4957,2020-04-09T08:00:00.000+08:00,1,"Morgan Stanley Downgrades Lilly On Valuation, Says Growth, Pipeline Potential Balanced By Stock Premium"
dbffe749-5f31-4d91-bfe1-6edc2663849e,2020-04-09T08:00:00.000+08:00,1,"Benzinga's Top Upgrades, Downgrades For April 9, 2020"
02c9e6c5-99e3-428d-ba7b-a9fa2e5a83ef,2020-04-09T08:00:00.000+08:00,2,Eli Lilly And Co shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight.
d5623011-a4ae-4482-878c-5f85410a1123,2020-04-09T08:00:00.000+08:00,3,Morgan Stanley Downgrades Eli Lilly to Equal-Weight
d0b47636-4970-428f-9a49-221d0c024dc2,2020-04-09T08:00:00.000+08:00,4,"Nadler Financial Group, Inc. Buys PIMCO Corporate & Income Opportunity Fds, Eli Lilly and ..."
91d5f000-723c-42d6-b2e2-cb80dbb8d03d,2020-04-09T08:00:00.000+08:00,5,Highly Rated Eli Lilly Near Buy Zone Ahead Of Earnings
78042e32-3910-4394-b7d3-e4bca9e6716a,2020-04-09T08:00:00.000+08:00,4,Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer
1c1ab1e2-9a30-4c32-86cd-a7f30711761e,2020-04-09T08:00:00.000+08:00,2,J&J (JNJ) Q1 Earnings May Indicate Coronavirus Impact on Pharma
bf81f31a-cf47-497f-8c26-feea13e6b940,2020-04-09T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: A10 Networks, Chemed, Core-Mark, Eli Lilly and Masimo"
67cac7c0-9547-42ec-b7f4-a80f5640ab96,2020-04-09T08:00:00.000+08:00,1,"Morgan Stanley Downgrades Lilly On Valuation, Says Growth, Pipeline Potential Balanced By Stock Premium"
49513878-bb5c-468f-8cd5-c4b18e7a9551,2020-04-09T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For April 9, 2020"
ddedb6c5-4bea-4ca1-93c5-37afcd559b07,2020-04-09T08:00:00.000+08:00,2,Eli Lilly And Co shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight.
2a29545c-071f-45c1-9c1d-44c7da131c16,2020-04-09T08:00:00.000+08:00,3,Morgan Stanley Downgrades Eli Lilly to Equal-Weight
2e552ab9-565a-44b1-b86c-a85fdfa38f01,2020-04-09T08:00:00.000+08:00,4,"Nadler Financial Group, Inc. Buys PIMCO Corporate & Income Opportunity Fds, Eli Lilly and ..."
39171f04-4dfc-409d-a20b-7f2a1372bdc6,2020-04-09T08:00:00.000+08:00,5,Highly Rated Eli Lilly Near Buy Zone Ahead Of Earnings
cd580ce3-7731-44b1-9fe6-abc86a9cbb5e,2020-04-09T08:00:00.000+08:00,1,Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer
e4681082-0a87-469c-9730-f1f9cd923873,2020-04-09T08:00:00.000+08:00,2,J&J (JNJ) Q1 Earnings May Indicate Coronavirus Impact on Pharma
e885be0d-c9bf-4d06-8844-ca91692597b7,2020-04-09T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: A10 Networks, Chemed, Core-Mark, Eli Lilly and Masimo"
1e9580bd-1e15-4893-b362-54155545c739,2020-04-08T08:00:00.000+08:00,3,"Eli Lilly shares are trading higher, not seeing company-specific news from the session. NOTE: The healthcare sector has been strong this week amid positive market sentiment as well as increased demand for therapies and medical supplies due to coronavirus."
1ee2778e-a9f8-4eed-b896-29957fa5cb7a,2020-04-08T08:00:00.000+08:00,4,Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market
fd8bd970-ab5b-488b-9263-011308b8aa8b,2020-04-08T08:00:00.000+08:00,5,Lilly Confirms Date and Conference Call for First-Quarter —…—… Financial Results ...
0c25a15c-928c-4892-ab54-e1fce29f7385,2020-04-08T08:00:00.000+08:00,4,"Eli Lilly shares are trading higher, not seeing company-specific news from the session. NOTE: The healthcare sector has been strong this week amid positive market sentiment as well as increased demand for therapies and medical supplies due to coronavirus."
9262e1e3-834f-45ad-811d-85efdef97603,2020-04-08T08:00:00.000+08:00,3,Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market
646eb489-cde3-4e1c-aada-e517e6015908,2020-04-08T08:00:00.000+08:00,3,Lilly Confirms Date and Conference Call for First-Quarter —…—… Financial Results ...
6755c55d-67d2-4d1d-a25e-c0086957abb0,2020-04-07T08:00:00.000+08:00,4,Eli Lilly And Co Says New $35 Co-Pay Now Available Through Lilly Insulin Value Program In Response To Coronavirus Crisus
e1661972-d96d-4f2a-94a0-38a7247ec30c,2020-04-07T08:00:00.000+08:00,5,Eli Lilly and Company to Hold —…—… Annual Meeting of Shareholders Virtually
34ff9df2-b757-4986-b611-c8b18344494a,2020-04-07T08:00:00.000+08:00,4,"The Zacks Analyst Blog Highlights: Eli Lilly, Qualcomm and Electronic Arts"
db978451-ad05-4d86-9857-11f6b8446e3e,2020-04-07T08:00:00.000+08:00,3,"Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day"
8e1f913b-3db5-4d99-8ead-7c58a3ceec9c,2020-04-07T08:00:00.000+08:00,5,New $'5 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-–9 ...
8841667b-e6aa-40b7-9f51-ce461b305929,2020-04-07T08:00:00.000+08:00,4,Eli Lilly And Co Says New $35 Co-Pay Now Available Through Lilly Insulin Value Program In Response To Coronavirus Crisus
1830384b-dcb4-45cd-aca2-222b1274bc89,2020-04-07T08:00:00.000+08:00,2,Eli Lilly and Company to Hold —…—… Annual Meeting of Shareholders Virtually
cac187e2-93ef-4ad4-a363-a5d4cbb49128,2020-04-07T08:00:00.000+08:00,4,"The Zacks Analyst Blog Highlights: Eli Lilly, Qualcomm and Electronic Arts"
8b7bd533-1b27-4d9b-9114-adcc7de1ff72,2020-04-07T08:00:00.000+08:00,5,"Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day"
522d95fa-6d89-4b74-ab4a-fa7ef701879a,2020-04-07T08:00:00.000+08:00,3,New $'5 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-–9 ...
85f433f8-d10c-485f-9e2c-921a3e36b532,2020-04-06T08:00:00.000+08:00,4,"'There are four main antibody programs underway in U.S. by Lilly, Regeneron, Vir, and Amgen. Regeneron may be furthest along and have the best chance of doing this at the scale required...' -Weekend Tweet From Former FDA Commish Gottlieb"
66488057-fe11-4160-ac16-2ace6988c4e7,2020-04-06T08:00:00.000+08:00,5,Another Drug to Fight Coronavirus & 3 Picks
87cef95b-119b-481a-9c35-281da5193446,2020-04-06T08:00:00.000+08:00,4,Why the Earnings Surprise Streak Could Continue for Lilly (LLY)
05027109-d43b-4901-bac2-16245206f68b,2020-04-06T08:00:00.000+08:00,4,"The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck"
b9205b5a-4c99-41fd-8698-eaaecf233413,2020-04-06T08:00:00.000+08:00,3,"'There are four main antibody programs underway in U.S. by Lilly, Regeneron, Vir, and Amgen. Regeneron may be furthest along and have the best chance of doing this at the scale required...' -Weekend Tweet From Former FDA Commish Gottlieb"
91cd3a7e-0897-4db8-b373-41156b73f35e,2020-04-06T08:00:00.000+08:00,5,Another Drug to Fight Coronavirus & 3 Picks
07388489-b3e1-41f0-8abc-2ed488f0876e,2020-04-06T08:00:00.000+08:00,4,Why the Earnings Surprise Streak Could Continue for Lilly (LLY)
d57ec201-658c-4006-a858-94102b641786,2020-04-06T08:00:00.000+08:00,4,"The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck"
dba85591-e383-41ad-86ef-7743e8a8fda0,2020-04-04T08:00:00.000+08:00,2,Stocks Move Lower but Stay Calm After Dreary Jobs Report
0cbf6178-f4ac-4a50-8525-562e354672eb,2020-04-04T08:00:00.000+08:00,2,Stocks Move Lower but Stay Calm After Dreary Jobs Report
4ea4ca76-56d3-4674-9d5e-1c6bab0048ae,2020-04-03T08:00:00.000+08:00,5,IBD Stock Of The Day: Why Eli Lilly Is Outplaying Its Pharma Giant Peers
8fe6a67c-cfa8-4a36-b4a7-e9e8ee3d9e5b,2020-04-03T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: Eli Lilly, Charter, Eaton, Autodesk and Cypress Semiconductor"
0bd79c54-96bd-43be-a031-894ac0464de7,2020-04-03T08:00:00.000+08:00,4,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
c3f92a65-0d37-4426-a5d1-e34995d5cf62,2020-04-03T08:00:00.000+08:00,5,IBD Stock Of The Day: Why Eli Lilly Is Outplaying Its Pharma Giant Peers
05c1922e-46d7-4b84-9ebb-2dcaf7248155,2020-04-03T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: Eli Lilly, Charter, Eaton, Autodesk and Cypress Semiconductor"
d3bb04a8-75c3-4397-ad6f-51a4a7c5e326,2020-04-03T08:00:00.000+08:00,4,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
279e4968-ec52-4854-ab6d-e8f5aef68387,2020-04-02T08:00:00.000+08:00,4,"Morgan Stanley Maintains Overweight on Eli Lilly, Lowers Price Target to $148"
1751a84b-d273-4302-b6f8-bc14e13e3c11,2020-04-02T08:00:00.000+08:00,4,Stock Indexes Jump As Jobless Claims Soar Again
c778094a-6088-423c-970d-98a25c641c3c,2020-04-02T08:00:00.000+08:00,3,"Top Analyst Reports for Eli Lilly, Charter Communications & Eaton"
8f32ebb7-5a23-404b-9fbf-bd6eab23fa20,2020-04-02T08:00:00.000+08:00,5,Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis
00d8fef0-bf4c-43af-bd57-027eef11aab9,2020-04-02T08:00:00.000+08:00,4,Bull of the Day: Eli Lilly (LLY)
963e5b1e-3c87-4abd-9cad-12dd63bce6b6,2020-04-02T08:00:00.000+08:00,2,"Morgan Stanley Maintains Overweight on Eli Lilly, Lowers Price Target to $148"
3cb00419-0b01-4164-b3c3-8b2ed1486276,2020-04-02T08:00:00.000+08:00,2,Stock Indexes Jump As Jobless Claims Soar Again
770c7275-f33d-4056-9e40-2fea2cb4b0c0,2020-04-02T08:00:00.000+08:00,4,"Top Analyst Reports for Eli Lilly, Charter Communications & Eaton"
74504dad-cb88-4766-9fde-46659a7877cc,2020-04-02T08:00:00.000+08:00,5,Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis
ea4e3451-82ee-4a6a-8d07-cf42a43b715a,2020-04-02T08:00:00.000+08:00,3,Bull of the Day: Eli Lilly (LLY)
ae8d6c87-86f5-4b24-b3e2-28a8027a8a13,2020-04-01T08:00:00.000+08:00,1,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.
6726d63c-2a83-4d97-90d8-3d68117c50d0,2020-04-01T08:00:00.000+08:00,4,Pharma Giant Eli Lilly (LLY) Stock is a Buy During the Coronavirus Economy
024740fb-3d3d-4858-aa07-2deae44d6440,2020-04-01T08:00:00.000+08:00,5,"Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA"
2c2de7ee-f0be-4d29-9816-fa8f6d094eca,2020-04-01T08:00:00.000+08:00,3,Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?
0f63bcaa-0ed0-410f-a309-ad2f23738b73,2020-04-01T08:00:00.000+08:00,4,3 Drugmakers Still Worth Betting on Amid Coronavirus Woes
2750f588-8e44-4df8-9e83-4dd629d579b6,2020-04-01T08:00:00.000+08:00,2,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.
ca4b0bc5-19b1-42a9-8483-0950a0e35a4f,2020-04-01T08:00:00.000+08:00,4,Pharma Giant Eli Lilly (LLY) Stock is a Buy During the Coronavirus Economy
bede8fba-ba06-457d-875a-7222f10fe09e,2020-04-01T08:00:00.000+08:00,2,"Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA"
07aa778e-78fc-4916-9ef4-5122cf8745f1,2020-04-01T08:00:00.000+08:00,3,Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?
bf7281d7-1e4e-4348-bf32-eea3c99450fb,2020-04-01T08:00:00.000+08:00,1,3 Drugmakers Still Worth Betting on Amid Coronavirus Woes
40ec70fd-da12-47fc-9feb-127c66446209,2020-03-31T08:00:00.000+08:00,1,Patent Court Rejects Eli Lilly Challenge To Teva Patents On Migraine Drug Ajovy
c591d722-22ac-4bcf-b764-e935720b3a55,2020-03-31T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions"
cf76bbfe-64d1-4b80-92d6-e7cc2bbdc933,2020-03-31T08:00:00.000+08:00,4,Lilly And Sitryx Announce Licensing And Research Collaboration To Discover And Develop New Immunometabolic Medicines
813333d1-f6e2-4eb5-9e6f-35da78a4bdda,2020-03-31T08:00:00.000+08:00,5,Buy this High-Yield Large Cap Pharma Stock for Income Amid Coronavirus
46950875-1d68-4317-93dc-3abaf8097b52,2020-03-31T08:00:00.000+08:00,2,Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children
0d1aae0c-c6f7-4298-9038-a16250079cc6,2020-03-31T08:00:00.000+08:00,1,Patent Court Rejects Eli Lilly Challenge To Teva Patents On Migraine Drug Ajovy
f7bd9789-d009-493d-ab11-2ed6b124bf0d,2020-03-31T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions"
a2137d6a-e995-41c4-8a3a-22d4f91112c6,2020-03-31T08:00:00.000+08:00,4,Lilly And Sitryx Announce Licensing And Research Collaboration To Discover And Develop New Immunometabolic Medicines
63412230-1e85-438a-b985-22820c237c16,2020-03-31T08:00:00.000+08:00,3,Buy this High-Yield Large Cap Pharma Stock for Income Amid Coronavirus
f125beab-87b7-4c94-a90f-3ea9e2d0c3d7,2020-03-31T08:00:00.000+08:00,5,Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children
7e54301b-1810-4493-9b60-3866af1dd6ab,2020-03-30T08:00:00.000+08:00,4,Why Eli Lilly's Stock Is Trading Higher Today
15055dd2-9743-4f1f-8a54-fd0159f562bc,2020-03-30T08:00:00.000+08:00,5,Eli Lilly shares are trading higher after the company received FDA approval for Taltz for treatment of pediatric patients with moderate to severe plaque psoriasis.
9a776a18-f25e-4eda-8622-1706f4ed8ca8,2020-03-30T08:00:00.000+08:00,5,Eli Lilly's Taltz Receives FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
db638934-4cd4-45e3-a0f0-f778b2219209,2020-03-30T08:00:00.000+08:00,1,"Vertex to Halt Enrollment Due to Coronavirus, Keeps Sales View"
d16222e8-d043-45b5-be73-deb0a8ae657a,2020-03-30T08:00:00.000+08:00,4,Lilly's Taltz® (ixekizumab) Receives U.S. ...
8e0d0269-5e60-4f52-8d30-1b45e7fbacd3,2020-03-30T08:00:00.000+08:00,5,Why Eli Lilly's Stock Is Trading Higher Today
c77f1864-1c1e-4812-b808-b7af584750ee,2020-03-30T08:00:00.000+08:00,5,Eli Lilly shares are trading higher after the company received FDA approval for Taltz for treatment of pediatric patients with moderate to severe plaque psoriasis.
f28fbe8b-7138-4d90-8b6a-35fbebdc82be,2020-03-30T08:00:00.000+08:00,5,Eli Lilly's Taltz Receives FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
80fb4dcc-0d42-4f2f-a021-a22e64f78ed9,2020-03-30T08:00:00.000+08:00,1,"Vertex to Halt Enrollment Due to Coronavirus, Keeps Sales View"
35daf613-fd8c-4fc2-a831-dd615ffdecf2,2020-03-30T08:00:00.000+08:00,4,Lilly's Taltz® (ixekizumab) Receives U.S. ...
cbf71d9f-6b93-4504-9839-9cefd95d3838,2020-03-27T08:00:00.000+08:00,2,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak."
06447f9e-78be-425a-884a-8e55c819f930,2020-03-27T08:00:00.000+08:00,4,Veeva Systems' CRM Product Is Seeing Ten Times More Usage During Coronavirus Pandemic
a28abe07-85c2-4c2e-96f2-be5a46bd4693,2020-03-27T08:00:00.000+08:00,3,Spiros Segalas Starts the New Year Adding 5 Stocks to Portfolio
8840baba-b0aa-41dd-af1a-acf7d5ecd7bb,2020-03-27T08:00:00.000+08:00,5,Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia
2eea5e7f-e8ef-42fe-8d45-7079934f85df,2020-03-27T08:00:00.000+08:00,4,"Eli Lilly Clears Key Benchmark, Hitting 90-Plus RS Rating"
98d19d1c-eb42-450f-8233-ece494e2586c,2020-03-27T08:00:00.000+08:00,2,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak."
299fec74-fd64-4302-a3a4-a3d7f9422497,2020-03-27T08:00:00.000+08:00,4,Veeva Systems' CRM Product Is Seeing Ten Times More Usage During Coronavirus Pandemic
41eb09c2-19a2-4a29-957c-7760e23fa523,2020-03-27T08:00:00.000+08:00,3,Spiros Segalas Starts the New Year Adding 5 Stocks to Portfolio
f311814f-e1aa-4b25-b8f7-6bd5cac78236,2020-03-27T08:00:00.000+08:00,1,Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia
ba8310ac-d2b3-4002-88c4-20f4cb895088,2020-03-27T08:00:00.000+08:00,5,"Eli Lilly Clears Key Benchmark, Hitting 90-Plus RS Rating"
9b437164-47bb-4fa4-93c4-ebccaad61fc2,2020-03-26T08:00:00.000+08:00,4,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors."
a9d0fbe6-dd49-4e26-94e2-4c4b51711f07,2020-03-26T08:00:00.000+08:00,4,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors."
0e59dc06-66b2-46df-9224-a1e116212eb4,2020-03-24T08:00:00.000+08:00,4,"Shares of several healthcare companies are trading higher as equities gain amid hopes of a US stimulus agreement. Additionally, the coronavirus outbreak has increased demand for certain medical supplies."
fa672b69-e65c-49fa-b8c9-ca26c2e70b69,2020-03-24T08:00:00.000+08:00,3,"Eli Lilly Offers Update On Insulin Supply, Affordability, Says Does Not Source Active Pharma Ingredients From China, Says US Pharmacies Temporarily Unavailable For Co. Medicines Can Order From Wholesalers"
8e21e38e-7691-4dac-a08b-682e9d7a2b1b,2020-03-24T08:00:00.000+08:00,2,Agios' IND for PKR Activator AG-946 Gets FDA Clearance
5eb2e9eb-4174-4dc0-970c-bc42c1a400d6,2020-03-24T08:00:00.000+08:00,1,"Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure"
7fb089ab-b38c-4d8b-9f74-3104798965c8,2020-03-24T08:00:00.000+08:00,2,Updates from Lilly about insulin supply and affordability
d340bf8c-61b5-473b-85f6-9757b3ee6d56,2020-03-24T08:00:00.000+08:00,4,"Shares of several healthcare companies are trading higher as equities gain amid hopes of a US stimulus agreement. Additionally, the coronavirus outbreak has increased demand for certain medical supplies."
3a12fd21-1d45-475c-bd7e-e79697ec63c7,2020-03-24T08:00:00.000+08:00,3,"Eli Lilly Offers Update On Insulin Supply, Affordability, Says Does Not Source Active Pharma Ingredients From China, Says US Pharmacies Temporarily Unavailable For Co. Medicines Can Order From Wholesalers"
b8fb5d14-4683-4c39-aed4-16c74085ef60,2020-03-24T08:00:00.000+08:00,1,Agios' IND for PKR Activator AG-946 Gets FDA Clearance
daa4abbc-b614-4aa8-b3db-738f17364a4c,2020-03-24T08:00:00.000+08:00,1,"Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure"
8a3a86da-943c-4598-9eaa-04fe006589b7,2020-03-24T08:00:00.000+08:00,2,Updates from Lilly about insulin supply and affordability
aa2c7041-b072-4e00-871d-b7002dace96e,2020-03-23T08:00:00.000+08:00,3,Eli Lilly Delays New Study Starts
f2dd7717-700f-4779-8594-f73a0fe958f2,2020-03-23T08:00:00.000+08:00,1,Eli Lilly and Co. shares are trading lower after the company announced it will delay most of the new study starts and pause enrollment in most of the ongoing studies amid Coronavirus.
9aafcd00-a700-4757-b4b3-459022588c55,2020-03-23T08:00:00.000+08:00,4,AC Immune Receives a Second Milestone Payment of CHF 10M From Eli Lilly
7d65dcd3-80e1-4f9b-a106-ea7bac7c1bbd,2020-03-23T08:00:00.000+08:00,2,Eli Lilly Says it Will Delay Most New Trial Starts and Pause Enrollment in Ongoing Studies Amid Coronavirus
b3f29606-8f61-465b-9a48-e20106a15818,2020-03-23T08:00:00.000+08:00,1,Lilly Gets CRL for Jardiance in Type I Diabetes Indication
46b9d7ff-ca8f-4a24-9b40-af19521bdd41,2020-03-23T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck"
6b23a17f-fefd-4781-a145-0a79e217cc32,2020-03-23T08:00:00.000+08:00,3,Lilly Provides Update on Clinical Trial Activities During COVID-–9 Pandemic
b1887c34-dcaa-4953-833b-96c3719bbcf5,2020-03-23T08:00:00.000+08:00,2,Eli Lilly Delays New Study Starts
ade791d0-851b-43fc-84da-343cfd5e20be,2020-03-23T08:00:00.000+08:00,1,Eli Lilly and Co. shares are trading lower after the company announced it will delay most of the new study starts and pause enrollment in most of the ongoing studies amid Coronavirus.
c6a6fc29-b9f0-4d14-96f9-df24a4c25707,2020-03-23T08:00:00.000+08:00,2,AC Immune Receives a Second Milestone Payment of CHF 10M From Eli Lilly
69819cfd-8022-4d45-a5cf-a033b870df76,2020-03-23T08:00:00.000+08:00,3,Eli Lilly Says it Will Delay Most New Trial Starts and Pause Enrollment in Ongoing Studies Amid Coronavirus
477547ea-e279-478b-a153-aa49d9a9c2eb,2020-03-23T08:00:00.000+08:00,1,Lilly Gets CRL for Jardiance in Type I Diabetes Indication
a24f176b-8d9b-4b93-b65c-04c26efe33ca,2020-03-23T08:00:00.000+08:00,4,"The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck"
7c18a49c-ec17-4270-8dcc-1650895c31fc,2020-03-23T08:00:00.000+08:00,3,Lilly Provides Update on Clinical Trial Activities During COVID-–9 Pandemic
726bb828-8442-45bb-b205-9fb0d9165182,2020-03-22T08:00:00.000+08:00,2,Lilly to Provide Drive-Through COVID-–9 Testing for Indianapolis Health Care Workers
207fb464-ccc3-479b-a346-627d43170aa5,2020-03-22T08:00:00.000+08:00,2,Lilly to Provide Drive-Through COVID-–9 Testing for Indianapolis Health Care Workers
27efda26-cdb2-40b9-ba64-935219675d8e,2020-03-20T08:00:00.000+08:00,3,"FDA Issues Complete Response Letter For Empagliflozin 2.5 Mg As Adjunct To Insulin For Adults With Type 1 Diabetes, Indicates FDA Is Unable To Approve Application In Current Form; Empagliflozin 2.5 Mg Is Being Developed By Boehringer Ingelheim & Lilly"
251562b5-1eb7-4ead-ac07-1b079a2a02b9,2020-03-20T08:00:00.000+08:00,1,US FDA issues complete response letter for empagliflozin —. ...
196c81ee-1674-41d3-995f-e2eb784d3f4d,2020-03-20T08:00:00.000+08:00,3,"Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates"
36c50fab-8b80-4ad3-b97b-72b9dfb69e82,2020-03-20T08:00:00.000+08:00,2,"FDA Issues Complete Response Letter For Empagliflozin 2.5 Mg As Adjunct To Insulin For Adults With Type 1 Diabetes, Indicates FDA Is Unable To Approve Application In Current Form; Empagliflozin 2.5 Mg Is Being Developed By Boehringer Ingelheim & Lilly"
4d81a4a8-76b1-44ce-bfbc-e19f7f78ec54,2020-03-20T08:00:00.000+08:00,3,US FDA issues complete response letter for empagliflozin —. ...
67484605-0d09-4a99-804b-29c499bd13b3,2020-03-20T08:00:00.000+08:00,3,"Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates"
d77777f5-5093-440c-abc6-74979a915983,2020-03-19T08:00:00.000+08:00,4,"Thinking about trading options or stock in Akamai Technologies, Citrix Systems, Eli Lilly, ..."
090eea41-dd72-4c8a-b637-f7b23a7a1dfb,2020-03-19T08:00:00.000+08:00,4,"Thinking about trading options or stock in Akamai Technologies, Citrix Systems, Eli Lilly, ..."
67a72af6-243c-491e-8bbe-e19eb7480a98,2020-03-18T08:00:00.000+08:00,4,Eli Lilly Reports Partnership With Indiana State Dept. Of Health With Support From FDA To Accelerate Testing For Coronavirus In Indiana
837a09a4-f747-4d6e-a2bb-474fdfdaba64,2020-03-18T08:00:00.000+08:00,4,"Lilly, Indiana State Department of Health Partner to Accelerate COVID-–9 Testing Using Lilly ..."
db3719df-06a5-4417-bf32-1f59c22c76f4,2020-03-18T08:00:00.000+08:00,4,Eli Lilly Reports Partnership With Indiana State Dept. Of Health With Support From FDA To Accelerate Testing For Coronavirus In Indiana
96481dc5-cb20-4aee-8483-79de5ba9c889,2020-03-18T08:00:00.000+08:00,3,"Lilly, Indiana State Department of Health Partner to Accelerate COVID-–9 Testing Using Lilly ..."
f8b3e8b0-c626-4358-8ce6-fc8c4059b648,2020-03-17T08:00:00.000+08:00,2,"Shares of several healthcare companies are trading higher, rebounding from Monday's crash. Stocks may also potentially be getting a boost from expectations of further stimulus proposals."
445c9f55-9dfa-475f-84fe-79e64d71d76b,2020-03-17T08:00:00.000+08:00,4,Lilly's Olumiant Gets Breakthrough Therapy Tag for Hair Loss
5cd6f35c-af88-4269-bf11-a153dd667725,2020-03-17T08:00:00.000+08:00,2,"Shares of several healthcare companies are trading higher, rebounding from Monday's crash. Stocks may also potentially be getting a boost from expectations of further stimulus proposals."
d381acd9-1a59-456e-a349-a10f9df9414a,2020-03-17T08:00:00.000+08:00,4,Lilly's Olumiant Gets Breakthrough Therapy Tag for Hair Loss
d2f8dad8-b8a0-4f58-b54f-425f2d868c8d,2020-03-16T08:00:00.000+08:00,1,"Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors."
37683cc8-eceb-42d2-8a7a-82a341cc4948,2020-03-16T08:00:00.000+08:00,5,Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
888187a9-243b-4622-aef3-62522b21c15c,2020-03-16T08:00:00.000+08:00,4,"Coronavirus Correction: Eli Lilly Stock Shows Strength Amid Accelerating Earnings, Sales"
28ace1df-29dd-4f58-8f9a-58ab12256b71,2020-03-16T08:00:00.000+08:00,2,4 Big Drug/Biotech Stocks Up in Coronavirus-Hit Economy
dc78595f-4c57-41d6-93b7-444096590755,2020-03-16T08:00:00.000+08:00,5,Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of ...
e7ac06bc-2223-4b42-a743-8a6a7fa5e3a8,2020-03-16T08:00:00.000+08:00,1,"Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors."
381807ef-b7b3-4f01-975e-a3943fa10bf7,2020-03-16T08:00:00.000+08:00,5,Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
28af1505-5333-4565-97c3-4db209e08a01,2020-03-16T08:00:00.000+08:00,4,"Coronavirus Correction: Eli Lilly Stock Shows Strength Amid Accelerating Earnings, Sales"
af3e5da0-a0b7-485c-84ad-a39110ea7228,2020-03-16T08:00:00.000+08:00,3,4 Big Drug/Biotech Stocks Up in Coronavirus-Hit Economy
3adb01b7-5f91-4b66-ae74-ee1c0b42e541,2020-03-16T08:00:00.000+08:00,5,Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of ...
f54be27d-8dbe-40d0-adfb-012be703c043,2020-03-13T08:00:00.000+08:00,4,"The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals"
8c2b85d9-9e32-4e63-8d96-34c662af00d8,2020-03-13T08:00:00.000+08:00,2,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.
cce0cb16-c928-4086-a52c-955592651d07,2020-03-13T08:00:00.000+08:00,4,"Thinking about trading options or stock in Alphabet, Eli Lilly, Microsoft, Procter & ..."
5986cbbd-ead2-4943-8a44-685c884238d1,2020-03-13T08:00:00.000+08:00,5,"Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates"
228f2cf0-59bb-4ee6-a51d-551fc55ff505,2020-03-13T08:00:00.000+08:00,3,Weekly Biotech Update After WHO Declares Coronavirus a Pandemic
d13d4f58-ac26-4707-b340-2a6a5640ada9,2020-03-13T08:00:00.000+08:00,4,Coronavirus Drug Development Efforts Pick Up Amid Sell-Off
94257769-561d-4b9b-91ef-fbf9f2ac25b9,2020-03-13T08:00:00.000+08:00,4,When To Buy Large Cap Stocks During A Stock Market Crash: These 2 Sectors Offer Clues
3d618b82-6c9d-4e5f-aee4-20e2e1467a63,2020-03-13T08:00:00.000+08:00,2,"The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals"
3b32a389-110a-4ea6-a8c2-a05d9323ff0e,2020-03-13T08:00:00.000+08:00,3,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.
b2f1f03c-c951-4984-8c1d-3c20f36628e7,2020-03-13T08:00:00.000+08:00,3,"Thinking about trading options or stock in Alphabet, Eli Lilly, Microsoft, Procter & ..."
30f2846a-0fe3-4860-a31d-8fc6b34f7fff,2020-03-13T08:00:00.000+08:00,4,"Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates"
5d254b42-af0c-49eb-8eee-a7924287ec7b,2020-03-13T08:00:00.000+08:00,5,Weekly Biotech Update After WHO Declares Coronavirus a Pandemic
16e758b2-5808-4ed6-9a27-b43fac386706,2020-03-13T08:00:00.000+08:00,2,Coronavirus Drug Development Efforts Pick Up Amid Sell-Off
a182aac2-7307-4461-a464-89f2e14ed651,2020-03-13T08:00:00.000+08:00,4,When To Buy Large Cap Stocks During A Stock Market Crash: These 2 Sectors Offer Clues
267c29c4-11ed-48b1-a0a9-77a2fa19dab0,2020-03-12T08:00:00.000+08:00,3,"Eli Lilly Shares Make Parabolic Move, Spike Higher Then Sell Off; Hearing Co. Said To Join Race To Develop Coronavirus Treatment"
45686936-b8e7-4e1d-8c29-095fe1e3717f,2020-03-12T08:00:00.000+08:00,1,Eli Lilly & Co shares are trading lower despite receiving fast track designation to Jardiance by the FDA for the treatment of chronic kidney diseases. NOTE: Markets continue to drop amid the global coronavirus outbreak.
853ab277-23e9-4541-a5dc-6bc7d2d60a42,2020-03-12T08:00:00.000+08:00,5,US FDA Grants Fast Track Designation to Jardiance® for The Treatment of Chronic Kidney Disease
1f00f87a-5b21-44e4-9c3b-9df14818a964,2020-03-12T08:00:00.000+08:00,2,AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-–9
2a76976e-5309-4518-97dd-2611ff1e7249,2020-03-12T08:00:00.000+08:00,4,US FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease
19c97191-091f-4234-857a-2cd3d967fd2f,2020-03-12T08:00:00.000+08:00,3,"Eli Lilly Shares Make Parabolic Move, Spike Higher Then Sell Off; Hearing Co. Said To Join Race To Develop Coronavirus Treatment"
a9fc1c43-a451-4c35-9e51-38899ebcc8dd,2020-03-12T08:00:00.000+08:00,1,Eli Lilly & Co shares are trading lower despite receiving fast track designation to Jardiance by the FDA for the treatment of chronic kidney diseases. NOTE: Markets continue to drop amid the global coronavirus outbreak.
6ca9f8b0-b618-4946-bbf5-dfeb0e662e60,2020-03-12T08:00:00.000+08:00,4,US FDA Grants Fast Track Designation to Jardiance® for The Treatment of Chronic Kidney Disease
3afb6649-f6d6-4f04-9793-717e11b7969c,2020-03-12T08:00:00.000+08:00,4,AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-–9
5119cb60-27a2-4293-9b02-08f993ec83c6,2020-03-12T08:00:00.000+08:00,5,US FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease
7ff6c24b-46af-4a69-9506-995a19015779,2020-03-11T08:00:00.000+08:00,3,Lilly To Participate In New Model Designed To Make Insulins More Affordable For Seniors In Medicare Part D
e87bb4d2-e34a-4272-9306-9945aa921d06,2020-03-11T08:00:00.000+08:00,4,"Goldman Sachs Maintains Buy on Eli Lilly, Announces $168 Price Target; Adds To Conviction Buy List"
c62f259b-9f91-4b7a-b61a-5735226a3fd2,2020-03-11T08:00:00.000+08:00,2,"Dow Jones Futures: Coronavirus Stock Market Correction Is A Bear; Apple, Tesla, AMD Show Strength"
c76b9f7b-ad41-4b0d-8450-dea4523b17c9,2020-03-11T08:00:00.000+08:00,4,Lilly to Participate in New Model Designed to Make Insulins More Affordable for Seniors in ...
d320bc4d-ee76-4f35-9053-7e695c90fc76,2020-03-11T08:00:00.000+08:00,2,Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4
4b6a8d03-bdec-449b-b4fc-1ab39e8dd50a,2020-03-11T08:00:00.000+08:00,3,"\"Dow Jones Slammed 1,151 Points On Coronavirus Fears; Will \"\"Stay At Home\"\" Stocks Win Big In 2020?\""
055882fc-d099-499d-8f8d-8e38d1bc6af3,2020-03-11T08:00:00.000+08:00,1,Pharma M&A Has Slowed to a Crawl
62177142-3e3b-439a-85d5-5926f9a77842,2020-03-11T08:00:00.000+08:00,5,Lilly To Participate In New Model Designed To Make Insulins More Affordable For Seniors In Medicare Part D
bc6ed62d-2ccc-42eb-af6e-786e0264748a,2020-03-11T08:00:00.000+08:00,5,"Goldman Sachs Maintains Buy on Eli Lilly, Announces $168 Price Target; Adds To Conviction Buy List"
ee518e85-037b-42f3-b8b6-96fd3e983a11,2020-03-11T08:00:00.000+08:00,2,"Dow Jones Futures: Coronavirus Stock Market Correction Is A Bear; Apple, Tesla, AMD Show Strength"
0d5fe3fa-f8ba-43a3-97f8-da76005d417b,2020-03-11T08:00:00.000+08:00,3,Lilly to Participate in New Model Designed to Make Insulins More Affordable for Seniors in ...
e57e1c3a-785c-441a-b664-aca1dc775930,2020-03-11T08:00:00.000+08:00,1,Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4
8dba8d63-7665-4223-969c-a14692d0eb2a,2020-03-11T08:00:00.000+08:00,2,"\"Dow Jones Slammed 1,151 Points On Coronavirus Fears; Will \"\"Stay At Home\"\" Stocks Win Big In 2020?\""
179af4d0-4ef2-4335-bcd2-332637e9987d,2020-03-11T08:00:00.000+08:00,2,Pharma M&A Has Slowed to a Crawl
edf3f4b3-b6d5-4058-b793-a96e1f8781ed,2020-03-09T08:00:00.000+08:00,3,Lilly to Participate in Barclays Global Healthcare Conference
786e1e21-9c0f-4399-b84d-9b4c7e17adc3,2020-03-09T08:00:00.000+08:00,3,"Thinking about trading options or stock in Dollar General, Eli Lilly, 'M, Regeneron ..."
bdcbc614-3e6f-4589-8af3-bae39cf62b34,2020-03-09T08:00:00.000+08:00,2,Lilly to Participate in Barclays Global Healthcare Conference
90cb9a4b-adc4-439a-90ce-6c7bfdc63e56,2020-03-09T08:00:00.000+08:00,2,"Thinking about trading options or stock in Dollar General, Eli Lilly, 'M, Regeneron ..."
ca4c0bcf-8b8d-477b-bede-4dbea8b0714d,2020-03-07T08:00:00.000+08:00,4,Week In Review: Abpro Bio Signs $1.1 Billion Deal For China-Asian Rights To Two Bi-Specifics
d20ee971-2771-44ab-8171-2840b6a23d99,2020-03-07T08:00:00.000+08:00,4,Week In Review: Abpro Bio Signs $1.1 Billion Deal For China-Asian Rights To Two Bi-Specifics
63577eae-5f95-48b7-8fd6-508135d47d8d,2020-03-06T08:00:00.000+08:00,3,"Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates"
a440e9f9-db56-4c22-9e86-77c07b6fc109,2020-03-06T08:00:00.000+08:00,2,"Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates"
b3438728-fec4-4e17-a012-b88c55aa053f,2020-03-04T08:00:00.000+08:00,1,Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.
0ac77bc7-df64-4285-812b-28932de952ef,2020-03-04T08:00:00.000+08:00,4,Lilly Expects No Drug Supply Shortages Due to Coronavirus
ba8279d8-db16-495e-8cf6-12c3b695003c,2020-03-04T08:00:00.000+08:00,3,Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.
f3c0fd54-cd74-4ae5-bb1b-ebb188a2f08d,2020-03-04T08:00:00.000+08:00,3,Lilly Expects No Drug Supply Shortages Due to Coronavirus
993dbf02-bc53-416a-815e-914bd42ce98c,2020-03-03T08:00:00.000+08:00,4,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More"
6c4b4fb6-d6c5-4054-b14a-e3cd68ed97e4,2020-03-03T08:00:00.000+08:00,5,"Lilly Issued A Statement On Coronavirus And The Reliable Syooly Of The Company's Medicines; The Company Does Not Anticioae Shortage For Any Of Its Products, Including All Forms Of Insulin"
1612c752-a6fb-4ddd-b61b-064d7b649e87,2020-03-03T08:00:00.000+08:00,2,Sometimes The Best Trade Is No Trade
4ad00473-811e-4fa5-b215-f944aeec76e0,2020-03-03T08:00:00.000+08:00,4,"Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA"
fecb14ab-b764-43c3-94eb-4dfb1c74ff6a,2020-03-03T08:00:00.000+08:00,3,Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines
fa0a908f-b224-468b-a614-2e87c02295e7,2020-03-03T08:00:00.000+08:00,4,"The Zacks Analyst Blog Highlights: Eli Lilly, Union Pacific, Lockheed Martin, Bayer and Prologis"
da01d061-1fb8-485c-99b6-3e7aa007ad77,2020-03-03T08:00:00.000+08:00,5,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More"
39c04d2d-0a6a-435b-88a3-019b0cd9dcd5,2020-03-03T08:00:00.000+08:00,4,"Lilly Issued A Statement On Coronavirus And The Reliable Syooly Of The Company's Medicines; The Company Does Not Anticioae Shortage For Any Of Its Products, Including All Forms Of Insulin"
854293ff-d9cf-43eb-98d0-e17869f11a56,2020-03-03T08:00:00.000+08:00,2,Sometimes The Best Trade Is No Trade
1f9c9ceb-1c21-4a15-9be2-53756a9caa00,2020-03-03T08:00:00.000+08:00,1,"Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA"
a955f436-c630-4466-af2d-503821e8c86f,2020-03-03T08:00:00.000+08:00,3,Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines
3f3d1a6f-e8e1-48b8-bbaf-2899406382fd,2020-03-03T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: Eli Lilly, Union Pacific, Lockheed Martin, Bayer and Prologis"
43b38b8f-6ba9-4e09-9e9a-f78e6eee9ac2,2020-03-02T08:00:00.000+08:00,5,Pfizer's Biologics License Application for Tanezumab Accepted for Review by the FDA
58ae6de2-4de5-49db-8a6c-76944dc45a96,2020-03-02T08:00:00.000+08:00,3,"Top Stock Reports for Eli Lilly, Union Pacific & Lockheed"
f71cfaf1-d107-4ded-9f39-ba8a3ec4d4de,2020-03-02T08:00:00.000+08:00,4,This is Why Eli Lilly (LLY) is a Great Dividend Stock
1e926a85-a297-4f84-b064-a15c09e58aea,2020-03-02T08:00:00.000+08:00,5,"U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for ..."
ae22aef5-aaf5-463b-b458-37f80fc4090d,2020-03-02T08:00:00.000+08:00,2,Radius (RDUS) Q4 Earnings Beat Estimates on Tymlos Strength
fd461be3-f58f-4ebc-99b7-2b62698ac5ad,2020-03-02T08:00:00.000+08:00,5,Pfizer's Biologics License Application for Tanezumab Accepted for Review by the FDA
c8f914f5-11af-4f00-8a7b-4144b513cc5b,2020-03-02T08:00:00.000+08:00,3,"Top Stock Reports for Eli Lilly, Union Pacific & Lockheed"
38decf4c-7364-4583-b58e-de25f02848d6,2020-03-02T08:00:00.000+08:00,4,This is Why Eli Lilly (LLY) is a Great Dividend Stock
0c3bdbc5-dedf-4d0b-a065-8206d699f69c,2020-03-02T08:00:00.000+08:00,5,"U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for ..."
8571ce2e-1a88-461d-b1e5-4c1e70fc6ae5,2020-03-02T08:00:00.000+08:00,2,Radius (RDUS) Q4 Earnings Beat Estimates on Tymlos Strength
203fc1ef-c3d1-446d-bc14-6f12f185984d,2020-02-29T08:00:00.000+08:00,1,Lilly (LLY) Down 11.6% Since Last Earnings Report: Can It Rebound?
cc69cc29-8d99-4b42-ba48-f7c873fd108f,2020-02-29T08:00:00.000+08:00,1,Lilly (LLY) Down 11.6% Since Last Earnings Report: Can It Rebound?
e839450e-6c1d-49e1-93c0-b8d781e8b5f8,2020-02-28T08:00:00.000+08:00,2,Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.
36df7bdd-c5c4-4bf6-8665-60884a224751,2020-02-28T08:00:00.000+08:00,3,EMA Says Adopted Negative Opinion For Eli Lilly's Indication Extension For Emgality To Add Prevention Of Attacks In Adults With Episodic Cluster Headache
139867e0-ffd9-47b5-8d56-cd6a088299c7,2020-02-28T08:00:00.000+08:00,2,"Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit"
a0399c4f-1805-42a3-9c0d-42c34019b72d,2020-02-28T08:00:00.000+08:00,5,"Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up"
7c2b2afc-22ac-4365-bf29-8fa1b7b86be2,2020-02-28T08:00:00.000+08:00,2,Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.
0f7f2f00-d5f3-4c14-87a8-fda555cd49bc,2020-02-28T08:00:00.000+08:00,3,EMA Says Adopted Negative Opinion For Eli Lilly's Indication Extension For Emgality To Add Prevention Of Attacks In Adults With Episodic Cluster Headache
69941f7e-c75c-4b3c-bc7b-2327b70cb80b,2020-02-28T08:00:00.000+08:00,4,"Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit"
8ea48a59-08ac-484f-a845-4b3fa0454216,2020-02-28T08:00:00.000+08:00,5,"Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up"
69000353-5503-4838-831c-009d7a96652f,2020-02-27T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy"
cbb50e04-124d-4999-952b-c1f81aa0fd49,2020-02-27T08:00:00.000+08:00,5,FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
76451737-b478-49b3-977c-7a797926078d,2020-02-27T08:00:00.000+08:00,3,Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
8924a1cb-4843-413a-902b-6085285d7238,2020-02-27T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy"
05f1a52b-ac2f-455a-a05d-9f4da3102f48,2020-02-27T08:00:00.000+08:00,5,FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
90f518b3-8ad5-48b8-95fd-1b887af6278d,2020-02-27T08:00:00.000+08:00,2,Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
ef5ef71c-6d4d-4439-bd26-f884b77ee70b,2020-02-26T08:00:00.000+08:00,1,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates"
2e3b8ab6-ea82-4c6a-b926-089ac72584e4,2020-02-26T08:00:00.000+08:00,3,FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line ...
9a0650cf-c471-4245-ba0f-6323840f37f1,2020-02-26T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates"
30eaf215-53e7-415e-8584-42b7d85d308c,2020-02-26T08:00:00.000+08:00,5,FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line ...
12f21b34-fcb0-4d89-8fbb-c786b6b608b5,2020-02-24T08:00:00.000+08:00,5,"Eli Lilly Earlier Announced It Has Received FDA Approval For Trulicity, The First And Only Type 2 Diabetes Medicine Approved To Reduce Cardiovascular Events In Adults With And Without Established Cardiovascular Disease"
67a9e64f-233e-40df-9440-c17f8be4dc97,2020-02-24T08:00:00.000+08:00,4,Weekly Trades With Yields Up To 165%
236a698b-c8c5-473a-88d9-06bede9af103,2020-02-24T08:00:00.000+08:00,3,"Eli Lilly Earlier Announced It Has Received FDA Approval For Trulicity, The First And Only Type 2 Diabetes Medicine Approved To Reduce Cardiovascular Events In Adults With And Without Established Cardiovascular Disease"
ef6d4ead-8b81-49ca-aae8-651cccd4c058,2020-02-24T08:00:00.000+08:00,4,Weekly Trades With Yields Up To 165%
1c55a037-b06d-4edd-b8b3-d4dcaf3390cd,2020-02-23T08:00:00.000+08:00,2,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
7d4e16aa-4ba4-4ab7-8369-f09becd96f0f,2020-02-23T08:00:00.000+08:00,3,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
00cd927c-06c1-4128-a652-667da00126da,2020-02-21T08:00:00.000+08:00,5,Trulicity® (dulaglutide) is the first and only type — diabetes medicine approved to reduce ...
db718531-8fbe-4ac8-9d9b-06800a8c3d24,2020-02-21T08:00:00.000+08:00,2,Mairs and Power: Top 4th-Quarter Trades
93b58e5a-e6a9-4abb-a4eb-a9ca7f6cc689,2020-02-21T08:00:00.000+08:00,4,Lilly To Participate in SVB Leerink Global Healthcare Conference
6c2d1d8e-70ab-4622-a4f2-da1023e34210,2020-02-21T08:00:00.000+08:00,4,Lilly to Participate in Cowen Health Care Conference
ff20b6a7-f324-46f2-af59-2a04e5959975,2020-02-21T08:00:00.000+08:00,4,Trulicity® (dulaglutide) is the first and only type — diabetes medicine approved to reduce ...
31159cfd-a9cc-4beb-abf2-d16d870e4eb7,2020-02-21T08:00:00.000+08:00,3,Mairs and Power: Top 4th-Quarter Trades
764af556-bed6-46d4-a593-a79aa10afd7b,2020-02-21T08:00:00.000+08:00,4,Lilly To Participate in SVB Leerink Global Healthcare Conference
d470db35-3ba0-483d-981a-7d7844c5e429,2020-02-21T08:00:00.000+08:00,2,Lilly to Participate in Cowen Health Care Conference
9477818f-d394-4987-8842-95850a06c027,2020-02-20T08:00:00.000+08:00,1,"Watching Sanofi Shares As Hearing Co., Eli Lilly Will Face Claims Of Violation Of RICO Act Related To Pricing Of Insulin"
fe9915e2-5ce0-4733-9173-c988411a7704,2020-02-20T08:00:00.000+08:00,2,"North Point Portfolio Managers Corp Buys Church & Dwight Co Inc, Gildan Activewear Inc, Eli ..."
4529d18f-6116-420a-b102-57a68702089a,2020-02-20T08:00:00.000+08:00,3,"Watching Sanofi Shares As Hearing Co., Eli Lilly Will Face Claims Of Violation Of RICO Act Related To Pricing Of Insulin"
afbe468d-07ba-4fdd-8be4-d654f374b29f,2020-02-20T08:00:00.000+08:00,3,"North Point Portfolio Managers Corp Buys Church & Dwight Co Inc, Gildan Activewear Inc, Eli ..."
f6903d55-261c-4b1c-a27d-80731c230502,2020-02-17T08:00:00.000+08:00,4,"Mirova Buys First Solar Inc, Air Products & Chemicals Inc, Waste Management Inc, Sells ..."
04fc3a9b-cacb-4bda-9b99-4cc332ed07b2,2020-02-17T08:00:00.000+08:00,5,"Woodley Farra Manion Portfolio Management Inc Buys Comcast Corp, JPMorgan Chase, iShares Core ..."
3abe4f53-27ca-4e04-808d-c57c911ba3b5,2020-02-17T08:00:00.000+08:00,4,"Reynders McVeigh Capital Management, LLC Buys Becton, Dickinson and Co, Envista Holdings Corp, ..."
6f6388b1-5dea-4a51-b05b-d929b93392fa,2020-02-17T08:00:00.000+08:00,2,"Mirova Buys First Solar Inc, Air Products & Chemicals Inc, Waste Management Inc, Sells ..."
3b44129f-2fd1-415d-9051-e3b884724fce,2020-02-17T08:00:00.000+08:00,3,"Woodley Farra Manion Portfolio Management Inc Buys Comcast Corp, JPMorgan Chase, iShares Core ..."
69520eb2-875f-4729-b64b-b90520135b35,2020-02-17T08:00:00.000+08:00,4,"Reynders McVeigh Capital Management, LLC Buys Becton, Dickinson and Co, Envista Holdings Corp, ..."
61bb1f8a-a513-465b-893e-a5d7b856aa8b,2020-02-16T08:00:00.000+08:00,1,Healthcare (Top 30 Weights) Earnings Estimates And Revisions
e627e414-3b6f-4c0d-8a5b-a78d36941c48,2020-02-16T08:00:00.000+08:00,2,Healthcare (Top 30 Weights) Earnings Estimates And Revisions
a47c40ce-dabd-4ab3-9273-8a7fda37b3ff,2020-02-14T08:00:00.000+08:00,3,"Fayez Sarofim & Co Buys Progressive Corp, Booking Holdings Inc, Blackstone Group Inc, Sells ..."
2da09530-e9a2-4091-922c-2319c6927a7e,2020-02-14T08:00:00.000+08:00,3,"Buckingham Capital Management, Inc. Buys iShares Short Maturity Bond, TJX Inc, Bristol-Myers ..."
bb2c61b3-3da4-43f1-847f-294731ea27c0,2020-02-14T08:00:00.000+08:00,1,"Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails"
03ea1f8d-9ef1-45c6-be29-97607f9c3725,2020-02-14T08:00:00.000+08:00,3,Stocks Stay Resilient Amid New Coronavirus Cases
301f8af5-77ca-4208-bad7-a05000246533,2020-02-14T08:00:00.000+08:00,2,"Fayez Sarofim & Co Buys Progressive Corp, Booking Holdings Inc, Blackstone Group Inc, Sells ..."
673bc40d-f3a4-42cc-9bcf-c86701a162d6,2020-02-14T08:00:00.000+08:00,3,"Buckingham Capital Management, Inc. Buys iShares Short Maturity Bond, TJX Inc, Bristol-Myers ..."
ce6010fc-64b3-41b0-b908-91ab9bb37758,2020-02-14T08:00:00.000+08:00,1,"Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails"
4cd40fad-b1bd-4a4e-9dd1-188f9a5ecc6a,2020-02-14T08:00:00.000+08:00,3,Stocks Stay Resilient Amid New Coronavirus Cases
3ff7f914-8f81-409a-88ad-2eab4600cba5,2020-02-13T08:00:00.000+08:00,4,"Greenwood Capital Associates Llc Buys iShares Core MSCI Emerging Markets, Vanguard ..."
54d11e22-e5b9-4d75-a597-8e916bf389f6,2020-02-13T08:00:00.000+08:00,4,"Leaner, More Agile Teva Has Brighter Days Ahead"
a27247e4-36e7-40ee-890e-6e11e3b5dbd6,2020-02-13T08:00:00.000+08:00,4,"Leaner, More Agile Teva Sees Brighter Days Ahead"
51c8e1a3-636c-4e4d-93c0-615aa5ebc748,2020-02-13T08:00:00.000+08:00,3,Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales
9c40d997-5148-4d15-97d4-4f628cf9231e,2020-02-13T08:00:00.000+08:00,5,"Hudson Canyon Investment Counselors Llc Buys The Walt Disney Co, Zscaler Inc, Incyte Corp, ..."
aa868765-ea74-4d2a-ac7a-d2831f9ec807,2020-02-13T08:00:00.000+08:00,4,"Greenwood Capital Associates Llc Buys iShares Core MSCI Emerging Markets, Vanguard ..."
d69515f3-f34a-4c92-bab2-c00618e316e8,2020-02-13T08:00:00.000+08:00,4,"Leaner, More Agile Teva Has Brighter Days Ahead"
c39d60c0-1bbc-4c17-a99e-b4605949c16a,2020-02-13T08:00:00.000+08:00,4,"Leaner, More Agile Teva Sees Brighter Days Ahead"
80905dd5-9b85-475e-982a-ab7b45024179,2020-02-13T08:00:00.000+08:00,3,Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales
1cd61483-9bf9-4298-825f-1e9facc21d3f,2020-02-13T08:00:00.000+08:00,5,"Hudson Canyon Investment Counselors Llc Buys The Walt Disney Co, Zscaler Inc, Incyte Corp, ..."
4ee81fd0-5222-4bba-8103-0e9bf27d8e00,2020-02-12T08:00:00.000+08:00,5,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data"
1fc3ef8e-4d2a-4857-9157-81c6ed033ec9,2020-02-12T08:00:00.000+08:00,4,Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatitis
6b47b662-3640-4e65-a9f2-c3db43c552cf,2020-02-12T08:00:00.000+08:00,2,"Halbert, Hargrove Buys iShares ESG USD Corporate Bond ETF, Bristol-Myers Squibb Company, ..."
3e3087dd-7645-4528-b4e4-3b5f1a49c8d1,2020-02-12T08:00:00.000+08:00,3,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data"
c8572f28-32e0-4240-9823-bd33cb4c6ff7,2020-02-12T08:00:00.000+08:00,4,Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatitis
ebe73347-8b0b-44f6-a0af-9159e0a5f5cf,2020-02-12T08:00:00.000+08:00,1,"Halbert, Hargrove Buys iShares ESG USD Corporate Bond ETF, Bristol-Myers Squibb Company, ..."
8d6b8d49-4575-4210-a004-e1363a40533a,2020-02-11T08:00:00.000+08:00,2,Citizens & Northern Corp Buys iShares J.P. ...
ed7d5fd4-ff75-4d95-bd47-6605d432be7b,2020-02-11T08:00:00.000+08:00,3,"Ci Investments Inc. Buys Berry Global Group Inc, DuPont de Nemours Inc, iShares Core MSCI EAFE ..."
31f9e78d-101f-4749-aec7-2ccd71437961,2020-02-11T08:00:00.000+08:00,1,Lilly Reports Disappointing Data on Alzheimer's Candidate
5359462e-2fbc-4650-8865-b8b933eaa979,2020-02-11T08:00:00.000+08:00,3,Citizens & Northern Corp Buys iShares J.P. ...
34c15413-48e9-44dd-af71-41a528ce90b9,2020-02-11T08:00:00.000+08:00,2,"Ci Investments Inc. Buys Berry Global Group Inc, DuPont de Nemours Inc, iShares Core MSCI EAFE ..."
8c202647-5edb-4bc7-b077-c76a5fa9e35f,2020-02-11T08:00:00.000+08:00,1,Lilly Reports Disappointing Data on Alzheimer's Candidate
4473af1d-7445-4bf9-bef8-619fb5d07772,2020-02-10T08:00:00.000+08:00,2,Eli Lilly Suffers Setback As Alzheimer's Study Fails To Meet Primary Endpoint
d5defcce-3b3c-47bf-a6f0-959c2825c0dd,2020-02-10T08:00:00.000+08:00,3,12 Healthcare Stocks Moving In Monday's Pre-Market Session
ae493cd1-f9a1-4589-8a08-49f33d1ad2f4,2020-02-10T08:00:00.000+08:00,2,30 Stocks Moving in Monday's Pre-Market Session
d3ed9da7-eaf3-475d-bcee-ed6b23ea608d,2020-02-10T08:00:00.000+08:00,1,Eli Lilly And Co shares are trading lower after the company reported the results for Solanezumba from the Alzheimer's study did not meet its primary endpoint.
08fb3531-2230-4bc6-80b3-2e5ad4806a75,2020-02-10T08:00:00.000+08:00,2,Lilly Announces Alzheimer's Study Did Not Meet Primary Endpoint
197abebb-d5e8-4dd6-ba49-0f007684900a,2020-02-10T08:00:00.000+08:00,1,"Lcnb Corp Buys Eli Lilly and Co, Bank of America Corp, Carnival Corp, Sells iShares Core MSCI ..."
8eff5284-30cb-45c5-95ce-367ae1ce1643,2020-02-10T08:00:00.000+08:00,3,"Compton Capital Management Inc Buys Bristol-Myers Squibb Company, Eli Lilly and Co, Truist ..."
696f7497-9e52-47e2-99d0-20435f22de5b,2020-02-10T08:00:00.000+08:00,4,Spiros Segalas Comments on Eli Lilly
1c928933-c361-4b24-bdf0-32de7f04f8b3,2020-02-10T08:00:00.000+08:00,4,Spiros Segalas' Harbor Capital Appreciation Fund 4th-Quarter Commentary
65ea892c-f3dd-41c1-b0d6-8d55f358c5a3,2020-02-10T08:00:00.000+08:00,2,"Thinking about buying stock in L Brands, Eli Lilly, Netflix, Tesla, or Xylem?"
9494cb49-b2df-418e-875f-d07821112870,2020-02-10T08:00:00.000+08:00,4,Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network ...
9ad3e99b-2693-4bc9-9319-b9a76145644e,2020-02-10T08:00:00.000+08:00,1,Eli Lilly Suffers Setback As Alzheimer's Study Fails To Meet Primary Endpoint
9e96d4c6-478c-4f40-a52c-9b59f8a7face,2020-02-10T08:00:00.000+08:00,3,12 Healthcare Stocks Moving In Monday's Pre-Market Session
3240c301-fa3c-4593-a86e-ac6589153325,2020-02-10T08:00:00.000+08:00,3,30 Stocks Moving in Monday's Pre-Market Session
cb689a9c-d483-4a59-b588-9308a78bb6d5,2020-02-10T08:00:00.000+08:00,1,Eli Lilly And Co shares are trading lower after the company reported the results for Solanezumba from the Alzheimer's study did not meet its primary endpoint.
09fa46d4-352d-45d0-9d3f-14f45045f7a2,2020-02-10T08:00:00.000+08:00,2,Lilly Announces Alzheimer's Study Did Not Meet Primary Endpoint
bf28092a-1c1b-450b-a000-c0c601d396ad,2020-02-10T08:00:00.000+08:00,3,"Lcnb Corp Buys Eli Lilly and Co, Bank of America Corp, Carnival Corp, Sells iShares Core MSCI ..."
5b870725-2390-4d2e-bb19-b19e81c22de8,2020-02-10T08:00:00.000+08:00,4,"Compton Capital Management Inc Buys Bristol-Myers Squibb Company, Eli Lilly and Co, Truist ..."
a107ac14-fce3-4709-9d1f-e6401f61811d,2020-02-10T08:00:00.000+08:00,3,Spiros Segalas Comments on Eli Lilly
4b6ab131-7f2f-4bac-b64f-8cc0972204e3,2020-02-10T08:00:00.000+08:00,2,Spiros Segalas' Harbor Capital Appreciation Fund 4th-Quarter Commentary
c70b328c-da32-4943-b342-69c8c63ef6fe,2020-02-10T08:00:00.000+08:00,3,"Thinking about buying stock in L Brands, Eli Lilly, Netflix, Tesla, or Xylem?"
883ef15a-e3b1-46ef-899f-d79cad9d25e6,2020-02-10T08:00:00.000+08:00,4,Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network ...
f0d897b8-5f7a-4815-8f09-2852e5f06983,2020-02-07T08:00:00.000+08:00,1,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns"
947705b9-a0d4-454f-8fc8-8b828615b37d,2020-02-07T08:00:00.000+08:00,3,"Smith, Moore & Co. Buys Vanguard Dividend Appreciation ETF, MPLX LP, Becton, Dickinson and ..."
ad2236ae-9506-4fe6-8af4-fca089eb9983,2020-02-07T08:00:00.000+08:00,2,Med Stock Dexcom In Buy Range Ahead Of Earnings
aacaa63d-6cff-4c0f-8edd-058aab6995db,2020-02-07T08:00:00.000+08:00,3,Lilly to Participate in Guggenheim Healthcare Talks Idea Forum
d74f5c1b-47bd-4b43-bbf8-7da94be94906,2020-02-07T08:00:00.000+08:00,3,"Jennison Associates Llc Buys Coupa Software Inc, Boston Scientific Corp, Eli Lilly and Co, ..."
2da0fed1-4522-4097-8ed3-0e4ad42d4df6,2020-02-07T08:00:00.000+08:00,1,Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
40d0a062-6668-4e83-87f6-0626cbc48e6c,2020-02-07T08:00:00.000+08:00,1,Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
b35d8a23-02d5-4224-b08d-922f3ccf3abd,2020-02-07T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns"
d95ed3da-5e94-4efe-9df6-aab8d1c0af62,2020-02-07T08:00:00.000+08:00,3,"Smith, Moore & Co. Buys Vanguard Dividend Appreciation ETF, MPLX LP, Becton, Dickinson and ..."
5e94f32d-81b6-452e-92f9-d1d13ac71bc1,2020-02-07T08:00:00.000+08:00,4,Med Stock Dexcom In Buy Range Ahead Of Earnings
af3ff905-9f7d-4fac-83d3-c0a60a54600e,2020-02-07T08:00:00.000+08:00,3,Lilly to Participate in Guggenheim Healthcare Talks Idea Forum
0f554a99-9637-42b5-8ff6-49204208ee76,2020-02-07T08:00:00.000+08:00,4,"Jennison Associates Llc Buys Coupa Software Inc, Boston Scientific Corp, Eli Lilly and Co, ..."
3ea73cac-5e01-463e-baaa-dfe7f409bbc8,2020-02-07T08:00:00.000+08:00,2,Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
9c0dddf8-8f2e-49d1-9d8b-4af27628e43f,2020-02-07T08:00:00.000+08:00,3,Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
84457a66-06db-42ad-bc21-c44a4e5a08b7,2020-02-06T08:00:00.000+08:00,4,"UPDATE: Mizuho Initiates Coverage On Eli Lilly with Neutral Rating, Announces $148 Price Target Notes 'we expect Verzenio's impact to increase following recent positive data releases and see the Loxo acquisition providing additional mid-term growth drivers.'"
1cf390ff-b2a8-4fbb-bd07-91481d6f59f3,2020-02-06T08:00:00.000+08:00,1,Stocks That Hit 52-Week Highs On Thursday
45c2b34a-fc88-4f5b-ae5e-bd3350c277d9,2020-02-06T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs"
e304b3e5-0a60-4e19-81f5-54bd1f870ce3,2020-02-06T08:00:00.000+08:00,2,"Mizuho Initiates Coverage On Eli Lilly with Neutral Rating, Announces $148 Price Target"
bf57b5bf-6617-4082-a7d3-66324179d793,2020-02-06T08:00:00.000+08:00,4,Paragon Capital Management Ltd Buys Vanguard Global ex-U.S. ...
d703cc89-14e8-4c20-9190-ccf5eb7bc0a1,2020-02-06T08:00:00.000+08:00,3,"Thinking about trading options or stock in Apple, Eli Lilly, Microchip Technology, Tesla, or ..."
c469aab8-bda5-4fe4-af7e-b6dad44ed682,2020-02-06T08:00:00.000+08:00,4,"UPDATE: Mizuho Initiates Coverage On Eli Lilly with Neutral Rating, Announces $148 Price Target Notes 'we expect Verzenio's impact to increase following recent positive data releases and see the Loxo acquisition providing additional mid-term growth drivers.'"
8c7850b5-6897-423b-81e5-1587a5f0188a,2020-02-06T08:00:00.000+08:00,1,Stocks That Hit 52-Week Highs On Thursday
76821bb0-26b9-4848-a937-bce3049f29ca,2020-02-06T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs"
850f07c9-0e37-49b8-abb4-b00db2d97c5e,2020-02-06T08:00:00.000+08:00,3,"Mizuho Initiates Coverage On Eli Lilly with Neutral Rating, Announces $148 Price Target"
141ac2af-838a-40f6-8e98-38552b21c2bd,2020-02-06T08:00:00.000+08:00,4,Paragon Capital Management Ltd Buys Vanguard Global ex-U.S. ...
e91c886b-6d1e-44e4-9ee7-fc6c440cb2eb,2020-02-06T08:00:00.000+08:00,1,"Thinking about trading options or stock in Apple, Eli Lilly, Microchip Technology, Tesla, or ..."
c8b8b2c8-485f-4ff2-9019-9445c646a6b6,2020-02-05T08:00:00.000+08:00,4,"Mizuho Initiates AbbVie, Biohaven With Buy Ratings, Eli Lilly, Alkermes With Neutral Ratings"
c751b609-b2ec-4c83-a696-b39ac492f4a8,2020-02-05T08:00:00.000+08:00,4,Stocks That Hit 52-Week Highs On Wednesday
cd47801e-acf5-444a-a9a2-6bfb26650a25,2020-02-05T08:00:00.000+08:00,2,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.
d5f192a0-7aa3-4b63-8395-8d5a6d097593,2020-02-05T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data"
248d6303-1b93-4412-ac9e-e99106fa5e24,2020-02-05T08:00:00.000+08:00,4,Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
0d5696f5-f9e1-4e2b-ab55-ec25184c6b9f,2020-02-05T08:00:00.000+08:00,3,"Mizuho Initiates AbbVie, Biohaven With Buy Ratings, Eli Lilly, Alkermes With Neutral Ratings"
db97365a-756c-4ad3-bdec-1dc851b2256c,2020-02-05T08:00:00.000+08:00,4,Stocks That Hit 52-Week Highs On Wednesday
d0446b6c-a5d8-4a4b-a42c-8d84bdd8b60e,2020-02-05T08:00:00.000+08:00,2,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.
dbdd757a-90e9-4dd7-b5fc-970a692ce768,2020-02-05T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data"
345ff803-36d6-4be2-b368-c4693d999ac5,2020-02-05T08:00:00.000+08:00,4,Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
91d82176-a0bc-4304-aa39-980b3ba2aaa6,2020-02-04T08:00:00.000+08:00,5,A Pick and Shovel Strategy to Avoid Competition and Speculation
9728b1bc-3621-4338-8169-c4e86c99f30d,2020-02-04T08:00:00.000+08:00,4,Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal
824d9f4f-9bbb-4b62-b5c5-6d3834604d89,2020-02-04T08:00:00.000+08:00,3,Foster Dykema Cabot & Co Inc Buys iShares Core U.S. ...
4fb0cb7f-1940-4811-86e4-3f77f5837c88,2020-02-04T08:00:00.000+08:00,5,"Analysts Forecast Huge Upsides for Aimmune, Biohaven"
80e5b4ab-db42-4dd0-9c2e-2c2e3a870a02,2020-02-04T08:00:00.000+08:00,4,A Pick and Shovel Strategy to Avoid Competition and Speculation
6c81250a-5a82-42c6-9e73-d0849256bebd,2020-02-04T08:00:00.000+08:00,4,Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal
8bedc393-e5fd-4df6-8dfe-5db9a88ec72d,2020-02-04T08:00:00.000+08:00,2,Foster Dykema Cabot & Co Inc Buys iShares Core U.S. ...
ad05bf84-fa61-467b-b584-8171603e0992,2020-02-04T08:00:00.000+08:00,4,"Analysts Forecast Huge Upsides for Aimmune, Biohaven"
c141f136-0150-4e2a-9672-711d8167b237,2020-02-03T08:00:00.000+08:00,3,3 Dividend-Paying Stocks for Investors to Buy to Fight Off Market Uncertainty
a1aff3bb-077c-4f8b-87de-4c3b8563cc4c,2020-02-03T08:00:00.000+08:00,4,"Miller Investment Management, LP Buys Comcast Corp, Tortoise Pipeline & Energy Fund Inc, ..."
1d574caf-42c6-4f66-bc0c-fcde7ed710da,2020-02-03T08:00:00.000+08:00,1,"United Bank Buys iShares Global Infrastructure ETF, Southern Co, Truist Financial Corp, Sells ..."
06990197-54ee-4b40-bba6-ed847b101619,2020-02-03T08:00:00.000+08:00,2,Amarillo National Bank Buys iShares Core U.S. ...
9f41045b-b7a6-4c62-801c-f0ef3fe2642f,2020-02-03T08:00:00.000+08:00,4,3 Dividend-Paying Stocks for Investors to Buy to Fight Off Market Uncertainty
002d19ee-7dc9-420b-9edc-5083594d2c98,2020-02-03T08:00:00.000+08:00,3,"Miller Investment Management, LP Buys Comcast Corp, Tortoise Pipeline & Energy Fund Inc, ..."
f836d69d-740b-4d97-8687-8b74fb7ebd37,2020-02-03T08:00:00.000+08:00,4,"United Bank Buys iShares Global Infrastructure ETF, Southern Co, Truist Financial Corp, Sells ..."
da18e9fe-29e7-41a6-a50b-86f67b565ac4,2020-02-03T08:00:00.000+08:00,2,Amarillo National Bank Buys iShares Core U.S. ...
6b390fba-e20c-45fc-915b-7e14038e6900,2020-02-02T08:00:00.000+08:00,4,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus"
17946c5a-cefb-44ff-a5c0-481182ab8ec9,2020-02-02T08:00:00.000+08:00,3,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus"
309a925f-2fc0-429e-b953-4fa3dc181d2f,2020-01-31T08:00:00.000+08:00,5,Lilly's Announces That Its REYVOW C-V Is The First And Only Medicine In a New Class Of Acute Treatment For Migraine
d85f96ee-ff09-4bff-a0e4-75ec7e838aee,2020-01-31T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO"
3580198e-e30a-4a39-ad3f-952fade44542,2020-01-31T08:00:00.000+08:00,5,Eli Lilly Reports Its Liumjev Receives Positive CHMP Opinion
62720f96-d078-43ff-8f69-9c300bd93e4d,2020-01-31T08:00:00.000+08:00,4,"Opus Capital Group, LLC Buys iShares Short Treasury Bond ETF, Truist Financial Corp, SPDR ..."
9b259a4c-3e8b-4de9-9a26-c8d110a0ca63,2020-01-31T08:00:00.000+08:00,5,"Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute ..."
5d69a73d-3cfc-4972-9e8a-e9004a9f5551,2020-01-31T08:00:00.000+08:00,3,Bayer Seeks FDA Approval for New Formulation of Nifurtimox
2e8d118b-3340-435c-bfe6-952ceba0cc4a,2020-01-31T08:00:00.000+08:00,5,Lilly's Announces That Its REYVOW C-V Is The First And Only Medicine In a New Class Of Acute Treatment For Migraine
35354f9f-2382-46bc-99b5-69c1d784edbf,2020-01-31T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO"
7545abe8-d32e-49c6-b2f4-c52bb3f4cca0,2020-01-31T08:00:00.000+08:00,5,Eli Lilly Reports Its Liumjev Receives Positive CHMP Opinion
dc7e1419-bbec-4ba7-9b91-3a73db899eff,2020-01-31T08:00:00.000+08:00,2,"Opus Capital Group, LLC Buys iShares Short Treasury Bond ETF, Truist Financial Corp, SPDR ..."
0403b250-ce00-467b-985e-e1e0ceff197b,2020-01-31T08:00:00.000+08:00,3,"Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute ..."
128466a6-30f4-48ef-9fe1-fedc57364e55,2020-01-31T08:00:00.000+08:00,4,Bayer Seeks FDA Approval for New Formulation of Nifurtimox
63f5b569-b506-4b4e-978d-7daf29de5e19,2020-01-30T08:00:00.000+08:00,4,Eli Lilly shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.
a2db78b9-e3c3-40f6-9162-3f112a16007e,2020-01-30T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance"
ac5ead59-1cec-4798-a857-ff4a62dfca2e,2020-01-30T08:00:00.000+08:00,2,"A Peek Into The Markets: US Stock Futures Tumble Ahead Of Earnings, GDP Data"
0c87fe30-c163-4cfe-8536-5f2b58ca59cd,2020-01-30T08:00:00.000+08:00,3,Eli Lilly Reaffirms FY20 Adj. EPS Guidance $6.70-$6.80
0efce7b4-0c1d-44b8-9483-c483629c5306,2020-01-30T08:00:00.000+08:00,4,"Eli Lilly Q4 Adj. EPS $1.73 Beats $1.51 Estimate, Sales $6.114B Beat $5.9B Estimate"
3620c428-e393-4d67-bb84-b866bf3364ab,2020-01-30T08:00:00.000+08:00,5,Eli Lilly Reports Top-Line Results From BREEZE-AD5 Phase 3 Study Of Oral Selective JAK Inhibitor In Patients With Moderate To Severe Atopic Dermatitis
f7a4f102-cf98-4a60-a918-8050fb5dece9,2020-01-30T08:00:00.000+08:00,2,"Earnings Scheduled For January 30, 2020"
30bdb4ad-725f-4138-9489-f3656b3c5799,2020-01-30T08:00:00.000+08:00,3,"14 Stocks To Watch For January 30, 2020"
24ebbf45-cbf8-4ad0-aa1a-5f8c821034a6,2020-01-30T08:00:00.000+08:00,3,"Thinking about buying stock in Applied Materials, General Electric, Eli Lilly, Qorvo, or Tesla?"
845e3519-e10b-4441-b530-77a9f7b32182,2020-01-30T08:00:00.000+08:00,4,Lilly's NDA for Selpercatinib Gets FDA's Priority Review
82e5f47f-0da3-45fe-9c53-eac847f8b5c1,2020-01-30T08:00:00.000+08:00,5,"Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up"
2e1551ea-b27b-40a1-8083-e4be8e9b3acf,2020-01-30T08:00:00.000+08:00,4,Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase ...
80bdae87-0f4b-4722-b6f6-27f354bb8f9b,2020-01-30T08:00:00.000+08:00,2,"Tesla soars on upbeat earnings, Facebook struggles with expenses"
82963082-d39a-4442-9a9f-ec55ca2e950e,2020-01-30T08:00:00.000+08:00,5,Eli Lilly shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.
66cb9cff-a906-4fba-960f-14ed57bc0d69,2020-01-30T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance"
5fec56f9-0888-4d47-961e-49adb8eaa1bd,2020-01-30T08:00:00.000+08:00,1,"A Peek Into The Markets: US Stock Futures Tumble Ahead Of Earnings, GDP Data"
2ac9f4e3-4c37-4639-9622-1d04a96d7e85,2020-01-30T08:00:00.000+08:00,4,Eli Lilly Reaffirms FY20 Adj. EPS Guidance $6.70-$6.80
8097f6cb-3f9c-4fc9-979e-7817c21517e2,2020-01-30T08:00:00.000+08:00,5,"Eli Lilly Q4 Adj. EPS $1.73 Beats $1.51 Estimate, Sales $6.114B Beat $5.9B Estimate"
0769ff10-0894-4c64-871f-f4b055b61f7c,2020-01-30T08:00:00.000+08:00,3,Eli Lilly Reports Top-Line Results From BREEZE-AD5 Phase 3 Study Of Oral Selective JAK Inhibitor In Patients With Moderate To Severe Atopic Dermatitis
f50c919b-4063-44a8-b6c6-9681f4c6c237,2020-01-30T08:00:00.000+08:00,2,"Earnings Scheduled For January 30, 2020"
99b7941a-a227-44b7-8b37-3e35e950fbd1,2020-01-30T08:00:00.000+08:00,1,"14 Stocks To Watch For January 30, 2020"
ece54560-4a7f-49fd-a8a8-6ed2fcaa0f16,2020-01-30T08:00:00.000+08:00,4,"Thinking about buying stock in Applied Materials, General Electric, Eli Lilly, Qorvo, or Tesla?"
807025f7-93c7-452a-b237-05a1af737dd2,2020-01-30T08:00:00.000+08:00,5,Lilly's NDA for Selpercatinib Gets FDA's Priority Review
cbc7e049-01eb-41d4-a82b-f129c81d34da,2020-01-30T08:00:00.000+08:00,3,"Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up"
1616dae9-5526-4f51-bf08-41496c999eb7,2020-01-30T08:00:00.000+08:00,5,Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase ...
7549c67b-48bc-4043-a7de-ce805671736b,2020-01-30T08:00:00.000+08:00,1,"Tesla soars on upbeat earnings, Facebook struggles with expenses"
fcf43df9-2755-42d8-ae88-0acdf6d2b6ac,2020-01-29T08:00:00.000+08:00,2,Lilly Receives FDA Priority Review For Selpercatinib New Drug Application
364933fe-1ef8-473d-9a64-5fafe9fca71e,2020-01-29T08:00:00.000+08:00,3,5 Top Non-Tech Earnings Charts
ac4e32c8-04e9-4bc3-bf1b-4dd5d1ea2a0f,2020-01-29T08:00:00.000+08:00,3,"Amazon Earnings, Q4 GDP Report Lead Investing Action Plan"
4b45228d-d54a-46ae-8209-cce3e0177f22,2020-01-29T08:00:00.000+08:00,4,Lilly and Incyte Announce Top-Line Results from Phase ' Study (BREEZE-AD4) of Oral Selective ...
77c3054a-5d19-4f62-910f-acf473be8be2,2020-01-29T08:00:00.000+08:00,3,Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review
e10b777b-2731-4229-b6e6-8e351ba8e2b5,2020-01-29T08:00:00.000+08:00,2,"Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More"
fd465477-7c91-4fe6-a646-6693cfa74d25,2020-01-29T08:00:00.000+08:00,3,Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
c6681f51-daa4-4dce-8a69-e3bd66bd4c25,2020-01-29T08:00:00.000+08:00,3,Lilly Receives FDA Priority Review For Selpercatinib New Drug Application
7bccec49-e992-4af3-9e68-a72d5b9cc033,2020-01-29T08:00:00.000+08:00,1,5 Top Non-Tech Earnings Charts
0cb6c80a-68f1-44fa-a211-4d8ca781e03c,2020-01-29T08:00:00.000+08:00,1,"Amazon Earnings, Q4 GDP Report Lead Investing Action Plan"
c0e3df03-9278-4120-b50a-781c020ceb8a,2020-01-29T08:00:00.000+08:00,4,Lilly and Incyte Announce Top-Line Results from Phase ' Study (BREEZE-AD4) of Oral Selective ...
8adc8459-36dd-41e8-8c5f-698d788c1dff,2020-01-29T08:00:00.000+08:00,3,Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review
d30ef537-207f-4032-a806-e973743ceb76,2020-01-29T08:00:00.000+08:00,3,"Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More"
4e6aeeea-6243-48f4-b966-a0c3d6644949,2020-01-29T08:00:00.000+08:00,5,Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
ed07dabe-7cf9-4b7f-adef-3f124b763544,2020-01-28T08:00:00.000+08:00,5,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics"
25c3508f-26ab-4ab4-abf8-c349c2c18d80,2020-01-28T08:00:00.000+08:00,4,AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study
02e972c0-52c8-41e5-bd29-e038db4086c1,2020-01-28T08:00:00.000+08:00,5,Lilly's Olumiant Meets Primary Goal in Dermatitis Study
83d97ae5-bafa-42a6-a33d-44a37fe83c02,2020-01-28T08:00:00.000+08:00,3,"Lilly plans donation of —……,……… insulin KwikPens over next three years to support ..."
2b8563fa-159e-4563-b1e3-e26d6aa77d6d,2020-01-28T08:00:00.000+08:00,1,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics"
4419e8dc-3f06-42bb-8165-fffddaade964,2020-01-28T08:00:00.000+08:00,4,AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study
24487004-380e-42da-b9b4-c1ccb70b0c49,2020-01-28T08:00:00.000+08:00,5,Lilly's Olumiant Meets Primary Goal in Dermatitis Study
5fd7a65f-45e1-49a5-8122-3f33879cabf6,2020-01-28T08:00:00.000+08:00,5,"Lilly plans donation of —……,……… insulin KwikPens over next three years to support ..."
74f2cc79-1e4f-4157-b5cc-e662835cd804,2020-01-27T08:00:00.000+08:00,5,FDA Approves Lilly's Trijardy
15eaa3c6-0b7f-41fa-a7d4-cfb03ba908ce,2020-01-27T08:00:00.000+08:00,5,Eli Lilly and Incyte's Phase 3 BREEZE-AD4 Study Met its Primary Endpoint
97e4f11c-7092-4976-a774-f04e93969e34,2020-01-27T08:00:00.000+08:00,5,US FDA approves only triple-combination tablet with Jardiance® for adults with type — diabetes
00492fde-9a72-42c5-b2c0-4427c7368c2d,2020-01-27T08:00:00.000+08:00,3,"Bremer Bank National Association Buys Bristol-Myers Squibb Company, Eli Lilly and Co, Marsh ..."
a2dbed0f-5ed9-4790-8798-57c8bc6179a4,2020-01-27T08:00:00.000+08:00,2,"British Airways Pensions Investment Management Ltd Buys Bristol-Myers Squibb Company, Zimmer ..."
1c18d3d0-15cb-4441-a7fa-e86812a9670e,2020-01-27T08:00:00.000+08:00,4,Eli Lilly Trading Near Top Of Buy Zone With Earnings On Tap
51394c57-d405-4506-9061-c8687e985ec2,2020-01-27T08:00:00.000+08:00,1,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
99aded02-0a3c-4ee5-acb1-db7894a57170,2020-01-27T08:00:00.000+08:00,4,Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
f956c1af-7ef7-42a8-b667-dc462b40b87e,2020-01-27T08:00:00.000+08:00,4,Lilly and Incyte Announce Top-Line Results from Phase ' Study (BREEZE-AD4) of Oral Selective ...
3ff1ae74-dedb-4ea2-93e9-f1be3d5d9624,2020-01-27T08:00:00.000+08:00,5,FDA Approves Lilly's Trijardy
73dbfeec-d628-44aa-8418-4e972f2e9b57,2020-01-27T08:00:00.000+08:00,5,Eli Lilly and Incyte's Phase 3 BREEZE-AD4 Study Met its Primary Endpoint
e2c70d63-554e-498e-ae99-9de49c35ad72,2020-01-27T08:00:00.000+08:00,5,US FDA approves only triple-combination tablet with Jardiance® for adults with type — diabetes
b0ccaa7d-2faa-4e32-ba90-3340dd866308,2020-01-27T08:00:00.000+08:00,3,"Bremer Bank National Association Buys Bristol-Myers Squibb Company, Eli Lilly and Co, Marsh ..."
484e2880-6dfd-4c70-bfd7-c922b120d6c2,2020-01-27T08:00:00.000+08:00,2,"British Airways Pensions Investment Management Ltd Buys Bristol-Myers Squibb Company, Zimmer ..."
8614fc32-8352-4589-8263-39797e2b386b,2020-01-27T08:00:00.000+08:00,3,Eli Lilly Trading Near Top Of Buy Zone With Earnings On Tap
9b44e564-dc58-45a2-bf4e-06d2233c4fde,2020-01-27T08:00:00.000+08:00,3,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
171a7b65-c182-4b63-850e-7c1e9ea6a00b,2020-01-27T08:00:00.000+08:00,3,Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
6eb902c0-dc1e-49ed-9eaf-b2d36223ae88,2020-01-27T08:00:00.000+08:00,4,Lilly and Incyte Announce Top-Line Results from Phase ' Study (BREEZE-AD4) of Oral Selective ...
e57b97f9-e830-4cec-b79d-c29eee9d0854,2020-01-26T08:00:00.000+08:00,2,"The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes"
20bc94ee-76a2-401a-80cc-51851cb7b738,2020-01-26T08:00:00.000+08:00,2,"The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes"
bfd3fdb5-636c-4d74-ac6d-ebd6fdcbb367,2020-01-24T08:00:00.000+08:00,4,J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children
c78389da-cc0f-4ced-b77c-33df852bc6ca,2020-01-24T08:00:00.000+08:00,3,Anat Hakim to join Lilly as General Counsel
7759074c-fa78-480b-80f2-1dfd70f0b170,2020-01-24T08:00:00.000+08:00,1,"Acima Private Wealth, Llc Buys SPDR Barclays Short Term Corporate Bond ETF, iShares MSCI ..."
a5911646-2f01-44a6-9438-4efa7683815c,2020-01-24T08:00:00.000+08:00,2,J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children
0a2e0303-421d-4d61-a278-fff4d446b47f,2020-01-24T08:00:00.000+08:00,4,Anat Hakim to join Lilly as General Counsel
844ac409-cbfd-4783-bf68-914a6bd69c70,2020-01-24T08:00:00.000+08:00,3,"Acima Private Wealth, Llc Buys SPDR Barclays Short Term Corporate Bond ETF, iShares MSCI ..."
5bcfdd23-a446-4982-8f3b-a6f30287a519,2020-01-23T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment"
56d3bca6-4edf-4b4e-98d3-2b945484000c,2020-01-23T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment"
8217b1aa-577e-46bb-8333-def1fa61fe10,2020-01-22T08:00:00.000+08:00,2,Steven Cohen's Point7— Piles Into Menlo Therapeutics
b17d59f3-1220-4de1-873f-f28c2c35ee4b,2020-01-22T08:00:00.000+08:00,3,"Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP"
865b3771-8b1e-4060-aacc-df7b5cce89a1,2020-01-22T08:00:00.000+08:00,4,Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review
0c64c0a0-4895-406f-bcb5-2a120b53ec4e,2020-01-22T08:00:00.000+08:00,1,Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
f37ce6f0-02cf-4481-b469-f18540f26560,2020-01-22T08:00:00.000+08:00,2,Steven Cohen's Point7— Piles Into Menlo Therapeutics
c11f5ea4-038f-492e-a87d-6af79f3fc19c,2020-01-22T08:00:00.000+08:00,2,"Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP"
35a671ef-b9a0-4aee-aa9e-7f9ac284cfe0,2020-01-22T08:00:00.000+08:00,4,Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review
7cb039c0-ea68-45da-b9f2-19a5c10c0e6a,2020-01-22T08:00:00.000+08:00,3,Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
657ec45d-6a78-47f5-8f34-2f8bf1f9d149,2020-01-21T08:00:00.000+08:00,1,Pharma Company Buybacks: Do They Really Benefit Shareholders?
e1608c41-2457-489b-94b2-8744da392ab2,2020-01-21T08:00:00.000+08:00,4,Governor Cooper Announces over 46… Jobs in Durham as Eli Lilly and Company Selects North ...
9bb2087e-ac07-4e5f-979d-3b5f905f6688,2020-01-21T08:00:00.000+08:00,2,Pharma Company Buybacks: Do They Really Benefit Shareholders?
f593ad71-f59f-4414-8228-04a4be51a8ac,2020-01-21T08:00:00.000+08:00,4,Governor Cooper Announces over 46… Jobs in Durham as Eli Lilly and Company Selects North ...
6976dbba-7dc7-4025-b549-3cd38ef13f05,2020-01-17T08:00:00.000+08:00,3,9 Takeaways From The JPMorgan Healthcare Conference
715b2385-4889-4849-9e5c-abf032f1a93b,2020-01-17T08:00:00.000+08:00,5,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares"
e27b4e9c-3867-4eb3-bc31-46de287eb3a7,2020-01-17T08:00:00.000+08:00,5,Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction
5c5c847c-aeea-44c2-a207-69a0a24e68ef,2020-01-17T08:00:00.000+08:00,2,Castle Could Crumble When IPO Lockup Expires
e75da93d-d4cb-45ed-8ea2-e04ca9d77f82,2020-01-17T08:00:00.000+08:00,3,9 Takeaways From The JPMorgan Healthcare Conference
2cf93779-ac5a-4673-afae-8dbe2b7d0b42,2020-01-17T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares"
ec26c4e5-9696-4660-a151-9af6920c69a8,2020-01-17T08:00:00.000+08:00,5,Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction
f973a88e-85ce-4e97-86b9-50fb036e36d1,2020-01-17T08:00:00.000+08:00,1,Castle Could Crumble When IPO Lockup Expires
c8bc37ab-fae6-440e-98f7-d50eabcea8bd,2020-01-16T08:00:00.000+08:00,2,Stocks That Hit 52-Week Highs On Thursday
1cb1a907-d664-47a6-972e-b88cdd2fdab0,2020-01-16T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics"
5ad8c6b9-8803-4bd1-a09a-7f8ee5415eab,2020-01-16T08:00:00.000+08:00,3,Eli Lilly (LLY) Gains But Lags Market: What You Should Know
55e52d92-dd82-4659-9247-11e6d9f40382,2020-01-16T08:00:00.000+08:00,4,Lilly Confirms Date and Conference Call for Fourth-Quarter —…–9 Financial Results Announcement
931aa300-39ef-4762-b75b-21bd3c95562d,2020-01-16T08:00:00.000+08:00,1,Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA
8a9a2506-2c97-4e3f-95b9-70e50bb4339f,2020-01-16T08:00:00.000+08:00,2,Stocks That Hit 52-Week Highs On Thursday
aa10ab7a-1499-4493-a6a6-65ea8d26ef0b,2020-01-16T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics"
10f04cdd-7f4c-422e-bbc4-42cbb6acd24b,2020-01-16T08:00:00.000+08:00,3,Eli Lilly (LLY) Gains But Lags Market: What You Should Know
7187bccc-290a-446f-913a-01595ac3401e,2020-01-16T08:00:00.000+08:00,4,Lilly Confirms Date and Conference Call for Fourth-Quarter —…–9 Financial Results Announcement
ec8be218-bc65-4e1e-b438-e68d056ef8ce,2020-01-16T08:00:00.000+08:00,1,Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA
a9b00663-2e3a-4361-9d1a-5f2060d0a0d6,2020-01-15T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance"
fec10b8f-68a5-4401-bbb4-750b552aadb3,2020-01-15T08:00:00.000+08:00,3,Which Stocks Join Market For Another New High?
82956529-60bf-4db2-a47f-091f1102a299,2020-01-15T08:00:00.000+08:00,4,Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins
fe172a9d-05fc-479b-962a-777fa5edfc43,2020-01-15T08:00:00.000+08:00,1,"Lilly, Anna Kaiser Launch ''…-Day Thriver Challenge' to Increase Awareness of Daily Stress ..."
8509268f-c257-41b8-85c1-cc050f397b86,2020-01-15T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance"
99706f57-a0da-4c22-ab07-9dd4184ab200,2020-01-15T08:00:00.000+08:00,4,Which Stocks Join Market For Another New High?
d0392793-01b8-4638-9caa-1ddc64fb0fba,2020-01-15T08:00:00.000+08:00,3,Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins
cfd477a9-f20b-4030-9a27-00b1763ac560,2020-01-15T08:00:00.000+08:00,2,"Lilly, Anna Kaiser Launch ''…-Day Thriver Challenge' to Increase Awareness of Daily Stress ..."
7beb5727-9355-4b76-b56a-ec06cd54d1d6,2020-01-14T08:00:00.000+08:00,1,"The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug"
892c0b45-8513-471d-8c7e-ada1ed92885b,2020-01-14T08:00:00.000+08:00,5,"Lilly Announces Insulin Cost-Saving Options; Lower-Priced Versions Of Humalog Junior KwikPen And Humalog Mix75/25 KwikPen To Have 50% Lower List Price Than Branded Versions, Will Be Available By Mid April"
8decebce-a4a2-4277-aa47-b466d8f44ddb,2020-01-14T08:00:00.000+08:00,4,"The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug"
0b13e5f1-962b-4a62-a81d-f1721ff280f1,2020-01-14T08:00:00.000+08:00,5,"Lilly Announces Insulin Cost-Saving Options; Lower-Priced Versions Of Humalog Junior KwikPen And Humalog Mix75/25 KwikPen To Have 50% Lower List Price Than Branded Versions, Will Be Available By Mid April"
4fe2b39d-4a96-48bf-be7c-23fe03a50e7c,2020-01-13T08:00:00.000+08:00,3,Eli Lilly's Phase 3 ORIENT-11 Study of Tyvyt Combined with ALIMTA Met its Primary Endpoint
ef82f50e-2ce4-4fe9-8970-1d2b57f8702d,2020-01-13T08:00:00.000+08:00,2,Glaxo Files Marketing Application for Fostemsavir in Europe
eff1701d-c3c1-4bf7-96cf-06ca462708af,2020-01-13T08:00:00.000+08:00,1,"Company News for Jan 13, 2020"
a7015a83-5ef5-4f62-babe-734116d1b28e,2020-01-13T08:00:00.000+08:00,4,Eli Lilly's Phase 3 ORIENT-11 Study of Tyvyt Combined with ALIMTA Met its Primary Endpoint
072da151-8f89-4e85-af9d-016f659b1974,2020-01-13T08:00:00.000+08:00,3,Glaxo Files Marketing Application for Fostemsavir in Europe
0e429ce6-5344-41c2-aeed-f1b7cf0e2548,2020-01-13T08:00:00.000+08:00,2,"Company News for Jan 13, 2020"
19f7ac27-5533-4db1-b9d0-d6d92ec270dd,2020-01-11T08:00:00.000+08:00,3,Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020
608be065-ef3b-440c-8d2d-eccf98c4b41c,2020-01-11T08:00:00.000+08:00,3,Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020
134c335e-2408-4b46-b07b-4d7ea48c0c8f,2020-01-10T08:00:00.000+08:00,2,Mid-Afternoon Market Update: Dow Falls 90 Points; RumbleON Shares Plummet
6751133f-9f2a-411d-8ed0-8ad659f73073,2020-01-10T08:00:00.000+08:00,4,"'California Gov. Gavin Newsom wants the state to become the first to create its own generic drug label, an attempt to create more competition and bring down prices.' -Axios, From Earlier"
2f541903-fed8-4354-b668-40238ef3c77d,2020-01-10T08:00:00.000+08:00,3,40 Stocks Moving In Friday's Mid-Day Session
8027159e-9aa4-4798-a94a-9a7321401b41,2020-01-10T08:00:00.000+08:00,5,Stocks That Hit 52-Week Highs On Friday
c83050b6-ad04-4aaf-a4c9-3cfce06df6ff,2020-01-10T08:00:00.000+08:00,1,Mid-Day Market Update: Crude Oil Down Over 1%; Ultragenyx Pharmaceutical Shares Jump
55cf507e-18e9-411e-8564-24a62efbea81,2020-01-10T08:00:00.000+08:00,4,Mid-Morning Market Update: Markets Open Higher; Eli Lilly To Buy Dermira For $18.75/Share
fb60c015-4b95-4098-951d-d548edb924ef,2020-01-10T08:00:00.000+08:00,3,"Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR"
ae7b3d53-1d4b-4f26-b923-a0e69cc89daa,2020-01-10T08:00:00.000+08:00,2,Eli Lilly Reports Deal To Buy Dermira For $1.1B
57231f34-2f28-4642-9348-d3190fe9a18b,2020-01-10T08:00:00.000+08:00,4,33 Stocks Moving in Friday's Pre-Market Session
b47983e7-f109-4e29-a501-beafa6b6425d,2020-01-10T08:00:00.000+08:00,5,Eli Lilly Reports Deal To Buy Dermira For $18.75/Share In Cash
4f82ea2a-571a-4d11-b5ec-de62398cf7d9,2020-01-10T08:00:00.000+08:00,2,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
5354556d-5561-4303-a0dc-5ad2750b13ef,2020-01-10T08:00:00.000+08:00,3,Mid-Afternoon Market Update: Dow Falls 90 Points; RumbleON Shares Plummet
0f90a323-cc5d-49bc-a1fb-4c02d7ef782c,2020-01-10T08:00:00.000+08:00,4,"'California Gov. Gavin Newsom wants the state to become the first to create its own generic drug label, an attempt to create more competition and bring down prices.' -Axios, From Earlier"
941571df-bd54-48a0-88a0-276ef34fd4a0,2020-01-10T08:00:00.000+08:00,5,40 Stocks Moving In Friday's Mid-Day Session
5fc7fbc1-ac76-47c4-a62e-49c48d791dc2,2020-01-10T08:00:00.000+08:00,1,Stocks That Hit 52-Week Highs On Friday
56e6085b-cd72-444e-b30f-4f0ff832993c,2020-01-10T08:00:00.000+08:00,4,Mid-Day Market Update: Crude Oil Down Over 1%; Ultragenyx Pharmaceutical Shares Jump
776be0f9-990b-42a0-a73e-1aeef03e5a6c,2020-01-10T08:00:00.000+08:00,5,Mid-Morning Market Update: Markets Open Higher; Eli Lilly To Buy Dermira For $18.75/Share
6919c0e4-9c5b-467f-aad5-a08812f5715a,2020-01-10T08:00:00.000+08:00,3,"Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR"
79c66ecd-55f0-4b03-878f-76b74bee1b84,2020-01-10T08:00:00.000+08:00,2,Eli Lilly Reports Deal To Buy Dermira For $1.1B
d55d6b8f-801f-472e-99a3-134e53345258,2020-01-10T08:00:00.000+08:00,1,33 Stocks Moving in Friday's Pre-Market Session
ab6ea3a5-3a9b-479f-85ae-1dd36d16ed81,2020-01-10T08:00:00.000+08:00,4,Eli Lilly Reports Deal To Buy Dermira For $18.75/Share In Cash
9821eb39-e404-4701-9608-4dc24ac78def,2020-01-10T08:00:00.000+08:00,3,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
9e326c71-cb23-4469-88c9-39709382c1cd,2020-01-09T08:00:00.000+08:00,4,"Eli Lilly, In Collaboration With Strateos, Inc. Launches Remote-Controlled Robotic Cloud Lab"
11f409e7-715b-44a7-8fe2-e4f7ad56e3b7,2020-01-09T08:00:00.000+08:00,5,Stocks With Rising Composite Ratings: Eli Lilly
8ee4cbd1-7ff7-4986-a232-395df15e0f89,2020-01-09T08:00:00.000+08:00,5,"Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up"
921a04a1-d4e5-46c1-a734-97d602f7831e,2020-01-09T08:00:00.000+08:00,4,"Eli Lilly, In Collaboration With Strateos, Inc. Launches Remote-Controlled Robotic Cloud Lab"
c42c4350-b2d4-484c-bf3d-809c5f0c7094,2020-01-09T08:00:00.000+08:00,5,Stocks With Rising Composite Ratings: Eli Lilly
048a9e0a-e123-4eb6-a5eb-9d7e24508b65,2020-01-09T08:00:00.000+08:00,4,"Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up"
c10d1980-8ff9-4ade-abf7-7758d4a48ebd,2020-01-08T08:00:00.000+08:00,3,"Zacks.com featured highlights include: Ruth's Hospitality, Cadence Design System, Toro Company and Eli Lilly and Company"
209a7b39-dff6-438c-a549-2826107ab59d,2020-01-08T08:00:00.000+08:00,4,"Zacks.com featured highlights include: Ruth's Hospitality, Cadence Design System, Toro Company and Eli Lilly and Company"
d9f2d2dc-134c-4dc3-b9cf-f9ce22666bf0,2020-01-06T08:00:00.000+08:00,4,AstraZeneca's Farxiga sNDA Gets Priority Review Status by FDA
aea0aadc-0e3f-49eb-9af4-70b630af433c,2020-01-06T08:00:00.000+08:00,4,AstraZeneca's Farxiga sNDA Gets Priority Review Status by FDA
fe8ff3b5-d2e2-4b51-8cbc-0a46a993f8fe,2020-01-02T08:00:00.000+08:00,5,3 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2020
f236454a-53c6-4e89-990a-2255f34aa186,2020-01-02T08:00:00.000+08:00,1,3 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2020
2f1c7acc-804b-4894-b3e8-85a6e1423f1a,2019-12-31T08:00:00.000+08:00,2,Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study
f73779d6-ad92-474c-9e62-5b9578088580,2019-12-31T08:00:00.000+08:00,4,Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study
c992a545-ea3e-4975-bafc-d0fa57d409e8,2019-12-30T08:00:00.000+08:00,5,U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit
bd3ec2d4-a469-461e-8d21-b074e582936e,2019-12-30T08:00:00.000+08:00,3,"UPDATE: Argus Maintains Buy On Eli Lilly, Raises Target To $165 Notes 'We see increased volume and expanded indications for existing drugs, along with potential regulatory approvals, as cat-alysts for growth in 2020'"
3d5b6b58-cc63-4590-a65f-b67bc412664f,2019-12-30T08:00:00.000+08:00,4,10 Biggest Price Target Changes For Monday
1b06c57d-f2ea-4e79-af05-a258327c72de,2019-12-30T08:00:00.000+08:00,5,"Argus Research Maintains Buy on Eli Lilly, Raises Price Target to $165"
bbcb89c0-ee04-43bf-a9e7-e2527c0d51e5,2019-12-30T08:00:00.000+08:00,4,Lilly Opens Phase 3 Clinical Trial In RET-Mutant Medullary Thyroid Cancer
3f0e3c75-3034-4c93-8d68-c8d5e5f52728,2019-12-30T08:00:00.000+08:00,5,U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit
59eb5bc0-3ef3-4df7-9c54-a40ee270a9f7,2019-12-30T08:00:00.000+08:00,3,"UPDATE: Argus Maintains Buy On Eli Lilly, Raises Target To $165 Notes 'We see increased volume and expanded indications for existing drugs, along with potential regulatory approvals, as cat-alysts for growth in 2020'"
399fe3eb-d1cf-42c5-bc8f-1c90c54aa85e,2019-12-30T08:00:00.000+08:00,4,10 Biggest Price Target Changes For Monday
51562c83-cf6f-4454-ad92-221ae18cdefe,2019-12-30T08:00:00.000+08:00,5,"Argus Research Maintains Buy on Eli Lilly, Raises Price Target to $165"
3280a2bb-6c28-4a76-97d8-d64f6d2d69d8,2019-12-30T08:00:00.000+08:00,2,Lilly Opens Phase 3 Clinical Trial In RET-Mutant Medullary Thyroid Cancer
0b9fcc0d-281a-4522-a45c-9aac7055f1e7,2019-12-29T08:00:00.000+08:00,3,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus"
df57e3b4-3a74-4c4b-81cc-130a9f156428,2019-12-29T08:00:00.000+08:00,3,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus"
8089d329-1315-4e40-9bd2-e1017531d09c,2019-12-26T08:00:00.000+08:00,4,Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance
f4e72073-135b-4259-a4c9-149aed03cd9b,2019-12-26T08:00:00.000+08:00,5,Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance
59294394-0ee0-4787-89a1-ba00abbe6719,2019-12-24T08:00:00.000+08:00,4,Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy
4318390b-098c-4652-a88f-cf913d1207ba,2019-12-24T08:00:00.000+08:00,3,Buy These 5 Low-Beta Stocks to Counter Market Volatility
e1a5e4f2-3979-45fe-aba8-c5d4c1eff343,2019-12-24T08:00:00.000+08:00,4,Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy
eaf94b37-2a1a-45a5-9157-8f4581eb8080,2019-12-24T08:00:00.000+08:00,3,Buy These 5 Low-Beta Stocks to Counter Market Volatility
40d19431-e520-4b2b-973a-424924e3238a,2019-12-23T08:00:00.000+08:00,2,A Perspective On Biopharma's Record M&A Run In 2019
bdafd7c3-f3b4-4b32-b642-a48fdaa992bf,2019-12-23T08:00:00.000+08:00,2,"PreMarket Prep Recap: $TSLAQ Crowd Continues To Be Punished, Eli Lilly's Incredible Friday Open"
2df9e07c-a27c-4103-b1f6-ebe1bd52dfa1,2019-12-23T08:00:00.000+08:00,3,"Top Stock Reports for SAP, AbbVie & Sinopec"
1bcfdee5-51b9-42db-9486-123d2e4cf114,2019-12-23T08:00:00.000+08:00,3,A Perspective On Biopharma's Record M&A Run In 2019
2a0e6088-af80-4d06-b04f-4fd906666311,2019-12-23T08:00:00.000+08:00,2,"PreMarket Prep Recap: $TSLAQ Crowd Continues To Be Punished, Eli Lilly's Incredible Friday Open"
8fe2cd74-6d58-4af6-ad68-09f20b216a17,2019-12-23T08:00:00.000+08:00,3,"Top Stock Reports for SAP, AbbVie & Sinopec"
875aff6a-ff0f-4746-9398-a6a723b83876,2019-12-20T08:00:00.000+08:00,4,PreMarket Prep Recap: Buyers And More Buyers On Quadruple Witch Expiration
c33fa7bb-c37c-4e0b-8444-95c3c1d03de7,2019-12-20T08:00:00.000+08:00,5,Stocks That Hit 52-Week Highs On Friday
fb9d2af7-3abc-4d69-80f5-91e1e1939fd2,2019-12-20T08:00:00.000+08:00,3,"S&P 500, Transports Lead Market; These 2 Stocks Drag The IBD 50"
8f319481-ee9b-49c5-94c8-f7d7bedf4c4e,2019-12-20T08:00:00.000+08:00,2,"Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs"
c5bcdcc2-0fb6-40fd-b3cb-c2a22aadef42,2019-12-20T08:00:00.000+08:00,1,Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib
f1a9c58d-744f-4b52-aecf-f232f5b84313,2019-12-20T08:00:00.000+08:00,4,PreMarket Prep Recap: Buyers And More Buyers On Quadruple Witch Expiration
967c7a3d-c336-47ce-b3bb-5591e0eb09c1,2019-12-20T08:00:00.000+08:00,5,Stocks That Hit 52-Week Highs On Friday
57f684d7-c9bf-4271-8375-960b1914434f,2019-12-20T08:00:00.000+08:00,3,"S&P 500, Transports Lead Market; These 2 Stocks Drag The IBD 50"
bd70a7dd-33af-42ae-9df9-32c400edfae3,2019-12-20T08:00:00.000+08:00,2,"Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs"
546cdc0c-1017-4803-8630-29b2ea975aa4,2019-12-20T08:00:00.000+08:00,1,Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib
c1f08a11-446a-4a69-869e-36dd40b9efc7,2019-12-19T08:00:00.000+08:00,4,Eli Lilly Sees IBD RS Rating Climb To 72
c917c347-5298-4dcc-a643-00776891962e,2019-12-19T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland"
7dd6ffad-b9d4-4a2e-b37a-7da0907fc88e,2019-12-19T08:00:00.000+08:00,3,Eli Lilly Sees IBD RS Rating Climb To 72
dacb3ed3-547d-402e-80da-63f1bb2ace33,2019-12-19T08:00:00.000+08:00,4,"The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland"
a62d06fa-686b-4523-af08-1d2e209e0dc5,2019-12-18T08:00:00.000+08:00,5,"UPDATE: Morgan Stanley On Eli Lilly Notes 'While Novo appears set to win market share in diabetes, we still expect strong and durable Lilly franchise growth, including benefits from initial high-dose Trulicity sales in 2021 and tirzepatide in 2022'"
2505b9cc-200a-434d-9ca7-42cc7aab0165,2019-12-18T08:00:00.000+08:00,5,"UPDATE: Morgan Stanley Upgrades Eli Lilly To Overweight, Raises Target To $150 Notes 'We expect LLY shares to outperform, driven by strong growth and pipeline optionality'"
a5f07017-e371-4bd6-b156-68067227fba6,2019-12-18T08:00:00.000+08:00,4,"Eli Lilly CEO Hits Back At Elizabeth Warren, Blames PBMs, Insurance For Blocking Affordable Insulin"
f1c47af5-4c59-4550-a943-91831c25c2e5,2019-12-18T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For December 18, 2019"
12f388b8-428f-4499-b7d7-2eeb8f83f7b5,2019-12-18T08:00:00.000+08:00,4,Eli Lilly And Co shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised the price target from $116 to $150 per share.
f2370b48-c9b7-4d9d-8d77-dfec4f0c30d6,2019-12-18T08:00:00.000+08:00,5,"JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $150"
410fb371-ff44-4f6a-975d-5a2770455dca,2019-12-18T08:00:00.000+08:00,4,30 Healthcare Stocks Moving In Wednesday's Pre-Market Session
fd3a471f-4ac2-458e-bade-981c6774fcfe,2019-12-18T08:00:00.000+08:00,5,"Morgan Stanley Upgrades Eli Lilly to Overweight, Raises Price Target to $150"
8ba35b42-2fe5-42c9-b583-fdaf9af89e35,2019-12-18T08:00:00.000+08:00,3,Lilly Announces Launch Of TRIUMPH Real-World Evidence Study Of Emgality For Migraine Prevention
efa529b8-8fc7-41f6-bda4-19a121be36c2,2019-12-18T08:00:00.000+08:00,2,"Top Stock Reports for Johnson & Johnson, Eli Lilly & PNC Financial"
dee9af17-33b2-4c4c-882f-dda3c9d0dae8,2019-12-18T08:00:00.000+08:00,1,Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU
e25ce336-e762-4ede-88d5-29eab7bdd6ed,2019-12-18T08:00:00.000+08:00,5,Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020
bd228875-e49d-4d82-84bb-56aeddcc86c1,2019-12-18T08:00:00.000+08:00,4,"UPDATE: Morgan Stanley On Eli Lilly Notes 'While Novo appears set to win market share in diabetes, we still expect strong and durable Lilly franchise growth, including benefits from initial high-dose Trulicity sales in 2021 and tirzepatide in 2022'"
5b194b83-8ef7-4a58-888b-f9be76d7ab9e,2019-12-18T08:00:00.000+08:00,3,"UPDATE: Morgan Stanley Upgrades Eli Lilly To Overweight, Raises Target To $150 Notes 'We expect LLY shares to outperform, driven by strong growth and pipeline optionality'"
8d53cc5a-5f58-4084-bc42-2e7b076881c7,2019-12-18T08:00:00.000+08:00,2,"Eli Lilly CEO Hits Back At Elizabeth Warren, Blames PBMs, Insurance For Blocking Affordable Insulin"
482e16a8-b1f6-4bf1-ac8c-ea977264a54b,2019-12-18T08:00:00.000+08:00,1,"Benzinga's Top Upgrades, Downgrades For December 18, 2019"
9992fee2-1745-4039-8cee-f31f92ef41de,2019-12-18T08:00:00.000+08:00,5,Eli Lilly And Co shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised the price target from $116 to $150 per share.
8f70d343-80fd-453c-ac3d-83f36230a7bb,2019-12-18T08:00:00.000+08:00,5,"JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $150"
838ddbdb-5caf-4137-9704-532a6c17ffb4,2019-12-18T08:00:00.000+08:00,3,30 Healthcare Stocks Moving In Wednesday's Pre-Market Session
8081a1e4-4cbb-4d09-8ea1-6bc8e95a910a,2019-12-18T08:00:00.000+08:00,4,"Morgan Stanley Upgrades Eli Lilly to Overweight, Raises Price Target to $150"
9675bb5f-c2f8-4856-beaf-5dd709b7ab8d,2019-12-18T08:00:00.000+08:00,4,Lilly Announces Launch Of TRIUMPH Real-World Evidence Study Of Emgality For Migraine Prevention
3ca90d99-0be2-432a-bf2a-bd96995cb0e3,2019-12-18T08:00:00.000+08:00,4,"Top Stock Reports for Johnson & Johnson, Eli Lilly & PNC Financial"
44182615-8d48-49b7-99da-4ba125d51aa4,2019-12-18T08:00:00.000+08:00,5,Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU
b2280f5c-f518-432d-8a5e-c680560e48a9,2019-12-18T08:00:00.000+08:00,3,Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020
5260deb4-3ae3-4aaa-86a5-8a6ead04af7e,2019-12-17T08:00:00.000+08:00,4,Eli Lilly shares are trading higher after the company issued upbeat FY20 guidance.
8649ab47-cc7d-4a41-96b5-1fbb426ebaee,2019-12-17T08:00:00.000+08:00,2,Eli Lilly Executive Says Reasonable To Expect Net Price Declines In The Low Single-Digit Level Going Forward
c157a2d2-ae04-4544-92e8-8dbc0df1244c,2019-12-17T08:00:00.000+08:00,4,"Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 17, 2019: BA, AAPL, BLPH, JNJ, LLY"
7e06b43d-6151-40e7-b5ec-a5cb0a23e2ed,2019-12-17T08:00:00.000+08:00,3,"Lilly Reaffirms Prelim. FY19 Adj. EPS Guidance $5.75-$5.85 vs $5.81 Est., Sales Guidance $22B-$22.5B vs $22.16B Est."
a1fcd08e-5ec9-4f21-8102-a3ffd7a030cc,2019-12-17T08:00:00.000+08:00,5,"Lilly Sees FY20 Adj. EPS $6.70-$6.80 vs $6.61 Est., Sales $23.6B-$24.1B vs $23.52B Est."
36c91239-d422-4f20-a9ad-5f9d16fd28de,2019-12-17T08:00:00.000+08:00,2,Eli Lilly shares are trading higher after the company issued upbeat FY20 guidance.
f55d61d3-dbaf-4a1a-b10e-e83c1a66fae7,2019-12-17T08:00:00.000+08:00,1,Eli Lilly Executive Says Reasonable To Expect Net Price Declines In The Low Single-Digit Level Going Forward
74e3bc92-a5e3-4356-99e8-b01b533e8c1a,2019-12-17T08:00:00.000+08:00,4,"Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 17, 2019: BA, AAPL, BLPH, JNJ, LLY"
f9177e94-1580-4657-8001-b0fa28cb1592,2019-12-17T08:00:00.000+08:00,3,"Lilly Reaffirms Prelim. FY19 Adj. EPS Guidance $5.75-$5.85 vs $5.81 Est., Sales Guidance $22B-$22.5B vs $22.16B Est."
40333d11-0dc6-431f-9dbc-aafe7a3535e4,2019-12-17T08:00:00.000+08:00,4,"Lilly Sees FY20 Adj. EPS $6.70-$6.80 vs $6.61 Est., Sales $23.6B-$24.1B vs $23.52B Est."
03055bcf-47e6-4dbe-84d5-3f4c56c5f1bc,2019-12-16T08:00:00.000+08:00,5,Eli Lilly Raises Qtr. Dividend From $0.645 To $0.74/Share
24dc0f3e-5e63-428f-8d1c-acbcaa645dd0,2019-12-16T08:00:00.000+08:00,5,DexCom Says Eli Lilly Will Integrate its Continuous Glucose Monitoring into Lilly's Personalized Diabetes Management System
b7617e9a-fa6e-42db-ace7-e98d7de448e4,2019-12-16T08:00:00.000+08:00,5,Eli Lilly Raises Qtr. Dividend From $0.645 To $0.74/Share
e1b10542-c44d-464a-b94a-0662249b1f3d,2019-12-16T08:00:00.000+08:00,4,DexCom Says Eli Lilly Will Integrate its Continuous Glucose Monitoring into Lilly's Personalized Diabetes Management System
406be083-8e55-4251-9d80-788138496a21,2019-12-15T08:00:00.000+08:00,3,Boris Bounce; Trump Tripwire
df13d186-0346-4a47-86d0-b80d41171e6b,2019-12-15T08:00:00.000+08:00,4,Investors Dig Into Trade War Halt (Stocks To Watch Podcast)
0f309516-792b-4b97-88bc-4f91c3d2268d,2019-12-15T08:00:00.000+08:00,3,Boris Bounce; Trump Tripwire
c49db21b-0654-41b4-bc7e-dba458651e27,2019-12-15T08:00:00.000+08:00,2,Investors Dig Into Trade War Halt (Stocks To Watch Podcast)
d092e49a-e02c-45cd-87da-394c14484dbf,2019-12-14T08:00:00.000+08:00,2,Stocks To Watch: Investors Dig Into Trade War Halt
4a246296-f8ab-4bac-963f-4d8e66caad58,2019-12-14T08:00:00.000+08:00,2,Stocks To Watch: Investors Dig Into Trade War Halt
491be742-7a94-4345-b208-ed3c7d63ef98,2019-12-13T08:00:00.000+08:00,1,'Fast Money' Picks For December 13
2c792133-aec0-483b-80b1-83a4dcfad607,2019-12-13T08:00:00.000+08:00,4,"Boehringer Ingelheim, Lilly Offer Update On Jardiance Phase 3 Exercise Ability Studies In Chronic Heart Failure"
0452fda3-c9fe-413e-842d-a13784202eba,2019-12-13T08:00:00.000+08:00,4,Lilly Reports CHMP Issues Positive Opinion Related To Expanded Label Of CYRAMZA To Include Results From RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
9e18b12f-dbac-4b9f-97c5-9af457b46f6d,2019-12-13T08:00:00.000+08:00,2,"Merger Mating Dance: We Explore Who Gets The Rose Next - Sectors And Targets, Part I"
56489da9-c03c-486f-81c4-232542dfaf98,2019-12-13T08:00:00.000+08:00,3,Eagle Pharma on go to launch Alimta alternative in early 2022
5cd7e0a3-eb3b-40df-a9c7-c6603482588d,2019-12-13T08:00:00.000+08:00,4,Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies ...
d1a14cb6-cfe4-490e-bbbe-6fb9fbed307b,2019-12-13T08:00:00.000+08:00,3,"Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study"
12282c19-43d0-49e5-8e18-69ab5f6c8e87,2019-12-13T08:00:00.000+08:00,5,CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from ...
377dda7f-cf14-4d85-96e6-f81e21321838,2019-12-13T08:00:00.000+08:00,5,European advisory group backs expanded use of Lilly's Cyramza
ca85f67d-28e6-40ef-8764-aea84874c3f4,2019-12-13T08:00:00.000+08:00,3,'Fast Money' Picks For December 13
9a2218b2-203a-4fa1-a5a7-c989812e8222,2019-12-13T08:00:00.000+08:00,4,"Boehringer Ingelheim, Lilly Offer Update On Jardiance Phase 3 Exercise Ability Studies In Chronic Heart Failure"
04f73b0e-8083-4dc4-b424-7953c05a5453,2019-12-13T08:00:00.000+08:00,5,Lilly Reports CHMP Issues Positive Opinion Related To Expanded Label Of CYRAMZA To Include Results From RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
57b3bf21-2ae9-4e1f-968a-d56985af448f,2019-12-13T08:00:00.000+08:00,4,"Merger Mating Dance: We Explore Who Gets The Rose Next - Sectors And Targets, Part I"
2ab18875-51d1-42d4-95b3-752cf65bdf85,2019-12-13T08:00:00.000+08:00,5,Eagle Pharma on go to launch Alimta alternative in early 2022
b247b46e-ce40-4156-8d4a-ee610d159251,2019-12-13T08:00:00.000+08:00,3,Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies ...
058bd519-31de-47cf-8dba-edd6d506a8db,2019-12-13T08:00:00.000+08:00,4,"Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study"
b2879586-c911-44fb-9742-b3feb363ea23,2019-12-13T08:00:00.000+08:00,5,CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from ...
4161bed3-c951-403b-910b-43a0d336f48f,2019-12-13T08:00:00.000+08:00,4,European advisory group backs expanded use of Lilly's Cyramza
efe17711-0dd4-490c-992f-01145b81bc8d,2019-12-12T08:00:00.000+08:00,1,Elanco Animal Health: Still Not Very Healthy
fc721d96-ffaa-4711-9494-8d4ef5a3fb7d,2019-12-12T08:00:00.000+08:00,2,"House passes drug pricing bill, Senate unlikely to support"
26949d14-9db3-4690-aeab-34db77343287,2019-12-12T08:00:00.000+08:00,3,Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor
b8a4bfe0-ef99-469c-ab3d-3bb70d86618b,2019-12-12T08:00:00.000+08:00,1,Elanco Animal Health: Still Not Very Healthy
3461abf9-d229-4bcd-8795-a9b174e7a911,2019-12-12T08:00:00.000+08:00,2,"House passes drug pricing bill, Senate unlikely to support"
7622053c-ff81-4e61-9e4c-7de8bb9c8019,2019-12-12T08:00:00.000+08:00,4,Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor
e006face-b157-4139-8a5e-d47ab5593412,2019-12-11T08:00:00.000+08:00,3,Lilly Opens Randomized Phase 3 Clinical Trial Of LOXO-292 In Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer
a7a8b9d6-9e12-4d46-b0a5-8958a1bfa1d5,2019-12-11T08:00:00.000+08:00,4,Lilly Opens First Ever Randomized Phase ' Clinical Trial in Treatment-Naïve RET ...
d9a992a6-0650-42e7-a605-ec3de5351aff,2019-12-11T08:00:00.000+08:00,5,Lilly opens late-stage RET fusion-positive NSCLC study
addfda05-47d4-4843-858a-b3e43d5339b1,2019-12-11T08:00:00.000+08:00,2,Lilly Opens Randomized Phase 3 Clinical Trial Of LOXO-292 In Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer
3da55e30-813f-4969-ba4e-aedb1b6f3ac2,2019-12-11T08:00:00.000+08:00,3,Lilly Opens First Ever Randomized Phase ' Clinical Trial in Treatment-Naïve RET ...
faf7abd6-5e31-4fdc-abed-8d2ac1665220,2019-12-11T08:00:00.000+08:00,1,Lilly opens late-stage RET fusion-positive NSCLC study
b0b0ee66-eba1-4de5-b0d2-6eb0720f1bf5,2019-12-10T08:00:00.000+08:00,4,Aptose Shoots Up As Investors Focus On Reversible BTK Inhibitors
87c0243e-150b-4f5a-bd71-9f29abe854c7,2019-12-10T08:00:00.000+08:00,1,Sanofi to exit diabetes research; shares up 4% premarket
8aef5063-1518-4299-b698-dd0cd25af7c1,2019-12-10T08:00:00.000+08:00,5,Aptose Shoots Up As Investors Focus On Reversible BTK Inhibitors
4ba044a1-ded9-46f8-b30a-cbbbb36e0650,2019-12-10T08:00:00.000+08:00,4,Sanofi to exit diabetes research; shares up 4% premarket
cd40f86e-21d4-41bc-84eb-78a9fc70ae96,2019-12-09T08:00:00.000+08:00,3,Highlights From The Deutsche Bank ADR Virtual Investor Conference
143fdadf-a514-43d6-83d7-fa38b46a0531,2019-12-09T08:00:00.000+08:00,4,Kinase inhibitors in focus after Merck bid for ArQule
6e20593b-18db-4485-9e2d-a1284ffa4e2d,2019-12-09T08:00:00.000+08:00,4,Highlights From The Deutsche Bank ADR Virtual Investor Conference
0243e558-2424-4d60-9bb9-b9b5d858ebcc,2019-12-09T08:00:00.000+08:00,2,Kinase inhibitors in focus after Merck bid for ArQule
e21d0368-fcb8-4fce-9e05-f1030454b607,2019-12-08T08:00:00.000+08:00,3,Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at ASH 2019
458a8f68-6330-48f7-a7fb-799aaf52bacc,2019-12-08T08:00:00.000+08:00,3,Lilly Presents Interim Clinical Data from LOXO-'…5 Dose Escalation Trial in B-Cell ...
78f6557a-381d-422a-97f0-425bd7432b75,2019-12-08T08:00:00.000+08:00,1,"Netflix, Cisco And Chewy On The Marquee (Stocks To Watch Podcast)"
fd6c5ea1-8653-46aa-aa67-eb4206d96756,2019-12-08T08:00:00.000+08:00,4,Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at ASH 2019
9a16ba13-af74-4f20-9f9f-6c5c6d8b820b,2019-12-08T08:00:00.000+08:00,2,Lilly Presents Interim Clinical Data from LOXO-'…5 Dose Escalation Trial in B-Cell ...
0db3e31b-2487-4868-98ee-ea6a45a9012f,2019-12-08T08:00:00.000+08:00,3,"Netflix, Cisco And Chewy On The Marquee (Stocks To Watch Podcast)"
6bf54801-b104-4eec-bd00-b40f149feb1d,2019-12-07T08:00:00.000+08:00,3,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling"
c9b78c5d-a254-41b8-8152-bb2a84a4bd38,2019-12-07T08:00:00.000+08:00,4,Dividend Challenger Highlights: Week Of December 8
cc02b321-d2fb-4558-acd4-6bbbafe5e34a,2019-12-07T08:00:00.000+08:00,3,"Stocks To Watch: Netflix, Cisco And Chewy On The Marquee"
e7a723b1-a690-41d7-8bef-bdd445ac0304,2019-12-07T08:00:00.000+08:00,2,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling"
0a2e2e63-b198-4b56-a17c-985441950057,2019-12-07T08:00:00.000+08:00,4,Dividend Challenger Highlights: Week Of December 8
f79db19c-aad7-4ba9-9909-9ef07bbf3c26,2019-12-07T08:00:00.000+08:00,3,"Stocks To Watch: Netflix, Cisco And Chewy On The Marquee"
0d70e312-c1b9-404b-bda2-f35fffa1803b,2019-12-06T08:00:00.000+08:00,5,Dicerna Pharmaceuticals: A Solid Pick For 2020
b787916d-5d1f-47ec-bc54-0ef57bad69da,2019-12-06T08:00:00.000+08:00,5,Dicerna Pharmaceuticals: A Solid Pick For 2020
96cecb3b-10c9-4ef1-8af3-195b0ab9b463,2019-12-05T08:00:00.000+08:00,4,Health Care Select Sector SPDR Fund: Long-Term Growth Outlook Remains Intact
896aedd4-f740-4079-afd1-5179d32921ac,2019-12-05T08:00:00.000+08:00,3,Lilly to combine Loxo with oncology research group
33915f2f-382b-4e75-b75c-566d5945a8b3,2019-12-05T08:00:00.000+08:00,4,Lilly Announces New Leadership and Strategy in Oncology Research and Development
40983796-e088-4150-942f-5d64d0c0d4c3,2019-12-05T08:00:00.000+08:00,4,Health Care Select Sector SPDR Fund: Long-Term Growth Outlook Remains Intact
8e8620ca-2c74-4da0-bba3-e51d11079d1e,2019-12-05T08:00:00.000+08:00,4,Lilly to combine Loxo with oncology research group
128a1e89-1138-46db-8ab8-ac8e6aa6061e,2019-12-05T08:00:00.000+08:00,2,Lilly Announces New Leadership and Strategy in Oncology Research and Development
28b9461d-de5b-4277-a3fc-f53671a6dffa,2019-12-02T08:00:00.000+08:00,3,U.S. Considers Scaling Back IP Protections For Big Drugmakers To Help Win Democratic Support For New Trade Pact With Mexico And Canada
dac3be54-c5b6-44a8-ada1-9a5ecd997c98,2019-12-02T08:00:00.000+08:00,1,"Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade"
a36310fc-6feb-44c8-8c2e-9e93db834003,2019-12-02T08:00:00.000+08:00,4,Lilly to Participate in Evercore ISI —nd Annual HealthCONx Conference
7c9b134b-a4c6-46a1-bb68-d94e732fa489,2019-12-02T08:00:00.000+08:00,3,Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco
40e23c53-2161-49d3-ab51-f1881c563901,2019-12-02T08:00:00.000+08:00,2,Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory ...
237fc475-0180-4792-a36f-203493b9c65b,2019-12-02T08:00:00.000+08:00,4,Now Is A Good Time To Buy XLV
3bacfc5b-5daa-4656-95a4-50386ebe8790,2019-12-02T08:00:00.000+08:00,3,U.S. Considers Scaling Back IP Protections For Big Drugmakers To Help Win Democratic Support For New Trade Pact With Mexico And Canada
e7379b60-623e-4fc0-bf4d-c1ef41c14677,2019-12-02T08:00:00.000+08:00,1,"Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade"
e76a5841-aa4a-49b4-b163-82d6a41d7066,2019-12-02T08:00:00.000+08:00,3,Lilly to Participate in Evercore ISI —nd Annual HealthCONx Conference
cbc7c597-a85f-4e33-ae97-f5a952e55de6,2019-12-02T08:00:00.000+08:00,4,Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco
2b397239-d296-480c-84f5-a75888fc9a4a,2019-12-02T08:00:00.000+08:00,5,Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory ...
5204e6c1-fed8-4f05-8085-97f10f1a6f1c,2019-12-02T08:00:00.000+08:00,3,Now Is A Good Time To Buy XLV
817dd9e3-f765-4876-8d3e-2c173b2db667,2019-11-27T08:00:00.000+08:00,2,"Top Research Reports for Merck, Eli Lilly & Charter Communications"
f6375f4d-912a-4a25-8418-a5b4d3f71f99,2019-11-27T08:00:00.000+08:00,2,"Top Research Reports for Merck, Eli Lilly & Charter Communications"
b63ce3aa-72f1-4a1e-b2b6-90067bbc9f28,2019-11-24T08:00:00.000+08:00,2,Acreage Holdings: The Best Investment In The Cannabis Space
6079fcdb-656a-4745-90f6-7ca57457f1ea,2019-11-24T08:00:00.000+08:00,2,Acreage Holdings: The Best Investment In The Cannabis Space
b08be62e-2690-449b-9089-484c2d449893,2019-11-22T08:00:00.000+08:00,1,"\"Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are \"\"MUCH CHEAPER\"\"\""
6614bbca-b275-4ece-b80f-06a182088641,2019-11-22T08:00:00.000+08:00,1,"\"Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are \"\"MUCH CHEAPER\"\"\""
cfe2330a-767b-4572-b1c4-c22e990a3549,2019-11-21T08:00:00.000+08:00,3,Why Eli Lilly Can't Match Novo Nordisk
b289763b-fbd3-48f7-bef5-2ef6af3e728a,2019-11-21T08:00:00.000+08:00,2,Why Eli Lilly Can't Match Novo Nordisk
026dab1d-f446-4783-bfbb-7542a376044a,2019-11-20T08:00:00.000+08:00,4,Lilly Announces $400M Capital Investment In Manufacturing Facilities In Indianapolis
264d9d1b-3ff1-484a-8eed-5314b912c641,2019-11-20T08:00:00.000+08:00,3,Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug
fcdcbf6b-628a-4f7a-b614-1f152d3169a1,2019-11-20T08:00:00.000+08:00,4,Lilly announces $4…… million capital investment in manufacturing facilities in Indianapolis
99959fa0-370b-4df5-911f-73103a9d55d6,2019-11-20T08:00:00.000+08:00,1,Launch of new generic drugs in U.S. still lags - WSJ
5cd42029-9616-4f42-857c-023c65936558,2019-11-20T08:00:00.000+08:00,5,Lilly to invest $400M in Indianapolis manufacturing facilities
0d290e42-f385-4080-ae11-46e858c678d5,2019-11-20T08:00:00.000+08:00,5,Lilly Announces $400M Capital Investment In Manufacturing Facilities In Indianapolis
79c46552-2a10-433a-9b4b-46ce804b6835,2019-11-20T08:00:00.000+08:00,3,Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug
89ffc6fb-4e57-4a72-926b-379b26324c1d,2019-11-20T08:00:00.000+08:00,2,Lilly announces $4…… million capital investment in manufacturing facilities in Indianapolis
ba3bd283-db04-413b-9db7-8cd18ffa1ae6,2019-11-20T08:00:00.000+08:00,1,Launch of new generic drugs in U.S. still lags - WSJ
7d3e5460-af35-40cd-ab4b-22fd9abd7d61,2019-11-20T08:00:00.000+08:00,4,Lilly to invest $400M in Indianapolis manufacturing facilities
44e62e02-63b0-4107-bc0b-550c1b238ae7,2019-11-19T08:00:00.000+08:00,3,Lilly Confirms Date and Conference Call for —…—… Financial Guidance Announcement
c0cfab6d-b6c6-4187-898c-dba2fb830aba,2019-11-19T08:00:00.000+08:00,2,"Ccm Investment Advisers Llc Buys MDU Resources Group Inc, Gilead Sciences Inc, Automatic Data ..."
b17d3b1c-aaf4-43d7-a150-3a23871dd6ea,2019-11-19T08:00:00.000+08:00,1,Steven Cohen's Top 5 Buys in the 'rd Quarter
900d9cac-1463-4a2a-93fe-55a88e89e539,2019-11-19T08:00:00.000+08:00,1,Drug Legislation Likely to Dry Up Biotech Funding
c29ae146-0180-4d4f-9870-b6468eef1d6a,2019-11-19T08:00:00.000+08:00,2,Nektar: Poised For A Rebound
9b764301-b312-45c8-828b-a6b60e759edb,2019-11-19T08:00:00.000+08:00,3,Lilly Confirms Date and Conference Call for —…—… Financial Guidance Announcement
faf0df8b-af35-4cd6-baf6-faae98be4ef5,2019-11-19T08:00:00.000+08:00,4,"Ccm Investment Advisers Llc Buys MDU Resources Group Inc, Gilead Sciences Inc, Automatic Data ..."
5c93c194-c8db-4298-8ee3-9021f7be5ec5,2019-11-19T08:00:00.000+08:00,1,Steven Cohen's Top 5 Buys in the 'rd Quarter
ca58f074-83bb-4520-9694-828d9edc37ee,2019-11-19T08:00:00.000+08:00,1,Drug Legislation Likely to Dry Up Biotech Funding
bf5ff2d2-0bfa-45a0-b5f2-8b2d65773096,2019-11-19T08:00:00.000+08:00,5,Nektar: Poised For A Rebound
507b3ad4-d8b1-4bb8-9e1d-6a359937800f,2019-11-17T08:00:00.000+08:00,5,Interim Analysis From Emprise Real-world Study Shows Lilly's Jardiance Decreased Risk of Hospitalization for Heart Failure vs Dpp-4 Inhibitors and Glp-1 Receptor Agonists
bdd362f7-505c-489b-b900-0326597b3983,2019-11-17T08:00:00.000+08:00,3,Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of ...
06dcbad0-a543-451f-9046-bc1fee6d45a2,2019-11-17T08:00:00.000+08:00,5,Interim Analysis From Emprise Real-world Study Shows Lilly's Jardiance Decreased Risk of Hospitalization for Heart Failure vs Dpp-4 Inhibitors and Glp-1 Receptor Agonists
52c1a38a-9282-457b-8fba-40dcd6208d6a,2019-11-17T08:00:00.000+08:00,5,Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of ...
f6f14674-a4a5-450e-907f-6cd39e47f971,2019-11-15T08:00:00.000+08:00,3,"Willis Investment Counsel Buys Paychex Inc, Eli Lilly and Co, Pfizer Inc, Sells United Parcel ..."
00154b31-c1e9-4e10-bf2a-6f51ebf9fd56,2019-11-15T08:00:00.000+08:00,4,UCB's bimekizumab success in second late-stage psoriasis study
727b7e57-88b7-4d09-aa08-f3d5876ab0aa,2019-11-15T08:00:00.000+08:00,3,"Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates"
d7aa2937-178c-445e-81df-71f963501383,2019-11-15T08:00:00.000+08:00,3,"Willis Investment Counsel Buys Paychex Inc, Eli Lilly and Co, Pfizer Inc, Sells United Parcel ..."
97632ce1-c9d3-4176-920f-bd007cc9df2b,2019-11-15T08:00:00.000+08:00,4,UCB's bimekizumab success in second late-stage psoriasis study
c72b5632-60d5-4347-bb7d-9a6aa22067a8,2019-11-15T08:00:00.000+08:00,2,"Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates"
cc092234-aadf-41ca-a3c0-f713210b42e0,2019-11-14T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing"
2ea58230-5282-4ad4-babf-f6081e1b87c3,2019-11-14T08:00:00.000+08:00,3,"HBK Sorce Advisory LLC Buys Global Payments Inc, SPDR Barclays Convertible Securities ETF, ..."
74c38551-da9b-4f8d-8fc9-86d8cf04cfee,2019-11-14T08:00:00.000+08:00,4,Livongo Bounces Back After Revenue Guidance Boost
030d4292-5c9d-4996-8778-687fab39f72f,2019-11-14T08:00:00.000+08:00,1,"Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss"
86ebe372-c0cd-441b-a3b1-a90abd7ce21f,2019-11-14T08:00:00.000+08:00,1,FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
0b3d6c2b-6b64-4506-afd2-587cc11bfde6,2019-11-14T08:00:00.000+08:00,2,FDA Ad Com thumbs down on BI and Lilly's empagliflozin for T1D
c1df9e1a-b079-4941-8b23-05e7109fb472,2019-11-14T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing"
f96f9fe2-32f9-49aa-b969-88e33e5c5695,2019-11-14T08:00:00.000+08:00,4,"HBK Sorce Advisory LLC Buys Global Payments Inc, SPDR Barclays Convertible Securities ETF, ..."
a18e88b3-cff0-4680-9f14-a68d26ab4d02,2019-11-14T08:00:00.000+08:00,5,Livongo Bounces Back After Revenue Guidance Boost
0e411053-ad5f-412e-9d79-07a1763205b1,2019-11-14T08:00:00.000+08:00,1,"Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss"
3fe94ad2-af52-4dee-94d9-c9edc553b5b3,2019-11-14T08:00:00.000+08:00,1,FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
199d7580-450d-4aee-a74d-4332ade8a991,2019-11-14T08:00:00.000+08:00,3,FDA Ad Com thumbs down on BI and Lilly's empagliflozin for T1D
6947b1e3-425b-41cd-b06f-f5845668391d,2019-11-13T08:00:00.000+08:00,4,"Eli Lilly, Boehringer Ingleheim Report FDA Endocrinologic and Metabolic Drugs Advisory Committee Vote 14-2 Benefits Of Empagliflozin 2.5mg Do Not Outweigh Risks"
c2f14d61-2754-45a2-9228-e8a5ce36ea5b,2019-11-13T08:00:00.000+08:00,1,FDA Panel Votes 14-2 Against Approval Of Eli Lilly And Boehringer Ingelheim's Empagliflozin As An Add On To Insulin Therapy For Type 1 Diabetes
bf006193-feb1-49fe-b8a6-703aa51b2011,2019-11-13T08:00:00.000+08:00,2,Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for ...
a0cde436-8649-45d1-942a-d9781fe492c7,2019-11-13T08:00:00.000+08:00,1,"Eli Lilly, Boehringer Ingleheim Report FDA Endocrinologic and Metabolic Drugs Advisory Committee Vote 14-2 Benefits Of Empagliflozin 2.5mg Do Not Outweigh Risks"
106eceeb-c662-4829-8837-6d2cf56c1016,2019-11-13T08:00:00.000+08:00,3,FDA Panel Votes 14-2 Against Approval Of Eli Lilly And Boehringer Ingelheim's Empagliflozin As An Add On To Insulin Therapy For Type 1 Diabetes
551d54c6-ffe6-4808-8201-e2321d908eea,2019-11-13T08:00:00.000+08:00,4,Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for ...
4e89f34c-6b97-44a2-8a2e-b9e7375ea3c5,2019-11-12T08:00:00.000+08:00,3,Boehringer Ingelheim And Lilly Initiate Study To Assess Jardiance In People Hospitalized For Acute Heart Failure Who Have Been Stabilized
975a73da-2c4b-4855-ae94-fb8b085407d6,2019-11-12T08:00:00.000+08:00,4,Eli Lilly And Co Announces 52-Week Head-To-Head Data From Taltz Versus Humira Trial In Psoriatic Arthritis Met The Primary And All Major Secondary Endpoints Of The Study
e2aaf8a5-dc0a-4b8c-b33d-5eff3884ade2,2019-11-12T08:00:00.000+08:00,3,"Diversified Portfolios, Inc. Buys Schwab Intermediate-Term U.S. ..."
4d72cc53-0fd6-4a55-8c8e-e52f443ea881,2019-11-12T08:00:00.000+08:00,2,"Palladium Partners Llc Buys iShares Edge MSCI USA Value Factor ETF, Facebook Inc, Eli Lilly and ..."
149b3865-e90e-44f0-ad91-40531e3069a7,2019-11-12T08:00:00.000+08:00,4,Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people ...
ea2d2f6f-c788-4286-b73a-3f4571e0fd55,2019-11-12T08:00:00.000+08:00,5,"Buckingham Capital Management, Inc. Buys Schwab Intermediate-Term U.S. ..."
0cb4c07a-a207-47d0-ac9f-72a3056aeff6,2019-11-12T08:00:00.000+08:00,5,Lilly's Taltz tops Humira in psoriatic arthritis study
b4a6fddc-ac77-4912-9cc8-2448a03a3202,2019-11-12T08:00:00.000+08:00,5,ACR —…–9: Lilly Presents 5—-Week Head-to-Head (SPIRIT-H—H) Data from Taltz® ...
9d572cea-b4cd-405b-89e3-2e3ea2a8104c,2019-11-12T08:00:00.000+08:00,4,"ACR —…–9: Lilly Presents Positive New Data from COAST-X, a Phase ' Study of Taltz® ..."
3642ce1f-1c10-442c-8dbe-a3cd08022e81,2019-11-12T08:00:00.000+08:00,3,Boehringer Ingelheim And Lilly Initiate Study To Assess Jardiance In People Hospitalized For Acute Heart Failure Who Have Been Stabilized
84b580ba-40ac-4c34-9018-05f58d742e7f,2019-11-12T08:00:00.000+08:00,5,Eli Lilly And Co Announces 52-Week Head-To-Head Data From Taltz Versus Humira Trial In Psoriatic Arthritis Met The Primary And All Major Secondary Endpoints Of The Study
435b17a0-d853-420c-8a19-eea7c47bf5da,2019-11-12T08:00:00.000+08:00,2,"Diversified Portfolios, Inc. Buys Schwab Intermediate-Term U.S. ..."
e9058e4a-a45a-4b86-9abe-30973333ccb5,2019-11-12T08:00:00.000+08:00,1,"Palladium Partners Llc Buys iShares Edge MSCI USA Value Factor ETF, Facebook Inc, Eli Lilly and ..."
efb2e470-2fc3-4396-900d-515df5761c68,2019-11-12T08:00:00.000+08:00,3,Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people ...
26699e95-f6f1-4624-8665-a574a1b1b49e,2019-11-12T08:00:00.000+08:00,4,"Buckingham Capital Management, Inc. Buys Schwab Intermediate-Term U.S. ..."
90ffe39d-57fc-4e25-82ab-240d74dc7a36,2019-11-12T08:00:00.000+08:00,5,Lilly's Taltz tops Humira in psoriatic arthritis study
0dee0bc8-b21a-49b1-bc02-0d2a0cbada9f,2019-11-12T08:00:00.000+08:00,3,ACR —…–9: Lilly Presents 5—-Week Head-to-Head (SPIRIT-H—H) Data from Taltz® ...
2db23b21-51d2-4970-bf4d-1c0af1f3a208,2019-11-12T08:00:00.000+08:00,4,"ACR —…–9: Lilly Presents Positive New Data from COAST-X, a Phase ' Study of Taltz® ..."
cfe0cace-7866-46ad-aa71-8a411d7e9c84,2019-11-11T08:00:00.000+08:00,2,ImmunoGen: Profiting And Turning Around
cec3dec3-8808-409c-b7c2-9192335dbc4d,2019-11-11T08:00:00.000+08:00,4,4 Biotech Stocks That Could Keep Beating Wall Street
1c9e0e94-78ce-4a1a-a9eb-52638236e569,2019-11-11T08:00:00.000+08:00,5,Nektar up 5% premarket on encouraging NKTR-358 data
45c55658-34d5-4325-acff-a984a36e86b1,2019-11-11T08:00:00.000+08:00,4,ImmunoGen: Profiting And Turning Around
b12523ff-cd6f-4f2f-94a0-e2d412edb52e,2019-11-11T08:00:00.000+08:00,3,4 Biotech Stocks That Could Keep Beating Wall Street
522c96d3-bdc9-4015-95eb-53cc74653a03,2019-11-11T08:00:00.000+08:00,4,Nektar up 5% premarket on encouraging NKTR-358 data
b7fe42fd-7a87-408a-9223-f8a39be00198,2019-11-09T08:00:00.000+08:00,4,Dividend Challenger Highlights: Week Of November 10
72f9bdbd-ea8d-4dce-93c6-f68746af1e16,2019-11-09T08:00:00.000+08:00,4,Dividend Challenger Highlights: Week Of November 10
81d25d61-8eb0-4968-95af-a199af7a1048,2019-11-08T08:00:00.000+08:00,4,Ad Com on Lilly and BI's Jardiance for T1D
9fa4a61f-1bb2-408f-bdbf-9b84a0f9adc5,2019-11-08T08:00:00.000+08:00,3,"Andesa Financial Management Inc. Buys Comcast Corp, Texas Instruments Inc, First Trust Value ..."
48614b39-f868-4605-8e09-01808f683b4d,2019-11-08T08:00:00.000+08:00,5,"Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales"
e796b5f9-daa5-490d-9844-86acb5302d9a,2019-11-08T08:00:00.000+08:00,4,Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting
99a3e268-fa24-4d8c-8edd-60963b7511f0,2019-11-08T08:00:00.000+08:00,4,Ad Com on Lilly and BI's Jardiance for T1D
89bee4dc-9d47-4801-a9ec-3d7f68b663f0,2019-11-08T08:00:00.000+08:00,3,"Andesa Financial Management Inc. Buys Comcast Corp, Texas Instruments Inc, First Trust Value ..."
68a6f1dd-86d2-4e00-abb5-3b05d54b689e,2019-11-08T08:00:00.000+08:00,4,"Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales"
d8834aa5-329f-400f-a89e-323784facce0,2019-11-08T08:00:00.000+08:00,4,Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting
01fefe29-22f1-4f00-94ea-f88ab5dea523,2019-11-07T08:00:00.000+08:00,1,Lilly Announces The Pricing Terms Of Its Cash Tender Offer For Up to $2B Aggregate Principal Amount Of Its Outstanding Debt Securities
06a69540-9bc2-4ad8-977b-0eb5a88e67c4,2019-11-07T08:00:00.000+08:00,2,"Abbrea Capital, LLC Buys JPMorgan Ultra-Short Income ETF, Vanguard Short-Term ..."
ca1cb3fd-ac58-4633-9a97-095958a5ad84,2019-11-07T08:00:00.000+08:00,2,Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to ...
01d7f18c-13cb-4832-8c42-d3155f8d8deb,2019-11-07T08:00:00.000+08:00,4,4 RNA Therapy Stocks For A Biotech Portfolio
5a630a1e-e45c-4906-b54e-9fc72cb2395b,2019-11-07T08:00:00.000+08:00,3,"Holistic Financial Partners Buys Eli Lilly and Co, Schwab Emerging Markets Equity ETF, Schwab ..."
282c5bd5-d1b2-4e02-a628-88ecbe495bfa,2019-11-07T08:00:00.000+08:00,4,Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to ...
57da959b-a074-4828-9b45-2be1676a0eb5,2019-11-07T08:00:00.000+08:00,5,"Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up"
0d4b6dbf-6161-491b-a4c5-22bab7d552c1,2019-11-07T08:00:00.000+08:00,3,Fidelity MSCI Health Care Index ETF Is Undervalued
ba63b6f7-3269-4ead-a5b4-2e72da42a4d0,2019-11-07T08:00:00.000+08:00,2,Lilly Announces The Pricing Terms Of Its Cash Tender Offer For Up to $2B Aggregate Principal Amount Of Its Outstanding Debt Securities
b5c63ae0-b78e-49ad-a509-013c4e1575de,2019-11-07T08:00:00.000+08:00,1,"Abbrea Capital, LLC Buys JPMorgan Ultra-Short Income ETF, Vanguard Short-Term ..."
d0625ad8-df04-4fc2-8e4a-17f6727183a2,2019-11-07T08:00:00.000+08:00,4,Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to ...
80e25f71-2788-4c60-8d7f-0701a3ba3605,2019-11-07T08:00:00.000+08:00,5,4 RNA Therapy Stocks For A Biotech Portfolio
6da849b6-e77c-4427-be95-0f125cb4cc6a,2019-11-07T08:00:00.000+08:00,2,"Holistic Financial Partners Buys Eli Lilly and Co, Schwab Emerging Markets Equity ETF, Schwab ..."
9640110f-4723-4de2-a2df-681133c018c8,2019-11-07T08:00:00.000+08:00,4,Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to ...
dfc98f59-fd11-4fd8-b34b-e83c905bd587,2019-11-07T08:00:00.000+08:00,5,"Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up"
4e646c03-42d9-4484-af69-4a9cb1b586a7,2019-11-07T08:00:00.000+08:00,3,Fidelity MSCI Health Care Index ETF Is Undervalued
a65cc292-66b9-4771-84f1-7722e9feb6eb,2019-11-06T08:00:00.000+08:00,1,Eli Lilly shares are trading higher. Not seeing any news to justify the price action.
74dca360-90df-4c9f-937d-49d8941524ed,2019-11-06T08:00:00.000+08:00,4,AstraZeneca Named The Most Innovative Global Pharma Company
e70c0176-b67a-480d-8606-1ac2a3656238,2019-11-06T08:00:00.000+08:00,2,Eli Lilly To Present Multiple Abstracts For LOXO-305 At ASH 2019 Dec. 7-10
52428008-641b-4d06-9d8f-f9c40f5e55ee,2019-11-06T08:00:00.000+08:00,3,US Indexes Close Mostly Flat Wednesday
74f115c1-a1f6-4a3e-8363-546c0f82b967,2019-11-06T08:00:00.000+08:00,4,Eli Lilly and Company to Present Multiple Abstracts for LOXO-'…5 at ASH —…–9
7d1bb69d-e88d-46d4-9c51-87ece61c6a61,2019-11-06T08:00:00.000+08:00,1,Radius (RDUS) Q3 Earnings Beat Estimates on Tymlos Strength
f89c073d-584d-49a9-ab9d-5f33b0fa0d11,2019-11-06T08:00:00.000+08:00,2,ArQule down 17% on early-stage data on ARQ 531
610d26f8-6750-4b17-97b3-c923cb8054a1,2019-11-06T08:00:00.000+08:00,3,Eli Lilly shares are trading higher. Not seeing any news to justify the price action.
dcdbaa82-6dba-4cc1-9f50-d09800a22b1f,2019-11-06T08:00:00.000+08:00,4,AstraZeneca Named The Most Innovative Global Pharma Company
dc9aa460-4f62-48ef-9165-f546eba4836b,2019-11-06T08:00:00.000+08:00,1,Eli Lilly To Present Multiple Abstracts For LOXO-305 At ASH 2019 Dec. 7-10
d28df7a7-46b4-4e54-a242-6a3d91d1d153,2019-11-06T08:00:00.000+08:00,3,US Indexes Close Mostly Flat Wednesday
755ae085-a3df-49fd-978a-15b8606e9992,2019-11-06T08:00:00.000+08:00,2,Eli Lilly and Company to Present Multiple Abstracts for LOXO-'…5 at ASH —…–9
79f4bad1-d460-466e-95d3-c905738f9130,2019-11-06T08:00:00.000+08:00,4,Radius (RDUS) Q3 Earnings Beat Estimates on Tymlos Strength
e4e81a5e-85a9-4bbf-8f86-2ac259501a4b,2019-11-06T08:00:00.000+08:00,1,ArQule down 17% on early-stage data on ARQ 531
e696dbc4-2848-4265-8871-c1b8a6ac6851,2019-11-05T08:00:00.000+08:00,3,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2019 Update
0a69e344-5c84-43ec-9242-4b288b00b27b,2019-11-05T08:00:00.000+08:00,4,"Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View"
ca671261-b23f-41a5-883e-2f40484ece69,2019-11-05T08:00:00.000+08:00,2,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2019 Update
5162485e-a7c9-4ca8-bbd2-dd6f79ff470d,2019-11-05T08:00:00.000+08:00,4,"Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View"
c123ca72-a768-4798-92e0-60c8b2ee42a1,2019-11-04T08:00:00.000+08:00,3,"Boehringer Ingelheim, Eli Lilly Report Modernization Of Alliance To Focus Full Expertise On Jardiance"
cc87072e-8373-4382-a43f-e57a517c0fb2,2019-11-04T08:00:00.000+08:00,1,Boston nonprofit playing big role in drug pricing
ad7f6f69-68a4-4b13-b150-b9f3eb31e26e,2019-11-04T08:00:00.000+08:00,1,Boston nonprofit playing big role in drug pricing
9b6a0697-af7a-4f64-b1d2-0e6b0ecfcadd,2019-11-04T08:00:00.000+08:00,2,Boston nonprofit playing big role in drug pricing
3c1032cc-c8c3-4419-9317-d712713db36e,2019-11-04T08:00:00.000+08:00,2,Boston nonprofit playing big role in drug pricing
f13706e5-739d-465c-86a8-df0fdc8404cf,2019-11-04T08:00:00.000+08:00,3,Value Biotech ETFs & Stocks to Buy Now
ef3bd042-7200-4f40-90c5-2c6d57a67fbd,2019-11-04T08:00:00.000+08:00,1,What's in the Cards for Teva (TEVA) This Earnings Season?
51aaae08-fb77-4c93-b911-be4080d486ec,2019-11-04T08:00:00.000+08:00,4,Incyte: An Undervalued Biotech With Catalysts
212ee5d3-f970-4105-b93b-0f109b09c6d4,2019-11-04T08:00:00.000+08:00,4,Incyte: An Undervalued Biotech With Catalysts
558c1795-7243-40e3-a35f-96aa162fa8e8,2019-11-04T08:00:00.000+08:00,3,"Boehringer Ingelheim, Eli Lilly Report Modernization Of Alliance To Focus Full Expertise On Jardiance"
ec83c6db-47dd-481d-b278-c459dd0357c1,2019-11-04T08:00:00.000+08:00,2,Boston nonprofit playing big role in drug pricing
4072115c-4a8a-418d-8b35-0821a75c37e5,2019-11-04T08:00:00.000+08:00,2,Boston nonprofit playing big role in drug pricing
a943551e-bf91-4adf-9589-16cdb9752113,2019-11-04T08:00:00.000+08:00,1,Boston nonprofit playing big role in drug pricing
dee59271-939b-4f32-818c-bad7f5b551fe,2019-11-04T08:00:00.000+08:00,2,Boston nonprofit playing big role in drug pricing
8a3b86a6-3785-4f23-93b8-6bc6d7b9bb6d,2019-11-04T08:00:00.000+08:00,4,Value Biotech ETFs & Stocks to Buy Now
535274aa-7935-483b-b3e7-105e86710c01,2019-11-04T08:00:00.000+08:00,3,What's in the Cards for Teva (TEVA) This Earnings Season?
2ae54611-6e05-4be7-9b9b-e27a81132a4e,2019-11-04T08:00:00.000+08:00,5,Incyte: An Undervalued Biotech With Catalysts
f1034548-dfe5-442e-95f1-61b93697a593,2019-11-04T08:00:00.000+08:00,5,Incyte: An Undervalued Biotech With Catalysts
8c5c9367-f694-4538-b1cf-6a549c60cd23,2019-11-03T08:00:00.000+08:00,4,Week In Review: BeiGene Forms Blockbuster $2.7 Billion Collaboration With Amgen
71b4a35a-0393-4d50-a498-25bca7825487,2019-11-03T08:00:00.000+08:00,4,Week In Review: BeiGene Forms Blockbuster $2.7 Billion Collaboration With Amgen
b89dd364-f8b8-4595-b313-b941b11a25b5,2019-11-01T08:00:00.000+08:00,2,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates
310dba03-2f0d-4024-b6ba-ac82e472e003,2019-11-01T08:00:00.000+08:00,1,"Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss"
6960440d-b9ef-462f-984f-a65c87769ecc,2019-11-01T08:00:00.000+08:00,4,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates
ff22386c-7632-41dd-a6bd-db0463090948,2019-11-01T08:00:00.000+08:00,2,"Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss"
e3790268-ba4c-4a0b-a939-9a98432eeecb,2019-10-31T08:00:00.000+08:00,4,"United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up"
2ad8bfd2-a151-47d8-af06-7aabaecd44e2,2019-10-31T08:00:00.000+08:00,1,"Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales"
070fc39e-c35b-4919-83f0-cf9d84299179,2019-10-31T08:00:00.000+08:00,4,"United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up"
94b8124d-b540-4298-b216-3f74a237a1f1,2019-10-31T08:00:00.000+08:00,1,"Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales"
cc683692-876f-4d3e-b49f-9b64d25885f9,2019-10-30T08:00:00.000+08:00,4,Daily Insider Ratings Round Up 10/28/19
86e09ea5-3e64-4c03-895f-a86c72d6d1a1,2019-10-30T08:00:00.000+08:00,5,Eli Lilly's Approval For Migraine Drug Provides A Unique Treatment Option
45bea7ec-e599-419d-b518-8981318500ef,2019-10-30T08:00:00.000+08:00,3,Daily Insider Ratings Round Up 10/28/19
0397575b-49e7-431e-9db4-693fb47c7504,2019-10-30T08:00:00.000+08:00,2,Eli Lilly's Approval For Migraine Drug Provides A Unique Treatment Option
5decc4a1-a681-4ca8-a241-d4424f37bdcd,2019-10-29T08:00:00.000+08:00,1,"\"Drug shortages reflect \"\"broken market\"\" - FDA\""
516e1338-a33a-493a-b8dc-403f42c39f93,2019-10-29T08:00:00.000+08:00,4,"Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View"
a805cc9e-3d18-45a6-927b-e6d77e162945,2019-10-29T08:00:00.000+08:00,2,"\"Drug shortages reflect \"\"broken market\"\" - FDA\""
1a6d24df-7aa8-43bf-9054-93230140c1b1,2019-10-29T08:00:00.000+08:00,4,"Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View"
e1177161-7d3e-495e-9694-ecfb13adac48,2019-10-28T08:00:00.000+08:00,5,"Eli Lilly Reports Results For Taltz In Pediatric Patients With Moderate To Severe Plaque Psoriasis, Met Co-Primary Endpoints; Co. To Submit For US Regulatory Approval"
55bd952c-4810-42b3-bf98-a41999ced276,2019-10-28T08:00:00.000+08:00,3,Daily Insider Ratings Round Up 10/25/19
0b236ac7-98a8-41f0-8fb6-ef188106ac2c,2019-10-28T08:00:00.000+08:00,4,Lilly's Taltz successful in pediatric psoriasis study; shares up 2%
034467e8-e0dd-4f89-aba6-c047cb7b3a18,2019-10-28T08:00:00.000+08:00,3,"Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More"
91ba064b-ffff-4eb9-902d-f9a12c93ace8,2019-10-28T08:00:00.000+08:00,4,"Eli Lilly Reports Results For Taltz In Pediatric Patients With Moderate To Severe Plaque Psoriasis, Met Co-Primary Endpoints; Co. To Submit For US Regulatory Approval"
1ca2a3dc-b067-4d60-b627-c87c8e617931,2019-10-28T08:00:00.000+08:00,4,Daily Insider Ratings Round Up 10/25/19
6d238559-5aa4-480c-86f6-7be34882e7ea,2019-10-28T08:00:00.000+08:00,5,Lilly's Taltz successful in pediatric psoriasis study; shares up 2%
33f48b32-0f82-47c0-b244-0faffcb691ef,2019-10-28T08:00:00.000+08:00,2,"Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More"
5f31b515-db25-4fdc-b457-37e8d135892d,2019-10-27T08:00:00.000+08:00,4,3 Stocks Seeing Notable Insider Buying
c177d5ab-8b54-46ce-a789-d40ef0f61c19,2019-10-27T08:00:00.000+08:00,3,Top Insider Buys Highlight for the Week of Oct. —5
26a265af-2f9e-43cd-a2a0-35605a8e7c12,2019-10-27T08:00:00.000+08:00,2,"FOMC, Streaming Wars And JEDI In Focus (Stocks To Watch Podcast)"
0d2503bc-7cf2-4a45-b9af-e9f0797ae38c,2019-10-27T08:00:00.000+08:00,4,3 Stocks Seeing Notable Insider Buying
5d5ce9a1-b36e-4bd0-bfb3-d268ee49579a,2019-10-27T08:00:00.000+08:00,2,Top Insider Buys Highlight for the Week of Oct. —5
f5ea0b66-6dad-45fc-9e3a-454d52d4ed2b,2019-10-27T08:00:00.000+08:00,3,"FOMC, Streaming Wars And JEDI In Focus (Stocks To Watch Podcast)"
3b5e9cdb-f18f-48f8-9ae9-f4be586f5b2b,2019-10-26T08:00:00.000+08:00,4,"Notable Insider Buys In The Past Week: Eli Lilly, JPMorgan, Thor Industries"
1e3a96e3-c2a0-4a1a-b21e-0247e3676235,2019-10-26T08:00:00.000+08:00,1,"Week In Review: How Trump's Policies Moved Stocks - October 26, 2019"
11c40b26-dc6a-4ed9-a41e-37886ab7c53f,2019-10-26T08:00:00.000+08:00,3,"Stocks To Watch: FOMC, Streaming Wars And JEDI In Focus"
e9222af7-6bdf-40af-ac8f-f812dbc22899,2019-10-26T08:00:00.000+08:00,4,"Notable Insider Buys In The Past Week: Eli Lilly, JPMorgan, Thor Industries"
11df1159-d79b-417d-a168-339f6bdd845c,2019-10-26T08:00:00.000+08:00,2,"Week In Review: How Trump's Policies Moved Stocks - October 26, 2019"
07d7d794-838b-4847-9bc0-d615e3d7510e,2019-10-26T08:00:00.000+08:00,3,"Stocks To Watch: FOMC, Streaming Wars And JEDI In Focus"
a97557b2-72ae-428c-acca-c55f43bd7820,2019-10-25T08:00:00.000+08:00,4,"Eli Lilly And Co (LLY) President & CEO David A Ricks Bought $5……,–74 of Shares"
c5169abf-68b0-49a8-b5e0-ab7ced88dea7,2019-10-25T08:00:00.000+08:00,3,"Pharma Stock Roundup: LLY, NVS, AZN's Q3 Earnings, Updates From FDA"
50a8200d-823c-4283-921f-991ecf673c4a,2019-10-25T08:00:00.000+08:00,2,"Eli Lilly And Co (LLY) President & CEO David A Ricks Bought $5……,–74 of Shares"
64a230f6-9ed6-46c4-b440-021dedef0f1f,2019-10-25T08:00:00.000+08:00,4,"Pharma Stock Roundup: LLY, NVS, AZN's Q3 Earnings, Updates From FDA"
4c997d19-83d0-4314-b357-162a0754bd99,2019-10-24T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise"
08e064e5-f25a-44d0-98a3-e1316c2dc66e,2019-10-24T08:00:00.000+08:00,4,Lilly Announces Cash Tender Offer for Up to $—. ...
a8355b54-95d2-4a98-a54f-7237b3dfc5b7,2019-10-24T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise"
a985718b-b745-4148-abfc-1f45719d92c0,2019-10-24T08:00:00.000+08:00,2,Lilly Announces Cash Tender Offer for Up to $—. ...
96ba8972-cc9f-4373-a35f-a1cd4f2f8077,2019-10-23T08:00:00.000+08:00,1,Stocks That Hit 52-Week Lows On Wednesday
7528cfc8-0edf-4239-9d48-08990d9f64b0,2019-10-23T08:00:00.000+08:00,3,33 Healthcare Stocks Moving In Wednesday's Pre-Market Session
722815bd-5ed7-474d-a77e-1d7a409b689d,2019-10-23T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data"
b7224c3b-64b4-40af-b8b1-bdbabe8a73ec,2019-10-23T08:00:00.000+08:00,3,"Eli Lilly Reports Mixed Q3 Earnings, Raises Guidance"
e7d6c45c-1c1e-4443-bbee-b29e89a80e1f,2019-10-23T08:00:00.000+08:00,2,Eli Lilly And Co shares are trading lower after the company reported worse-than-expected Q3 sales results.
b5e60b68-4115-44fa-8b7c-d5f725a39612,2019-10-23T08:00:00.000+08:00,3,"Lilly Raises FY19 Adj. EPS Guidance From $5.67-$5.77 To $5.75-$5.85 vs $5.72 Est., Sees Sales $22B-$22.5B vs $22.23B Est."
a5dab8b4-0820-48f6-9d12-79571a95d6a3,2019-10-23T08:00:00.000+08:00,1,"Eli Lilly Q3 Adj. EPS $1.48 Beats $1.4 Estimate, Sales $5.48B Miss $5.5B Estimate"
8f14060a-8ca5-4ca6-a60f-4613481ec2bd,2019-10-23T08:00:00.000+08:00,4,"12 Stocks To Watch For October 23, 2019"
d583f32c-5532-429b-abd0-337a0a95805d,2019-10-23T08:00:00.000+08:00,3,"Earnings Scheduled For October 23, 2019"
00d58465-e8fa-4b78-b209-ffd975003b68,2019-10-23T08:00:00.000+08:00,2,Eli Lilly and Company (LLY) CEO Dave Ricks on Q3 2019 Results - Earnings Call Transcript
91502467-6e75-4503-b262-5dd21ce5dbf3,2019-10-23T08:00:00.000+08:00,4,Biogen: A Trading Strategy
72c1a802-4ee3-44e0-bb02-0678e3ed1759,2019-10-23T08:00:00.000+08:00,1,"Lilly (LLY) Q3 Earnings Top Estimates, Sales Lag, Stock Down"
2dca69ee-0d59-4202-9ca5-2baeec08e67b,2019-10-23T08:00:00.000+08:00,1,Lilly down 3% as sales lag expectations
8b10af6d-a86f-4548-a505-80c8bd49f79f,2019-10-23T08:00:00.000+08:00,3,"Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to ..."
d23add37-383e-479a-9437-dc3786e8de7e,2019-10-23T08:00:00.000+08:00,5,Eli Lilly (LLY) Surpasses Q3 Earnings Estimates
acebeb94-5a89-46a3-b596-d65e8fd19e2e,2019-10-23T08:00:00.000+08:00,4,Eli Lilly raises EPS guidance after Q3 earnings beat
a4a8d1f4-d608-4cc7-9059-63ebcd498ef7,2019-10-23T08:00:00.000+08:00,2,"Eli Lilly EPS beats by $0.07, misses on revenue"
7b5ab94d-91d1-4b25-b740-fd9bdafa369a,2019-10-23T08:00:00.000+08:00,1,Stocks That Hit 52-Week Lows On Wednesday
9433d425-f574-4860-90f7-3fab6967b1b1,2019-10-23T08:00:00.000+08:00,3,33 Healthcare Stocks Moving In Wednesday's Pre-Market Session
dc76991d-d3c0-47a8-92c7-34194c930bbe,2019-10-23T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data"
4a324f8e-b75b-421a-ac83-a0b3be3c69fa,2019-10-23T08:00:00.000+08:00,3,"Eli Lilly Reports Mixed Q3 Earnings, Raises Guidance"
b1249034-5460-4979-9ed8-6de82b87c543,2019-10-23T08:00:00.000+08:00,3,Eli Lilly And Co shares are trading lower after the company reported worse-than-expected Q3 sales results.
ebd4ea04-146c-4cf2-93c0-6c6d41963924,2019-10-23T08:00:00.000+08:00,4,"Lilly Raises FY19 Adj. EPS Guidance From $5.67-$5.77 To $5.75-$5.85 vs $5.72 Est., Sees Sales $22B-$22.5B vs $22.23B Est."
57ab3bc2-f613-4d09-8219-45751ff65e5f,2019-10-23T08:00:00.000+08:00,1,"Eli Lilly Q3 Adj. EPS $1.48 Beats $1.4 Estimate, Sales $5.48B Miss $5.5B Estimate"
19cffc7a-74f8-4a0a-95ac-46b5384a0b75,2019-10-23T08:00:00.000+08:00,2,"12 Stocks To Watch For October 23, 2019"
08a2c5ff-cf59-4bc3-b632-f3dbcfb7ff84,2019-10-23T08:00:00.000+08:00,1,"Earnings Scheduled For October 23, 2019"
15a54d73-2283-4662-babb-36ec55c9142c,2019-10-23T08:00:00.000+08:00,3,Eli Lilly and Company (LLY) CEO Dave Ricks on Q3 2019 Results - Earnings Call Transcript
f79c0bb5-b48f-468c-80d0-3fad036467be,2019-10-23T08:00:00.000+08:00,4,Biogen: A Trading Strategy
16036777-1c90-4ad4-a2d2-0976c8bfdf26,2019-10-23T08:00:00.000+08:00,1,"Lilly (LLY) Q3 Earnings Top Estimates, Sales Lag, Stock Down"
e1803401-d129-4eaf-851b-4745807ff4a3,2019-10-23T08:00:00.000+08:00,2,Lilly down 3% as sales lag expectations
730c4ac1-605d-46c4-aedf-63c70e2ebf1d,2019-10-23T08:00:00.000+08:00,4,"Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to ..."
1fde8657-853e-47cb-a13e-dad51f7b6677,2019-10-23T08:00:00.000+08:00,5,Eli Lilly (LLY) Surpasses Q3 Earnings Estimates
bc1277fe-38f2-40aa-b52a-20bc6f9e266e,2019-10-23T08:00:00.000+08:00,4,Eli Lilly raises EPS guidance after Q3 earnings beat
8606fac6-a022-426c-b644-13299ea7fd43,2019-10-23T08:00:00.000+08:00,1,"Eli Lilly EPS beats by $0.07, misses on revenue"
36324271-db94-44b2-a07c-deec673dbb54,2019-10-22T08:00:00.000+08:00,2,"Mixed Bag: Better Outlooks From Lockheed, United Technologies, But McDonald's Misses"
6fba7577-c546-47c9-9374-d66c5b5064de,2019-10-22T08:00:00.000+08:00,3,Notable earnings before Wednesday's open
ef1c7acb-5a64-41c8-9a67-85f6f5f3d52f,2019-10-22T08:00:00.000+08:00,4,— Large-Cap Stocks Announce Dividends
44092dfa-5b99-4ad2-804d-ba2f105456cf,2019-10-22T08:00:00.000+08:00,2,"Mixed Bag: Better Outlooks From Lockheed, United Technologies, But McDonald's Misses"
221f8bd9-0c36-4c02-b579-819e9d09bc11,2019-10-22T08:00:00.000+08:00,3,Notable earnings before Wednesday's open
d4021b27-6f34-4d92-98c3-ca6b1b6c4517,2019-10-22T08:00:00.000+08:00,4,— Large-Cap Stocks Announce Dividends
17269a29-3ef6-47ab-9b56-1291c68074a4,2019-10-21T08:00:00.000+08:00,2,Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition
89db2401-bfe6-4421-bccc-3c1556be32a6,2019-10-21T08:00:00.000+08:00,5,Lilly Declares Fourth-Quarter —…–9 Dividend
bc99bc5a-e170-4db2-a522-d3394660694e,2019-10-21T08:00:00.000+08:00,5,Eli Lilly declares $0.645 dividend
845304a9-20d7-40e9-9323-aef8ed6ca50b,2019-10-21T08:00:00.000+08:00,2,Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition
97ae1b5b-346a-4383-9f21-8d2b0346447b,2019-10-21T08:00:00.000+08:00,4,Lilly Declares Fourth-Quarter —…–9 Dividend
dbcc36cb-d817-4955-a1a7-95ee0edc965d,2019-10-21T08:00:00.000+08:00,4,Eli Lilly declares $0.645 dividend
c5841ea4-1227-41a4-bf36-6e5a0c83afde,2019-10-20T08:00:00.000+08:00,3,"The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict"
6eb0acc9-40be-40dc-a21f-902a72c3a958,2019-10-20T08:00:00.000+08:00,4,"The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict"
f32affbf-e0be-4b41-8423-06087facc304,2019-10-18T08:00:00.000+08:00,5,European Medicines Agency Says CHMP Recommended Granting A Marketing Authorization For Eli Lilly's BAQSIMI
82061cc5-dd84-4e65-9e42-65d4ade185ac,2019-10-18T08:00:00.000+08:00,4,"Supplemental Annuity Collective Trust of NJ Buys Mastercard Inc, L'Harris Technologies Inc, ..."
9912a7ae-af7f-4444-9846-61a00b088039,2019-10-18T08:00:00.000+08:00,2,"Hills Bank & Trust Co Buys Mastercard Inc, Alexion Pharmaceuticals Inc, NextEra Energy Inc, ..."
d1d06503-e222-4fda-9537-efdeb641d8ef,2019-10-18T08:00:00.000+08:00,3,"Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow"
ca4e12ca-2425-4bf8-8024-7668a0ced72e,2019-10-18T08:00:00.000+08:00,1,New Gilead CFO: Let's Make A Deal
05a03542-d1cd-4c38-a0a6-4135c20fc73b,2019-10-18T08:00:00.000+08:00,5,European advisory group backs Lilly's nasally administered glucagon
18ece381-5f13-4d2e-ad01-a5e60952cf03,2019-10-18T08:00:00.000+08:00,4,European Medicines Agency Says CHMP Recommended Granting A Marketing Authorization For Eli Lilly's BAQSIMI
8776fbc7-6ddd-4ea1-a597-674569a9eb0d,2019-10-18T08:00:00.000+08:00,2,"Supplemental Annuity Collective Trust of NJ Buys Mastercard Inc, L'Harris Technologies Inc, ..."
7375730f-f228-4bd1-9e70-176f89824c7c,2019-10-18T08:00:00.000+08:00,3,"Hills Bank & Trust Co Buys Mastercard Inc, Alexion Pharmaceuticals Inc, NextEra Energy Inc, ..."
457a0b90-f029-4670-9806-320fe34b9173,2019-10-18T08:00:00.000+08:00,4,"Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow"
e4f5f064-b20e-4d97-a071-2230ccacc093,2019-10-18T08:00:00.000+08:00,1,New Gilead CFO: Let's Make A Deal
505537ab-7c10-4f8d-8be2-81a1b254339e,2019-10-18T08:00:00.000+08:00,4,European advisory group backs Lilly's nasally administered glucagon
6802f4db-24aa-46d7-8505-a767db279a65,2019-10-17T08:00:00.000+08:00,5,"UBS Maintains Buy on Eli Lilly, Lowers Price Target to $133"
b8867436-8bf0-4a1c-8085-36eec049e06a,2019-10-17T08:00:00.000+08:00,3,"Bank of America Reinstates Buy on Eli Lilly, Announces $133 Price Target"
871ea44a-9fdc-4fc0-8f4b-356509908ee3,2019-10-17T08:00:00.000+08:00,2,Pelosi drug bill passes first House committee
db8b5d7c-ed3c-4066-8b58-9c56290284c9,2019-10-17T08:00:00.000+08:00,1,Lilly's Pancreatic Cancer Candidate Fails in Phase III Study
e4e97a24-38b6-45b1-b0b4-0130654b77aa,2019-10-17T08:00:00.000+08:00,4,Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?
48854900-04aa-46da-a73a-cfedb559c2e7,2019-10-17T08:00:00.000+08:00,5,"UBS Maintains Buy on Eli Lilly, Lowers Price Target to $133"
7fff5ac6-8a6e-4b55-9197-a5434c77de6c,2019-10-17T08:00:00.000+08:00,5,"Bank of America Reinstates Buy on Eli Lilly, Announces $133 Price Target"
b5d3a7bc-119b-42a4-b517-ac065b66b110,2019-10-17T08:00:00.000+08:00,3,Pelosi drug bill passes first House committee
730c7027-a713-471c-be87-fef45367f7e0,2019-10-17T08:00:00.000+08:00,1,Lilly's Pancreatic Cancer Candidate Fails in Phase III Study
8486f77e-290c-42c9-8519-4e5dff5ee971,2019-10-17T08:00:00.000+08:00,2,Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?
a931afc4-245c-4ad1-9a2b-19e4022c20c1,2019-10-16T08:00:00.000+08:00,1,Eli Lilly And Co shares are trading lower after the company reported that its Phase 3 study in patients with Metastatic pancreatic cancer did not meet its primary endpoint.
86f62aca-d7bf-416d-b706-f86f1c595de7,2019-10-16T08:00:00.000+08:00,3,17 Healthcare Stocks Moving In Wednesday's Pre-Market Session
6cfc428d-efd6-4e37-8f91-e05f2dfb6964,2019-10-16T08:00:00.000+08:00,4,Eli Lilly Reports Phase 3 Study In Patients With Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint
906520ac-65a9-42a4-8bc3-092bb5d1d73d,2019-10-16T08:00:00.000+08:00,5,BofA Merrill Lynch sees 25% upside in Vertex in after-hours analyst action
13941f36-b0cf-4d5a-910e-18fe557433e8,2019-10-16T08:00:00.000+08:00,2,Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
0bf80ef4-c866-4c34-9aa1-41c5f952e817,2019-10-16T08:00:00.000+08:00,1,Lilly Announces Phase ' Study in Patients with Metastatic Pancreatic Cancer Did Not Meet ...
eb0037c8-d63b-4697-9138-1bf41059cce7,2019-10-16T08:00:00.000+08:00,4,Lilly's pegilodecakin flunks late-stage study; shares down 2% premarket
e19e3a71-e2c7-4deb-9451-4024b5300ea2,2019-10-16T08:00:00.000+08:00,3,Eli Lilly And Co shares are trading lower after the company reported that its Phase 3 study in patients with Metastatic pancreatic cancer did not meet its primary endpoint.
f0bf1917-34ea-4448-9857-eae4aa745cd4,2019-10-16T08:00:00.000+08:00,2,17 Healthcare Stocks Moving In Wednesday's Pre-Market Session
3060f8ee-303a-4397-b4db-0939cc65e32b,2019-10-16T08:00:00.000+08:00,1,Eli Lilly Reports Phase 3 Study In Patients With Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint
8b2ca10a-9627-4688-b4b4-4d6116e4850b,2019-10-16T08:00:00.000+08:00,4,BofA Merrill Lynch sees 25% upside in Vertex in after-hours analyst action
2ff93f32-a97f-46c7-aa4a-e83392da750e,2019-10-16T08:00:00.000+08:00,3,Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
431c4780-bca4-4b0b-8ecf-61ada2015253,2019-10-16T08:00:00.000+08:00,1,Lilly Announces Phase ' Study in Patients with Metastatic Pancreatic Cancer Did Not Meet ...
578fa87a-be61-43b8-8ac7-7be9fea0cfb8,2019-10-16T08:00:00.000+08:00,1,Lilly's pegilodecakin flunks late-stage study; shares down 2% premarket
1a34e2e5-c919-43e8-917f-f86b0e0685ae,2019-10-15T08:00:00.000+08:00,4,Pelosi drug bill would save $345B - CBO
cf3039d9-3057-46ca-80c4-b0fec78c5d65,2019-10-15T08:00:00.000+08:00,1,Lilly to close UK research facility
ccffc9e4-539c-46b9-8a33-2af00f7ef677,2019-10-15T08:00:00.000+08:00,4,Pelosi drug bill would save $345B - CBO
d3051462-4b81-47b2-a5a5-223783cf6746,2019-10-15T08:00:00.000+08:00,1,Lilly to close UK research facility
deee1747-8f5b-4716-90f1-fc40642d5540,2019-10-14T08:00:00.000+08:00,2,5—-Week Company Lows
23637852-bcaa-4a4c-80b4-b5b144ce372e,2019-10-14T08:00:00.000+08:00,4,Pfenex up 2% premarket on positive human factor data on PF708
fb0fcbfa-d269-4a7e-8bb4-bb5cdce606be,2019-10-14T08:00:00.000+08:00,3,Lilly's Taltz successful in late-stage pediatric psoriasis study
d1349287-86c6-410b-9a2f-08f1874bc308,2019-10-14T08:00:00.000+08:00,1,5—-Week Company Lows
4d7f7a1f-9522-44ed-bf06-506dd39be6c9,2019-10-14T08:00:00.000+08:00,4,Pfenex up 2% premarket on positive human factor data on PF708
79ae5499-f163-42a2-9c03-6e5b098fdc9d,2019-10-14T08:00:00.000+08:00,5,Lilly's Taltz successful in late-stage pediatric psoriasis study
5918fbbb-7717-4f27-a523-13476559b029,2019-10-13T08:00:00.000+08:00,4,New Sanofi CEO Looks to Shake Things Up
eec55958-5671-4417-8ae1-d2ce3db1fba2,2019-10-13T08:00:00.000+08:00,4,New Sanofi CEO Looks to Shake Things Up
c63312a1-d289-4cd6-a4bf-b4ba5c72465c,2019-10-12T08:00:00.000+08:00,5,Lilly Presents Positive Results for Taltz in Pediatric Patients with Moderate to Severe Plaque Psoriasis at EADV 2019
b52e4ff2-bc05-47b3-81c0-498d0ca0d94a,2019-10-12T08:00:00.000+08:00,5,Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to ...
50370bf3-45c6-4b04-9d0a-902b865839e0,2019-10-12T08:00:00.000+08:00,5,Lilly Presents Positive Results for Taltz in Pediatric Patients with Moderate to Severe Plaque Psoriasis at EADV 2019
0e0a9554-8965-4bb3-ab16-84218685584d,2019-10-12T08:00:00.000+08:00,4,Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to ...
b04cd6a7-f4bb-4eb3-9f81-c553917d5bce,2019-10-11T08:00:00.000+08:00,5,Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.
0da2b4d9-c520-4a91-a276-ea909e117219,2019-10-11T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout"
7dfb5d6d-5caf-4b6a-8401-959392659102,2019-10-11T08:00:00.000+08:00,4,FDA OKs Lilly's lasmiditan for migraine
652ec82b-b8d9-441d-830a-579e1c5946c3,2019-10-11T08:00:00.000+08:00,5,"Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment ..."
b398d70d-05ea-4823-af2f-94559ee7176e,2019-10-11T08:00:00.000+08:00,4,Eli Lilly Shows Its Strength With Taltz In Positive Head To Head Study
06066b09-935c-46dd-8e46-0cd496303235,2019-10-11T08:00:00.000+08:00,3,"Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals"
b56d26b4-9f81-491c-b883-0064e35e9748,2019-10-11T08:00:00.000+08:00,2,Gilead-Galapagos Report Efficacy & Safety Results on RA Drug
bcdee371-86e9-4423-9412-12e5771a9f03,2019-10-11T08:00:00.000+08:00,5,"Affiance Financial, LLC Buys Eli Lilly and Co, Mondelez International Inc, U.S. ..."
888d3247-8c5b-411f-ad42-c7e4974ab929,2019-10-11T08:00:00.000+08:00,4,Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.
87b87cef-fc76-4eb5-b01c-84b03a9ddf4c,2019-10-11T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout"
9681b12a-8607-4cb6-b019-e8b34a076bb7,2019-10-11T08:00:00.000+08:00,5,FDA OKs Lilly's lasmiditan for migraine
32f32c90-fbef-44cc-a31a-7ca8a0a1724d,2019-10-11T08:00:00.000+08:00,3,"Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment ..."
00105e0f-d7a0-4c74-a448-ee1fa3e2c5e7,2019-10-11T08:00:00.000+08:00,4,Eli Lilly Shows Its Strength With Taltz In Positive Head To Head Study
8cecee45-946f-4f98-b899-7985fe2dfc6b,2019-10-11T08:00:00.000+08:00,4,"Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals"
1a38f9d2-a2e6-4801-b806-f5a02c99c78e,2019-10-11T08:00:00.000+08:00,4,Gilead-Galapagos Report Efficacy & Safety Results on RA Drug
54a4afae-1c15-4626-b7ce-af007310368d,2019-10-11T08:00:00.000+08:00,3,"Affiance Financial, LLC Buys Eli Lilly and Co, Mondelez International Inc, U.S. ..."
2b7f61c7-304e-4d95-8d63-c35ba513fbb1,2019-10-10T08:00:00.000+08:00,5,"Lilly Says Taltz Met Primary, Secondary Endpoints of Ixora-R Study in People With Moderate to Severe Plaque Psoriasis"
fcc7dd4e-6306-4385-8b7b-9606f6440b99,2019-10-10T08:00:00.000+08:00,2,"Country Trust Bank Buys Ingersoll-Rand PLC, PepsiCo Inc, NVIDIA Corp, Sells The Walt Disney Co, ..."
39021c35-c2f1-4449-a021-cf08f0bedc10,2019-10-10T08:00:00.000+08:00,1,Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study
0b2d76db-c3d1-4925-b244-74f893303dbe,2019-10-10T08:00:00.000+08:00,4,"Lilly Says Taltz Met Primary, Secondary Endpoints of Ixora-R Study in People With Moderate to Severe Plaque Psoriasis"
a0bf690b-2670-46d6-af59-e50fc5eb8d2b,2019-10-10T08:00:00.000+08:00,3,"Country Trust Bank Buys Ingersoll-Rand PLC, PepsiCo Inc, NVIDIA Corp, Sells The Walt Disney Co, ..."
1d89d6f7-2e3b-46e1-adc8-3bf32a78cc5d,2019-10-10T08:00:00.000+08:00,2,Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study
ea637ef0-4138-4969-a70a-ddfada41f1ce,2019-10-09T08:00:00.000+08:00,1,"Novartis Delivers In Breast Cancer Study, Could Lead To A Major Battle With Competitors"
2a68f6f2-f805-41a2-b821-b51c2ef05717,2019-10-09T08:00:00.000+08:00,3,Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan
72d386c5-748f-46ae-bd08-f902edc1b14a,2019-10-09T08:00:00.000+08:00,2,"First National Bank of Mount Dora, Trust Investmen Buys Eli Lilly and Co, TJX Inc, The Hartford ..."
97b99baa-af1b-459c-8e54-38c6765e0db9,2019-10-09T08:00:00.000+08:00,4,"Novartis Delivers In Breast Cancer Study, Could Lead To A Major Battle With Competitors"
c0231329-ce54-448a-8858-14bf0780b8d3,2019-10-09T08:00:00.000+08:00,3,Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan
3e26d0c2-8676-4f2c-b6bc-36d91f4ee301,2019-10-09T08:00:00.000+08:00,1,"First National Bank of Mount Dora, Trust Investmen Buys Eli Lilly and Co, TJX Inc, The Hartford ..."
6e2bd548-035e-4dc9-bb63-9328f12e8307,2019-10-08T08:00:00.000+08:00,1,Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on $250 billion worth of goods from 25% to 30% on Oct 15.
bcd0bd67-a64a-4b4f-9b00-ce715bb3af2f,2019-10-08T08:00:00.000+08:00,2,BioNTech IPO: What You Need To Know
603a108d-8c70-4eaf-97de-80b9838cfb2e,2019-10-08T08:00:00.000+08:00,3,Lilly To Present New Data For Treatments Of Complex Dermatological Conditions At The 28th Annual European Academy Of Dermatology and Venereology Congress Ot. 9-13
d02c38ea-c25c-4cc7-8aff-71ff2d429d56,2019-10-08T08:00:00.000+08:00,1,AbbVie and Roche price hike leaders past two years
3c0061b7-44f9-4d91-b2b0-78d66f03695b,2019-10-08T08:00:00.000+08:00,4,"A Look At Merck's Keytruda And Other Headlines: The Good, Bad, And Ugly Of Biopharma"
63c18ced-d1e3-48b6-9f5c-f4f92b8720fb,2019-10-08T08:00:00.000+08:00,3,Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the —8th ...
7f93253e-0647-468b-9649-44ae7e24b01d,2019-10-08T08:00:00.000+08:00,2,MannKind: Q3 Afrezza Sales In The Books - Brazil Launch Pending
f73c3739-aed2-4242-aed2-52f89d0410c4,2019-10-08T08:00:00.000+08:00,1,Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on $250 billion worth of goods from 25% to 30% on Oct 15.
314aa2fb-79e7-4a06-b25d-a2308fda660d,2019-10-08T08:00:00.000+08:00,3,BioNTech IPO: What You Need To Know
f701d5ec-90c7-440f-a69f-855180458c52,2019-10-08T08:00:00.000+08:00,4,Lilly To Present New Data For Treatments Of Complex Dermatological Conditions At The 28th Annual European Academy Of Dermatology and Venereology Congress Ot. 9-13
5ea18378-ffad-4609-9a5a-8e3074b3f7c4,2019-10-08T08:00:00.000+08:00,2,AbbVie and Roche price hike leaders past two years
ab2efe23-c10b-458b-8c2b-0275faa2100d,2019-10-08T08:00:00.000+08:00,2,"A Look At Merck's Keytruda And Other Headlines: The Good, Bad, And Ugly Of Biopharma"
4f50ec3a-1615-42e7-b585-4cca2dd2abea,2019-10-08T08:00:00.000+08:00,4,Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the —8th ...
99ffcae8-9945-43ac-8c04-0b54ff438914,2019-10-08T08:00:00.000+08:00,3,MannKind: Q3 Afrezza Sales In The Books - Brazil Launch Pending
d32e0da8-d724-46f5-9f9a-17d4be520095,2019-10-07T08:00:00.000+08:00,1,Eli Lilly Announces that Phase 3 CYRAMZA Results Were Published in the Journal Lancet Oncology
2edfca27-929e-4004-b5a0-dd791cc917f6,2019-10-07T08:00:00.000+08:00,2,IPO Update: Innate Pharma Readies Plan For U.S. IPO
e04ed653-1b9a-45e1-a253-c674b5030611,2019-10-07T08:00:00.000+08:00,4,"Enterprise Bank & Trust Co Buys Intercontinental Exchange Inc, Eli Lilly and Co, JPMorgan ..."
c14fb701-9264-4685-9733-af2e064fb99d,2019-10-07T08:00:00.000+08:00,2,UCB challenges Roche patent covering IL-17-targeting antibodies
8b1e1b2d-3e47-4a2d-b560-d57c482d7873,2019-10-07T08:00:00.000+08:00,3,5—-Week Company Lows
a921bf3e-ea5e-4d76-a72e-c363fcf7b178,2019-10-07T08:00:00.000+08:00,4,Novo Nordisk Focuses on Pipeline Development Amid Competition
1cad75fc-7c4b-4163-bd30-c3d366dcc0e5,2019-10-07T08:00:00.000+08:00,5,Lilly's CYRAMZA® (ramucirumab) Phase ' Data in First-Line EGFR-Mutated Non-Small Cell Lung ...
fe3f2366-1b8c-481b-ba27-98994927be98,2019-10-07T08:00:00.000+08:00,4,FDA OKs Pfenex Forteo biosimilar; shares up 9% premarket
b959a6f9-2360-4cf5-b808-148fd511af33,2019-10-07T08:00:00.000+08:00,3,Eli Lilly Announces that Phase 3 CYRAMZA Results Were Published in the Journal Lancet Oncology
80feb83a-8061-4b2f-a11e-725a5ed54da0,2019-10-07T08:00:00.000+08:00,2,IPO Update: Innate Pharma Readies Plan For U.S. IPO
29f58330-6e9e-4ba4-a367-f35e2d6781cf,2019-10-07T08:00:00.000+08:00,1,"Enterprise Bank & Trust Co Buys Intercontinental Exchange Inc, Eli Lilly and Co, JPMorgan ..."
44b60288-a19b-459e-a0c0-0ae01e85a2df,2019-10-07T08:00:00.000+08:00,5,UCB challenges Roche patent covering IL-17-targeting antibodies
df41afb9-8af2-4d1c-af0d-24eb2b073c6c,2019-10-07T08:00:00.000+08:00,1,5—-Week Company Lows
8c913ac2-9dac-4f2f-8026-273460ba869d,2019-10-07T08:00:00.000+08:00,3,Novo Nordisk Focuses on Pipeline Development Amid Competition
20c66ae4-1237-44e9-a450-11621d48f2f4,2019-10-07T08:00:00.000+08:00,4,Lilly's CYRAMZA® (ramucirumab) Phase ' Data in First-Line EGFR-Mutated Non-Small Cell Lung ...
f394d083-779e-4818-9510-ed939c612b8a,2019-10-07T08:00:00.000+08:00,5,FDA OKs Pfenex Forteo biosimilar; shares up 9% premarket
5cdbac3f-4b1a-4b92-9f0d-92fd1a8708aa,2019-10-06T08:00:00.000+08:00,4,"The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck"
6b776a14-aa3a-44df-9af8-5c461f8942cc,2019-10-06T08:00:00.000+08:00,2,"The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck"
06c7f730-e092-49f3-92ec-fbf7876fd709,2019-10-04T08:00:00.000+08:00,5,"Keytruda on path to become world's no. 1 selling drug, research firm says"
8ed084e8-7a18-47be-bfb2-53cecde7baaa,2019-10-04T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly"
ad141083-cd72-4c2c-83f8-fd559f8ea7af,2019-10-04T08:00:00.000+08:00,4,"Keytruda on path to become world's no. 1 selling drug, research firm says"
67f81915-3385-4a44-8c3a-537e111ada91,2019-10-04T08:00:00.000+08:00,4,"The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly"
24b307c5-8d5c-430f-88b9-8f3e09748e13,2019-10-03T08:00:00.000+08:00,2,Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar
b531aafb-82eb-4cd4-91fa-f331e7a7a4ad,2019-10-03T08:00:00.000+08:00,4,Eli Lilly Highlights Head-To-Head Data Showed Taltz Superiority Vs. TREMFYA In People with Moderate to Severe Plaque Psoriasis
247c6ae9-6137-4641-929e-9281122b0c09,2019-10-03T08:00:00.000+08:00,3,"Top Research Reports for Bank of America, Home Depot & Philip Morris"
aa246df5-e62a-4b1b-b124-7802dadaeed7,2019-10-03T08:00:00.000+08:00,5,Why Lilly (LLY) Could Beat Earnings Estimates Again
decf35a6-7993-4bd7-ac79-cf3664a15715,2019-10-03T08:00:00.000+08:00,1,Novartis Reports Additional Data on Spondylitis Drug Cosentyx
58b61f35-1800-45e8-984a-40a294e98bbd,2019-10-03T08:00:00.000+08:00,5,Here's Why You Should Add Thermo Fisher to Your Portfolio
139763d0-7612-490b-9f7c-89f6958e4b01,2019-10-03T08:00:00.000+08:00,4,Eli Lilly issues positive update on Taltz
d64d3929-4c89-44eb-acfb-35c76bc03b26,2019-10-03T08:00:00.000+08:00,3,Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar
c61909e7-0302-4b22-a85e-c397558b97f8,2019-10-03T08:00:00.000+08:00,4,Eli Lilly Highlights Head-To-Head Data Showed Taltz Superiority Vs. TREMFYA In People with Moderate to Severe Plaque Psoriasis
8ea20837-c483-4cbf-8c61-99f6cb8f22ff,2019-10-03T08:00:00.000+08:00,2,"Top Research Reports for Bank of America, Home Depot & Philip Morris"
f5f83ed6-b812-47b1-a74e-a4bc67acf995,2019-10-03T08:00:00.000+08:00,5,Why Lilly (LLY) Could Beat Earnings Estimates Again
9e79a660-aa6a-4d53-975a-026ec731c1a3,2019-10-03T08:00:00.000+08:00,2,Novartis Reports Additional Data on Spondylitis Drug Cosentyx
080f6adc-2df9-4c05-98b3-fd3791de1157,2019-10-03T08:00:00.000+08:00,3,Here's Why You Should Add Thermo Fisher to Your Portfolio
47f911b0-0d48-4905-a960-66553da5a7bb,2019-10-03T08:00:00.000+08:00,4,Eli Lilly issues positive update on Taltz
6097dc6a-3458-40f7-9e89-d68800a92ed7,2019-10-02T08:00:00.000+08:00,4,Eli Lilly Highlights Availability Of Emgality In Canada
bc76dad3-1d23-42c8-b105-0ce62e04bbcd,2019-10-02T08:00:00.000+08:00,2,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.
22fdfcde-4352-4adc-8672-ba6d500eb98a,2019-10-02T08:00:00.000+08:00,3,Eli Lilly and Company's (LLY) Management Presents at Lilly Oncology Update at ESMO 2019 Conference (Transcript)
70452db5-94db-4a94-8296-6e3ea46092ba,2019-10-02T08:00:00.000+08:00,4,Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study
ad131395-662b-45aa-91ba-371165922cb9,2019-10-02T08:00:00.000+08:00,1,Novartis (NVS) Announces Data on Asthma Drugs & Kisqali
d67b8760-d903-489d-b1ff-59a0112024be,2019-10-02T08:00:00.000+08:00,3,Lilly Oncology Update at ESMO
5d6f40cd-ee53-41e1-8f6c-d506d49cabfa,2019-10-02T08:00:00.000+08:00,2,Eli Lilly Highlights Availability Of Emgality In Canada
f9094a2d-e72e-4e5d-97be-e42609f80bae,2019-10-02T08:00:00.000+08:00,1,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.
d0e03f31-6c9d-4455-875d-41920357d0c5,2019-10-02T08:00:00.000+08:00,3,Eli Lilly and Company's (LLY) Management Presents at Lilly Oncology Update at ESMO 2019 Conference (Transcript)
35d626af-1900-4d84-a497-899e43dc6a3a,2019-10-02T08:00:00.000+08:00,4,Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study
2e72f86f-13b5-4a24-a81c-809609b145c0,2019-10-02T08:00:00.000+08:00,3,Novartis (NVS) Announces Data on Asthma Drugs & Kisqali
c15eae55-bd25-45f8-82d2-ecf423a90c2b,2019-10-02T08:00:00.000+08:00,2,Lilly Oncology Update at ESMO
f3056164-6084-46e7-a929-b04d00867828,2019-09-30T08:00:00.000+08:00,3,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates
827c1ad7-11cf-423f-8939-48b845aa917c,2019-09-30T08:00:00.000+08:00,4,IPO Update: Annovis Bio Readies $10 Million IPO
515b45df-12e3-46a0-9bca-cbb40b55c5df,2019-09-30T08:00:00.000+08:00,2,Earnings Estimates/Revisions - Healthcare
be14e2ae-f807-482f-98d6-23e46b553e43,2019-09-30T08:00:00.000+08:00,2,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates
585246ca-a562-41e1-ab69-b80549c01e75,2019-09-30T08:00:00.000+08:00,2,IPO Update: Annovis Bio Readies $10 Million IPO
df280d7a-091a-4475-82ec-b6879eb9d09c,2019-09-30T08:00:00.000+08:00,3,Earnings Estimates/Revisions - Healthcare
7f56755c-9550-4d76-ac1c-1756e94b28e1,2019-09-29T08:00:00.000+08:00,3,"Spotlight On Microsoft, Tesla And Xilinx (Stocks To Watch Podcast)"
328011f9-9a65-46bf-9f5b-a9c58fd94bc3,2019-09-29T08:00:00.000+08:00,3,"Spotlight On Microsoft, Tesla And Xilinx (Stocks To Watch Podcast)"
4f84cd1c-4cd9-415e-9f3c-0c252deecba5,2019-09-28T08:00:00.000+08:00,3,"Stocks To Watch: Spotlight On Microsoft, Tesla And Xilinx"
a3e1f4c1-eb1d-4bf0-852e-57cd2b89ba19,2019-09-28T08:00:00.000+08:00,2,Daily Insider Ratings Round Up 9/23/19
b98484dd-687b-4ab3-be1a-7975d34ea11a,2019-09-28T08:00:00.000+08:00,3,"Stocks To Watch: Spotlight On Microsoft, Tesla And Xilinx"
823db157-dd92-4c9b-81f6-3f9b1ba89da7,2019-09-28T08:00:00.000+08:00,2,Daily Insider Ratings Round Up 9/23/19
fa9d5fef-d693-43fe-87c2-e70ec3d3112e,2019-09-27T08:00:00.000+08:00,1,IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA
557124b8-d169-485f-b9e5-0601e448147d,2019-09-27T08:00:00.000+08:00,3,Key events next week - healthcare
6b1cdd34-9b91-41cf-bea2-9581598b1b6b,2019-09-27T08:00:00.000+08:00,2,IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA
73363152-7e6e-4557-bc3c-43f9ff9d9718,2019-09-27T08:00:00.000+08:00,3,Key events next week - healthcare
4d61449c-267e-40ec-83c3-b40c0708602c,2019-09-26T08:00:00.000+08:00,4,Immuno-Oncology Firm Innate Pharma Files For U.S. IPO
6385d634-68ad-4099-845c-6e861935fc95,2019-09-26T08:00:00.000+08:00,1,6 Declining Stocks in Gurus' Portfolios
cf299110-05aa-483b-9651-50fc7cd449ba,2019-09-26T08:00:00.000+08:00,3,IPO Update: ADC Therapeutics Readies $200 Million IPO
d2568d76-f2ff-42a3-9584-a64331862021,2019-09-26T08:00:00.000+08:00,4,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
a1b920d3-b207-45b4-be8a-a54eb4279081,2019-09-26T08:00:00.000+08:00,2,Immuno-Oncology Firm Innate Pharma Files For U.S. IPO
ba900a59-91e3-4086-a8c8-2fe6be5d0fae,2019-09-26T08:00:00.000+08:00,3,6 Declining Stocks in Gurus' Portfolios
8f186b50-f2b7-4a6c-8f17-54bad0d972cc,2019-09-26T08:00:00.000+08:00,4,IPO Update: ADC Therapeutics Readies $200 Million IPO
9251de1f-90a7-47d9-a395-3484243dcb02,2019-09-26T08:00:00.000+08:00,4,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
44cb1734-fc9c-4baa-991c-fb8f63ae4753,2019-09-25T08:00:00.000+08:00,2,"Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company"
d6e5fdfa-2ae6-40bc-a537-ccb507051d3e,2019-09-25T08:00:00.000+08:00,4,"Eli Lilly Throws Hat In The Ring For Lung Cancer Space, Takes Targeted Treatment Approach"
8af4245c-84ae-4f05-81fb-6606373e8442,2019-09-25T08:00:00.000+08:00,2,"Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company"
785c61aa-115d-4bfb-8c11-29ddf9eba7d4,2019-09-25T08:00:00.000+08:00,4,"Eli Lilly Throws Hat In The Ring For Lung Cancer Space, Takes Targeted Treatment Approach"
eb81a80b-a0fc-482e-ad42-305a45811d71,2019-09-23T08:00:00.000+08:00,3,Eli Lilly to Present Data at the European Society for Medical Oncology
eaf17dc3-5a6f-4502-813d-c798b3aa72b7,2019-09-23T08:00:00.000+08:00,4,Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids
14a12a29-b80f-42b3-908f-e02750e54b2c,2019-09-23T08:00:00.000+08:00,5,Lilly Gets CHMP Nod to Add Heart Indication to Trulicity Label
b518b0a1-273a-4900-8dd5-ad5269fe54c7,2019-09-23T08:00:00.000+08:00,3,Eli Lilly to Present Data at the European Society for Medical Oncology
c4e69440-fe2e-423e-b258-49fdb821ef95,2019-09-23T08:00:00.000+08:00,4,Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids
221c21ad-f87c-42cc-acd6-26c61d0fe9a8,2019-09-23T08:00:00.000+08:00,5,Lilly Gets CHMP Nod to Add Heart Indication to Trulicity Label
da839b61-de35-4493-8513-4f93cb52b42e,2019-09-20T08:00:00.000+08:00,2,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.
b0320680-ff63-4352-b1ea-eadd5233a844,2019-09-20T08:00:00.000+08:00,4,AC Immune Receives First Milestone Payment From Lilly In Small Molecule Tau Morphomer Program
0041bce1-6558-4d8d-8463-c182a8acf338,2019-09-20T08:00:00.000+08:00,5,CHMP Issues Positive Opinion To Expand Lilly's Trulicity Label To Include Results From REWIND Cardiovascular Outcomes Trial
6f68a416-4c25-4811-936a-26141e1c8fa7,2019-09-20T08:00:00.000+08:00,3,' Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices
9e336f8f-8010-4022-8421-9ec668b94768,2019-09-20T08:00:00.000+08:00,1,Nektar Hammered On Multiple Setbacks; Core Efficacy Questions Remain Open
3a96d980-2076-4a84-83bb-0e94f162a057,2019-09-20T08:00:00.000+08:00,4,' Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices
e93ef177-907f-47ca-967c-bf24efce04d5,2019-09-20T08:00:00.000+08:00,3,Drug makers up after McConnell thumbs down on Pelosi price pricing plan
939f0d68-3841-4e43-8b87-79134a88ae74,2019-09-20T08:00:00.000+08:00,5,CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from ...
41fc06f3-ae26-4a2a-967b-888df97b9c5a,2019-09-20T08:00:00.000+08:00,2,Key events next week - healthcare
47cf05d9-6cfc-4e60-bfb2-2686dbfaf147,2019-09-20T08:00:00.000+08:00,5,European advisory group backs label update to Lilly's Trulicity
8d81e632-dfd6-45d7-94d6-d43a227012a4,2019-09-20T08:00:00.000+08:00,4,AC Immune earns CHF30M milestone from Eli Lilly
166910a3-d1ee-40d1-9ddd-3027c9a58b3e,2019-09-20T08:00:00.000+08:00,2,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.
193c79a5-be18-435c-966c-9441a66d603a,2019-09-20T08:00:00.000+08:00,5,AC Immune Receives First Milestone Payment From Lilly In Small Molecule Tau Morphomer Program
d0f118c9-3e2f-49cf-9663-b4390cad2dcf,2019-09-20T08:00:00.000+08:00,3,CHMP Issues Positive Opinion To Expand Lilly's Trulicity Label To Include Results From REWIND Cardiovascular Outcomes Trial
96181a31-a900-4410-afaf-17517c4ccb0d,2019-09-20T08:00:00.000+08:00,4,' Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices
2e00f86d-06ea-4b85-ba85-5710e7298316,2019-09-20T08:00:00.000+08:00,2,Nektar Hammered On Multiple Setbacks; Core Efficacy Questions Remain Open
67ee759e-9e15-466a-aa20-73ed92b11559,2019-09-20T08:00:00.000+08:00,3,' Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices
a3c33e8f-2bad-497c-8025-e0124aa34dba,2019-09-20T08:00:00.000+08:00,4,Drug makers up after McConnell thumbs down on Pelosi price pricing plan
e75a2845-fe7f-4e84-a796-8c507472bc96,2019-09-20T08:00:00.000+08:00,5,CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from ...
e82d641b-b6cc-494d-b486-90d35093391e,2019-09-20T08:00:00.000+08:00,3,Key events next week - healthcare
3327d32c-c915-418b-a4d9-d37022b58f5a,2019-09-20T08:00:00.000+08:00,4,European advisory group backs label update to Lilly's Trulicity
f2d3b187-e48f-431a-b0ed-2e14ad4e6bb6,2019-09-20T08:00:00.000+08:00,5,AC Immune earns CHF30M milestone from Eli Lilly
ef4bcdaf-7e80-4ac7-ad39-5e32cd11f4c4,2019-09-17T08:00:00.000+08:00,3,Biotech Stock On The Radar: vTv Therapeutics' Diabetes Pipeline
d93cb1c7-bfba-4f8d-bc59-61556bcf483d,2019-09-17T08:00:00.000+08:00,1,Kitov Pharma: NT-219 Data Reveals Ability To Reverse Pancreatic Cancer Drugs Resistance And The Market Doesn't Care
1aee0d70-bbdd-4901-a8b1-07f654611938,2019-09-17T08:00:00.000+08:00,2,Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck
aa9518de-e500-4fac-a308-bac4afc500b9,2019-09-17T08:00:00.000+08:00,2,"Lundbeck Makes A Large M&A Move, But The Target Will Be Somewhat Controversial"
ce65b220-9d44-4d1a-892c-c00f078877a6,2019-09-17T08:00:00.000+08:00,4,Biotech Stock On The Radar: vTv Therapeutics' Diabetes Pipeline
2af6b966-e652-4b6d-979f-26b9d10f24e0,2019-09-17T08:00:00.000+08:00,3,Kitov Pharma: NT-219 Data Reveals Ability To Reverse Pancreatic Cancer Drugs Resistance And The Market Doesn't Care
bd7efbc9-5849-4452-b37d-c46a2036be36,2019-09-17T08:00:00.000+08:00,1,Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck
010f1d40-7b3e-4f93-8fed-6b70357acbee,2019-09-17T08:00:00.000+08:00,2,"Lundbeck Makes A Large M&A Move, But The Target Will Be Somewhat Controversial"
d4c54078-9bf4-4ba4-b571-6a00cea7b38a,2019-09-16T08:00:00.000+08:00,2,Fitch Planning To Withdraw Ratings For Eli Lilly
d6488efa-ee09-4ccb-8066-245ece916872,2019-09-16T08:00:00.000+08:00,4,ADC Therapeutics Begins U.S. IPO Process
7cd2717d-06a5-402c-ad72-b18311d9b438,2019-09-16T08:00:00.000+08:00,3,Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert
b5176c1f-c7d1-41d9-869a-a05f01d5cb5e,2019-09-16T08:00:00.000+08:00,2,Fitch Planning To Withdraw Ratings For Eli Lilly
dd41b781-83b6-4c6c-b8b2-1c7fecbc7968,2019-09-16T08:00:00.000+08:00,4,ADC Therapeutics Begins U.S. IPO Process
b5d3c25c-22c5-4abe-b2b7-1c65337f4da0,2019-09-16T08:00:00.000+08:00,1,Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert
45ce92b0-de0e-4941-b9a6-7717598ba7e4,2019-09-13T08:00:00.000+08:00,1,FDA warns on rare side effect of breast cancer meds
3c584402-f759-4d59-8622-424e821b753c,2019-09-13T08:00:00.000+08:00,3,"Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival"
b14382f0-2123-4433-8874-ced3a5142bf0,2019-09-13T08:00:00.000+08:00,2,"Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others"
9c949f33-b129-42d3-8f96-eb99aaca780d,2019-09-13T08:00:00.000+08:00,1,FDA warns on rare side effect of breast cancer meds
2a07b50b-a777-4b71-ac18-4fa11f06e3f7,2019-09-13T08:00:00.000+08:00,2,"Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival"
82ab29ab-4fc5-43eb-98d1-03870d6a77e3,2019-09-13T08:00:00.000+08:00,3,"Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others"
0214ef5a-0747-49cc-993a-c0d54cb508a0,2019-09-12T08:00:00.000+08:00,4,Rising P/E: An Often-Ignored Trick to Pick 5 Winning Stocks
16cd3681-c151-4409-b81b-a1342c465378,2019-09-12T08:00:00.000+08:00,1,Rising P/E: An Often-Ignored Trick to Pick 5 Winning Stocks
de057eb5-70fd-4a37-92a7-3ec8742c949a,2019-09-10T08:00:00.000+08:00,1,Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries.
abddc037-0259-45e2-bead-41465b5884f3,2019-09-10T08:00:00.000+08:00,4,"Bank of America Reiterates Neutral on Eli Lilly, Raises Price Target to $120"
adf3317a-e8ae-47f5-81b6-d3cac3cc25f3,2019-09-10T08:00:00.000+08:00,3,Pfizer's Pneumococcal Vaccine Shows Potential in Infants
42b035da-49ad-452d-876a-0dfc752a47cd,2019-09-10T08:00:00.000+08:00,5,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice
bde90416-c16c-49a9-a41c-a8f43fbf096d,2019-09-10T08:00:00.000+08:00,2,"Novo Nordisk Joins Insulin Discount Party, But Prices Still Unlikely To Fall"
05e765b3-b425-44f6-b9c0-7d9e263f0c34,2019-09-10T08:00:00.000+08:00,1,Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries.
abfd4b3f-a024-4577-9fb5-6a2407b36b71,2019-09-10T08:00:00.000+08:00,4,"Bank of America Reiterates Neutral on Eli Lilly, Raises Price Target to $120"
d78865f1-3638-44e6-86c4-ed8b3a762013,2019-09-10T08:00:00.000+08:00,3,Pfizer's Pneumococcal Vaccine Shows Potential in Infants
5885d0b1-a8ac-42bd-ac62-1155532f8341,2019-09-10T08:00:00.000+08:00,4,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice
2300e58d-69ac-4337-b3c9-c49adb833885,2019-09-10T08:00:00.000+08:00,2,"Novo Nordisk Joins Insulin Discount Party, But Prices Still Unlikely To Fall"
c31c2eb3-6220-4cbb-90ec-5cbe06f29429,2019-09-09T08:00:00.000+08:00,1,Eli Lilly shares are trading lower. Shares traded higher on light volume in Monday's pre-market session after the company reported results from its clinical trial of LOXO-292 and have since reversed.
d06f8655-6487-4218-b5d3-999367316455,2019-09-09T08:00:00.000+08:00,5,30 Stocks Moving in Monday's Pre-Market Session
02e37b4f-80a0-46b6-a341-50674e851dd2,2019-09-09T08:00:00.000+08:00,5,"Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer"
d60f8e9e-2ab4-42fc-934d-89f80e849bac,2019-09-09T08:00:00.000+08:00,3,"Wall Street's Top Stories For Monday, September 9, 2019"
5fa3a39c-2615-4c0a-8694-71921a7fb68c,2019-09-09T08:00:00.000+08:00,4,Eli Lilly and Company (LLY) Presents At IASLC 2019 World Conference On Lung Cancer - Slideshow
bb30062a-8a5f-468e-be8c-2e1886d8b02d,2019-09-09T08:00:00.000+08:00,5,Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study
c1a832db-53e6-49b0-b749-dfa674d4b42a,2019-09-09T08:00:00.000+08:00,4,Thermo Fisher to develop companion diagnostic for Lilly's selpercatinib
980fbc2f-073a-424d-9e4d-feb73f51a180,2019-09-09T08:00:00.000+08:00,2,Eli Lilly up 3% premarket on positive selpercatinib data
b4836495-9605-4ffa-bc99-1c9e39cc64b0,2019-09-09T08:00:00.000+08:00,3,Eli Lilly shares are trading lower. Shares traded higher on light volume in Monday's pre-market session after the company reported results from its clinical trial of LOXO-292 and have since reversed.
30ba2138-ce67-469f-9e17-cc4bfbd092ab,2019-09-09T08:00:00.000+08:00,5,30 Stocks Moving in Monday's Pre-Market Session
250ecdc5-f6c6-4bb2-9258-2370f178b463,2019-09-09T08:00:00.000+08:00,5,"Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer"
f0925d5c-e0c3-4abd-b7cc-382f7edae703,2019-09-09T08:00:00.000+08:00,4,"Wall Street's Top Stories For Monday, September 9, 2019"
b001ee23-d167-460b-acd8-db681457dd9a,2019-09-09T08:00:00.000+08:00,5,Eli Lilly and Company (LLY) Presents At IASLC 2019 World Conference On Lung Cancer - Slideshow
5c754fb8-405f-447f-aea4-b16404a4ee7a,2019-09-09T08:00:00.000+08:00,3,Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study
4575eacb-de01-4401-ae70-981d153919d1,2019-09-09T08:00:00.000+08:00,4,Thermo Fisher to develop companion diagnostic for Lilly's selpercatinib
4647d155-fbbb-4c1c-90c1-8ceb655df83d,2019-09-09T08:00:00.000+08:00,5,Eli Lilly up 3% premarket on positive selpercatinib data
dac0b4b4-074c-4c99-bb93-c105c1ff890e,2019-09-08T08:00:00.000+08:00,2,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight"
4efc9d3e-161a-491c-809c-dea1852ef578,2019-09-08T08:00:00.000+08:00,2,"Apple, IPOs And German Auto (Stocks To Watch Podcast)"
2fb4dc18-1c4e-426d-b4ea-5fb7ac761b7e,2019-09-08T08:00:00.000+08:00,2,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight"
5f8dce26-c29b-4c87-b309-4f8246685b6c,2019-09-08T08:00:00.000+08:00,2,"Apple, IPOs And German Auto (Stocks To Watch Podcast)"
523ed9ef-9470-4bde-8f51-cfed7d785183,2019-09-07T08:00:00.000+08:00,1,Dividend Challenger Highlights: Week Of September 8
5ca18493-475c-40c5-adea-1efa856a423f,2019-09-07T08:00:00.000+08:00,4,Vanguard Health Care ETF: A Good Fund To Benefit From An Ageing Demographic Trend
59f61ea8-a99d-4476-83ac-54dc51a07d9d,2019-09-07T08:00:00.000+08:00,1,"Stocks To Watch: Apple, IPOs And German Auto"
b3dbd709-b489-4e06-bea0-6c79e010e9ba,2019-09-07T08:00:00.000+08:00,3,Dividend Challenger Highlights: Week Of September 8
c0b6c550-d03a-4c47-ae54-ef47652886b5,2019-09-07T08:00:00.000+08:00,4,Vanguard Health Care ETF: A Good Fund To Benefit From An Ageing Demographic Trend
4df01459-192b-48d7-a0cd-b066d089a173,2019-09-07T08:00:00.000+08:00,1,"Stocks To Watch: Apple, IPOs And German Auto"
ad9accb5-16b4-44f6-a12f-b0d966825e76,2019-09-06T08:00:00.000+08:00,2,"Xeris Pharma's Gvoke: Strong Approval Chances, But This Is A Highly Competitive Space"
c1bcaeb1-8779-45a4-837e-3c7ee5866558,2019-09-06T08:00:00.000+08:00,2,"Xeris Pharma's Gvoke: Strong Approval Chances, But This Is A Highly Competitive Space"
e0623f1b-4f98-499d-9a62-d17b12690169,2019-09-05T08:00:00.000+08:00,3,Eli Lilly Reports FDA Accepted Application To Enter Complex Innovative Trial Designs Pilot Meeting Program
2c6f4ab8-7134-4b61-8c82-22dd99738a5b,2019-09-05T08:00:00.000+08:00,4,Xeris: Preparing For The Gvoke PDUFA
e7e4f043-a125-4699-92fb-0e6f98134fc0,2019-09-05T08:00:00.000+08:00,5,Lilly into FDA pilot program to modernize drug development
ce52ddd1-fa7b-411e-8f23-4b92671aaf9d,2019-09-05T08:00:00.000+08:00,2,AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC
0ab484b3-5e47-40a1-988e-e35817459491,2019-09-05T08:00:00.000+08:00,3,J&J's Stelara Gets Approval in EU for Ulcerative Colitis
d3211ed7-b5a2-40f2-8138-41a5182866a9,2019-09-05T08:00:00.000+08:00,3,Eli Lilly Reports FDA Accepted Application To Enter Complex Innovative Trial Designs Pilot Meeting Program
ea06f6f4-d231-4304-9aaa-9afa69bb2ad1,2019-09-05T08:00:00.000+08:00,1,Xeris: Preparing For The Gvoke PDUFA
da9a061a-ee4d-486d-a616-fa3cc48cac0d,2019-09-05T08:00:00.000+08:00,4,Lilly into FDA pilot program to modernize drug development
dfbb5e36-1816-40fd-8f3b-bc37e4334392,2019-09-05T08:00:00.000+08:00,2,AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC
01739405-3b68-4d4d-9800-cbe9dabc822f,2019-09-05T08:00:00.000+08:00,1,J&J's Stelara Gets Approval in EU for Ulcerative Colitis
6de424a9-b196-4927-9b19-ba4d6fc8a818,2019-09-04T08:00:00.000+08:00,3,Satsuma IPO: At Phase 3 Of Development
d0963e78-adfe-4796-a24b-3de80c9ed7e0,2019-09-04T08:00:00.000+08:00,4,Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M
8669ce69-e085-49f1-88a5-ce556e549dfe,2019-09-04T08:00:00.000+08:00,3,Satsuma IPO: At Phase 3 Of Development
caabb39b-f44f-4314-ab3b-65b59c677abd,2019-09-04T08:00:00.000+08:00,4,Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M
901c3409-1232-4cdb-90a3-57cd03824e0a,2019-09-03T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie"
db2bd011-c8b4-45cd-8680-fb8e2c039c9e,2019-09-03T08:00:00.000+08:00,3,5 Cancer-Fighting Stocks to Add to Your Portfolio
62c8d02c-5653-4671-881a-0fed7e47fc38,2019-09-03T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie"
f6338723-1842-4732-a55b-b848039fe4e0,2019-09-03T08:00:00.000+08:00,4,5 Cancer-Fighting Stocks to Add to Your Portfolio
c8a16ade-d666-4e8a-8b54-be58cbf232b5,2019-08-31T08:00:00.000+08:00,2,"Barron's Picks And Pans: Activision Blizzard, Best Buy, Coca-Cola, Microsoft And More"
e6fe01c8-0d40-401c-bd84-7200c0519303,2019-08-31T08:00:00.000+08:00,4,Week In Review: HiFiBiO Raises $67 Million For Immune Modulator Portfolio
caef0bda-17e0-4a85-8039-a9301723d838,2019-08-31T08:00:00.000+08:00,3,"Barron's Picks And Pans: Activision Blizzard, Best Buy, Coca-Cola, Microsoft And More"
4365bf75-fd0d-4d0c-b587-1c22a8fe6dcd,2019-08-31T08:00:00.000+08:00,4,Week In Review: HiFiBiO Raises $67 Million For Immune Modulator Portfolio
81f06a9d-acaf-484c-a39c-eaaaf220df5f,2019-08-30T08:00:00.000+08:00,1,Key events next week - healthcare
a8ff1a93-55e1-4eaf-826d-683721e8540d,2019-08-30T08:00:00.000+08:00,3,Key events next week - healthcare
91364218-02b7-47c8-b5fd-a7c3fb31600f,2019-08-29T08:00:00.000+08:00,5,FDA tentatively OK's Mylan's pemetrexed; shares up 4%
e1b36de1-8c48-4254-85e0-4cf96219c226,2019-08-29T08:00:00.000+08:00,3,Lilly (LLY) Up 1.9% Since Last Earnings Report: Can It Continue?
74602cf6-1591-4bda-9915-29deab860035,2019-08-29T08:00:00.000+08:00,5,FDA tentatively OK's Mylan's pemetrexed; shares up 4%
6fd3daf1-2a01-457f-92fb-cfd2d615f84f,2019-08-29T08:00:00.000+08:00,5,Lilly (LLY) Up 1.9% Since Last Earnings Report: Can It Continue?
2f64bc9f-8f65-4861-9fc8-cb2555fbc419,2019-08-28T08:00:00.000+08:00,5,Eli Lilly's Latest Approval Adds To An Ever-Growing Market For Taltz
251b8de0-d6ad-41c1-944d-54540e8c0f54,2019-08-28T08:00:00.000+08:00,1,J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?
bb2622c9-1ce3-4aaf-a2d7-a4bf5617a7c0,2019-08-28T08:00:00.000+08:00,5,Eli Lilly's Latest Approval Adds To An Ever-Growing Market For Taltz
d4062be1-c0db-4605-a127-0becbc3d45f4,2019-08-28T08:00:00.000+08:00,4,J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?
4cc4f2bd-946e-4117-9211-355af2e5f3bf,2019-08-26T08:00:00.000+08:00,5,Lilly Receives FDA Approval for Taltz for the Treatment of Active Ankylosing Spondylitis
fbf837c9-46ac-421e-abe1-d8a5d46c7cac,2019-08-26T08:00:00.000+08:00,4,TFF Pharmaceuticals Readies $22 Million IPO
cf60cc84-6e2f-457b-a008-2c792012a24b,2019-08-26T08:00:00.000+08:00,5,Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study
cdd7c315-1374-4cc8-a5d8-114373aa4ed0,2019-08-26T08:00:00.000+08:00,5,FDA OKs expanded use of Lilly's Taltz
3fe7cd0b-9a34-4c98-a979-5fe8a55f4186,2019-08-26T08:00:00.000+08:00,5,Lilly Receives FDA Approval for Taltz for the Treatment of Active Ankylosing Spondylitis
414b3bf3-7155-4da8-97aa-1d469366e1a3,2019-08-26T08:00:00.000+08:00,2,TFF Pharmaceuticals Readies $22 Million IPO
242f2b02-3fa8-4d5b-a9a4-ba53dede3276,2019-08-26T08:00:00.000+08:00,4,Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study
6e89516f-0155-4fc9-9988-d79fb517b065,2019-08-26T08:00:00.000+08:00,5,FDA OKs expanded use of Lilly's Taltz
2848fe58-0554-4583-aa8d-287509e0fa86,2019-08-25T08:00:00.000+08:00,3,Week In Review: Biotheus Acquires China Rights To 3 Bi-Specifics In $142 Million Deal
49e48948-446c-4705-ac79-b034f539f5c2,2019-08-25T08:00:00.000+08:00,4,Week In Review: Biotheus Acquires China Rights To 3 Bi-Specifics In $142 Million Deal
d49cd0c0-a4d9-4563-ba9f-d517110ef887,2019-08-24T08:00:00.000+08:00,4,Week In Review: Biotheus Acquires China Rights To Three Bi-specifics In $142 Million Deal
4492b44e-a1d6-4de4-ab03-4b1e26f75b55,2019-08-24T08:00:00.000+08:00,2,Elanco: Greater Risks And Rewards Following The Bayer Deal
bea9f566-c380-49f9-8646-3636270dedf9,2019-08-24T08:00:00.000+08:00,4,Week In Review: Biotheus Acquires China Rights To Three Bi-specifics In $142 Million Deal
f2c6a0e3-ce69-4c08-9576-fe6b00900828,2019-08-24T08:00:00.000+08:00,2,Elanco: Greater Risks And Rewards Following The Bayer Deal
a6dbafde-4aff-47f6-bcbe-6317d020e063,2019-08-23T08:00:00.000+08:00,5,"Eli Lilly Reports Baricitinib Met Primary Endpoint In Breeze-AD7, Third Pivotal Phase 3 Trial In Breeze-AD Program To Be Completed In 2019"
81a4a29d-c329-4bd8-a141-66626fc7cf7b,2019-08-23T08:00:00.000+08:00,5,Lilly's baricitinib successful in third late-stage dermatitis study
3f766b5c-a30f-4bdd-aad3-44a75714d8d3,2019-08-23T08:00:00.000+08:00,5,Arbitration panel backs Lilly in dispute with former collaboration partner Adocia
647d84a0-d84b-4133-8bea-5287ee2ddead,2019-08-23T08:00:00.000+08:00,4,"Eli Lilly Reports Baricitinib Met Primary Endpoint In Breeze-AD7, Third Pivotal Phase 3 Trial In Breeze-AD Program To Be Completed In 2019"
6bb534f8-e2b2-4626-8ea3-decfd79d7fa0,2019-08-23T08:00:00.000+08:00,3,Lilly's baricitinib successful in third late-stage dermatitis study
91ae129a-a6c5-4b1d-a826-80c2a7e94774,2019-08-23T08:00:00.000+08:00,2,Arbitration panel backs Lilly in dispute with former collaboration partner Adocia
4c4511fa-3ba1-44f9-b709-e756e7956aea,2019-08-22T08:00:00.000+08:00,1,AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
a424c778-ea36-4f51-81da-ba021338261c,2019-08-22T08:00:00.000+08:00,4,Novo Nordisk: A Secular Growth Engine
34b68f80-f39f-44c3-bd63-624b3bae7dec,2019-08-22T08:00:00.000+08:00,2,Satsuma Pharmaceuticals Files For U.S. IPO
ce88b3ad-845e-4efd-820b-cb65d3221e31,2019-08-22T08:00:00.000+08:00,3,MannKind - 'Fireside' Chat With CEO Mike Castagna
fb59af51-5e53-48dd-89da-d8e666d5d825,2019-08-22T08:00:00.000+08:00,4,AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
afea05f5-05e3-4723-92bb-7738c92cca30,2019-08-22T08:00:00.000+08:00,5,Novo Nordisk: A Secular Growth Engine
2845cdde-e633-4a1d-ac7c-d3784ce04b90,2019-08-22T08:00:00.000+08:00,2,Satsuma Pharmaceuticals Files For U.S. IPO
b8003601-9369-4566-ae51-42504bd73cc1,2019-08-22T08:00:00.000+08:00,4,MannKind - 'Fireside' Chat With CEO Mike Castagna
81199f3f-39e4-4a2c-a32e-2110592e5f8b,2019-08-21T08:00:00.000+08:00,3,NuCana Stops Patient Enrollment in Pancreatic Cancer Study
8a8b4f2c-8dad-495d-899e-1f2ff7ca4dce,2019-08-21T08:00:00.000+08:00,4,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice
c96bb144-8034-4d44-832e-ce1c13dde4f3,2019-08-21T08:00:00.000+08:00,1,NuCana Stops Patient Enrollment in Pancreatic Cancer Study
09fe0000-dbb2-4d11-8956-28aa6d9a03a9,2019-08-21T08:00:00.000+08:00,4,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice
0a5fa693-ba9c-4a5e-9854-95279c47fee2,2019-08-19T08:00:00.000+08:00,5,Eli Lilly Taltz Data Points To A Solid Push Into The Psoriasis Space
ce98f544-20bb-4c81-b709-6a07ccdc91e3,2019-08-19T08:00:00.000+08:00,3,Roche prices Rozlytrek below Bayer & Lilly's Vitrakvi
576f1776-ffe9-4ef1-8c41-3dbd8675fed5,2019-08-19T08:00:00.000+08:00,4,High-Quality Dividend Stocks
d1a7b8fb-f9f3-49ad-b9c5-ce2778506b29,2019-08-19T08:00:00.000+08:00,5,Eli Lilly Taltz Data Points To A Solid Push Into The Psoriasis Space
83f5791e-eab0-4ebb-a8f7-17c823b2af28,2019-08-19T08:00:00.000+08:00,4,Roche prices Rozlytrek below Bayer & Lilly's Vitrakvi
f070e46d-ed24-4c1b-a2c7-65f02263ed50,2019-08-19T08:00:00.000+08:00,3,High-Quality Dividend Stocks
69c755b1-096d-4a22-bd6d-34a4382b1d06,2019-08-18T08:00:00.000+08:00,5,AbbVie's FDA Approval For RINVOQ Sets Up First Phase Of Deployment Plan To Counter Humira Issue
c606f607-3420-40cc-ab68-c1304888f2a6,2019-08-18T08:00:00.000+08:00,4,AbbVie's FDA Approval For RINVOQ Sets Up First Phase Of Deployment Plan To Counter Humira Issue
72edbca2-20af-4c16-9781-82edc5947e55,2019-08-16T08:00:00.000+08:00,4,FDA OKs AbbVie's Rinvoq rheumatoid arthritis; shares up 2%
a28800d5-f953-4d5c-a074-db213dda26e5,2019-08-16T08:00:00.000+08:00,4,Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe
b9a41d9f-f746-477d-94b3-47b9547b0822,2019-08-16T08:00:00.000+08:00,2,FDA OKs AbbVie's Rinvoq rheumatoid arthritis; shares up 2%
af1c8b83-d433-4cf8-bfc4-16cd950aa0ad,2019-08-16T08:00:00.000+08:00,3,Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe
92b02cdf-d3e9-4174-9d4c-43550b51901a,2019-08-15T08:00:00.000+08:00,5,"Gotham Asset Management, LLC Buys Intuit Inc, Oracle Corp, Cisco Systems Inc, Sells PayPal ..."
3707cc94-2975-43a7-a7a4-520896d7ee7f,2019-08-15T08:00:00.000+08:00,4,Agios Rides High on Tibsovo Sales Amid Acute Competition
0da185db-6c9b-49c2-b90b-a80d2f3a36a4,2019-08-15T08:00:00.000+08:00,3,"Gotham Asset Management, LLC Buys Intuit Inc, Oracle Corp, Cisco Systems Inc, Sells PayPal ..."
4ffe39df-56c7-4bb7-a7bb-16d9223e1ae4,2019-08-15T08:00:00.000+08:00,4,Agios Rides High on Tibsovo Sales Amid Acute Competition
91e4ae5a-b6f2-4eec-9c28-84a06dd86b3e,2019-08-14T08:00:00.000+08:00,1,"Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially signaling an oncoming recession."
58c4b535-59a9-40e0-bf7b-5fbe77aff03f,2019-08-14T08:00:00.000+08:00,3,Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study
49c4b0bf-fa67-46cc-88df-1b39d97483c3,2019-08-14T08:00:00.000+08:00,2,"Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially signaling an oncoming recession."
b59b396d-8c63-4d55-b713-18b9f8defa2a,2019-08-14T08:00:00.000+08:00,5,Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study
b8ee0f1a-47d5-4921-b2e2-5cf8315f6b14,2019-08-13T08:00:00.000+08:00,5,Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study
ca16cd0b-8eb5-4df3-86e6-358a5c8e0892,2019-08-13T08:00:00.000+08:00,3,Lilly Announces Taltz Met Primary And All Major Secondary Endpoints In Phase 4 IXORA-R Study
fe07bd34-497b-4666-bd86-e59f6c91b68b,2019-08-13T08:00:00.000+08:00,5,Lilly's Taltz beats J&J's Tremfya in post-market psoriasis study
40148f74-d98f-47f8-bb51-6614ea8f98bb,2019-08-13T08:00:00.000+08:00,5,Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study
bcdad2c7-0580-40f2-bf4a-818046363735,2019-08-13T08:00:00.000+08:00,5,Lilly Announces Taltz Met Primary And All Major Secondary Endpoints In Phase 4 IXORA-R Study
76582c8c-1137-4ab9-b5de-54195bf0603c,2019-08-13T08:00:00.000+08:00,4,Lilly's Taltz beats J&J's Tremfya in post-market psoriasis study
2cc15d42-dcfb-470e-95b4-225adea1f771,2019-08-12T08:00:00.000+08:00,3,Eli Lilly Looks To Positive Data To Expand Its Market Opportunity For Emgality
c90d1da2-d31b-4799-ac44-75ddbf9b1ca3,2019-08-12T08:00:00.000+08:00,4,Q2 Biotech Updates
92086437-7be5-41a3-84e0-186a22560a9c,2019-08-12T08:00:00.000+08:00,5,Eli Lilly Looks To Positive Data To Expand Its Market Opportunity For Emgality
add336b6-6b43-454c-8d0e-6070f678831d,2019-08-12T08:00:00.000+08:00,2,Q2 Biotech Updates
5d314ea3-a844-485c-9b50-d34eabb03617,2019-08-10T08:00:00.000+08:00,4,Dividend Challenger Highlights: Week Of August 11
16a9d243-e041-478c-8885-91cce65e6666,2019-08-10T08:00:00.000+08:00,3,Dividend Challenger Highlights: Week Of August 11
c4bf0e2a-aa07-428e-aa39-98a08c90af6b,2019-08-09T08:00:00.000+08:00,1,Eli Lilly Shares Unaffected As Hearing US Appeals Court Ruled In Favor Of Co. In Alimta Alternate Salt Form Patent Suit
a5aa59c5-4f67-47da-9771-55a12eb6ff4e,2019-08-09T08:00:00.000+08:00,2,"Intersect Capital LLC Buys Lockheed Martin Corp, Vornado Realty Trust, Berkshire Hathaway Inc, ..."
a005f855-4d0b-47c3-a545-a47dd47ada51,2019-08-09T08:00:00.000+08:00,4,Lilly prevails in Alimta patent challenge
b13b59ef-5f0c-451a-9fb6-11f536fbebf7,2019-08-09T08:00:00.000+08:00,2,Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2
cc2be48c-c6a5-4cff-8249-0ab2789ce416,2019-08-09T08:00:00.000+08:00,3,"Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients"
4ce5ada9-689a-4e87-8be7-844fccaa4d41,2019-08-09T08:00:00.000+08:00,1,Eli Lilly Shares Unaffected As Hearing US Appeals Court Ruled In Favor Of Co. In Alimta Alternate Salt Form Patent Suit
b7f98e13-34bf-4a4b-95eb-ed94f5093e0d,2019-08-09T08:00:00.000+08:00,3,"Intersect Capital LLC Buys Lockheed Martin Corp, Vornado Realty Trust, Berkshire Hathaway Inc, ..."
14a8a9ce-c7e6-469e-b0ac-167d776b741c,2019-08-09T08:00:00.000+08:00,5,Lilly prevails in Alimta patent challenge
c42dab3a-08fd-4344-81fc-e5707d827359,2019-08-09T08:00:00.000+08:00,2,Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2
7e233ed7-f100-4d33-a565-3c19e3de80fc,2019-08-09T08:00:00.000+08:00,3,"Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients"
27925e2b-b0ff-4753-afd8-4fd5ea5a3722,2019-08-08T08:00:00.000+08:00,4,Eli Lilly shares are trading higher after the company announced positive results for Emgality from the CONQUER study.
d010d816-58f6-4abf-8c9d-5ddf551b70d8,2019-08-08T08:00:00.000+08:00,4,"Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia"
0d8622b0-ccd4-4be6-a7ed-35518f66926e,2019-08-08T08:00:00.000+08:00,2,"Top Stock Reports: Disney, Eli Lilly, ADP & More"
5057879b-0924-4b43-a1ea-e2a03794a6b5,2019-08-08T08:00:00.000+08:00,4,"Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid"
9ec49aaf-97d9-497a-ab8d-27bec9937844,2019-08-08T08:00:00.000+08:00,3,"Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down"
d38f788b-073c-408a-9e97-7af04e2765d4,2019-08-08T08:00:00.000+08:00,4,Apple devices + mobile apps show potential to screen for Alzheimer's
6e63add6-039e-433a-abb1-f3731e1043f2,2019-08-08T08:00:00.000+08:00,5,Eli Lilly shares are trading higher after the company announced positive results for Emgality from the CONQUER study.
d29658e3-c728-4529-aa12-a0d8859df2f2,2019-08-08T08:00:00.000+08:00,4,"Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia"
0211e309-839d-485b-86ef-4246b5772ab6,2019-08-08T08:00:00.000+08:00,3,"Top Stock Reports: Disney, Eli Lilly, ADP & More"
05466ae3-4458-4d3c-89e6-e74fd20b3855,2019-08-08T08:00:00.000+08:00,5,"Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid"
cc62fcae-5154-4e86-b997-e9cc5374679f,2019-08-08T08:00:00.000+08:00,1,"Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down"
4d119371-593a-49d2-930c-8bfa3859dcd9,2019-08-08T08:00:00.000+08:00,4,Apple devices + mobile apps show potential to screen for Alzheimer's
c027a71e-cad0-4b6c-b055-f44d291c06da,2019-08-07T08:00:00.000+08:00,4,"Trellis Advisors, LLC Buys Amgen Inc, Eli Lilly and Co, Laboratory Corp of America Holdings"
4b217e6f-5391-4f4e-9f1e-022e3216ee06,2019-08-07T08:00:00.000+08:00,3,Companies In The Healthcare Sector To Consider/Avoid Taking Into Account Patent Activity
7f3ffd9a-9ce4-4fc8-9f3e-d16ac368f5b0,2019-08-07T08:00:00.000+08:00,3,Execs on the move at Eli Lilly
073d2a03-6c7d-4bab-8776-28589d65d0e4,2019-08-07T08:00:00.000+08:00,4,"Trellis Advisors, LLC Buys Amgen Inc, Eli Lilly and Co, Laboratory Corp of America Holdings"
7d97c016-3a14-494e-9fdd-6cca4b32e9cd,2019-08-07T08:00:00.000+08:00,2,Companies In The Healthcare Sector To Consider/Avoid Taking Into Account Patent Activity
2e63206b-8440-481e-a184-e220fc30def2,2019-08-07T08:00:00.000+08:00,2,Execs on the move at Eli Lilly
a37445f9-614b-4914-bdfa-371848d72532,2019-08-06T08:00:00.000+08:00,3,"Eli Lilly shares trading higher, rebounding following a more than 3% decline on Monday. Not seeing company-specific news to justify the rebound today."
42261309-4b08-4f75-8112-9fae9a500311,2019-08-06T08:00:00.000+08:00,4,"Eli Lilly shares trading higher, rebounding following a more than 3% decline on Monday. Not seeing company-specific news to justify the rebound today."
d1ea2380-5cac-42b6-8f17-79d12af09ceb,2019-08-05T08:00:00.000+08:00,5,Shares of several drug/pharma/medical equipment companies trading lower given weakness in broader stock market following concerns with China trade tensions.
e28d436a-45e1-45e7-b4e3-42e3f143ae12,2019-08-05T08:00:00.000+08:00,1,Eli Lilly Announces Positive Results For Emgality
11e33599-eea3-43e7-b4fb-01986869cd0c,2019-08-05T08:00:00.000+08:00,4,Lilly Announces 'Positive' Results for Emgality from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
ba94af89-cccc-425f-a5cb-5b11710341eb,2019-08-05T08:00:00.000+08:00,2,Lexicon Pharmaceuticals Now Walking A Fine Line
5962bd10-2a83-4723-8686-da8f990a148e,2019-08-05T08:00:00.000+08:00,3,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q2 2019 Update
440bb6da-c409-4917-8659-db888808ff2b,2019-08-05T08:00:00.000+08:00,5,Lilly's Emgality successful in late-stage study in treatment-resistant migraine
f3636c17-515b-4c6d-b685-6dbe3f843178,2019-08-05T08:00:00.000+08:00,1,Shares of several drug/pharma/medical equipment companies trading lower given weakness in broader stock market following concerns with China trade tensions.
d41d0c25-b581-4c9c-9a71-251add30942c,2019-08-05T08:00:00.000+08:00,5,Eli Lilly Announces Positive Results For Emgality
7d7a3001-f345-46fb-a9ca-0f733853ee74,2019-08-05T08:00:00.000+08:00,5,Lilly Announces 'Positive' Results for Emgality from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
c3102c0c-9bef-47ad-bd23-5774e26c6367,2019-08-05T08:00:00.000+08:00,3,Lexicon Pharmaceuticals Now Walking A Fine Line
53f0656f-ec32-423a-8523-6be7a25455dc,2019-08-05T08:00:00.000+08:00,4,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q2 2019 Update
83bb9b5e-fdcd-4b00-b1fd-af9e153b8943,2019-08-05T08:00:00.000+08:00,5,Lilly's Emgality successful in late-stage study in treatment-resistant migraine
ac2826db-8e63-484f-946e-a5e229d9648f,2019-08-02T08:00:00.000+08:00,1,"Eli Lilly 10-Q Shows Co. Received Subpoena From New York Attorney General's Office, Civil Investigative Demands From Washing, New Mexico AG's Related To Pricing, Sale Of Its Insulin Products"
ebf00cd0-b317-4176-8d9d-bac6348e6fba,2019-08-02T08:00:00.000+08:00,1,Lilly subpoenaed over insulin pricing
0cbb8dc0-37eb-4696-a6a5-ebb7323e85e8,2019-08-02T08:00:00.000+08:00,3,"Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger"
20b2f46e-2bc6-4a1d-9563-ddaca92aea2e,2019-08-02T08:00:00.000+08:00,2,"Eli Lilly 10-Q Shows Co. Received Subpoena From New York Attorney General's Office, Civil Investigative Demands From Washing, New Mexico AG's Related To Pricing, Sale Of Its Insulin Products"
a1042b78-83cf-42c6-bded-8b0c55e6c6ea,2019-08-02T08:00:00.000+08:00,1,Lilly subpoenaed over insulin pricing
f8626163-0932-4275-9c32-19c35b3cefad,2019-08-02T08:00:00.000+08:00,2,"Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger"
b2ea037e-db47-4bef-adf7-34491e9629fe,2019-07-31T08:00:00.000+08:00,3,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates
64388efe-5447-4da7-8fed-9102670e5036,2019-07-31T08:00:00.000+08:00,4,"Stevens Capital Management Lp Buys Merck Inc, Eli Lilly and Co, Morgan Stanley, Sells Duke ..."
96c92c20-9acb-4d5d-8352-7538a3523a08,2019-07-31T08:00:00.000+08:00,1,Wall Street Breakfast: First Rate Cut Since The Financial Crisis
d638b678-1914-46e2-a3f7-9ceb587ae02d,2019-07-31T08:00:00.000+08:00,2,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates
35a8a29c-ef6d-41cf-b66b-4eca5d4672a7,2019-07-31T08:00:00.000+08:00,4,"Stevens Capital Management Lp Buys Merck Inc, Eli Lilly and Co, Morgan Stanley, Sells Duke ..."
9d05e3cb-f092-439c-9d26-2019f04f417b,2019-07-31T08:00:00.000+08:00,3,Wall Street Breakfast: First Rate Cut Since The Financial Crisis
fe19f31f-06c0-4249-a042-bc319591a576,2019-07-30T08:00:00.000+08:00,5,"Apple On Today's Menu, With Starring Roles From China Talks, Fed Meeting"
237e3e34-f11e-41d8-b931-90f5b589ca6b,2019-07-30T08:00:00.000+08:00,4,Eli Lilly Reports Q2 Earnings Beat
c6f80666-5367-4921-8ec8-1fe88eb52740,2019-07-30T08:00:00.000+08:00,5,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings"
1666d030-bd2d-4d22-bd0b-7d2e2d1544dd,2019-07-30T08:00:00.000+08:00,4,Eli Lilly Sees FY19 Adj. EPS $5.67-$5.77 vs $5.66 Est.
a6eba86f-008a-42c3-afc9-599c5233f901,2019-07-30T08:00:00.000+08:00,5,"Eli Lilly Q2 Adj. EPS $1.5 Beats $1.45 Estimate, Sales $5.637B Beat $5.59B Estimate"
b2f9aa61-6026-48f0-9349-5c377c47d196,2019-07-30T08:00:00.000+08:00,4,Lilly Announces Verzenio Demonstrated Significant Improvement In Overall Survival In Phase 3 MONARCH 2 The Clinical Trial
f5f58ba4-4a67-4189-aab6-bd02ac86c3f2,2019-07-30T08:00:00.000+08:00,1,"15 Stocks To Watch For July 30, 2019"
ab82f5b3-f073-4f53-b135-c03983a93a54,2019-07-30T08:00:00.000+08:00,1,"Earnings Scheduled For July 30, 2019"
b534a099-6be7-42af-b112-24c104550208,2019-07-30T08:00:00.000+08:00,4,Flexion: The Time To Buy Is Now
ee31c881-1a66-4d0c-96fb-ff28c34aea8b,2019-07-30T08:00:00.000+08:00,3,Eli Lilly and Company's (LLY) CEO Dave Ricks on Q2 2019 Results - Earnings Call Transcript
81d663de-f5d0-4731-8438-9283f114982c,2019-07-30T08:00:00.000+08:00,5,"Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y"
0a71cff0-a667-4cb7-b298-9f26ab6746bb,2019-07-30T08:00:00.000+08:00,5,"Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up"
084f146d-6551-4e66-b80a-dd7218740a7c,2019-07-30T08:00:00.000+08:00,4,"Svenska Handelsbanken AB (publ) Buys Welbilt Inc, Eli Lilly and Co, Service Corp International, ..."
8041a8cb-16da-478d-91f2-6c4b5bc973a7,2019-07-30T08:00:00.000+08:00,1,Economic and Earnings Date Deluge
1f53352a-13f5-4f98-bef2-fe5d3bdd7f95,2019-07-30T08:00:00.000+08:00,3,"Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More"
ebcf0e00-1f19-48ae-b64f-d73b00c22e32,2019-07-30T08:00:00.000+08:00,4,Eli Lilly and Company 2019 Q2 - Results - Earnings Call Slides
dbba861c-40ba-4534-8170-de85938064f9,2019-07-30T08:00:00.000+08:00,2,5 Monster Stocks To Watch For the July 30 Trading Session
e3dd5e85-f961-4457-abbf-29e40afff6c7,2019-07-30T08:00:00.000+08:00,3,Trump readies plan allow drug imports from Canada
8dae247c-d156-440b-b7b3-b84be9dffada,2019-07-30T08:00:00.000+08:00,5,Eli Lilly (LLY) Tops Q2 Earnings Estimates
59f61f8d-76ce-4b14-8523-65b1e42a364f,2019-07-30T08:00:00.000+08:00,4,Eli Lilly up 1% premarket on Q2 beat
317f4252-eb33-40a4-a6ed-b0b052ff7ee6,2019-07-30T08:00:00.000+08:00,5,Lilly's abemaciclib extends survival in late-stage breast cancer study
68e6ef82-ddb8-4d11-9a88-b6c1d68cf0e2,2019-07-30T08:00:00.000+08:00,4,"Eli Lilly EPS beats by $0.05, beats on revenue"
80d7d066-9e69-41b7-abc9-69e4e2676ace,2019-07-30T08:00:00.000+08:00,2,"Apple On Today's Menu, With Starring Roles From China Talks, Fed Meeting"
38f8af9e-c5ae-4eb6-a706-7041ff208b83,2019-07-30T08:00:00.000+08:00,4,Eli Lilly Reports Q2 Earnings Beat
10afee00-5133-4717-b7eb-aed604d713af,2019-07-30T08:00:00.000+08:00,4,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings"
1223f08b-1971-4d89-a222-105f51579531,2019-07-30T08:00:00.000+08:00,3,Eli Lilly Sees FY19 Adj. EPS $5.67-$5.77 vs $5.66 Est.
4310a083-905d-4488-b391-35ee83688846,2019-07-30T08:00:00.000+08:00,4,"Eli Lilly Q2 Adj. EPS $1.5 Beats $1.45 Estimate, Sales $5.637B Beat $5.59B Estimate"
47d411f9-c609-4b4c-8ff7-58e60a0fc888,2019-07-30T08:00:00.000+08:00,5,Lilly Announces Verzenio Demonstrated Significant Improvement In Overall Survival In Phase 3 MONARCH 2 The Clinical Trial
3b68ed43-ac8e-4fc6-98da-f4a1dee9b7c3,2019-07-30T08:00:00.000+08:00,3,"15 Stocks To Watch For July 30, 2019"
7b37c163-5abe-4845-a359-96f08a7a77e8,2019-07-30T08:00:00.000+08:00,4,"Earnings Scheduled For July 30, 2019"
be1e96cd-1522-42c2-9966-4deea46167b7,2019-07-30T08:00:00.000+08:00,5,Flexion: The Time To Buy Is Now
af3521ed-b390-4743-8698-386c99a33356,2019-07-30T08:00:00.000+08:00,1,Eli Lilly and Company's (LLY) CEO Dave Ricks on Q2 2019 Results - Earnings Call Transcript
5867dae6-757d-49ea-afc6-90c90f48a352,2019-07-30T08:00:00.000+08:00,2,"Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y"
dff66198-5944-4f51-bee4-eb190e0dc208,2019-07-30T08:00:00.000+08:00,5,"Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up"
d65524d3-6777-441d-853e-dd2c34e2d86f,2019-07-30T08:00:00.000+08:00,4,"Svenska Handelsbanken AB (publ) Buys Welbilt Inc, Eli Lilly and Co, Service Corp International, ..."
e9aaf70a-ca2b-4a27-b6bb-2ef2ddb814ed,2019-07-30T08:00:00.000+08:00,3,Economic and Earnings Date Deluge
64b708ff-54da-40f0-b1fb-ba9a69007d7a,2019-07-30T08:00:00.000+08:00,4,"Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More"
92ca08db-a7f9-4e91-a420-dffacaa03398,2019-07-30T08:00:00.000+08:00,5,Eli Lilly and Company 2019 Q2 - Results - Earnings Call Slides
b166fd1d-a847-427d-882a-8e39be7b2d6f,2019-07-30T08:00:00.000+08:00,4,5 Monster Stocks To Watch For the July 30 Trading Session
9560d290-f848-4eae-858e-3e9daa62cb3d,2019-07-30T08:00:00.000+08:00,3,Trump readies plan allow drug imports from Canada
2237749b-cff0-40e6-ad0f-a0942e4752c8,2019-07-30T08:00:00.000+08:00,5,Eli Lilly (LLY) Tops Q2 Earnings Estimates
37467e20-956b-49d9-b4eb-02de96d5ec57,2019-07-30T08:00:00.000+08:00,4,Eli Lilly up 1% premarket on Q2 beat
c110c266-3ba3-4633-9c6c-06eee7a54d32,2019-07-30T08:00:00.000+08:00,5,Lilly's abemaciclib extends survival in late-stage breast cancer study
62290c5f-b975-475c-9197-2fa9188c4a9e,2019-07-30T08:00:00.000+08:00,5,"Eli Lilly EPS beats by $0.05, beats on revenue"
d614c1eb-eb70-425a-91a5-cbee0727af38,2019-07-29T08:00:00.000+08:00,5,Q2 Earnings Preview For Eli Lilly
3d5d7234-379f-4ad4-b722-1ac3594e6666,2019-07-29T08:00:00.000+08:00,3,"Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up"
7181126b-df40-48ab-82a9-c82056f4cf03,2019-07-29T08:00:00.000+08:00,2,What's in Store for Array BioPharma (ARRY) in Q4 Earnings?
35dfd682-51dc-4f76-b39e-7304cc82aa2e,2019-07-29T08:00:00.000+08:00,1,DivGro Stocks Ranked By Quality Score
1ef46a2a-ebe3-4e5c-829d-19d7efe4a27b,2019-07-29T08:00:00.000+08:00,2,Q2 Earnings Preview For Eli Lilly
bc1809ba-b0b7-4b2c-895f-2158ccdff417,2019-07-29T08:00:00.000+08:00,5,"Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up"
7e4effb6-77ed-4060-9ef0-d8ff7508e2a8,2019-07-29T08:00:00.000+08:00,3,What's in Store for Array BioPharma (ARRY) in Q4 Earnings?
e51e7db9-b261-477d-b6c2-689e3b68b61b,2019-07-29T08:00:00.000+08:00,1,DivGro Stocks Ranked By Quality Score
9d47333a-b05b-4c71-8934-4933833bd4dc,2019-07-28T08:00:00.000+08:00,1,"Week In Review: How Trump's Policies Moved Stocks - July 28th, 2019"
490fd7f9-66a8-4ab2-b11d-a063ca8b5a5c,2019-07-28T08:00:00.000+08:00,3,"Week In Review: How Trump's Policies Moved Stocks - July 28th, 2019"
c0f1f4bf-d85c-409b-9737-38963e63aa76,2019-07-27T08:00:00.000+08:00,4,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate"
1259295c-953a-40ac-907a-f3978885d419,2019-07-27T08:00:00.000+08:00,3,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate"
d584799a-2af7-4ba9-9527-f2c825f62ccb,2019-07-26T08:00:00.000+08:00,4,Drug pricing bill passes Senate committee
c07197aa-8bb1-4d1a-9872-ad71095ddccd,2019-07-26T08:00:00.000+08:00,5,"Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment"
1e9d06e7-3e48-478e-be8c-cc9cc0c362ed,2019-07-26T08:00:00.000+08:00,4,Drug pricing bill passes Senate committee
57db4ec3-b5bd-4e8c-9ade-fb62c5fe06f4,2019-07-26T08:00:00.000+08:00,5,"Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment"
12fdf679-9d01-4382-b4f1-113c25e65fe9,2019-07-25T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug"
e0296a06-98e0-40cd-8745-47c54f2055cb,2019-07-25T08:00:00.000+08:00,5,Lilly Announces FDA Approval of BAQSIMI to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older
f67b499e-eb52-4b1b-a7a1-82e2b2edfa1a,2019-07-25T08:00:00.000+08:00,2,Bulletproof Investing Performance Update: Week 87
a3e75a6e-b721-4a23-90cc-73d7c5f1684d,2019-07-25T08:00:00.000+08:00,5,FDA OKs Lilly's glucagon nasal powder for severe low blood sugar
92463d4b-1d8b-4cf2-a5e3-b05210de5a50,2019-07-25T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug"
baf6edd5-e5bd-493a-821b-d58f963876d7,2019-07-25T08:00:00.000+08:00,3,Lilly Announces FDA Approval of BAQSIMI to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older
3afdd15e-5659-458c-a6e7-bef92fe98f84,2019-07-25T08:00:00.000+08:00,2,Bulletproof Investing Performance Update: Week 87
bfbe20a0-60e0-4ebb-8ed3-c97c1b4b51df,2019-07-25T08:00:00.000+08:00,5,FDA OKs Lilly's glucagon nasal powder for severe low blood sugar
d07c6e0e-f484-4874-9bd2-a79c13c44477,2019-07-24T08:00:00.000+08:00,4,Johnson & Johnson's Stock May Be Too Cheap In A Low Interest Rate World
ca5cae74-3378-4378-9b04-8f96b2fb7f2c,2019-07-24T08:00:00.000+08:00,3,Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?
dc5d1be1-7343-4a8c-b018-b9387162bfaf,2019-07-24T08:00:00.000+08:00,4,Johnson & Johnson's Stock May Be Too Cheap In A Low Interest Rate World
4d34b87d-7207-4177-8bdd-aa3dfeea229d,2019-07-24T08:00:00.000+08:00,3,Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?
a68cda77-0194-47ea-9ef6-b44b1cb2d476,2019-07-23T08:00:00.000+08:00,1,Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline
bfa435cc-6ddc-4234-92fe-99cb10dba995,2019-07-23T08:00:00.000+08:00,2,Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline
6eeaaeaa-4895-43c8-8cb8-64ffe887294f,2019-07-22T08:00:00.000+08:00,4,U.S. Senator introduces bill to cut insulin prices
dccfd5ed-21fc-4114-b7d2-c09bef8c6108,2019-07-22T08:00:00.000+08:00,3,Annovis Bio Begins U.S. IPO Effort
f8dcefa3-23b2-4844-91ac-0f3af966fc0f,2019-07-22T08:00:00.000+08:00,4,U.S. Senator introduces bill to cut insulin prices
a72feafd-1a7d-4beb-87e8-68b0554e1549,2019-07-22T08:00:00.000+08:00,3,Annovis Bio Begins U.S. IPO Effort
23accded-5cb6-44d9-bb00-6654a33b4ba8,2019-07-21T08:00:00.000+08:00,2,"Week In Review: How Trump's Policies Moved Stocks - July 21, 2019"
de08a4d2-918c-469b-be9b-dede5f5be61a,2019-07-21T08:00:00.000+08:00,3,"Week In Review: How Trump's Policies Moved Stocks - July 21, 2019"
a8a6893c-5619-4572-b433-6c2c044f882c,2019-07-19T08:00:00.000+08:00,4,"Bessemer Securities Llc Buys Kirkland Lake Gold, Eli Lilly and Co, Capri Holdings, Sells ..."
0254424d-3a7c-463c-b8db-15ffe53c1205,2019-07-19T08:00:00.000+08:00,4,Eli Lilly (LLY) is a Top Dividend Stock Right Now: Should You Buy?
ff8403f6-cf69-4999-a4ce-6420b58939ed,2019-07-19T08:00:00.000+08:00,3,"Bessemer Securities Llc Buys Kirkland Lake Gold, Eli Lilly and Co, Capri Holdings, Sells ..."
59f2bd37-655d-41d1-9fb0-c3b721904948,2019-07-19T08:00:00.000+08:00,2,Eli Lilly (LLY) is a Top Dividend Stock Right Now: Should You Buy?
f4927f80-cbad-4a44-b194-593982c40784,2019-07-18T08:00:00.000+08:00,3,"The Pharma Scoop: Vanda Meets Endpoints, Aratana To Be Acquired, Einhorn Invests In NeuBase"
08645c61-b468-4027-a78c-828ac4c795ea,2019-07-18T08:00:00.000+08:00,4,Bulletproof Investing Performance Update: Week 86
9c95e609-cc0e-4586-9fbd-61d8a1f38226,2019-07-18T08:00:00.000+08:00,3,NuCana Initiates Dosing in Phase I Study for Solid Tumors
9cc0e0d0-2b38-4bb3-aaf7-ac1545d38ec6,2019-07-18T08:00:00.000+08:00,1,AC Immune Initiates Phase I Study for Alzheimer's Disease
7d19d1e8-dee4-4cb7-a82f-fc1e0582249b,2019-07-18T08:00:00.000+08:00,4,Healthcare Sector Innovation: How Biopharma Scientists Save Lives Globally
e7f90e75-aedd-4bf0-a762-2ac635610274,2019-07-18T08:00:00.000+08:00,5,"The Pharma Scoop: Vanda Meets Endpoints, Aratana To Be Acquired, Einhorn Invests In NeuBase"
ee63b585-f69b-4ef0-823e-ae8af7c1a751,2019-07-18T08:00:00.000+08:00,3,Bulletproof Investing Performance Update: Week 86
ee665d3a-88af-4c26-88d5-63d7f59593f6,2019-07-18T08:00:00.000+08:00,2,NuCana Initiates Dosing in Phase I Study for Solid Tumors
a2ab10a8-dfc1-4137-a41e-8cd026cbbd1e,2019-07-18T08:00:00.000+08:00,1,AC Immune Initiates Phase I Study for Alzheimer's Disease
3a3def84-e7b0-41eb-8b10-5033ec4b7b6b,2019-07-18T08:00:00.000+08:00,2,Healthcare Sector Innovation: How Biopharma Scientists Save Lives Globally
f0266884-0a0f-4fcf-a03f-46035e6049c2,2019-07-17T08:00:00.000+08:00,3,"AC Immune Initiates Phase 1 Study Of ACI-3024 Small Molecule Tau Morphomer, An Investigational Treatment For Alzheimer's Disease"
7015254d-62bc-4ebd-8276-f7a3ccc03cca,2019-07-17T08:00:00.000+08:00,3,"AC Immune Initiates Phase – Study of ACI-'…—4 Small Molecule Tau Morphomer™, an ..."
5c76b762-2a5a-4e88-a015-99b067744815,2019-07-17T08:00:00.000+08:00,2,"AC Immune Initiates Phase 1 Study Of ACI-3024 Small Molecule Tau Morphomer, An Investigational Treatment For Alzheimer's Disease"
a08cd210-23a2-456e-866f-f3f37196ac47,2019-07-17T08:00:00.000+08:00,2,"AC Immune Initiates Phase – Study of ACI-'…—4 Small Molecule Tau Morphomer™, an ..."
97574085-4943-4a29-ba25-64186af1ff3d,2019-07-16T08:00:00.000+08:00,4,"Jim Cramer Weighs In On Marvell, General Motors And More"
4688460e-8b8c-4f69-8dd9-b52ec698f83c,2019-07-16T08:00:00.000+08:00,5,Recent Progress With Filgotinib Plus Latest Partnership Expansion Points To Gilead's New Solid Path
52a5af27-5302-456b-9d64-bb57c02d2f75,2019-07-16T08:00:00.000+08:00,3,"Gradient Investments LLC Buys SPDR Portfolio Short Term Corporate Bond, iShares MBS ETF, ..."
936e73b3-2d24-4f65-bcfa-a88440cf3fed,2019-07-16T08:00:00.000+08:00,4,"Whitnell & Co. Buys iShares Russell –……… Value, DuPont de Nemours Inc, Fastenal Co, ..."
685febf7-7145-4e32-b6d7-dbd95fc99c86,2019-07-16T08:00:00.000+08:00,2,ImmunoGen: Bold Move To Position A Comeback
385809fc-fa9f-4000-8985-8f0e0b547b1c,2019-07-16T08:00:00.000+08:00,4,"Jim Cramer Weighs In On Marvell, General Motors And More"
28ccd24a-97a8-47a7-aefb-a7ff66911cef,2019-07-16T08:00:00.000+08:00,5,Recent Progress With Filgotinib Plus Latest Partnership Expansion Points To Gilead's New Solid Path
3fbab41b-d448-4b9b-a5ac-22281cc3c3bd,2019-07-16T08:00:00.000+08:00,3,"Gradient Investments LLC Buys SPDR Portfolio Short Term Corporate Bond, iShares MBS ETF, ..."
46d75609-ff7f-4cf3-b529-2097b6b193c2,2019-07-16T08:00:00.000+08:00,4,"Whitnell & Co. Buys iShares Russell –……… Value, DuPont de Nemours Inc, Fastenal Co, ..."
c326899c-02a6-4a50-893d-3f441861c245,2019-07-16T08:00:00.000+08:00,2,ImmunoGen: Bold Move To Position A Comeback
3e7d554b-5ab6-4641-b6b1-696f788d0c24,2019-07-15T08:00:00.000+08:00,2,"Legacy Advisors, LLC Buys DuPont de Nemours Inc, PNC Financial Services Group Inc, Wells Fargo, ..."
4e404d6f-208c-4f6c-b2ad-bb8efb417734,2019-07-15T08:00:00.000+08:00,1,AbbVie enters STING field with Mavupharma buy
b45307a4-1a5a-49f3-856f-6b0d5c5807c6,2019-07-15T08:00:00.000+08:00,3,"Legacy Advisors, LLC Buys DuPont de Nemours Inc, PNC Financial Services Group Inc, Wells Fargo, ..."
752b104a-c72f-4f88-95dd-9aa764eac985,2019-07-15T08:00:00.000+08:00,4,AbbVie enters STING field with Mavupharma buy
5dc8c9f0-6f74-4b48-9bbd-da6e62234d22,2019-07-14T08:00:00.000+08:00,5,45 Fortune 500 Stocks Projected Top Total Returns To Investors To July 2020
b285d3ad-ce1d-40a0-a084-0e6c002a5ca9,2019-07-14T08:00:00.000+08:00,2,"Week In Review: How Trump's Policies Moved Stocks - July 14, 2019"
0fbc4244-ded2-41b7-8a1d-0c6757641638,2019-07-14T08:00:00.000+08:00,4,45 Fortune 500 Stocks Projected Top Total Returns To Investors To July 2020
9600b824-5618-47a3-bece-32a82fed2b72,2019-07-14T08:00:00.000+08:00,3,"Week In Review: How Trump's Policies Moved Stocks - July 14, 2019"
a42a81fd-0389-4240-8b50-e9bc34ecab54,2019-07-13T08:00:00.000+08:00,1,"Barron's Picks And Pans: Dollar Tree, Expedia, Nvidia, Prudential And More"
7d854d07-e298-4621-b0b2-7b4a7523c3dc,2019-07-13T08:00:00.000+08:00,2,Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study
576b6b6c-e178-4b53-9964-5a07c0f52dac,2019-07-13T08:00:00.000+08:00,2,"Barron's Picks And Pans: Dollar Tree, Expedia, Nvidia, Prudential And More"
6e50ab99-b5f4-44df-b552-05d9b4ca344d,2019-07-13T08:00:00.000+08:00,4,Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study
057c177c-cd12-43ea-9c95-5e6ece0fa594,2019-07-12T08:00:00.000+08:00,3,"Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug"
353f5bac-8c6c-46c6-b7ff-1548623a48e4,2019-07-12T08:00:00.000+08:00,1,Stock Market Eyes Records On Dovish Commentary From Federal Reserve
e2b62c01-91f6-496d-95f4-af14b89d5276,2019-07-12T08:00:00.000+08:00,2,"Shares of several drug manufacturing companies are trading lower, potentially on continued weakness after the Trump Administration on Thursday rolled back a proposal to eliminate rebates from government drug plans."
3f387bc8-6565-40db-be09-9d7d0e89cc3a,2019-07-12T08:00:00.000+08:00,2,Eli Lilly Highlights Upcoming Presentation Of Data From OVERCOME Study
d090658d-c1cc-4ea0-9e84-47650634e3da,2019-07-12T08:00:00.000+08:00,3,"Univest Corp Of Pennsylvania Buys Monster Beverage Corp, Vanguard Total Bond Market ETF, ..."
572fed13-9cf4-45e7-b875-d247e9a28a3e,2019-07-12T08:00:00.000+08:00,3,Drug Pricing Woes Linger on Repealing Drug Rebate Proposal
9034b880-ee0a-4ce3-b048-2bf97344e134,2019-07-12T08:00:00.000+08:00,4,"Handelsbanken Fonder AB Buys AbbVie Inc, Columbia Sportswear Co, Boingo Wireless Inc, Sells ..."
f954dbca-4b67-4962-bc86-22dc868a7459,2019-07-12T08:00:00.000+08:00,5,Pooled post-hoc data support efficacy of Lilly's migraine med Emaglity
6410788d-166e-4ed3-8fdc-b4b142770e22,2019-07-12T08:00:00.000+08:00,2,"Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug"
831cfe66-28c7-423a-a162-3d3f9c0ffcb3,2019-07-12T08:00:00.000+08:00,4,Stock Market Eyes Records On Dovish Commentary From Federal Reserve
982ae3da-bf2f-4324-b8db-501aea90d8eb,2019-07-12T08:00:00.000+08:00,3,"Shares of several drug manufacturing companies are trading lower, potentially on continued weakness after the Trump Administration on Thursday rolled back a proposal to eliminate rebates from government drug plans."
392de5ba-badc-4ec4-a910-9bde4d22cba1,2019-07-12T08:00:00.000+08:00,1,Eli Lilly Highlights Upcoming Presentation Of Data From OVERCOME Study
9bc36452-c502-4768-9890-d8b16754630d,2019-07-12T08:00:00.000+08:00,2,"Univest Corp Of Pennsylvania Buys Monster Beverage Corp, Vanguard Total Bond Market ETF, ..."
af4b4623-770c-416b-9887-174f319c5030,2019-07-12T08:00:00.000+08:00,2,Drug Pricing Woes Linger on Repealing Drug Rebate Proposal
57a501b2-07ce-41d3-ba36-a41c69ba87a3,2019-07-12T08:00:00.000+08:00,3,"Handelsbanken Fonder AB Buys AbbVie Inc, Columbia Sportswear Co, Boingo Wireless Inc, Sells ..."
62087519-8951-4d99-8d5e-0db3e9379ef5,2019-07-12T08:00:00.000+08:00,4,Pooled post-hoc data support efficacy of Lilly's migraine med Emaglity
ae82ac38-1d57-4c8c-a779-a808826ca245,2019-07-11T08:00:00.000+08:00,1,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.
465a5fce-7ccd-4d3f-97c7-36ec1d29ee12,2019-07-11T08:00:00.000+08:00,3,Eli Lilly Names Mike Harrington New General Counsel
8f0cbbaf-8ae2-4ccd-80b1-b07b88091242,2019-07-11T08:00:00.000+08:00,2,Eli Lilly Highlights Phase 3 Study Results Of Emgality For Treatment Of Episodic Cluster Headache Published In 'New England Journal Of Medicine'
84900dfb-17c6-47f7-8da8-ab5b97c669f6,2019-07-11T08:00:00.000+08:00,3,Here's Why The Stock Market May Make Its Next Move Higher On July 12
2b8419e6-a47a-4833-9f35-fa5248b153f3,2019-07-11T08:00:00.000+08:00,1,Big Biopharma in the red as investors wait for Trump's drug price plan
ac342694-e5c1-40e9-a34c-efea65ba4319,2019-07-11T08:00:00.000+08:00,2,4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal
cc8e92ac-9998-430e-9655-3e9a91803f2e,2019-07-11T08:00:00.000+08:00,3,Bulletproof Investing Performance Update: Week 85
2d8a0d18-4975-4c1e-990b-e336016ff080,2019-07-11T08:00:00.000+08:00,2,"The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices"
9f3fdd29-bfbb-4fa2-a0bc-264e32e4db25,2019-07-11T08:00:00.000+08:00,1,Lilly Bio-Medicines chief to depart next month; shares down 3%
a66cda5a-0f11-4c14-9507-a4641b925ec5,2019-07-11T08:00:00.000+08:00,3,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.
75bd546b-5af4-475c-972e-98748279dacf,2019-07-11T08:00:00.000+08:00,4,Eli Lilly Names Mike Harrington New General Counsel
d1415742-8c97-4bc2-a230-9e72924faa31,2019-07-11T08:00:00.000+08:00,5,Eli Lilly Highlights Phase 3 Study Results Of Emgality For Treatment Of Episodic Cluster Headache Published In 'New England Journal Of Medicine'
66ba54f6-7042-452a-82ad-408631b86793,2019-07-11T08:00:00.000+08:00,3,Here's Why The Stock Market May Make Its Next Move Higher On July 12
98fc55f2-9abb-4874-950a-1fb8a413416f,2019-07-11T08:00:00.000+08:00,2,Big Biopharma in the red as investors wait for Trump's drug price plan
048158ca-a16c-4731-921d-32911b829d30,2019-07-11T08:00:00.000+08:00,3,4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal
7511712d-7e87-4d3c-847f-4f9fa889fea5,2019-07-11T08:00:00.000+08:00,4,Bulletproof Investing Performance Update: Week 85
9cff2337-d9cf-4cb1-a2ba-50449f8c9f5b,2019-07-11T08:00:00.000+08:00,5,"The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices"
a0d16e8d-f55a-45dc-a8ad-b19b4b5a4fc3,2019-07-11T08:00:00.000+08:00,2,Lilly Bio-Medicines chief to depart next month; shares down 3%
64fd0577-1073-4ae2-b1c2-2c08be437a19,2019-07-10T08:00:00.000+08:00,3,Enbridge Portfolio: Final Performance
3582c100-e9f3-4b33-bd74-b326f2df72c1,2019-07-10T08:00:00.000+08:00,4,Eli Lilly And Baricitinib In PBC: What's The Story?
eb2b6132-c52c-4d10-bdc4-c4083e9baa00,2019-07-10T08:00:00.000+08:00,4,"Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific"
8c28d857-5b59-4f52-8cd9-62d2c19b5c80,2019-07-10T08:00:00.000+08:00,1,"Court Ruling Topples Trump Order, No Price Display in TV Ads"
27001754-8786-4891-bbc5-85a9e4f74b94,2019-07-10T08:00:00.000+08:00,2,Enbridge Portfolio: Final Performance
6527926e-bc26-42fd-ac70-1bf4d625cf7f,2019-07-10T08:00:00.000+08:00,4,Eli Lilly And Baricitinib In PBC: What's The Story?
b2375ca1-ba78-40ba-965a-bb8ebcedd39d,2019-07-10T08:00:00.000+08:00,3,"Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific"
901a7782-0688-4e3f-b978-62d2b97aee64,2019-07-10T08:00:00.000+08:00,1,"Court Ruling Topples Trump Order, No Price Display in TV Ads"
d53e0b7a-68d4-4457-be27-b7bc9c924f32,2019-07-09T08:00:00.000+08:00,5,Judge Rules Against Trump Proposal Forcing Pharma Companies To Disclose Drug Prices In Commercials
d54589f6-9ad9-4e30-8fc1-69e3f0e74513,2019-07-09T08:00:00.000+08:00,2,"Ready, Set, Fedspeak (Wall Street Breakfast Podcast)"
0dafbb17-dd21-4123-b939-bd2f363da485,2019-07-09T08:00:00.000+08:00,2,"Wall Street Breakfast: Ready, Set, Fedspeak"
c10bc51a-63c8-42d8-b7de-efc027c4010f,2019-07-09T08:00:00.000+08:00,3,Rule requiring drug prices in TV ads blocked
cab62a07-62da-489e-856f-1731ac363e0c,2019-07-09T08:00:00.000+08:00,4,Judge Rules Against Trump Proposal Forcing Pharma Companies To Disclose Drug Prices In Commercials
6e9c7d13-c4be-47f8-8b3c-0b6ef79ede47,2019-07-09T08:00:00.000+08:00,2,"Ready, Set, Fedspeak (Wall Street Breakfast Podcast)"
44b41c6e-07c8-4c53-b378-d5d9433e9b1d,2019-07-09T08:00:00.000+08:00,2,"Wall Street Breakfast: Ready, Set, Fedspeak"
753aec15-a5ef-4537-a67e-8b69785c224c,2019-07-09T08:00:00.000+08:00,3,Rule requiring drug prices in TV ads blocked
8195d6f5-0e78-476d-bc31-c5dec5200d55,2019-07-08T08:00:00.000+08:00,1,U.S. Judge Halts Trump Administration Rule Requiring Drug Prices in TV Ads
5bb940e6-932e-4f37-8eb8-a66bb3af9cbc,2019-07-08T08:00:00.000+08:00,4,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs."
020e1388-b154-4982-8064-efe01fb344a8,2019-07-08T08:00:00.000+08:00,5,Biophytis files for 8.75M-share U.S. IPO at $7-$9/ADS
82b180ec-ad7a-45ee-9944-39ddbfb3cf28,2019-07-08T08:00:00.000+08:00,2,Biotechs and biopharmas under pressure ahead of Trump order on drug prices
11c79b09-837d-4f03-8256-49cad91958a6,2019-07-08T08:00:00.000+08:00,3,U.S. Judge Halts Trump Administration Rule Requiring Drug Prices in TV Ads
992dd8e9-afe4-40b5-b934-9f56489702ad,2019-07-08T08:00:00.000+08:00,3,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs."
a64d703d-bb82-4012-8df3-5deb6d2054a7,2019-07-08T08:00:00.000+08:00,1,Biophytis files for 8.75M-share U.S. IPO at $7-$9/ADS
410dd90e-a2f8-44d5-b045-2d614464fda6,2019-07-08T08:00:00.000+08:00,2,Biotechs and biopharmas under pressure ahead of Trump order on drug prices
0d2d9ea0-065b-4ad3-8d19-1dc510fca2ab,2019-07-06T08:00:00.000+08:00,2,Most Favored Nation Protection For Abbott Laboratories
d8ade2de-d4d0-42f4-aabb-cc822ed278c8,2019-07-06T08:00:00.000+08:00,2,Most Favored Nation Protection For Abbott Laboratories
b2bda464-5877-4d79-a3a8-743dcdd04557,2019-07-05T08:00:00.000+08:00,3,"Verde Servicos Internacionais S.A. Buys iShares Inc MSCI Brazil, NXP Semiconductors NV, ..."
34868c6f-a99c-4402-a681-fa62f5f30a84,2019-07-05T08:00:00.000+08:00,1,Drug stocks slip after Trump talks up 'favored nations' plan
750cb03e-bce3-4dea-ab5b-9645984a7bb3,2019-07-05T08:00:00.000+08:00,3,A First-Half Review Of The Markets
16cdc4af-a4db-48eb-b18c-ffe9814706cf,2019-07-05T08:00:00.000+08:00,2,"Verde Servicos Internacionais S.A. Buys iShares Inc MSCI Brazil, NXP Semiconductors NV, ..."
555b6053-0a93-4544-90c7-9fc469cf2152,2019-07-05T08:00:00.000+08:00,1,Drug stocks slip after Trump talks up 'favored nations' plan
6939f82a-0ea4-4085-af9f-df74ec498f29,2019-07-05T08:00:00.000+08:00,3,A First-Half Review Of The Markets
a4965b69-291c-473c-8004-894a55a00cfa,2019-07-04T08:00:00.000+08:00,4,Bulletproof Investing Performance Update: Week 84
fb32b3ff-6b4c-4ebe-aa62-74b5bde2644f,2019-07-04T08:00:00.000+08:00,4,Bulletproof Investing Performance Update: Week 84
1bfd17d3-229b-4bf5-9022-9968822bfc2e,2019-07-03T08:00:00.000+08:00,3,Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab
9f773dfa-d2e3-4e6b-a5fd-f0c3136cd8c8,2019-07-03T08:00:00.000+08:00,4,Will the Pharma Space Witness More Mega-Merger Deals in 2H?
110a5404-2a86-4a97-b27e-7cfce67b3013,2019-07-03T08:00:00.000+08:00,5,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
820abc1a-2113-4e5d-b435-c1f3d8e55735,2019-07-03T08:00:00.000+08:00,1,Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab
8dbe1e81-9979-4eac-852d-b4a3e36de299,2019-07-03T08:00:00.000+08:00,4,Will the Pharma Space Witness More Mega-Merger Deals in 2H?
f76b2b17-148f-4901-95fe-4995b5e0ecde,2019-07-03T08:00:00.000+08:00,3,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
9cff1f5f-703a-426a-ac11-34458e81efb2,2019-07-02T08:00:00.000+08:00,2,Entera Announces Initiation Of Phase 2 Dose Ranging Study For Oral PTH
215acbe7-668a-4c04-863d-e95eebdb3a12,2019-07-02T08:00:00.000+08:00,4,Bristol-Myers: Otezla Divestiture Highlights Compelling Opportunity
a9d87af3-cb9d-49e1-ad1c-07010875ffc0,2019-07-02T08:00:00.000+08:00,1,U.S. drugmakers institute new round of increases
206b73f8-793b-45a5-b0a9-ed77335bea60,2019-07-02T08:00:00.000+08:00,5,Gilead to Submit NDA for Inflammation Drug Filgotinib in '19
7b48bf8e-eed7-4e38-b5af-e0614f07a2f8,2019-07-02T08:00:00.000+08:00,2,M&A Activity A Favored Prescription For Biopharmaceutical Companies
c125a4bc-b0a5-4bbb-a9cc-abcfe5485da2,2019-07-02T08:00:00.000+08:00,3,Entera Announces Initiation Of Phase 2 Dose Ranging Study For Oral PTH
fcd25dfd-fce0-4417-aa5c-9e2c0ea855cc,2019-07-02T08:00:00.000+08:00,4,Bristol-Myers: Otezla Divestiture Highlights Compelling Opportunity
8e99c504-4b07-4fd1-870f-b6a1baa812c5,2019-07-02T08:00:00.000+08:00,1,U.S. drugmakers institute new round of increases
67d3a485-5738-4cee-914d-54bb35013713,2019-07-02T08:00:00.000+08:00,5,Gilead to Submit NDA for Inflammation Drug Filgotinib in '19
1e32bf26-1344-4184-8424-53f82d16dd64,2019-07-02T08:00:00.000+08:00,2,M&A Activity A Favored Prescription For Biopharmaceutical Companies
adef5be0-da61-479f-93ea-a78c97bfb0b3,2019-07-01T08:00:00.000+08:00,4,"Cox Capital Co LLC Buys Digital Realty Trust Inc, AbbVie Inc, CVS Health Corp, Sells SPDR ..."
0c8b0f43-f30e-4184-894b-1d2ffe5ac0b8,2019-07-01T08:00:00.000+08:00,3,"Cox Capital Co LLC Buys Digital Realty Trust Inc, AbbVie Inc, CVS Health Corp, Sells SPDR ..."
1ef1d4db-70fd-43fd-ba35-5da69d920b7c,2019-06-28T08:00:00.000+08:00,4,Bulletproof Investing Performance Update: Week 83
3cb0d601-d03f-48de-9630-513cff76cda0,2019-06-28T08:00:00.000+08:00,1,5 Stocks With Low Price-Sales Ratios
20efd7cc-197e-47ce-97e1-f333dd558ab7,2019-06-28T08:00:00.000+08:00,2,"Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger"
a890c322-e81d-4e6d-bfee-c4d7a18deb84,2019-06-28T08:00:00.000+08:00,4,European advisory group backs Lilly's Cyramza for liver cancer
d02d0ecb-3dfa-46ce-b1c3-e27556649d12,2019-06-28T08:00:00.000+08:00,3,Bulletproof Investing Performance Update: Week 83
40f96565-23e8-40bc-9ec2-244c7cd198ba,2019-06-28T08:00:00.000+08:00,4,5 Stocks With Low Price-Sales Ratios
a50e1c36-4910-43a1-9da5-b382c67e898b,2019-06-28T08:00:00.000+08:00,2,"Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger"
3f0a53ff-665d-483f-89cf-e9123bcc915a,2019-06-28T08:00:00.000+08:00,4,European advisory group backs Lilly's Cyramza for liver cancer
bbe35c28-89da-4709-87ad-dfe9600dbd66,2019-06-26T08:00:00.000+08:00,2,Eli Lilly shares trading lower with the other major drugmakers. The downside comes despite news empagliflozin was granted Fast Track Designation by the FDA. The company also announced a Type-2 diabetes drug trial met endpoints.
482c7d51-6ede-4799-94fb-a36d9fe2e683,2019-06-26T08:00:00.000+08:00,3,Lilly's Heart Drug Snags Fast Track Designation; Type 2 Diabetes Drug Found Effective At Higher Doses
a9536849-55c9-4ddc-bc31-0a82ed9aa3a5,2019-06-26T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart"
0f714bef-6207-4533-8f66-2868cb21de9b,2019-06-26T08:00:00.000+08:00,5,Lilly Announces AWARD-11 Trial Studying Higher Investigational Doses Of Trulicity Demonstrated Superiority In A1C Reduction In People With Type 2 Diabetes
e49107be-bffa-4c11-abbb-65b83b66c361,2019-06-26T08:00:00.000+08:00,5,"Eli Lilly, Boehringer Ingelheim Announce FDA Grants Fast Track Designation To Empagliflozin For The Reduction Of The Risk Of Cardiovascular Death And Hospitalization For Heart Failure In People With Chronic Heart Failure"
01d35839-de5e-46a0-ba10-d96c3dc99aa5,2019-06-26T08:00:00.000+08:00,4,Will Democrats Slam Drug Prices? Health Care Stocks Dive Ahead Of Debate
3158b931-4b65-48f1-901a-0a0462d6c8d6,2019-06-26T08:00:00.000+08:00,3,Healthcare stocks under pressure ahead of Dem debate
75ace089-f247-478e-a700-09bfccb6d69a,2019-06-26T08:00:00.000+08:00,4,Higher doses of Lilly's Trulicity successful in late-stage T2D study
36b33b4a-4816-4eaa-9da3-d5e8a23d5662,2019-06-26T08:00:00.000+08:00,5,Lilly's empagliflozin Fast Track'd for CV benefit claim in heart failure patients
b34867b6-c8fa-4bb0-9aa4-cd4eb7400e35,2019-06-26T08:00:00.000+08:00,4,Eli Lilly shares trading lower with the other major drugmakers. The downside comes despite news empagliflozin was granted Fast Track Designation by the FDA. The company also announced a Type-2 diabetes drug trial met endpoints.
9750549f-7d6b-42dd-9237-50e1b032aac0,2019-06-26T08:00:00.000+08:00,3,Lilly's Heart Drug Snags Fast Track Designation; Type 2 Diabetes Drug Found Effective At Higher Doses
57e2d21c-84de-42bd-8729-827fd5f3278e,2019-06-26T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart"
449ea264-01c1-4529-8b44-48b9fec04e70,2019-06-26T08:00:00.000+08:00,5,Lilly Announces AWARD-11 Trial Studying Higher Investigational Doses Of Trulicity Demonstrated Superiority In A1C Reduction In People With Type 2 Diabetes
52175e58-1854-43e0-85d9-0e00e4c701d5,2019-06-26T08:00:00.000+08:00,5,"Eli Lilly, Boehringer Ingelheim Announce FDA Grants Fast Track Designation To Empagliflozin For The Reduction Of The Risk Of Cardiovascular Death And Hospitalization For Heart Failure In People With Chronic Heart Failure"
55b05fda-92b5-4204-952d-5907ba044472,2019-06-26T08:00:00.000+08:00,3,Will Democrats Slam Drug Prices? Health Care Stocks Dive Ahead Of Debate
985bdd52-f43d-43c8-8613-d31db44015b7,2019-06-26T08:00:00.000+08:00,4,Healthcare stocks under pressure ahead of Dem debate
a2d26977-c7a0-452d-b12b-dba8609b24b4,2019-06-26T08:00:00.000+08:00,5,Higher doses of Lilly's Trulicity successful in late-stage T2D study
7f82232f-e358-411b-a9ed-b8d6be860143,2019-06-26T08:00:00.000+08:00,4,Lilly's empagliflozin Fast Track'd for CV benefit claim in heart failure patients
e482e76d-8bfb-4d05-871b-eec63c685f52,2019-06-25T08:00:00.000+08:00,1,Axsome Initiates Phase III Study on Depression Candidate
97a8b367-b022-4760-89e9-92f698d4b72f,2019-06-25T08:00:00.000+08:00,2,Key Factors Aligning To Short Pharmaceuticals
8062496f-2575-46b1-bd27-15b136a59977,2019-06-25T08:00:00.000+08:00,4,Pharma players in green on AbbVie/Allergan deal
5c8c5bfd-c91d-47b3-a161-0591cfe3b276,2019-06-25T08:00:00.000+08:00,3,Axsome Initiates Phase III Study on Depression Candidate
6963ac96-e79a-48d7-80db-ec5b12f4922b,2019-06-25T08:00:00.000+08:00,2,Key Factors Aligning To Short Pharmaceuticals
4975be50-58a9-4079-8694-006de18c4ba5,2019-06-25T08:00:00.000+08:00,4,Pharma players in green on AbbVie/Allergan deal
8cba00d0-cf64-4b7a-b373-90f0730d5c0e,2019-06-22T08:00:00.000+08:00,2,Bulletproof Investing Performance Update: Week 82
87662008-1f65-4ebc-8264-d101ab202669,2019-06-22T08:00:00.000+08:00,2,Bulletproof Investing Performance Update: Week 82
741bd9f8-8101-475e-9f6f-186e2fac5f14,2019-06-21T08:00:00.000+08:00,4,Karuna Therapeutics Readies Plan For $70 Million IPO
4a38e4f9-0c78-4da2-8c3f-9e3f0ba39ab9,2019-06-21T08:00:00.000+08:00,5,Karuna Therapeutics Readies Plan For $70 Million IPO
5c58980d-9070-4133-8ea4-c4391faaea3f,2019-06-19T08:00:00.000+08:00,3,NASH And Diabetes Markets Could Soon Be Disrupted
883b22e0-6106-4877-8a1f-7a926ef6688d,2019-06-19T08:00:00.000+08:00,4,Eli Lilly declares $0.645 dividend
4d9c4d4e-2cfc-4be4-a2e6-e922c7198f40,2019-06-19T08:00:00.000+08:00,3,Eli Lilly Looks Into The Foray Of Developing Its Own NASH Drug
4b51d6cc-0aa9-40af-8bbb-cfaee1d23e49,2019-06-19T08:00:00.000+08:00,2,Zai Lab: A Pearl In The Healthcare Market
82a7fba9-95ac-4906-af74-486f949618d7,2019-06-19T08:00:00.000+08:00,4,NASH And Diabetes Markets Could Soon Be Disrupted
1fc886c1-e4b0-46ec-a301-39aca24f16cd,2019-06-19T08:00:00.000+08:00,4,Eli Lilly declares $0.645 dividend
9ec3d379-3685-4e8c-b2d9-2760c5138d8e,2019-06-19T08:00:00.000+08:00,2,Eli Lilly Looks Into The Foray Of Developing Its Own NASH Drug
07995b40-f9c9-4b2b-bda4-8a43913f3a60,2019-06-19T08:00:00.000+08:00,3,Zai Lab: A Pearl In The Healthcare Market
0ecffbac-58c9-407a-9515-107737e660f8,2019-06-18T08:00:00.000+08:00,4,Stock Spotlight: A New Lifesaving Drug Is Reviving This Drugmaker's Stock
b8f522b4-1c71-4f30-9af6-932d67d63d36,2019-06-18T08:00:00.000+08:00,4,The Best Places To Work: Delivering Strong Results Compared To The S&P 500 Over 10 Years
88e225a2-8f59-43e5-8ad0-b1eee1c42666,2019-06-18T08:00:00.000+08:00,5,Stock Upgrades: Eli Lilly Shows Rising Relative Strength
7771772b-c891-42db-851e-3caadd7624d5,2019-06-18T08:00:00.000+08:00,5,"Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio"
fc7c5d30-ed19-4763-b16d-7e8664463047,2019-06-18T08:00:00.000+08:00,2,Microsoft: Final Performance
5ce23253-8a8c-4017-a0d8-4e82c55ea2f6,2019-06-18T08:00:00.000+08:00,3,Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients
89f972f3-e261-41f5-8c7c-bf641db1e6ee,2019-06-18T08:00:00.000+08:00,4,Stock Spotlight: A New Lifesaving Drug Is Reviving This Drugmaker's Stock
116f99e8-8456-48c1-ae5c-65e27a1cbd5b,2019-06-18T08:00:00.000+08:00,4,The Best Places To Work: Delivering Strong Results Compared To The S&P 500 Over 10 Years
e4d91f31-b094-4702-8b16-815f8033cd54,2019-06-18T08:00:00.000+08:00,5,Stock Upgrades: Eli Lilly Shows Rising Relative Strength
7206c764-220c-49df-89a3-ec8992fd09c9,2019-06-18T08:00:00.000+08:00,2,"Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio"
85054525-a904-48db-a6b5-72d465a7bb40,2019-06-18T08:00:00.000+08:00,3,Microsoft: Final Performance
99c40bdf-0870-4873-833e-55395cbaf54d,2019-06-18T08:00:00.000+08:00,4,Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients
db08ba5d-a61f-4575-8282-076da7532afb,2019-06-17T08:00:00.000+08:00,1,How Pfizer's $11.4 Billion Takeover Of Array Signals More Mergers
1e13bf79-935b-4a43-9539-be6d9e74afc8,2019-06-17T08:00:00.000+08:00,2,How Pfizer's $11.4 Billion Takeover Of Array Signals More Mergers
01f45edd-0a2a-4c85-a732-a669437b99a4,2019-06-14T08:00:00.000+08:00,1,"From Earlier: 'Drug makers Amgen, Merck, Lilly and the Association of National Advertisers file suit to prevent the disclosure of drug prices in television ads.'"
06c81603-a421-45e7-9443-8b9f2588b6f7,2019-06-14T08:00:00.000+08:00,3,Eli Lilly Presents Data on its Taltz Versus AbbVie's Humira in Patients With Active Psoriatic Arthiritis at the European Congress of Rheumatology
cce48108-51b8-47cd-9eac-9463d6526b2d,2019-06-14T08:00:00.000+08:00,4,Drug companies file suit to block disclosure of drug prices in TV ads
64aa6ef7-d46d-41ce-8d11-54e2bffa7da4,2019-06-14T08:00:00.000+08:00,5,Bulletproof Investing Performance Update: Week 81
041ba957-a438-478a-9946-b39d0763c7d9,2019-06-14T08:00:00.000+08:00,2,"Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod"
dfeb14c3-098d-4b63-906d-e9d4d4dfe9ee,2019-06-14T08:00:00.000+08:00,1,"From Earlier: 'Drug makers Amgen, Merck, Lilly and the Association of National Advertisers file suit to prevent the disclosure of drug prices in television ads.'"
8df57186-16d5-4cc3-a8d7-2c87bb6bf3a9,2019-06-14T08:00:00.000+08:00,3,Eli Lilly Presents Data on its Taltz Versus AbbVie's Humira in Patients With Active Psoriatic Arthiritis at the European Congress of Rheumatology
1525950b-edeb-49e2-ad0d-7aac3424bf38,2019-06-14T08:00:00.000+08:00,4,Drug companies file suit to block disclosure of drug prices in TV ads
6241f36a-2b2a-4678-becd-ef3ad939b1fd,2019-06-14T08:00:00.000+08:00,5,Bulletproof Investing Performance Update: Week 81
28fbb40f-4bd1-4877-b77a-c1bbbbb2d05a,2019-06-14T08:00:00.000+08:00,2,"Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod"
fcc7f9be-1caf-494e-86cf-7830ffd28375,2019-06-13T08:00:00.000+08:00,3,Akero Therapeutics Readies $75 Million IPO
eb749be5-985c-4e55-a2d4-80f68cc23e93,2019-06-13T08:00:00.000+08:00,4,NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag
2cab2c47-c672-494e-afd2-be8c8d1a1448,2019-06-13T08:00:00.000+08:00,3,Akero Therapeutics Readies $75 Million IPO
9a3f96e8-ca71-448f-8a5d-0ade1ba9193f,2019-06-13T08:00:00.000+08:00,4,NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag
98964757-4c76-4b90-8b06-11d5cb82d008,2019-06-12T08:00:00.000+08:00,4,Eli Lilly and Company's (LLY) Management Presents at Goldman Sachs 40th Annual Global Helathcare Conference (Transcript)
e6e42cf9-f3a6-4202-8cb6-b87af4a2b79c,2019-06-12T08:00:00.000+08:00,4,Boost Your Portfolio's Health With These 3 Big Drug Stocks
3a56e3cd-11ca-4071-a4bd-14829bbd7707,2019-06-12T08:00:00.000+08:00,4,Eli Lilly and Company's (LLY) Management Presents at Goldman Sachs 40th Annual Global Helathcare Conference (Transcript)
f0738401-27f4-4e71-9631-9d8a236903fe,2019-06-12T08:00:00.000+08:00,4,Boost Your Portfolio's Health With These 3 Big Drug Stocks
ae89c02b-c537-4851-a73d-4dcd595f0847,2019-06-11T08:00:00.000+08:00,5,"The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering"
89b62bb0-44a3-400a-85b3-9a59ae559917,2019-06-11T08:00:00.000+08:00,4,These 27 Fortune 500 Dividend Stocks Made The Best Total Returns To Investors
964e77a8-d005-463d-936a-46bd1e734e8a,2019-06-11T08:00:00.000+08:00,5,Lilly's Taltz shows long-term benefit in psoriasis study
a53f4d31-86ff-495b-ae98-8d468619a2c9,2019-06-11T08:00:00.000+08:00,3,Lilly Announces Tradjenta Cardiovascular Outcome Study Data
cf8bee49-5ea2-4f02-984c-3b57d256736c,2019-06-11T08:00:00.000+08:00,2,Zymeworks: Leader In Bispecifics Space Makes Substantial Headway
59eee562-7c2f-4ea4-8365-0aecfe5209cb,2019-06-11T08:00:00.000+08:00,1,Antares Pharma: What The Market Is Missing
f86fe0cf-d06b-4c05-902e-a274dfeea896,2019-06-11T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering"
100550a0-da33-45e0-9324-2fc3680df390,2019-06-11T08:00:00.000+08:00,3,These 27 Fortune 500 Dividend Stocks Made The Best Total Returns To Investors
d5bb486d-4ba1-4899-a274-f6b4bfe76e1a,2019-06-11T08:00:00.000+08:00,5,Lilly's Taltz shows long-term benefit in psoriasis study
970053b5-665a-411b-89d2-33cb9f97da59,2019-06-11T08:00:00.000+08:00,4,Lilly Announces Tradjenta Cardiovascular Outcome Study Data
92756269-64ce-45ed-931d-008d7a77c3e3,2019-06-11T08:00:00.000+08:00,2,Zymeworks: Leader In Bispecifics Space Makes Substantial Headway
e3749c8f-9926-440c-b2af-ee83711fcfc3,2019-06-11T08:00:00.000+08:00,2,Antares Pharma: What The Market Is Missing
c4830d40-a3c0-4ea7-aa50-2f8f4e7aa060,2019-06-10T08:00:00.000+08:00,1,Eli Lilly shares are trading lower after the company announced disappointing data for the treatment of type 2 diabetes.
43d2cb30-0bb0-4ece-a914-ca9de64db07e,2019-06-10T08:00:00.000+08:00,3,Xeris: Gvoke PDUFA Gets Delayed And Creates Buying Opportunity
d04e9a9a-b399-4123-bb4d-fb565a7a4647,2019-06-10T08:00:00.000+08:00,4,Eli Lilly and Company (LLY) Presents Webcast to Discuss ADA Presentations and Diabetes Portfolio Conference (Transcript)
1455816b-f0ec-4502-ac31-65fbc72aa770,2019-06-10T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca"
c45dc8e1-67fd-4143-bdaf-60cbbb441b7a,2019-06-10T08:00:00.000+08:00,4,ADA Presentations and Diabetes Portfolio
85970f99-5489-4353-88e5-d7e5f7ac1399,2019-06-10T08:00:00.000+08:00,5,Lilly's Trulicity reduced CV risk in large-scale T2D study
412aabcf-0310-475a-ac0f-3576399d7484,2019-06-10T08:00:00.000+08:00,5,Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet
f1606911-8c6d-4c81-86bd-cedf86958b89,2019-06-10T08:00:00.000+08:00,3,"Week In Review: Frontage, A U.S.-China CRO, Stages $205 Million Hong Kong IPO"
9d330767-5648-4854-901d-207fc96e8ff3,2019-06-10T08:00:00.000+08:00,1,Eli Lilly shares are trading lower after the company announced disappointing data for the treatment of type 2 diabetes.
9785ca61-3b64-441b-b10b-4b154ecf114f,2019-06-10T08:00:00.000+08:00,4,Xeris: Gvoke PDUFA Gets Delayed And Creates Buying Opportunity
ae035aee-a8af-4634-9fa3-3a1145d717d5,2019-06-10T08:00:00.000+08:00,3,Eli Lilly and Company (LLY) Presents Webcast to Discuss ADA Presentations and Diabetes Portfolio Conference (Transcript)
13dfca99-935c-428d-996b-0b08b7fd1e92,2019-06-10T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca"
6c0caacc-6a99-4860-b0be-5cf7e910be3a,2019-06-10T08:00:00.000+08:00,4,ADA Presentations and Diabetes Portfolio
a41d1b26-2d18-4e12-bea8-d7e21c747139,2019-06-10T08:00:00.000+08:00,5,Lilly's Trulicity reduced CV risk in large-scale T2D study
9f58121b-5ba2-4b22-859b-99a062e7a553,2019-06-10T08:00:00.000+08:00,4,Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet
f1d8ef81-cd52-463c-8cff-7a549e7f8b3e,2019-06-10T08:00:00.000+08:00,3,"Week In Review: Frontage, A U.S.-China CRO, Stages $205 Million Hong Kong IPO"
3defe0cb-80cf-4d11-a913-ce0f7f8f316b,2019-06-09T08:00:00.000+08:00,5,Lilly Announces Trulicity Significantly Reduced Major Cardiovascular Events for Broad Range of People With Type 2 Diabetes
68bdb8e2-355f-448c-a939-9cd32c23c5ec,2019-06-09T08:00:00.000+08:00,5,Lilly Announces Tirzepatide Demonstrates Benefits in Data Presented at American Diabetes Association's Scientific Sessions
3904a3e4-5f59-4ede-9a4f-f8c8d39ffa39,2019-06-09T08:00:00.000+08:00,5,"Lilly Announces Ultra Rapid Lispro Provided Similar A1C Reductions vs Humalog, With Superior Post-meal Blood Glucose Reductions at ADA Scientific Sessions"
be4cac0a-04f7-48cc-ae53-f2416948c3e6,2019-06-09T08:00:00.000+08:00,5,Lilly Announces Trulicity Significantly Reduced Major Cardiovascular Events for Broad Range of People With Type 2 Diabetes
b8c4f2de-e6b0-403c-a12c-2b8de8513eec,2019-06-09T08:00:00.000+08:00,5,Lilly Announces Tirzepatide Demonstrates Benefits in Data Presented at American Diabetes Association's Scientific Sessions
8a9993bf-323e-4cc9-9211-4148716ec1df,2019-06-09T08:00:00.000+08:00,4,"Lilly Announces Ultra Rapid Lispro Provided Similar A1C Reductions vs Humalog, With Superior Post-meal Blood Glucose Reductions at ADA Scientific Sessions"
649d02fa-859e-45aa-9455-3544c03e979e,2019-06-08T08:00:00.000+08:00,3,Novo's oral semaglutide successful in two late-stage T2D studies
1483ccf2-d65b-4194-bf50-6d061951f204,2019-06-08T08:00:00.000+08:00,3,Novo's oral semaglutide successful in two late-stage T2D studies
bc30aa63-0163-4b50-8978-208c75fc32a6,2019-06-07T08:00:00.000+08:00,4,Primecap Management Buys More Albemarle Corp
b8e8f3d8-17b1-43c9-bf39-1f65e69e9161,2019-06-07T08:00:00.000+08:00,2,Bulletproof Investing Performance Update: Week 80
cc61062c-5b90-4a51-9d30-2061b612c923,2019-06-07T08:00:00.000+08:00,5,Lilly petitions Supreme Court to protect Cialis BPH patent
2f7b83ec-1eb4-4e0d-b3b1-491bb9e15d6f,2019-06-07T08:00:00.000+08:00,3,"Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache"
35ce917f-883d-4a73-bf65-a8872884fcb4,2019-06-07T08:00:00.000+08:00,1,Key events next week - healthcare
cc60fa73-f67d-4352-95fc-417db19aa096,2019-06-07T08:00:00.000+08:00,4,Primecap Management Buys More Albemarle Corp
655ba581-6eb3-4c05-b067-7f64981bb75b,2019-06-07T08:00:00.000+08:00,2,Bulletproof Investing Performance Update: Week 80
76062b66-5240-4841-acae-c801aa3e35a7,2019-06-07T08:00:00.000+08:00,5,Lilly petitions Supreme Court to protect Cialis BPH patent
befda8f3-3c33-411f-adc0-72338ed4cf09,2019-06-07T08:00:00.000+08:00,3,"Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache"
234940d1-7257-47ed-8298-b599c27e0c00,2019-06-07T08:00:00.000+08:00,1,Key events next week - healthcare
33d46bda-339a-435d-8b28-6e399da77208,2019-06-06T08:00:00.000+08:00,2,"Eli Lilly Highlights Will Present Data For Taltz, Olumiant At EULAR 2019 Jun. 12-15, 2019"
234006f4-5dd7-4440-a10c-4042fa8a1015,2019-06-06T08:00:00.000+08:00,4,Incyte Begins Phase III Study for Treatment of Duct Cancer
ef282db6-4e4e-4f61-bb7b-c83cff756b7e,2019-06-06T08:00:00.000+08:00,3,Lilly's Emgality Gets FDA Approval for Cluster Headache
a75097b3-92be-45e8-891e-3233eb7159e0,2019-06-06T08:00:00.000+08:00,2,"Eli Lilly Highlights Will Present Data For Taltz, Olumiant At EULAR 2019 Jun. 12-15, 2019"
d1c370c9-78e6-4541-8609-aacab20cc4be,2019-06-06T08:00:00.000+08:00,1,Incyte Begins Phase III Study for Treatment of Duct Cancer
73def677-327a-4c5b-9df8-50c5fe5890fc,2019-06-06T08:00:00.000+08:00,4,Lilly's Emgality Gets FDA Approval for Cluster Headache
82c39ee5-e9d8-46b9-b021-2cc20dc18ed7,2019-06-05T08:00:00.000+08:00,5,"The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache"
ed90c0e6-d778-42ef-9b6d-56c589282390,2019-06-05T08:00:00.000+08:00,3,"Jim Cramer Shares His Thoughts On AMD, CME Group, Microsoft And More"
f1e5b230-2a18-4d16-a05e-0d0e3feae1de,2019-06-05T08:00:00.000+08:00,4,Lilly To Present Data From Dermatology Portfolio At 24th World Congress Of Dermatology
6e70e4df-e287-421b-bc94-04b8075f04be,2019-06-05T08:00:00.000+08:00,5,EliLilly Announces FDA Approval of Emgality as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks
4a6876d1-e6bd-4dbf-936f-d44623d396f5,2019-06-05T08:00:00.000+08:00,2,FDA OKs expanded label for Lilly's migraine med Emgality
076a0aa4-4a1c-48f4-8c04-31c810207492,2019-06-05T08:00:00.000+08:00,3,"Credit Ratings And Quality Indicators For Dividend Champions, Contenders And Challengers"
4a0cbae3-045a-4f69-a318-6dbeb7d1df08,2019-06-05T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache"
1ea5c7cb-530d-48cb-bb78-a4e07e27efb3,2019-06-05T08:00:00.000+08:00,5,"Jim Cramer Shares His Thoughts On AMD, CME Group, Microsoft And More"
85bfca31-9cc2-4c0b-bfbc-d88d541dd7d7,2019-06-05T08:00:00.000+08:00,4,Lilly To Present Data From Dermatology Portfolio At 24th World Congress Of Dermatology
d92bee12-4f6b-431a-83b4-e8348ad02627,2019-06-05T08:00:00.000+08:00,5,EliLilly Announces FDA Approval of Emgality as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks
f24746e5-c16f-4826-802b-6078ed8612e2,2019-06-05T08:00:00.000+08:00,4,FDA OKs expanded label for Lilly's migraine med Emgality
1f3f8788-408e-4cc0-b681-72b66867bf40,2019-06-05T08:00:00.000+08:00,3,"Credit Ratings And Quality Indicators For Dividend Champions, Contenders And Challengers"
60e94601-327a-40b6-888c-bf76cf85b5e0,2019-06-04T08:00:00.000+08:00,4,FDA Approves Eli Lilly's Emgality For Injection For Treatment Of Episodic Cluster Headache In Adults
6f3eb482-58d2-4fee-84c0-7ac25ae473d4,2019-06-04T08:00:00.000+08:00,4,Eli Lilly Reports FDA Accepted New Drug Application For Triple Combo Tablet For Adults with Type 2 Diabetes
a445dd02-4a63-416a-9b82-b2e68dcc13f4,2019-06-04T08:00:00.000+08:00,5,FDA accepts Eli Lilly's NDA for triple combination tablet for adults with type 2 diabetes
0482aad3-3c70-4581-9244-e69a6d6580e3,2019-06-04T08:00:00.000+08:00,5,FDA Approves Eli Lilly's Emgality For Injection For Treatment Of Episodic Cluster Headache In Adults
6a0eff90-9227-4827-a5c3-28ae4313c813,2019-06-04T08:00:00.000+08:00,4,Eli Lilly Reports FDA Accepted New Drug Application For Triple Combo Tablet For Adults with Type 2 Diabetes
eb57d916-c58c-448b-83ab-7da6b84f7d70,2019-06-04T08:00:00.000+08:00,5,FDA accepts Eli Lilly's NDA for triple combination tablet for adults with type 2 diabetes
f9a73c90-b85d-49f7-a21e-0b742e27e085,2019-06-03T08:00:00.000+08:00,3,"Atomwise Announces Multi-Year, Multi-Target Agreement With Lilly For AI-Driven Drug Discovery Program"
664edff8-670c-42c3-8f32-2d72fdc8b3be,2019-06-03T08:00:00.000+08:00,4,Merck's Keytruda Improves 5-Year Survival in Lung Cancer
fb136048-759d-47ce-8504-b7465c00db72,2019-06-03T08:00:00.000+08:00,2,XBI: Biotech Performance And Valuation Update - June 2019
4c2376ed-a44f-44ef-9af5-0193da2476bc,2019-06-03T08:00:00.000+08:00,3,"Atomwise Announces Multi-Year, Multi-Target Agreement With Lilly For AI-Driven Drug Discovery Program"
a1b69315-a3ea-4303-ac0f-06039ed1ece5,2019-06-03T08:00:00.000+08:00,4,Merck's Keytruda Improves 5-Year Survival in Lung Cancer
db3f6577-e556-4f75-9c4e-ffe832eaf030,2019-06-03T08:00:00.000+08:00,2,XBI: Biotech Performance And Valuation Update - June 2019
22e97d4f-d9df-4412-8a3d-d085f69c2dbf,2019-06-02T08:00:00.000+08:00,1,Dividend Challenger Highlights: Week Of June 2
275e845b-e874-4a92-ada7-2182017f5135,2019-06-02T08:00:00.000+08:00,1,Dividend Challenger Highlights: Week Of June 2
7a5230c9-1e16-4056-a737-031f72bbf3ea,2019-05-30T08:00:00.000+08:00,1,Bulletproof Investing Performance Update: Week 79
eb25fae2-6c2c-43ba-af0b-11df123bb909,2019-05-30T08:00:00.000+08:00,2,Lilly (LLY) Down 2.3% Since Last Earnings Report: Can It Rebound?
18923f53-3fa2-43d0-8af9-9e27e28d31d5,2019-05-30T08:00:00.000+08:00,4,Mereo Bio's setrusumab shows encouraging action in mid-stage bone disorder study
f53095e5-753e-48f7-a05a-fa791533afd2,2019-05-30T08:00:00.000+08:00,2,Bulletproof Investing Performance Update: Week 79
f4f82761-e4d6-4d8e-bb06-cc8f830730a1,2019-05-30T08:00:00.000+08:00,1,Lilly (LLY) Down 2.3% Since Last Earnings Report: Can It Rebound?
ff9b5079-567b-45fb-b231-c4357b4a1cf8,2019-05-30T08:00:00.000+08:00,3,Mereo Bio's setrusumab shows encouraging action in mid-stage bone disorder study
70b0fe37-cd1c-46bb-8f2e-c26e1f35ef9a,2019-05-29T08:00:00.000+08:00,4,Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate
e59b71a2-54d3-4bfb-ad07-b5e2b3af64f7,2019-05-29T08:00:00.000+08:00,2,Here's Why Eli Lilly Is Cutting The Price Of Humalog
5619c4e6-b38d-4c36-a301-32cbad2fadfa,2019-05-29T08:00:00.000+08:00,2,Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate
d0a1cd23-8c39-48b5-ae1a-73561a6f124e,2019-05-29T08:00:00.000+08:00,3,Here's Why Eli Lilly Is Cutting The Price Of Humalog
18911cd1-c3bc-43cf-85c0-a40ce5bc3fdb,2019-05-28T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For May 28, 2019"
efbbf9ba-6e95-4353-9935-87718ae3390a,2019-05-28T08:00:00.000+08:00,4,Lilly Announces Licensing Agreement For Non-Opioid Pain Asset From Centrexion Therapeutics; Lilly To Pay Centrexion $47.5M Up Front And Up To $575M In Potential Development Milestones
288efa69-795d-41b2-805e-1c20464b84ed,2019-05-28T08:00:00.000+08:00,5,"Goldman Sachs Initiates Coverage On Eli Lilly with Buy Rating, Announces $135 Price Target"
41a0ffc0-696a-4c63-852a-617bab055245,2019-05-28T08:00:00.000+08:00,5,Lilly in-licenses non-opioid pain candidate from Centrexion for up ~$1B
6be4a01e-d105-4b7e-807b-28a93f79c07e,2019-05-28T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For May 28, 2019"
4a5570e8-18cd-424c-a2d2-0aa0810f10d9,2019-05-28T08:00:00.000+08:00,4,Lilly Announces Licensing Agreement For Non-Opioid Pain Asset From Centrexion Therapeutics; Lilly To Pay Centrexion $47.5M Up Front And Up To $575M In Potential Development Milestones
dc6e0d21-0772-4d2f-9f77-5b10cd6834b9,2019-05-28T08:00:00.000+08:00,5,"Goldman Sachs Initiates Coverage On Eli Lilly with Buy Rating, Announces $135 Price Target"
055bb621-cdf2-4366-8770-ac6cc0f0fd52,2019-05-28T08:00:00.000+08:00,5,Lilly in-licenses non-opioid pain candidate from Centrexion for up ~$1B
b4e1d716-3198-45e5-af37-a4c862a48f05,2019-05-27T08:00:00.000+08:00,5,Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi
8a7a5edf-8bf3-4e4e-9310-cf7948025140,2019-05-27T08:00:00.000+08:00,5,Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi
1b0eace6-b9a6-4070-bb69-c571558d9d0b,2019-05-24T08:00:00.000+08:00,3,"Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates"
638020a3-53dc-4165-be27-ebfee9c78040,2019-05-24T08:00:00.000+08:00,4,"Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates"
d6298ae1-e447-4373-93f8-5d97c743d0f3,2019-05-23T08:00:00.000+08:00,4,FDA OKs Novocure's TTF for mesothelioma under HDE status; shares up 4% after hours
cba24c9a-6f9a-4271-9f5f-dbbb74f01c37,2019-05-23T08:00:00.000+08:00,2,"Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY)"
e2a85751-039a-4e3e-afbe-f86a01f4d4f4,2019-05-23T08:00:00.000+08:00,3,Bulletproof Investing Performance Update: Week 78
d4a373fd-c9b2-433b-b8a8-8fda228e3ddf,2019-05-23T08:00:00.000+08:00,4,Lilly (LLY) Launches Half-Priced Version of Humalog Insulin
ec73b5e4-d2bf-4b87-b784-c4675d4eec56,2019-05-23T08:00:00.000+08:00,5,FDA OKs Novocure's TTF for mesothelioma under HDE status; shares up 4% after hours
e7c89508-89e0-42e3-9421-f03f3d416693,2019-05-23T08:00:00.000+08:00,2,"Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY)"
4e79085b-d993-486f-9514-783c1d55d3db,2019-05-23T08:00:00.000+08:00,4,Bulletproof Investing Performance Update: Week 78
8bf8dfce-12bd-4f00-bc4d-3b116a4b46a3,2019-05-23T08:00:00.000+08:00,5,Lilly (LLY) Launches Half-Priced Version of Humalog Insulin
0ec345b2-40b5-4f21-9e49-f299f00c485b,2019-05-22T08:00:00.000+08:00,3,"Eli Lilly Reports Insulin Lispro Injection Now Available For Order In Pharmacies For People Who Use Co.'s Rapid-Acting Insulin, Need For Lower-Cost Option"
6812b432-f37c-4cab-bdf4-4e0a94ce8fa7,2019-05-22T08:00:00.000+08:00,4,Array BioPharma Gains on Colorectal Cancer Study Success
dd6a8e04-c43c-4a40-a80b-f4a494524783,2019-05-22T08:00:00.000+08:00,4,3 Tech Stocks for Growth Investors to Buy Right Now
c04f6112-a4cf-4a84-b285-16b88e0bee6a,2019-05-22T08:00:00.000+08:00,4,Philip Morris International: Final Performance
ded139d4-ec82-4b6e-8882-dd511a03e1e3,2019-05-22T08:00:00.000+08:00,5,Lilly's Crohn's Disease Candidate Meets Phase II Study Goals
4402fbc0-c006-400f-b875-92e9607c263b,2019-05-22T08:00:00.000+08:00,3,Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
8c4e5660-3520-47d5-9bb4-1f92bee07471,2019-05-22T08:00:00.000+08:00,4,"Eli Lilly Reports Insulin Lispro Injection Now Available For Order In Pharmacies For People Who Use Co.'s Rapid-Acting Insulin, Need For Lower-Cost Option"
b3b4de1e-b155-45ce-950d-3858600085f7,2019-05-22T08:00:00.000+08:00,5,Array BioPharma Gains on Colorectal Cancer Study Success
23705264-2de5-44d2-8736-09d805d286c6,2019-05-22T08:00:00.000+08:00,4,3 Tech Stocks for Growth Investors to Buy Right Now
5a85dc87-405d-4233-86d5-6afdeaba7b2a,2019-05-22T08:00:00.000+08:00,2,Philip Morris International: Final Performance
e71634eb-05fa-432c-ba79-4123ec92bffe,2019-05-22T08:00:00.000+08:00,5,Lilly's Crohn's Disease Candidate Meets Phase II Study Goals
3e41328d-5de7-4466-ac96-2bb62175b7db,2019-05-22T08:00:00.000+08:00,3,Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
d1fa00d3-fabb-45ab-a441-1cd1fad5a802,2019-05-21T08:00:00.000+08:00,5,"Eli Lilly Reports Mirikizumab Met Primary, Key Secondary Endpoints"
e515ca2b-e593-4af3-a26a-05af02806e9c,2019-05-21T08:00:00.000+08:00,5,An FDA Win For AstraZeneca Shifts To An Expanded Label In The Type 2 Diabetes Market
12d9ff9b-9dbe-4166-ba56-8a7f95769708,2019-05-21T08:00:00.000+08:00,4,Lilly's mirikizumab shows positive effect in mid-stage Crohn's study
931682e9-03f9-427d-826c-ccb29d082b67,2019-05-21T08:00:00.000+08:00,3,Array Bio down 5% premarket on uneven results for Braftovi/Mektovi in CRC
1b225fd9-fa56-4f3f-a4f1-8cbac66c98b4,2019-05-21T08:00:00.000+08:00,5,"Eli Lilly Reports Mirikizumab Met Primary, Key Secondary Endpoints"
9ae2da54-f7fe-4e44-84a1-91c0bfc33ea1,2019-05-21T08:00:00.000+08:00,5,An FDA Win For AstraZeneca Shifts To An Expanded Label In The Type 2 Diabetes Market
740317f8-184b-4c4c-b7e8-c299603f995e,2019-05-21T08:00:00.000+08:00,4,Lilly's mirikizumab shows positive effect in mid-stage Crohn's study
bda8ea88-da84-464c-865d-2714de4161e0,2019-05-21T08:00:00.000+08:00,1,Array Bio down 5% premarket on uneven results for Braftovi/Mektovi in CRC
e0813686-5d4a-4a8c-8558-7e6ad2c671d5,2019-05-20T08:00:00.000+08:00,5,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
13babe89-7c35-481a-a184-30e5a390c9b1,2019-05-20T08:00:00.000+08:00,3,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
c819ad6f-e7a4-47c1-b303-76433ef737e8,2019-05-19T08:00:00.000+08:00,2,6 Stock That May Drop During the Week of May 20
83edb598-def7-49d9-85bf-3462754e0986,2019-05-19T08:00:00.000+08:00,2,6 Stock That May Drop During the Week of May 20
af504ece-577b-45e4-b969-2ea13413eb1a,2019-05-18T08:00:00.000+08:00,3,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs"
7b8af170-129c-41cd-a34a-b4f5a0066798,2019-05-18T08:00:00.000+08:00,3,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs"
96d24ec2-55ce-4ffd-97dd-c5d023f353aa,2019-05-17T08:00:00.000+08:00,4,ImmunoGen: Assessing The Possibility Of A Turnaround
93ad9d34-43f5-426e-a4b8-1dcc205cd8a0,2019-05-17T08:00:00.000+08:00,5,ImmunoGen: Assessing The Possibility Of A Turnaround
cf17be13-a732-4910-843c-55ca8587b0dc,2019-05-16T08:00:00.000+08:00,2,Bulletproof Investing Performance Update: Week 77
a72ee127-74a0-4b67-b12e-ac609b568135,2019-05-16T08:00:00.000+08:00,4,"Citadel Advisors LLC Buys Eli Lilly and Co, McDonald's Corp, The Walt Disney Co, Sells Amazon. ..."
38ea59eb-ad63-4833-a0c4-904b620c261a,2019-05-16T08:00:00.000+08:00,3,Bulletproof Investing Performance Update: Week 77
d551eeb7-8b7a-40b0-a860-8212647f81b0,2019-05-16T08:00:00.000+08:00,1,"Citadel Advisors LLC Buys Eli Lilly and Co, McDonald's Corp, The Walt Disney Co, Sells Amazon. ..."
50c6af09-fbea-4cdc-baf1-302ee8c70815,2019-05-15T08:00:00.000+08:00,2,"Hunting Hill Global Capital, LLC Buys Red Hat Inc, Celgene Corp, iShares China Large-Cap, Sells ..."
eec03d69-e070-4508-930f-50363d09b305,2019-05-15T08:00:00.000+08:00,2,"The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, CVS, Marriott and TELUS"
8bf1fbfe-8811-423b-8cc8-d2b6c8c3cc97,2019-05-15T08:00:00.000+08:00,2,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2019 Update
54675471-b547-40ea-a5e3-860e422445e2,2019-05-15T08:00:00.000+08:00,3,"Hunting Hill Global Capital, LLC Buys Red Hat Inc, Celgene Corp, iShares China Large-Cap, Sells ..."
6ccdb720-c720-4261-9578-141910e8a9a8,2019-05-15T08:00:00.000+08:00,2,"The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, CVS, Marriott and TELUS"
99987dbe-3783-4d41-822d-d20083f00228,2019-05-15T08:00:00.000+08:00,2,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2019 Update
571ec556-3e8d-45db-8d3b-3cc4f8cb9ec3,2019-05-14T08:00:00.000+08:00,4,"Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks."
319e37c8-589c-4996-add0-9151f864a5ff,2019-05-14T08:00:00.000+08:00,3,"Top Research Reports for Alphabet, Eli Lilly & CVS Health"
4ed75b3f-8d36-4e77-b163-6d5f4f81f74e,2019-05-14T08:00:00.000+08:00,5,Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer
81719783-2d49-4fed-a343-122a7236bc10,2019-05-14T08:00:00.000+08:00,4,"Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks."
708685ef-0f76-4bb9-a090-65039c76814d,2019-05-14T08:00:00.000+08:00,4,"Top Research Reports for Alphabet, Eli Lilly & CVS Health"
1a7bf057-917c-4c75-ac15-765258840295,2019-05-14T08:00:00.000+08:00,4,Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer
d3252c2f-8ada-4cd6-a14f-8f67352188d8,2019-05-13T08:00:00.000+08:00,2,A Peek Into The Markets: US Stock Futures Tumble; Dow Futures Down Over 300 Points
a5db26ac-1537-4edc-87dc-62c108ed14e6,2019-05-13T08:00:00.000+08:00,5,Eli Lilly Announces FDA Approval for its CYRAMZA for the Treatment of Patients with Hepatocellular Carcinoma
0fd35067-187a-4ce3-a4f7-49b8642cf5ea,2019-05-13T08:00:00.000+08:00,3,"Hyman Charles D Buys International Business Machines Corp, Merck Inc, Cisco Systems Inc, Sells ..."
dd46756f-7c6e-4bdb-a840-928ce4b1e975,2019-05-13T08:00:00.000+08:00,1,FDA finalizes guidance on interchangeable biosimilars
cfa05abb-96aa-4de7-afdc-aa6483c39564,2019-05-13T08:00:00.000+08:00,5,FDA OK's Lilly's CYRAMZA for liver cancer
57e47483-43a6-4ac3-acba-48d1887d6599,2019-05-13T08:00:00.000+08:00,2,A Peek Into The Markets: US Stock Futures Tumble; Dow Futures Down Over 300 Points
1e8b9a72-ece4-499b-b106-3946dcb44003,2019-05-13T08:00:00.000+08:00,3,Eli Lilly Announces FDA Approval for its CYRAMZA for the Treatment of Patients with Hepatocellular Carcinoma
7f2290b0-7276-4571-974d-e42a32126714,2019-05-13T08:00:00.000+08:00,4,"Hyman Charles D Buys International Business Machines Corp, Merck Inc, Cisco Systems Inc, Sells ..."
3ec20c31-36b4-41b8-81e4-97bfd607b057,2019-05-13T08:00:00.000+08:00,1,FDA finalizes guidance on interchangeable biosimilars
107103de-1988-43ee-beb6-163d4b784f11,2019-05-13T08:00:00.000+08:00,4,FDA OK's Lilly's CYRAMZA for liver cancer
062dda02-2593-4006-a95e-bc632656c826,2019-05-12T08:00:00.000+08:00,3,"Week In Review: How Trump's Policies Moved Stocks - May 12, 2019"
abe081d8-938b-4d68-9afd-18199e963a7e,2019-05-12T08:00:00.000+08:00,2,"Week In Review: How Trump's Policies Moved Stocks - May 12, 2019"
f74aea4e-c023-47b5-87d1-63804c064259,2019-05-10T08:00:00.000+08:00,1,"Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Fri., May 10, 2019"
fc71c8a3-4763-45f9-8325-835632f5697f,2019-05-10T08:00:00.000+08:00,3,"Bluestein R H & Co Buys Deere, Palo Alto Networks Inc, Delta Air Lines Inc, Sells ..."
8711f87e-77e5-4b12-9477-8decfb4d01ca,2019-05-10T08:00:00.000+08:00,4,Nektar: Undervalued And A Tremendous Prospect
8b6114fa-0f8e-4fb3-9434-99d6e8eae895,2019-05-10T08:00:00.000+08:00,3,"Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Fri., May 10, 2019"
51df6942-de0b-46a4-9650-c642fe68d0aa,2019-05-10T08:00:00.000+08:00,2,"Bluestein R H & Co Buys Deere, Palo Alto Networks Inc, Delta Air Lines Inc, Sells ..."
3960f36b-0040-46af-bc58-9b975186b224,2019-05-10T08:00:00.000+08:00,5,Nektar: Undervalued And A Tremendous Prospect
608f2830-fafe-4837-b21f-bd7a7e07f3c5,2019-05-09T08:00:00.000+08:00,1,"Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues"
73a92e90-e676-4432-8c42-d35683095b13,2019-05-09T08:00:00.000+08:00,2,TV ad disclosures to affect small group of drug makers
6c42bd1d-18e9-4d59-b00b-407fa656e511,2019-05-09T08:00:00.000+08:00,3,Bulletproof Investing Performance Update: Week 76
ff5b4244-68c6-41e7-bb9e-30e70264b98d,2019-05-09T08:00:00.000+08:00,4,"Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues"
5e35703d-82bd-4da9-825b-d5d53c5a027f,2019-05-09T08:00:00.000+08:00,2,TV ad disclosures to affect small group of drug makers
1731e096-4f3b-4ea2-ab18-3f47f1c54265,2019-05-09T08:00:00.000+08:00,3,Bulletproof Investing Performance Update: Week 76
69d357cb-ef84-497c-aac6-190323652c9b,2019-05-08T08:00:00.000+08:00,2,The Nextcure IPO: What You Need To Know
feda0628-deb3-4798-900f-87968e54b186,2019-05-08T08:00:00.000+08:00,4,Drug makers to disclose prices in TV ads as early as this summer
7c9a333e-d88c-4cfc-9f1b-6bb3e2e85982,2019-05-08T08:00:00.000+08:00,2,The Nextcure IPO: What You Need To Know
80926e32-0f8a-4492-93bc-437d0ee5ee5f,2019-05-08T08:00:00.000+08:00,4,Drug makers to disclose prices in TV ads as early as this summer
1993c6a8-60e0-43f8-ae03-c0e70291ceb1,2019-05-07T08:00:00.000+08:00,3,NextCure IPO: The Enterprise Value Could Increase In 2020
b8a0e1e2-52b4-437a-86c0-c95e9194519e,2019-05-07T08:00:00.000+08:00,4,"Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View"
f9aacfbd-29af-402e-9584-5370bc20f237,2019-05-07T08:00:00.000+08:00,5,NextCure IPO: The Enterprise Value Could Increase In 2020
80754178-bef3-4dba-af2b-25a3329b99a9,2019-05-07T08:00:00.000+08:00,3,"Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View"
c854807e-d15d-49e3-8c0b-a880ce8bbb8d,2019-05-06T08:00:00.000+08:00,4,"Eli Lilly Highlights Upcoming Presentation Of Results From Pooled Subgroup Analyses Of Efficacy Data From Phase 3 EVOLVE-1, EVOLVE-2 Studies"
f63f03e9-a244-4d40-8075-f7fc0396b05b,2019-05-06T08:00:00.000+08:00,5,"Oral Ozempic: Finally, An Alpha Catalyst For Novo Nordisk?"
1d0a9535-c61a-414c-b38a-2754aaeae756,2019-05-06T08:00:00.000+08:00,4,Cortexyme IPO Isn't Cheap
81333c04-6d7c-414f-ae4f-e8baf9bddf86,2019-05-06T08:00:00.000+08:00,5,Eli Lilly declares $0.645 dividend
77318982-d080-4b1f-ba1b-86b90acc5002,2019-05-06T08:00:00.000+08:00,3,"Eli Lilly Highlights Upcoming Presentation Of Results From Pooled Subgroup Analyses Of Efficacy Data From Phase 3 EVOLVE-1, EVOLVE-2 Studies"
189c4ac9-5dc3-48e6-8307-9edacdfd5d1d,2019-05-06T08:00:00.000+08:00,1,"Oral Ozempic: Finally, An Alpha Catalyst For Novo Nordisk?"
c823df08-2e1b-4514-90e9-b133c62a214f,2019-05-06T08:00:00.000+08:00,4,Cortexyme IPO Isn't Cheap
0d5a6cad-6f65-4d2b-b6a0-ed0c39990349,2019-05-06T08:00:00.000+08:00,4,Eli Lilly declares $0.645 dividend
fc121df8-ff4d-49b1-af5e-e098ca868665,2019-05-05T08:00:00.000+08:00,3,Dogs Of The Champions: An Improvement Over The Dogs Of The Dow
a1b28ad4-e543-4d17-9c68-8b0116cbf148,2019-05-05T08:00:00.000+08:00,3,Uber Time (Stocks To Watch Podcast)
72b37b21-77e9-4b60-b70e-b68cf3900c93,2019-05-05T08:00:00.000+08:00,3,Dogs Of The Champions: An Improvement Over The Dogs Of The Dow
fa757829-64d2-4a81-afb1-9fbd64718dd3,2019-05-05T08:00:00.000+08:00,3,Uber Time (Stocks To Watch Podcast)
ef5a704e-e741-4dd3-bff6-f17dabf4214c,2019-05-04T08:00:00.000+08:00,3,Stocks To Watch: Uber Time
eba36d98-b4c0-4ebb-80e3-9f9f3362aeb2,2019-05-04T08:00:00.000+08:00,3,Stocks To Watch: Uber Time
44d98b75-8f93-48cb-b261-1320519fe52f,2019-05-03T08:00:00.000+08:00,4,Bulletproof Investing Performance Update: Week 75
182d61b6-3d89-4767-965e-b2fadebe4bbc,2019-05-03T08:00:00.000+08:00,1,Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates
f54e3796-ed7c-471a-b73a-a88ba51e27be,2019-05-03T08:00:00.000+08:00,5,FDA OKs AstraZeneca's combo pill for T2D
b657696c-5eea-4766-a47e-08ee3c7401f3,2019-05-03T08:00:00.000+08:00,3,"Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down"
a0bae209-8eca-43c2-94ef-65cf7371a1a6,2019-05-03T08:00:00.000+08:00,4,"Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod"
c9155154-b173-412b-8e79-481e8bfa4412,2019-05-03T08:00:00.000+08:00,5,Bulletproof Investing Performance Update: Week 75
8182cc0c-c79c-48e2-bd69-c84b7a929a4e,2019-05-03T08:00:00.000+08:00,1,Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates
577f05db-0194-431e-91a6-d414c6b3c40d,2019-05-03T08:00:00.000+08:00,4,FDA OKs AstraZeneca's combo pill for T2D
d81a3c21-33a7-4537-9a95-a5d29df91a18,2019-05-03T08:00:00.000+08:00,2,"Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down"
f2b4da2d-5be7-4b0f-8b4d-2d3890a70488,2019-05-03T08:00:00.000+08:00,3,"Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod"
63fef11f-2b1d-456e-914b-8826f4b3d3de,2019-05-02T08:00:00.000+08:00,4,Eli Lilly Announces It Will Present 19 Scientific Abstracts For Emgality (Galcanezumab-Gnlm) And Lasmiditan At The 71St Annual Meeting Of The American Academy Of Neurology Taking Place In Philadelphia From May 4-10
7c7bf9ea-666a-4369-ab6c-89cff245efec,2019-05-02T08:00:00.000+08:00,1,"Newport Trust Co Buys Westinghouse Air Brake Technologies Corp, LiveRamp Holdings Inc, Eli ..."
0098e67d-88c1-4c13-b0a1-458db1776eb1,2019-05-02T08:00:00.000+08:00,1,"German American Bancorp, Inc. Buys Vanguard Real Estate, Morgan Stanley, General Electric Co, ..."
b43b773e-eb13-4015-a71a-eda183279719,2019-05-02T08:00:00.000+08:00,2,United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
85695fc9-716e-4904-84c0-5b696cc225d3,2019-05-02T08:00:00.000+08:00,4,Eli Lilly Announces It Will Present 19 Scientific Abstracts For Emgality (Galcanezumab-Gnlm) And Lasmiditan At The 71St Annual Meeting Of The American Academy Of Neurology Taking Place In Philadelphia From May 4-10
6c63291b-9ff0-4211-b816-29a60d19b750,2019-05-02T08:00:00.000+08:00,3,"Newport Trust Co Buys Westinghouse Air Brake Technologies Corp, LiveRamp Holdings Inc, Eli ..."
ae43a10d-d2aa-43f1-9a3d-2f7b05921a6a,2019-05-02T08:00:00.000+08:00,4,"German American Bancorp, Inc. Buys Vanguard Real Estate, Morgan Stanley, General Electric Co, ..."
8ddd54c6-174f-4e05-a1df-5205408abc8b,2019-05-02T08:00:00.000+08:00,2,United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
67f6164c-f374-4c4a-9cb9-97070d2f0408,2019-05-01T08:00:00.000+08:00,4,"BMO Capital Maintains Outperform on Eli Lilly and Company Common Stock, Raises Price Target to $133"
db0c9ed5-c4d3-4628-bc6f-389da47c9cce,2019-05-01T08:00:00.000+08:00,2,"Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure"
638f7457-7b6e-48f3-91b4-0149f59e6bf5,2019-05-01T08:00:00.000+08:00,3,"BMO Capital Maintains Outperform on Eli Lilly and Company Common Stock, Raises Price Target to $133"
ecc3c2bb-ba65-44de-9751-e0ea6024434b,2019-05-01T08:00:00.000+08:00,2,"Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure"
d704a8cc-1ead-4372-84ed-4a5a67ca585d,2019-04-30T08:00:00.000+08:00,1,Eli Lilly And Co shares are trading lower after the the company reported mixed Q1 results and FY19 guidance which was slightly below the consensus estimate.
ef4ad11b-1bfa-4ec5-ac94-11c3dcec0a55,2019-04-30T08:00:00.000+08:00,2,30 Stocks Moving In Tuesday's Pre-Market Session
a1d527d3-51b3-4280-809a-f9b9f120f7ef,2019-04-30T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering"
4bbc3464-967e-4258-8fe6-c134087a61f7,2019-04-30T08:00:00.000+08:00,3,"A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Fed Meeting"
4e9c7668-2e0e-4c97-aa28-87c790e2ea21,2019-04-30T08:00:00.000+08:00,1,"15 Stocks To Watch For April 30, 2019"
cbd8032f-d845-4dd9-9222-0822797459cb,2019-04-30T08:00:00.000+08:00,1,Eli Lilly Sees FY19 EPS $5.60-$5.70 vs $5.64 Est.
1276094b-4aa2-4b41-8b51-44cee21c6d8e,2019-04-30T08:00:00.000+08:00,2,"Eli Lilly Q1 Adj. EPS $1.33 Beats $1.26 Estimate, Sales $5.09B Miss $5.11B Estimate"
28e3d3d6-f908-4439-a14c-adbe9f29531a,2019-04-30T08:00:00.000+08:00,4,"Earnings Scheduled For April 30, 2019"
1a84c89a-b9c6-42c1-9049-5fefb6e9b3a6,2019-04-30T08:00:00.000+08:00,3,"Biotech News Recap: Merck Boasts Another Impressive Quarter, Keytruda Dominance Highlighted"
6d7691d3-fcb9-4f27-b671-70f983dbd5e9,2019-04-30T08:00:00.000+08:00,5,Eli Lilly and Company's (LLY) CEO Dave Ricks on Q1 2019 Results - Earnings Call Transcript
78b6275b-33ab-4aaa-860c-908a85c806ff,2019-04-30T08:00:00.000+08:00,4,3 Tech Stocks for Growth Investors to Buy Right Now
7b225c9e-f917-4cab-92c4-00c7e6e67d78,2019-04-30T08:00:00.000+08:00,2,Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut
b02a032a-82a1-45ed-92d1-540a5f23e737,2019-04-30T08:00:00.000+08:00,3,Eli Lilly and Company 2019 Q1 - Results - Earnings Call Slides
2ad86651-2aec-4bd1-9b6f-617145247ec9,2019-04-30T08:00:00.000+08:00,4,Eli Lilly down 2% on Q1 miss and lowered revenue guidance
4591efad-15b8-4a6f-9522-e72ea74c4400,2019-04-30T08:00:00.000+08:00,2,"Eli Lilly EPS in-line, misses on revenue"
cbc1b74f-5a35-471b-a753-97f3a83efafe,2019-04-30T08:00:00.000+08:00,3,Eli Lilly And Co shares are trading lower after the the company reported mixed Q1 results and FY19 guidance which was slightly below the consensus estimate.
25cf51af-a3e1-4a85-a37b-c8509cdc5a1c,2019-04-30T08:00:00.000+08:00,2,30 Stocks Moving In Tuesday's Pre-Market Session
c038d35d-23bb-4fe8-bb67-06979200d399,2019-04-30T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering"
939f3e83-2de6-4179-8fc8-f0d2a7f56df5,2019-04-30T08:00:00.000+08:00,3,"A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Fed Meeting"
a650e4b8-c918-4ca6-8b13-b957e8953b0b,2019-04-30T08:00:00.000+08:00,1,"15 Stocks To Watch For April 30, 2019"
c64daed1-b0c9-4893-abed-2323685279e9,2019-04-30T08:00:00.000+08:00,1,Eli Lilly Sees FY19 EPS $5.60-$5.70 vs $5.64 Est.
ba50ab90-f524-462c-9ec2-2622f933fdfc,2019-04-30T08:00:00.000+08:00,2,"Eli Lilly Q1 Adj. EPS $1.33 Beats $1.26 Estimate, Sales $5.09B Miss $5.11B Estimate"
3f848825-3152-4871-9c8a-507f5860bc3e,2019-04-30T08:00:00.000+08:00,4,"Earnings Scheduled For April 30, 2019"
0a1207d0-840b-4a85-ae9f-a5c14f130780,2019-04-30T08:00:00.000+08:00,3,"Biotech News Recap: Merck Boasts Another Impressive Quarter, Keytruda Dominance Highlighted"
630cd298-0caa-4050-b64b-a06d72441c6f,2019-04-30T08:00:00.000+08:00,5,Eli Lilly and Company's (LLY) CEO Dave Ricks on Q1 2019 Results - Earnings Call Transcript
5a378f66-2748-4002-a3cc-7b1fc8f460fc,2019-04-30T08:00:00.000+08:00,4,3 Tech Stocks for Growth Investors to Buy Right Now
b7e60f99-6997-453e-bee5-be56d569834d,2019-04-30T08:00:00.000+08:00,3,Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut
6cecc1ac-8802-458e-88e8-574d15d2bbcd,2019-04-30T08:00:00.000+08:00,4,Eli Lilly and Company 2019 Q1 - Results - Earnings Call Slides
60bec88a-93ae-4643-a0c3-369479367614,2019-04-30T08:00:00.000+08:00,2,Eli Lilly down 2% on Q1 miss and lowered revenue guidance
b54c5d8a-b395-4a1e-a6db-30b25d2f6c7c,2019-04-30T08:00:00.000+08:00,2,"Eli Lilly EPS in-line, misses on revenue"
cfa59c88-0090-4972-bb7d-052b25565009,2019-04-29T08:00:00.000+08:00,1,"Market At New Highs, But Healthcare And Biotechs Feel The Heat"
9af5b223-1cfc-40e0-b0bd-0d6081e9b38d,2019-04-29T08:00:00.000+08:00,2,New migraine meds face tough price talks with PBMs
8fceba65-4725-4a4e-9ab8-8962367504d6,2019-04-29T08:00:00.000+08:00,4,Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice
f3f3af4f-998a-4aa2-aea0-2ebed05b2632,2019-04-29T08:00:00.000+08:00,3,"Market At New Highs, But Healthcare And Biotechs Feel The Heat"
a7df06ee-23e6-4f0a-9a04-82a3cec355b3,2019-04-29T08:00:00.000+08:00,2,New migraine meds face tough price talks with PBMs
791b5c3f-7ff0-4069-8b42-915d4419635a,2019-04-29T08:00:00.000+08:00,4,Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice
23d67de8-a112-47d9-9399-0f346f82c1cc,2019-04-28T08:00:00.000+08:00,4,5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates
2791f916-0d75-438b-987c-1c89dbf6a552,2019-04-28T08:00:00.000+08:00,3,Bulletproof Investing Performance Update: Week 74
7d742c07-e5cf-4a7a-94e4-ad9e5be1a79f,2019-04-28T08:00:00.000+08:00,4,Week In Review: Eddingpharm To Pay $375 Million For 2 Lilly Antibiotics And A Suzhou Manufacturing Facility
5033de7f-7c7e-44ae-9925-db4d8ac39036,2019-04-28T08:00:00.000+08:00,4,Summers Value Partners Q1 2019 Investor Letter
62f3967f-0bb4-434a-9720-63cad29cff05,2019-04-28T08:00:00.000+08:00,4,5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates
58fb0ba9-e7c1-42dc-aed9-34e0728e0621,2019-04-28T08:00:00.000+08:00,4,Bulletproof Investing Performance Update: Week 74
720a90e1-99ed-453b-9d4e-a76283e0fc47,2019-04-28T08:00:00.000+08:00,5,Week In Review: Eddingpharm To Pay $375 Million For 2 Lilly Antibiotics And A Suzhou Manufacturing Facility
17cb6626-2e65-4171-a589-ac76df233a53,2019-04-28T08:00:00.000+08:00,3,Summers Value Partners Q1 2019 Investor Letter
2330b680-f422-48e0-9201-5b0ed90a9ef1,2019-04-27T08:00:00.000+08:00,5,Week In Review: Eddingpharm To Pay $375 Million For Two Lilly Antibiotics And A Suzhou Manufacturing Facility
9cd52f51-6dfb-498e-bffc-be7cb64bdebc,2019-04-27T08:00:00.000+08:00,5,Week In Review: Eddingpharm To Pay $375 Million For Two Lilly Antibiotics And A Suzhou Manufacturing Facility
6f711054-c628-4447-bccd-b601bbf92354,2019-04-26T08:00:00.000+08:00,2,Recommends Withdrawal Of Marketing Authorisation For Eli Lilly's Cancer Medicine Lartruvo
4664d86f-1f62-4e65-924a-07a4e32dd673,2019-04-26T08:00:00.000+08:00,4,US Court Of Appeals Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit
da517471-31f6-463a-8028-6bb96aedecaa,2019-04-26T08:00:00.000+08:00,3,"Arrow Financial Corp Buys Occidental Petroleum Corp, iShares National Muni Bond, Air Products ..."
24c29af7-9111-40da-b960-54e00e2a35ba,2019-04-26T08:00:00.000+08:00,1,Biotech News Recap: Gilead Sciences' STELLAR Data Falls Short
66dbeeed-ce72-4a47-aabe-ca1d50584ec7,2019-04-26T08:00:00.000+08:00,4,Lilly prevails in Alimta patent appeal
549e7525-fe92-4f12-9122-57d0c26bbde1,2019-04-26T08:00:00.000+08:00,2,European advisory group backs withdrawal of Lilly's Lartruvo
5d5c8d9e-03ef-45e7-925a-a173abaef5be,2019-04-26T08:00:00.000+08:00,4,"AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales"
5b756f6a-18b3-4fec-8bf7-4c18b4539cbd,2019-04-26T08:00:00.000+08:00,3,Recommends Withdrawal Of Marketing Authorisation For Eli Lilly's Cancer Medicine Lartruvo
cfb40594-2295-4b3e-a2eb-ce3923fbca7f,2019-04-26T08:00:00.000+08:00,1,US Court Of Appeals Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit
67599f54-8b7b-4bef-982e-66c275eb08ca,2019-04-26T08:00:00.000+08:00,1,"Arrow Financial Corp Buys Occidental Petroleum Corp, iShares National Muni Bond, Air Products ..."
fbf3a492-3b41-4a1a-ae99-9282df0d7bcd,2019-04-26T08:00:00.000+08:00,2,Biotech News Recap: Gilead Sciences' STELLAR Data Falls Short
8de56829-2192-4599-a5c5-06e61647d2e1,2019-04-26T08:00:00.000+08:00,4,Lilly prevails in Alimta patent appeal
70277674-7a59-43b1-b7e9-2bed50b03654,2019-04-26T08:00:00.000+08:00,3,European advisory group backs withdrawal of Lilly's Lartruvo
77f417c2-9480-4742-be41-065a9a760ce9,2019-04-26T08:00:00.000+08:00,2,"AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales"
fba0eded-fa80-4201-8df7-3e1b77067d17,2019-04-25T08:00:00.000+08:00,1,Lilly Prepares To Withdraw Lartruvo From Global Market
91a69cd0-3b2b-45bc-8a77-fc08b4dc830a,2019-04-25T08:00:00.000+08:00,2,MannKind up 2% on new Afrezza data
25736931-ff6c-46c6-9c7d-917cbef4d983,2019-04-25T08:00:00.000+08:00,4,"Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y"
9f2249fa-31f0-462b-b17b-a82121bae42a,2019-04-25T08:00:00.000+08:00,1,Lilly pulling Lartruvo from market after failed late-stage study
5338b3ec-3f04-4592-930d-1c50bf764c0e,2019-04-25T08:00:00.000+08:00,5,Eli Lilly Receives Approval For Hard-To-Detect Inflammatory Arthritis
4aecdc24-feab-401c-9ac5-32df223e0b38,2019-04-25T08:00:00.000+08:00,3,Lilly Prepares To Withdraw Lartruvo From Global Market
cd04faa2-d232-4e97-bef2-126736402db3,2019-04-25T08:00:00.000+08:00,2,MannKind up 2% on new Afrezza data
88786305-9f47-46b8-aa74-934623b886d9,2019-04-25T08:00:00.000+08:00,4,"Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y"
963f1860-abf9-497b-a05b-b5341265cf1f,2019-04-25T08:00:00.000+08:00,1,Lilly pulling Lartruvo from market after failed late-stage study
04f31510-521f-4028-bab4-659294887ca8,2019-04-25T08:00:00.000+08:00,5,Eli Lilly Receives Approval For Hard-To-Detect Inflammatory Arthritis
713597f9-6303-4715-be00-fb049ce03830,2019-04-24T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For April 24, 2019"
917a31d9-3614-4a9e-a42c-dc295bf52fa0,2019-04-24T08:00:00.000+08:00,5,Edward Jones Upgrades Eli Lilly and Company Common Stock to Buy
0de6cffa-4daa-4de0-b4d3-4d7ff6577653,2019-04-24T08:00:00.000+08:00,4,Eli Lilly Looks To Tap Potential Groundbreaking Technology From Avidity
b6939322-eea1-479c-9646-d1d144886ed4,2019-04-24T08:00:00.000+08:00,3,Needham likes Zimmer Biomet in premarket analyst action
5a7a2e80-f7ff-4874-a74b-55fef56c9d29,2019-04-24T08:00:00.000+08:00,2,"Benzinga's Top Upgrades, Downgrades For April 24, 2019"
4c5c18f0-dcb7-4e3b-830b-fe7907a76db2,2019-04-24T08:00:00.000+08:00,5,Edward Jones Upgrades Eli Lilly and Company Common Stock to Buy
d6fbbcdb-a078-4890-ab25-587238441849,2019-04-24T08:00:00.000+08:00,4,Eli Lilly Looks To Tap Potential Groundbreaking Technology From Avidity
376d75a1-06d3-4f63-9f82-e45247619c8e,2019-04-24T08:00:00.000+08:00,2,Needham likes Zimmer Biomet in premarket analyst action
ed0739ff-7d1f-40c7-966a-87774061b2fb,2019-04-23T08:00:00.000+08:00,3,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'"
ff8feee1-a136-4863-9ef7-faf8580169d3,2019-04-23T08:00:00.000+08:00,4,"The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale"
e21435e1-8b33-4c4c-b0e1-ab69985025d0,2019-04-23T08:00:00.000+08:00,5,Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China for $375M
0d5f53d4-9c42-4ffc-a693-6cf2ecb826b3,2019-04-23T08:00:00.000+08:00,2,Futures Tepid As Investors Await Earnings Jolt (Wall Street Breakfast Podcast)
2fbf2bd5-ba2a-48f5-88fc-0181879824a5,2019-04-23T08:00:00.000+08:00,2,Wall Street Breakfast: Futures Tepid As Investors Await Earnings Jolt
6887a1dd-6e77-41e8-bccf-450bb58efa4a,2019-04-23T08:00:00.000+08:00,3,"Lilly to sell two antibiotics, plant in China for $375M"
33752eb9-d6aa-4f33-a237-de64ec1fcb03,2019-04-23T08:00:00.000+08:00,4,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'"
4ccf6d94-6c2f-4701-bd35-1d9c1989c252,2019-04-23T08:00:00.000+08:00,5,"The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale"
c60b0237-3110-4d32-bd87-28e470361d0d,2019-04-23T08:00:00.000+08:00,2,Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China for $375M
4a9f2bba-9210-4068-9bdb-d6e029777d2b,2019-04-23T08:00:00.000+08:00,1,Futures Tepid As Investors Await Earnings Jolt (Wall Street Breakfast Podcast)
618001e7-5004-49c2-95bc-ceb94acdaa57,2019-04-23T08:00:00.000+08:00,3,Wall Street Breakfast: Futures Tepid As Investors Await Earnings Jolt
e2a74fd8-c417-4271-9610-03316e9fbcce,2019-04-23T08:00:00.000+08:00,4,"Lilly to sell two antibiotics, plant in China for $375M"
24002e27-1945-4dbe-9d1f-e1620db4fd06,2019-04-22T08:00:00.000+08:00,2,"Eli Lilly-Pfizer's Non-Opioid Painkiller Faces Safety, Efficacy Concerns"
71f1609e-cf3c-4ab8-8a53-07e9c6976869,2019-04-22T08:00:00.000+08:00,2,"Pfizer, Eli Lilly Late Thurs. Announced Top-Line Results From Long-Term Phase 3 Study Of Tanezumab In Patients With Osteoarthritis"
ed3e5a8e-b6ee-4a62-8751-a2e510061464,2019-04-22T08:00:00.000+08:00,4,Eli Lilly Says its COAST-X Study of Taltz Met its Primary and Key Secondary Endpoints
55dcb5f8-eb7e-4473-b31c-2873cbce35b5,2019-04-22T08:00:00.000+08:00,3,"Eli Lilly Announces Research and Licensing Collaboration with Avidity Biosciences to Pursue Therapeutics Targets Focused on Immunology, Eli Lilly to Pay $20M Upfront and Make a $15M Investment in Avidity"
7a736924-376d-42cf-9620-70e54c7a884f,2019-04-22T08:00:00.000+08:00,1,"First National Bank Sioux Falls Buys Boeing Co, iShares MSCI EAFE, 'M Co, Sells Vectren Corp, ..."
62bac2ee-4a59-4c8b-a82d-bbbebda828a5,2019-04-22T08:00:00.000+08:00,1,Biotech News Recap: Pressure On Shares Of Novartis Continues Following Zolgensma Patient Death
9dc74a21-617b-4572-b834-ff09f7df1ec6,2019-04-22T08:00:00.000+08:00,4,Lilly's Taltz successful in late-stage study in axial skeleton arthritis
7dd72451-27ab-4a2d-a849-b1b0ce9dd3e1,2019-04-22T08:00:00.000+08:00,2,Lilly teams up with Avidity Bio to develop new medicines
c3fc47b2-5080-4721-9974-9069cd8a551e,2019-04-22T08:00:00.000+08:00,1,"Eli Lilly-Pfizer's Non-Opioid Painkiller Faces Safety, Efficacy Concerns"
92c7e19f-7e85-498b-971d-0f5d354962d7,2019-04-22T08:00:00.000+08:00,5,"Pfizer, Eli Lilly Late Thurs. Announced Top-Line Results From Long-Term Phase 3 Study Of Tanezumab In Patients With Osteoarthritis"
25d68290-32d2-4cde-8b76-2578ab1b06a0,2019-04-22T08:00:00.000+08:00,5,Eli Lilly Says its COAST-X Study of Taltz Met its Primary and Key Secondary Endpoints
cd5f05f3-2821-4129-b7a1-365515508151,2019-04-22T08:00:00.000+08:00,4,"Eli Lilly Announces Research and Licensing Collaboration with Avidity Biosciences to Pursue Therapeutics Targets Focused on Immunology, Eli Lilly to Pay $20M Upfront and Make a $15M Investment in Avidity"
335b7ef7-e7b8-4c6b-8f7c-72ed7be70a0d,2019-04-22T08:00:00.000+08:00,2,"First National Bank Sioux Falls Buys Boeing Co, iShares MSCI EAFE, 'M Co, Sells Vectren Corp, ..."
1ec59378-f609-490b-b677-d8d2cf02716f,2019-04-22T08:00:00.000+08:00,3,Biotech News Recap: Pressure On Shares Of Novartis Continues Following Zolgensma Patient Death
123e558d-ed0d-4aab-ae54-95f484cf020b,2019-04-22T08:00:00.000+08:00,5,Lilly's Taltz successful in late-stage study in axial skeleton arthritis
1ee42ad3-0ab0-4bad-90d5-d2f6d03ee7d7,2019-04-22T08:00:00.000+08:00,4,Lilly teams up with Avidity Bio to develop new medicines
996eea79-fa17-4022-a62c-f2b1f9e84cb2,2019-04-19T08:00:00.000+08:00,2,Bulletproof Investing Performance Update: Week 73
a494f715-5f16-4157-b371-0692a34210d0,2019-04-19T08:00:00.000+08:00,2,Bulletproof Investing Performance Update: Week 73
083df0fe-ea72-446b-8bba-268f08332dc0,2019-04-18T08:00:00.000+08:00,1,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.
1c764b9d-0b78-4dcc-abb8-3bb1a9c1796a,2019-04-18T08:00:00.000+08:00,4,Lilly and Pfizer's tanezumab shows mixed results in late-stage osteoarthritis study
53b54ed0-504c-4e59-8a92-da882a3889ce,2019-04-18T08:00:00.000+08:00,3,Pfizer-Lilly painkiller in lower dose misses main goals in Phase 3 study
a5ff07e9-a1ba-476b-bf0b-c53c2baef7ea,2019-04-18T08:00:00.000+08:00,2,Realty Income: Final Performance
82d213f8-9f95-4bc2-a689-728a698c7fa8,2019-04-18T08:00:00.000+08:00,5,Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
eccc6048-26fe-44d7-bcaa-b95cedc4018a,2019-04-18T08:00:00.000+08:00,5,Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
89c76565-a52f-4556-884c-40f9ccb3d2e0,2019-04-18T08:00:00.000+08:00,1,Is Healthcare Berning?
e3faab31-28bc-4bce-b3d0-8417cabdfb18,2019-04-18T08:00:00.000+08:00,1,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.
4a0c427a-8d57-4494-b174-fb81ff3c3343,2019-04-18T08:00:00.000+08:00,2,Lilly and Pfizer's tanezumab shows mixed results in late-stage osteoarthritis study
16b89fef-6601-46f5-8452-a6a036259826,2019-04-18T08:00:00.000+08:00,3,Pfizer-Lilly painkiller in lower dose misses main goals in Phase 3 study
d85be1ff-c39e-4468-88dd-259e9197ed40,2019-04-18T08:00:00.000+08:00,4,Realty Income: Final Performance
71890491-f237-428e-86d4-18eea7354577,2019-04-18T08:00:00.000+08:00,5,Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
e9b60844-d0ac-48b5-90e3-a1d59a1ded8f,2019-04-18T08:00:00.000+08:00,5,Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
39b46584-2248-469e-937c-238cd0dac340,2019-04-18T08:00:00.000+08:00,1,Is Healthcare Berning?
5ef5052f-255e-450c-97f5-193f6e045f5c,2019-04-17T08:00:00.000+08:00,3,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.
ac22a98b-ff6d-4323-b29e-31504c1d960f,2019-04-17T08:00:00.000+08:00,4,Johnson & Johnson Looks To Help Type 2 Diabetes Patients With Key Advancement
4f5e5657-047c-4614-a62d-e330e616f8e3,2019-04-17T08:00:00.000+08:00,2,The Great Biotech Massacre As The Ghost Of Drug Pricing Past Return
dfc86727-abdf-4c8c-be9c-6b6ba32cb073,2019-04-17T08:00:00.000+08:00,3,"Chesapeake Wealth Management Buys The Communication Services Select Sector SPDR Fund, Comcast ..."
048ce825-f82f-4c26-8614-7de185bdbba4,2019-04-17T08:00:00.000+08:00,1,Drugmaker selloff intensifies on D.C. pricing headwinds
e4d9b78d-3a60-4a1a-95ef-6a2c2a95f7ef,2019-04-17T08:00:00.000+08:00,3,Cortexyme Files For U.S. IPO
9292da54-3f7f-47e6-bd26-0cdafdbf29fa,2019-04-17T08:00:00.000+08:00,4,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.
82fab57c-2d19-41c1-af47-eb0b5173d69f,2019-04-17T08:00:00.000+08:00,5,Johnson & Johnson Looks To Help Type 2 Diabetes Patients With Key Advancement
fd5ea3a5-6af4-4f13-96d6-745c4988e7e2,2019-04-17T08:00:00.000+08:00,2,The Great Biotech Massacre As The Ghost Of Drug Pricing Past Return
15e33378-1611-442b-984a-dba3b475273b,2019-04-17T08:00:00.000+08:00,2,"Chesapeake Wealth Management Buys The Communication Services Select Sector SPDR Fund, Comcast ..."
84e85d19-be25-4e5e-a1cb-19ddfb28d418,2019-04-17T08:00:00.000+08:00,1,Drugmaker selloff intensifies on D.C. pricing headwinds
eeee91f1-b87d-4414-be77-976ff67ba5af,2019-04-17T08:00:00.000+08:00,3,Cortexyme Files For U.S. IPO
ba2b7a46-80f1-4e0c-9151-b5b957ac0307,2019-04-16T08:00:00.000+08:00,4,Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.
7d495813-e375-4375-a058-a1daba07d51e,2019-04-16T08:00:00.000+08:00,5,Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales
7c9ed815-7baf-4b52-9405-0197dfa51550,2019-04-16T08:00:00.000+08:00,1,Johnson & Johnson's Legal Troubles Eat Into Earnings
f7d2298e-2833-443b-86b5-ed9329bda6ac,2019-04-16T08:00:00.000+08:00,2,"Amgen prices Evenity at $1,825 per month"
49c63b08-5b22-4a69-a6d0-8c18c2c4b0e2,2019-04-16T08:00:00.000+08:00,3,Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.
a30f167b-3a05-4c86-83ee-5d4e40be7901,2019-04-16T08:00:00.000+08:00,2,Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales
e630938f-325a-469c-b724-f7a19026af52,2019-04-16T08:00:00.000+08:00,1,Johnson & Johnson's Legal Troubles Eat Into Earnings
4dd1c2bc-a315-4845-ab07-e20bc38d64e8,2019-04-16T08:00:00.000+08:00,4,"Amgen prices Evenity at $1,825 per month"
20cc3851-68b2-4aa0-8bd4-465fb091a538,2019-04-15T08:00:00.000+08:00,5,J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer
154a45ca-075e-4715-8049-73c17f7abcea,2019-04-15T08:00:00.000+08:00,3,J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer
76810179-883b-4aff-adbf-032f1483a235,2019-04-12T08:00:00.000+08:00,2,"Jones Collombin Investment Counsel Inc Buys Eli Lilly and Co, Visa Inc, New Relic Inc, Sells ..."
8d11c374-fa28-4a4a-be5c-66ace4cfc21c,2019-04-12T08:00:00.000+08:00,1,Bulletproof Investing Performance Update: Week 72
7826dd1e-d56b-440c-a3dd-808bef213618,2019-04-12T08:00:00.000+08:00,2,"Jones Collombin Investment Counsel Inc Buys Eli Lilly and Co, Visa Inc, New Relic Inc, Sells ..."
7ff987ab-ffbb-4fd5-b65f-11676c42f2af,2019-04-12T08:00:00.000+08:00,3,Bulletproof Investing Performance Update: Week 72
1d1956b8-a452-4674-b2db-7f92592a3e20,2019-04-11T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For April 11, 2019"
6a3e3952-77ec-48f3-93bf-fbac819933c0,2019-04-11T08:00:00.000+08:00,1,Guggenheim Downgrades Eli Lilly to Neutral
850d249a-7301-42ff-b98f-9acdeb3ade8d,2019-04-11T08:00:00.000+08:00,4,"AbbVie's Psoriasis Drug Approved For Japan, But The Main Event Is Yet To Come"
40384b6d-5bc5-43d1-aa0a-ce6c47b35b02,2019-04-11T08:00:00.000+08:00,2,Biotechnology Market on a Tear: 5 ETFs in Spotlight
5349fb96-a062-4cbc-8c9e-07ae6797a736,2019-04-11T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors"
46ef6f6f-d431-4773-8738-6fb342cb4777,2019-04-11T08:00:00.000+08:00,4,This Is Why Stocks Are Poised To Surge Higher on April 11
3440b7fb-9cc7-4af4-ae23-4fd76884163b,2019-04-11T08:00:00.000+08:00,1,Stifel neutral on Incyte in premarket analyst action
cb6098d2-24bc-4afb-91e3-b44fd0e51fbd,2019-04-11T08:00:00.000+08:00,2,"Benzinga's Top Upgrades, Downgrades For April 11, 2019"
ec8da821-6738-41fa-920d-b6d41fbfc056,2019-04-11T08:00:00.000+08:00,2,Guggenheim Downgrades Eli Lilly to Neutral
3a9856d9-916f-49d2-bced-4c35a40caecb,2019-04-11T08:00:00.000+08:00,3,"AbbVie's Psoriasis Drug Approved For Japan, But The Main Event Is Yet To Come"
8ee8d260-2935-45a9-8f88-fa1b9a3230bc,2019-04-11T08:00:00.000+08:00,3,Biotechnology Market on a Tear: 5 ETFs in Spotlight
f878be04-8f2d-4267-8028-077a8f6b79db,2019-04-11T08:00:00.000+08:00,4,"The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors"
2f6a96d3-4b2c-4d02-a312-ede808a6b9bf,2019-04-11T08:00:00.000+08:00,5,This Is Why Stocks Are Poised To Surge Higher on April 11
7e34bddd-3a1a-4626-af55-63321b2323d4,2019-04-11T08:00:00.000+08:00,2,Stifel neutral on Incyte in premarket analyst action
733582bd-4c13-4ea4-b5d6-3e2c659b7e50,2019-04-10T08:00:00.000+08:00,4,"BKD Wealth Advisors, LLC Buys iShares S&P 5…… Growth, Eli Lilly and Co, Vanguard ..."
96c2ff68-a2b7-4689-9be0-0e02145b2bef,2019-04-10T08:00:00.000+08:00,3,"Top Stock Reports for Eli Lilly, Altria & Becton Dickinson"
d90eae39-7b74-4607-ae22-a9828cf84ed3,2019-04-10T08:00:00.000+08:00,4,Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice
6e72b8a9-2b86-4aa0-b71f-55c4670a0ba5,2019-04-10T08:00:00.000+08:00,1,Managing Biotech Investing Risk With Jonathan Faison (Podcast)
4d046266-a8e8-4e84-970b-abb3839208c3,2019-04-10T08:00:00.000+08:00,2,"BKD Wealth Advisors, LLC Buys iShares S&P 5…… Growth, Eli Lilly and Co, Vanguard ..."
e8d24166-60dc-484a-a324-86b9f2c88537,2019-04-10T08:00:00.000+08:00,4,"Top Stock Reports for Eli Lilly, Altria & Becton Dickinson"
8a128102-de63-45c2-a706-9e7490f5d658,2019-04-10T08:00:00.000+08:00,5,Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice
36297146-2b4a-459b-a841-1b091d9fffa7,2019-04-10T08:00:00.000+08:00,1,Managing Biotech Investing Risk With Jonathan Faison (Podcast)
3ebae007-21f5-491b-8939-c1930ae79223,2019-04-09T08:00:00.000+08:00,3,Enbridge: Halftime Report
c2d0ff7b-ca73-4b03-9584-a376f1bdebad,2019-04-09T08:00:00.000+08:00,2,Enbridge: Halftime Report
24794d95-ac08-4254-8795-f4d5557868ab,2019-04-08T08:00:00.000+08:00,4,"Indiana Trust & Investment Management CO Buys Eli Lilly and Co, Amazon. ..."
07fb88a7-82a2-4899-9bbe-8cf0725fa12a,2019-04-08T08:00:00.000+08:00,3,"XR Securities LLC Buys VanEck Vectors Gold Miners, SPDR S&P 5……, VanEck Vectors Junior ..."
33a0ec28-ea44-4314-a62a-d8859fdc2a95,2019-04-08T08:00:00.000+08:00,1,"Indiana Trust & Investment Management CO Buys Eli Lilly and Co, Amazon. ..."
cae38717-1b8f-49cc-98fe-0e5219acc485,2019-04-08T08:00:00.000+08:00,2,"XR Securities LLC Buys VanEck Vectors Gold Miners, SPDR S&P 5……, VanEck Vectors Junior ..."
aad4e294-2051-49fa-bae9-12bbea5b472f,2019-04-07T08:00:00.000+08:00,2,Disney+ And Bank Majors Step Out (Stocks To Watch Podcast)
9fed7128-d10c-4c82-ba5e-36adb682b210,2019-04-07T08:00:00.000+08:00,2,Disney+ And Bank Majors Step Out (Stocks To Watch Podcast)
f93d138c-7eb3-4130-bcb3-fd915d301473,2019-04-06T08:00:00.000+08:00,2,Stocks To Watch: Disney+ And Bank Majors Step Out
1ed9af16-cd75-4e65-9152-59ba3d413f4f,2019-04-06T08:00:00.000+08:00,2,Stocks To Watch: Disney+ And Bank Majors Step Out
5d36720f-ae86-4f19-8355-f63b0c4f2e4b,2019-04-05T08:00:00.000+08:00,1,Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
d3b3d651-57ab-4fff-83b0-2235341e2013,2019-04-05T08:00:00.000+08:00,2,Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig
bd8e6cfe-f8fc-401d-9347-fa1869b5b80a,2019-04-05T08:00:00.000+08:00,5,Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
f3dc4876-ceab-4614-b720-37c861d78118,2019-04-05T08:00:00.000+08:00,2,Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig
bd1d944c-15c5-4d0e-a5f2-2b4de358b70f,2019-04-04T08:00:00.000+08:00,4,"Tibra Equities Europe Ltd Buys Union Pacific Corp, Walmart Inc, SPDR Select Sector Fund - ..."
0546e9d5-a6ea-4616-b77d-eebc9c0e6a52,2019-04-04T08:00:00.000+08:00,4,"Tibra Equities Europe Ltd Buys Union Pacific Corp, Walmart Inc, SPDR Select Sector Fund - ..."
28ab8d78-6882-426e-836d-cffc24246a2e,2019-04-03T08:00:00.000+08:00,2,"Cox Capital Co LLC Buys American Tower Corp, Crown Castle International Corp, Community ..."
f7c9c888-8cdf-483f-9e42-c84d369231df,2019-04-03T08:00:00.000+08:00,3,Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003
035c1f1a-4de4-45ce-8d4f-fc62771cf863,2019-04-03T08:00:00.000+08:00,3,"Cox Capital Co LLC Buys American Tower Corp, Crown Castle International Corp, Community ..."
4361719c-60ed-4e60-bec4-dc8a747a15c4,2019-04-03T08:00:00.000+08:00,4,Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003
5eaab772-87fb-4964-8c76-2a7d478e1c03,2019-04-02T08:00:00.000+08:00,5,Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe
ab59f26c-0122-4d17-b574-32cd4eff003f,2019-04-02T08:00:00.000+08:00,2,Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe
b08d872d-0cc4-4c84-8c5a-903b4ed5cf15,2019-04-01T08:00:00.000+08:00,4,Arteaus Sold its Royalty Interest on Future Global Net Sales of Eli Lilly's Emgality to Royalty Pharma for $260M
6fc197e1-5760-4207-b5fb-50c703f5b975,2019-04-01T08:00:00.000+08:00,3,3 Big Pharma Stocks to Add to Your Portfolio This April
bdf0e2ef-58e2-4db0-80b1-d34f16d2e7b8,2019-04-01T08:00:00.000+08:00,4,Arteaus Therapeutics sells Emgality royalty for $260M
a91e2ca5-9f4b-4336-aa78-459a63f018ef,2019-04-01T08:00:00.000+08:00,4,Arteaus Sold its Royalty Interest on Future Global Net Sales of Eli Lilly's Emgality to Royalty Pharma for $260M
989c16d8-e45a-4f39-abaf-f7960458d140,2019-04-01T08:00:00.000+08:00,2,3 Big Pharma Stocks to Add to Your Portfolio This April
2a7f290a-c4ba-4f5b-a2cf-aaee5692f3d7,2019-04-01T08:00:00.000+08:00,4,Arteaus Therapeutics sells Emgality royalty for $260M
0d523e3d-3e50-404a-ac1e-d8530df3a469,2019-03-30T08:00:00.000+08:00,3,How To Retire: Don't Go To College
d6b274c1-b656-4d7b-b862-d2d4473c4949,2019-03-30T08:00:00.000+08:00,4,How To Retire: Don't Go To College
99b6fd65-47e4-4000-9e69-a5ff8bee9216,2019-03-29T08:00:00.000+08:00,1,"Jim Cramer Advised His Viewers On Canopy Growth, DowDuPont And More"
12189c6a-0e19-40e5-9e30-7dfe1740ec32,2019-03-29T08:00:00.000+08:00,2,"Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals"
32bcff87-883e-4392-b5b9-14cc54cfa45f,2019-03-29T08:00:00.000+08:00,4,Filgotinib worth as much as $6/share to Gilead - Leerink
1f0325d6-6a3d-4be3-be65-bbb0abc82868,2019-03-29T08:00:00.000+08:00,3,"Jim Cramer Advised His Viewers On Canopy Growth, DowDuPont And More"
b97bddf1-611b-4447-88b5-2fc9acfc8089,2019-03-29T08:00:00.000+08:00,4,"Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals"
d83903b4-aa86-4fe9-ac1c-d622222eeb0f,2019-03-29T08:00:00.000+08:00,4,Filgotinib worth as much as $6/share to Gilead - Leerink
41ec89f5-4051-4d0a-b069-f82c6f0565f8,2019-03-27T08:00:00.000+08:00,4,"The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO"
e1b125cb-b61b-4df7-8a98-e37bba23a95b,2019-03-27T08:00:00.000+08:00,2,"Eli Lilly, EOG, McDonald's, Gold Miners ETF: 'Fast Money' Picks For March 27"
a6bfeb83-6beb-45e2-97dd-e09b49fd386e,2019-03-27T08:00:00.000+08:00,3,5 Cancer-Fighting Stocks to Boost Portfolio Gains
80017bb5-da70-4099-b306-34fa808917bb,2019-03-27T08:00:00.000+08:00,4,Turning Point Therapeutics Files For U.S. IPO
9d844265-dd50-493f-9706-cdba508580d4,2019-03-27T08:00:00.000+08:00,5,Lilly (LLY) Signs New Immunology Deal With Private Biotech
b8e111b3-bfe5-4976-83e8-dbb31dc64113,2019-03-27T08:00:00.000+08:00,4,"The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO"
6bf6ac3a-b839-45cf-b9c9-a0d877e34d12,2019-03-27T08:00:00.000+08:00,2,"Eli Lilly, EOG, McDonald's, Gold Miners ETF: 'Fast Money' Picks For March 27"
67b2a8a4-3f21-418a-bc04-5bf909831af1,2019-03-27T08:00:00.000+08:00,3,5 Cancer-Fighting Stocks to Boost Portfolio Gains
b9006d4c-b900-4f10-82f0-dd7909c0eac6,2019-03-27T08:00:00.000+08:00,4,Turning Point Therapeutics Files For U.S. IPO
08154caf-daa0-4575-acf1-7d29a15501dd,2019-03-27T08:00:00.000+08:00,5,Lilly (LLY) Signs New Immunology Deal With Private Biotech
ac2ab862-8404-4657-b196-9e319fffae1a,2019-03-26T08:00:00.000+08:00,4,"Eli Lilly Announces Collaboration with ImmuNext to Develop Medicines for Autoimmune Diseases, Eli Lilly to Make a $40M Upfront Payment"
785d3913-5112-4515-ab40-5a98e6a2ea48,2019-03-26T08:00:00.000+08:00,3,Lilly teams up with ImmuNext in autoimmune diseases
322978df-7b73-4a04-a10e-1ff2255f619c,2019-03-26T08:00:00.000+08:00,2,Trump reaches across the aisle on drug prices
ac2bc55a-eee9-4ada-af1b-471c58c0c0ec,2019-03-26T08:00:00.000+08:00,4,"Eli Lilly Announces Collaboration with ImmuNext to Develop Medicines for Autoimmune Diseases, Eli Lilly to Make a $40M Upfront Payment"
331aec3a-09ce-4649-a326-3cb976495530,2019-03-26T08:00:00.000+08:00,3,Lilly teams up with ImmuNext in autoimmune diseases
303f21d4-5fcc-4544-98df-d922f04fa0b2,2019-03-26T08:00:00.000+08:00,2,Trump reaches across the aisle on drug prices
b4aaa839-8e30-4def-be95-fe7870fe5267,2019-03-25T08:00:00.000+08:00,3,"Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash ..."
74647289-d4db-480d-8060-8b86b1603b54,2019-03-25T08:00:00.000+08:00,4,What Will Provide Gilead The Growth Needed For Multiple Expansion?
c370aa03-a99d-44b5-a6e2-f80c3962ec16,2019-03-25T08:00:00.000+08:00,3,"Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash ..."
5b21a72b-a24e-4b05-b254-7fb08e834e52,2019-03-25T08:00:00.000+08:00,4,What Will Provide Gilead The Growth Needed For Multiple Expansion?
dd6bfbf3-2927-48a2-8e40-6995d3a6fa23,2019-03-24T08:00:00.000+08:00,2,Lilly Says Net Price for Humalog Insulin Declines 8.1% from 2014-2018
8c75000c-ca89-4342-a54e-470753a3876a,2019-03-24T08:00:00.000+08:00,2,Lilly Says Net Price for Humalog Insulin Declines 8.1% from 2014-2018
68aeab86-fe0a-4cef-948d-8f1202296b1b,2019-03-22T08:00:00.000+08:00,3,Eli Lilly (LLY) Stock Moves -0.01%: What You Should Know
05f12569-8711-4378-8857-9911626ddc79,2019-03-22T08:00:00.000+08:00,4,Bull of the Day: DexCom (DXCM)
dc38d5aa-9827-4b2a-98c6-d09b777a63a6,2019-03-22T08:00:00.000+08:00,2,Eli Lilly (LLY) Stock Moves -0.01%: What You Should Know
52058c69-ece7-4e19-a2e2-78c188d4766a,2019-03-22T08:00:00.000+08:00,4,Bull of the Day: DexCom (DXCM)
81099208-cb75-4dc6-aa31-b0aeba664838,2019-03-20T08:00:00.000+08:00,3,"National Comprehensive Cancer Network Announces Its Oncology Research Program, Eli Lilly To Take On 6 Projects Aimed To Improve Delivery Of Gastric, Gastroesophageal Junction Cancer Care In US"
07648fc7-6ffb-4ed5-b9ce-ef3686b85455,2019-03-20T08:00:00.000+08:00,2,"National Comprehensive Cancer Network Announces Its Oncology Research Program, Eli Lilly To Take On 6 Projects Aimed To Improve Delivery Of Gastric, Gastroesophageal Junction Cancer Care In US"
2c460d00-ce83-4c22-add5-a29abec3afbb,2019-03-19T08:00:00.000+08:00,5,IPO Update: Precision BioSciences Readies Plan For IPO
c8ffedd5-bd98-44c7-ab55-d5f25c10aabd,2019-03-19T08:00:00.000+08:00,4,Why The Future Looks Bright For Incyte Pharmaceuticals
ee24bf19-74c8-4aab-a57f-eb6470660db8,2019-03-19T08:00:00.000+08:00,2,IPO Update: Precision BioSciences Readies Plan For IPO
165c9b45-6bf1-449b-a73c-706169b5ca21,2019-03-19T08:00:00.000+08:00,4,Why The Future Looks Bright For Incyte Pharmaceuticals
5b3647d1-7dce-4ee0-a2b2-ff17ed69207c,2019-03-15T08:00:00.000+08:00,3,Microsoft Portfolio: Halftime Report
dae71423-7cb2-4843-80e1-51030da1cd47,2019-03-15T08:00:00.000+08:00,1,"Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others"
55779bcd-2a4f-4211-aca1-72fcda965550,2019-03-15T08:00:00.000+08:00,3,Microsoft Portfolio: Halftime Report
d1d496ff-ab0a-4943-b2d1-61294db1fb44,2019-03-15T08:00:00.000+08:00,2,"Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others"
938d0fd2-0e01-40eb-ac56-ec05ba82704b,2019-03-14T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering"
9ef8c015-68f6-4666-898e-2c417c12c6e8,2019-03-14T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering"
0d5105d2-c4bd-4a7e-b723-795106f39bfb,2019-03-13T08:00:00.000+08:00,4,"Most Active Equity Options And Strikes For Midday - Wednesday, March 13"
9fcb9d8e-12d1-4412-b3c2-e9680726cc55,2019-03-13T08:00:00.000+08:00,5,Lilly's Cyramza Successful in Phase III First-Line NSCLC Study
75db1b78-dfdf-41d0-be05-e0aff5b3a6f7,2019-03-13T08:00:00.000+08:00,4,"Most Active Equity Options And Strikes For Midday - Wednesday, March 13"
fd350384-f0d5-49bb-867a-3d475abcb6f9,2019-03-13T08:00:00.000+08:00,5,Lilly's Cyramza Successful in Phase III First-Line NSCLC Study
0b410086-e765-40e4-8f1e-a06ff0a75850,2019-03-12T08:00:00.000+08:00,3,"Eli Lilly Could Sustain Industry-Leading Growth, Says Bullish JPMorgan"
a1fbf9cb-f0ab-4a4f-853e-d4b1e46d4e30,2019-03-12T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug"
df9fed98-9bd9-4e2d-9930-767957856c4a,2019-03-12T08:00:00.000+08:00,5,Lilly Announces CYRAMZA Phase 3 RELAY Trial Met Primary Endpoint In Patients With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
a2ef71c3-bb42-41fe-9e17-61bbf7094f53,2019-03-12T08:00:00.000+08:00,1,Eli Lilly (LLY) Flat As Market Gains: What You Should Know
97419c27-799b-4fe1-85e9-92593661cbad,2019-03-12T08:00:00.000+08:00,3,"Hot Options Report For End Of Day - Tuesday, March 12"
66c78cfc-89f3-49a8-a147-9fe15c6e494d,2019-03-12T08:00:00.000+08:00,4,Trump 2020 drug pricing initiatives - part 2
e5f5df5c-c903-46b5-9328-a297ca9eab50,2019-03-12T08:00:00.000+08:00,5,Trump aiming to rein in drug cost with range of proposals
13d08ed8-58b4-4944-8ec2-6c9d92d0ec20,2019-03-12T08:00:00.000+08:00,4,"Most Active Equity Options And Strikes For Midday - Tuesday, March 12"
cf480975-a7b9-403b-a4cb-cd6cad64efe0,2019-03-12T08:00:00.000+08:00,4,Allergan Announces FDA Acceptance of Migraine Candidate NDA
b27f5e11-a6ce-4f85-bef6-414c495441a7,2019-03-12T08:00:00.000+08:00,5,Lilly's Cyramza shows positive effect in first-line lung cancer
cc4fa26c-577b-487e-b399-cdd99c9ccc0c,2019-03-12T08:00:00.000+08:00,4,"Eli Lilly Could Sustain Industry-Leading Growth, Says Bullish JPMorgan"
51811894-1352-4136-94a5-c2a3e50a7ee1,2019-03-12T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug"
d7d42114-399e-4c6a-bd2e-fedb54d240c9,2019-03-12T08:00:00.000+08:00,5,Lilly Announces CYRAMZA Phase 3 RELAY Trial Met Primary Endpoint In Patients With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
9a11998e-220c-465d-903d-e84173e63e5f,2019-03-12T08:00:00.000+08:00,1,Eli Lilly (LLY) Flat As Market Gains: What You Should Know
22b030c1-2a05-440f-9167-2fc9304abc84,2019-03-12T08:00:00.000+08:00,3,"Hot Options Report For End Of Day - Tuesday, March 12"
3423529c-fc33-4b05-a871-47e7e2758976,2019-03-12T08:00:00.000+08:00,4,Trump 2020 drug pricing initiatives - part 2
c2d9d56c-ecd1-4306-b09b-2ea9cf16a5c4,2019-03-12T08:00:00.000+08:00,5,Trump aiming to rein in drug cost with range of proposals
0ddbb2b2-25a3-43e2-88fa-7f9531b722f3,2019-03-12T08:00:00.000+08:00,4,"Most Active Equity Options And Strikes For Midday - Tuesday, March 12"
1105fab1-f735-42d9-af51-92d9cb14526f,2019-03-12T08:00:00.000+08:00,4,Allergan Announces FDA Acceptance of Migraine Candidate NDA
a99d9abd-e0df-4c72-84c0-5d7000a514eb,2019-03-12T08:00:00.000+08:00,5,Lilly's Cyramza shows positive effect in first-line lung cancer
e66303a7-4725-4e97-8f68-aaa3a4008f8e,2019-03-11T08:00:00.000+08:00,3,Elanco Animal Health Begins Trading After Eli Lilly Split
0750e03f-7206-4b37-85cc-95579ca3d128,2019-03-11T08:00:00.000+08:00,4,Eli Lilly and Company (LLY) Presents at Cowen and Company 39th Annual Health Care Conference (Transcript)
838fc721-ee6d-43d0-9ce5-3b6d3e3c16b1,2019-03-11T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Monday, March 11"
bfa1bd0f-1fc1-4e5e-96f9-1c61dde26b30,2019-03-11T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Monday, March 11"
23bbcb79-c59d-4278-9232-fc7949c686a3,2019-03-11T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Monday, March 11"
d6c208d7-1dbf-4752-9978-39733d511466,2019-03-11T08:00:00.000+08:00,4,Elanco Animal Health Begins Trading After Eli Lilly Split
09e108d3-d7c0-409e-a5a0-fac7e32bbcb6,2019-03-11T08:00:00.000+08:00,3,Eli Lilly and Company (LLY) Presents at Cowen and Company 39th Annual Health Care Conference (Transcript)
4a42ab5e-d441-4ad3-b4d1-b40e6442163c,2019-03-11T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Monday, March 11"
f64f91d2-55dc-4e2f-b88b-6084be051d4e,2019-03-11T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Monday, March 11"
71d6b136-690a-4158-953b-298f6615fe75,2019-03-11T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Monday, March 11"
8969de70-f39f-4970-bd93-50f70e6aef7c,2019-03-08T08:00:00.000+08:00,3,"Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs"
3fc159a9-f0bd-4ed2-b3a5-7eb4382dc1ea,2019-03-08T08:00:00.000+08:00,4,"Biotech Analysis Central Pharma News: Evoke's Mishap, ImmunoGen's Struggle, Eli Lilly's Priority Review"
371dd647-8f8c-49a0-8f8f-971dc2ebc585,2019-03-08T08:00:00.000+08:00,1,"Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat"
7958cce7-23ff-45fb-b178-4d8992142c65,2019-03-08T08:00:00.000+08:00,3,Lilly (LLY) Up 7.5% Since Last Earnings Report: Can It Continue?
c0881b9e-6f51-49e1-80ff-6e50598b2ffe,2019-03-08T08:00:00.000+08:00,2,"Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs"
22269bdf-9b46-49fd-a33b-44787bf65221,2019-03-08T08:00:00.000+08:00,3,"Biotech Analysis Central Pharma News: Evoke's Mishap, ImmunoGen's Struggle, Eli Lilly's Priority Review"
b65708cd-3832-4795-ae70-c5168dae1b01,2019-03-08T08:00:00.000+08:00,4,"Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat"
a9823a92-dc8c-4d23-9d36-637bb007757f,2019-03-08T08:00:00.000+08:00,3,Lilly (LLY) Up 7.5% Since Last Earnings Report: Can It Continue?
907f28c0-ad20-4440-954f-db4ea619ec30,2019-03-07T08:00:00.000+08:00,2,Eli Lilly Reports Final Exchange Ratio OF 4.5121 Shares For Elanco
e09c2383-69dd-45a4-9b8f-dda3102628bc,2019-03-07T08:00:00.000+08:00,3,"Hot Options Report For End Of Day - Thursday, March 7"
6ef5a835-5a65-42ad-8ab4-7992c99db6a5,2019-03-07T08:00:00.000+08:00,3,"Most Active Equity Options And Strikes For Midday - Thursday, March 7"
68c02207-689c-4f81-b4bb-00a4998abef6,2019-03-07T08:00:00.000+08:00,4,Xeris: Looking For Entry Before PDUFA
4f2d6d4a-cc22-49cb-8be9-63cb40f5c941,2019-03-07T08:00:00.000+08:00,1,"Allergan's Depression Candidate Fails in Studies, Stock Down"
71e5f438-5cfb-4e25-a597-b398702eead0,2019-03-07T08:00:00.000+08:00,2,Lilly announces final exchange offering for Elanco shares
95d2b40e-034f-4036-9900-a72b7f015449,2019-03-07T08:00:00.000+08:00,4,Eli Lilly Reports Final Exchange Ratio OF 4.5121 Shares For Elanco
2192e835-e9fd-4316-af0d-85f57a02c40b,2019-03-07T08:00:00.000+08:00,3,"Hot Options Report For End Of Day - Thursday, March 7"
4d7b67f4-6bcb-4057-8758-296ed1729d23,2019-03-07T08:00:00.000+08:00,1,"Most Active Equity Options And Strikes For Midday - Thursday, March 7"
c7f1fc81-1aee-4b42-917c-6282fb529caf,2019-03-07T08:00:00.000+08:00,5,Xeris: Looking For Entry Before PDUFA
32c94a1a-0263-4312-990c-6975ea4de346,2019-03-07T08:00:00.000+08:00,2,"Allergan's Depression Candidate Fails in Studies, Stock Down"
1df806b2-1e1b-45e6-b434-32d05c265a02,2019-03-07T08:00:00.000+08:00,4,Lilly announces final exchange offering for Elanco shares
a183df5a-a503-4dec-a840-4c5dfc69f6b1,2019-03-06T08:00:00.000+08:00,3,"Cigna Says In Discussions With Lilly About Humalog Authorized Alternative, And If The Net Cost Is Lowest For Plans, Will Add It To Flex Formulary"
528785d9-af95-4495-beab-d7a0079c4a83,2019-03-06T08:00:00.000+08:00,5,FDA Approves Major Novel Depression Drug For First Time In 3 Decades
c4282884-51c5-4a3e-b0e2-f4dd40770ab1,2019-03-06T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Wednesday, March 6"
a584e7da-56f8-4d16-98c6-17f38e4f07b6,2019-03-06T08:00:00.000+08:00,4,"Most Active Equity Options And Strikes For Midday - Wednesday, March 6"
5a129afe-264b-45bd-a433-756a30b28f2d,2019-03-06T08:00:00.000+08:00,5,J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression
948123bc-da6e-4caa-a295-43c29c7344e7,2019-03-06T08:00:00.000+08:00,2,"Cigna Says In Discussions With Lilly About Humalog Authorized Alternative, And If The Net Cost Is Lowest For Plans, Will Add It To Flex Formulary"
edfc71a5-3f65-4a0b-88f9-7148fbae854b,2019-03-06T08:00:00.000+08:00,4,FDA Approves Major Novel Depression Drug For First Time In 3 Decades
609867e2-0944-40a3-b40f-99b1a5c6b207,2019-03-06T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Wednesday, March 6"
64af7453-8006-430a-892d-50876f833f92,2019-03-06T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Wednesday, March 6"
a74a15cd-a029-4e0f-b1e2-e0078127671c,2019-03-06T08:00:00.000+08:00,4,J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression
1f3dca40-d683-48e1-9c02-ebd90b11c101,2019-03-05T08:00:00.000+08:00,3,Lilly Receives FDA Priority Review Designation For Emgality Injection For The Preventive Treatment Of Episodic Cluster Headache In Adults
cb85a216-1776-43fe-9869-fa4ea8c28c89,2019-03-05T08:00:00.000+08:00,1,"If The Celgene Deal Fails, Who Would Buy Bristol-Myers Squibb?"
8034a5dd-0bba-43b6-be5d-3b0bc2faf988,2019-03-05T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Tuesday, March 5"
9540e2b6-a8c5-4b58-b875-b35a61754ebc,2019-03-05T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Tuesday, March 5"
18ae5ad6-e893-4827-8efd-5ff1766e92f8,2019-03-05T08:00:00.000+08:00,4,Lilly to Bring Half-Priced Version of Popular Humalog Insulin
b801c1dc-6575-43ea-ba7b-936d5dc9194f,2019-03-05T08:00:00.000+08:00,3,Lilly nabs accelerated review for Emgality injection
0d5ef446-4821-4a2c-ad50-aa09417fcb63,2019-03-05T08:00:00.000+08:00,5,Lilly Receives FDA Priority Review Designation For Emgality Injection For The Preventive Treatment Of Episodic Cluster Headache In Adults
48924f74-46ee-47ac-9826-20a4c84a4c17,2019-03-05T08:00:00.000+08:00,1,"If The Celgene Deal Fails, Who Would Buy Bristol-Myers Squibb?"
69035cf4-dde4-4e07-bf61-4d0c86c94603,2019-03-05T08:00:00.000+08:00,4,"Hot Options Report For End Of Day - Tuesday, March 5"
390d0a5a-f8ec-4506-bad3-4c7cba1f0f36,2019-03-05T08:00:00.000+08:00,3,"Most Active Equity Options And Strikes For Midday - Tuesday, March 5"
1c97dfb1-4a94-41af-b966-c1a5737519a3,2019-03-05T08:00:00.000+08:00,5,Lilly to Bring Half-Priced Version of Popular Humalog Insulin
812d2027-0caf-4fbd-8d82-c45030e9307e,2019-03-05T08:00:00.000+08:00,4,Lilly nabs accelerated review for Emgality injection
cebd7b62-244c-4ab8-a44c-703decf15186,2019-03-04T08:00:00.000+08:00,5,Eli Lilly Announces the Launch of Lower Priced Insulin
6e93278e-023e-426d-9b17-9eef1947c24a,2019-03-04T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Monday, March 4"
eda71e11-5a02-40c4-86b4-0ea79975d413,2019-03-04T08:00:00.000+08:00,3,"\"Senate committee \"\"looking into\"\" high insulin prices\""
ad8df215-7ecd-4cc3-b661-012a0920adf6,2019-03-04T08:00:00.000+08:00,3,"Most Active Equity Options And Strikes For Midday - Monday, March 4"
c10b3ee0-3b0f-4718-a259-f72ae28bbf51,2019-03-04T08:00:00.000+08:00,4,Lilly to launch lower-priced insulin in U.S.
217944ea-c643-45f6-8250-0caa16199529,2019-03-04T08:00:00.000+08:00,5,Eli Lilly Announces the Launch of Lower Priced Insulin
6a9cd2fc-39aa-412d-a319-fdad0cbfadc2,2019-03-04T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Monday, March 4"
7bbb5a25-85e5-4e9a-babd-4763cda2644a,2019-03-04T08:00:00.000+08:00,3,"\"Senate committee \"\"looking into\"\" high insulin prices\""
d86a25c1-5ad2-48bf-8ee7-60f2168190ef,2019-03-04T08:00:00.000+08:00,3,"Most Active Equity Options And Strikes For Midday - Monday, March 4"
34a257e5-85f1-4b70-a2bd-941e5e1b7d50,2019-03-04T08:00:00.000+08:00,4,Lilly to launch lower-priced insulin in U.S.
6da721e3-dec4-4ca5-85fc-0ac8dedbcd68,2019-03-01T08:00:00.000+08:00,5,"The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis"
0e973a2b-424d-411f-9afd-65e55e5bcb43,2019-03-01T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Friday, March 1"
e2db03e8-cc6a-4599-9f5f-81b223ef4793,2019-03-01T08:00:00.000+08:00,4,Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales
b871fb05-ab28-4da9-bf10-ddbab7b37855,2019-03-01T08:00:00.000+08:00,3,"Most Active Equity Options And Strikes For Midday - Friday, March 1"
0e0b4928-c795-4f54-b55a-ded3457ee8ec,2019-03-01T08:00:00.000+08:00,1,Dividend Champions For March 2019
b914b9d6-e928-44b8-bc4b-3d3ba5e43d3c,2019-03-01T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis"
20c6e522-ec4b-4d91-a123-49a2334388a9,2019-03-01T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Friday, March 1"
fb38ff27-8b8d-4023-948d-82c591072063,2019-03-01T08:00:00.000+08:00,3,Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales
d9eea400-5878-4e90-8209-0b3faef539c2,2019-03-01T08:00:00.000+08:00,4,"Most Active Equity Options And Strikes For Midday - Friday, March 1"
34b609f6-31ea-4d25-a1d9-b3205146f49f,2019-03-01T08:00:00.000+08:00,5,Dividend Champions For March 2019
713cb966-ff5e-40f1-9779-f10311922b23,2019-02-28T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems"
131c63a9-f022-4e35-a1bc-30cca21cfed7,2019-02-28T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Thursday, Feb. 28"
14c717f5-862d-4038-a912-c2f32c8b8987,2019-02-28T08:00:00.000+08:00,1,Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates
6fdc3233-1ad2-44da-a9f2-a2e42404302d,2019-02-28T08:00:00.000+08:00,3,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 28"
7e50375e-69c9-44cf-9cbb-97ce02cbd0b5,2019-02-28T08:00:00.000+08:00,4,Pfenex expands PF708 deal with Alvogen
be254ff6-317e-4a4a-9ecb-c1186692d655,2019-02-28T08:00:00.000+08:00,5,United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates
95d793b0-b663-4beb-a577-950dfc46ad64,2019-02-28T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems"
d7458fed-6ff7-44c1-9c58-4e17c93363eb,2019-02-28T08:00:00.000+08:00,3,"Hot Options Report For End Of Day - Thursday, Feb. 28"
d2255fd3-e67a-419d-80a5-b37c76e5c11f,2019-02-28T08:00:00.000+08:00,1,Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates
80c8c1fa-6f78-4140-a798-9714a4bfa32d,2019-02-28T08:00:00.000+08:00,4,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 28"
6507440f-0e78-4d08-aadb-0889891a7b6d,2019-02-28T08:00:00.000+08:00,3,Pfenex expands PF708 deal with Alvogen
0955ea06-7af4-4770-abfa-115e94fc9829,2019-02-28T08:00:00.000+08:00,2,United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates
c0d93fe4-6888-44d8-b6e2-673d8e60490c,2019-02-27T08:00:00.000+08:00,3,"The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings"
42073e7f-28d3-4f2b-bf1a-11a6b57144d7,2019-02-27T08:00:00.000+08:00,4,Eli Lilly and Company (LLY) Management Presents at Leerink Partners Global Healthcare Conference (Transcript)
765143f2-d550-45b1-8777-85c00fedf435,2019-02-27T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Wednesday, Feb. 27"
032e6940-887d-464d-828a-e3c084a05e37,2019-02-27T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 27"
c7716a1d-640f-4904-b01c-25ecb75377c1,2019-02-27T08:00:00.000+08:00,1,"The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings"
51b11d03-84cd-4d43-9bfa-13fae2d16451,2019-02-27T08:00:00.000+08:00,3,Eli Lilly and Company (LLY) Management Presents at Leerink Partners Global Healthcare Conference (Transcript)
cb1376f5-d8b9-4b2f-a70d-b5ae3672313f,2019-02-27T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Wednesday, Feb. 27"
ceb235aa-6a97-480e-8645-a0a988b37f69,2019-02-27T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 27"
46bef6b8-41a7-4b40-aa7c-2d57d21fea06,2019-02-26T08:00:00.000+08:00,1,FDA rejects Adamis Pharma's application for sublingual tadalafil; shares down 13% after hours
b1a1a59f-f0ae-4698-8ae8-6d9acbbc258c,2019-02-26T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Tuesday, Feb. 26"
218b92ae-75e2-4919-b5bf-d489d682f071,2019-02-26T08:00:00.000+08:00,1,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 26"
9a923bcd-0080-4229-aa7c-e18ea1da0935,2019-02-26T08:00:00.000+08:00,3,FDA rejects Adamis Pharma's application for sublingual tadalafil; shares down 13% after hours
37d2da24-02e7-46c0-92fe-d5c34928deef,2019-02-26T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Tuesday, Feb. 26"
684fe26f-a076-4678-8914-27f069384836,2019-02-26T08:00:00.000+08:00,1,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 26"
1cd3fa31-ab91-4023-bd6b-8dbb2fd5bb97,2019-02-25T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Monday, Feb. 25"
c223b6f4-9545-4e99-94fc-e3c39aeed678,2019-02-25T08:00:00.000+08:00,1,"Most Active Equity Options And Strikes For Midday - Monday, Feb. 25"
0c0044d4-757f-4eb4-9f04-4a1e1535abfe,2019-02-25T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft"
0605dcb5-96df-483d-a83b-5625002b3d75,2019-02-25T08:00:00.000+08:00,2,According To Sources: Scandal In The Chicken And Pork Industries (Podcast)
38495922-1250-415d-8fd1-3f159633939f,2019-02-25T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Monday, Feb. 25"
ccffd1c7-620c-44df-8397-dfc2acae8ebf,2019-02-25T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Monday, Feb. 25"
91083b90-a0ec-4371-953d-2f04035d5623,2019-02-25T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft"
98dcf9f4-5255-4a33-9836-59267730a2a2,2019-02-25T08:00:00.000+08:00,3,According To Sources: Scandal In The Chicken And Pork Industries (Podcast)
c6380922-fbde-4fb7-b249-d4cac49a273b,2019-02-24T08:00:00.000+08:00,4,"Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers"
297315f1-16ba-436c-a3d8-8b930132e61a,2019-02-24T08:00:00.000+08:00,5,"Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers"
ac121ace-9b2c-4f52-b18e-5067aed5e9f8,2019-02-22T08:00:00.000+08:00,2,"US Senate Finance Committee Launches Bipartisan Investigation Into Rising Insulin Prices; Sends Letters To Eli Lilly, Novo Nordisk And Sanofi"
a5651023-28b6-49f8-94ad-060e1889742b,2019-02-22T08:00:00.000+08:00,3,"The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data"
67bf913b-8fd5-4590-b0be-74d1f4086d18,2019-02-22T08:00:00.000+08:00,4,Merck to Buy Immunotherapy Developer Immune Design for $300M
44eff1ed-cb7d-45cf-af9b-07e1fcd6003a,2019-02-22T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Friday, Feb 22"
aef0f485-21e9-4efb-84de-d02e979c80d9,2019-02-22T08:00:00.000+08:00,2,"Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates"
762ecc4a-8ae2-4f37-80ff-101be2420061,2019-02-22T08:00:00.000+08:00,2,"New Research Coverage Highlights FedEx, Honeywell International, Nielsen Holdings Plc, ..."
5a133791-32a5-49ab-ab59-98b52b436907,2019-02-22T08:00:00.000+08:00,3,"Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review"
940d0e5d-1cc7-427a-96cd-744989018f77,2019-02-22T08:00:00.000+08:00,4,"US Senate Finance Committee Launches Bipartisan Investigation Into Rising Insulin Prices; Sends Letters To Eli Lilly, Novo Nordisk And Sanofi"
1b1d3901-116e-4513-b09b-71f07f0d802d,2019-02-22T08:00:00.000+08:00,1,"The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data"
563baaa1-9246-4cef-b86b-2256803ce610,2019-02-22T08:00:00.000+08:00,5,Merck to Buy Immunotherapy Developer Immune Design for $300M
b3d6ba8c-bfa9-4acf-9ffa-176611956aaf,2019-02-22T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Friday, Feb 22"
b0ef82da-0d21-44d4-a8ad-3aa896a546e7,2019-02-22T08:00:00.000+08:00,3,"Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates"
78916303-32ce-4c76-a113-38940ca4d9e7,2019-02-22T08:00:00.000+08:00,4,"New Research Coverage Highlights FedEx, Honeywell International, Nielsen Holdings Plc, ..."
5d048d13-458d-4a00-aa0f-889acbc0bd59,2019-02-22T08:00:00.000+08:00,1,"Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review"
33ee8373-97cf-4066-93d1-04a40df5e06c,2019-02-21T08:00:00.000+08:00,5,Merck To Buy Immune Design For $300M
a49071cb-2b4e-4fe7-bb40-1f8b7786848e,2019-02-21T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Thursday, Feb. 21"
0eca65ca-beb3-4eec-8bf1-3b7203821828,2019-02-21T08:00:00.000+08:00,3,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 21"
2abedf71-a43f-4dd9-8a9a-896e17bb3b3e,2019-02-21T08:00:00.000+08:00,4,Philip Morris International: Halftime Report
95548866-4ddc-49ca-9b1c-735d3909bfaf,2019-02-21T08:00:00.000+08:00,1,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
fcc8abf9-4070-43dd-a857-8b93aec53f5f,2019-02-21T08:00:00.000+08:00,2,U.S. healthcare spending to rise 5.5% per annum over next decade
ea912a8b-9678-4f7e-895f-9c0f727e4935,2019-02-21T08:00:00.000+08:00,2,Merck To Buy Immune Design For $300M
9018df3c-d69b-4922-8725-9f1ff538251a,2019-02-21T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Thursday, Feb. 21"
91f1a069-f79e-4729-ba79-5657384803a9,2019-02-21T08:00:00.000+08:00,3,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 21"
180de2d1-25e1-4850-8f74-2435f44e2ae1,2019-02-21T08:00:00.000+08:00,4,Philip Morris International: Halftime Report
f2bdaf79-3aea-4f0f-aec0-b0f6f5577351,2019-02-21T08:00:00.000+08:00,3,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
148dc33c-f3c5-4319-96fc-b0f682b48aea,2019-02-21T08:00:00.000+08:00,2,U.S. healthcare spending to rise 5.5% per annum over next decade
563922f7-f363-4079-8cd7-fdb9d66f151e,2019-02-20T08:00:00.000+08:00,3,"Hot Options Report For End Of Day - Wednesday, Feb. 20"
110fe80d-60ed-412a-b0a7-026a81b0132b,2019-02-20T08:00:00.000+08:00,3,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 20"
8cfa4ac4-6508-4125-ac9c-fe8b428a874b,2019-02-20T08:00:00.000+08:00,4,Allergan Responds to Investor's Call for CEO/Chair Role Split
314ef8fc-e862-4fcb-aeeb-1833898bda24,2019-02-20T08:00:00.000+08:00,5,Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study
2a840700-5330-4d3b-b4b8-b6d5f573270b,2019-02-20T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Wednesday, Feb. 20"
bdba5a9c-bf48-4e17-bdcd-204513891cd1,2019-02-20T08:00:00.000+08:00,1,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 20"
8d1c8031-7bb5-4bc5-8766-bf570e96747d,2019-02-20T08:00:00.000+08:00,3,Allergan Responds to Investor's Call for CEO/Chair Role Split
66dc5ecc-3710-4e68-90ab-70a07e16ed24,2019-02-20T08:00:00.000+08:00,4,Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study
f12a66c1-6d38-4953-acec-f34254f7bb56,2019-02-19T08:00:00.000+08:00,1,S&P Downgrades Eli Lilly Credit Rating From AA- To A+; Outlook Raised From Credit Watch Negative To Stable
50f38b26-a398-4490-9cd8-af40acb9860f,2019-02-19T08:00:00.000+08:00,2,"Eli Lilly Files For Mixed Shelf Offering, Size Not Disclosed"
5d0f2098-4c9e-40de-8efc-081a0e9d6ee6,2019-02-19T08:00:00.000+08:00,3,"Eli Lilly 10-K Just Recently Out; 1 Highlight: Co. Employed ~38,680 Employees At End Of 2018"
8e1dd77f-e562-4bd2-90e7-382be489a01d,2019-02-19T08:00:00.000+08:00,3,"Supreme Court Rejects Maryland's Bid To Revive A Law Aimed At Preventing Price Gouging By Pharmaceutical Companies, Reuters Reports"
ba14f891-7a56-4f85-9b6c-5f0a39505c17,2019-02-19T08:00:00.000+08:00,4,Pfizer And Lilly Announce Top-line Results From Phase 3 Study Of Tanezumab In Chronic Low Back Pain; Tanezumab Met Primary Endpoint
6b6cce88-da74-4777-9c6d-5b29ca31e68a,2019-02-19T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Tuesday, Feb. 19"
2b3f8534-0c20-44ff-8c54-9b7d65bac175,2019-02-19T08:00:00.000+08:00,2,Lilly files for mixed shelf offering
6c80f91d-c6ad-4d75-b202-9a1adc061ee0,2019-02-19T08:00:00.000+08:00,5,Lilly wins review of Teva migraine patents in U.S.
9e03cd61-ff15-431d-9aaa-5a46a7e5dadb,2019-02-19T08:00:00.000+08:00,3,Maryland strikes out in reviving drug price-gouging law
c7cd8739-2b74-4f7d-b483-f009903617c3,2019-02-19T08:00:00.000+08:00,4,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 19"
33e04f4f-e6a8-4cce-b19d-22c282bb44dd,2019-02-19T08:00:00.000+08:00,1,"Merger Arbitrage Mondays - February 18, 2019"
ae8e7a7d-1474-4b1f-b8c4-da2c36330c7e,2019-02-19T08:00:00.000+08:00,4,Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo
65e43645-981e-4944-ad3f-266861db9200,2019-02-19T08:00:00.000+08:00,5,Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why
da07ecc3-27ed-4aeb-8d31-cb62a7570f57,2019-02-19T08:00:00.000+08:00,3,Lilly and Pfizer's tanezumab successful in late-stage back pain study
94a5ee77-e2de-46b0-b0a3-8a384c6710df,2019-02-19T08:00:00.000+08:00,2,Teva: Reasons To Avoid It In Favor Of Innovative Biotechs
5560c2ed-6820-4401-a063-b77ec1bb9cdf,2019-02-19T08:00:00.000+08:00,1,S&P Downgrades Eli Lilly Credit Rating From AA- To A+; Outlook Raised From Credit Watch Negative To Stable
fa3448eb-93cd-40ac-a03a-db28c41af3e7,2019-02-19T08:00:00.000+08:00,2,"Eli Lilly Files For Mixed Shelf Offering, Size Not Disclosed"
706b43af-83e3-4f6f-9e84-74d302aea000,2019-02-19T08:00:00.000+08:00,3,"Eli Lilly 10-K Just Recently Out; 1 Highlight: Co. Employed ~38,680 Employees At End Of 2018"
14edbc7e-95a4-4786-8e3d-3b9329774c67,2019-02-19T08:00:00.000+08:00,3,"Supreme Court Rejects Maryland's Bid To Revive A Law Aimed At Preventing Price Gouging By Pharmaceutical Companies, Reuters Reports"
d60ebcd2-0eae-4939-a4e8-10cc1b1b7c8b,2019-02-19T08:00:00.000+08:00,4,Pfizer And Lilly Announce Top-line Results From Phase 3 Study Of Tanezumab In Chronic Low Back Pain; Tanezumab Met Primary Endpoint
37a1e2a3-2872-4c6b-88f9-a2e5a3745fb2,2019-02-19T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Tuesday, Feb. 19"
498f5415-eaf5-4c4e-bbca-b811425f490e,2019-02-19T08:00:00.000+08:00,2,Lilly files for mixed shelf offering
e130eb5e-4091-4e62-91a7-6546fe6f419d,2019-02-19T08:00:00.000+08:00,5,Lilly wins review of Teva migraine patents in U.S.
4580e1e1-9752-4ef8-bea7-db771aeedae0,2019-02-19T08:00:00.000+08:00,3,Maryland strikes out in reviving drug price-gouging law
3a921119-a1ff-4390-9d8c-f9109bcfe26b,2019-02-19T08:00:00.000+08:00,4,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 19"
98b2f7c9-8c21-4d9b-95b0-2734514e17ea,2019-02-19T08:00:00.000+08:00,1,"Merger Arbitrage Mondays - February 18, 2019"
8353072b-84a3-4ddb-97ad-61cdd58a045c,2019-02-19T08:00:00.000+08:00,2,Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo
99be9d70-a06e-4e0d-91cf-8a5475f5d91f,2019-02-19T08:00:00.000+08:00,4,Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why
3018da19-4702-4172-a00d-20f0dc71c6a2,2019-02-19T08:00:00.000+08:00,5,Lilly and Pfizer's tanezumab successful in late-stage back pain study
a5d27f20-0147-4872-92e1-e3b4aca8f683,2019-02-19T08:00:00.000+08:00,3,Teva: Reasons To Avoid It In Favor Of Innovative Biotechs
c823786a-db2b-4322-95b3-1d037e6ef9d9,2019-02-18T08:00:00.000+08:00,1,Novo Nordisk: Solid Performance Marred By Currency Fluctuations
264f7a4f-981c-4c2f-8078-8fe11b114d19,2019-02-18T08:00:00.000+08:00,2,How To Retire: Kill The TV
5f2cd1a6-3d55-489b-8423-e689cd44eaa6,2019-02-18T08:00:00.000+08:00,3,Novo Nordisk: Solid Performance Marred By Currency Fluctuations
5b1eaf96-7839-4143-a941-5ad392fc09dd,2019-02-18T08:00:00.000+08:00,2,How To Retire: Kill The TV
7b0b7c74-d8ad-403b-8d84-80ac1c215b5f,2019-02-15T08:00:00.000+08:00,1,"Bayer To Obtain Full Rights To Global Development And Commercialization Of Oncology Compounds VITRAKVI And AND BAY 2731954, Will Be Solely Responsible For Global Development And Commercialization Of Both"
76d4f63d-d42c-42b4-9660-84454ebb7682,2019-02-15T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Friday, Feb. 15"
241b3128-ada5-4b01-8afe-d8e1fd9c4e2b,2019-02-15T08:00:00.000+08:00,2,FDA creates new accelerated review pathway for generic drug applications
c1c07307-e0d2-421e-8491-007fec506a81,2019-02-15T08:00:00.000+08:00,1,Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates
ef85fb78-81fb-4a24-b794-41d1db59de49,2019-02-15T08:00:00.000+08:00,3,Bayer in-licenses Loxo's Vitrakvi and LOXO-195
668cc79a-7e63-49ed-a343-d7efb826ef94,2019-02-15T08:00:00.000+08:00,4,Lilly finalizes Loxo buy
b8b27517-e8c2-4617-8e35-918903a4106b,2019-02-15T08:00:00.000+08:00,5,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice
2c9f42ee-02e8-401b-9a79-ebcf663fbd08,2019-02-15T08:00:00.000+08:00,2,"Bayer To Obtain Full Rights To Global Development And Commercialization Of Oncology Compounds VITRAKVI And AND BAY 2731954, Will Be Solely Responsible For Global Development And Commercialization Of Both"
9a5c43cf-fee5-438c-8627-143c07cebbb9,2019-02-15T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Friday, Feb. 15"
a55cde43-ab6b-4829-97cf-7ed42a30a9f8,2019-02-15T08:00:00.000+08:00,3,FDA creates new accelerated review pathway for generic drug applications
40ee3281-a69f-42f1-bff2-886e1cf22bc0,2019-02-15T08:00:00.000+08:00,1,Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates
0b17f9c7-44a9-4e17-ba13-e1a6e560ddff,2019-02-15T08:00:00.000+08:00,4,Bayer in-licenses Loxo's Vitrakvi and LOXO-195
00d910f3-fb52-4523-8336-8de6280da4b1,2019-02-15T08:00:00.000+08:00,4,Lilly finalizes Loxo buy
46df42b9-8536-4f8d-b385-7101ddde10c6,2019-02-15T08:00:00.000+08:00,5,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice
32b52917-0acc-4bd9-95eb-38d03502ce6f,2019-02-14T08:00:00.000+08:00,3,"Stocks Trading Ex Dividend For Thurs., Feb. 14, 2019"
5da60313-818a-4df9-aed9-2ceb39d4a8f9,2019-02-14T08:00:00.000+08:00,4,"Eli Lilly, Boehringer Ingelheim Report CAROLINA Trial Of Tradjenta Met Primary Endpoint, Showed 'no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk'"
ad036ff6-7e98-4fa0-8b20-7e63e1287f87,2019-02-14T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Thursday, Feb. 14"
4c0186ea-43ee-45a9-9819-1108e32b8dc3,2019-02-14T08:00:00.000+08:00,2,"Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat"
e4930083-264b-4602-8af8-87c5126ec92b,2019-02-14T08:00:00.000+08:00,4,5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
a01d5325-3377-4937-b854-8e83367607aa,2019-02-14T08:00:00.000+08:00,3,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 14"
996376e6-8a50-4e8b-ada3-2c0db2a8aaa2,2019-02-14T08:00:00.000+08:00,1,"Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down"
6173cc73-a2d7-43ec-b81d-4c74258562d1,2019-02-14T08:00:00.000+08:00,4,Eli Lilly and Boehringer Ingelheim's Tradjenta successful in CV outcomes study
89668c45-057c-43e9-9fa7-6b972abe4bab,2019-02-14T08:00:00.000+08:00,2,"Stocks Trading Ex Dividend For Thurs., Feb. 14, 2019"
2876ab34-4911-48a9-b929-d9de3902fc23,2019-02-14T08:00:00.000+08:00,3,"Eli Lilly, Boehringer Ingelheim Report CAROLINA Trial Of Tradjenta Met Primary Endpoint, Showed 'no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk'"
98a93998-7718-442e-8deb-f412dcd896e7,2019-02-14T08:00:00.000+08:00,3,"Hot Options Report For End Of Day - Thursday, Feb. 14"
a437c221-aa52-44ce-9a57-0abd0962e87c,2019-02-14T08:00:00.000+08:00,1,"Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat"
16376236-aa7a-4267-9ef0-4303d0c845c6,2019-02-14T08:00:00.000+08:00,4,5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
9b0e7db3-014b-4b54-ba03-d8a25363bbb7,2019-02-14T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 14"
55bf8527-bfda-433f-8d36-feb103f131ce,2019-02-14T08:00:00.000+08:00,1,"Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down"
bcfc7f56-3bc2-4fc0-a28c-5fbd5517f646,2019-02-14T08:00:00.000+08:00,4,Eli Lilly and Boehringer Ingelheim's Tradjenta successful in CV outcomes study
9987ecea-cdd5-483d-8d30-3bc9848e47b4,2019-02-13T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Wednesday, Feb. 13"
3c2547dd-92fe-4f9b-9137-1ee430729f7d,2019-02-13T08:00:00.000+08:00,3,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 13"
bf648145-e1ad-4018-969f-f6eefd26e174,2019-02-13T08:00:00.000+08:00,2,5 Tiny Biotech Stocks With Superb Growth Potential
0c10b688-b281-40b6-938c-0a0d3d476863,2019-02-13T08:00:00.000+08:00,3,"Hot Options Report For End Of Day - Wednesday, Feb. 13"
522c9427-a270-45c4-9ee0-51fee7b60303,2019-02-13T08:00:00.000+08:00,3,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 13"
369611e8-3a67-40e7-9ab9-ce465a377780,2019-02-13T08:00:00.000+08:00,2,5 Tiny Biotech Stocks With Superb Growth Potential
d3058a88-5921-4709-aafa-f2efa2e13490,2019-02-12T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Tuesday, Feb. 12"
fb16d987-7043-4bea-97d0-baeb3d3f6b91,2019-02-12T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 12"
cf012ec6-af20-4086-baae-1a4f53de0305,2019-02-12T08:00:00.000+08:00,3,Boehringer Ingelheim teams up with IBM to explore use of blockchain in clinical trials
6e3b832b-4977-4cd2-829f-504be5d259c9,2019-02-12T08:00:00.000+08:00,3,"Hot Options Report For End Of Day - Tuesday, Feb. 12"
55e4b610-42dc-4f24-a518-94da45131a6d,2019-02-12T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 12"
002d5e59-db3e-40d3-9262-4f0c18831f9f,2019-02-12T08:00:00.000+08:00,2,Boehringer Ingelheim teams up with IBM to explore use of blockchain in clinical trials
a0da869b-c8bd-42dd-8d2e-adfe55db14e3,2019-02-11T08:00:00.000+08:00,4,"Hot Options Report For End Of Day - Monday, Feb. 11"
a22056d1-450f-4d0a-b55f-27bb1479a55f,2019-02-11T08:00:00.000+08:00,5,Alkermes Is Still An Attractive Pick
ce6d2c3b-7165-4d46-9691-30dc0bb7719d,2019-02-11T08:00:00.000+08:00,3,Regeneron: Cheap Enough To Look Past The Eylea Valley
d7cd0547-9632-4dfd-91f5-f4185e616cce,2019-02-11T08:00:00.000+08:00,2,Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake
331c7bc8-55ef-4e45-a9eb-388d05b9949b,2019-02-11T08:00:00.000+08:00,4,"Hot Options Report For End Of Day - Monday, Feb. 11"
dfd80cda-0273-470a-96ef-93d95e5895fd,2019-02-11T08:00:00.000+08:00,4,Alkermes Is Still An Attractive Pick
c5d74503-3ae3-4943-9520-5ac09dd52b6e,2019-02-11T08:00:00.000+08:00,3,Regeneron: Cheap Enough To Look Past The Eylea Valley
bb50bd60-bc4f-4c67-9800-09fa8a884a62,2019-02-11T08:00:00.000+08:00,2,Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake
12c68318-03af-4b56-b741-cdbaa29c576c,2019-02-08T08:00:00.000+08:00,1,Eli Lilly Reports Will Initiate Divestiture Of Its Remaining Interest In Elanco Animal Health
2af4fbfa-1eef-4111-b552-79ed3b408a0e,2019-02-08T08:00:00.000+08:00,5,"Hot Options Report For End Of Day - Friday, Feb. 8"
4e34e711-c339-4214-9825-3bbbc06eb5e4,2019-02-08T08:00:00.000+08:00,2,Incyte Down as FDA Extends Review Period of Jakafi for GVHD
d97816b0-729a-42d9-9eb6-94790d67f28f,2019-02-08T08:00:00.000+08:00,3,Lilly Q4: Looking At Low Verzenio Sales And The Loxo Oncology Acquisition
0cd6a50c-df6c-4ae7-8124-e3ec31673604,2019-02-08T08:00:00.000+08:00,4,"Most Active Equity Options And Strikes For Midday - Friday, Feb. 8"
202301ad-4e95-4986-84c1-ba622d3dc9b9,2019-02-08T08:00:00.000+08:00,1,The Diabetes Landscape Is Changing — Can This Stock Lead The Pack?
91d9ca28-a7db-4879-aeb0-376563ec4e54,2019-02-08T08:00:00.000+08:00,2,Lilly launches exchange offer for Elanco shares
fc50dea8-423b-4102-888a-231297eb4149,2019-02-08T08:00:00.000+08:00,2,Eli Lilly Reports Will Initiate Divestiture Of Its Remaining Interest In Elanco Animal Health
01f5abdb-d18b-4d3a-8676-59da19efcc7f,2019-02-08T08:00:00.000+08:00,1,"Hot Options Report For End Of Day - Friday, Feb. 8"
8dfe52be-eb84-4d49-971f-d0782944a03d,2019-02-08T08:00:00.000+08:00,3,Incyte Down as FDA Extends Review Period of Jakafi for GVHD
251d4933-1931-4da0-a1bb-5d13e25c5f6e,2019-02-08T08:00:00.000+08:00,2,Lilly Q4: Looking At Low Verzenio Sales And The Loxo Oncology Acquisition
866b1ea2-f141-46ac-9e50-5694065ed81e,2019-02-08T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Friday, Feb. 8"
8d49774e-a094-4c69-a537-b14058addc86,2019-02-08T08:00:00.000+08:00,4,The Diabetes Landscape Is Changing — Can This Stock Lead The Pack?
eeb58182-6d6c-43c0-b376-aad000745723,2019-02-08T08:00:00.000+08:00,3,Lilly launches exchange offer for Elanco shares
893eda59-afc3-456b-8405-8b9e4779e7fa,2019-02-07T08:00:00.000+08:00,5,Vertex: Shareholders Might Have Reason To Breathe More Easily
3080398d-1c93-4c99-9838-c21dd52b010f,2019-02-07T08:00:00.000+08:00,1,Is Big Pharma Poised For A 2019 Buying Spree In Biotech Stocks?
6c639cb4-eff5-4f7d-b018-ece7824db920,2019-02-07T08:00:00.000+08:00,2,Array BioPharma: Fairly Valued After Q2 Report
379f06f0-526d-4b07-b0b4-35de02f4274a,2019-02-07T08:00:00.000+08:00,3,"Stock Market News For Feb 7, 2019"
d045a71a-9240-4475-ae11-1972756a9e15,2019-02-07T08:00:00.000+08:00,4,Vertex: Shareholders Might Have Reason To Breathe More Easily
98004334-6444-4ff3-bfbf-cf76e0809c67,2019-02-07T08:00:00.000+08:00,3,Is Big Pharma Poised For A 2019 Buying Spree In Biotech Stocks?
b6058e23-2b1e-40ce-a30e-e0e53d6ecae1,2019-02-07T08:00:00.000+08:00,3,Array BioPharma: Fairly Valued After Q2 Report
1bfb1b47-7678-4b54-ac6a-5a2a2bf553ca,2019-02-07T08:00:00.000+08:00,3,"Stock Market News For Feb 7, 2019"
9c2f23f5-ef6e-44d7-8e31-bff5f0a3c654,2019-02-06T08:00:00.000+08:00,2,"After State Of the Union, Focus Turns Again To Earnings News, Geopolitics, Fed"
1e7dde96-1d02-4319-b0e2-333930625a11,2019-02-06T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering"
add22c74-f007-4dd4-a234-c71ac67f0eff,2019-02-06T08:00:00.000+08:00,3,Eli Lilly Guides FY19 EPS Of $5.55-5.65 vs $5.77 Est; Lowers FY19 Revenue Guidance From $25.3-25.8 Bln To $25.1-25.6 Bln vs $25.27 Bln Est
91dd3fd2-2eb6-4d1f-af19-bca6ca9e671b,2019-02-06T08:00:00.000+08:00,4,"Lilly Q4 EPS $1.33 Misses $1.34 Est, Sales $6.438B Beat $6.28B Est."
7b5344e2-b2bf-4b18-8cdd-76b3562ddcb8,2019-02-06T08:00:00.000+08:00,2,A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings
8db7af7e-e6f6-461f-bcd8-0fdda288e8ea,2019-02-06T08:00:00.000+08:00,2,"13 Stocks To Watch For February 6, 2019"
a1fe022e-804a-4789-a6e3-cbc434cb65bc,2019-02-06T08:00:00.000+08:00,3,"Earnings Scheduled For February 6, 2019"
25bee80a-34ab-44af-a691-535f2b5137ec,2019-02-06T08:00:00.000+08:00,4,This Top Pharma Stock Undercut A Buy Point On Its Earnings Lag
7fddaab9-e389-420b-9ac8-cb145d257d50,2019-02-06T08:00:00.000+08:00,5,Array: Poised For Growth
61e56a19-8f19-44b7-b44f-9540ac7f8d83,2019-02-06T08:00:00.000+08:00,1,Lilly bails on BTK inhibitor LY3337641
f85310e5-797e-41b1-a5e3-e4ba77f2e613,2019-02-06T08:00:00.000+08:00,1,Eli Lilly and Company (LLY) CEO Dave Ricks on Q4 2018 Results - Earnings Call Transcript
e23abc2d-8fea-4e14-834a-af0b668f18d3,2019-02-06T08:00:00.000+08:00,2,"Elanco down 5% after Q4 report, Lilly plan to divest remaining shares"
74112aa2-d611-474c-b830-ffc9d3359370,2019-02-06T08:00:00.000+08:00,3,"Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down"
b507300a-4d10-45cf-bff8-addc40f4e8d9,2019-02-06T08:00:00.000+08:00,2,"Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View"
9d09d651-85a8-4c67-80f3-b988fd578138,2019-02-06T08:00:00.000+08:00,3,Eli Lilly and Company 2018 Q4 - Results - Earnings Call Slides
0c9fa6e2-cb3a-4db7-bbd3-f8c0b9ebfc22,2019-02-06T08:00:00.000+08:00,2,"Eli Lilly misses by $0.01, beats on revenue"
54dcd947-57e9-4b5b-8212-44088b1ba7c3,2019-02-06T08:00:00.000+08:00,3,"After State Of the Union, Focus Turns Again To Earnings News, Geopolitics, Fed"
822d7de1-f7ed-40f7-b11a-c597cdbe39dd,2019-02-06T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering"
c1016991-8758-41dd-9b24-8f85c796fd1c,2019-02-06T08:00:00.000+08:00,2,Eli Lilly Guides FY19 EPS Of $5.55-5.65 vs $5.77 Est; Lowers FY19 Revenue Guidance From $25.3-25.8 Bln To $25.1-25.6 Bln vs $25.27 Bln Est
5cfd2f18-a59a-4b99-9a73-90ae0585a834,2019-02-06T08:00:00.000+08:00,1,"Lilly Q4 EPS $1.33 Misses $1.34 Est, Sales $6.438B Beat $6.28B Est."
ea39d02c-cf09-4e6a-ba97-7cdf3da1fec4,2019-02-06T08:00:00.000+08:00,2,A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings
e977c3d3-bf53-422b-b0eb-211009227857,2019-02-06T08:00:00.000+08:00,3,"13 Stocks To Watch For February 6, 2019"
aa20abed-360f-4310-b838-efb001a7aae4,2019-02-06T08:00:00.000+08:00,3,"Earnings Scheduled For February 6, 2019"
43988501-ffb6-4d84-894a-3455fb069e4a,2019-02-06T08:00:00.000+08:00,4,This Top Pharma Stock Undercut A Buy Point On Its Earnings Lag
964b3100-62fe-464b-959e-2bfadd8358ed,2019-02-06T08:00:00.000+08:00,5,Array: Poised For Growth
473f169e-61c3-4070-b23d-8d16a91ea4c3,2019-02-06T08:00:00.000+08:00,1,Lilly bails on BTK inhibitor LY3337641
4a3b6cb4-618f-4616-9545-0e3e274f8b2e,2019-02-06T08:00:00.000+08:00,2,Eli Lilly and Company (LLY) CEO Dave Ricks on Q4 2018 Results - Earnings Call Transcript
6365cb56-e5ad-4504-85c5-78ed4df576f5,2019-02-06T08:00:00.000+08:00,3,"Elanco down 5% after Q4 report, Lilly plan to divest remaining shares"
cce0928c-c911-4052-a174-ccccac5fd449,2019-02-06T08:00:00.000+08:00,2,"Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down"
e61d7880-a2e6-4068-9d6f-e6838b6da3a8,2019-02-06T08:00:00.000+08:00,2,"Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View"
b6da99e2-3c49-47b7-b071-f4e783c84275,2019-02-06T08:00:00.000+08:00,2,Eli Lilly and Company 2018 Q4 - Results - Earnings Call Slides
9f6d4376-a272-45ea-9f45-82c46d983b31,2019-02-06T08:00:00.000+08:00,4,"Eli Lilly misses by $0.01, beats on revenue"
2e74d057-2d63-4612-ac3b-73d8a083723c,2019-02-05T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results"
a41a99fd-8ec1-4c40-a2c5-06792b036e49,2019-02-05T08:00:00.000+08:00,1,Selling Roche: Sector And Company-Specific Reasons
71d5d556-588c-4cf9-aaf5-4efcd43eb277,2019-02-05T08:00:00.000+08:00,2,Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer
be605333-5b64-4880-8441-cb55cc0b74dd,2019-02-05T08:00:00.000+08:00,4,Roche Submits sBLA to FDA for Label Expansion of Kadcyla
dda9d653-2a69-44fe-8757-68769aa33778,2019-02-05T08:00:00.000+08:00,5,Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies
3e7d7d66-0af9-4231-9a01-08eb6636a904,2019-02-05T08:00:00.000+08:00,3,Lilly's baricitinib successful in late-stage dermatitis studies
54d40abb-1b0c-4bc0-858e-65729068cc16,2019-02-05T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results"
db5d3fcb-41ae-43ce-bc50-fa2c40e5db2f,2019-02-05T08:00:00.000+08:00,2,Selling Roche: Sector And Company-Specific Reasons
f3942928-2144-4d7a-961d-93514a86973f,2019-02-05T08:00:00.000+08:00,5,Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer
a3d1855e-4763-4a30-865d-902a268bd8a8,2019-02-05T08:00:00.000+08:00,4,Roche Submits sBLA to FDA for Label Expansion of Kadcyla
2f5a6251-5ca4-4fd9-b63f-1365b653b5e1,2019-02-05T08:00:00.000+08:00,3,Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies
6c54e223-958f-497c-a166-9d8956e25416,2019-02-05T08:00:00.000+08:00,4,Lilly's baricitinib successful in late-stage dermatitis studies
2f392179-7d19-4fe5-9ebd-2b312ea7094f,2019-02-04T08:00:00.000+08:00,5,Eli Lilly Announces Two Phase 3 Trials of Baricitinib Met Their Primary Endpoints
1d521a98-ce93-4f07-8fc0-ebf9c5333031,2019-02-04T08:00:00.000+08:00,5,Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy
62613adc-b05b-4b9f-97c0-da96a44e169d,2019-02-04T08:00:00.000+08:00,1,"Merger Arbitrage Mondays - February 4, 2019"
f96b58e7-a7e1-4f31-8ed3-d51c2750b600,2019-02-04T08:00:00.000+08:00,3,Eli Lilly Announces Two Phase 3 Trials of Baricitinib Met Their Primary Endpoints
d58d91cd-8401-4c23-bc49-ac531938151e,2019-02-04T08:00:00.000+08:00,5,Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy
fb2e5234-077b-4b48-9818-082eacabe7cd,2019-02-04T08:00:00.000+08:00,1,"Merger Arbitrage Mondays - February 4, 2019"
5d1e78da-16c0-49d2-b6d1-6a80dbc90b67,2019-02-01T08:00:00.000+08:00,2,Trump At State Of The Union Will Ask For Drug Pricing Cuts
55e90b4b-ff0e-4ea7-95f1-8c8addda872a,2019-02-01T08:00:00.000+08:00,4,"Optum To Cover Amgen, Eli Lilly Migraine Drugs, Exclude Teva"
55c829f2-190d-4b0a-9273-a84be37fc220,2019-02-01T08:00:00.000+08:00,3,Pharma Catches Another Case Of M&A Fever
728d74ed-8ecc-49c5-92ef-f55bc61a1fba,2019-02-01T08:00:00.000+08:00,1,"The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of Titan's Opioid Disorder Treatment Implant"
5d262f3e-da39-4913-9a4e-8193ef8bd686,2019-02-01T08:00:00.000+08:00,2,"Eli Lilly, Loxo Oncology Reports Expiration Of Hart-Scott-Rodino Antitrust Act Waiting Period For Proposed Deal"
b6171190-e0c6-424f-a380-a979cbbcefbf,2019-02-01T08:00:00.000+08:00,2,"Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat"
f9a4bdab-b0af-43a4-aad4-16973c086cbd,2019-02-01T08:00:00.000+08:00,3,"UnitedHealth's Optum to cover Amgen and Lilly migraine meds, Teva excluded"
419eac93-d303-4176-b1e9-24ccad597dd7,2019-02-01T08:00:00.000+08:00,4,"Lilly (LLY) Hits 52-Week High, Can the Run Continue?"
1c709b3d-6a65-4918-9bd5-1fd60c176647,2019-02-01T08:00:00.000+08:00,1,"Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY"
cdd2f908-b6e9-4ac4-916c-4782cbdac12f,2019-02-01T08:00:00.000+08:00,2,Trump At State Of The Union Will Ask For Drug Pricing Cuts
9d77cf8e-6c27-4cf3-967e-a30d826a4c96,2019-02-01T08:00:00.000+08:00,2,"Optum To Cover Amgen, Eli Lilly Migraine Drugs, Exclude Teva"
f79d88ef-8579-4cd8-b81c-a6e0725a963a,2019-02-01T08:00:00.000+08:00,3,Pharma Catches Another Case Of M&A Fever
5da08234-144c-4fc8-95c6-20906c282895,2019-02-01T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of Titan's Opioid Disorder Treatment Implant"
7d98e037-1eb5-45ae-8dce-c00ed30be8cd,2019-02-01T08:00:00.000+08:00,1,"Eli Lilly, Loxo Oncology Reports Expiration Of Hart-Scott-Rodino Antitrust Act Waiting Period For Proposed Deal"
d9309518-0085-49d1-9023-050d69075e45,2019-02-01T08:00:00.000+08:00,2,"Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat"
8128e601-b54b-43fc-8a4a-19817ccd13c2,2019-02-01T08:00:00.000+08:00,4,"UnitedHealth's Optum to cover Amgen and Lilly migraine meds, Teva excluded"
9f5e8f0d-3504-4b74-9349-98483b6c11ac,2019-02-01T08:00:00.000+08:00,5,"Lilly (LLY) Hits 52-Week High, Can the Run Continue?"
5fdde8e7-9d5d-493e-b086-65c69b39a8ec,2019-02-01T08:00:00.000+08:00,3,"Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY"
95d3f94e-ba37-45d5-8c79-9c0f37b8887f,2019-01-31T08:00:00.000+08:00,2,"Earnings, Volatility, Brexit Are Key Topics Heading Into February"
274f07b1-a640-40ff-bc8b-ec141a96e85b,2019-01-31T08:00:00.000+08:00,5,"Eli Lilly Reports FDA Expanded ALIMTA's Label To Combine KEYTRUDA, Platinum Chemotherapy For First-Line Treatment Of Metastatic Nonsquamous Non-Small Cell Lunch Cancer"
8a4e91a8-967e-4540-99b0-2e5dab3cfa14,2019-01-31T08:00:00.000+08:00,3,J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study
5ff04747-844d-4381-8857-fba416b1782c,2019-01-31T08:00:00.000+08:00,4,Entera Bio advancing osteoporosis candidate EB-613; shares up 3%
599be444-b39a-426c-96e8-b00fd58d139a,2019-01-31T08:00:00.000+08:00,2,Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?
86dfa99e-3838-45d8-8b75-03321fc7d633,2019-01-31T08:00:00.000+08:00,5,FDA OKs new use for Lilly's Alimta
a22769ff-a2e2-49f2-bcc8-eb53e34e392b,2019-01-31T08:00:00.000+08:00,1,Another Alzheimer's Antibody Fails. There Will Be More
325cb83b-9b4c-4782-aea2-41a79e846db7,2019-01-31T08:00:00.000+08:00,2,"Earnings, Volatility, Brexit Are Key Topics Heading Into February"
4ed9aa1a-9c95-47ad-af7f-1b40929a17c0,2019-01-31T08:00:00.000+08:00,5,"Eli Lilly Reports FDA Expanded ALIMTA's Label To Combine KEYTRUDA, Platinum Chemotherapy For First-Line Treatment Of Metastatic Nonsquamous Non-Small Cell Lunch Cancer"
ba8a5968-e0d9-4bde-8b54-4905f66309e1,2019-01-31T08:00:00.000+08:00,3,J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study
60bd2986-1383-47fe-bab9-5c84ad7fc2be,2019-01-31T08:00:00.000+08:00,4,Entera Bio advancing osteoporosis candidate EB-613; shares up 3%
93040d67-134b-40dd-9a35-3501af2813e6,2019-01-31T08:00:00.000+08:00,1,Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?
64e4ace0-6004-4d44-bfa2-4376accdc6ad,2019-01-31T08:00:00.000+08:00,4,FDA OKs new use for Lilly's Alimta
8ae8d4de-42ca-475a-83ef-9032197bcf77,2019-01-31T08:00:00.000+08:00,2,Another Alzheimer's Antibody Fails. There Will Be More
741675b7-9e76-412a-9a0f-6d7a9dfee1fe,2019-01-30T08:00:00.000+08:00,3,Stocks Going Ex-Dividend In February 2019
6540639d-b3bf-4fbc-8c6e-0e01745dd8ef,2019-01-30T08:00:00.000+08:00,3,Stocks Going Ex-Dividend In February 2019
46215676-cec5-4d06-bd6c-882fdf87b1e2,2019-01-29T08:00:00.000+08:00,5,Pfizer And Lilly Announce Second Phase 3 Study Of Tanezumab In Osteoarthritis Pain Met All Three Co-Primary Endpoints At 24 Weeks
db8b2039-3c10-4b79-8509-c6f5ee1bd6a0,2019-01-29T08:00:00.000+08:00,2,Tiny Israeli firm touts cancer cure
5634d204-41f8-4cb4-940d-1a5b37da63fb,2019-01-29T08:00:00.000+08:00,4,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
56b8f2bd-4372-4d72-a706-f0149e728ded,2019-01-29T08:00:00.000+08:00,5,Pfizer and Lilly's tanezumab successful in second late-stage study
ff16d74a-6529-4bfd-ac59-8e6b1fe11c11,2019-01-29T08:00:00.000+08:00,4,Pfizer And Lilly Announce Second Phase 3 Study Of Tanezumab In Osteoarthritis Pain Met All Three Co-Primary Endpoints At 24 Weeks
53592bb5-38b2-4ee6-a637-b27012bea551,2019-01-29T08:00:00.000+08:00,1,Tiny Israeli firm touts cancer cure
710ea14f-3f57-4496-b99b-68152d58246a,2019-01-29T08:00:00.000+08:00,4,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
86571ae4-9bf7-436b-900d-3728104f4306,2019-01-29T08:00:00.000+08:00,5,Pfizer and Lilly's tanezumab successful in second late-stage study
ec7db654-0ece-4341-9dcd-f8b0384fafb4,2019-01-28T08:00:00.000+08:00,2,"A Peek Into The Markets: US Stock Futures Down, Caterpillar Earnings In Focus"
d1c54ddb-cba4-4bbd-8d19-8d4c5ec23cb6,2019-01-28T08:00:00.000+08:00,4,111 and Eli Lilly to Collaborate on Pharmaceutical Distribution With a Focus on Big Data and E-Prescriptions
1674095c-470d-43ab-ba77-6930add707c0,2019-01-28T08:00:00.000+08:00,1,Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?
b66ef413-ac09-485b-8044-2dd49d3be1f1,2019-01-28T08:00:00.000+08:00,2,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2018 Update
2a3fad70-6ec2-46f6-839c-59d351d46489,2019-01-28T08:00:00.000+08:00,4,Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results
3d97ddbc-2ff7-4fe6-a19b-a4f0933241c8,2019-01-28T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck"
b68e859d-0656-430d-9ca5-38d14ad89b2d,2019-01-28T08:00:00.000+08:00,1,"A Peek Into The Markets: US Stock Futures Down, Caterpillar Earnings In Focus"
4b031331-a47f-483c-8a56-1bfc5604ce43,2019-01-28T08:00:00.000+08:00,4,111 and Eli Lilly to Collaborate on Pharmaceutical Distribution With a Focus on Big Data and E-Prescriptions
b8757b41-08ee-48a4-b77d-5a5d9dc64157,2019-01-28T08:00:00.000+08:00,3,Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?
1c9b7528-c7c0-403e-9c7a-1d369c64f9a0,2019-01-28T08:00:00.000+08:00,2,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2018 Update
73a7ed07-1ada-4db7-bf05-4cdf17391a6e,2019-01-28T08:00:00.000+08:00,4,Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results
fa06bb2a-efcb-4182-acc5-08877570c178,2019-01-28T08:00:00.000+08:00,5,"The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck"
8d193b77-d039-4017-9ed2-cf8808368d03,2019-01-27T08:00:00.000+08:00,1,AbbVie: Not Driving Via The Rearview Mirror
2f77af6e-af0e-41da-9772-40036fd19e72,2019-01-27T08:00:00.000+08:00,2,AbbVie: Not Driving Via The Rearview Mirror
29a89e8b-b67d-49b9-a049-25d121e895ff,2019-01-25T08:00:00.000+08:00,1,"CVS Says Puts New Migraine Drugs From Teva And Eli Lilly On List Of Covered Medicines, Excludes Amgen's AIMOVIG"
c52257de-4182-4cd6-9742-cafe885bb133,2019-01-25T08:00:00.000+08:00,3,Amgen's Aimovig reportedly excluded from CVS plans
ec9efcc7-f739-4f91-9d70-e140950444f6,2019-01-25T08:00:00.000+08:00,2,"Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV"
538b3c6c-5ceb-410d-813b-43fbd3e36a79,2019-01-25T08:00:00.000+08:00,3,Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds
8e830021-bcb0-49f9-9f42-daa44d48b4ba,2019-01-25T08:00:00.000+08:00,2,"CVS Says Puts New Migraine Drugs From Teva And Eli Lilly On List Of Covered Medicines, Excludes Amgen's AIMOVIG"
c49c56c4-31e9-433c-b70f-df617dc552cd,2019-01-25T08:00:00.000+08:00,1,Amgen's Aimovig reportedly excluded from CVS plans
862ade79-9842-4829-8536-c40966c51e2e,2019-01-25T08:00:00.000+08:00,3,"Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV"
2ff04ecd-a089-496d-876b-cf11bd9cffda,2019-01-25T08:00:00.000+08:00,4,Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds
c83d7568-de3d-4c2e-ad82-b3e5a179a7bb,2019-01-24T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Thursday, Jan. 24"
68e0d27c-da7c-433b-8274-3c9a818c414a,2019-01-24T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Thursday, Jan. 24"
61738b5b-f1af-4091-bde7-7fa6919d8a16,2019-01-24T08:00:00.000+08:00,1,Early Q4 reports weigh on large cap drug makers
7edd6dae-7232-48f0-b7a1-b11f61064b1a,2019-01-24T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: Archer Daniels Midland, Molina Healthcare, Eli Lilly, Spark Energy and Lamb Weston"
3dd13e5c-39c4-4234-8951-549779b5fb2e,2019-01-24T08:00:00.000+08:00,4,Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids
6d891f3a-ab19-4ec8-9c74-30ab670720b6,2019-01-24T08:00:00.000+08:00,2,"Hot Options Report For End Of Day - Thursday, Jan. 24"
0f9e0e0f-c10c-4a8b-9a4a-20ce6a7a7105,2019-01-24T08:00:00.000+08:00,2,"Most Active Equity Options And Strikes For Midday - Thursday, Jan. 24"
2583609f-e7ec-4b8c-b623-45e3f3ba27cb,2019-01-24T08:00:00.000+08:00,1,Early Q4 reports weigh on large cap drug makers
b4900236-cc80-48e8-8065-500fc0636fe5,2019-01-24T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: Archer Daniels Midland, Molina Healthcare, Eli Lilly, Spark Energy and Lamb Weston"
40f41006-f060-4d43-80d1-10c012c9e2ac,2019-01-24T08:00:00.000+08:00,4,Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids
b6271d1e-1033-4b76-bd46-b87fe591cff7,2019-01-23T08:00:00.000+08:00,1,European Medicines Agency Says No New Patients Should Start Treatment With Lilly's Lartruvo After Study Shows Cancer Medicine Does Not Prolong Life
24ae09f7-9770-4ac1-9de8-bb4ad8b0b684,2019-01-23T08:00:00.000+08:00,5,UBS Initiates Coverage On Eli Lilly with Buy Rating
fea1ac03-eca5-4262-be89-479b137540c5,2019-01-23T08:00:00.000+08:00,4,5 Best Biotech Bets Likely to Outperform Estimates in Q4
7cee3c5b-cfef-47dc-826f-4f16593a74b5,2019-01-23T08:00:00.000+08:00,4,UBS likes Lilly in premarket analyst action
d6311566-1a4b-44d4-81d2-3bddf24a7a0c,2019-01-23T08:00:00.000+08:00,2,6 Stocks to Prepare for a Global Economic Slowdown
6315692c-ceaa-4ba9-acd4-785d85e2b911,2019-01-23T08:00:00.000+08:00,1,Teva up 3% premarket on bullish call at UBS
c55a9290-4b02-46f5-95fc-94d4916671b6,2019-01-23T08:00:00.000+08:00,2,Treatment with Lilly's Lartruvo to cease in Europe
213f0d7e-942f-49b1-945d-47a9a5986290,2019-01-23T08:00:00.000+08:00,1,Insulin costs in U.S. doubled from 2012 - 2016
4bb101cd-12bb-47f0-9d46-292692e9f0cb,2019-01-23T08:00:00.000+08:00,3,European Medicines Agency Says No New Patients Should Start Treatment With Lilly's Lartruvo After Study Shows Cancer Medicine Does Not Prolong Life
2c7f6b66-983b-46d8-83ec-bc27bf3d00ee,2019-01-23T08:00:00.000+08:00,4,UBS Initiates Coverage On Eli Lilly with Buy Rating
4e9fbd05-0089-4d8f-9445-4348c47d1c17,2019-01-23T08:00:00.000+08:00,4,5 Best Biotech Bets Likely to Outperform Estimates in Q4
87aa8ca6-ac46-4536-900c-24ad9b881100,2019-01-23T08:00:00.000+08:00,4,UBS likes Lilly in premarket analyst action
5f595982-8b79-4b10-a1ba-6b938b120d17,2019-01-23T08:00:00.000+08:00,1,6 Stocks to Prepare for a Global Economic Slowdown
52cc00c2-9f74-4c5a-9742-b08b9eb3bf48,2019-01-23T08:00:00.000+08:00,3,Teva up 3% premarket on bullish call at UBS
c0d0755c-8ecb-45c2-8237-2515729ed62e,2019-01-23T08:00:00.000+08:00,2,Treatment with Lilly's Lartruvo to cease in Europe
d0716745-01c3-4be0-8c0b-a1b3afe1931f,2019-01-23T08:00:00.000+08:00,1,Insulin costs in U.S. doubled from 2012 - 2016
2642ba3d-668e-4c42-b96b-04ce6718c648,2019-01-22T08:00:00.000+08:00,1,Johnson & Johnson Shares Fall on Disappointing —…–9 Outlook
e1c3e99c-2daa-472d-a850-f70bc0609719,2019-01-22T08:00:00.000+08:00,1,"Company News For Jan 22, 2019"
4acbcf62-9aaf-426b-abae-28d9fda7ad3c,2019-01-22T08:00:00.000+08:00,1,Johnson & Johnson Shares Fall on Disappointing —…–9 Outlook
7365a9ee-e797-4372-89f1-dcc039a37033,2019-01-22T08:00:00.000+08:00,1,"Company News For Jan 22, 2019"
788b4626-438b-4878-8336-12ce6f49a359,2019-01-18T08:00:00.000+08:00,2,Eli Lilly shares are trading lower after the company announced the Phase 3 study of LARTRUVO did not meet its primary endpoint.
0d40866d-c636-4929-aaec-1874422c0fc9,2019-01-18T08:00:00.000+08:00,1,40 Stocks Moving In Friday's Pre-Market Session
1e1c6ffb-4b54-4d80-92f1-5f12ca7da690,2019-01-18T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug"
18ab402b-914b-49f1-9c71-fca7430e15f5,2019-01-18T08:00:00.000+08:00,3,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
ebd4a4e0-3dc9-4a0a-ace2-d2661d1473dc,2019-01-18T08:00:00.000+08:00,1,Eli Lilly's Phase 3 Study of LARTRUVO Did Not Meet Its Primary Endpoint
4ab01082-bfd9-4b2c-9f05-e6bf695cdb45,2019-01-18T08:00:00.000+08:00,3,Realty Income: Halftime Report
364f826e-9641-43ea-b200-33a195057b8c,2019-01-18T08:00:00.000+08:00,1,Eli Lilly to stop promoting Lartruvo after Phase 3 flop; shares down 3%
24273fc5-88d1-4af9-ac01-d40e6645f960,2019-01-18T08:00:00.000+08:00,2,"Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY"
86016ae9-99de-40fe-92f7-03d0f1762aab,2019-01-18T08:00:00.000+08:00,3,Lilly's olaratumab flunks late-stage soft tissue sarcoma study
c95a9951-2e5a-4c1b-9e57-5c23d1a7587b,2019-01-18T08:00:00.000+08:00,4,Zymeworks earns $8M milestone from licensee Lilly
95b79ae0-02b1-4740-88c4-090eb24432f5,2019-01-18T08:00:00.000+08:00,1,Eli Lilly shares are trading lower after the company announced the Phase 3 study of LARTRUVO did not meet its primary endpoint.
814271f1-c60b-4baf-9706-4957d3473ed7,2019-01-18T08:00:00.000+08:00,1,40 Stocks Moving In Friday's Pre-Market Session
26e2d2db-4d0a-4168-a827-b991f32cb433,2019-01-18T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug"
61d63fc0-83a3-45f9-8715-9f7915639ae9,2019-01-18T08:00:00.000+08:00,3,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
166b0c26-c1ca-4bbb-9a1a-6b3d95533f80,2019-01-18T08:00:00.000+08:00,1,Eli Lilly's Phase 3 Study of LARTRUVO Did Not Meet Its Primary Endpoint
74fb912a-f25c-48cb-8467-2f02eb891ea6,2019-01-18T08:00:00.000+08:00,3,Realty Income: Halftime Report
bc2a4c0c-b38c-4be3-ba65-fe40158a56d2,2019-01-18T08:00:00.000+08:00,1,Eli Lilly to stop promoting Lartruvo after Phase 3 flop; shares down 3%
4d0403bb-af50-46bc-9339-499d8ac84a92,2019-01-18T08:00:00.000+08:00,2,"Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY"
ce48ec14-5eb6-49ed-82f1-5579da26caa3,2019-01-18T08:00:00.000+08:00,3,Lilly's olaratumab flunks late-stage soft tissue sarcoma study
8ae05e1a-e533-4b71-97c8-d37e78f44e17,2019-01-18T08:00:00.000+08:00,4,Zymeworks earns $8M milestone from licensee Lilly
e73f5fb2-6675-429f-91e9-2b49dbb816c0,2019-01-17T08:00:00.000+08:00,5,Zymeworks to Receive an 8M Milestone Payment from Eli Lilly
996a1c09-216b-4426-81bc-12c2aa403920,2019-01-17T08:00:00.000+08:00,4,Eli Lilly And Ablexis Announces Expansion Of Non-Exclusive Perpetual License Agreement; Expanded Rights To Allow For Broader Use Of ALIVAMAB Mouse Platform
ebcc6bd7-dc9c-4cd9-bb51-25ceed1d4b25,2019-01-17T08:00:00.000+08:00,1,Ligand (LGND) Takes a Hit on Citron's Negative Research Report
5f33d75d-c5a5-4b73-adf4-a271a49249e6,2019-01-17T08:00:00.000+08:00,3,Eli Lilly: An Update
b02f6955-5806-42e3-b70e-d8125beeec78,2019-01-17T08:00:00.000+08:00,5,Zymeworks to Receive an 8M Milestone Payment from Eli Lilly
43391b2b-68d8-4699-8bfb-7a2e598fd034,2019-01-17T08:00:00.000+08:00,4,Eli Lilly And Ablexis Announces Expansion Of Non-Exclusive Perpetual License Agreement; Expanded Rights To Allow For Broader Use Of ALIVAMAB Mouse Platform
b3d9f679-9416-427d-9c28-10bd9e16c7de,2019-01-17T08:00:00.000+08:00,2,Ligand (LGND) Takes a Hit on Citron's Negative Research Report
ef0074a0-b483-4bff-a4f2-4cd65c9a11a8,2019-01-17T08:00:00.000+08:00,3,Eli Lilly: An Update
09e4dff2-16b7-491d-9874-d69c3d2090ab,2019-01-16T08:00:00.000+08:00,3,Eli Lilly Form 4 From Lilly Endowment Shows Open Market Sale Of ~51.8K Shares At $117.744/Share
db8f5902-8cf8-488b-a687-170bd403af16,2019-01-16T08:00:00.000+08:00,4,Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings
a77e019f-d883-40de-8b58-d9db7951b030,2019-01-16T08:00:00.000+08:00,1,Intrexon Signs Licensing Agreement with Next Green Wave
27373954-6746-4c4d-a4f6-4b3ed8ef6ae4,2019-01-16T08:00:00.000+08:00,2,Hospitals squeezed by high drug costs
e832cc31-55b2-491c-a6a0-fe510372bcd1,2019-01-16T08:00:00.000+08:00,3,Biopharma firms under pressure on Brexit uncertainty
cdd96703-4dd0-4177-9dc4-245fe23f20b2,2019-01-16T08:00:00.000+08:00,5,6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019
9531c8b3-f453-4d73-99bf-e7feb15d2529,2019-01-16T08:00:00.000+08:00,1,Eli Lilly Form 4 From Lilly Endowment Shows Open Market Sale Of ~51.8K Shares At $117.744/Share
4e97a0ca-aabc-4bbb-90d7-9db0873014e4,2019-01-16T08:00:00.000+08:00,4,Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings
3d30c1be-50ff-47b5-b9be-9944ed6c00fb,2019-01-16T08:00:00.000+08:00,2,Intrexon Signs Licensing Agreement with Next Green Wave
844d5673-81a4-48ff-96f1-b218cf4d443f,2019-01-16T08:00:00.000+08:00,1,Hospitals squeezed by high drug costs
2b968bb6-f14b-4818-967d-0fd9dfc52cf7,2019-01-16T08:00:00.000+08:00,3,Biopharma firms under pressure on Brexit uncertainty
2906f500-433b-4d2c-af7b-4e9a9d6d8f32,2019-01-16T08:00:00.000+08:00,4,6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019
a2ed16f3-93d1-445e-8952-8bd7bdc64e60,2019-01-15T08:00:00.000+08:00,5,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding ..."
8bbf5919-3a68-4c93-80ee-af2c510a4834,2019-01-15T08:00:00.000+08:00,4,FDA to beef up cell and gene therapy staff
f959987c-3644-4979-832f-8dda3e7b3df8,2019-01-15T08:00:00.000+08:00,5,FDA Commish touts advances/successes
e16c3736-f795-4d87-8b55-3d10a70ccba1,2019-01-15T08:00:00.000+08:00,3,Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer
98bede78-d07f-4723-baaf-ddb74f952ae2,2019-01-15T08:00:00.000+08:00,1,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding ..."
121e8181-fca6-4013-8c85-5eac917417b8,2019-01-15T08:00:00.000+08:00,4,FDA to beef up cell and gene therapy staff
9a305053-5b83-4597-aae8-8cc33d0dfd9b,2019-01-15T08:00:00.000+08:00,4,FDA Commish touts advances/successes
398c52f3-8490-4362-92e2-78bf101e6f0d,2019-01-15T08:00:00.000+08:00,3,Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer
3033b2f5-44b1-445d-ac18-65bcdf783874,2019-01-14T08:00:00.000+08:00,2,"Merger Arbitrage Mondays - January 14, 2018"
0618fb83-788d-4603-b485-e76035eed8b7,2019-01-14T08:00:00.000+08:00,1,Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
d4535fb6-2ed6-4e86-8fef-b7f250ae792b,2019-01-14T08:00:00.000+08:00,5,"Eli Lilly, Loxo Make More Sense Than Bristol Myers, Celgene"
3a348a74-b9c2-4742-8bbd-c7cd3be1a40b,2019-01-14T08:00:00.000+08:00,2,Rep. Cummings opens investigation into drug prices
707d341b-5837-4aaa-8aba-3b66bcf06eb4,2019-01-14T08:00:00.000+08:00,3,A Planned Spinoff Of Cancer Vaccines At Generex
a50f3cff-f63b-455c-9a66-d673e377a6b0,2019-01-14T08:00:00.000+08:00,3,"Merger Arbitrage Mondays - January 14, 2018"
90289b8e-3891-45cf-9cab-e1b779a1bc40,2019-01-14T08:00:00.000+08:00,1,Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
4c4c1cce-a981-4a42-a359-3a90fd5df33f,2019-01-14T08:00:00.000+08:00,4,"Eli Lilly, Loxo Make More Sense Than Bristol Myers, Celgene"
0d7956e0-60df-447d-956d-6a73721f7272,2019-01-14T08:00:00.000+08:00,2,Rep. Cummings opens investigation into drug prices
4deaf21e-90d4-4906-b0de-64593e535da4,2019-01-14T08:00:00.000+08:00,4,A Planned Spinoff Of Cancer Vaccines At Generex
335d9919-b0a0-4c86-b35b-77668665f0d8,2019-01-13T08:00:00.000+08:00,3,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials"
c787a8c5-31a3-4737-936b-d6fa23de8c6e,2019-01-13T08:00:00.000+08:00,3,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials"
1cd693b6-5337-4d4e-94d6-5aad66e27db6,2019-01-12T08:00:00.000+08:00,1,"Alector IPO: AbbVie Is Helping, But It Is At Early Stage Of Development"
9eaf3e86-8a47-4b8c-85e8-f1395193a0c5,2019-01-12T08:00:00.000+08:00,2,"Alector IPO: AbbVie Is Helping, But It Is At Early Stage Of Development"
18ea11a2-9d1e-4c7d-b20b-97416b74559a,2019-01-11T08:00:00.000+08:00,4,4 Biotech Pipeline Areas To Keep An Eye On In 2019
779222ff-725f-4ce2-9521-06aa702bdda7,2019-01-11T08:00:00.000+08:00,3,5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019
e29d0b7e-5309-4e5e-9a50-7a85ad1a6201,2019-01-11T08:00:00.000+08:00,5,Composite Rating For Eli Lilly Jumps To 98
70d29578-48f8-467a-802b-16181f419e1e,2019-01-11T08:00:00.000+08:00,1,Dem lawmakers introduce bill to lower U.S. drug prices
924418b0-49c8-4c82-a6af-ab2efad5aeb5,2019-01-11T08:00:00.000+08:00,1,Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why
60590d2e-d18a-480b-b231-100046af15f5,2019-01-11T08:00:00.000+08:00,3,"Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet"
debe8396-fed6-4fd8-9609-938447aecb77,2019-01-11T08:00:00.000+08:00,2,4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019
ef97ea20-c492-45ae-a46a-88f49557c089,2019-01-11T08:00:00.000+08:00,3,4 Biotech Pipeline Areas To Keep An Eye On In 2019
87550475-d8cd-4f96-9790-a6951f3a6b5f,2019-01-11T08:00:00.000+08:00,3,5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019
4c6d2c41-9410-4396-80d8-c341ac179d13,2019-01-11T08:00:00.000+08:00,5,Composite Rating For Eli Lilly Jumps To 98
37851a53-09fe-4420-92dd-02782f9b4dc1,2019-01-11T08:00:00.000+08:00,2,Dem lawmakers introduce bill to lower U.S. drug prices
785e8370-b208-4615-bf1b-cc205087632a,2019-01-11T08:00:00.000+08:00,3,Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why
998d095c-8ead-4f9f-ad49-ad17ae8e2188,2019-01-11T08:00:00.000+08:00,4,"Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet"
03a32c5c-a23b-4c4e-a8d9-9545be4c4cac,2019-01-11T08:00:00.000+08:00,4,4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019
07dae80c-3616-4d29-a922-54aeeb56d0f3,2019-01-10T08:00:00.000+08:00,2,2018 In The Numbers And What It Means For 2019 - Part I: Stocks
fab3928b-6bc9-40bb-bfa0-ee6179414703,2019-01-10T08:00:00.000+08:00,4,Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting
1c38c707-3a7e-4b80-a6dc-f712b76f811b,2019-01-10T08:00:00.000+08:00,3,Drug applications take back seat to safety surveillance at FDA during shutdown
a1be82f9-676e-467e-957a-b1788aa023ca,2019-01-10T08:00:00.000+08:00,2,2018 In The Numbers And What It Means For 2019 - Part I: Stocks
ca1eeb51-41eb-44c4-a3b0-09f9e1e96033,2019-01-10T08:00:00.000+08:00,4,Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting
f457ddc0-8ae5-4f81-b8d4-116403cf6a26,2019-01-10T08:00:00.000+08:00,2,Drug applications take back seat to safety surveillance at FDA during shutdown
077268f4-36f6-418c-8c5a-5a2f4dc2b891,2019-01-09T08:00:00.000+08:00,3,Building A Bulletproof Portfolio Around Enbridge
85bf6ccb-f967-4624-b7d9-5adc372b995e,2019-01-09T08:00:00.000+08:00,4,"The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo"
be21e860-3481-465b-a2b3-3b464c050602,2019-01-09T08:00:00.000+08:00,5,NantKwest launches mid-stage study of triplet therapy for rare skin cancer
eab5b269-8675-4a91-bedd-e83f9180d20f,2019-01-09T08:00:00.000+08:00,1,Novartis' Crizanlizumab Gets Breakthrough Therapy Status
f2c4e5f8-5b6f-467f-98e5-e0adfdcc7f1a,2019-01-09T08:00:00.000+08:00,2,"Report: Exploring Fundamental Drivers Behind Virtusa, Eli Lilly, Cree, NewJersey Resources, ..."
00d66896-f2b6-4bd9-b540-cca2c6f5a89d,2019-01-09T08:00:00.000+08:00,3,Where Will M&A Strike Next Across Biotech?
fa85f7de-b69d-484c-8be9-f5a36a7abdae,2019-01-09T08:00:00.000+08:00,4,Building A Bulletproof Portfolio Around Enbridge
ce54aef8-1341-4f5f-8c42-db247612cce2,2019-01-09T08:00:00.000+08:00,5,"The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo"
210bc767-5010-4053-9fda-e06e115653dc,2019-01-09T08:00:00.000+08:00,1,NantKwest launches mid-stage study of triplet therapy for rare skin cancer
796d08f0-d1f4-4d3f-bf90-c3eb6ee8ba4b,2019-01-09T08:00:00.000+08:00,4,Novartis' Crizanlizumab Gets Breakthrough Therapy Status
3d7b91b4-f2e6-4f50-9f34-2dd6ca3a87eb,2019-01-09T08:00:00.000+08:00,3,"Report: Exploring Fundamental Drivers Behind Virtusa, Eli Lilly, Cree, NewJersey Resources, ..."
873672b5-703a-46ab-9696-ce7c340f46a1,2019-01-09T08:00:00.000+08:00,2,Where Will M&A Strike Next Across Biotech?
af14bbd0-1b82-4227-af63-c1fc0383037f,2019-01-08T08:00:00.000+08:00,1,"The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase"
e58aa7d8-367a-406f-aa95-28c2beb6fddd,2019-01-08T08:00:00.000+08:00,3,65 Biggest Movers From Yesterday
d611e34b-b780-4855-be75-83bed3ecb75e,2019-01-08T08:00:00.000+08:00,4,Eli Lilly and Company (LLY) CEO David Ricks presents at 37th Annual JPMorgan Healthcare Conference (Transcript)
0122b8f1-a1cd-4a52-9f44-4574c420df29,2019-01-08T08:00:00.000+08:00,5,"Eli Lilly Buys Loxo, This Year Looks To Be An M&A Year To Never Forget"
9b8db2a8-e180-4aab-ad5a-8bab969f1c9a,2019-01-08T08:00:00.000+08:00,3,Eli Lilly: Loxo To Drive Growth?
3b67dd03-4756-48f5-a37d-93faa3686b16,2019-01-08T08:00:00.000+08:00,4,Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?
2f0d2646-1278-4021-aa10-de72d941fc0f,2019-01-08T08:00:00.000+08:00,5,Lilly Offers $8B to Acquire Cancer-Focused Small Biotech Loxo
155fea56-d810-435e-8264-6be6a88a8116,2019-01-08T08:00:00.000+08:00,2,Crowded Cancer Space Triggers Big M&A Deals: More in Store?
206e1fe8-4bb7-4c46-903e-4be662715264,2019-01-08T08:00:00.000+08:00,3,"Company News For Jan 8, 2019"
6f50953c-eeb7-4500-971b-21fe1a20e289,2019-01-08T08:00:00.000+08:00,3,U.S.-China Wrap Up Trade Meeting (Wall Street Breakfast Podcast)
9ed7beff-53bc-47e2-b8c8-5b803cb84443,2019-01-08T08:00:00.000+08:00,4,Wall Street Breakfast: U.S.-China Wrap Up Trade Meeting
1c1c83ac-db44-4260-8237-9e79147aff76,2019-01-08T08:00:00.000+08:00,5,"The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase"
084ee684-867b-438a-b677-ceb920dcf725,2019-01-08T08:00:00.000+08:00,4,65 Biggest Movers From Yesterday
a9b382a1-b170-464a-b455-2890229bc2eb,2019-01-08T08:00:00.000+08:00,5,Eli Lilly and Company (LLY) CEO David Ricks presents at 37th Annual JPMorgan Healthcare Conference (Transcript)
7c18d0b5-ca4d-4cc3-85ba-8b73f461e2c0,2019-01-08T08:00:00.000+08:00,3,"Eli Lilly Buys Loxo, This Year Looks To Be An M&A Year To Never Forget"
6138558a-8ff4-40dd-a343-2de34e281613,2019-01-08T08:00:00.000+08:00,4,Eli Lilly: Loxo To Drive Growth?
ed8c8acd-cebd-4e6a-b839-3c72f3ef6c9d,2019-01-08T08:00:00.000+08:00,4,Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?
242cb3ae-6a98-46a6-b18e-82e61b0b9e76,2019-01-08T08:00:00.000+08:00,2,Lilly Offers $8B to Acquire Cancer-Focused Small Biotech Loxo
81a17e08-2d43-4e59-bcac-cce8ad22d2e9,2019-01-08T08:00:00.000+08:00,3,Crowded Cancer Space Triggers Big M&A Deals: More in Store?
e95f4840-fd88-485e-81ae-2d91b464b0a8,2019-01-08T08:00:00.000+08:00,1,"Company News For Jan 8, 2019"
2ec91bf3-48f9-4e7e-a8e8-3978c2811d85,2019-01-08T08:00:00.000+08:00,3,U.S.-China Wrap Up Trade Meeting (Wall Street Breakfast Podcast)
43d758e3-c926-47bc-b347-61c32d4568c0,2019-01-08T08:00:00.000+08:00,3,Wall Street Breakfast: U.S.-China Wrap Up Trade Meeting
9fe74e1d-3766-48d6-96a5-c4618684088c,2019-01-07T08:00:00.000+08:00,5,Mid-Afternoon Market Update: Dow Up 125 Points; Axsome Therapeutics Shares Spike Higher
6c1b54a2-5a3d-4100-aecb-57fe7fd69278,2019-01-07T08:00:00.000+08:00,4,42 Stocks Moving In Monday's Mid-Day Session
17627142-112c-465d-bd5b-49124bba59eb,2019-01-07T08:00:00.000+08:00,3,Mid-Day Market Update: Luxoft Jumps On Acquisition News; PG&E Shares Tumble
39d3c668-d0c1-4123-b88d-2433580a7e8e,2019-01-07T08:00:00.000+08:00,2,Mid-Morning Market Update: Markets Mixed; Commercial Metals Misses Q1 Views
8e969fcc-8819-46eb-b569-4e0e68676ca6,2019-01-07T08:00:00.000+08:00,5,Eli Lilly Agrees To Buy Loxo For $8B In Bid To Expand Oncology Franchise
db7e3661-2690-4d71-bd74-3d2b049563d4,2019-01-07T08:00:00.000+08:00,2,Eli Lilly Says it Will Limit Share Buybacks to $3.5M in 1H 2019
56772712-6e9d-4efc-9c48-ab0d1c334814,2019-01-07T08:00:00.000+08:00,3,21 Stocks Moving In Monday's Pre-Market Session
48ccc2ba-994d-49b3-b7c0-ad42f8ec089e,2019-01-07T08:00:00.000+08:00,1,Loxo Oncology to be Acquired by Eli Lilly For $235/Share Cash in Deal Worth $8B
fd1256be-766a-4ac7-a8c2-a64494ed2db8,2019-01-07T08:00:00.000+08:00,4,"Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Loxo Oncology, Inc. ..."
da4cc2e8-701f-44f9-8c4a-347eb075dd37,2019-01-07T08:00:00.000+08:00,3,Eli Lilly (LLY) Gains But Lags Market: What You Should Know
544dac09-b802-4583-9e06-bfca4b5f9a08,2019-01-07T08:00:00.000+08:00,4,"Stock Market News: Nasdaq Leads Up Session, Helped By Biotech Stocks"
3840b9bc-c97c-4ff4-a97f-9a79c1e48dd4,2019-01-07T08:00:00.000+08:00,2,Tech Stocks Set The Pace; This FANG Stock Is At A Critical Level
a8416770-e958-45a0-a1d4-9d5aa690b799,2019-01-07T08:00:00.000+08:00,5,Eli Lilly to acquire Loxo Oncology for $8B
70e11248-cd05-4d07-98fa-9ded28d01958,2019-01-07T08:00:00.000+08:00,4,3 Things To Watch For Monday In Biotech Land
0a59d626-dc1e-41aa-a9b0-fcff7913daab,2019-01-07T08:00:00.000+08:00,5,What The Celgene Deal Means For The Biotech Sector
d546632d-9b9b-4890-a846-835d801053d1,2019-01-07T08:00:00.000+08:00,5,Mid-Afternoon Market Update: Dow Up 125 Points; Axsome Therapeutics Shares Spike Higher
cb4cc82b-87f5-4b04-ad3a-d7480fc68ffa,2019-01-07T08:00:00.000+08:00,4,42 Stocks Moving In Monday's Mid-Day Session
3d570085-6d2f-438f-a4f5-d5a629c07af5,2019-01-07T08:00:00.000+08:00,3,Mid-Day Market Update: Luxoft Jumps On Acquisition News; PG&E Shares Tumble
353d8510-7754-4aec-8406-d5138ebd59bc,2019-01-07T08:00:00.000+08:00,2,Mid-Morning Market Update: Markets Mixed; Commercial Metals Misses Q1 Views
a2868e54-c6f5-418d-8431-4c56930c8952,2019-01-07T08:00:00.000+08:00,5,Eli Lilly Agrees To Buy Loxo For $8B In Bid To Expand Oncology Franchise
d4339185-1ba7-4b55-89e6-d6e300a2385f,2019-01-07T08:00:00.000+08:00,2,Eli Lilly Says it Will Limit Share Buybacks to $3.5M in 1H 2019
4bbe81e6-9b77-45e7-9c5f-69c376ff8de7,2019-01-07T08:00:00.000+08:00,3,21 Stocks Moving In Monday's Pre-Market Session
93bc77b0-fed0-4b6d-b537-899b1b1bf73a,2019-01-07T08:00:00.000+08:00,1,Loxo Oncology to be Acquired by Eli Lilly For $235/Share Cash in Deal Worth $8B
4e61b69a-6c34-44be-af26-81e72aed18dc,2019-01-07T08:00:00.000+08:00,4,"Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Loxo Oncology, Inc. ..."
8d3e599e-f8d2-4bf3-8f35-bbf3e12af1b7,2019-01-07T08:00:00.000+08:00,3,Eli Lilly (LLY) Gains But Lags Market: What You Should Know
2ce50307-a6a6-4e5e-9af2-d1b6ddb0b623,2019-01-07T08:00:00.000+08:00,4,"Stock Market News: Nasdaq Leads Up Session, Helped By Biotech Stocks"
b07485b6-49eb-4a5c-a28d-26ca1b005d99,2019-01-07T08:00:00.000+08:00,2,Tech Stocks Set The Pace; This FANG Stock Is At A Critical Level
e36fb727-31ba-48af-93a3-6cb0e233a515,2019-01-07T08:00:00.000+08:00,5,Eli Lilly to acquire Loxo Oncology for $8B
63ff0742-fc99-4d7c-9dcd-48ce5a154aea,2019-01-07T08:00:00.000+08:00,4,3 Things To Watch For Monday In Biotech Land
e34a570d-6712-4046-bb68-ececd9c9ba61,2019-01-07T08:00:00.000+08:00,5,What The Celgene Deal Means For The Biotech Sector
0eb4b9c7-93ed-47c7-8285-d4686d271863,2019-01-06T08:00:00.000+08:00,2,"Dow Jones Futures: Stock Market Rally Picks Up Steam, But This Is Missing"
c69afe1c-2398-443d-9c18-411f072a3d31,2019-01-06T08:00:00.000+08:00,2,"Dow Jones Futures: Stock Market Rally Picks Up Steam, But This Is Missing"
85cb868c-c6a1-4ea3-ba24-b1d95a5609b6,2019-01-04T08:00:00.000+08:00,4,"Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate"
9fff4bfa-cda9-4a30-bbb6-dd25a816dd3d,2019-01-04T08:00:00.000+08:00,3,"Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration"
92fe7647-db6d-47a0-98f5-b3068b5689aa,2019-01-04T08:00:00.000+08:00,4,"Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate"
ded8468b-490b-4277-a3c3-c8e996926edf,2019-01-04T08:00:00.000+08:00,2,"Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration"
d497ed9a-8063-4596-b983-181e677e3342,2019-01-03T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: TripAdvisor, Advance Auto, Red Hat, Salesforce and Eli Lily"
d11ca94f-0111-4bee-9f06-4be2353c44d5,2019-01-03T08:00:00.000+08:00,4,Japan OKs five new indications for Merck's Keytruda
a86ccc57-4248-49ce-a9e8-dce0a745e603,2019-01-03T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: TripAdvisor, Advance Auto, Red Hat, Salesforce and Eli Lily"
3cd214cc-a552-4bc8-8c80-0fcd43f93226,2019-01-03T08:00:00.000+08:00,4,Japan OKs five new indications for Merck's Keytruda
35e7156d-1caf-4d49-9cfe-ecc52f4b4615,2019-01-02T08:00:00.000+08:00,4,"Adamis Has 'Favorable' Pipeline Setup, Says Bullish Raymond James"
ee9521c1-2a06-4161-aa46-7d04b985fa33,2019-01-02T08:00:00.000+08:00,3,The Best Performing Stocks Of 2018
8e882fa6-b91a-40fd-9bdc-2a8c0b706914,2019-01-02T08:00:00.000+08:00,2,Drug makers OK with price inclusion in TV ads if done fairly
2a0fe81a-946f-456d-9179-7edd5a2a53d9,2019-01-02T08:00:00.000+08:00,4,Eli Lilly Looks To Newly Acquired Assets For Pain Market
f7ff987c-5447-4d34-ba5d-9976144066f6,2019-01-02T08:00:00.000+08:00,5,5 Great S&P 500 Stocks to Buy in 2019
7dc549ca-0e4f-4544-88dc-fe7510951b63,2019-01-02T08:00:00.000+08:00,4,"Adamis Has 'Favorable' Pipeline Setup, Says Bullish Raymond James"
0a1d5eaa-3b86-485c-a243-f042dd01cab6,2019-01-02T08:00:00.000+08:00,3,The Best Performing Stocks Of 2018
f44f3b38-b60b-4ceb-9075-424611f0db94,2019-01-02T08:00:00.000+08:00,2,Drug makers OK with price inclusion in TV ads if done fairly
def8f8b0-b8f6-4dd9-ae1d-2f3c39c2ac5e,2019-01-02T08:00:00.000+08:00,4,Eli Lilly Looks To Newly Acquired Assets For Pain Market
55ef8773-b635-469c-98b8-29594cde4b65,2019-01-02T08:00:00.000+08:00,5,5 Great S&P 500 Stocks to Buy in 2019
a372012e-c65c-447a-86db-733853cbf63b,2019-01-01T08:00:00.000+08:00,2,Biotech Bonanza: 2019 Outlook
4997d352-2ee6-4e15-9461-d033d2c812c7,2019-01-01T08:00:00.000+08:00,2,Biotech Bonanza: 2019 Outlook
2aa33300-29aa-47dd-950d-c2819bc4e9d6,2018-12-31T08:00:00.000+08:00,3,"Centene finishes first, Coty last on S&P 500 for 2018"
2405b08e-2e58-44c4-871a-d0509c8807ff,2018-12-31T08:00:00.000+08:00,4,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
994a7547-a338-4da2-934b-a91849f9fbc7,2018-12-31T08:00:00.000+08:00,5,Adamis Pharma files U.S. marketing application for fast-dissolving sublingual tadalafil tablet for ED
15dd7893-9c7c-4c21-b24c-7c788355c16f,2018-12-31T08:00:00.000+08:00,2,"Centene finishes first, Coty last on S&P 500 for 2018"
9a2971df-70e8-4dbb-b976-965bc329daf0,2018-12-31T08:00:00.000+08:00,4,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
654922a2-2a62-40d9-9b77-7fd18f99c0f4,2018-12-31T08:00:00.000+08:00,1,Adamis Pharma files U.S. marketing application for fast-dissolving sublingual tadalafil tablet for ED
d67daa15-0a3d-4363-a399-43def463a858,2018-12-29T08:00:00.000+08:00,1,Week In Review: Shanghai Industrial To Start $7.3 Billion Biomedical Fund In 2019
22841d19-5659-40ce-af8e-8350b09b089d,2018-12-29T08:00:00.000+08:00,1,Week In Review: Shanghai Industrial To Start $7.3 Billion Biomedical Fund In 2019
12b3278f-f708-4334-a0be-95d5442ed28f,2018-12-27T08:00:00.000+08:00,4,Lilly Announces China's NMPA Approves Innovent's Anti-PD-1 Antibody Tyvyt for Hodgkin's Lymphoma
52711cbc-27b7-4b4b-b743-b4debd9e13b0,2018-12-27T08:00:00.000+08:00,3,Teva Stock Rises on Patent Settlement With Neos Therapeutics
2fe25056-4852-4e0a-8f93-dfc7d5188770,2018-12-27T08:00:00.000+08:00,3,"Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019"
18a3c29b-a4f3-40d5-85fd-6e77df2d2527,2018-12-27T08:00:00.000+08:00,4,Lilly Announces China's NMPA Approves Innovent's Anti-PD-1 Antibody Tyvyt for Hodgkin's Lymphoma
8421c176-adde-4a73-865e-de45f1a5fa34,2018-12-27T08:00:00.000+08:00,3,Teva Stock Rises on Patent Settlement With Neos Therapeutics
6c102765-0e29-48d4-bccc-4b54bdbf7e6e,2018-12-27T08:00:00.000+08:00,2,"Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019"
86998108-5d1f-4d87-b98f-86220c79a2aa,2018-12-26T08:00:00.000+08:00,1,Bayer (BAYRY) Faces Generic Threat & Rising Competition
723ad7f1-edae-43df-bf68-3bc432d76dfd,2018-12-26T08:00:00.000+08:00,1,Bayer (BAYRY) Faces Generic Threat & Rising Competition
f954cdfa-f93d-4566-b0a3-96eb7e68d726,2018-12-24T08:00:00.000+08:00,4,"Dividend Increases: December 17-21, 2018"
b9613350-c454-407d-a1bc-8d15f5293b38,2018-12-24T08:00:00.000+08:00,4,"Dividend Increases: December 17-21, 2018"
981126e2-42e3-4889-aae8-b81dda738bc5,2018-12-21T08:00:00.000+08:00,5,Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study
d928da87-4514-4ad7-a4f0-6a532eae484b,2018-12-21T08:00:00.000+08:00,5,Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study
defe8a16-2474-48b9-b543-7acf8d04f653,2018-12-20T08:00:00.000+08:00,2,Dicerna Pharma 13D Filing From Eli Lilly Shows New 8.6% Stake
e97f86bc-0883-482c-ae8b-aa73615dada2,2018-12-20T08:00:00.000+08:00,4,Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company
cc8c6734-3a7c-4fcf-99b8-0e1f861196f2,2018-12-20T08:00:00.000+08:00,4,"Lilly's Shares Rise on Robust 2019 View, Dividend Hike"
04ca3cb5-5160-412f-b164-5bfa625686d7,2018-12-20T08:00:00.000+08:00,2,"Allergan Drops, Stops Textured Breast Implant Sales in Europe"
b4784a5b-3961-404d-8b55-570259f94731,2018-12-20T08:00:00.000+08:00,3,"The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab"
253d5b48-a069-4aa5-9210-3809a4f0ab48,2018-12-20T08:00:00.000+08:00,3,Dicerna Pharma 13D Filing From Eli Lilly Shows New 8.6% Stake
53977d8f-7c22-458a-b0b0-6087048f1a85,2018-12-20T08:00:00.000+08:00,4,Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company
b941cdff-531c-49a9-a9d5-309bbb11f59d,2018-12-20T08:00:00.000+08:00,5,"Lilly's Shares Rise on Robust 2019 View, Dividend Hike"
d58bf2da-fcf5-4841-9770-85c606657134,2018-12-20T08:00:00.000+08:00,2,"Allergan Drops, Stops Textured Breast Implant Sales in Europe"
6111f36b-95c0-4321-84db-267b92e10db2,2018-12-20T08:00:00.000+08:00,4,"The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab"
1202a6b1-9bf3-4d0f-8a19-b393891c876b,2018-12-19T08:00:00.000+08:00,3,Eli Lilly shares are trading up after the company reaffirmed strong guidance for FY18 and FY19 and raised its quarterly dividend.
11a35414-a9db-477a-bc66-43d636303611,2018-12-19T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas"
05ffb650-89dc-4555-b1eb-23cca15abdaa,2018-12-19T08:00:00.000+08:00,1,Eli Lilly Reaffirms FY18 Sales Guidance $24.3B-$24.5B vs $24.43B Estimate
dade4611-2ca9-4226-93d3-a781ffd55d8c,2018-12-19T08:00:00.000+08:00,4,Eli Lilly Sees FY19 Sales $25.3B-$25.8B vs $24.77B Estimate
2c875eca-10b8-4d0e-9e6d-998a167c8c1b,2018-12-19T08:00:00.000+08:00,3,Eli Lilly Reaffirms FY18 Adj. EPS Guidance $5.55-$5.60 vs $5.58 Estimate
cd6b36b6-7764-4b54-a6e9-bafef640651a,2018-12-19T08:00:00.000+08:00,4,Eli Lilly Sees FY19 Adj. EPS $5.90-$6 vs $5.82 Estimate
5cb3bcc8-dacc-43f1-b694-872eb3f9e231,2018-12-19T08:00:00.000+08:00,5,Eli Lilly Raises Qtr. Dividend From $0.5625 To $0.645/Share
4ca7a432-388e-4022-a932-a3dfe8ac29db,2018-12-19T08:00:00.000+08:00,5,Eli Lilly shares are trading up after the company reaffirmed strong guidance for FY18 and FY19 and raised its quarterly dividend.
7b1d1ffb-fbb1-40a4-ab71-ea89382388e4,2018-12-19T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas"
d45f5b68-ef6c-45d8-9c45-0fa74038a2c6,2018-12-19T08:00:00.000+08:00,2,Eli Lilly Reaffirms FY18 Sales Guidance $24.3B-$24.5B vs $24.43B Estimate
e68f6f15-bdb0-48ee-9dfc-951d66342aa1,2018-12-19T08:00:00.000+08:00,4,Eli Lilly Sees FY19 Sales $25.3B-$25.8B vs $24.77B Estimate
e1599785-dde4-4c81-8fed-4c18a27624b0,2018-12-19T08:00:00.000+08:00,4,Eli Lilly Reaffirms FY18 Adj. EPS Guidance $5.55-$5.60 vs $5.58 Estimate
292da3ba-ab1e-480a-84fc-7d4b6b17aca8,2018-12-19T08:00:00.000+08:00,4,Eli Lilly Sees FY19 Adj. EPS $5.90-$6 vs $5.82 Estimate
2a026901-7ee2-4f7b-aaf3-ce38a0c58a88,2018-12-19T08:00:00.000+08:00,5,Eli Lilly Raises Qtr. Dividend From $0.5625 To $0.645/Share
c171b9e8-d52f-4288-bbd2-ae91c4266d59,2018-12-18T08:00:00.000+08:00,4,"UPDATE: Aduro Will Be Eligible For Development, Commercial Milestones Up To ~$620M/Product"
44afec4d-c3b9-4c97-8211-e0aced19bb1d,2018-12-18T08:00:00.000+08:00,3,UPDATE: Aduro To Receive Upfront Payment Of $12M
4ab5a93b-a629-41ea-9111-19fe89b456f4,2018-12-18T08:00:00.000+08:00,4,"Eli Lilly, Aduro Biotech Report Research Collaboration, Exclusive License Deal For Aduro's cGAS-STRING Pathway Inhibitor Program"
4bd8d2f7-0609-42cd-8285-21e6adbdf2f8,2018-12-18T08:00:00.000+08:00,5,Lilly Highlights Publication Of Analysis Showing Benefit Of The Addition Of Verzenio In Certain Breast Cancer Patients
ec92256f-1f67-44ff-b0b6-880789763c60,2018-12-18T08:00:00.000+08:00,4,"UPDATE: Aduro Will Be Eligible For Development, Commercial Milestones Up To ~$620M/Product"
eceb6c3a-f4f4-4784-91b1-89c37f6b45cd,2018-12-18T08:00:00.000+08:00,3,UPDATE: Aduro To Receive Upfront Payment Of $12M
503d6c99-d1d4-44c3-8de6-d6ace4b680fb,2018-12-18T08:00:00.000+08:00,5,"Eli Lilly, Aduro Biotech Report Research Collaboration, Exclusive License Deal For Aduro's cGAS-STRING Pathway Inhibitor Program"
41cf11bb-8937-4df9-ab9a-b749da4994b7,2018-12-18T08:00:00.000+08:00,4,Lilly Highlights Publication Of Analysis Showing Benefit Of The Addition Of Verzenio In Certain Breast Cancer Patients
1b9d20d6-8f6b-408f-9b95-7cc5fefc699e,2018-12-17T08:00:00.000+08:00,1,Health insurers and healthcare providers are trading down today after a Texas court ruled that ObamaCare was unconstitutional.
48f1cb61-87cd-40f4-b3dd-39e8b284d517,2018-12-17T08:00:00.000+08:00,4,"Eli Lilly Says Taltz, in a Superiority Study Vs AbbVie's Humira, in Patients with Active Psoriatic Arthritis Met All Primary and Major Secondary Endpoints"
c59c0155-5c34-4d26-95ed-39b4f1babda8,2018-12-17T08:00:00.000+08:00,2,Health insurers and healthcare providers are trading down today after a Texas court ruled that ObamaCare was unconstitutional.
05d9e436-415c-4706-8857-b2b08738cbd0,2018-12-17T08:00:00.000+08:00,3,"Eli Lilly Says Taltz, in a Superiority Study Vs AbbVie's Humira, in Patients with Active Psoriatic Arthritis Met All Primary and Major Secondary Endpoints"
3be25f2b-57af-4a01-b43f-d78db28fa920,2018-12-14T08:00:00.000+08:00,4,"Eli Lilly Reports Purchase Of Pre-Clinical Pain Program From Hydra Biosciences, No Terms Disclosed"
4e4a0863-1fd5-48f1-aaec-b44a36731464,2018-12-14T08:00:00.000+08:00,5,Eli Lilly Reports Expansion Of Collaboration With Evidation Health For Andromeda Data Platform
a0047d1b-7218-4428-9305-bdabf6641279,2018-12-14T08:00:00.000+08:00,3,"Eli Lilly Reports Purchase Of Pre-Clinical Pain Program From Hydra Biosciences, No Terms Disclosed"
f3af6867-4d2e-4668-9f79-b31d7c1e94e0,2018-12-14T08:00:00.000+08:00,4,Eli Lilly Reports Expansion Of Collaboration With Evidation Health For Andromeda Data Platform
b5337c44-b0b2-44a4-bc94-1bb5e749574c,2018-12-13T08:00:00.000+08:00,3,"A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Jobless Claims, Import Prices Data"
d98450c3-1315-4f80-b310-45e7693ef93d,2018-12-13T08:00:00.000+08:00,5,Eli Lilly Reports Fast Track Designation To Baricitinib Development Program For Treatment Of Systemic Lupus Erythematosus
19e0a159-2b6f-44df-92c9-fcb5aae06757,2018-12-13T08:00:00.000+08:00,4,"Eli Lilly Announces Co. Boehringer Ingelheim Partner With Duke Clinical Research Institute To Advance Multidisciplinary Care For People With Type-2 Diabetes, Cardiovascular Disease"
c0e4e8b7-3dc8-480b-9dcf-0fab3559ecf6,2018-12-13T08:00:00.000+08:00,4,"A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Jobless Claims, Import Prices Data"
47685cc2-4883-4b51-8e73-d0d4c21cc86a,2018-12-13T08:00:00.000+08:00,5,Eli Lilly Reports Fast Track Designation To Baricitinib Development Program For Treatment Of Systemic Lupus Erythematosus
c6926a13-3af7-42fe-81e4-25f915365767,2018-12-13T08:00:00.000+08:00,3,"Eli Lilly Announces Co. Boehringer Ingelheim Partner With Duke Clinical Research Institute To Advance Multidisciplinary Care For People With Type-2 Diabetes, Cardiovascular Disease"
d3c7c2c5-ea8a-45c4-9631-e9130c7a42f4,2018-12-12T08:00:00.000+08:00,4,Lilly And AC Immune Announce License And Collaboration Agreement To Focus On Potential Alzheimers Treatment; AC Immune To Receive CHF80M Upfront And IS Eligible For Additional Milestones While Lilly Will Purchase A $50M Note Convertible Equity Position
5cd92727-d5f7-4522-9064-a4bce3564dcf,2018-12-12T08:00:00.000+08:00,5,Lilly And AC Immune Announce License And Collaboration Agreement To Focus On Potential Alzheimers Treatment; AC Immune To Receive CHF80M Upfront And IS Eligible For Additional Milestones While Lilly Will Purchase A $50M Note Convertible Equity Position
015f8911-eeff-4aaf-b603-65fd2848c65a,2018-12-07T08:00:00.000+08:00,1,"Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week"
85eddf68-6cab-404f-91c4-dadd6eb8b7a7,2018-12-07T08:00:00.000+08:00,1,"Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week"
26018cc6-2ad2-476a-ac03-5400a6cfcd96,2018-12-06T08:00:00.000+08:00,2,"The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering"
7911f8e2-7b31-41e6-99dd-9ac8c7f61f42,2018-12-06T08:00:00.000+08:00,3,"The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering"
d670356c-b773-4973-a58a-2a2c913412dc,2018-12-04T08:00:00.000+08:00,2,"Ahead Of Mid-Week Pause, Investors Fret Over Trade Pact Details"
ce091f73-f05c-44bb-8606-d61318a3c5f6,2018-12-04T08:00:00.000+08:00,2,"Ahead Of Mid-Week Pause, Investors Fret Over Trade Pact Details"
1e29996f-f2fc-4aaa-a945-79c1366722dc,2018-11-30T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 29, 2018"
f8defce9-0dbc-403b-b984-f63f00055236,2018-11-30T08:00:00.000+08:00,4,"The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings"
ddb00db5-8ce6-47d6-9aa4-566e6b56b97b,2018-11-30T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 29, 2018"
ebefbc2a-53d2-451a-b151-51b0a96c6dac,2018-11-30T08:00:00.000+08:00,4,"The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings"
89710c1f-b273-4c54-ae05-7a2f45a2bf25,2018-11-29T08:00:00.000+08:00,4,Eli Lilly Highlights Will Present Data For Verzenio At San Antonio Breast Cancer Symposium Dec. 4-8
114eaa91-73e8-4121-9ec2-a6ec7c5f4bea,2018-11-29T08:00:00.000+08:00,4,Eli Lilly Highlights Will Present Data For Verzenio At San Antonio Breast Cancer Symposium Dec. 4-8
55e41323-ff31-42b0-8132-50ad0767bc60,2018-11-26T08:00:00.000+08:00,5,Expert Consensus Decision Pathway Issued By American College Of Cardiology Recommended Lilly's Jardiance As Preferred SGLT2 Inhibitor For Adults With Type 2 Diabetes And Established Cardiovascular Disease
182ba401-834d-44e0-ab7a-0a436ddc213a,2018-11-26T08:00:00.000+08:00,3,"Data Dive, Trade Talks And Powell: Busy Post-Holiday Week On The Way"
85ceb07c-84d5-4329-8d2c-00049f32a225,2018-11-26T08:00:00.000+08:00,2,"Benzinga's Top Upgrades, Downgrades For November 26, 2018"
07545d40-03c3-4bad-8ef9-49de8e635910,2018-11-26T08:00:00.000+08:00,4,"A Peek Into The Markets: US Stock Futures Surge, Dow Futures Up Over 250 Points"
50a6db4c-4617-4ed6-b52c-206736d1e104,2018-11-26T08:00:00.000+08:00,3,Citigroup Downgrades Eli Lilly to Neutral
55daff71-ca2d-4c92-b961-60e5dfbd1da9,2018-11-26T08:00:00.000+08:00,5,Expert Consensus Decision Pathway Issued By American College Of Cardiology Recommended Lilly's Jardiance As Preferred SGLT2 Inhibitor For Adults With Type 2 Diabetes And Established Cardiovascular Disease
93548422-e346-41e9-b4b8-2a7f566e400c,2018-11-26T08:00:00.000+08:00,2,"Data Dive, Trade Talks And Powell: Busy Post-Holiday Week On The Way"
6825940c-f536-4b67-9e9b-6cf8119ab300,2018-11-26T08:00:00.000+08:00,1,"Benzinga's Top Upgrades, Downgrades For November 26, 2018"
6fab8ee7-ce8a-4dad-b7dd-d8201750d7e1,2018-11-26T08:00:00.000+08:00,4,"A Peek Into The Markets: US Stock Futures Surge, Dow Futures Up Over 250 Points"
345a1197-cdc3-4346-b31e-1f1a6e1dd4e7,2018-11-26T08:00:00.000+08:00,2,Citigroup Downgrades Eli Lilly to Neutral
f8ad190d-8172-4c41-8680-baac2f49100a,2018-11-16T08:00:00.000+08:00,3,"'Eli Lilly Considers Sale of China Assets to Raise Cash' -Bloomberg, Citing Sources"
1ac2fb91-6ee1-4e48-ab68-dc736553b60c,2018-11-16T08:00:00.000+08:00,5,"'Eli Lilly Considers Sale of China Assets to Raise Cash' -Bloomberg, Citing Sources"
2743b4ee-7e4c-4d05-bdad-9e2ff3c33542,2018-11-14T08:00:00.000+08:00,5,"Eli Lilly Reports Submission Of New Drug Application For Lasmiditan For Acute Treatment Of Migraine, Receives Breakthrough Designation For Emgality For Preventation Of Episodic Cluster Headache"
6a3fcc1c-eb3e-4b68-b87c-31734a3681d5,2018-11-14T08:00:00.000+08:00,4,"Eli Lilly Reports Submission Of New Drug Application For Lasmiditan For Acute Treatment Of Migraine, Receives Breakthrough Designation For Emgality For Preventation Of Episodic Cluster Headache"
c60d03f3-9a2c-4451-9d41-76e85fda35a3,2018-11-06T08:00:00.000+08:00,2,Long Wait Is Over: Election Day Dawns With Markets Under Light Pressure
b06d7b01-87f2-424e-9b12-0f9b69138181,2018-11-06T08:00:00.000+08:00,3,A Peek Into The Markets: US Stock Futures Drop Ahead Of Earnings
bccf1e1a-2e6f-413f-8cff-118a7d4f2b71,2018-11-06T08:00:00.000+08:00,4,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering"
d90a5e28-6dfa-47d8-a24f-fbe370b132b8,2018-11-06T08:00:00.000+08:00,5,UPDATE: Eli Lilly Raises FY18 Adj. EPS Guidance From $5.40-$5.50 To $5.55-$5.60 vs $5.48 Estimate
9727b2a8-023f-44ab-bc0a-16e8c82e02fc,2018-11-06T08:00:00.000+08:00,4,"Eli Lilly Q3 EPS $1.39 Beats $1.36 Estimate, Sales $6.062B Beat $6.02B Estimate; Raises Guidance"
329de12c-fa73-4e21-bc01-afd30f8312ce,2018-11-06T08:00:00.000+08:00,2,"10 Stocks To Watch For November 6, 2018"
4444965a-ae30-4252-8883-67b0263547a3,2018-11-06T08:00:00.000+08:00,3,"Earnings Scheduled For November 6, 2018"
93dcc7f5-6dde-4024-80a5-6c75db0d5860,2018-11-06T08:00:00.000+08:00,1,Long Wait Is Over: Election Day Dawns With Markets Under Light Pressure
9ce50fc0-a561-4032-b1be-8fcf1c75c326,2018-11-06T08:00:00.000+08:00,2,A Peek Into The Markets: US Stock Futures Drop Ahead Of Earnings
bcdc3c61-021a-49a0-9b85-3111234d21e3,2018-11-06T08:00:00.000+08:00,4,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering"
e1e8f9cd-5ae9-42cc-bb89-8c1001cabbea,2018-11-06T08:00:00.000+08:00,5,UPDATE: Eli Lilly Raises FY18 Adj. EPS Guidance From $5.40-$5.50 To $5.55-$5.60 vs $5.48 Estimate
94244b6f-0e26-4c92-a6e7-5cd8285a6cb3,2018-11-06T08:00:00.000+08:00,3,"Eli Lilly Q3 EPS $1.39 Beats $1.36 Estimate, Sales $6.062B Beat $6.02B Estimate; Raises Guidance"
8a2ee7b8-12e7-42e5-8811-148f34ecfe04,2018-11-06T08:00:00.000+08:00,2,"10 Stocks To Watch For November 6, 2018"
6e7d23e0-e30c-4fe5-885f-0ebb1adc9946,2018-11-06T08:00:00.000+08:00,1,"Earnings Scheduled For November 6, 2018"
62cfe535-3edd-4317-ae06-b44429181e71,2018-11-05T08:00:00.000+08:00,4,"Eli Lilly, NextCure Report Collaboration To Discover, Develop Novel Immuno-Oncology Medicines; NextCure To Receive Upfront Payment Of $25M, Lilly Has Made $15M Equity Investment In NextCure"
87261bc6-7c21-44fa-a01e-f8f8595b4652,2018-11-05T08:00:00.000+08:00,5,Eli Lilly shares are trading up 3.8% after the company reported positive early results from a study of jardiance; The company also reported its trulicity demonstrated a 'superior' reduction of cardiovascular events in type 2 diabetes patients.
c966d4c4-e000-4ee8-adfb-a0ba50a02cf9,2018-11-05T08:00:00.000+08:00,3,Eli Lilly Gets Ready For First Report Post-Elanco IPO
d2acaed1-21d2-404e-aeed-3909f5e66b68,2018-11-05T08:00:00.000+08:00,4,Eli Lilly Says Trulicity Demonstrates a Superior Reduction of Cardiovascular Events for People with Type 2 Diabetes
a50138b7-035f-4152-b91e-46d8f0878d89,2018-11-05T08:00:00.000+08:00,1,Rally Fizzles As Apple's Guidance Seen Weak; Mixed Signals On China Keep Market Buzzing
618efa1a-afcb-4d94-a49e-1ec508e0d8fd,2018-11-05T08:00:00.000+08:00,5,Eli Lilly Announces Positive Early Results From a Study of the First 5 Years of Jardiance Use
03a3fb9d-b6b8-4131-af8e-ad9be0be4579,2018-11-05T08:00:00.000+08:00,4,"Eli Lilly, NextCure Report Collaboration To Discover, Develop Novel Immuno-Oncology Medicines; NextCure To Receive Upfront Payment Of $25M, Lilly Has Made $15M Equity Investment In NextCure"
59aecc5b-9d70-4755-94aa-6ed47263ca8f,2018-11-05T08:00:00.000+08:00,3,Eli Lilly shares are trading up 3.8% after the company reported positive early results from a study of jardiance; The company also reported its trulicity demonstrated a 'superior' reduction of cardiovascular events in type 2 diabetes patients.
e2674f5e-60dd-48f5-bd54-9c90539e326c,2018-11-05T08:00:00.000+08:00,4,Eli Lilly Gets Ready For First Report Post-Elanco IPO
9c4f2305-1788-4446-9252-a7585f473887,2018-11-05T08:00:00.000+08:00,5,Eli Lilly Says Trulicity Demonstrates a Superior Reduction of Cardiovascular Events for People with Type 2 Diabetes
3f45ce1a-05da-40eb-b717-5a84dd06db7a,2018-11-05T08:00:00.000+08:00,2,Rally Fizzles As Apple's Guidance Seen Weak; Mixed Signals On China Keep Market Buzzing
f177885a-4270-4a7a-9944-3e8ff3d1661a,2018-11-05T08:00:00.000+08:00,4,Eli Lilly Announces Positive Early Results From a Study of the First 5 Years of Jardiance Use
95af5be1-48ae-42e5-a42c-55528c371846,2018-11-04T08:00:00.000+08:00,3,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs"
9549c7ea-8e4c-49b6-9060-0c2381b50026,2018-11-04T08:00:00.000+08:00,3,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs"
7a5f3d3c-2e92-4de3-b897-e26fdd35fa84,2018-11-01T08:00:00.000+08:00,5,SIGA Technologies Reports Sale of Medical Countermeasures Priority Review Voucher to Eli Lilly for $80M
bc667f9f-10c1-4fc4-a2f9-e2c0817ff2c5,2018-11-01T08:00:00.000+08:00,2,SIGA Technologies Reports Sale of Medical Countermeasures Priority Review Voucher to Eli Lilly for $80M
2c26f4da-65ef-4f0f-97cc-0b8dac6bacc9,2018-10-31T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For October 31, 2018"
96c974df-02d8-4225-b9d4-6ac4e76d2e57,2018-10-31T08:00:00.000+08:00,3,Credit Suisse Upgrades Eli Lilly to Neutral
6a653245-a560-4fb6-8a6e-b01864674050,2018-10-31T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For October 31, 2018"
5c32813f-cd0f-4ad1-937d-311a06437c71,2018-10-31T08:00:00.000+08:00,3,Credit Suisse Upgrades Eli Lilly to Neutral
d4dd4e6d-6668-4eb2-bb74-e93a0ed5be98,2018-10-30T08:00:00.000+08:00,4,"Eli Lilly, Lowe's, Macy's, XLU: 'Fast Money' Picks For October 30"
8c49c184-ed33-4ddf-b0a7-3ffe1a1e3b3d,2018-10-30T08:00:00.000+08:00,4,"Eli Lilly, Lowe's, Macy's, XLU: 'Fast Money' Picks For October 30"
6c23a819-c0ba-4104-b4c2-33da722646f6,2018-10-29T08:00:00.000+08:00,5,"Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal"
f67f52bb-31e5-4697-86d8-3f0b79b4be5f,2018-10-29T08:00:00.000+08:00,4,"Dicerna Pharma Announces Licensing and Research Collaboration with Eli Lilly for Development and Commercialization of New Medicines in Cardio-Metabolic Disease, Neurodegeneration and Pain"
4fa3b902-2a6c-45cb-b986-d4781a50099d,2018-10-29T08:00:00.000+08:00,5,"Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal"
a70f39dd-4469-45eb-9960-695972ad87de,2018-10-29T08:00:00.000+08:00,4,"Dicerna Pharma Announces Licensing and Research Collaboration with Eli Lilly for Development and Commercialization of New Medicines in Cardio-Metabolic Disease, Neurodegeneration and Pain"
e95eedf9-5151-4a95-83a3-b42e06d9d677,2018-10-24T08:00:00.000+08:00,1,"Benzinga's Top Upgrades, Downgrades For October 24, 2018"
87a1991f-a6f7-422d-9e85-18c7fc5b6e80,2018-10-24T08:00:00.000+08:00,2,"Wolfe Research Initiates Coverage On Eli Lilly with Peer Perform Rating, Announces $119 Price Target"
938c2033-e450-403d-9720-67bb73336166,2018-10-24T08:00:00.000+08:00,4,"Pfizer, Lilly Announce Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients"
b7f13a47-3b80-4a12-83d0-ca5f0794b848,2018-10-24T08:00:00.000+08:00,1,"Benzinga's Top Upgrades, Downgrades For October 24, 2018"
1b77f627-1e20-449f-ac34-5681215a1353,2018-10-24T08:00:00.000+08:00,4,"Wolfe Research Initiates Coverage On Eli Lilly with Peer Perform Rating, Announces $119 Price Target"
acac7de3-eb86-48cb-b4fd-96d3a68f6784,2018-10-24T08:00:00.000+08:00,5,"Pfizer, Lilly Announce Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients"
2c93f947-a707-441e-bff1-3fb5811371aa,2018-10-23T08:00:00.000+08:00,3,"Earnings Scheduled For October 23, 2018"
1d9825ac-7049-4f78-9082-a1649e9a6336,2018-10-23T08:00:00.000+08:00,4,"Earnings Scheduled For October 23, 2018"
aecf17b6-1096-45d6-a79c-e5b4c21d98b9,2018-10-22T08:00:00.000+08:00,5,Eli Lilly Reports Results For 2 Phase 3 Studies Of Taltz In Ankylosing Spondylitis: 'COAST-V is the first successful AS trial to use ASAS40 as the primary endpoint'
24941bd8-2601-4c30-aac1-7912a3dd694b,2018-10-22T08:00:00.000+08:00,4,A Preview Of Eli Lilly's Q3 Earnings
8741987b-5235-48a5-b400-e7d28d974e24,2018-10-22T08:00:00.000+08:00,5,Eli Lilly Reports Results For 2 Phase 3 Studies Of Taltz In Ankylosing Spondylitis: 'COAST-V is the first successful AS trial to use ASAS40 as the primary endpoint'
3d542524-871d-4a4d-a03f-922dc2a4e134,2018-10-22T08:00:00.000+08:00,3,A Preview Of Eli Lilly's Q3 Earnings
8c023864-8817-4d37-8db3-cf438d727fb8,2018-10-16T08:00:00.000+08:00,2,"Sanofi, Novo Nordisk, Lilly Shares Unaffected Amid Report State Of Minnesota Filed Suit Accusing Insulin Manufacturers Of Deceptive Drug Pricing Practices"
bd1c6db5-2dd6-4d26-9055-47515f1a048f,2018-10-16T08:00:00.000+08:00,1,"Sanofi, Novo Nordisk, Lilly Shares Unaffected Amid Report State Of Minnesota Filed Suit Accusing Insulin Manufacturers Of Deceptive Drug Pricing Practices"
06580ff0-2009-4c39-8788-2cee27cc3a8b,2018-10-14T08:00:00.000+08:00,2,4 Major Market Opportunities For The Cannabis Industry
3d9c4849-d322-4f2a-a6db-31e4e19aeb6f,2018-10-14T08:00:00.000+08:00,3,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs"
ce8c1caa-8d0f-4d67-83e3-7253f3f7540a,2018-10-14T08:00:00.000+08:00,2,4 Major Market Opportunities For The Cannabis Industry
a418a4d2-d902-496e-b9ea-346b59ea0de1,2018-10-14T08:00:00.000+08:00,4,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs"
76323d7c-4ed6-4cfd-b7af-05032e49f250,2018-10-12T08:00:00.000+08:00,5,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $120"
fc25e814-2915-41b6-8d99-5374dcdaf99b,2018-10-12T08:00:00.000+08:00,4,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $120"
3d9744b8-8bcf-4166-8d62-5213934be349,2018-10-10T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares"
0115d685-da6d-44f0-8d39-bf78f3076ca2,2018-10-10T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares"
25c4f36a-3fa8-492f-a703-30fe3de70dff,2018-10-09T08:00:00.000+08:00,2,FDA Commissioner Scott Gottlieb Issues Statement On 'new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines'
36702149-5440-45f6-b9d7-8d02422c9072,2018-10-09T08:00:00.000+08:00,1,"The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial"
2c3b32ce-b10a-42d2-8be3-067526598753,2018-10-09T08:00:00.000+08:00,2,FDA Commissioner Scott Gottlieb Issues Statement On 'new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines'
0531c375-5710-4263-8f0d-566238db6650,2018-10-09T08:00:00.000+08:00,1,"The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial"
621ae91f-d32b-4c01-9dbc-8af152862b47,2018-10-08T08:00:00.000+08:00,3,"Stocks That Made New 52-Week Highs So Far Today Include: Ameren, Pfizer, Eli Lilly, Envision Healthcare, AES, McCormick, Archer-Daniels Midland, and Ball Corp."
15066c8d-9e3a-4e86-94d7-234b71ed7dbe,2018-10-08T08:00:00.000+08:00,4,"Stocks That Made New 52-Week Highs So Far Today Include: Ameren, Pfizer, Eli Lilly, Envision Healthcare, AES, McCormick, Archer-Daniels Midland, and Ball Corp."
870d45a4-e991-43c8-9084-0ffb4ee73058,2018-10-05T08:00:00.000+08:00,3,3 Screens That Hint At Which Stocks May Outperform In Q4
a9933683-0b4f-4e9f-ad51-7f7b1722b63b,2018-10-05T08:00:00.000+08:00,4,10 Biggest Price Target Changes For Friday
419a82c5-cf65-46e6-91bf-fd775ab67512,2018-10-05T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For October 5, 2018"
59294fc2-c18f-4e09-9030-a8babfd9de75,2018-10-05T08:00:00.000+08:00,2,"Stocks Which Set New 52-Week High Yesterday, October 4th"
fdcb3347-c12c-45db-93b1-ebcb175c35b3,2018-10-05T08:00:00.000+08:00,5,"The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker"
423960ff-2120-4a60-b138-129896d1f291,2018-10-05T08:00:00.000+08:00,1,"BMO Capital Upgrades Eli Lilly to Outperform, Raises Price Target to $130"
f0fe8a44-1542-40cf-955a-94a8e3980f6e,2018-10-05T08:00:00.000+08:00,2,3 Screens That Hint At Which Stocks May Outperform In Q4
1092c4cd-9c95-46a3-a48c-fd2cf9ad7299,2018-10-05T08:00:00.000+08:00,1,10 Biggest Price Target Changes For Friday
01fe079c-8289-44b8-83d6-0354ad0472bf,2018-10-05T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For October 5, 2018"
6a29e51c-8683-427e-8208-198d7a02351b,2018-10-05T08:00:00.000+08:00,4,"Stocks Which Set New 52-Week High Yesterday, October 4th"
33cd533a-89d2-43a3-9929-7bbedde98f1c,2018-10-05T08:00:00.000+08:00,5,"The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker"
cdb615bc-a5a7-4804-afb7-ebd503076583,2018-10-05T08:00:00.000+08:00,4,"BMO Capital Upgrades Eli Lilly to Outperform, Raises Price Target to $130"
42c5bf64-d598-4399-a6d8-cb8ec84adcf7,2018-10-04T08:00:00.000+08:00,5,"Stocks That Made New 52-Week Highs So Far Today Include: Ball Corp, CF Industries, Jacobs Engineering, Mosaic, CME Group, and Eli Lilly"
901227be-ace4-4831-b5e7-f7a3faf00053,2018-10-04T08:00:00.000+08:00,3,Eli Lilly shares are up 2.8% to $111.68 after the company earlier reported its empagliflozin in a Phase III trial met its primary efficacy endpoint.
2857d03d-e3e6-4c8f-b541-aa1838803b1e,2018-10-04T08:00:00.000+08:00,4,"Stocks Which Set New 52-Week High Yesterday, October 3rd"
bf221702-fa2f-46ff-a6b5-449327e82622,2018-10-04T08:00:00.000+08:00,2,"The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut"
6843596e-7928-41c3-bebf-78a34d4eb28c,2018-10-04T08:00:00.000+08:00,4,"Boehringer Ingelheim, Eli Lilly Report Empagliflozin In Phase III Trial Met Primary Efficacy Endpoint"
1a84e7d9-4b5e-4902-84dd-51333968eebf,2018-10-04T08:00:00.000+08:00,4,"Eli Lilly Reports Investigational Dual GIP, GLP-1 Receptor Agonist Showed Reduction In HbA1c, Body Weight In People With Type 2 Diabetes"
0a6bd8a5-cef4-48fc-813f-a8c1102c7509,2018-10-04T08:00:00.000+08:00,3,"Stocks That Made New 52-Week Highs So Far Today Include: Ball Corp, CF Industries, Jacobs Engineering, Mosaic, CME Group, and Eli Lilly"
f2e6f235-3292-4b9e-9de1-a0cda2bd0902,2018-10-04T08:00:00.000+08:00,5,Eli Lilly shares are up 2.8% to $111.68 after the company earlier reported its empagliflozin in a Phase III trial met its primary efficacy endpoint.
1dee8b88-bdd2-4a57-8c62-4da22b99df4b,2018-10-04T08:00:00.000+08:00,2,"Stocks Which Set New 52-Week High Yesterday, October 3rd"
a3d9415b-8994-4963-9f07-803df5d26bb2,2018-10-04T08:00:00.000+08:00,4,"The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut"
e72d98fc-41c4-4f82-9fa8-965004b7fe16,2018-10-04T08:00:00.000+08:00,5,"Boehringer Ingelheim, Eli Lilly Report Empagliflozin In Phase III Trial Met Primary Efficacy Endpoint"
e2297bf9-2c62-45d9-b669-934c144046e8,2018-10-04T08:00:00.000+08:00,3,"Eli Lilly Reports Investigational Dual GIP, GLP-1 Receptor Agonist Showed Reduction In HbA1c, Body Weight In People With Type 2 Diabetes"
bdfb2840-892c-42d1-8f01-7cc55908ab3c,2018-10-03T08:00:00.000+08:00,4,"Stocks Which Set New 52-Week High Yesterday, October 2nd"
6ee56d3a-022e-4771-b080-cafd9bf0b72b,2018-10-03T08:00:00.000+08:00,1,10 Biggest Price Target Changes For Wednesday
fe361209-54c0-45dd-9152-1a08bcdafe7f,2018-10-03T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares"
83954d9a-0580-4373-8f44-02bc6517f89c,2018-10-03T08:00:00.000+08:00,5,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $107"
1586d2f6-c514-4e9f-90b0-b864b75fa379,2018-10-03T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Yesterday, October 2nd"
3c3c1de9-ae07-4e19-957c-1549ccfb4a85,2018-10-03T08:00:00.000+08:00,2,10 Biggest Price Target Changes For Wednesday
889a65e1-d692-42ce-8efa-59d721ff605b,2018-10-03T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares"
dc2ec312-298e-4707-aa9f-25fc1bbd11de,2018-10-03T08:00:00.000+08:00,4,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $107"
ba940167-a4fd-42eb-95d5-88d1bcbf90cb,2018-10-02T08:00:00.000+08:00,5,Results From Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint In People With Type 1 And Type 2 Diabetes
29e2f5e9-8c59-4b67-892f-e7e3be01492c,2018-10-02T08:00:00.000+08:00,3,Results From Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint In People With Type 1 And Type 2 Diabetes
05d6a24e-5cc7-4067-b9a4-41e2be91b044,2018-10-01T08:00:00.000+08:00,4,Leerink: Improving Fundamentals Drive Teva Upgrade
c5687391-2492-472c-8557-c9e3ffb25154,2018-10-01T08:00:00.000+08:00,4,Leerink: Improving Fundamentals Drive Teva Upgrade
b434e340-1953-4d0e-acf5-0a004d4fb563,2018-09-28T08:00:00.000+08:00,4,"The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results"
cd70201b-82c4-4a2b-90d4-e3fcef056be4,2018-09-28T08:00:00.000+08:00,4,"The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results"
e43e1b68-8cb2-4405-a0b4-39263532ce9b,2018-09-27T08:00:00.000+08:00,5,Lilly's Emgality Receives FDA Approval for the Preventive Treatment of Migraine in Adults
cd342f22-f69f-4572-bdb3-50a97f70a041,2018-09-27T08:00:00.000+08:00,3,US Judge Has Dismissed Patent Suits By Teva Against Eli Lilly Related To Its Migraine Drug
8ffd4112-2f4d-4f7a-91e9-2ca68bc6e8b9,2018-09-27T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron"
5483c4c2-6c88-401f-bcfc-a3021fca8210,2018-09-27T08:00:00.000+08:00,4,Lilly's Emgality Receives FDA Approval for the Preventive Treatment of Migraine in Adults
1f84dccd-3814-4bea-8a3d-dc51b78d6d1f,2018-09-27T08:00:00.000+08:00,3,US Judge Has Dismissed Patent Suits By Teva Against Eli Lilly Related To Its Migraine Drug
82b90579-04a8-411d-9252-16be3d003ea5,2018-09-27T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron"
ac37a425-4d9c-4885-9dca-3f50bf0dd58e,2018-09-26T08:00:00.000+08:00,5,JPMorgan Resumes Coverage Of Eli Lilly: 'One Of The Best-Positioned Names In Our Group'
327f174a-7881-4c59-866d-7efa28d5402c,2018-09-26T08:00:00.000+08:00,5,"From Earlier, JP Morgan Reinstated Eli Lilly at Overweight, Announces $117 Price Target"
1157a0e1-0bd6-4b53-a219-ddb061b04ea9,2018-09-26T08:00:00.000+08:00,4,JPMorgan Resumes Coverage Of Eli Lilly: 'One Of The Best-Positioned Names In Our Group'
78ce7434-42ce-4305-9962-a6c6bed2b809,2018-09-26T08:00:00.000+08:00,5,"From Earlier, JP Morgan Reinstated Eli Lilly at Overweight, Announces $117 Price Target"
62941e78-7902-4901-ae80-5f93a3f53f6f,2018-09-21T08:00:00.000+08:00,3,Lilly Receives Positive CHMP Opinion for Emgality for the Prophylaxis of Migraine in Adults
58420b16-f327-4003-8ef5-40723f562f4d,2018-09-21T08:00:00.000+08:00,4,Lilly Receives Positive CHMP Opinion for Emgality for the Prophylaxis of Migraine in Adults
9a5823ac-1ec6-4cf8-a55b-6b4eb043f9b2,2018-09-20T08:00:00.000+08:00,2,Elanco Animal Health Shares Indicated $26 on 750K Shares; IPO Priced at $24/Share
46f1674b-61e6-4237-a337-75fd6d447e0a,2018-09-20T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut"
9ddf95e8-a529-4100-8d64-a1676dbd42ef,2018-09-20T08:00:00.000+08:00,3,Elanco Animal Health Prices $62.9M Share IPO @$24/Share
e5370d49-9904-43a3-8d48-cb04e3458e61,2018-09-20T08:00:00.000+08:00,3,Elanco Animal Health Shares Indicated $26 on 750K Shares; IPO Priced at $24/Share
6518da36-1333-4bde-838d-6956fefe8874,2018-09-20T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut"
d8094eea-90ed-4dc9-868d-5200481b7b9c,2018-09-20T08:00:00.000+08:00,5,Elanco Animal Health Prices $62.9M Share IPO @$24/Share
c28bafd5-f7b9-4273-902b-c979f1a4099b,2018-09-19T08:00:00.000+08:00,4,"Eli Lilly And Company Subsidiary, Elanco, Prices IPO Of 62.9M Shares At $24/Share; Shares Expected To Open For Trade Thursday On NYSE Under Symbol 'ELAn'"
51bb9da8-e5e7-47db-9d63-2aefd75a7c2e,2018-09-19T08:00:00.000+08:00,4,"Eli Lilly And Company Subsidiary, Elanco, Prices IPO Of 62.9M Shares At $24/Share; Shares Expected To Open For Trade Thursday On NYSE Under Symbol 'ELAn'"
dc287f4e-5157-47dc-a438-7af271d850f9,2018-09-18T08:00:00.000+08:00,3,10 Biggest Price Target Changes For Tuesday
acf5e58e-61f8-47a6-ae98-30f2b16aee22,2018-09-18T08:00:00.000+08:00,5,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $112"
79e52bcb-0b61-4281-991f-69301f5691cf,2018-09-18T08:00:00.000+08:00,4,10 Biggest Price Target Changes For Tuesday
50bda519-8e30-4e5a-bb16-ba37eb72e6c3,2018-09-18T08:00:00.000+08:00,4,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $112"
3cf36339-3f03-4361-841f-8b6819d61940,2018-09-17T08:00:00.000+08:00,2,"Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug"
a71ca18c-a0d4-4593-8f9a-bf38aa2421b4,2018-09-17T08:00:00.000+08:00,3,Teva's Preventive Migraine Treatment Approved By FDA
f7a82b74-f927-4eb7-aaa1-8417371f9671,2018-09-17T08:00:00.000+08:00,2,"Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug"
165125b5-d29b-4cbf-baf4-e50fb85af741,2018-09-17T08:00:00.000+08:00,3,Teva's Preventive Migraine Treatment Approved By FDA
3873e33e-3045-41c4-953d-580e3e2303e4,2018-09-16T08:00:00.000+08:00,2,"The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs"
ce93b53b-d2a1-4e47-9883-f562dcb4a203,2018-09-16T08:00:00.000+08:00,2,"The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs"
ea5922fd-f621-4e7a-b08f-ed65115a52db,2018-09-14T08:00:00.000+08:00,3,"The IPO Outlook For The Week: Eventbrite, Animal Health And Luxury Fashion"
1259215c-a108-4ba6-9a93-80022a527988,2018-09-14T08:00:00.000+08:00,3,"The IPO Outlook For The Week: Eventbrite, Animal Health And Luxury Fashion"
633cdd25-ac79-4667-aaec-1a5c83b0662a,2018-09-11T08:00:00.000+08:00,1,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet"
3fdfcdd3-bf89-4317-b463-3828b78a5055,2018-09-11T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet"
657564fc-0654-4f43-be81-b37e16bb1730,2018-09-10T08:00:00.000+08:00,4,"Stocks Which Set New 52-Week High Friday, September 7th"
5cb8d7ac-7070-4c69-9726-472c0da15b5f,2018-09-10T08:00:00.000+08:00,3,Eli Lilly Initiates IXORA-R Head-To-Head Clinical Trial Comparing Taltz And Tremfya
7ec781dc-686e-46ac-a59e-e122a108ba0f,2018-09-10T08:00:00.000+08:00,4,"Stocks Which Set New 52-Week High Friday, September 7th"
c3bca1e9-2696-4327-9e14-de24a75aa5f6,2018-09-10T08:00:00.000+08:00,3,Eli Lilly Initiates IXORA-R Head-To-Head Clinical Trial Comparing Taltz And Tremfya
7e940889-ac46-4b40-b464-b33761fc226f,2018-09-07T08:00:00.000+08:00,4,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $107"
1afbfca0-f761-45fe-a20c-0a90cdcf94b9,2018-09-07T08:00:00.000+08:00,4,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $107"
e1601876-565a-4918-8abb-a91237853332,2018-09-06T08:00:00.000+08:00,3,New Class of Migraine Drug Creates Four-Way Pharma Development Race
23c27498-3e83-44dc-800d-7333b1097862,2018-09-06T08:00:00.000+08:00,4,Eli Lilly's Elanco Sets IPO Of 62.9M Shares In $20-$23/Share Range
2bd10520-0741-472d-9a4d-7a274873b5d1,2018-09-06T08:00:00.000+08:00,4,New Class of Migraine Drug Creates Four-Way Pharma Development Race
4790a5ce-a251-4dd1-880e-4b8851186bbf,2018-09-06T08:00:00.000+08:00,4,Eli Lilly's Elanco Sets IPO Of 62.9M Shares In $20-$23/Share Range
83c7c0dd-1f3b-4771-bbf1-2060a1cb9cbb,2018-09-05T08:00:00.000+08:00,5,Eli Lilly Says Phase 3 Results In Flortaucipir PET Imaging Agent Showed That Flortaucipir Demonstrated Statistically Significant Sensitivity And specificity For Detecting A High Level Of Total Alzheimer's Disease Neuropathologic Change
d8322761-664d-4a4e-a6bf-7e8f5ced4855,2018-09-05T08:00:00.000+08:00,3,Eli Lilly Says Phase 3 Results In Flortaucipir PET Imaging Agent Showed That Flortaucipir Demonstrated Statistically Significant Sensitivity And specificity For Detecting A High Level Of Total Alzheimer's Disease Neuropathologic Change
615e444c-f89d-4183-b0d0-5185a25683fa,2018-09-04T08:00:00.000+08:00,4,Zymeworks Reports IND-Submission Milestone Achieved In Eli Lilly Collaboration; Co. Will Receive $2M Milestone Payment For Eli Lily's Submission Of IND Application For Bispecific Antibody Enabled By Zymeworks' Azymetric Platform
ef6e21a0-9b72-4098-9b23-13cd56b12c70,2018-09-04T08:00:00.000+08:00,5,Zymeworks Reports IND-Submission Milestone Achieved In Eli Lilly Collaboration; Co. Will Receive $2M Milestone Payment For Eli Lily's Submission Of IND Application For Bispecific Antibody Enabled By Zymeworks' Azymetric Platform
0372ea14-065c-4069-b732-48194745bee2,2018-08-31T08:00:00.000+08:00,2,Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates
f2091741-9780-4ce6-93c4-6c69dafb9770,2018-08-31T08:00:00.000+08:00,2,Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates
56c9cc7d-e815-4685-8bac-9a4667bdea28,2018-08-30T08:00:00.000+08:00,3,"UPDATE: Adocia Notes Eli Lilly Filed Counterclaims Against Co. Seeking ~$188M, Including Prejudgment Interest"
211ba633-32b6-4e8b-ad7e-706ab38e04ca,2018-08-30T08:00:00.000+08:00,4,"French Biopharma Co. Focused On Treatment For Diabetes, Etc, Adocia, Issues Press Release Highlighting Update To Amount Of Damages In Case Against Eli Lilly To ~$1.8B"
d3142e4c-3810-4ecf-9ae4-90474c45cf61,2018-08-30T08:00:00.000+08:00,2,"UPDATE: Adocia Notes Eli Lilly Filed Counterclaims Against Co. Seeking ~$188M, Including Prejudgment Interest"
48990151-75f0-416a-9e06-3f9ab4fe48aa,2018-08-30T08:00:00.000+08:00,2,"French Biopharma Co. Focused On Treatment For Diabetes, Etc, Adocia, Issues Press Release Highlighting Update To Amount Of Damages In Case Against Eli Lilly To ~$1.8B"
379f332f-b3a4-42a4-bb63-50f4661c202f,2018-08-28T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic"
26e0b324-bc80-475b-8ff3-8d1531340efd,2018-08-28T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic"
700e2a7c-77d5-46a8-a49f-1e1bae2a71a9,2018-08-27T08:00:00.000+08:00,4,"Stocks That Made New 52-Week Highs So Far Today Include: IHS Markit, Cooper Cos., IDEXX Labs, Motorola Solutions, Emerson, Sherwin-Williams, Kansas City Southern, Norfolk Southern, Archer-Daniels, Verisk, Illumina, CSX, AMD, Eli Lilly, & Union Pacific"
a819914d-38f2-4ec0-9223-2120db521aa4,2018-08-27T08:00:00.000+08:00,1,"Stocks That Made New 52-Week Highs So Far Today Include: IHS Markit, Cooper Cos., IDEXX Labs, Motorola Solutions, Emerson, Sherwin-Williams, Kansas City Southern, Norfolk Southern, Archer-Daniels, Verisk, Illumina, CSX, AMD, Eli Lilly, & Union Pacific"
9d4f21f6-542e-4fba-a454-41ddd0ac0a53,2018-08-25T08:00:00.000+08:00,4,"Barron's Picks And Pans: Electronic Arts, GlaxoSmithKline, Microsoft, Tesla And More"
3dc0b6eb-cf35-468d-a360-d52269259660,2018-08-25T08:00:00.000+08:00,4,"Barron's Picks And Pans: Electronic Arts, GlaxoSmithKline, Microsoft, Tesla And More"
e9ff7ac7-afd0-47b4-b4a1-275722ff779f,2018-08-21T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows"
050a760a-e50b-4747-84c3-78e585a5b807,2018-08-21T08:00:00.000+08:00,5,"The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows"
92c2e01d-25fa-49b9-9f46-18e6280b28de,2018-08-17T08:00:00.000+08:00,1,"Stocks Which Set New 52-Week High Yesterday, August 16th"
0ecaff57-0dcb-4ff1-9932-6ab149011a96,2018-08-17T08:00:00.000+08:00,2,"The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns"
c46cafec-9921-44ad-8ef3-934667aec3d8,2018-08-17T08:00:00.000+08:00,4,"Stocks Which Set New 52-Week High Yesterday, August 16th"
6c5d1121-df95-4024-be31-3e545bd39f11,2018-08-17T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns"
ac5f0e04-8eae-4969-8782-242a0d3ac449,2018-08-16T08:00:00.000+08:00,5,"Stocks That Made New 52-Week Highs So Far Today Include: Ingersoll-Rand, Dollar General, Progressive, SunTrust Banks, Eli Lilly, Express Scripts, CenturyLink, Cintas, Fastenal, Aetna, O'Reilly Automotive, Darden Restaurants, Chipotle, and Centene"
ffd2f40f-ffad-4e93-a395-4180b9639df2,2018-08-16T08:00:00.000+08:00,4,"Stocks That Made New 52-Week Highs So Far Today Include: Ingersoll-Rand, Dollar General, Progressive, SunTrust Banks, Eli Lilly, Express Scripts, CenturyLink, Cintas, Fastenal, Aetna, O'Reilly Automotive, Darden Restaurants, Chipotle, and Centene"
2bd76d94-c003-435f-9157-f8244640ac4c,2018-08-14T08:00:00.000+08:00,2,"Stocks Trading Ex Dividend Today, August 14th"
8b8fbd4c-5f1f-417c-b9fa-ae5eab74339d,2018-08-14T08:00:00.000+08:00,2,"Stocks Trading Ex Dividend Today, August 14th"
6c9d0f02-67a0-47f8-b8a2-29fc77403c4e,2018-08-13T08:00:00.000+08:00,3,"Stocks That Will Be Trading Ex Dividend Tomorrow, August 14th"
9533e421-ce3f-4d21-b37b-dd689c6f6154,2018-08-13T08:00:00.000+08:00,4,"Stocks That Will Be Trading Ex Dividend Tomorrow, August 14th"
7eacef8f-ed94-4b33-b740-77652d947931,2018-08-08T08:00:00.000+08:00,1,"Stocks Which Set New 52-Week High Yesterday, August 7th"
56064242-422c-458a-a92d-ed8ce7986c0b,2018-08-08T08:00:00.000+08:00,2,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict"
6bc1d8d2-7427-4f78-95fc-2b8547f7fbc2,2018-08-08T08:00:00.000+08:00,4,"Stocks Which Set New 52-Week High Yesterday, August 7th"
0243d0d4-5afd-4088-b9c7-c03491c74d3a,2018-08-08T08:00:00.000+08:00,3,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict"
996e9300-e46e-45a8-b3e4-bebda6068ebc,2018-08-07T08:00:00.000+08:00,5,"Stocks That Made New 52-Week Highs Earlier Today Include: SL Green Realty, Verisk Analytics, Medtronics, Pfizer, Conoco Phillips, Archer-Daniels, Eli Lilly, Merck, Phillips 66, Costco, Advance Auto Parts, Norfolk Southern, CSX, Zoetis, Apple, and Disney"
c0d45b1a-c103-4a12-b544-53571449a05c,2018-08-07T08:00:00.000+08:00,1,"Stocks Which Set New 52-Week High Yesterday, August 6th"
0d7bfd58-1dc8-4d1d-800b-4c1c985561bf,2018-08-07T08:00:00.000+08:00,2,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel"
52e02072-9627-406e-82a0-b8a9cdd5fefe,2018-08-07T08:00:00.000+08:00,4,"Stocks That Made New 52-Week Highs Earlier Today Include: SL Green Realty, Verisk Analytics, Medtronics, Pfizer, Conoco Phillips, Archer-Daniels, Eli Lilly, Merck, Phillips 66, Costco, Advance Auto Parts, Norfolk Southern, CSX, Zoetis, Apple, and Disney"
da7a7d37-5d92-4649-86dd-9f8ed9059e79,2018-08-07T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Yesterday, August 6th"
b3290843-4fb3-4849-b6d1-cd645007ba82,2018-08-07T08:00:00.000+08:00,1,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel"
7bf64897-481e-4740-8bd4-64737541498d,2018-08-06T08:00:00.000+08:00,5,"Stocks Which Set New 52-Week Highs Friday, August 3rd"
83caf638-6652-42dc-9919-925dbd94600d,2018-08-06T08:00:00.000+08:00,4,"Stocks Which Set New 52-Week Highs Friday, August 3rd"
221506a3-dd24-4c15-a28e-476c6a2a44aa,2018-08-03T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Yesterday, August 2nd"
2ca3e85f-ee96-45d8-9241-963fbe9643a5,2018-08-03T08:00:00.000+08:00,1,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings"
2fd16286-2540-41ea-af70-5b68c9c70a7b,2018-08-03T08:00:00.000+08:00,4,"Stocks Which Set New 52-Week High Yesterday, August 2nd"
8860dce2-543e-4e58-9d96-1a6a4b8e269c,2018-08-03T08:00:00.000+08:00,1,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings"
ba5ccafd-8ba4-478d-80a3-ef12c93553e4,2018-08-02T08:00:00.000+08:00,4,Elanco Animal Health F-1 Shows Registration For $100M IPO; Co. Planning To List On NYSE Under Symbol 'ELAN'; BZ NOTE: Co. Is Eli Lilly's Animal Health Unit
af8038d5-66ad-48cc-a726-d10827276455,2018-08-02T08:00:00.000+08:00,5,"Stocks That Made New 52 Week Highs So Far Today Include: PerkinElmer, Eli Lilly, Zoetis, Apple, Simon Property Group, Global Payments, and Church & Dwight"
447dc7eb-0d24-42f9-a9fc-5c354f5ba1c8,2018-08-02T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Yesterday, August 1st"
3296c085-4d70-4377-a059-ce8a5743bd10,2018-08-02T08:00:00.000+08:00,4,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter"
6f20e561-7580-4378-8a8c-f5b010a96510,2018-08-02T08:00:00.000+08:00,2,Elanco Animal Health F-1 Shows Registration For $100M IPO; Co. Planning To List On NYSE Under Symbol 'ELAN'; BZ NOTE: Co. Is Eli Lilly's Animal Health Unit
7d5219d5-204f-4f88-8a22-77aae65f2e51,2018-08-02T08:00:00.000+08:00,5,"Stocks That Made New 52 Week Highs So Far Today Include: PerkinElmer, Eli Lilly, Zoetis, Apple, Simon Property Group, Global Payments, and Church & Dwight"
bc6faccb-2e12-4d1c-804f-6e66e2f92166,2018-08-02T08:00:00.000+08:00,4,"Stocks Which Set New 52-Week High Yesterday, August 1st"
ed2f7c85-1781-4000-a11f-150d361e9d4a,2018-08-02T08:00:00.000+08:00,3,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter"
8c18eacc-d13e-493a-a691-61b795cf0224,2018-08-01T08:00:00.000+08:00,4,"Stocks That Have Made New 52 Week Highs Thus Far Today Include: Robert Half, Eli Lilly, Pfizer, Phillips 66, Humana, HCA Healthcare, Genworth, Republic Services, Illumina, Aflac, Medtronic, Waste Management, and Apple"
7357eae1-0809-4152-ae1f-20c8847c6072,2018-08-01T08:00:00.000+08:00,4,"Stocks Which Set New 52-Week High Yesterday, July 31"
ae7e9b62-2df8-4f48-b5a8-4c91fd480afb,2018-08-01T08:00:00.000+08:00,2,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial"
d82087d7-65a6-435f-b5d0-14a43f09b450,2018-08-01T08:00:00.000+08:00,4,Dan Nathan Sees Unusual Options Activity In Eli Lilly
fb7550ea-ea05-4281-acc1-65ec0b5cb152,2018-08-01T08:00:00.000+08:00,3,"Stocks That Have Made New 52 Week Highs Thus Far Today Include: Robert Half, Eli Lilly, Pfizer, Phillips 66, Humana, HCA Healthcare, Genworth, Republic Services, Illumina, Aflac, Medtronic, Waste Management, and Apple"
13da3d7f-e4d0-401c-b910-745d655a963d,2018-08-01T08:00:00.000+08:00,5,"Stocks Which Set New 52-Week High Yesterday, July 31"
9db84954-cc6e-4b02-8863-ca86873cfed5,2018-08-01T08:00:00.000+08:00,1,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial"
42224aad-2a41-422b-8370-98dd4fe143a2,2018-08-01T08:00:00.000+08:00,2,Dan Nathan Sees Unusual Options Activity In Eli Lilly
9244ecf7-2cb8-46af-b915-2accef2720cd,2018-07-31T08:00:00.000+08:00,4,"Morgan Stanley Maintains Equal-Weight on Eli Lilly, Raises Price Target to $102"
f77f8d3a-6aee-4892-9f07-6f8ce9da49b6,2018-07-31T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Yesterday, July 30th"
1496c7ec-c1f3-4add-bf84-8df01886c966,2018-07-31T08:00:00.000+08:00,4,"Morgan Stanley Maintains Equal-Weight on Eli Lilly, Raises Price Target to $102"
760fc487-7709-4d3b-9ff8-6a6ca733ca01,2018-07-31T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Yesterday, July 30th"
9658d666-ef28-4bb4-94fb-983dcf68ef3f,2018-07-30T08:00:00.000+08:00,4,"Stocks That Made New 52 Week Highs So Far Today Include: AMD, Ingersoll-Rand, Aflac, Fortiv, Kansas City Southern, Union Pacific, HCA Healthcare, ConocoPhillips, Waste Management, and EOG Resources"
d7f989de-17c5-47f8-9985-9c817cd43701,2018-07-30T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Friday, July 27th"
eedea2d8-1b4b-45f6-954b-ab7a9ac31614,2018-07-30T08:00:00.000+08:00,2,Eli Lilly Announces a 3 Year Extension of its Cancer Research Collaboration with Dana-Farber Cancer Institute
3fcd0af2-f58d-4b83-9002-b0f39c505faf,2018-07-30T08:00:00.000+08:00,1,"Stocks That Made New 52 Week Highs So Far Today Include: AMD, Ingersoll-Rand, Aflac, Fortiv, Kansas City Southern, Union Pacific, HCA Healthcare, ConocoPhillips, Waste Management, and EOG Resources"
a781b2f8-c063-4e4c-804e-d77ac3b60675,2018-07-30T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Friday, July 27th"
4ac6a8ae-3783-4265-b958-73418b248b8c,2018-07-30T08:00:00.000+08:00,4,Eli Lilly Announces a 3 Year Extension of its Cancer Research Collaboration with Dana-Farber Cancer Institute
bace536d-0dd0-404e-8db8-aec386d0b8e6,2018-07-29T08:00:00.000+08:00,3,"Barron's Picks And Pans: Amazon, Eli Lilly, Fiat Chrysler And More"
5b3fde50-feda-4823-897e-da6f5e47662f,2018-07-29T08:00:00.000+08:00,3,"Barron's Picks And Pans: Amazon, Eli Lilly, Fiat Chrysler And More"
0caa595e-916c-40bd-912b-776513fa0161,2018-07-28T08:00:00.000+08:00,3,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs"
0f809a59-f115-42c1-bc23-918792ecda20,2018-07-28T08:00:00.000+08:00,3,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs"
d3f948ec-9eac-4f6a-9154-aacaca71f836,2018-07-27T08:00:00.000+08:00,2,"Stocks Which Set New 52-Week High Yesterday, July 26th:"
2b0ba32a-6534-470e-bbc5-b84b7e46dc96,2018-07-27T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Yesterday, July 26th:"
97c6fdcb-8a68-4169-985c-f18970bb6c1f,2018-07-26T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Yesterday, July 25th"
a3d699b8-4446-46dd-8291-02a461efb924,2018-07-26T08:00:00.000+08:00,1,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold"
81e79ab7-1045-477d-95a9-87ceb9b35800,2018-07-26T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Yesterday, July 25th"
e1dbd801-d53c-44d2-9bd3-293ef7f0e690,2018-07-26T08:00:00.000+08:00,2,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold"
8f11d0b0-4610-47bd-a891-9a2265f4f7d6,2018-07-25T08:00:00.000+08:00,4,"Stocks That Made New 52-Week Highs Earlier Include: Adobe, S&P Global, Baxter, Salesforce, Microsoft, Biogen, Becton, Norfolk Southern, Target, IHS Markit, Tiffany, Eli Lilly, Thermo Fisher, Facebook, FLIR Systems, Medtronic, and Mastercard"
63ba7f8a-cdc2-4f3e-97cc-e469cf2d0e42,2018-07-25T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Yesterday, July 24th:"
bae4e7b4-346e-4545-bf7a-b96e188e5aea,2018-07-25T08:00:00.000+08:00,4,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $90"
b0235fdc-7b1f-4935-bd2b-0fcf51f8b3fa,2018-07-25T08:00:00.000+08:00,1,"Credit Suisse Maintains Underperform on Eli Lilly, Raises Price Target to $86"
33a9ad9f-564d-4199-a563-411c4d57422f,2018-07-25T08:00:00.000+08:00,2,"Concerns About Trade Picture Overshadowing Earnings As GM, Boeing Report"
a2694e3f-eca7-41af-82c8-94a06933bf8b,2018-07-25T08:00:00.000+08:00,3,10 Biggest Price Target Changes For Wednesday
2a7d7df2-9bad-47ce-b659-a579b2641d7a,2018-07-25T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For July 25, 2018"
2927c6de-a477-4569-9297-dc6119177299,2018-07-25T08:00:00.000+08:00,4,Berenberg Downgrades Eli Lilly to Hold
1914aa1c-0c58-4cbe-8ceb-c876e324f290,2018-07-25T08:00:00.000+08:00,5,"Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $110"
cf75acc2-e33d-4ee2-8c71-38aec65688fe,2018-07-25T08:00:00.000+08:00,4,"Stocks That Made New 52-Week Highs Earlier Include: Adobe, S&P Global, Baxter, Salesforce, Microsoft, Biogen, Becton, Norfolk Southern, Target, IHS Markit, Tiffany, Eli Lilly, Thermo Fisher, Facebook, FLIR Systems, Medtronic, and Mastercard"
b48c3f09-85e6-49a2-95ff-ca784d7faba0,2018-07-25T08:00:00.000+08:00,3,"Stocks Which Set New 52-Week High Yesterday, July 24th:"
9c78706d-dabd-4e11-8b7e-b7be7ba96aa1,2018-07-25T08:00:00.000+08:00,2,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $90"
afd1bc96-eb40-4a0c-ae88-e767c1a2a809,2018-07-25T08:00:00.000+08:00,1,"Credit Suisse Maintains Underperform on Eli Lilly, Raises Price Target to $86"
7fae5a73-75ad-4789-bd18-540a6da1231b,2018-07-25T08:00:00.000+08:00,3,"Concerns About Trade Picture Overshadowing Earnings As GM, Boeing Report"
9c9453cb-8f80-4775-b295-8bd35ddf8f18,2018-07-25T08:00:00.000+08:00,2,10 Biggest Price Target Changes For Wednesday
5b8bda4e-1b58-4912-8408-f63d5a1134d3,2018-07-25T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For July 25, 2018"
bf163578-1384-421c-ad2e-6243c80943b8,2018-07-25T08:00:00.000+08:00,4,Berenberg Downgrades Eli Lilly to Hold
f2ea98f2-cb76-40fc-b931-0b29cb47a7fa,2018-07-25T08:00:00.000+08:00,5,"Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $110"
fbb16b7e-bb87-450f-8ad3-f57683022acb,2018-07-24T08:00:00.000+08:00,1,Earnings Season Optimism Seems To Help Lift Market
535aede4-894b-4d5e-bafe-3b7113e75ef3,2018-07-24T08:00:00.000+08:00,3,"From Eli Lilly Q2 Earnings Conference Call, Co. Says It Is 'Preparing For All Scenarios' Regarding Trump Administration's Plans To Address Rising Healthcare Costs"
5e53e453-afb4-49cb-bdfb-e19f9fd0713d,2018-07-24T08:00:00.000+08:00,4,Benzinga Pro's 5 Stocks To Watch Today
49d155d3-5b8f-4663-84dc-7748f0d41c7c,2018-07-24T08:00:00.000+08:00,3,"Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering"
38a05c2d-da02-4ace-8372-acb8ef452c5c,2018-07-24T08:00:00.000+08:00,4,25 Stocks Moving In Tuesday's Pre-Market Session
2603ce44-5b61-4352-b134-502a9010e3ab,2018-07-24T08:00:00.000+08:00,5,A Peek Into The Markets: US Stock Futures Rise Ahead Of Earnings
99d72b5c-e75e-4bc1-897d-71a276b1d533,2018-07-24T08:00:00.000+08:00,4,Eli Lilly Raises FY18 Sales Outlook From $23.7B-$24.2B To $24.0B-$24.5B vs $23.99B Est.
ba690ab6-687f-4da0-aaa6-631a50149b58,2018-07-24T08:00:00.000+08:00,5,Eli Lilly Raises FY18 Adj. EPS Outlook From $5.10-$5.20 To $5.40-$5.50 vs $5.15 Est.
35dbf4cc-4253-4ccd-9be6-9eb88aa53054,2018-07-24T08:00:00.000+08:00,3,Eli Lilly Revises FY18 Outlook
d280c331-c1f7-47e5-93a3-25fc74f7e2bc,2018-07-24T08:00:00.000+08:00,4,"Eli Lilly Q2 Adj. EPS $1.50 Beats $1.30 Estimate, Sales $6.36B Beat $6.05B Estimate"
92b5b603-56d8-46d9-b1c0-f3686bda7a25,2018-07-24T08:00:00.000+08:00,2,"Lilly to Separate Elanco Animal Health with IPO, Offering Is Expected To Represent An Ownership Stake Of Less Than 20% And Process Will Be Complete During Second Half Of 2018"
898bc7d4-f127-4b57-bda8-286eac2ec705,2018-07-24T08:00:00.000+08:00,4,"12 Stocks To Watch For July 24, 2018"
42a293c2-07ba-488b-8b73-77a831739496,2018-07-24T08:00:00.000+08:00,3,"Earnings Scheduled For July 24, 2018"
e5914aae-4f8e-4b9a-aa4e-d4237258d0bb,2018-07-24T08:00:00.000+08:00,4,Earnings Season Optimism Seems To Help Lift Market
db33ba62-c7bf-4bd4-bb9a-8acec6389ae8,2018-07-24T08:00:00.000+08:00,3,"From Eli Lilly Q2 Earnings Conference Call, Co. Says It Is 'Preparing For All Scenarios' Regarding Trump Administration's Plans To Address Rising Healthcare Costs"
e4a02f93-5df9-4861-9306-e6fcbd374109,2018-07-24T08:00:00.000+08:00,4,Benzinga Pro's 5 Stocks To Watch Today
76cd2594-68fa-4147-b668-a4a5202f5af3,2018-07-24T08:00:00.000+08:00,4,"Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering"
d3e75203-1d0f-4eac-8a6c-53b969b94f7b,2018-07-24T08:00:00.000+08:00,2,25 Stocks Moving In Tuesday's Pre-Market Session
ff650bc9-12bf-486c-880f-c3513e106c62,2018-07-24T08:00:00.000+08:00,3,A Peek Into The Markets: US Stock Futures Rise Ahead Of Earnings
d47d7a4b-8917-4d5a-a47c-3bc5cdb44c48,2018-07-24T08:00:00.000+08:00,4,Eli Lilly Raises FY18 Sales Outlook From $23.7B-$24.2B To $24.0B-$24.5B vs $23.99B Est.
b3031508-ddda-4113-8449-3cab0e748788,2018-07-24T08:00:00.000+08:00,5,Eli Lilly Raises FY18 Adj. EPS Outlook From $5.10-$5.20 To $5.40-$5.50 vs $5.15 Est.
714974e7-ad8b-4bd4-a95c-c73700581727,2018-07-24T08:00:00.000+08:00,4,Eli Lilly Revises FY18 Outlook
d49d976b-7651-466a-b3df-9840b78ac27b,2018-07-24T08:00:00.000+08:00,5,"Eli Lilly Q2 Adj. EPS $1.50 Beats $1.30 Estimate, Sales $6.36B Beat $6.05B Estimate"
62c117f8-4237-4302-9bd9-c2fc22012905,2018-07-24T08:00:00.000+08:00,3,"Lilly to Separate Elanco Animal Health with IPO, Offering Is Expected To Represent An Ownership Stake Of Less Than 20% And Process Will Be Complete During Second Half Of 2018"
6f391fa4-600a-41f1-ab01-dccfaa9c5b5d,2018-07-24T08:00:00.000+08:00,2,"12 Stocks To Watch For July 24, 2018"
ffa19e0a-7a12-4c45-a6b1-2d94a683e496,2018-07-24T08:00:00.000+08:00,1,"Earnings Scheduled For July 24, 2018"
e8adbab6-d6ce-437d-bd7c-cf9b3a0db04f,2018-07-23T08:00:00.000+08:00,2,Eli Lilly's Q2 Earnings Preview
2e1b4a14-ee0f-4c32-9388-af1c13d9f8c4,2018-07-23T08:00:00.000+08:00,2,Eli Lilly's Q2 Earnings Preview
71cda6b1-809b-42c2-b2de-5bb0c7f93e0e,2018-07-22T08:00:00.000+08:00,3,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs"
cacd695f-5bda-4871-9386-66430857f4c9,2018-07-22T08:00:00.000+08:00,4,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs"
c370fb64-5480-4934-98cc-60886d7a2f17,2018-07-20T08:00:00.000+08:00,5,Eli Lilly And Incyte Late Thursday Announced Study Results Showing Benefit Of Baricitinib 4 mg For Treatment Of Systemic Lupus Erythematosus (SLE) Were Published In The Lancet
17539f0c-18b8-4f1d-96d2-52bd3a45425a,2018-07-20T08:00:00.000+08:00,4,Eli Lilly And Incyte Late Thursday Announced Study Results Showing Benefit Of Baricitinib 4 mg For Treatment Of Systemic Lupus Erythematosus (SLE) Were Published In The Lancet
cb238b4b-3231-45c0-8216-5d2ef180aa7a,2018-07-19T08:00:00.000+08:00,3,Boehringer Ingelheim and Lilly Announce Tradjenta's CARMELINA Outcome Trial Meets Primary Endpoint
4f6357db-ba78-4b3a-ab7b-cb80b6a1ea90,2018-07-19T08:00:00.000+08:00,3,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $80"
0c9bc491-0b04-42b6-b365-c95d5b300c92,2018-07-19T08:00:00.000+08:00,4,"Eli Lilly Reports Once-Weekly Trulicity Label Updated To Include Data Showing Benefits For Adults With Type 2 Diabetes, Chronic Kidney Disease"
aae9e6c0-f894-476b-b923-5a00c98d77b2,2018-07-19T08:00:00.000+08:00,5,Boehringer Ingelheim and Lilly Announce Tradjenta's CARMELINA Outcome Trial Meets Primary Endpoint
fcacb9c3-45ba-4986-b4d6-09ac1403ca95,2018-07-19T08:00:00.000+08:00,4,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $80"
82806dbf-532f-4c58-bc3c-9b87c7dd997f,2018-07-19T08:00:00.000+08:00,5,"Eli Lilly Reports Once-Weekly Trulicity Label Updated To Include Data Showing Benefits For Adults With Type 2 Diabetes, Chronic Kidney Disease"
f390e3c7-61bd-4efe-a04b-e082e3b803b4,2018-07-18T08:00:00.000+08:00,3,"Stocks That Made New 52-Week Highs Today Include: Alphabet (Both Classes), Facebook, Amazon, Eli Lilly, Intercontinental Exchange, Adobe, TripAdvisor, Darden Restaurants, Citrix, Marsh & McLennan, Norfolk Southern, Motorola, TJX, Intuit, Visa, and CSX"
7f139927-6a00-4147-bb39-eeddf7ea7354,2018-07-18T08:00:00.000+08:00,4,"Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares"
ea8b3ced-7d47-4824-9e36-3a8f204ee545,2018-07-18T08:00:00.000+08:00,5,"PFizer, Eli Lilly Report Phase 3 Trial Of Tanezumab Met All Thre Co-Primary Endpoints"
3be60471-d2c4-4dc8-b734-8b52658e6ea6,2018-07-18T08:00:00.000+08:00,4,"Stocks That Made New 52-Week Highs Today Include: Alphabet (Both Classes), Facebook, Amazon, Eli Lilly, Intercontinental Exchange, Adobe, TripAdvisor, Darden Restaurants, Citrix, Marsh & McLennan, Norfolk Southern, Motorola, TJX, Intuit, Visa, and CSX"
c33afb73-195f-4bf1-8b02-fb6c14188fa3,2018-07-18T08:00:00.000+08:00,3,"Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares"
32c7054a-0d03-4e8a-a294-f759d267261c,2018-07-18T08:00:00.000+08:00,5,"PFizer, Eli Lilly Report Phase 3 Trial Of Tanezumab Met All Thre Co-Primary Endpoints"
89d588fb-3c59-4ae4-90de-8c758bc54844,2018-07-17T08:00:00.000+08:00,4,"Stocks That Made New 52-Week Highs Today Include: Citrix, TripAdvisor, Microsoft, Alphabet (Both Classes), Medtronic, Accenture, Facebook, NetApp, S&P Global, Amazon, VeriSign, Motorola Solutions, Marsh & McLennan, IDEXX Labs, Eli Lilly, Sysco, and VF"
7f199520-0df0-401a-abb8-452f07827d7c,2018-07-17T08:00:00.000+08:00,4,"Stocks That Made New 52-Week Highs Today Include: Citrix, TripAdvisor, Microsoft, Alphabet (Both Classes), Medtronic, Accenture, Facebook, NetApp, S&P Global, Amazon, VeriSign, Motorola Solutions, Marsh & McLennan, IDEXX Labs, Eli Lilly, Sysco, and VF"
54b50e69-771e-4445-aa59-f6a3a472f6fc,2018-07-09T08:00:00.000+08:00,3,Health Care Sector Outlook: Checking In Ahead Of Q2 Earnings Reports
401cf737-11cc-4b3b-b9e2-6da207aecf87,2018-07-09T08:00:00.000+08:00,3,Health Care Sector Outlook: Checking In Ahead Of Q2 Earnings Reports
29fd8fb3-0e71-462a-bbe8-0ff0bbe07723,2018-07-05T08:00:00.000+08:00,3,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year
f8adaadc-0f5a-41da-b052-d70f1715713d,2018-07-05T08:00:00.000+08:00,4,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year
e63b44dc-1d32-4d10-8ebf-d8a4d6e44e60,2018-06-29T08:00:00.000+08:00,5,"UPDATE: Lilly Will Engage 40K People With Migraine In US Over Next 2 Years, Will Be Conducted By Kantar Health On Behalf Of Co."
c82072dc-8b57-4ce4-9576-777115c41009,2018-06-29T08:00:00.000+08:00,2,"Eli Lilly Reports Initiation Of OVERCOME Study To Advance Understanding Of Burden, Impact, Epidemiology Of Migraine"
b3c1588e-924d-4c3c-b324-b5afb241b51a,2018-06-29T08:00:00.000+08:00,2,"UPDATE: Lilly Will Engage 40K People With Migraine In US Over Next 2 Years, Will Be Conducted By Kantar Health On Behalf Of Co."
cf0cb31f-222c-46e9-87be-1c2a1426e1aa,2018-06-29T08:00:00.000+08:00,3,"Eli Lilly Reports Initiation Of OVERCOME Study To Advance Understanding Of Burden, Impact, Epidemiology Of Migraine"
8d4e49ca-5c9d-4dbc-a081-46f9867bed87,2018-06-28T08:00:00.000+08:00,4,"Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut"
7985bb91-10d1-49ab-8488-acd048299d13,2018-06-28T08:00:00.000+08:00,5,Eli Lilly Reports Taltz Met Primary and Secondary Endpoints in a Phase 3 Study
9d1cd1e4-00cf-441f-b8df-aa2361eb076d,2018-06-28T08:00:00.000+08:00,5,"Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut"
0ecd24dc-9376-4db8-bdff-5f51e06adbc8,2018-06-28T08:00:00.000+08:00,4,Eli Lilly Reports Taltz Met Primary and Secondary Endpoints in a Phase 3 Study
b0c3c3d8-4fea-429d-b625-59e567d0cfdc,2018-06-27T08:00:00.000+08:00,3,Eli Lilly Reports Intended Brand Name For Episodic Cluster Headache Treatment Approved As Emgality
9720d286-679d-424e-b202-2b04d0a3a2da,2018-06-27T08:00:00.000+08:00,4,Eli Lilly Announces Results Of Phase 3 Study Of Emgailty Which Met Primary and Secondary Endpoint
a291f57f-422f-4536-a0ed-663212d9237a,2018-06-27T08:00:00.000+08:00,5,Eli Lilly Reports Intended Brand Name For Episodic Cluster Headache Treatment Approved As Emgality
4996d862-fcd3-448d-9ea6-342749b04229,2018-06-27T08:00:00.000+08:00,5,Eli Lilly Announces Results Of Phase 3 Study Of Emgailty Which Met Primary and Secondary Endpoint
0926fed4-17f5-40aa-b7ee-27cb19ed6b0f,2018-06-25T08:00:00.000+08:00,4,Boehringer Ingelheim and Lilly Report EASE Phase III Program Met Primary Endpoint For All Investigated Doses Of empagliflozin
22efc895-ccfa-49e3-9702-55f9107ef84f,2018-06-25T08:00:00.000+08:00,3,Boehringer Ingelheim and Lilly Report EASE Phase III Program Met Primary Endpoint For All Investigated Doses Of empagliflozin
b582f9ff-874c-4f63-bd4b-2d8e380bd44b,2018-06-23T08:00:00.000+08:00,4,Lilly Announces Investigational Doses of Once-Weekly Trulicity Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes at #ADA2018
c0a73127-3ed4-4df7-8318-7ff8fb08b34f,2018-06-23T08:00:00.000+08:00,5,Lily Announces Jardiance Reduced Risk of Kidney Disease Progression in Adults With Type 2 Diabetes and Established Cardiovascular (Cv) Disease Independent of Control of Conventional Cv Risk Factors
ce1e9f4b-6325-4491-ad8e-946cbce5e72b,2018-06-23T08:00:00.000+08:00,5,Lilly Announces New Data Presented at #ADA2018 Reinforce Potential of Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes
6682bad7-014e-4940-8c8f-6fe911918fb6,2018-06-23T08:00:00.000+08:00,4,Lilly Announces Investigational Doses of Once-Weekly Trulicity Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes at #ADA2018
d226dc20-f119-44a9-af68-e6a3e33af453,2018-06-23T08:00:00.000+08:00,3,Lily Announces Jardiance Reduced Risk of Kidney Disease Progression in Adults With Type 2 Diabetes and Established Cardiovascular (Cv) Disease Independent of Control of Conventional Cv Risk Factors
65b57a25-79ae-49a7-9f5c-0999722d51cc,2018-06-23T08:00:00.000+08:00,5,Lilly Announces New Data Presented at #ADA2018 Reinforce Potential of Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes
d12c66e5-ee06-4b3f-bf5f-b7caa145de94,2018-06-22T08:00:00.000+08:00,1,"UPDATE: In Separate Decision June 15th District Court Ruled In Favor Of Eli Lilly Against Dr. Reddy's and Hospira, Preventing Them From Launching Alternative Salt Forms Of Pemetrexed Until Lilly's Patent Expires"
fc89e862-6715-43d2-81a1-bc4c2c3144cf,2018-06-22T08:00:00.000+08:00,4,U.S. District Court Rules In Favor Of Eli Lilly Against Dr. Reddy's Laboratories In Alimta Vitamin Regimen Patent Lawsuit
2f463067-f6ad-4f80-9a4c-5215934ade91,2018-06-22T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For June 22, 2018"
228d7f95-6d6d-495e-9e18-14ee178a206c,2018-06-22T08:00:00.000+08:00,2,"The Market In 5 Minutes: Stress Test Results, More Trade Talks, Viacom's Unexpected Risk"
96378876-cbea-4626-9aae-e7023024886b,2018-06-22T08:00:00.000+08:00,1,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
0f329d9c-fa27-483a-8927-7435450b2d38,2018-06-22T08:00:00.000+08:00,1,DZ Bank Downgrades Eli Lilly to Hold
3c52deb5-085f-46f0-af12-8901c3120653,2018-06-22T08:00:00.000+08:00,3,"UPDATE: In Separate Decision June 15th District Court Ruled In Favor Of Eli Lilly Against Dr. Reddy's and Hospira, Preventing Them From Launching Alternative Salt Forms Of Pemetrexed Until Lilly's Patent Expires"
ff1933d9-a798-4f85-85c6-639b5e106179,2018-06-22T08:00:00.000+08:00,4,U.S. District Court Rules In Favor Of Eli Lilly Against Dr. Reddy's Laboratories In Alimta Vitamin Regimen Patent Lawsuit
ddcac5a8-dd75-4672-b79a-55f4cada2043,2018-06-22T08:00:00.000+08:00,2,"Benzinga's Top Upgrades, Downgrades For June 22, 2018"
c219b524-50e1-439e-a432-9ba675090ff1,2018-06-22T08:00:00.000+08:00,1,"The Market In 5 Minutes: Stress Test Results, More Trade Talks, Viacom's Unexpected Risk"
cf0f13ea-cb92-41c3-bd48-e68a798ca67e,2018-06-22T08:00:00.000+08:00,3,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
b00bc214-4637-4b5b-b70b-cd805d0fa5ba,2018-06-22T08:00:00.000+08:00,2,DZ Bank Downgrades Eli Lilly to Hold
f0b5434d-c947-4705-9688-70e917005f67,2018-06-21T08:00:00.000+08:00,3,"Credit Suisse Maintains Underperform on Eli Lilly, Raises Price Target to $84"
e1087a8d-8e28-4414-b625-8c69148ea666,2018-06-21T08:00:00.000+08:00,3,"Credit Suisse Maintains Underperform on Eli Lilly, Raises Price Target to $84"
f667fe53-c50b-4760-ab38-1a118635f2e3,2018-06-13T08:00:00.000+08:00,4,Pop Star Pink Confronts SeaWorld On PETA's Behalf During Shareholder Meeting
4a0074cf-ff52-46c4-935d-7e6d063abd5f,2018-06-13T08:00:00.000+08:00,1,Pop Star Pink Confronts SeaWorld On PETA's Behalf During Shareholder Meeting
5342c526-547d-443c-8a42-6e45044634c8,2018-06-12T08:00:00.000+08:00,2,"Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate"
50aa0921-bbbc-4701-b852-23541d19d13e,2018-06-12T08:00:00.000+08:00,1,"Eli Lilly, AstraZeneca Discontinuing Global Phase 3 Clinical Trials of Lanabecestat"
cb46c3a2-5c70-4d8f-aaf8-52f9da4f7f8d,2018-06-12T08:00:00.000+08:00,3,"Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate"
67bc0e7e-aa17-4b19-be5c-43c3cbe580a6,2018-06-12T08:00:00.000+08:00,4,"Eli Lilly, AstraZeneca Discontinuing Global Phase 3 Clinical Trials of Lanabecestat"
7baa99af-dd58-453e-a8f7-a6aea0faf2e6,2018-06-11T08:00:00.000+08:00,5,"Eli Lilly Division, Elanco Animal Health, Introduces New Respiratory PRRS Vaccine"
36c92bb1-ed82-4763-98d3-4093d13179da,2018-06-11T08:00:00.000+08:00,4,Eli Lilly Reports Its Elanco Animal Health Unit Received Licensing Of Prevacent PRRS By USDA Shown To Be Effective In Reducing PRRS In Piglets 2 Weeks Or Older
26781a48-860d-45a1-b938-f42391016bb8,2018-06-11T08:00:00.000+08:00,4,"Eli Lilly Division, Elanco Animal Health, Introduces New Respiratory PRRS Vaccine"
c6ce4fb2-03ab-41a3-914f-12d78c18cf8e,2018-06-11T08:00:00.000+08:00,4,Eli Lilly Reports Its Elanco Animal Health Unit Received Licensing Of Prevacent PRRS By USDA Shown To Be Effective In Reducing PRRS In Piglets 2 Weeks Or Older
29f6bd5d-09ce-4d75-b25a-8ad9948144e6,2018-06-08T08:00:00.000+08:00,3,"Pharma Stock Roundup: Merck, Eli Lilly, AbbVie And More"
da9bc50f-6027-4f92-b655-24fcce639ed2,2018-06-08T08:00:00.000+08:00,2,"The Market In 5 Minutes: China, ZTE, McDonald's And More"
7655ac03-14e2-4779-a0a7-5a05160f4188,2018-06-08T08:00:00.000+08:00,4,"Benzinga's Top Upgrades, Downgrades For June 8, 2018"
532adbf6-179a-4e6e-a143-43f5ce6229c7,2018-06-08T08:00:00.000+08:00,5,"Cantor Fitzgerald Initiates Coverage On Eli Lilly with Overweight Rating, Announces $100 Price Target"
736d9dca-6649-4c53-ab9b-72caa1f7daf2,2018-06-08T08:00:00.000+08:00,3,"Pharma Stock Roundup: Merck, Eli Lilly, AbbVie And More"
bdaf9aa2-14aa-4def-b22e-05adb28b1394,2018-06-08T08:00:00.000+08:00,1,"The Market In 5 Minutes: China, ZTE, McDonald's And More"
17339be0-8cf2-4f62-a166-75e6f5d60605,2018-06-08T08:00:00.000+08:00,4,"Benzinga's Top Upgrades, Downgrades For June 8, 2018"
daf86325-31b0-48ac-b39f-721a4ccdcc40,2018-06-08T08:00:00.000+08:00,4,"Cantor Fitzgerald Initiates Coverage On Eli Lilly with Overweight Rating, Announces $100 Price Target"
30ab34fb-59a5-42d5-a227-e52878b15558,2018-06-07T08:00:00.000+08:00,3,"Eli Lilly CEO Calls For Uniform Prices, Better Use Of Technology In Health Care"
5873f54a-89b2-4ab3-af4d-d107ea0ec480,2018-06-07T08:00:00.000+08:00,3,"Lilly CEO Ricks, When Asked If Co. Will Participate In Right-To-Try Initiative, Tells Benzinga, Co. Has Supplied Medication To That Patient Population 'For Years,' Notes Co. Was Full Participant In Expanded Access Program, But Does Not Answer Directly"
58acaaf5-84e5-4b56-980c-57eb07841c54,2018-06-07T08:00:00.000+08:00,4,"Lilly CEO Ricks Positive On JP Morgan, Berkshire, Amazon Health Care Coalition, Says 'If these 3 large cos. can use their scale, technology to create real change and move to value-based payments, it could move [health care] system forward'"
f69ff31e-7dc7-4917-930c-193537a33b8d,2018-06-07T08:00:00.000+08:00,5,"Eli Lilly CEO David Ricks Currently Speaking At Detroit Economic Club, Highlights Co. Launching Recently-Approved RA Drug Olumiant At 60% Discount To Competitors"
5a2d3f29-b0d5-4ff0-b27c-64183334383a,2018-06-07T08:00:00.000+08:00,2,"Eli Lilly CEO Calls For Uniform Prices, Better Use Of Technology In Health Care"
67f614c8-f2c5-4f66-a152-075d573290dd,2018-06-07T08:00:00.000+08:00,4,"Lilly CEO Ricks, When Asked If Co. Will Participate In Right-To-Try Initiative, Tells Benzinga, Co. Has Supplied Medication To That Patient Population 'For Years,' Notes Co. Was Full Participant In Expanded Access Program, But Does Not Answer Directly"
85069539-9272-4fe0-9130-e9d32ae3f315,2018-06-07T08:00:00.000+08:00,3,"Lilly CEO Ricks Positive On JP Morgan, Berkshire, Amazon Health Care Coalition, Says 'If these 3 large cos. can use their scale, technology to create real change and move to value-based payments, it could move [health care] system forward'"
97bcfeb4-caaf-4564-9ce0-d847fcae3038,2018-06-07T08:00:00.000+08:00,5,"Eli Lilly CEO David Ricks Currently Speaking At Detroit Economic Club, Highlights Co. Launching Recently-Approved RA Drug Olumiant At 60% Discount To Competitors"
b62b345b-7a93-4f4e-9c41-d6489bbf271d,2018-06-05T08:00:00.000+08:00,1,UPDATE: Eli Lilly Reports Will Initiate Phase 3 Trial In Moderate To Severe Ulcerative Colitis In 2018
7bf9fd7c-456d-4bc9-839f-4a8051a73fd3,2018-06-05T08:00:00.000+08:00,5,"Eli Lilly Offers New Safety, Efficacy Data From Phase 2 Study Evaluating Mirikizumab In Patients With Moderate To Severe Ulcerative Colitis: Showed Achivement Of Greater Rates Of Clinical Remission At 12 Weeks vs Placebo"
2616afd2-4d2d-4847-876e-cfb7e9d704e2,2018-06-05T08:00:00.000+08:00,4,"FDA Expands Eli Lilly's ALIMTA (pemetrexed) Label To Include Combination With KEYTRUDA (pembrolizumab) And Carboplatin As First-Line Treatment For Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective Of PD-L1 Expression"
3bd06e67-501d-4ea4-b3e6-55e39a0c19c2,2018-06-05T08:00:00.000+08:00,3,UPDATE: Eli Lilly Reports Will Initiate Phase 3 Trial In Moderate To Severe Ulcerative Colitis In 2018
bc2531ac-9724-4671-8eb1-6ecd5cd82bbe,2018-06-05T08:00:00.000+08:00,5,"Eli Lilly Offers New Safety, Efficacy Data From Phase 2 Study Evaluating Mirikizumab In Patients With Moderate To Severe Ulcerative Colitis: Showed Achivement Of Greater Rates Of Clinical Remission At 12 Weeks vs Placebo"
de43ab3f-8d5b-4cd0-b16c-dc7e9ece78fb,2018-06-05T08:00:00.000+08:00,5,"FDA Expands Eli Lilly's ALIMTA (pemetrexed) Label To Include Combination With KEYTRUDA (pembrolizumab) And Carboplatin As First-Line Treatment For Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective Of PD-L1 Expression"
6467d056-c5c1-4da8-ad4f-5b50a96854b7,2018-06-04T08:00:00.000+08:00,2,"Donald Trump Tweets: 'We had Repeal & Replace done (and the saving to our country of one trillion dollars) except for one person, but it is getting done anyway'...'less expensive plans will be announced this month. Drug prices coming down & Right to Try!'"
453e05c5-a3ce-4028-9b9c-5c06919039b3,2018-06-04T08:00:00.000+08:00,2,"Donald Trump Tweets: 'We had Repeal & Replace done (and the saving to our country of one trillion dollars) except for one person, but it is getting done anyway'...'less expensive plans will be announced this month. Drug prices coming down & Right to Try!'"
cd2d9c23-7655-4622-a0b5-06c4aa81d5e3,2018-06-03T08:00:00.000+08:00,3,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines
8eeeb9a7-6e0e-4b8b-9e6b-8cf05213a54c,2018-06-03T08:00:00.000+08:00,4,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines
7092ae75-324a-49a8-a9f7-e664083e9e7e,2018-06-01T08:00:00.000+08:00,5,Eli Lilly Press Release Confirms Earlier News Of FDA Approval For Olumiant
67e5bb18-0ff6-4cc6-b200-2145b5d55e52,2018-06-01T08:00:00.000+08:00,4,Eli Lilly And Co.'s Olumiant Wins FDA Approval
83f6eda9-d0c1-45dd-b11c-ce289453ef28,2018-06-01T08:00:00.000+08:00,4,Eli Lilly Says Will Present New Data Evaluating Mirikizumab Fro Treatment Of Moderate To Severe Ulcerative Colitis At Digestive Disease Week Jun. 2-5
a5ad106a-370a-4920-95b3-4587629cfe04,2018-06-01T08:00:00.000+08:00,3,Eli Lilly Press Release Confirms Earlier News Of FDA Approval For Olumiant
5867e305-53fa-4e4f-b9d2-24807dffe8f4,2018-06-01T08:00:00.000+08:00,4,Eli Lilly And Co.'s Olumiant Wins FDA Approval
17fa9e13-a215-4611-adb3-a443a6065782,2018-06-01T08:00:00.000+08:00,4,Eli Lilly Says Will Present New Data Evaluating Mirikizumab Fro Treatment Of Moderate To Severe Ulcerative Colitis At Digestive Disease Week Jun. 2-5
91a79229-b000-466c-9cba-b758aa81531d,2018-05-22T08:00:00.000+08:00,4,Eli Lilly Announces FDA Approval for its Taltz to Include Psoriasis Involving the Genital Area on its Label
d294021b-97c4-4b27-8836-80ce59951bd3,2018-05-22T08:00:00.000+08:00,4,Lilly's Taltz® (ixekizumab) Receives First U.S. FDA Approval For Label Update To Include Data For Psoriasis Involving Genital Area
248ada6f-838a-4571-a28f-e171e4814462,2018-05-22T08:00:00.000+08:00,4,Eli Lilly Announces FDA Approval for its Taltz to Include Psoriasis Involving the Genital Area on its Label
2bf0a038-bd08-4ccc-a0f0-a1a61eea7496,2018-05-22T08:00:00.000+08:00,3,Lilly's Taltz® (ixekizumab) Receives First U.S. FDA Approval For Label Update To Include Data For Psoriasis Involving Genital Area
016a5b15-f828-467e-aeaf-2d73cdc5c34d,2018-05-14T08:00:00.000+08:00,5,"Eli Lilly To Buy AurKa Pharma For $110M Upfront Payment, Plus Eligibility To Receive Up To $465M In Regulatory, Sales Milestones Related To AK-01"
b3a1a565-9212-40b7-8737-1d43727afa32,2018-05-14T08:00:00.000+08:00,4,"Eli Lilly To Buy AurKa Pharma For $110M Upfront Payment, Plus Eligibility To Receive Up To $465M In Regulatory, Sales Milestones Related To AK-01"
aa2d5d92-60b8-4057-82d9-94c16aeda377,2018-05-11T08:00:00.000+08:00,3,55 Biggest Movers From Yesterday
34ebf7d7-9b5c-409b-b96d-d6688fc019a8,2018-05-11T08:00:00.000+08:00,3,UPDATE: Eli Lilly Announces Tender Offer for HBM-Portfolio Company ARMO BioSciences for $1.6B
f6b52fa2-d174-431a-abc5-44ac5c095023,2018-05-11T08:00:00.000+08:00,3,55 Biggest Movers From Yesterday
05ade9b3-5a80-4b36-87bb-c849ba2cff70,2018-05-11T08:00:00.000+08:00,5,UPDATE: Eli Lilly Announces Tender Offer for HBM-Portfolio Company ARMO BioSciences for $1.6B
1fb4a610-0a52-4a30-8f25-d8c48ae1899f,2018-05-10T08:00:00.000+08:00,2,Mid-Afternoon Market Update: Prestige Brands Gains On Earnings Beat; MDC Partners Shares Slide
f1a58a30-9b20-4cd5-b755-e2664825d082,2018-05-10T08:00:00.000+08:00,3,40 Stocks Moving In Thursday's Mid-Day Session
cf53737d-ccd6-4775-9797-bf9c0ead14a6,2018-05-10T08:00:00.000+08:00,4,Mid-Day Market Update: Dow Rises 150 Points; Hudson Technologies Shares Plunge
5e6c39da-5a80-40cb-a7e4-4ef6a4313448,2018-05-10T08:00:00.000+08:00,5,Mid-Morning Market Update: Markets Open Higher; Magna Tops Q1 Views
f7a71a55-009f-45c1-99b1-2ffa650780cd,2018-05-10T08:00:00.000+08:00,5,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results"
716941b9-2c6c-4272-b145-3e47245d806f,2018-05-10T08:00:00.000+08:00,4,32 Stocks Moving In Thursday's Pre-Market Session
dab7dc98-139f-4396-b96e-31e3e844c2a4,2018-05-10T08:00:00.000+08:00,5,Lilly Announces Agreement To Acquire ARMO BioSciences For $50/Share Or ~$1.6B
e4b6906c-6bc8-44d4-b4ac-7e32be666363,2018-05-10T08:00:00.000+08:00,3,Mid-Afternoon Market Update: Prestige Brands Gains On Earnings Beat; MDC Partners Shares Slide
baa761e5-8912-41c8-a2c1-d73f792f0c91,2018-05-10T08:00:00.000+08:00,2,40 Stocks Moving In Thursday's Mid-Day Session
bf73237a-af32-4d06-8600-40c22280f6b9,2018-05-10T08:00:00.000+08:00,1,Mid-Day Market Update: Dow Rises 150 Points; Hudson Technologies Shares Plunge
59035f96-6610-4793-b2e2-450b8f3ca514,2018-05-10T08:00:00.000+08:00,4,Mid-Morning Market Update: Markets Open Higher; Magna Tops Q1 Views
f85ed433-50da-43b0-b8f0-2710fab74ffc,2018-05-10T08:00:00.000+08:00,5,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results"
8e7d0ab6-3f31-42a6-83de-d29ea42926d6,2018-05-10T08:00:00.000+08:00,3,32 Stocks Moving In Thursday's Pre-Market Session
22c14de0-5e1c-4564-b316-461cc1079aa0,2018-05-10T08:00:00.000+08:00,4,Lilly Announces Agreement To Acquire ARMO BioSciences For $50/Share Or ~$1.6B
5ccedf6f-5aea-40df-ba94-fb1b44ecdcff,2018-05-07T08:00:00.000+08:00,2,What's In Store For Radius Health In Q1 Earnings?
e453c5ac-8e0a-4a96-92c1-aa1a1bf79c11,2018-05-07T08:00:00.000+08:00,2,What's In Store For Radius Health In Q1 Earnings?
acecdb5e-d93d-43a8-8b5a-b473390c0f24,2018-04-25T08:00:00.000+08:00,4,Eli Lilly and NCCD of China Collaborate to Advance Care for People Living with Diabetes and Cardiovascular Disease
fc33c3cd-666b-4874-9dad-74f774abe625,2018-04-25T08:00:00.000+08:00,4,Eli Lilly and NCCD of China Collaborate to Advance Care for People Living with Diabetes and Cardiovascular Disease
c5db531e-6c92-499b-b469-b585e37de9bb,2018-04-24T08:00:00.000+08:00,3,19 Companies Google Could Buy With Its $102 Billion In Cash
64466205-5d29-4dea-804a-bf98a85b58c4,2018-04-24T08:00:00.000+08:00,1,Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches
afa82b01-c7eb-4429-b74f-3d4a99103e77,2018-04-24T08:00:00.000+08:00,3,"Eli Lilly Says It Is Looking To Do More Deals In Oncology, Including Immuno-Oncology And Other Cancer Drugs"
50d114ba-f49d-4751-9d44-e4828853ea35,2018-04-24T08:00:00.000+08:00,2,28 Stocks Moving In Tuesday's Pre-Market Session
c87d0ca0-137c-421b-ae11-c8f1c6a6ffca,2018-04-24T08:00:00.000+08:00,4,"UPDATE: Eli Lilly Raises FY18 Adj. EPS Outlook From $4.81-$4.91 To $5.10-$5.20 vs $4.88 Est., Sales From $23B-$23.5B To $23.7B-$24.2B vs $23.4B Est."
c649062a-1dbd-499c-8d02-132c4a07a815,2018-04-24T08:00:00.000+08:00,4,Eli Lilly Raises FY18 Outlook
287bc644-d20b-43a6-9067-187a20b8046a,2018-04-24T08:00:00.000+08:00,5,"Eli Lilly Q1 Adj. EPS $1.34 Beats $1.14 Est., Sales $5.7B Beats $5.49B Est."
355b0d47-6199-49d6-9db8-a52c811d928b,2018-04-24T08:00:00.000+08:00,5,Lilly Reports Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies at #AAN2018
4c012fe9-0db0-491b-9b12-715fdc1802eb,2018-04-24T08:00:00.000+08:00,3,"12 Stocks To Watch For April 24, 2018"
52233713-5723-4e6c-aa04-5b1904e0040c,2018-04-24T08:00:00.000+08:00,3,"Earnings Scheduled For April 24, 2018"
b83b88ff-f9c6-4ebe-a6d0-8813ed82cc1c,2018-04-24T08:00:00.000+08:00,4,"Lilly, Incyte Announce FDA Advisory Committee Recommends Approval of Baricitinib 2mg, Not 4mg, for Treatment of Moderately-to-Severely Active RA"
4b12f94a-8ca3-4f1a-8581-4f8e2833dc0b,2018-04-24T08:00:00.000+08:00,1,19 Companies Google Could Buy With Its $102 Billion In Cash
d8339c79-3e8f-4695-be14-2aa5f5409402,2018-04-24T08:00:00.000+08:00,3,Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches
25422692-a14a-40fd-992d-380dbec274c4,2018-04-24T08:00:00.000+08:00,3,"Eli Lilly Says It Is Looking To Do More Deals In Oncology, Including Immuno-Oncology And Other Cancer Drugs"
609ddc83-ba3e-43a5-b6be-e687098160cf,2018-04-24T08:00:00.000+08:00,3,28 Stocks Moving In Tuesday's Pre-Market Session
7d36b170-5c8b-4951-a1e7-030b101877c6,2018-04-24T08:00:00.000+08:00,4,"UPDATE: Eli Lilly Raises FY18 Adj. EPS Outlook From $4.81-$4.91 To $5.10-$5.20 vs $4.88 Est., Sales From $23B-$23.5B To $23.7B-$24.2B vs $23.4B Est."
521615d2-5fec-409e-9f25-392c0b76c4be,2018-04-24T08:00:00.000+08:00,4,Eli Lilly Raises FY18 Outlook
3eba9891-5545-4901-aa74-e20b3f1d86a7,2018-04-24T08:00:00.000+08:00,5,"Eli Lilly Q1 Adj. EPS $1.34 Beats $1.14 Est., Sales $5.7B Beats $5.49B Est."
9c1b49b9-7485-4177-baae-840248fda85a,2018-04-24T08:00:00.000+08:00,5,Lilly Reports Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies at #AAN2018
e575053a-23b7-4d2d-82fb-d4337aff7a6b,2018-04-24T08:00:00.000+08:00,3,"12 Stocks To Watch For April 24, 2018"
bec2825a-33c9-4180-93f4-3a57e5bd5cc2,2018-04-24T08:00:00.000+08:00,4,"Earnings Scheduled For April 24, 2018"
4c84795d-3f95-4e90-be3f-67e04d1de67e,2018-04-24T08:00:00.000+08:00,4,"Lilly, Incyte Announce FDA Advisory Committee Recommends Approval of Baricitinib 2mg, Not 4mg, for Treatment of Moderately-to-Severely Active RA"
c1e109ff-70c8-45e7-a959-f6f8d56d8cd0,2018-04-23T08:00:00.000+08:00,2,"Top Ideas From The 2018 Sohn Conference: Box, Bitcoin, Facebook, Palo Alto And More"
42e34a99-376f-4dc7-bc43-2ee7a9bd5c4b,2018-04-23T08:00:00.000+08:00,3,Earnings Preview: Verizon And AT&T Report Q1 Results This Week
cc0ac04e-12f1-42fb-af3b-7912dd3d0e8b,2018-04-23T08:00:00.000+08:00,4,"Upcoming Earnings: CAT, LLY And BA Report This Week"
0368f20f-3e0f-4974-947d-5dcc494206fd,2018-04-23T08:00:00.000+08:00,5,"From Sohn Conference: Ecor1's Nodelman On Ascendis Pharma Highlighted 10 Potential Buyers Of Co., Including Eli Lilly, Pfizer"
3cccf53f-109f-4832-a94d-1302d8088633,2018-04-23T08:00:00.000+08:00,1,"The Week Ahead: Sohn Conference, FANG Earnings, DocuSign IPO"
059ddd6b-6a36-440a-8423-21ac065ddc58,2018-04-23T08:00:00.000+08:00,2,REMINDER: Eli Lilly and Incyte Have FDA AdCom Meeting For Baricitinib Today
a1d470bd-1fb2-4fb0-a3c3-6d6364501b70,2018-04-23T08:00:00.000+08:00,3,"Top Ideas From The 2018 Sohn Conference: Box, Bitcoin, Facebook, Palo Alto And More"
a7e5dd80-3c25-4a60-ad98-77bb297463a1,2018-04-23T08:00:00.000+08:00,3,Earnings Preview: Verizon And AT&T Report Q1 Results This Week
3cfed6e2-5f91-4c85-a687-f1cd136dccba,2018-04-23T08:00:00.000+08:00,4,"Upcoming Earnings: CAT, LLY And BA Report This Week"
c453e755-afb8-4259-b66e-4bc4066cc25f,2018-04-23T08:00:00.000+08:00,5,"From Sohn Conference: Ecor1's Nodelman On Ascendis Pharma Highlighted 10 Potential Buyers Of Co., Including Eli Lilly, Pfizer"
b400cd8a-a9e4-4af6-846b-e557ca83df53,2018-04-23T08:00:00.000+08:00,2,"The Week Ahead: Sohn Conference, FANG Earnings, DocuSign IPO"
8d91ea62-dd0d-44db-83e7-71ae3afe103e,2018-04-23T08:00:00.000+08:00,4,REMINDER: Eli Lilly and Incyte Have FDA AdCom Meeting For Baricitinib Today
2a44f18b-5c59-4983-8c49-0a60005b0e37,2018-04-20T08:00:00.000+08:00,3,"Eli Lilly Reports Add'l Topline Results From CYRAMZA Phase 3 RANGE Study, Positive Trend Seen In Secondary Endpoint But Did Not Reach Statistical Significance"
7e3c16fd-b7d1-4384-9af0-3399e5b44afc,2018-04-20T08:00:00.000+08:00,4,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More"
2f520947-67a4-4f06-8054-4095cef520bd,2018-04-20T08:00:00.000+08:00,4,"Eli Lilly Reports Add'l Topline Results From CYRAMZA Phase 3 RANGE Study, Positive Trend Seen In Secondary Endpoint But Did Not Reach Statistical Significance"
febaadcd-7d53-4442-8ef6-9e55151d2ef9,2018-04-20T08:00:00.000+08:00,2,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More"
21505871-4372-47ed-af00-86d6564cfaa9,2018-04-19T08:00:00.000+08:00,3,"FDA Staff Review Of Eli Lilly's Rheumatoid Arthritis Treatment Says Supportive Of 2mg Dose, But Not 4mg Dose"
c2bea36c-e648-4880-81f4-93bdeeb298ec,2018-04-19T08:00:00.000+08:00,3,"FDA Staff Review Of Eli Lilly's Rheumatoid Arthritis Treatment Says Supportive Of 2mg Dose, But Not 4mg Dose"
03aa52d3-dc10-45b1-9f1a-2174867bb2ca,2018-04-16T08:00:00.000+08:00,3,"Benzinga's Bulls & Bears Of The Week: Caterpillar, Facebook, Starbucks, Tesla And More"
29e5c68b-208d-4427-996c-bc27ab87d76f,2018-04-16T08:00:00.000+08:00,3,"Benzinga's Bulls & Bears Of The Week: Caterpillar, Facebook, Starbucks, Tesla And More"
502b83cf-8b53-456c-9d85-18c105a6d35a,2018-04-13T08:00:00.000+08:00,2,"Benzinga's Top Analyst Calls From April 13, 2018"
a877ae3d-5eb9-4ce9-a056-e3a144c08735,2018-04-13T08:00:00.000+08:00,4,BMO's Bearish Stance On Eli Lilly Comes To An End
2f98f8e5-b0cf-46ea-8c02-90d9f1f396ed,2018-04-13T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For April 13, 2018"
510960dd-f674-4c23-8d8e-86f858299fed,2018-04-13T08:00:00.000+08:00,4,BMO Capital Upgrades Eli Lilly to Market Perform
63bc33d6-f42f-4258-92ad-d711edd3f528,2018-04-13T08:00:00.000+08:00,2,"Benzinga's Top Analyst Calls From April 13, 2018"
a74c075b-4836-4e89-bb4d-2865473b7055,2018-04-13T08:00:00.000+08:00,4,BMO's Bearish Stance On Eli Lilly Comes To An End
7e2e653e-125b-441a-886e-84cf00d19a24,2018-04-13T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For April 13, 2018"
5f2cef9a-f6b1-4be9-a6c4-1823cf8c48db,2018-04-13T08:00:00.000+08:00,4,BMO Capital Upgrades Eli Lilly to Market Perform
278e66ac-1b72-4cbf-9f45-5f4f7b2b8a3a,2018-04-04T08:00:00.000+08:00,1,"Eli Lilly To Report Q1 Earnings On Tues., Apr. 24 Before Market Open"
defa74a4-8cd2-467a-a139-79495aa685ec,2018-04-04T08:00:00.000+08:00,2,"UPDATE: As A Result Of Lilly's Transaction, The Co. Will Incur An Acquired In-Process Research And Development Charge To Earnings Of ~$0.05/Share In Q2"
cdea6372-5ec3-4416-8f9c-a68bc390c8d4,2018-04-04T08:00:00.000+08:00,4,"Lilly, Sigilon Therapeutics Report Strategic Partnership to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes; Sigilon To Receive $63M Up Front And Lilly To Make An Undisclosed Equity Investment In Sigilon"
2764173d-8276-4d82-941a-eeda54163f0f,2018-04-04T08:00:00.000+08:00,5,Lilly Announces CYRAMZA Phase 3 Reach-2 Study Met Overall Survival Endpoint And Secondary Endpoint Of Progression-Free Survival
aeed4728-e887-4440-bdb3-e158d30e8582,2018-04-04T08:00:00.000+08:00,3,Terns Pharmaceutical Acquires Global Exclusive Rights To Develop And Commercialize 3 NASH Assets From Eli Lilly
5c688883-bfcb-48ad-ae06-7de92ded507a,2018-04-04T08:00:00.000+08:00,4,"Eli Lilly To Report Q1 Earnings On Tues., Apr. 24 Before Market Open"
9c762bd0-4c47-4b02-afe5-6f2ecc5c0b92,2018-04-04T08:00:00.000+08:00,1,"UPDATE: As A Result Of Lilly's Transaction, The Co. Will Incur An Acquired In-Process Research And Development Charge To Earnings Of ~$0.05/Share In Q2"
292d1ba6-f277-44ad-bc3f-3b839e1c19ae,2018-04-04T08:00:00.000+08:00,4,"Lilly, Sigilon Therapeutics Report Strategic Partnership to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes; Sigilon To Receive $63M Up Front And Lilly To Make An Undisclosed Equity Investment In Sigilon"
3ea79aa9-e1f5-4523-ba9f-8f3ffd92bab8,2018-04-04T08:00:00.000+08:00,5,Lilly Announces CYRAMZA Phase 3 Reach-2 Study Met Overall Survival Endpoint And Secondary Endpoint Of Progression-Free Survival
fd171cb6-7fdb-43c6-9fcd-b0802c203b8c,2018-04-04T08:00:00.000+08:00,3,Terns Pharmaceutical Acquires Global Exclusive Rights To Develop And Commercialize 3 NASH Assets From Eli Lilly
ed558236-f5c1-4938-969e-94a7c65bf2c2,2018-04-03T08:00:00.000+08:00,4,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates
d1cf9adb-8a10-4e17-bfb5-60e302d16ef3,2018-04-03T08:00:00.000+08:00,4,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates
1dcc2f36-d9be-4098-8df2-eaaacb829937,2018-03-20T08:00:00.000+08:00,2,Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season
febf1ae1-7d5e-4a4a-a09d-de05a0613cc2,2018-03-20T08:00:00.000+08:00,2,Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season
7cb304ad-ec36-4599-9400-80ac24b974e9,2018-03-15T08:00:00.000+08:00,3,"Jim Cramer Shares His Thoughts On Merck, Five Below And More"
b699f079-4e1b-41eb-8c09-58247e9a1988,2018-03-15T08:00:00.000+08:00,4,"Jim Cramer Shares His Thoughts On Merck, Five Below And More"
8f126989-fc71-445d-b630-15db7fb3224d,2018-03-14T08:00:00.000+08:00,1,"Citigroup, Eli Lilly, Square, Target: 'Fast Money' Picks For March 14"
50d0a76a-8ee9-44e8-8161-4bd256b53556,2018-03-14T08:00:00.000+08:00,4,"Citigroup, Eli Lilly, Square, Target: 'Fast Money' Picks For March 14"
edd41194-9196-46a9-bb6d-bd4febe87aaf,2018-03-07T08:00:00.000+08:00,2,Height Casts 65% Odds That Congress Rolls Back Pharma Discounts
dcc3fee2-b72e-47a6-a331-4b3f311e2b10,2018-03-07T08:00:00.000+08:00,3,Height Casts 65% Odds That Congress Rolls Back Pharma Discounts
18fb8cb8-b7ec-4359-86bc-f5f9745264df,2018-03-06T08:00:00.000+08:00,4,Dear Activists: Buying Stock Can Effect More Change Than Selling It
451d1c2c-668b-482e-a9c9-9064742596e3,2018-03-06T08:00:00.000+08:00,5,Boehringer Ingelheim and Eli Lilly Expand Their Heart Failure Program for Jardiance with New Exercise Capacity Trials
a9a83699-84c8-49b9-8631-e9eee5038eaa,2018-03-06T08:00:00.000+08:00,4,Dear Activists: Buying Stock Can Effect More Change Than Selling It
d5234412-52d5-46d2-9729-619544168c6c,2018-03-06T08:00:00.000+08:00,4,Boehringer Ingelheim and Eli Lilly Expand Their Heart Failure Program for Jardiance with New Exercise Capacity Trials
3cdfc595-2cfd-41ee-a803-1f3627630b45,2018-02-27T08:00:00.000+08:00,3,Benzinga Pro's 5 Stocks To Watch Today
e55904d1-d1fc-4746-a5be-f4c0e3783dbd,2018-02-27T08:00:00.000+08:00,4,Benzinga Pro's 5 Stocks To Watch Today
d665dc8c-bb06-4e41-aa4f-5a897dd70ca8,2018-02-26T08:00:00.000+08:00,5,"UPDATE: Eli Lilly Says 'New indication based on MONARCH 3 trial can help more women living with HR+, HER2- advanced breast cancer'"
39837ab1-026b-4943-bdda-615cf2ed2cca,2018-02-26T08:00:00.000+08:00,5,Eli Lilly Reports Received Added FDA Approval For Verzenio As Initial Treatment For Advanced Breast Cancer
3aea94a8-21eb-40d8-990f-3875ade9639b,2018-02-26T08:00:00.000+08:00,5,Eli Lilly's Says Trulicity in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes
7d2b6f2e-de40-44f4-a961-40d0eb66ae58,2018-02-26T08:00:00.000+08:00,3,"UPDATE: Eli Lilly Says 'New indication based on MONARCH 3 trial can help more women living with HR+, HER2- advanced breast cancer'"
2ada73d2-15dc-4d0d-9d60-813b3819c5ac,2018-02-26T08:00:00.000+08:00,5,Eli Lilly Reports Received Added FDA Approval For Verzenio As Initial Treatment For Advanced Breast Cancer
49adda24-a447-416a-882b-db8c26f5d870,2018-02-26T08:00:00.000+08:00,5,Eli Lilly's Says Trulicity in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes
83bb157b-deac-4a33-ac90-46cdd4d2ec7d,2018-02-22T08:00:00.000+08:00,4,"Eli Lilly Shares Near Session Highs, Up 0.4%; Traders Circulating Takeover Chatter Out Of Chat"
cf2f0b3f-5496-42c6-b460-b7ee9eff10f1,2018-02-22T08:00:00.000+08:00,2,"Eli Lilly Shares Near Session Highs, Up 0.4%; Traders Circulating Takeover Chatter Out Of Chat"
4aa87ec6-d669-45d1-9798-874b3c797c6c,2018-02-13T08:00:00.000+08:00,1,A Peek Into The Markets: U.S. Stock Futures Down; Crude Oil Falls
c6fae863-8441-4c95-940d-8e184814ae6b,2018-02-13T08:00:00.000+08:00,5,Eli Lilly Says its Top-Line Phase 3 Study of Taltz Met the Primary and All Key Secondary Endpoints
20367771-1123-492b-8fdd-69187fb9e174,2018-02-13T08:00:00.000+08:00,2,A Peek Into The Markets: U.S. Stock Futures Down; Crude Oil Falls
d4d1cbd5-c3f0-4e35-9458-477f0848d1b9,2018-02-13T08:00:00.000+08:00,4,Eli Lilly Says its Top-Line Phase 3 Study of Taltz Met the Primary and All Key Secondary Endpoints
1991fff2-45f3-4c73-9328-f3e9a9fe8ec3,2018-02-08T08:00:00.000+08:00,2,The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease
3092120c-2585-4238-bd3d-66d8b1f2458a,2018-02-08T08:00:00.000+08:00,3,The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease
127d01f3-a144-4757-909e-94511106c0dd,2018-02-07T08:00:00.000+08:00,4,Array's Melanoma Combo Shows Positive Overall Survival Data
3316f378-6fa1-4e98-aaae-03d92f8e0dc1,2018-02-07T08:00:00.000+08:00,5,Array's Melanoma Combo Shows Positive Overall Survival Data
77fe97c9-c0f4-4a2b-8836-3203f7382d04,2018-01-31T08:00:00.000+08:00,3,"Treasury Bounce, Boeing Results Appear To Give Slumping Market New Life"
ad826695-37cf-49c0-ae18-92d9b1696853,2018-01-31T08:00:00.000+08:00,2,A Peek Into The Markets: U.S. Stock Futures Rise; Fed Decision In Focus
cc438a49-2275-4170-8b8c-2161a39549f6,2018-01-31T08:00:00.000+08:00,4,"Eli Lilly Raises FY18 Adj. EPS Guidance From $4.60-$4.70 to $4.81-$4.91 vs $4.68 Est., Reaffirms Sales Guidance"
b42e5546-5362-4037-993b-7d3a02d3fd88,2018-01-31T08:00:00.000+08:00,4,"Eli Lilly Reports Q4 Adj. EPS $1.14 vs $1.07 Est., Sales $6.16B vs $5.94B Est."
d786355d-f8d2-4db0-90b0-281ea02f37a6,2018-01-31T08:00:00.000+08:00,1,"15 Stocks To Watch For January 31, 2018"
c284a70c-564d-486c-b1f3-a1edb24db8d2,2018-01-31T08:00:00.000+08:00,3,"Earnings Scheduled For January 31, 2018"
9b2805d4-3d67-4047-9c8d-5cef8f8d90bc,2018-01-31T08:00:00.000+08:00,2,"Treasury Bounce, Boeing Results Appear To Give Slumping Market New Life"
fe6fd0e9-5039-4c03-8844-e40ce32fcfce,2018-01-31T08:00:00.000+08:00,3,A Peek Into The Markets: U.S. Stock Futures Rise; Fed Decision In Focus
f4c34ff1-219f-4363-a5ee-e64f62040450,2018-01-31T08:00:00.000+08:00,4,"Eli Lilly Raises FY18 Adj. EPS Guidance From $4.60-$4.70 to $4.81-$4.91 vs $4.68 Est., Reaffirms Sales Guidance"
6ed60911-2602-41d9-9992-ebe8b8dc3727,2018-01-31T08:00:00.000+08:00,4,"Eli Lilly Reports Q4 Adj. EPS $1.14 vs $1.07 Est., Sales $6.16B vs $5.94B Est."
4449dc18-02cc-4461-a7b1-b36cbc2448c4,2018-01-31T08:00:00.000+08:00,2,"15 Stocks To Watch For January 31, 2018"
5acc649c-68f7-43cc-a0e0-7f0ddd0d929b,2018-01-31T08:00:00.000+08:00,1,"Earnings Scheduled For January 31, 2018"
1925aa49-7bd9-4996-b8c3-6fd4e4af2139,2018-01-30T08:00:00.000+08:00,3,Hang On: Rate Fears In Focus As Futures Point Lower After Monday's Big Losses
299f5a08-9b60-41dc-a1ae-c76168c00632,2018-01-30T08:00:00.000+08:00,4,Hang On: Rate Fears In Focus As Futures Point Lower After Monday's Big Losses
07793b62-b08c-4a19-8357-089e858b78b1,2018-01-29T08:00:00.000+08:00,3,"The Week Ahead: Big Tech Earnings, Fed Rate Decision Likely To Dominate Headlines"
b49dfd32-2596-4e58-8a74-29be867e56f6,2018-01-29T08:00:00.000+08:00,4,"Analyst: Radius Health Could Advance 50% With Osteoporosis Treatment, Breast Cancer Pipeline"
49c188da-737c-4a80-8ead-b58ab6f300b5,2018-01-29T08:00:00.000+08:00,3,"PFE, LLY, MRK Write Up 'Scripts For Q4"
4b841b9d-16ab-410d-81f7-fe6f81da4f28,2018-01-29T08:00:00.000+08:00,2,"Fed, Earnings Are Meaty Filling Between Slices Of Job, Price Data"
dae82937-004c-4c36-8c4a-486a1d6546e1,2018-01-29T08:00:00.000+08:00,5,"The Week Ahead: Big Tech Earnings, Fed Rate Decision Likely To Dominate Headlines"
e25bf634-23f1-403a-a75c-f39c86ae5146,2018-01-29T08:00:00.000+08:00,4,"Analyst: Radius Health Could Advance 50% With Osteoporosis Treatment, Breast Cancer Pipeline"
4c578d04-476c-4e17-acc8-3ceaa7905b49,2018-01-29T08:00:00.000+08:00,2,"PFE, LLY, MRK Write Up 'Scripts For Q4"
90d2f020-5210-4a09-92d0-1bdff8096959,2018-01-29T08:00:00.000+08:00,3,"Fed, Earnings Are Meaty Filling Between Slices Of Job, Price Data"
558652f6-99ad-445f-a8a0-e76890a14f64,2018-01-26T08:00:00.000+08:00,4,Jefferies On Gilead: 'We See Better Days Ahead'
49c84c0f-8a68-44ad-b53b-9d8a47b674c4,2018-01-26T08:00:00.000+08:00,5,Jefferies On Gilead: 'We See Better Days Ahead'
5564e0ac-72e7-4306-b208-97cdaf34a2cf,2018-01-25T08:00:00.000+08:00,5,Lilly receives EU Marketing Authorisation for Taltz for the Treatment of Active Psoriatic Arthritis
55f85465-40fd-4c72-9890-d41e4eecff60,2018-01-25T08:00:00.000+08:00,4,Lilly receives EU Marketing Authorisation for Taltz for the Treatment of Active Psoriatic Arthritis
01e9d388-9a08-4705-a385-c295eb140d69,2018-01-22T08:00:00.000+08:00,2,Eli Lilly's Challenges Leaves Credit Suisse With A 'Sour Taste'
6ce8d22b-bb01-4389-871a-8c31ecb99355,2018-01-22T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For January 22, 2018"
72e5c048-4a25-4f99-bee5-ddcb14d4f606,2018-01-22T08:00:00.000+08:00,4,"The Market In 5 Minutes: Celgene Buys Juno, Netflix Earnings Preview, Eagles And Patriots Advance To Super Bowl"
4e809dc9-0fff-4a74-8ee0-d056734a69c2,2018-01-22T08:00:00.000+08:00,5,Eli Lilly Announces FDA Approval of Credelio to Treat and Protect Against Ticks and Fleas
91e4853b-10b5-4921-907a-1634663b4b87,2018-01-22T08:00:00.000+08:00,2,Credit Suisse Downgrades Eli Lilly to Underperform
a4416308-8018-4ebf-b59b-f105bc91abb4,2018-01-22T08:00:00.000+08:00,1,Eli Lilly's Challenges Leaves Credit Suisse With A 'Sour Taste'
ba1a500d-019f-4dd3-8193-c4e9d505630f,2018-01-22T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For January 22, 2018"
78b530c6-708f-4442-841f-5a9568b8e818,2018-01-22T08:00:00.000+08:00,4,"The Market In 5 Minutes: Celgene Buys Juno, Netflix Earnings Preview, Eagles And Patriots Advance To Super Bowl"
3bfba2ae-15f8-4898-8fff-8a34d9c743ad,2018-01-22T08:00:00.000+08:00,5,Eli Lilly Announces FDA Approval of Credelio to Treat and Protect Against Ticks and Fleas
49f2d07d-250a-4ff1-bb73-a5febb8db347,2018-01-22T08:00:00.000+08:00,2,Credit Suisse Downgrades Eli Lilly to Underperform
cdf7cd84-ad03-4821-b84d-7b4d7535b1d3,2018-01-20T08:00:00.000+08:00,4,"Benzinga's Weekly Bulls & Bears: Apple, Eli Lilly, GE, Nike And More"
2ecacc17-8028-44b5-94e7-94284223932f,2018-01-20T08:00:00.000+08:00,4,"Benzinga's Weekly Bulls & Bears: Apple, Eli Lilly, GE, Nike And More"
6c07b311-58d7-42db-8613-2b27125db366,2018-01-19T08:00:00.000+08:00,3,The Top 10 Value Stocks In The S&P 500
63581df1-0c7f-48a2-b35e-1ea87bec54fb,2018-01-19T08:00:00.000+08:00,3,The Top 10 Value Stocks In The S&P 500
98621df4-4b78-48b9-b831-109afc289fa7,2018-01-16T08:00:00.000+08:00,2,"Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade"
f4b1a131-b528-4149-a0b0-2b7f3ba2cc60,2018-01-16T08:00:00.000+08:00,3,Goldman Sachs Downgrades Eli Lilly to Neutral
f6a5f91f-2b8b-44d2-9272-685915b1ecca,2018-01-16T08:00:00.000+08:00,4,Innventure and Eli Lilly's Elanco Announce Strategic Initiative to Commercialize Disruptive Technologies for Animal Health
b8101fa1-cfdc-47d5-b014-30e9a3ebd28c,2018-01-16T08:00:00.000+08:00,2,"Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade"
0825a224-116f-4ca7-b06b-b44f6228ed82,2018-01-16T08:00:00.000+08:00,3,Goldman Sachs Downgrades Eli Lilly to Neutral
4a9a0bd8-4b7e-48cb-ae5b-14b9ff78b001,2018-01-16T08:00:00.000+08:00,2,Innventure and Eli Lilly's Elanco Announce Strategic Initiative to Commercialize Disruptive Technologies for Animal Health
2231f5f5-1398-4cc6-92ab-039ebf3c988b,2018-01-11T08:00:00.000+08:00,3,"BZ NOTE: Eli Lilly's PDUFA Date For Amemaciclib-MONARCH 1 & 2 Estimated At Jan. 10 By Biotech Research Site; However, That NDA Was Approved Oct. 4, Separate NDA For This Drug Remains Under Review With Estimated Action In April"
2c4c7fd3-5801-41f6-9959-bb59057c4905,2018-01-11T08:00:00.000+08:00,3,"BZ NOTE: Eli Lilly's PDUFA Date For Amemaciclib-MONARCH 1 & 2 Estimated At Jan. 10 By Biotech Research Site; However, That NDA Was Approved Oct. 4, Separate NDA For This Drug Remains Under Review With Estimated Action In April"
e03886cb-2ed5-4cd5-b20b-9aef4fd3e112,2018-01-08T08:00:00.000+08:00,4,Alzheimer's Takes Another Hit As Pfizer Ends Research In The Area
892f00ec-66f3-47b7-9207-2f9d2c05a119,2018-01-08T08:00:00.000+08:00,1,"The Week Ahead: Conferences Take Center Stage, Earnings Begin To Trickle In"
cc9fd3b5-6d14-4ce6-a665-0037716b2a59,2018-01-08T08:00:00.000+08:00,2,Alzheimer's Takes Another Hit As Pfizer Ends Research In The Area
1ce381b9-0dca-4849-9bea-43481c83e32c,2018-01-08T08:00:00.000+08:00,3,"The Week Ahead: Conferences Take Center Stage, Earnings Begin To Trickle In"
76e77f3b-f155-434f-9c07-17e60d51cfbe,2018-01-05T08:00:00.000+08:00,4,"Argus Shares Eli Lilly's Optimism, Upgrades To Buy"
95b6b68a-710f-404e-a634-f27568087ab1,2018-01-05T08:00:00.000+08:00,1,"Benzinga's Top Upgrades, Downgrades For January 5, 2018"
bde219b4-36d6-48bd-962b-03ab6b9ef759,2018-01-05T08:00:00.000+08:00,1,"Eli Lilly To Report Q4 Earnings On Wed., Jan. 31 Before Market Open"
ef378b6c-878d-40a8-9bdb-23ffe1e9e5ef,2018-01-05T08:00:00.000+08:00,5,Argus Upgrades Eli Lilly to Buy
f2e1859d-6116-43bb-b594-898b2899a620,2018-01-05T08:00:00.000+08:00,5,"Argus Shares Eli Lilly's Optimism, Upgrades To Buy"
89e69c40-3909-44b4-88cf-d0cf0d23a05b,2018-01-05T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For January 5, 2018"
f35ee7bc-0754-4ddc-813c-8d87ac41dfd2,2018-01-05T08:00:00.000+08:00,2,"Eli Lilly To Report Q4 Earnings On Wed., Jan. 31 Before Market Open"
24295a88-271c-4c3a-9d22-ff84895d01b8,2018-01-05T08:00:00.000+08:00,5,Argus Upgrades Eli Lilly to Buy
53831a44-a435-4e0a-8c31-1eb3a80f8217,2018-01-04T08:00:00.000+08:00,2,"Goldman Sachs Healthcare CEOs Unscripted Conference Taking Place Today; Presenters Include Agilent, Bluebird Bio, Boston Scientific, Alexion, Eli Lilly, and Alnylam"
defc9adc-c10a-4572-a8c8-14f40848ac17,2018-01-04T08:00:00.000+08:00,2,"Goldman Sachs Healthcare CEOs Unscripted Conference Taking Place Today; Presenters Include Agilent, Bluebird Bio, Boston Scientific, Alexion, Eli Lilly, and Alnylam"
e0fe4af6-e22c-4b49-97c5-3a72b720343e,2017-12-21T08:00:00.000+08:00,1,"PETA Leverages Shareholder Power, Calls On SeaWorld To End All Animal Breeding"
db4d9112-91f6-4afc-b673-7333b9b46672,2017-12-21T08:00:00.000+08:00,1,"PETA Leverages Shareholder Power, Calls On SeaWorld To End All Animal Breeding"
df37cafa-a214-4602-b7cb-3e7fdeae3612,2017-12-20T08:00:00.000+08:00,4,3 Biotech Pipeline Areas To Keep An Eye On In 2018
d2c6ec13-8bb2-4bce-bb07-4dd932a5f2a6,2017-12-20T08:00:00.000+08:00,2,3 Biotech Pipeline Areas To Keep An Eye On In 2018
e02d921b-94ca-4da7-8214-a2134660cec7,2017-12-19T08:00:00.000+08:00,4,Entrega to Receive $5M Investment from Lilly To Advance Proprietary Oral Delivery Technology for Peptides
dee0723e-6017-4e96-86e9-6a86aa6391c7,2017-12-19T08:00:00.000+08:00,4,Entrega to Receive $5M Investment from Lilly To Advance Proprietary Oral Delivery Technology for Peptides
9fde0c42-9c5a-4f12-aedb-20a5c7fb8b89,2017-12-18T08:00:00.000+08:00,1,Eli Lilly Shares Volatile Over Last Few Mins. As Traders Circulate Chatter Co. Hired Bankers Related To Consideration Of Alternatives For Its Animal Health Unit
efceba18-0ebb-4867-88d2-63a8087d60cf,2017-12-18T08:00:00.000+08:00,1,Eli Lilly Shares Volatile Over Last Few Mins. As Traders Circulate Chatter Co. Hired Bankers Related To Consideration Of Alternatives For Its Animal Health Unit
d01be9f2-06d3-4f99-b962-904448de3436,2017-12-15T08:00:00.000+08:00,2,"Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More"
d69fc393-4d77-4c14-aa95-f8569eea73c0,2017-12-15T08:00:00.000+08:00,2,"Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More"
2e510082-2a04-4a51-bb32-87aa7ce8614d,2017-12-14T08:00:00.000+08:00,3,"Eli Lilly Issues Guidance For 2018, New Drugs To Drive Top Line"
7663ef35-6c70-4910-ad70-ea5d5e891c96,2017-12-14T08:00:00.000+08:00,3,"Eli Lilly Issues Guidance For 2018, New Drugs To Drive Top Line"
057df460-5757-458b-8ab2-dc08b763e58f,2017-12-13T08:00:00.000+08:00,3,Eli Lilly Sees FY2018 EPS $4.60-4.70 vs $4.64 Est; Sees Sales $23.0B-23.50B vs $23.10B Est
f2721ef7-b03e-44ad-86c1-3819de90b745,2017-12-13T08:00:00.000+08:00,2,Eli Lilly Sees FY2017 EPS $4.15-4.25 vs $4.21 Est
3a012c0f-ad37-40a7-9a18-3e3502af7ae7,2017-12-13T08:00:00.000+08:00,3,Eli Lilly Sees FY2018 EPS $4.60-4.70 vs $4.64 Est; Sees Sales $23.0B-23.50B vs $23.10B Est
0a29a9ff-0882-41ae-9994-fe368a0e4e05,2017-12-13T08:00:00.000+08:00,2,Eli Lilly Sees FY2017 EPS $4.15-4.25 vs $4.21 Est
4e479e85-6dd5-4af0-8c6c-cafa1e76a117,2017-12-11T08:00:00.000+08:00,4,Eli Lilly Raises Qtr. Dividend From $0.52/Share to $0.5625/Share
1f8c1b23-b9b3-42b3-ac9f-2365aac962e5,2017-12-11T08:00:00.000+08:00,1,A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street
a985dc53-49a2-4d73-a963-39c1929959e2,2017-12-11T08:00:00.000+08:00,4,Eli Lilly Reports FDA Accepted BLA For Galcanezumab Review For Prevention Of Migraine In Adults
909e3c3b-d1b3-4753-890c-cb019b5d965b,2017-12-11T08:00:00.000+08:00,5,Eli Lilly Raises Qtr. Dividend From $0.52/Share to $0.5625/Share
78fb708f-b426-4335-bc1e-887239100d88,2017-12-11T08:00:00.000+08:00,3,A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street
f9f1d2bf-6f13-4a3d-9a1a-57c9726feb4f,2017-12-11T08:00:00.000+08:00,4,Eli Lilly Reports FDA Accepted BLA For Galcanezumab Review For Prevention Of Migraine In Adults
2c98a163-82ff-4dcc-ba53-b1c50db7a0be,2017-12-08T08:00:00.000+08:00,2,"Eli Lilly Reports Top-Line Results From CYRAMZA Phase 3 Study: Met Endpoint Of PFS, But Did Not Improve A Secondary Endpoint Of Overall Survival"
60a50e20-92d3-4e88-b8fb-2068fda6244e,2017-12-08T08:00:00.000+08:00,2,"Eli Lilly Reports Top-Line Results From CYRAMZA Phase 3 Study: Met Endpoint Of PFS, But Did Not Improve A Secondary Endpoint Of Overall Survival"
51141346-231e-4c9d-89ec-7134d87e2b71,2017-12-06T08:00:00.000+08:00,3,"Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition"
cf10f312-65bf-4fbf-bce3-8f70e894c41c,2017-12-06T08:00:00.000+08:00,3,"Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition"
7b9061c8-3bc4-4074-a587-c5b112297f58,2017-12-04T08:00:00.000+08:00,4,Eli Lilly's Taltz Gets Approval For Label Expansion in US
c6376155-93ce-4e44-8eb8-97b1db3cb9ed,2017-12-04T08:00:00.000+08:00,5,Eli Lilly's Taltz Gets Approval For Label Expansion in US
32096147-f2ef-4b44-82f0-7690fb332ff0,2017-12-01T08:00:00.000+08:00,4,Eli Lilly Receives FDA Approval For Taltz
796350ab-f9d9-4a16-82a1-6f39cec34c94,2017-12-01T08:00:00.000+08:00,4,Eli Lilly Receives FDA Approval For Taltz
6a05f3ee-a97f-4516-b966-fe6d22b1b13c,2017-11-27T08:00:00.000+08:00,3,Lilly Option Alert: Dec 15 $81 Calls Sweep (27) at the Ask: 639 @ $3.847 vs 0 OI; Ref=$84.7
8809377a-8bc4-4245-8efb-cef87f5e9c28,2017-11-27T08:00:00.000+08:00,4,Lilly Option Alert: Dec 15 $81 Calls Sweep (27) at the Ask: 639 @ $3.847 vs 0 OI; Ref=$84.7
896ecf6d-ac97-4903-babf-c2c88fbca313,2017-11-21T08:00:00.000+08:00,5,"Morgan Stanley Earlier Maintained Equal-Weight Rating on Eli Lilly, Raised Price Target from $86.00 to $90.00"
5d4f8595-3326-48c2-b1f0-46e0de65ef64,2017-11-21T08:00:00.000+08:00,4,Dexcom Reports Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem
5f8e1555-0082-42a2-aab2-bca6bdd1570f,2017-11-21T08:00:00.000+08:00,3,"Morgan Stanley Earlier Maintained Equal-Weight Rating on Eli Lilly, Raised Price Target from $86.00 to $90.00"
74ee4d70-56cd-489d-800d-b50f5d39ca42,2017-11-21T08:00:00.000+08:00,4,Dexcom Reports Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem
a1c74b8e-e2c7-4bfb-8aef-333e479f33cc,2017-11-14T08:00:00.000+08:00,1,Who Is The Former Pharma Exec Trump Nominated To Lead HHS?
7bd7cc2d-6e2a-470a-9c99-13a383a1a78a,2017-11-14T08:00:00.000+08:00,1,Who Is The Former Pharma Exec Trump Nominated To Lead HHS?
f0570037-66c5-462c-a800-8b9a92548260,2017-11-13T08:00:00.000+08:00,4,Stocks Going Ex Dividend The Third Week of November
76c816f4-d3a9-41ac-92e8-178b7d926563,2017-11-13T08:00:00.000+08:00,2,Stocks Going Ex Dividend The Third Week of November
0df93594-5df0-4d1e-99bc-f688d9af77ce,2017-11-10T08:00:00.000+08:00,5,Eli Lilly Thursday Reported Positive New Data On FORTEO Showing Statistically Significant Reduced Risk For Fractures
1a9c5af9-b9fe-4d0f-aadc-6a9adbd825c6,2017-11-10T08:00:00.000+08:00,1,Eli Lilly Thursday Reported Positive New Data On FORTEO Showing Statistically Significant Reduced Risk For Fractures
f5848ff4-eb83-4cdc-9d4b-e334b61d5674,2017-11-09T08:00:00.000+08:00,2,Pharma ETFs Down Post Q3 Earnings
f493d3cf-ae15-4b4c-846e-67c32c8ddb50,2017-11-09T08:00:00.000+08:00,2,Pharma ETFs Down Post Q3 Earnings
70b12359-865f-40cf-8316-1e27ef148b52,2017-11-08T08:00:00.000+08:00,4,Eli Lilly Says Taltz Demonstrated Improvement In Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors; Also Showed Improvements In Secondary Measures At 52 Week Mark
d8cf306e-7d60-4d59-9cdc-701fa8d20fd0,2017-11-08T08:00:00.000+08:00,3,Eli Lilly Says Taltz Demonstrated Improvement In Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors; Also Showed Improvements In Secondary Measures At 52 Week Mark
ab06f40c-0d50-4f2d-82c8-cf091416b944,2017-10-25T08:00:00.000+08:00,1,"Evercore Out With A Note Saying Teva Is Suing Eli Lilly, Firm Says They Found A Lawsuit Where Teva Believes Other CGRP Mabs Like Lilly Are Infringing On Its Intellectual Property"
67072b1a-41f4-49e7-8e8a-6771283e130d,2017-10-25T08:00:00.000+08:00,1,"Evercore Out With A Note Saying Teva Is Suing Eli Lilly, Firm Says They Found A Lawsuit Where Teva Believes Other CGRP Mabs Like Lilly Are Infringing On Its Intellectual Property"
2aa7c4c2-ab68-4f3e-a8ea-d27f8c7832c1,2017-10-24T08:00:00.000+08:00,2,14 Technical Levels Discussed On Tuesday's PreMarket Prep
b9d5aa56-4364-4037-b5bd-19451c326067,2017-10-24T08:00:00.000+08:00,4,"A Peek Into The Markets: U.S. Stock Futures Gain; McDonald's, General Motors Earnings In Focus"
64dab388-6eb2-4b18-9e9e-ccc54ba77837,2017-10-24T08:00:00.000+08:00,3,"Eli Lilly Says it is Considering Strategic Alternatives for its Elanco Animal Health Unit, Including IPO or Sale"
7a54a861-4767-4179-ba68-8668a3253907,2017-10-24T08:00:00.000+08:00,4,"Eli Lilly Q3 EPS $1.05 vs $1.03 Est., Sales $5.66B vs $5.52B Est."
78f7ed37-f09e-4594-9910-d816475635d8,2017-10-24T08:00:00.000+08:00,1,"12 Stocks To Watch For October 24, 2017"
ccac064a-f38d-4091-abc5-dc5d54e087ce,2017-10-24T08:00:00.000+08:00,2,"Earnings Scheduled For October 24, 2017"
f90cfc5c-39a5-462f-872e-5014cdaaaddf,2017-10-24T08:00:00.000+08:00,4,14 Technical Levels Discussed On Tuesday's PreMarket Prep
6648f480-3fca-42c5-9417-17499c4a1738,2017-10-24T08:00:00.000+08:00,3,"A Peek Into The Markets: U.S. Stock Futures Gain; McDonald's, General Motors Earnings In Focus"
6261bebe-7391-4d4f-babe-9ace1701c966,2017-10-24T08:00:00.000+08:00,4,"Eli Lilly Says it is Considering Strategic Alternatives for its Elanco Animal Health Unit, Including IPO or Sale"
9f85c36f-af9e-496e-a0e9-73a60d57a12a,2017-10-24T08:00:00.000+08:00,4,"Eli Lilly Q3 EPS $1.05 vs $1.03 Est., Sales $5.66B vs $5.52B Est."
8d4a068f-92b8-45a0-9d92-b3556453df42,2017-10-24T08:00:00.000+08:00,4,"12 Stocks To Watch For October 24, 2017"
fb049f0f-3f3f-4c9d-80b6-cb580bf621d2,2017-10-24T08:00:00.000+08:00,2,"Earnings Scheduled For October 24, 2017"
98790386-9cf7-4259-b675-14d40dbe686f,2017-10-23T08:00:00.000+08:00,5,Buy Sierra Oncology Ahead Of A 2018 Full Of Catalysts
c999a721-1490-4282-bfed-c92e3ba4b2a4,2017-10-23T08:00:00.000+08:00,3,The Week Ahead: Earnings Season Starts In Earnest
4788fd2d-a8e2-4969-b468-8f03c1035722,2017-10-23T08:00:00.000+08:00,4,Eli Lilly Announces a $72M Investment in Insulin Manufacturing in Indianapolis
4d22d0b0-90ff-4c47-af5f-2cc85b95edaa,2017-10-23T08:00:00.000+08:00,5,Buy Sierra Oncology Ahead Of A 2018 Full Of Catalysts
c7d209ca-3942-4951-915f-14bb8d4ce753,2017-10-23T08:00:00.000+08:00,4,The Week Ahead: Earnings Season Starts In Earnest
fc75f46e-38ca-4512-b965-bb04c49aa4d9,2017-10-23T08:00:00.000+08:00,3,Eli Lilly Announces a $72M Investment in Insulin Manufacturing in Indianapolis
7b00cc8e-0b6b-4b6b-bc0b-ea914d751570,2017-10-20T08:00:00.000+08:00,4,Upcoming Earnings: Heavy-Equipment Maker Caterpillar And Pharma Giant Eli Lilly Report On Tuesday
97cd7ef0-8e29-41bf-90f6-23052eee3917,2017-10-20T08:00:00.000+08:00,4,Upcoming Earnings: Heavy-Equipment Maker Caterpillar And Pharma Giant Eli Lilly Report On Tuesday
51e40cc2-a5f4-4fba-8455-28f2b0ceb77b,2017-10-18T08:00:00.000+08:00,5,"Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever"
dc1b8c62-89fc-489b-b935-7ab0e2152b91,2017-10-18T08:00:00.000+08:00,4,"Eli Lilly, CureVac Report Global Collaboration For Development Of mRNA Cancer Vaccines"
fb3b543f-4024-4b1b-ba06-5c3ca2662dc0,2017-10-18T08:00:00.000+08:00,3,"Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever"
2420d919-f83f-4f6f-bd01-a57412b91aa9,2017-10-18T08:00:00.000+08:00,4,"Eli Lilly, CureVac Report Global Collaboration For Development Of mRNA Cancer Vaccines"
58b8fe83-6f1d-461e-bd24-97be85b91b11,2017-10-16T08:00:00.000+08:00,2,Eli Lilly Gives an Update on its CYRAMZA Trial
b64ef569-5902-4ead-9a41-0230ab0924da,2017-10-16T08:00:00.000+08:00,4,Eli Lilly Gives an Update on its CYRAMZA Trial
b83a2b75-b05a-4ec0-873a-9827259362ff,2017-10-13T08:00:00.000+08:00,2,"Pharma Stock Roundup: Pfizer Mulls Options For Consumer Healthcare, Eli Lilly's Pipeline Setback"
ab391e31-ba69-454a-b285-437a69509247,2017-10-13T08:00:00.000+08:00,3,"Pharma Stock Roundup: Pfizer Mulls Options For Consumer Healthcare, Eli Lilly's Pipeline Setback"
d131cb30-612d-4c7f-8493-2625641475f8,2017-10-12T08:00:00.000+08:00,5,Eli Lilly Granted Priority Review for Verzenio for Advanced Breast Cancer
d1253850-194f-4719-abc2-3f345aef257f,2017-10-12T08:00:00.000+08:00,5,Eli Lilly Granted Priority Review for Verzenio for Advanced Breast Cancer
e3426ac6-c45d-437b-aedf-39ce1180f827,2017-10-10T08:00:00.000+08:00,2,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings
74559c06-dcdc-4d5c-b9f7-d2bdf82f86d5,2017-10-10T08:00:00.000+08:00,4,7 Catalysts For Eli Lilly Over The Next Year
2f8eca9f-4fb2-4e73-bb18-e127d1a6d69c,2017-10-10T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For October 10, 2017"
319e6159-761a-40ee-81c5-eabb129f0369,2017-10-10T08:00:00.000+08:00,4,"The Market In 5 Minutes: Nvidia's Drive, Russia And Cryptos, And Carbon Emission Limits"
fffc7fe3-76b8-401a-92f5-e7b8be26ff18,2017-10-10T08:00:00.000+08:00,1,A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Fed Speakers
5c8baf95-e086-4775-89c1-80fcec8c8013,2017-10-10T08:00:00.000+08:00,4,"UPDATE: Eli Lilly Says 'analysis of the secondary study endpoints of both PFS, ORR showed evidence of monotherapy activity in the abemaciclib arm'"
385d78f7-087b-42a3-abd4-be291b7fedd4,2017-10-10T08:00:00.000+08:00,2,Eli Lilly Reports Topline Results From Phase 3 JUNIPER Trial Evaluating Verzenio In KRAS-Mutated Advanced NSCLC: 'did not meet its primary endpoint of overall survival'
ae52b9c4-cb21-4e21-9a2d-9d2021b1e274,2017-10-10T08:00:00.000+08:00,3,Credit Suisse Downgrades Eli Lilly to Neutral
ff057cff-4341-4ee3-a428-0e7ee4cf45dc,2017-10-10T08:00:00.000+08:00,4,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings
9bc978ba-3b67-448e-b5f9-0828d58ee79a,2017-10-10T08:00:00.000+08:00,4,7 Catalysts For Eli Lilly Over The Next Year
a96fa116-9193-47e5-9c01-5edec1799e07,2017-10-10T08:00:00.000+08:00,2,"Benzinga's Top Upgrades, Downgrades For October 10, 2017"
f9b98f25-bda1-4d48-9e50-30ac70cf2cf2,2017-10-10T08:00:00.000+08:00,1,"The Market In 5 Minutes: Nvidia's Drive, Russia And Cryptos, And Carbon Emission Limits"
aeed574e-a4c0-4837-afa9-8b67d6c42314,2017-10-10T08:00:00.000+08:00,3,A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Fed Speakers
26164e03-11e2-4e5a-86cd-4f6177984a42,2017-10-10T08:00:00.000+08:00,4,"UPDATE: Eli Lilly Says 'analysis of the secondary study endpoints of both PFS, ORR showed evidence of monotherapy activity in the abemaciclib arm'"
2a04496a-852d-45a8-813b-219a2356af16,2017-10-10T08:00:00.000+08:00,1,Eli Lilly Reports Topline Results From Phase 3 JUNIPER Trial Evaluating Verzenio In KRAS-Mutated Advanced NSCLC: 'did not meet its primary endpoint of overall survival'
b2ed94ca-2064-4f31-a8ec-411dac5ac63c,2017-10-10T08:00:00.000+08:00,2,Credit Suisse Downgrades Eli Lilly to Neutral
1b883fe6-94cc-48aa-b5d5-9bdd0d3ee6e5,2017-10-09T08:00:00.000+08:00,4,Health Care Sector Back In Focus In Congress Ahead Of Q3 Earnings Result
6de1b77d-a594-4d49-bc54-18bf8a48b739,2017-10-09T08:00:00.000+08:00,4,Health Care Sector Back In Focus In Congress Ahead Of Q3 Earnings Result
48569e53-cbda-407d-ae4c-01d78b59ef81,2017-10-06T08:00:00.000+08:00,1,"Teva Pharmaceuticals Responds To Patent Office Decision In Eli Lilly's Favor, Tells Benzinga: 'We are disappointed with the court's decision and evaluating our options to appeal'"
b395a8dc-3a95-4a8f-8d61-a790cb44493a,2017-10-06T08:00:00.000+08:00,1,"Teva Pharmaceuticals Responds To Patent Office Decision In Eli Lilly's Favor, Tells Benzinga: 'We are disappointed with the court's decision and evaluating our options to appeal'"
6a09e734-71e8-44a7-8b2c-95d6162f44b2,2017-10-05T08:00:00.000+08:00,5,Eli Lilly Shares Spike On Patent Victory
84be581f-96f0-4b86-bf51-18d4a7ec4ada,2017-10-05T08:00:00.000+08:00,5,Eli Lilly Reports US PTO Ruled In Favor Of Co.'s Alimta Vitamin Regimen Patent
53c9432a-a6b9-43cb-bb03-09375717cab4,2017-10-05T08:00:00.000+08:00,3,UPDATE: Eli Lilly Prevails In IPR Review Of '209 Patent For Alimta
db884df6-cc3f-40ad-bf94-bbb3e3a93a36,2017-10-05T08:00:00.000+08:00,4,Watching Shares Of Eli Lilly As Traders Pass Unconfirmed Chatter Of Favorable Patent Case Decision
77e176bd-91bc-475f-806d-4f6c72a2c741,2017-10-05T08:00:00.000+08:00,5,Eli Lilly Shares Spike On Patent Victory
23ddea36-4140-4a66-9c92-eb1e8e578183,2017-10-05T08:00:00.000+08:00,5,Eli Lilly Reports US PTO Ruled In Favor Of Co.'s Alimta Vitamin Regimen Patent
96367b10-1f56-4bfe-b279-db0f0fa783b5,2017-10-05T08:00:00.000+08:00,4,UPDATE: Eli Lilly Prevails In IPR Review Of '209 Patent For Alimta
b0781afb-65ed-446e-9cb7-17acf2bdfb3b,2017-10-05T08:00:00.000+08:00,3,Watching Shares Of Eli Lilly As Traders Pass Unconfirmed Chatter Of Favorable Patent Case Decision
819892f7-03f1-44b6-9829-ea5bbc241dee,2017-09-28T08:00:00.000+08:00,4,"Eli Lilly Has Said List Price For Its New Breast Cancer Treatment Verzenio Will Be ~$11K/Month, Will Be Available In US By End Of Oct."
37586bb1-458e-42e0-bd3a-5a8646057792,2017-09-28T08:00:00.000+08:00,5,"Eli Lilly Has Said List Price For Its New Breast Cancer Treatment Verzenio Will Be ~$11K/Month, Will Be Available In US By End Of Oct."
c78e48cf-f471-431b-abad-b9813427120c,2017-09-20T08:00:00.000+08:00,1,Johnson & Johnson Downgraded On Hefty Valuation Compared To Peers
22281cf7-d226-4952-8aa1-7e8fa3a6134f,2017-09-20T08:00:00.000+08:00,1,Johnson & Johnson Downgraded On Hefty Valuation Compared To Peers
0ffeb45c-c4e0-4219-b15c-7d3d369f5d8e,2017-09-19T08:00:00.000+08:00,3,"Wall Street's M&A Chatter From September 18: Walgreens-Rite Aid, Northrup Grumman-Orbital ATK, Itron-Silver Spring Networks"
e98fe2f8-d68f-4fc4-85bc-405dbacd3180,2017-09-19T08:00:00.000+08:00,4,"Wall Street's M&A Chatter From September 18: Walgreens-Rite Aid, Northrup Grumman-Orbital ATK, Itron-Silver Spring Networks"
e6056959-8f5a-47b0-9fdd-cc7b928a287d,2017-09-14T08:00:00.000+08:00,5,Eli Lilly's Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis
c105f076-4499-4128-bb54-487f4a509805,2017-09-14T08:00:00.000+08:00,5,Eli Lilly's Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis
dc640bcb-6c48-41a4-9741-ae6c64811dcc,2017-09-12T08:00:00.000+08:00,4,This Analyst Predicts Bullish Growth Outlook For Incyte
5d6af6cb-2463-42d3-aa4f-2a634d831ff7,2017-09-12T08:00:00.000+08:00,3,Eli Lilly Says Jardiance Tablets Reduced the Risk of Cardiovascular Death in People with Type 2 Diabetes
994ff692-ea2c-4278-bdec-8c63bac1b259,2017-09-12T08:00:00.000+08:00,4,This Analyst Predicts Bullish Growth Outlook For Incyte
14d7651d-4348-49dc-aa61-a3b4cba1dbca,2017-09-12T08:00:00.000+08:00,5,Eli Lilly Says Jardiance Tablets Reduced the Risk of Cardiovascular Death in People with Type 2 Diabetes
4164665d-b384-41c3-aa1e-64a30847b5c0,2017-09-11T08:00:00.000+08:00,5,Array BioPharma And Others Shine At The ESMO 2017 Congress
56be0514-0c9f-4236-a786-cb552e753467,2017-09-11T08:00:00.000+08:00,5,Array BioPharma And Others Shine At The ESMO 2017 Congress
fc316e42-1652-4fbb-a4b6-8177e9836e7c,2017-09-10T08:00:00.000+08:00,4,Lilly Announces Presentation of Phase 3 RANGE Data for CYRAMZA Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer at ESMO 2017
a529d5f0-f561-4c21-ab94-03dce3eae38e,2017-09-10T08:00:00.000+08:00,4,Lilly Announces Presentation of Phase 3 RANGE Data for CYRAMZA Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer at ESMO 2017
5cb0e445-f8c0-4ce3-ab44-6f81d61f6a1a,2017-09-09T08:00:00.000+08:00,2,What Pharmaceuticals Spend On Lobbying To Influence Trump
73ddda1e-8c08-424a-8938-2ac643f8053b,2017-09-09T08:00:00.000+08:00,4,Data Showing Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine to be Presented at IHC 2017
023d1c11-5c6b-43bd-b756-975e20b452a6,2017-09-09T08:00:00.000+08:00,2,What Pharmaceuticals Spend On Lobbying To Influence Trump
e6f508bc-b9c0-4228-ba2d-12290b9cc8fe,2017-09-09T08:00:00.000+08:00,3,Data Showing Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine to be Presented at IHC 2017
1bf9d6f9-92d0-47fb-b13e-5ec3440e2789,2017-09-08T08:00:00.000+08:00,5,"UPDATE: Eli Lilly Says Galcanezumab Showed 'statistically significant reduction in the number of monthly migraine headache days with both doses (5.6 days for 120 mg and 6.5 days for 240 mg, p<0.001 for both dosing groups)'"
4b5e4220-a076-449a-bfd3-d8563dd8dd39,2017-09-08T08:00:00.000+08:00,5,"Eli Lilly Reports Treatment With Self-Administered Galcanezumab For Up To 12 Months Showed Positive Safety, Tolerability Profile In Patients With Migraine"
5183507d-7c93-40b1-ae3c-2eeb96a81df2,2017-09-08T08:00:00.000+08:00,5,"UPDATE: Eli Lilly Says Galcanezumab Showed 'statistically significant reduction in the number of monthly migraine headache days with both doses (5.6 days for 120 mg and 6.5 days for 240 mg, p<0.001 for both dosing groups)'"
034036d7-f44f-4e05-b98d-6b65c098658e,2017-09-08T08:00:00.000+08:00,4,"Eli Lilly Reports Treatment With Self-Administered Galcanezumab For Up To 12 Months Showed Positive Safety, Tolerability Profile In Patients With Migraine"
04199d37-8003-4762-baf6-cb0d2f47d4da,2017-09-07T08:00:00.000+08:00,2,"UPDATE: Eli Lilly Sees Incurring ~$1.2B Pre-Tax Charge Related to Streamlining Of Operations, Or About $0.80/Share After Tax"
c942a5a2-5ba7-4010-8c8f-c093e1772f07,2017-09-07T08:00:00.000+08:00,1,"UPDATE: Eli Lilly Says Streamlining Of Operations Will Impact ~8% Of Workforce, Or About 3,500 Jobs"
30facdd9-9e4d-42ec-b5c1-e26b736f2f85,2017-09-07T08:00:00.000+08:00,4,"Eli Lilly Unveils Actions To Streamline Operations, Sees Annualized Savings Of ~$500M"
8240d287-3a5b-4c97-8e37-3337e0cfd322,2017-09-07T08:00:00.000+08:00,2,"UPDATE: Eli Lilly Sees Incurring ~$1.2B Pre-Tax Charge Related to Streamlining Of Operations, Or About $0.80/Share After Tax"
2b662a10-cd1f-4c96-8a17-62a205af6fc9,2017-09-07T08:00:00.000+08:00,1,"UPDATE: Eli Lilly Says Streamlining Of Operations Will Impact ~8% Of Workforce, Or About 3,500 Jobs"
d5d6f529-0611-4f3f-9ba3-f31746db9e6e,2017-09-07T08:00:00.000+08:00,3,"Eli Lilly Unveils Actions To Streamline Operations, Sees Annualized Savings Of ~$500M"
9f2fbde4-06ac-4a59-ab80-279e5951867d,2017-08-30T08:00:00.000+08:00,4,"UPDATE: Lilly, Incyte Expect FDA To Classify NDA For Baricitinib As Class I Resubmission, Which Will Start A New 6-Month Review Cycle"
797b32a1-07ef-4c89-9510-6a39ab58bced,2017-08-30T08:00:00.000+08:00,5,"Eli Lilly, Incyte Report Will Resubmit NDA For Baricitinib Before End Of Jan. '18"
e49689f5-7b02-4ce8-932c-586326afb171,2017-08-30T08:00:00.000+08:00,2,"UPDATE: Lilly, Incyte Expect FDA To Classify NDA For Baricitinib As Class I Resubmission, Which Will Start A New 6-Month Review Cycle"
a7f003e8-4665-4bcf-99c1-5ecc81c0289c,2017-08-30T08:00:00.000+08:00,3,"Eli Lilly, Incyte Report Will Resubmit NDA For Baricitinib Before End Of Jan. '18"
e4087d6c-634d-473b-be6b-ac1090ad5eba,2017-08-16T08:00:00.000+08:00,3,Shares of Lilly Fall on Positive Novo Nordisk SUSTAIN 7 Trial Results
0e7b1633-74a0-4bf9-8f2a-221336d06f5d,2017-08-16T08:00:00.000+08:00,4,Shares of Lilly Fall on Positive Novo Nordisk SUSTAIN 7 Trial Results
bde9c085-cf2b-4cff-8229-b1d34ae2546a,2017-08-14T08:00:00.000+08:00,5,13F From Farallon Capital Shows Liquidated ~1.6M Share Stake In Eli Lilly
3bec1fce-d2ad-4a8c-b0b1-9699ab8628fb,2017-08-14T08:00:00.000+08:00,2,13F From Farallon Capital Shows Liquidated ~1.6M Share Stake In Eli Lilly
da32ea65-365c-4346-99d1-e6ae1d96190e,2017-08-04T08:00:00.000+08:00,5,Eli Lilly Reports Results From Second Phase 3 Study Of Lasmiditan For Acute Treatment Of Migraine; Met Its Primary Endpoint In SPARTAN
a10e87a2-8543-463c-9204-017a04b5ffa7,2017-08-04T08:00:00.000+08:00,3,Eli Lilly Reports Results From Second Phase 3 Study Of Lasmiditan For Acute Treatment Of Migraine; Met Its Primary Endpoint In SPARTAN
771aab49-1ad5-4751-9e15-35d90ccd313f,2017-07-28T08:00:00.000+08:00,1,Eli Lilly Says California and Florida AGs Have Requested Info On Co.'s Insulin Products
28132c5e-403a-42a6-b227-377a9f1defdb,2017-07-28T08:00:00.000+08:00,2,Eli Lilly Says California and Florida AGs Have Requested Info On Co.'s Insulin Products
e9623cca-6666-426d-b033-a96d3d2866f5,2017-07-27T08:00:00.000+08:00,4,"On, Wisconsin: University Wins Half Billion In iPhone Patent Suit, Another Sign Schools Are Research Cash Cows"
c7e93faa-2cb7-4c0d-9e9b-39d856a7ec69,2017-07-27T08:00:00.000+08:00,3,"Samsung, Amazon — Everyone Is Getting Into Pharmaceuticals"
727cead0-f409-4e2f-a788-92141aa0445b,2017-07-27T08:00:00.000+08:00,4,"On, Wisconsin: University Wins Half Billion In iPhone Patent Suit, Another Sign Schools Are Research Cash Cows"
7c57764c-2507-4c91-a292-d9cc7f6f585f,2017-07-27T08:00:00.000+08:00,2,"Samsung, Amazon — Everyone Is Getting Into Pharmaceuticals"
38cda867-8fe0-41fc-bdbc-9734ef79de0d,2017-07-26T08:00:00.000+08:00,1,Zoetis Investors May Need Patience To See Bull Thesis Play Out
166b63c6-237c-44c6-8ab6-3b77cd637cdb,2017-07-26T08:00:00.000+08:00,1,"Intense Competition Pressures Eli Lilly, Leerink Downgrades"
4f209d82-231b-4ada-b6f8-8c393a3102c8,2017-07-26T08:00:00.000+08:00,4,"19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug"
7cd1af5f-ef37-462b-90d0-0b446937149a,2017-07-26T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For July 26, 2017"
fe4d2302-de78-4889-a54d-1eed23a2a973,2017-07-26T08:00:00.000+08:00,2,Leerink Swann Downgrades Eli Lilly to Market Perform
9b14ff0b-6250-42e0-bdfb-e2ae05a4fc1a,2017-07-26T08:00:00.000+08:00,1,Zoetis Investors May Need Patience To See Bull Thesis Play Out
cb34f270-ae4e-4cf3-8915-ef29e089f1a3,2017-07-26T08:00:00.000+08:00,2,"Intense Competition Pressures Eli Lilly, Leerink Downgrades"
b47a9902-0cba-46a7-adaa-86e62088cc1d,2017-07-26T08:00:00.000+08:00,4,"19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug"
f479e5d5-28b8-4410-9a16-6f7ee3b8b3a9,2017-07-26T08:00:00.000+08:00,3,"Benzinga's Top Upgrades, Downgrades For July 26, 2017"
293f5aa6-ea9b-4bad-9d01-2b3c62b45e53,2017-07-26T08:00:00.000+08:00,2,Leerink Swann Downgrades Eli Lilly to Market Perform
7100c3bb-3929-48d9-8383-ccd3f6f6a4ad,2017-07-25T08:00:00.000+08:00,4,"Eli Lilly Raises FY 2017 Guidance, Sees EPS $4.10-$4.20 from $4.05-$4.15 vs $4.12 Est., Sees Sales $22.0B-$22.5B from $21.8B-$22.3B vs $22.1B Est."
6e7444c0-62af-4dbf-99d4-2e8ba9783b2b,2017-07-25T08:00:00.000+08:00,2,"Eli Lilly Q2 EPS $1.11 vs $1.05 Est., Sales $5.82B vs $5.60B Est."
93a40105-65a6-428c-8789-562ade7cfcaf,2017-07-25T08:00:00.000+08:00,3,Eli Lilly and Incyte's Re-submission of a New Drug Application to the FDA Will be Delayed Beyond 2017
bb08c67e-5b4d-4ebd-9746-05ddfe21df48,2017-07-25T08:00:00.000+08:00,3,"12 Stocks To Watch For July 25, 2017"
e4abd40a-9842-40c5-bc90-1c0f125bb951,2017-07-25T08:00:00.000+08:00,4,"Earnings Scheduled For July 25, 2017"
07e8699c-8d51-4364-915e-9202b9dfff85,2017-07-25T08:00:00.000+08:00,4,"Eli Lilly Raises FY 2017 Guidance, Sees EPS $4.10-$4.20 from $4.05-$4.15 vs $4.12 Est., Sees Sales $22.0B-$22.5B from $21.8B-$22.3B vs $22.1B Est."
c9d4f389-9ecb-4f0d-8c2b-adeef15d45e1,2017-07-25T08:00:00.000+08:00,4,"Eli Lilly Q2 EPS $1.11 vs $1.05 Est., Sales $5.82B vs $5.60B Est."
f8d85b05-ee69-46f2-8daa-e2b98167d8d4,2017-07-25T08:00:00.000+08:00,1,Eli Lilly and Incyte's Re-submission of a New Drug Application to the FDA Will be Delayed Beyond 2017
e8a2681b-8a1c-4a8d-b30f-67e8e9d52b6c,2017-07-25T08:00:00.000+08:00,3,"12 Stocks To Watch For July 25, 2017"
562d13cd-cc09-45e8-bf2c-4bf5820b28bd,2017-07-25T08:00:00.000+08:00,3,"Earnings Scheduled For July 25, 2017"
5f2fd64e-fb31-4232-9ada-f99d52d89bf8,2017-07-24T08:00:00.000+08:00,2,2 Ways To Trade This Week's Healthcare Earnings
a22771af-34d7-42d7-8d6d-e41c63292ea6,2017-07-24T08:00:00.000+08:00,4,Eli Lilly and Nektar Therapeutics to Partner for Development and Commercialization of NKTR-358
e5aedd3a-cc69-4f0b-8ae9-e7ae02a8384d,2017-07-24T08:00:00.000+08:00,3,2 Ways To Trade This Week's Healthcare Earnings
c548ce5c-7e55-41bb-a524-bc73ba4c50a3,2017-07-24T08:00:00.000+08:00,4,Eli Lilly and Nektar Therapeutics to Partner for Development and Commercialization of NKTR-358
0da5a30d-5c2e-4085-a257-ba2239415a2e,2017-07-18T08:00:00.000+08:00,5,"Adimab Reports Deal With Eli Lilly To Transfer Co.'s Platform To Lilly For Discovery, Optimization Of Antibody-Based Drugs In Therapeutic Areas"
b6efb551-3342-4605-a932-bc5cd28500dd,2017-07-18T08:00:00.000+08:00,5,"Adimab Reports Deal With Eli Lilly To Transfer Co.'s Platform To Lilly For Discovery, Optimization Of Antibody-Based Drugs In Therapeutic Areas"
6a3c27c2-91d6-40b2-9c14-48eac87d64e8,2017-07-13T08:00:00.000+08:00,5,"Shares of Eli Lilly, AstraZeneca, Merck, Gilead, Abbvie, Other Large Cap Biotech Spiking Higher"
d9998993-a3d8-4fff-a36c-24d5271e8191,2017-07-13T08:00:00.000+08:00,4,6 Biggest Price Target Changes For Thursday
9e91d8ac-4a9d-431d-a689-afeff46116fc,2017-07-13T08:00:00.000+08:00,3,"Delta, United, Eli Lilly, General Electric: Fast Money Picks For July 13"
562b49bd-5453-4d7f-89fe-787fcdfeb209,2017-07-13T08:00:00.000+08:00,5,"Shares of Eli Lilly, AstraZeneca, Merck, Gilead, Abbvie, Other Large Cap Biotech Spiking Higher"
6e86e900-79a6-475f-92b7-d65418d98292,2017-07-13T08:00:00.000+08:00,4,6 Biggest Price Target Changes For Thursday
7d723a28-6e79-4581-a2e5-6c073eb33701,2017-07-13T08:00:00.000+08:00,4,"Delta, United, Eli Lilly, General Electric: Fast Money Picks For July 13"
5c66e6f7-27f7-4730-a5dd-10558a8aac9e,2017-07-12T08:00:00.000+08:00,3,"Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation, Cialis Exclusivity Expected To End At Earliest On Sept. 27th 2018"
ba3b69af-a8fa-4c11-8e27-b49c65d9b85b,2017-07-12T08:00:00.000+08:00,5,"Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation, Cialis Exclusivity Expected To End At Earliest On Sept. 27th 2018"
050c5862-2c5c-4054-ac1c-9ac19025faa8,2017-07-10T08:00:00.000+08:00,5,Eli Lilly's Abemaciclib is Granted Priority Review by the FDA for the Treatment of Breast Cancer
0053b0cb-9dfb-4493-aee4-660f376fa5ff,2017-07-10T08:00:00.000+08:00,5,Eli Lilly's Abemaciclib is Granted Priority Review by the FDA for the Treatment of Breast Cancer
41b4c198-09d4-40e3-ad85-73f93c5cff3f,2017-07-07T08:00:00.000+08:00,4,"UK Supreme Court Rules In Favor Of Eli Lilly's Alimta Vitamin Regimen Patents, Also Affirmed Indirect Infringement Finding By UK Court Of Appeal"
25a7ea28-4c72-494c-aef6-e6b3a71fccee,2017-07-07T08:00:00.000+08:00,2,"UK Supreme Court Rules In Favor Of Eli Lilly's Alimta Vitamin Regimen Patents, Also Affirmed Indirect Infringement Finding By UK Court Of Appeal"
aea2d2c0-9336-4c02-a444-d1b286983937,2017-07-06T08:00:00.000+08:00,1,Merck Falls As FDA Puts Hold On 3 Keytruda Myeloma Studies
7f541da3-d80f-42c8-8116-7ef56bab5a09,2017-07-06T08:00:00.000+08:00,1,Merck Falls As FDA Puts Hold On 3 Keytruda Myeloma Studies
4f10ee33-78af-465b-ab52-50af853ec49f,2017-07-03T08:00:00.000+08:00,4,UPDATE: Lilly Says Japanese Marketing Authorization Of Olumiant Triggered $15M Milestone Payment From Lilly To Incyte
89a2d995-9481-4126-aa0f-8da01190f1f3,2017-07-03T08:00:00.000+08:00,4,Eli Lilly and Incyte Announce Japan's Ministry of Health Grants Marketing Approval for Olumiant
289b63a4-6d84-4b3b-8187-802139fb2175,2017-07-03T08:00:00.000+08:00,5,UPDATE: Lilly Says Japanese Marketing Authorization Of Olumiant Triggered $15M Milestone Payment From Lilly To Incyte
c6127c37-a78d-4be9-a040-3902c51d9d22,2017-07-03T08:00:00.000+08:00,3,Eli Lilly and Incyte Announce Japan's Ministry of Health Grants Marketing Approval for Olumiant
b4629a48-4a9d-45f7-adbb-5eab4461e061,2017-06-28T08:00:00.000+08:00,2,Alder's Shares Dip Despite Positive Migraine Trial Results
9163d185-8a4b-4235-af32-3253d862da58,2017-06-28T08:00:00.000+08:00,1,Merck's CETP Inhibitor Reduces CV Risk in Phase III Study
6a0ad865-1b0b-446d-94a0-1303ee6c26b9,2017-06-28T08:00:00.000+08:00,2,Alder's Shares Dip Despite Positive Migraine Trial Results
1bb213d0-6c23-4cea-a7f1-67a69f2ab8c4,2017-06-28T08:00:00.000+08:00,4,Merck's CETP Inhibitor Reduces CV Risk in Phase III Study
6fdd848e-95d3-4ea8-86ea-e64704a412c5,2017-06-26T08:00:00.000+08:00,3,Attention To Details: Neos' ADHD Portfolio
194090fb-993b-4229-804e-098a2b83b1c8,2017-06-26T08:00:00.000+08:00,5,"Novartis Cardiovascular Drug Positive, NSCLC Drug Approved"
d42b9f89-0303-46c3-8af5-aa51f8354218,2017-06-26T08:00:00.000+08:00,5,"Novartis Cardiovascular Drug Positive, NSCLC Drug Approved"
b71b0a8c-c5e2-4b82-9a02-664b289287b1,2017-06-26T08:00:00.000+08:00,4,"Jim Cramer Shares His Thoughts On Helmerich & Payne, Tailored Brands And Eli Lilly"
bbc92efb-751e-480c-8f9c-df54e27e3ee0,2017-06-26T08:00:00.000+08:00,3,Attention To Details: Neos' ADHD Portfolio
d60636ed-d21b-4c26-b15d-7bddd6daaaa2,2017-06-26T08:00:00.000+08:00,5,"Novartis Cardiovascular Drug Positive, NSCLC Drug Approved"
3030a017-15c9-468d-9b06-442ee89e5641,2017-06-26T08:00:00.000+08:00,5,"Novartis Cardiovascular Drug Positive, NSCLC Drug Approved"
a87dde79-ff84-445e-806b-0767a6c67fab,2017-06-26T08:00:00.000+08:00,4,"Jim Cramer Shares His Thoughts On Helmerich & Payne, Tailored Brands And Eli Lilly"
ae9de0e4-e06f-4e90-847a-5c9c9d1dafe0,2017-06-22T08:00:00.000+08:00,4,Why You Should Add Novo Nordisk Stock to Your Portfolio
79e99140-5bcf-4664-80db-9bf3c89ea8a3,2017-06-22T08:00:00.000+08:00,3,Merck's Keytruda on a Roll: Can it Retain the Momentum?
98bd01f3-a4a2-4199-b8de-bd35ea1c8892,2017-06-22T08:00:00.000+08:00,4,Why You Should Add Novo Nordisk Stock to Your Portfolio
9debbe9b-5e24-4092-a408-95ce9e4be24e,2017-06-22T08:00:00.000+08:00,3,Merck's Keytruda on a Roll: Can it Retain the Momentum?
07d20dd3-d62c-4b22-a626-077de0de62ea,2017-06-21T08:00:00.000+08:00,2,Eli Lilly Unveils Expanded Biotechnology Center in San Diego As Part Of $850M U.S. Capital Investment In 2017
ed11b649-f88a-44b9-9d5c-54b8e0ebb73e,2017-06-21T08:00:00.000+08:00,2,Eli Lilly Unveils Expanded Biotechnology Center in San Diego As Part Of $850M U.S. Capital Investment In 2017
a4463df4-5efc-42c2-a257-f1dcc98d03aa,2017-06-18T08:00:00.000+08:00,4,Eli Lilly Receives FDA Orphan Designation for Humanized Immunoglobulin G4-Variant Monoclonal Antibody Directed Against P19 Subunit of Interleukin (IL)-23 in Treatment Of UC in Pediatric Patients
5e3cd5bb-2b4e-4cde-8a5d-3a7b8a934855,2017-06-18T08:00:00.000+08:00,3,Eli Lilly Receives FDA Orphan Designation for Humanized Immunoglobulin G4-Variant Monoclonal Antibody Directed Against P19 Subunit of Interleukin (IL)-23 in Treatment Of UC in Pediatric Patients
36aa25c4-efcd-4c4b-ba6c-59edcf5ef208,2017-06-16T08:00:00.000+08:00,1,"Dow 30 Stock Roundup: GE Appoints Flannery as CEO; UTX, CAT Hike Dividends"
a3b485dd-423b-4b26-8d50-5b8506c813fc,2017-06-16T08:00:00.000+08:00,2,"Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused"
de554c54-6bab-4a71-9678-2e6e881de120,2017-06-16T08:00:00.000+08:00,4,"Lilly, Incyte Announce Results from Long-term Extension of Phase 3 Studies Show Treatment With Baricitinib Slows Progression of Joint Damage, Controls Disease Activity over 2 Years #EULAR2017"
ef9fef64-6405-4743-a889-73df070c7afb,2017-06-16T08:00:00.000+08:00,1,"Dow 30 Stock Roundup: GE Appoints Flannery as CEO; UTX, CAT Hike Dividends"
7c6e3bf6-7303-4a4a-b9df-e70752bf84ae,2017-06-16T08:00:00.000+08:00,3,"Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused"
4bb7871f-88f4-4db2-be6a-bd42cfaaa72c,2017-06-16T08:00:00.000+08:00,2,"Lilly, Incyte Announce Results from Long-term Extension of Phase 3 Studies Show Treatment With Baricitinib Slows Progression of Joint Damage, Controls Disease Activity over 2 Years #EULAR2017"
ffaf673f-dfff-4ca6-aaf1-0e51609d4d0d,2017-06-15T08:00:00.000+08:00,1,"Regeneron Lower Day After 8-K Filing, Increased Competition For Pain Remedy"
0a797270-1ea7-48e5-a84f-0697bfe307ad,2017-06-15T08:00:00.000+08:00,5,Why Is ImmunoGen (IMGN) Stock Up 131% This Year?
f774c9e3-ffa4-4792-ac7e-41a5bd6c7ba1,2017-06-15T08:00:00.000+08:00,4,"Eli Lilly's Talz Showed Significant Improvements In Disease Signs, Symptoms At 24 Weeks Among Patients With Active Psoriatic Arthritis Who Had Prior Inadequate Response Or Intolerance To TNF Inhibitors"
ac0769f6-cb6c-4d0c-a2da-8a2622fed7f4,2017-06-15T08:00:00.000+08:00,3,"Regeneron Lower Day After 8-K Filing, Increased Competition For Pain Remedy"
6c314f29-c6d4-4013-9005-7da4ebc058b2,2017-06-15T08:00:00.000+08:00,5,Why Is ImmunoGen (IMGN) Stock Up 131% This Year?
a1917f14-457d-4d1f-a235-df76af5cbd31,2017-06-15T08:00:00.000+08:00,5,"Eli Lilly's Talz Showed Significant Improvements In Disease Signs, Symptoms At 24 Weeks Among Patients With Active Psoriatic Arthritis Who Had Prior Inadequate Response Or Intolerance To TNF Inhibitors"
71262f17-7856-4e58-9f9b-e5f2c3a3ce7d,2017-06-14T08:00:00.000+08:00,4,Pfizer & Lilly Get Fast Track Designation for Pain Candidate
fa7a938a-2e4b-4d5b-91e3-79d6ff3d16b3,2017-06-14T08:00:00.000+08:00,3,"Company News for June 14, 2017"
1dd7152e-8c0c-4ce9-a2c1-1de4fa15b814,2017-06-14T08:00:00.000+08:00,4,Pfizer & Lilly Get Fast Track Designation for Pain Candidate
2c0112b3-03c0-41ff-93fb-82f88a98987b,2017-06-14T08:00:00.000+08:00,4,"Company News for June 14, 2017"
6022c31b-6cd1-4fed-8ec2-c7f486d3aaa0,2017-06-13T08:00:00.000+08:00,5,"Lilly, Incyte Announce Presentation of New Data on Olumiant in RA, Taltz in PsA at #EULAR 2017"
69ca314b-3d5c-4286-be33-bdc83fb1afb9,2017-06-13T08:00:00.000+08:00,4,"UPDATE: Lilly Says 'Analysis of 12,500 adults with type 2 diabetes from 19 studies showed amputations and fractures were not increased with Jardiance compared with placebo'"
f00495ca-6003-47a3-98f0-addfe1cb19d4,2017-06-13T08:00:00.000+08:00,4,Eli Lilly Reports Jardiance Analysis Reinforces Established Safety Profile
b2b2a02a-748a-432f-9d4b-bd417014ccd8,2017-06-13T08:00:00.000+08:00,1,Merck Stalls Enrolment in Two Myeloma Studies of Keytruda
dc145202-14c1-4662-a03b-ee53686dd958,2017-06-13T08:00:00.000+08:00,5,Lilly Plans New Outcomes Study to Expand Jardiance Label
991dc1e6-12e3-4e41-a550-848d19900e08,2017-06-13T08:00:00.000+08:00,5,Lilly Plans New Outcomes Study to Expand Jardiance Label
4480638d-e11f-4541-a922-058ce5f47ad6,2017-06-13T08:00:00.000+08:00,4,"Pfizer, Eli Lilly Report Tanezumab Received FDA Fast Track Designation"
172f141e-b5d7-4d06-8215-884334b48324,2017-06-13T08:00:00.000+08:00,3,"Lilly, Incyte Announce Presentation of New Data on Olumiant in RA, Taltz in PsA at #EULAR 2017"
34a4e153-5434-4b5a-8a72-e8e445eae187,2017-06-13T08:00:00.000+08:00,5,"UPDATE: Lilly Says 'Analysis of 12,500 adults with type 2 diabetes from 19 studies showed amputations and fractures were not increased with Jardiance compared with placebo'"
e8ab3229-9760-41fa-8cf3-87eb2e3f5a83,2017-06-13T08:00:00.000+08:00,4,Eli Lilly Reports Jardiance Analysis Reinforces Established Safety Profile
a577a529-7439-4157-beb3-132199a042ae,2017-06-13T08:00:00.000+08:00,1,Merck Stalls Enrolment in Two Myeloma Studies of Keytruda
cceb0a45-80cf-4db0-97c2-e6503398ba2c,2017-06-13T08:00:00.000+08:00,4,Lilly Plans New Outcomes Study to Expand Jardiance Label
8ef695bb-5224-44d1-bffe-9ea465b9f8f2,2017-06-13T08:00:00.000+08:00,4,Lilly Plans New Outcomes Study to Expand Jardiance Label
36b6f19a-9779-4976-9e1e-981b9aaf3c48,2017-06-13T08:00:00.000+08:00,3,"Pfizer, Eli Lilly Report Tanezumab Received FDA Fast Track Designation"
69b8f29c-918f-4590-90a7-34f9e626e161,2017-06-12T08:00:00.000+08:00,2,Novartis Presents Positive Data on CAR-T Cell Therapy Drug
6a3c4e09-c530-4766-9df9-c37c59f32907,2017-06-12T08:00:00.000+08:00,5,"Eli Lilly, Boehringer Ingelheim Announce Plans To Conduct New, Large Clinical Outcomes Trial Investigating Jardance For Treatment Of Chronic Kidney Disease"
5e83b787-7dc6-4952-b0e5-efa7850f976e,2017-06-12T08:00:00.000+08:00,5,Novartis Presents Positive Data on CAR-T Cell Therapy Drug
05f473fe-8298-417e-bfe4-03bd67941c11,2017-06-12T08:00:00.000+08:00,4,"Eli Lilly, Boehringer Ingelheim Announce Plans To Conduct New, Large Clinical Outcomes Trial Investigating Jardance For Treatment Of Chronic Kidney Disease"
c648f6dc-4fd7-4511-93e7-1e8c4b620c66,2017-06-11T08:00:00.000+08:00,3,Lilly Announces Results Showing Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine Presented at AHS
9979fc72-10ea-401e-8f58-119e5df24789,2017-06-11T08:00:00.000+08:00,3,Lilly Announces Results Showing Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine Presented at AHS
5da68fc6-d35d-4d5e-a83a-f8036228f473,2017-06-09T08:00:00.000+08:00,4,Eli Lilly and the International Diabetes Federation Announce Second Phase of BRIDGES 2 Program
59cb899f-58ee-4814-a50d-c27837f3206f,2017-06-09T08:00:00.000+08:00,4,Eli Lilly and the International Diabetes Federation Announce Second Phase of BRIDGES 2 Program
6f4faeb4-3c7b-4ed9-b528-ceed398cef45,2017-06-08T08:00:00.000+08:00,1,AbbVie (ABBV) Announced Positive Phase III RA Candidate Data
cf2776fa-a4db-4552-b7bb-8b7054d7fcad,2017-06-08T08:00:00.000+08:00,3,Teva Migraine Candidate Succeeds in Second Phase III Study
40b3fb89-5873-47ba-964d-df33263aa102,2017-06-08T08:00:00.000+08:00,4,Eli Lilly to Collaborate with KeyBioscince on Dual Amylin Calcitonin Receptor Agonists
61066eef-c7ce-4d4f-a113-853019e46280,2017-06-08T08:00:00.000+08:00,2,AbbVie (ABBV) Announced Positive Phase III RA Candidate Data
f39b3c63-9ceb-410d-880f-eab926b4bb52,2017-06-08T08:00:00.000+08:00,4,Teva Migraine Candidate Succeeds in Second Phase III Study
7012404b-001f-4813-bbc1-1893f4db276a,2017-06-08T08:00:00.000+08:00,5,Eli Lilly to Collaborate with KeyBioscince on Dual Amylin Calcitonin Receptor Agonists
bb0840c9-d97b-4e72-ad80-db87de493ac5,2017-06-03T08:00:00.000+08:00,3,Lilly Announces Initiation of MonarchE Global Phase 3 Study of Abemaciclib as Adjuvant Therapy in Early Breast Cancer #ASCO17
435fc5ba-924e-482a-bc82-4f414d77e484,2017-06-03T08:00:00.000+08:00,3,Lilly Announces Initiation of MonarchE Global Phase 3 Study of Abemaciclib as Adjuvant Therapy in Early Breast Cancer #ASCO17
24d53101-1975-4f45-8a02-a405fe65c593,2017-06-01T08:00:00.000+08:00,2,"Eli Lilly Announces Derica Rice to Retire as CFO; Co. is Considering Internal, External Candidates"
a16087a4-45ec-44aa-9414-d255f58ba9a0,2017-06-01T08:00:00.000+08:00,3,"Eli Lilly Announces Derica Rice to Retire as CFO; Co. is Considering Internal, External Candidates"
2056c1fd-a650-4f3b-99c2-9381de820073,2017-05-31T08:00:00.000+08:00,4,"Bernstein Strategic Decisions Conference Begins Today, Presenters Include: Eli Lilly, Clorox, Celgene, Discovery Communications, Mastercard, Biogen, Nasdaq, Motorola, And Yum Brands"
8a4d6e7f-e808-4cfe-9c8a-080760aec885,2017-05-31T08:00:00.000+08:00,2,A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Beige Book
0fe7c8df-6641-4af1-be8a-c0dec2ba847d,2017-05-31T08:00:00.000+08:00,5,Eli Lilly Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA Meets Primary Endpoint
131d5464-ae45-40df-bde5-33c2c31f8862,2017-05-31T08:00:00.000+08:00,4,"Bernstein Strategic Decisions Conference Begins Today, Presenters Include: Eli Lilly, Clorox, Celgene, Discovery Communications, Mastercard, Biogen, Nasdaq, Motorola, And Yum Brands"
7faf8dd3-cb6d-4fb0-8236-4a8fba974379,2017-05-31T08:00:00.000+08:00,4,A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Beige Book
735c8180-f8fa-4951-9138-ec20b785ab29,2017-05-31T08:00:00.000+08:00,5,Eli Lilly Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA Meets Primary Endpoint
d9805231-2f06-4de1-b142-14ef234c373a,2017-05-30T08:00:00.000+08:00,3,Monday's Market In 5 Minutes
14f6a3f4-df73-40e6-b1ac-cb95515f02b3,2017-05-30T08:00:00.000+08:00,3,Monday's Market In 5 Minutes
91e56a9d-0241-4c99-a162-46a4b5dd1448,2017-05-25T08:00:00.000+08:00,2,A Look At Nvidia's Largest Shareholders And What Their Presence Means
a997135f-9936-4445-a558-6e30e9fa56a2,2017-05-25T08:00:00.000+08:00,2,A Look At Nvidia's Largest Shareholders And What Their Presence Means
3fa70c8b-1bec-4e00-ae5d-5271b645b6d3,2017-05-23T08:00:00.000+08:00,4,"Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst"
8dc84769-2669-4d82-9f0c-18ca5f563bb6,2017-05-23T08:00:00.000+08:00,4,"Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst"
716b5719-90a8-4552-87fe-7bbf3712597c,2017-05-17T08:00:00.000+08:00,1,Watch These 5 Huge Put Purchases In Wednesday Trade
cab77d0d-f68d-47e4-994f-f399076d513c,2017-05-17T08:00:00.000+08:00,1,Watch These 5 Huge Put Purchases In Wednesday Trade
0a921415-fdcd-4ce0-8f44-783c54b4ed81,2017-05-16T08:00:00.000+08:00,4,Benzinga's Option Alert Recap From May 16
d2771a48-5687-487d-8f4d-298e80e5144e,2017-05-16T08:00:00.000+08:00,1,Option Alert: Lilly Jun 77.5 Puts Sweep: 1000 @ ASK $1.008: 4230 traded vs 2903 OI: Earnings 7/25 Before Open $78.97 Ref
8102f8a7-400d-4701-8ebd-fac797346e86,2017-05-16T08:00:00.000+08:00,3,Benzinga's Option Alert Recap From May 16
d9be58c2-11f5-4f18-a5e1-02e17c122fb8,2017-05-16T08:00:00.000+08:00,5,Option Alert: Lilly Jun 77.5 Puts Sweep: 1000 @ ASK $1.008: 4230 traded vs 2903 OI: Earnings 7/25 Before Open $78.97 Ref
f54e4377-043e-4f25-b86d-31ea69c34f98,2017-05-12T08:00:00.000+08:00,5,Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine
00827f25-0025-4ffe-8954-eb3a7b360695,2017-05-12T08:00:00.000+08:00,4,Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine
faccc3d8-5b83-4b43-964e-452ea6507153,2017-05-04T08:00:00.000+08:00,2,"Incyte, Lilly Disagree With FDA CRL for Baricitinib; Expects Lilly to Engage With FDA to Discuss Agency's Concerns, Determine Potential Path Forward"
f00b6bba-5a01-4a48-9267-e53781e2e82e,2017-05-04T08:00:00.000+08:00,3,"Incyte, Lilly Disagree With FDA CRL for Baricitinib; Expects Lilly to Engage With FDA to Discuss Agency's Concerns, Determine Potential Path Forward"
a123ddd1-d36b-4b9a-be1b-2610a1c76529,2017-05-01T08:00:00.000+08:00,1,"10-K Just Recently Out from Eli Lilly Shows Co. Received CID from State of Washington's Office of AG Related to Pricing of Insulin Products, Relationships with PBMs"
7333303e-d5e1-4b78-bf53-d85687275689,2017-05-01T08:00:00.000+08:00,3,"Companies Holding Shareholder Meetings Today Include: American Express, Dish Network, Eli Lilly, And Zynga"
b9b687f5-e6e4-4b5b-8196-700af8fb9687,2017-05-01T08:00:00.000+08:00,2,"10-K Just Recently Out from Eli Lilly Shows Co. Received CID from State of Washington's Office of AG Related to Pricing of Insulin Products, Relationships with PBMs"
7b12d710-859e-4869-b21e-12dec10c087f,2017-05-01T08:00:00.000+08:00,3,"Companies Holding Shareholder Meetings Today Include: American Express, Dish Network, Eli Lilly, And Zynga"
401b273a-0846-4b3c-b442-2fbb856ef000,2017-04-27T08:00:00.000+08:00,3,"Analyst Sees Eli Lilly Fairly Valued At $81 Per Share, Downgrades To Hold"
74454ee9-1f70-4247-8304-9d33034fb519,2017-04-27T08:00:00.000+08:00,1,"Benzinga's Top Upgrades, Downgrades For April 27, 2017"
1c029600-379f-42e6-bbcd-10569300e382,2017-04-27T08:00:00.000+08:00,4,Argus Research Downgrades Eli Lilly to Hold
1b8cd48f-829b-425b-9ae5-0cf20d9cfee9,2017-04-27T08:00:00.000+08:00,2,"Analyst Sees Eli Lilly Fairly Valued At $81 Per Share, Downgrades To Hold"
794fbdc5-63f9-49e2-a06f-e8ae2235c762,2017-04-27T08:00:00.000+08:00,4,"Benzinga's Top Upgrades, Downgrades For April 27, 2017"
d2091ced-80ec-4809-9e47-c444eb978a88,2017-04-27T08:00:00.000+08:00,3,Argus Research Downgrades Eli Lilly to Hold
9cea074f-8053-4af9-a7ee-8e69807f99a3,2017-04-25T08:00:00.000+08:00,4,Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates
d7473396-169f-4437-acce-5b4a2c6dc05d,2017-04-25T08:00:00.000+08:00,4,"Eli Lilly Reaffirms FY 2017 Sales Guidance, Sees $21.8b to $22.3B vs $22.1B Est"
04d471f2-2b3e-4ddb-9306-c9c6f4655f35,2017-04-25T08:00:00.000+08:00,2,"Eli Lilly Reaffirms FY 2017 Adj EPS Guidance, Sees $4.05 to $4.15 vs $4.11 Est"
ebc6013f-900c-4b73-95c3-f9eab866cfc3,2017-04-25T08:00:00.000+08:00,4,"Eli Lilly Q1 EPS $0.98 vs $0.96 Est, Sales $5.23B vs $5.21B Est"
83a1b90b-17c5-49f2-90ef-ead62355b99f,2017-04-25T08:00:00.000+08:00,3,"15 Stocks To Watch For April 25, 2017"
04bedb6d-de05-4396-82d7-2f9d7c27a01b,2017-04-25T08:00:00.000+08:00,5,"Earnings Scheduled For April 25, 2017"
ce609c2e-e10c-40fa-9f3d-b8a6f4a17b57,2017-04-25T08:00:00.000+08:00,1,Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates
bbed2bbb-efc1-4f49-937a-253437f0b846,2017-04-25T08:00:00.000+08:00,4,"Eli Lilly Reaffirms FY 2017 Sales Guidance, Sees $21.8b to $22.3B vs $22.1B Est"
cd370faa-d9d2-4dff-a548-544e43345ac5,2017-04-25T08:00:00.000+08:00,3,"Eli Lilly Reaffirms FY 2017 Adj EPS Guidance, Sees $4.05 to $4.15 vs $4.11 Est"
ab9698e7-2175-488b-960e-b851222edce3,2017-04-25T08:00:00.000+08:00,2,"Eli Lilly Q1 EPS $0.98 vs $0.96 Est, Sales $5.23B vs $5.21B Est"
4c3edf26-690a-457e-a77b-fcdea0251ac4,2017-04-25T08:00:00.000+08:00,1,"15 Stocks To Watch For April 25, 2017"
633c0931-6fa8-4a2d-9803-856b4ebea00d,2017-04-25T08:00:00.000+08:00,1,"Earnings Scheduled For April 25, 2017"
2ede0a79-e9be-4272-9d37-9b59cd26be50,2017-04-24T08:00:00.000+08:00,4,"Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow"
2e94407b-f5ba-4f59-9232-ff889edd8f00,2017-04-24T08:00:00.000+08:00,4,Eli Lilly Announces Phase 3 study Comparing Abemaciclib in Combination with an aromatase Met its Primary Endpoint
b0bc743f-cac1-49c7-90fd-c58b2a6f5097,2017-04-24T08:00:00.000+08:00,3,"Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow"
3bda9395-1cc7-4d23-b7d4-6e33a556b638,2017-04-24T08:00:00.000+08:00,4,Eli Lilly Announces Phase 3 study Comparing Abemaciclib in Combination with an aromatase Met its Primary Endpoint
cc29996c-c0ce-4178-9826-11d4ce1e9df6,2017-04-20T08:00:00.000+08:00,1,What Would A $5.8 Billion NIH Cut Look Like? Devastation
886da679-1cbc-41d9-a3ce-5724cb46c179,2017-04-20T08:00:00.000+08:00,1,What Would A $5.8 Billion NIH Cut Look Like? Devastation
45ecb00c-1939-483c-9582-c70d5b81ddcb,2017-04-17T08:00:00.000+08:00,2,15 Biggest Mid-Day Losers For Monday
9b7acd36-284e-47ef-8beb-4b3ff8f29bc9,2017-04-17T08:00:00.000+08:00,3,Hearing Leerink Defending Eli Lilly
3c9b8315-7167-4380-9205-d7aff73ff2e5,2017-04-17T08:00:00.000+08:00,4,"Benzinga's Top Upgrades, Downgrades For April 17, 2017"
b4856a4d-c623-456f-8d5a-8c05e7c7b3fa,2017-04-17T08:00:00.000+08:00,2,20 Stocks Moving In Monday's Pre-Market Session
bc622329-b2a0-4a37-83b3-6a9260b16f4f,2017-04-17T08:00:00.000+08:00,2,BMO Capital Downgrades Eli Lilly to Underperform
b4d36a9c-c701-4a50-8f23-037a4d2516e5,2017-04-17T08:00:00.000+08:00,3,Morgan Stanley Downgrades Eli Lilly to Equal-Weight
4e1a1892-fb5a-4915-9168-41ea3ef4a460,2017-04-17T08:00:00.000+08:00,1,"Eli Lilly -4.7% Premarket @ $81.88, Incyte -12.7% @ $123; FDA on Friday Declined to Approve, Lilly, Incyte Arthritis Drug Olumiant"
0c6ecca5-6734-4141-991c-0c662fce01c5,2017-04-17T08:00:00.000+08:00,4,15 Biggest Mid-Day Losers For Monday
fa4a2056-7409-4891-b99c-7b1979294b26,2017-04-17T08:00:00.000+08:00,3,Hearing Leerink Defending Eli Lilly
4b5df949-ebe2-4938-b770-2ebda4043f3b,2017-04-17T08:00:00.000+08:00,1,"Benzinga's Top Upgrades, Downgrades For April 17, 2017"
d3a7bf11-1edf-49d0-b400-4a2e440155ca,2017-04-17T08:00:00.000+08:00,3,20 Stocks Moving In Monday's Pre-Market Session
cab65777-7cb7-499d-b4b5-524a6e544325,2017-04-17T08:00:00.000+08:00,2,BMO Capital Downgrades Eli Lilly to Underperform
8a1250c9-7bed-4cac-8ffa-1d4edb664ca3,2017-04-17T08:00:00.000+08:00,3,Morgan Stanley Downgrades Eli Lilly to Equal-Weight
0706feac-f883-4459-a681-8e18f207d62e,2017-04-17T08:00:00.000+08:00,1,"Eli Lilly -4.7% Premarket @ $81.88, Incyte -12.7% @ $123; FDA on Friday Declined to Approve, Lilly, Incyte Arthritis Drug Olumiant"
4ab61aa8-4dc6-4d23-96a4-b9222a1fcdf5,2017-04-14T08:00:00.000+08:00,2,"Lilly Reaffirms Financial Guidance for 2017, Mid-term Guidance for Remainder of this Decade"
1c2edef0-b414-4f06-bb58-34b6314b0e9e,2017-04-14T08:00:00.000+08:00,2,"Lilly, Incyte Announce FDA Issues CRL for Baricitinib"
152dfca7-4d3d-4cd4-8aea-1c247c8bed9b,2017-04-14T08:00:00.000+08:00,3,"Lilly Reaffirms Financial Guidance for 2017, Mid-term Guidance for Remainder of this Decade"
5a65229b-a13d-4064-b830-a6f84146b61a,2017-04-14T08:00:00.000+08:00,4,"Lilly, Incyte Announce FDA Issues CRL for Baricitinib"
dd272edf-fd7f-48aa-bad1-dda3a12def84,2017-04-12T08:00:00.000+08:00,4,Healthcare Sector Earnings: Making A Comeback In Q1 2017?
12319ce5-811b-443d-a7f5-a0c68a4d1935,2017-04-12T08:00:00.000+08:00,2,Endpoint Reporter John Carroll Tweets: $LLY spokesperson says they are not disclosing the exact date on bari PDUFA. Really? What's the point of that?
00b7c38c-a332-4af2-adbf-c9eff02febf9,2017-04-12T08:00:00.000+08:00,4,Healthcare Sector Earnings: Making A Comeback In Q1 2017?
76e53775-d5b1-4d16-8020-6b59c5d7dcab,2017-04-12T08:00:00.000+08:00,1,Endpoint Reporter John Carroll Tweets: $LLY spokesperson says they are not disclosing the exact date on bari PDUFA. Really? What's the point of that?
d34070c0-ab67-4e83-ba3a-3489d20e207d,2017-04-07T08:00:00.000+08:00,2,FDA Warns Of Dangerous Hidden Ingredient In 5 OTC Male Sexual Enhancement Supplements
c5ffd7e7-f114-404b-964e-86090ba899cd,2017-04-07T08:00:00.000+08:00,3,FDA Warns Of Dangerous Hidden Ingredient In 5 OTC Male Sexual Enhancement Supplements
5701a9c8-1549-4986-8628-98b33ed50161,2017-04-05T08:00:00.000+08:00,2,"Eli Lilly Spokesperson, Asked If 3-Month Delay In Baricitinib PDUFA Date Announced Jan. 13 Sets New PDUFA Date At Apr. 13, Tells Benzinga 'We Are Not Disclosing A Specific Date For PDUFA'"
cc1814bf-b963-46f7-b566-aad55368e17e,2017-04-05T08:00:00.000+08:00,2,"Eli Lilly Spokesperson, Asked If 3-Month Delay In Baricitinib PDUFA Date Announced Jan. 13 Sets New PDUFA Date At Apr. 13, Tells Benzinga 'We Are Not Disclosing A Specific Date For PDUFA'"
8f3f0ced-ced0-40ec-b145-0f61348c5c6b,2017-03-31T08:00:00.000+08:00,3,Eli Lilly Endowment Reports Open Market Sale Of 210K Shares Of Common Stock At $84.67 Per SEC Filing
4b9b1b1b-958c-447e-8d8d-c612d6c4cb2d,2017-03-31T08:00:00.000+08:00,4,Eli Lilly Endowment Reports Open Market Sale Of 210K Shares Of Common Stock At $84.67 Per SEC Filing
d69adb1e-83e2-47cb-83ca-4a85a053770b,2017-03-28T08:00:00.000+08:00,5,"If Gender Confirmation Becomes A Legal Human Right, Which Corporations Could Benefit?"
35640389-9477-4f4a-a2e2-e5a6bb405dce,2017-03-28T08:00:00.000+08:00,2,IntelGenx Reports Eli Lilly Granted Co. VersaFilm an Exclusive License for Tadalafil Film Under ED Dosing Patent
47daf6e2-947d-4dd0-a3d2-a84bf8e72ff1,2017-03-28T08:00:00.000+08:00,4,"If Gender Confirmation Becomes A Legal Human Right, Which Corporations Could Benefit?"
cff5010d-41a0-411d-b1bd-32d26d34d5d4,2017-03-28T08:00:00.000+08:00,2,IntelGenx Reports Eli Lilly Granted Co. VersaFilm an Exclusive License for Tadalafil Film Under ED Dosing Patent
a146bb34-aec4-4981-acd9-2c7ba2e2ca09,2017-03-24T08:00:00.000+08:00,1,Eli Lilly Announces Plans To Invest $850M In U.S. Operations In 2017
9000a7ce-e0c3-478f-9736-24fb9878b774,2017-03-24T08:00:00.000+08:00,1,Eli Lilly Announces Plans To Invest $850M In U.S. Operations In 2017
1abe83fd-ddeb-43e0-8bfc-c40f80540d89,2017-03-23T08:00:00.000+08:00,3,"Ignyta Announces Exploration Of Strategic Options For Taladegib, Enalbed By New License Agreement With Eli Lilly"
561bac28-94c9-4c2c-bbee-ed88de243739,2017-03-23T08:00:00.000+08:00,3,"Ignyta Announces Exploration Of Strategic Options For Taladegib, Enalbed By New License Agreement With Eli Lilly"
cb263d8f-7942-4b83-8b0f-fddad60deefe,2017-03-20T08:00:00.000+08:00,1,Leerink Presents: Your 2017 Biopharma Catalyst Tracker
c595dc85-355a-42fc-b59d-2e90a73543b3,2017-03-20T08:00:00.000+08:00,4,Eli Lilly Announces MONARCH 2 Trial of Abemaciclib Met Primary Endpoint of Progression Free Survival
29856013-299c-4b8e-a36c-a229518c59c1,2017-03-20T08:00:00.000+08:00,3,Leerink Presents: Your 2017 Biopharma Catalyst Tracker
77c9f7e0-0bea-40cf-8de5-3afaf20befea,2017-03-20T08:00:00.000+08:00,4,Eli Lilly Announces MONARCH 2 Trial of Abemaciclib Met Primary Endpoint of Progression Free Survival
79c4599c-037a-486c-b3ee-aa72ea8a867f,2017-03-17T08:00:00.000+08:00,3,"Eli Lilly, Boehringer Ingelheim Report 'EMPEROR HF clinical trial program will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes'"
64c231ea-649c-40b9-a387-e81334aa47d1,2017-03-17T08:00:00.000+08:00,1,"Eli Lilly, Boehringer Ingelheim Report 'EMPEROR HF clinical trial program will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes'"
ec1697b2-f8a5-4c45-a2c6-e08464a24a0c,2017-03-16T08:00:00.000+08:00,1,Lilly Drops to Low of $84.16 on Volume
3eebd3d6-61c7-4c56-a229-1dc14296d27f,2017-03-16T08:00:00.000+08:00,1,Lilly Drops to Low of $84.16 on Volume
8465723e-0ba6-4bb3-9bd1-3d9d77033ee4,2017-03-07T08:00:00.000+08:00,4,"Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio"
eda0ba4a-385b-4c5b-84b7-86ec8354d2a5,2017-03-07T08:00:00.000+08:00,3,"Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio"
f65c0202-08d7-4cb7-bba6-21b043c8d2e0,2017-03-05T08:00:00.000+08:00,5,New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz vs Stelara in Patients with Moderate-to-Severe Plaque Psoriasis
2944462c-f790-4f1d-9e08-40bc2237a920,2017-03-05T08:00:00.000+08:00,5,New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz vs Stelara in Patients with Moderate-to-Severe Plaque Psoriasis
1451c117-5107-45b2-af0c-8bb676e48cec,2017-03-03T08:00:00.000+08:00,2,Chi-Med Announces Positive Top-Line Results for FRESCO Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer
20ad0de2-f627-49c1-a53a-a0e49baef62c,2017-03-03T08:00:00.000+08:00,5,Chi-Med Announces Positive Top-Line Results for FRESCO Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer
414294ef-7415-48a3-823d-c33532711bd5,2017-02-24T08:00:00.000+08:00,2,Carl Icahn's Track Record In Big Pharma
e8ec0cb0-b62a-4ee3-a784-692606338976,2017-02-24T08:00:00.000+08:00,3,Carl Icahn's Track Record In Big Pharma
5a82626a-d859-4d63-9f67-6c70b26e0d2e,2017-02-16T08:00:00.000+08:00,4,"After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?"
effe7460-b1f1-4026-aa9e-0cfe5fd24742,2017-02-16T08:00:00.000+08:00,1,Border Tax Polarizes U.S Companies As Exporters Take Side With Trump Team
1115977b-addc-4781-b20f-dcd4a4900ce2,2017-02-16T08:00:00.000+08:00,2,"After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?"
5bec956c-ed2b-4021-9d03-cf7bdf73de4d,2017-02-16T08:00:00.000+08:00,3,Border Tax Polarizes U.S Companies As Exporters Take Side With Trump Team
e1b6853c-de15-43b6-8cc4-b03f919a570e,2017-02-15T08:00:00.000+08:00,4,Eli Lilly & Incyte Announce Add'l Results From Pivotal RA-BEAM Study In New England Journal Of Medicine
ad71e6f7-3a87-47d9-9455-4d1e3b2eadb1,2017-02-15T08:00:00.000+08:00,5,Eli Lilly & Incyte Announce Add'l Results From Pivotal RA-BEAM Study In New England Journal Of Medicine
f25d916f-187b-40e8-9a57-9bc4f6ae6ada,2017-02-13T08:00:00.000+08:00,5,"UPDATE: Eli Lilly Says, As a Result of Olumiant Approval by EC, Incyte Becomes Eligible to Receive $65M Milestone Payment"
98f6ebfd-3719-4fc9-8577-653ff3e7e70e,2017-02-13T08:00:00.000+08:00,4,Eli Lilly Reports EC Approved Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active RA
93d8631b-3fe7-4ab0-8e28-32f18442091f,2017-02-13T08:00:00.000+08:00,5,"UPDATE: Eli Lilly Says, As a Result of Olumiant Approval by EC, Incyte Becomes Eligible to Receive $65M Milestone Payment"
84637920-af4d-4536-89b6-daf7f4099399,2017-02-13T08:00:00.000+08:00,3,Eli Lilly Reports EC Approved Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active RA
44661fac-90cf-45af-a4dd-0d177ca87cb2,2017-02-08T08:00:00.000+08:00,4,Eli Lilly Reports Trulicity Label Updated to Include Use in Combo with Basal Insulin for Adults with Type 2 Diabetes
29ab9e5e-74fc-4653-a426-5830d3b75a25,2017-02-08T08:00:00.000+08:00,4,Eli Lilly Reports Trulicity Label Updated to Include Use in Combo with Basal Insulin for Adults with Type 2 Diabetes
63e4e543-79ed-4542-80ee-11678b8031fd,2017-02-02T08:00:00.000+08:00,2,Eli Lilly Reprots Japan IP High Court Rules In Favor In Invalidation Trials Initiated By Sawai Regarding Vitamin Regimen Patents For Alimta
abfc0e1d-e1ab-4d1f-80da-2a487af170b1,2017-02-02T08:00:00.000+08:00,3,Eli Lilly Reprots Japan IP High Court Rules In Favor In Invalidation Trials Initiated By Sawai Regarding Vitamin Regimen Patents For Alimta
9d529339-f5e5-4fbe-bd29-5906aa643565,2017-01-31T08:00:00.000+08:00,4,"Eli Lilly CEO Says Too Early To Say If Amyloid-Beta Hypothesis For Alzheihmer's Is Wrong, Believes BACE Inhibitors Data Will Shed More Light"
46f937b5-3048-4e78-b10e-a998a33a02ef,2017-01-31T08:00:00.000+08:00,5,"Eli Lilly CEO Says President Trump Didn't Get Into Collaborative Policy Detail In Terms Of U.S. Pricing Environment, Left Meeting With Confidence In People Who Would Work Closely With Legislation Moving Forward"
7c768def-60ac-4a8e-a834-0b6be1993fa2,2017-01-31T08:00:00.000+08:00,4,Eli Lilly Says Quarterly Rev. Growth Led By Volume On Conf. Call
fa4e5553-acf8-49fa-b002-362f3cc18388,2017-01-31T08:00:00.000+08:00,2,US Commercial News Managing Editor Mandy Jackson Tweets: $LLY terminated EXPEDITION PRO study in prodromal Alzheimer's disease.
ce337312-d38c-456c-aac2-e77af3be10f4,2017-01-31T08:00:00.000+08:00,3,"President Trump Doubles Down On Healthcare Criticism, Says Drug Prices Are 'Astronomical'"
a9b24e56-b940-47be-93b2-25c4afb457c0,2017-01-31T08:00:00.000+08:00,3,"Fed Meeting Starts Today, But Focus Remains On Key Earnings Data"
5ca52d7c-7ecc-4ed0-a6b1-7976f6caec36,2017-01-31T08:00:00.000+08:00,4,"CNBC's Meg Tirrell Tweets: $LLY CEO tells Trump tax, deregulation could really help us expand operations"
2cd47b6e-4e62-4627-a7ab-90876b41ab94,2017-01-31T08:00:00.000+08:00,3,"The Market In 5 Minutes: Under Armour's Miss, Apple's Q1 Primer"
0097b60d-c556-4880-a612-d6501308c9dd,2017-01-31T08:00:00.000+08:00,2,"Healthcare Q4: Eli Lilly Beats, Pfizer Misses"
d49a9511-f22c-4728-aa71-bc483d16a5f6,2017-01-31T08:00:00.000+08:00,3,A Peek Into The Markets: U.S. Stock Futures Down; Apple Earnings In Focus
68a54221-2e23-4180-82d6-b7a36d39563e,2017-01-31T08:00:00.000+08:00,3,Lilly Reaffirms FY17 Adj. EPS Outlook $4.05-$4.15 vs $4.10 Est.
6d92cc48-65f2-4003-bfd1-16badf4408a6,2017-01-31T08:00:00.000+08:00,1,"Eli Lilly Reports Q4 EPS $0.95 vs $0.98 Est., Sales $5.761B vs $5.55B Est."
16ff7b30-6061-4e92-a3c5-730398064f12,2017-01-31T08:00:00.000+08:00,3,15 Stocks You Should Be Watching Today
800742c4-0b94-4ed7-96af-35ecc8a7e0da,2017-01-31T08:00:00.000+08:00,5,Jaguar Animal Health +60% Premarket @$0.85 After Announcement of Deal with Lilly Subsidiary
4531c02f-089f-44b4-acf5-b6f08283d023,2017-01-31T08:00:00.000+08:00,4,"Earnings Scheduled For January 31, 2017"
eedc86b1-2732-4d5b-ab4d-07b2aef4cddf,2017-01-31T08:00:00.000+08:00,3,"Jaguar Animal Health, Elanco Announce Global Collaboration for Development, Co-Promotion of Canalevia; Jaguar to Receive Upfront Payment of $1.5M"
39f690f2-080c-4ba3-a4d4-bdd505c7a0db,2017-01-31T08:00:00.000+08:00,4,"Eli Lilly CEO Says Too Early To Say If Amyloid-Beta Hypothesis For Alzheihmer's Is Wrong, Believes BACE Inhibitors Data Will Shed More Light"
68dd93d9-ebe3-492f-ae94-a0a52d5f29e8,2017-01-31T08:00:00.000+08:00,2,"Eli Lilly CEO Says President Trump Didn't Get Into Collaborative Policy Detail In Terms Of U.S. Pricing Environment, Left Meeting With Confidence In People Who Would Work Closely With Legislation Moving Forward"
870a4b20-0c6a-42e8-8ea2-15ad781f1a6a,2017-01-31T08:00:00.000+08:00,2,Eli Lilly Says Quarterly Rev. Growth Led By Volume On Conf. Call
cc1a56d1-dd74-4673-9715-2fefe19fddc7,2017-01-31T08:00:00.000+08:00,1,US Commercial News Managing Editor Mandy Jackson Tweets: $LLY terminated EXPEDITION PRO study in prodromal Alzheimer's disease.
7baf94b7-0b55-4c4e-b48b-ad88c7b6cd08,2017-01-31T08:00:00.000+08:00,3,"President Trump Doubles Down On Healthcare Criticism, Says Drug Prices Are 'Astronomical'"
b446d64d-c860-4804-9b0a-5c116e476f17,2017-01-31T08:00:00.000+08:00,4,"Fed Meeting Starts Today, But Focus Remains On Key Earnings Data"
3723d243-7afb-4434-81a8-3564ad23703c,2017-01-31T08:00:00.000+08:00,5,"CNBC's Meg Tirrell Tweets: $LLY CEO tells Trump tax, deregulation could really help us expand operations"
99a17273-f78a-4743-ac81-39da3ef7c6c5,2017-01-31T08:00:00.000+08:00,3,"The Market In 5 Minutes: Under Armour's Miss, Apple's Q1 Primer"
f1812d12-f4a8-49bc-ab78-917b07d85939,2017-01-31T08:00:00.000+08:00,2,"Healthcare Q4: Eli Lilly Beats, Pfizer Misses"
8987b3be-5a1d-48b5-b0f9-85e240763bac,2017-01-31T08:00:00.000+08:00,1,A Peek Into The Markets: U.S. Stock Futures Down; Apple Earnings In Focus
6affb08a-4001-498b-bebd-ed62bd348356,2017-01-31T08:00:00.000+08:00,4,Lilly Reaffirms FY17 Adj. EPS Outlook $4.05-$4.15 vs $4.10 Est.
8d8fc707-6121-4a46-9a90-6dc4127aa109,2017-01-31T08:00:00.000+08:00,5,"Eli Lilly Reports Q4 EPS $0.95 vs $0.98 Est., Sales $5.761B vs $5.55B Est."
24ec6d6b-02f8-4bdb-ab38-0ec0f2f463e9,2017-01-31T08:00:00.000+08:00,4,15 Stocks You Should Be Watching Today
7a2fe447-bf99-40df-bb95-c97098acb227,2017-01-31T08:00:00.000+08:00,5,Jaguar Animal Health +60% Premarket @$0.85 After Announcement of Deal with Lilly Subsidiary
32dadd52-5c34-4f7d-8f51-2bed537b5b9c,2017-01-31T08:00:00.000+08:00,3,"Earnings Scheduled For January 31, 2017"
c52874f7-08f0-4495-8572-7c9a50de4935,2017-01-31T08:00:00.000+08:00,4,"Jaguar Animal Health, Elanco Announce Global Collaboration for Development, Co-Promotion of Canalevia; Jaguar to Receive Upfront Payment of $1.5M"
3a57b44b-110a-4fbb-9d66-9e60b394bf51,2017-01-30T08:00:00.000+08:00,2,"Recent Weakness In Eli Lilly, Novo Nordisk, Sanofi Due To New York Times Reporting Drug Makers Accused Of Fixing Drug Prices On Insulin"
85867938-2228-4419-847e-8547e49f929f,2017-01-30T08:00:00.000+08:00,2,Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail
3c48386a-d5ea-4b35-8ef0-bfaf319b5dd1,2017-01-30T08:00:00.000+08:00,3,"A Mixed Bag of Earnings Ahead: Eli Lilly, Pfizer, Exxon Mobil, And Under Armour"
814f5430-6e60-4ccc-8dbc-72bda3c31966,2017-01-30T08:00:00.000+08:00,3,"Mixing It Up: Markets Await Host Of Economic Data, Key Earnings, And Fed Meeting"
aceb9f3e-e377-4ffa-9039-ea779d5fa97a,2017-01-30T08:00:00.000+08:00,1,"Recent Weakness In Eli Lilly, Novo Nordisk, Sanofi Due To New York Times Reporting Drug Makers Accused Of Fixing Drug Prices On Insulin"
4b8ca2f8-adbe-474c-aad5-0204681cb47b,2017-01-30T08:00:00.000+08:00,5,Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail
689de748-b14a-4ca1-8b32-7f1934cd7127,2017-01-30T08:00:00.000+08:00,3,"A Mixed Bag of Earnings Ahead: Eli Lilly, Pfizer, Exxon Mobil, And Under Armour"
148b878a-7659-4ee3-ad15-6a46af04af09,2017-01-30T08:00:00.000+08:00,3,"Mixing It Up: Markets Await Host Of Economic Data, Key Earnings, And Fed Meeting"
ed503f73-b70b-446f-bfb2-8dd299868abb,2017-01-29T08:00:00.000+08:00,4,"Barron's Sees Dow At 30,000"
e90cb03a-c800-4d98-b28c-dfb6b1616983,2017-01-29T08:00:00.000+08:00,4,"Barron's Sees Dow At 30,000"
0ff088af-f38b-4e56-a6d5-d9307233c126,2017-01-26T08:00:00.000+08:00,5,Eli Lilly Reports Jardiance Is First Type 2 Diabetes Medicine In EU To Include Cardiovascular Death Reduction Data In Label
5335204b-0e23-4365-85e4-058698953321,2017-01-26T08:00:00.000+08:00,4,Eli Lilly Reports Jardiance Is First Type 2 Diabetes Medicine In EU To Include Cardiovascular Death Reduction Data In Label
fcb3da25-97a7-4dd0-be30-a409e597789c,2017-01-25T08:00:00.000+08:00,3,Which Pharma Players Dominate The Lung Cancer Space?
612744c5-8473-4a48-9437-677c8d56e106,2017-01-25T08:00:00.000+08:00,3,Which Pharma Players Dominate The Lung Cancer Space?
074fb105-f987-4152-9dda-1a04e15e3ab2,2017-01-24T08:00:00.000+08:00,4,"Elanco Animal Health, A Division of Eli Lilly and Aratana, Announces Galliprant Available For Canine Osteoarthritis"
aac1c523-84fe-45b6-8e3c-52e91ad74abf,2017-01-24T08:00:00.000+08:00,4,"Elanco Animal Health, A Division of Eli Lilly and Aratana, Announces Galliprant Available For Canine Osteoarthritis"
de9350d4-513f-445d-8357-ec52dd86819f,2017-01-18T08:00:00.000+08:00,2,Mid-Afternoon Market Update: Crude Oil Down 2.5%; Gigamon Shares Drop After Issuing Lower Forecast
0c9b6528-452d-49c6-a201-a301b3884115,2017-01-18T08:00:00.000+08:00,4,15 Biggest Mid-Day Gainers For Wednesday
3e67a983-331d-4ae5-9d04-4fc3c4be8bff,2017-01-18T08:00:00.000+08:00,3,Mid-Day Market Update: CoLucid Jumps On Acquisition News; Pearson Shares Tumble
cad159c1-482f-475b-8b76-3acd98cba8de,2017-01-18T08:00:00.000+08:00,1,Mid-Morning Market Update: Markets Mixed; Goldman Sachs Profit Beats Views
d4772d70-bff0-4f61-ab38-e3bdbef34e9b,2017-01-18T08:00:00.000+08:00,2,"The Market In 5 Minutes: Goldman Sachs, Chelsea Manning And Jerry Seinfeld"
b5a73385-7f03-415d-a40e-b9b70a9baa18,2017-01-18T08:00:00.000+08:00,4,18 Stocks Moving In Wednesday's Pre-Market Session
521b0f42-cc6a-4037-9f80-2abe0040cc73,2017-01-18T08:00:00.000+08:00,3,"A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Economic Data, Yellen Speech"
a83a255c-16ba-490d-8564-a013ed43d687,2017-01-18T08:00:00.000+08:00,5,CoLUcid Pharma to be Acquired by Eli Lilly for $46.50/Share Cash
c8871ed7-336d-4e70-aeb4-b8b4efc5123d,2017-01-18T08:00:00.000+08:00,1,Mid-Afternoon Market Update: Crude Oil Down 2.5%; Gigamon Shares Drop After Issuing Lower Forecast
a81e7ae6-36af-4db4-86a9-01b4fb9c9ccb,2017-01-18T08:00:00.000+08:00,2,15 Biggest Mid-Day Gainers For Wednesday
bf2b7b13-f8f1-4dea-8d81-366d0a7d115b,2017-01-18T08:00:00.000+08:00,2,Mid-Day Market Update: CoLucid Jumps On Acquisition News; Pearson Shares Tumble
a9cada26-26e0-48f4-afea-645348526392,2017-01-18T08:00:00.000+08:00,3,Mid-Morning Market Update: Markets Mixed; Goldman Sachs Profit Beats Views
01866149-8dcf-4648-b287-0c9fb9e0b4c6,2017-01-18T08:00:00.000+08:00,3,"The Market In 5 Minutes: Goldman Sachs, Chelsea Manning And Jerry Seinfeld"
73a1c5cf-ca8d-4866-aba3-a345b3df9ce6,2017-01-18T08:00:00.000+08:00,4,18 Stocks Moving In Wednesday's Pre-Market Session
896eb4ce-60a2-4dd1-8713-513aad66eac3,2017-01-18T08:00:00.000+08:00,5,"A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Economic Data, Yellen Speech"
10fb5a78-058c-45cb-a919-6f04c7ed719d,2017-01-18T08:00:00.000+08:00,5,CoLUcid Pharma to be Acquired by Eli Lilly for $46.50/Share Cash
5f15e9ae-f359-4d2b-99b1-4daf53b09a50,2017-01-17T08:00:00.000+08:00,4,"Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse"
2ee31a16-6ce7-4053-ad69-7781f646c5cb,2017-01-17T08:00:00.000+08:00,3,"Incyte PDUFA Date Pushed Back, JMP Discusses Impact"
aded2f3a-5ee9-4876-b472-317c4c90917b,2017-01-17T08:00:00.000+08:00,4,"Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse"
dac23c49-9c4e-4146-b368-40879a6980d3,2017-01-17T08:00:00.000+08:00,2,"Incyte PDUFA Date Pushed Back, JMP Discusses Impact"
959770a4-9f4e-4eec-8617-fc2a7cdc8b0c,2017-01-13T08:00:00.000+08:00,2,"Eli Lilly And Incyte Report FDA Has Extended Review Period For Baricitinib, PUDFA Goal Date Has Been Extended By 3 Months"
37d22ef0-8b32-4bc6-a5da-e49b2ac90127,2017-01-13T08:00:00.000+08:00,4,7 Biotech Catalysts Remaining In January
805aaa81-8576-40be-b06b-89efb2e75db3,2017-01-13T08:00:00.000+08:00,3,Watch These 5 Huge Put Purchases In Friday Trade
dcc47590-4a82-4cbd-bc97-4772b1faa483,2017-01-13T08:00:00.000+08:00,2,"Eli Lilly And Incyte Report FDA Has Extended Review Period For Baricitinib, PUDFA Goal Date Has Been Extended By 3 Months"
ae6a5c95-9dbe-46ab-b25b-18632ee5f1c5,2017-01-13T08:00:00.000+08:00,2,7 Biotech Catalysts Remaining In January
d8a4efc6-6862-45be-a2d8-604086f09740,2017-01-13T08:00:00.000+08:00,2,Watch These 5 Huge Put Purchases In Friday Trade
78571f80-f1fa-4f56-89d4-ca6c4a01cc84,2017-01-12T08:00:00.000+08:00,4,"Eli Lilly Releases PR On Earlier Report, Says U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent"
83bf7feb-964b-48b3-b236-fd89b2642c56,2017-01-12T08:00:00.000+08:00,3,Teva 'Disappointed' In Court's Patent Decision
2ccf25cd-c459-4006-aec7-9a0d3950be11,2017-01-12T08:00:00.000+08:00,5,Option Alert: Lilly Jan 75.0 Puts Sweep: 710 @ ASK $0.54: 740 traded vs 16k OI: Earnings 1/31 Before Open $76.22 Ref
02ac63e8-0eb5-4a40-a027-43e2975aa844,2017-01-12T08:00:00.000+08:00,5,U.S. Appeals Court Rules For Eli Lilly Against Teva In Alimta Patent Case
da96c07a-f897-490a-9eba-1f6c96c86821,2017-01-12T08:00:00.000+08:00,4,"Eli Lilly Releases PR On Earlier Report, Says U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent"
183870ee-c1e5-40c3-bb90-f158786439dd,2017-01-12T08:00:00.000+08:00,2,Teva 'Disappointed' In Court's Patent Decision
fb6b234d-2fd1-495a-8d01-ecaba116a481,2017-01-12T08:00:00.000+08:00,3,Option Alert: Lilly Jan 75.0 Puts Sweep: 710 @ ASK $0.54: 740 traded vs 16k OI: Earnings 1/31 Before Open $76.22 Ref
d5db8a03-78b0-46e5-ace2-9a455b13d2e4,2017-01-12T08:00:00.000+08:00,5,U.S. Appeals Court Rules For Eli Lilly Against Teva In Alimta Patent Case
dc8ac4d9-d87a-445c-85c8-b62ee04a451e,2017-01-11T08:00:00.000+08:00,4,"Lilly and Merck Expand Immuno-Oncology Collaboration, Financial Terms Not Disclosed"
5440654a-5299-4a28-9a66-5f36747139f1,2017-01-11T08:00:00.000+08:00,4,"Lilly and Merck Expand Immuno-Oncology Collaboration, Financial Terms Not Disclosed"
6c496d9b-8383-421e-b856-49d0aa26e361,2017-01-06T08:00:00.000+08:00,3,The MedTech Group: 2017 Top Picks And Catalysts
3c3dcb15-762b-45b5-94c8-422462f103bb,2017-01-06T08:00:00.000+08:00,3,The MedTech Group: 2017 Top Picks And Catalysts
2c2b06b3-c635-4237-a60a-adb988db2220,2017-01-05T08:00:00.000+08:00,4,Zymeworks Announces Successful Achievement of Research Milestone with Lilly in Bispecific Antibody Collaboration
4afd0dff-b13f-4dac-95b9-cd22b0a786bb,2017-01-05T08:00:00.000+08:00,5,Zymeworks Announces Successful Achievement of Research Milestone with Lilly in Bispecific Antibody Collaboration
28ad9d4a-1db6-4b9b-b288-6448ae20216a,2017-01-04T08:00:00.000+08:00,4,"Eli Lilly, Boehringer Ingelheim Announce FDA Approval of sNDA to Include Landmark Data in Product Labels for Synjardy, Synjardy XR, Glyxambi Tablets"
a4f620d0-6f69-4462-a4ca-d757f1fd3e5f,2017-01-04T08:00:00.000+08:00,4,"Eli Lilly, Boehringer Ingelheim Announce FDA Approval of sNDA to Include Landmark Data in Product Labels for Synjardy, Synjardy XR, Glyxambi Tablets"
1ba92eda-0c74-47d3-a231-0c3543b08499,2016-12-28T08:00:00.000+08:00,3,"FTC Will Require Boehringer Ingelheim To Make Divestitures To Eli Lilly, Bayer AG As Conditions For Sanofi Deal"
f2201c33-da22-4c86-925e-96b029840a26,2016-12-28T08:00:00.000+08:00,2,A Preview Of January PDUFA Dates
a8785c76-1c14-4686-9c34-b75b766234fb,2016-12-28T08:00:00.000+08:00,1,"FTC Will Require Boehringer Ingelheim To Make Divestitures To Eli Lilly, Bayer AG As Conditions For Sanofi Deal"
7e30a493-0e18-4b8e-8b58-da49e8ac8f49,2016-12-28T08:00:00.000+08:00,2,A Preview Of January PDUFA Dates
967be1da-e00d-4a48-98cc-3e7243fd1634,2016-12-27T08:00:00.000+08:00,4,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week
620fdc6c-2c3a-4aad-bb39-5333d024c6fd,2016-12-27T08:00:00.000+08:00,4,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week
4af3cc0b-247f-4b57-ab53-eef106b3298c,2016-12-23T08:00:00.000+08:00,1,6 Worst Biotech Stocks Of 2016
ed241706-af6e-40c8-a99b-75e25f984d88,2016-12-23T08:00:00.000+08:00,1,6 Worst Biotech Stocks Of 2016
36be6e61-baa6-4f87-bdc5-56f130ea9484,2016-12-19T08:00:00.000+08:00,4,Jefferies' 2017 Global Pharma Outlook
12768a8a-0bc3-4503-9e70-a94ccaa532e7,2016-12-19T08:00:00.000+08:00,4,Jefferies' 2017 Global Pharma Outlook
bcb26ccf-0935-4964-a45d-062553c725de,2016-12-16T08:00:00.000+08:00,5,"Eli Lilly, Boehringer Welcome New Recommendation For Jardiance Tablets; Includes New Recommendations To consider JARDIANCE Use In People With Type 2 Diabetes and Established Cardiovascular Disease To Reduce Risk Of Cardiovascular Death"
de043067-b3a6-43fb-bc0f-253d27c971ce,2016-12-16T08:00:00.000+08:00,3,"Eli Lilly Biochaperone Lispro U100 and Humalog Showed SImilar Safety Result, Well Tolerated"
134d0718-6660-49fd-8bf5-8f285cfb5a34,2016-12-16T08:00:00.000+08:00,2,"Eli Lilly's Guidance Supported By Short-Term Boosts, Not Better Fundamentals"
2f3dc3b1-15d7-4336-afc6-26dc91208e2c,2016-12-16T08:00:00.000+08:00,4,"The Market In 5 Minutes: Adobe, Oracle Take The Earnings Stage"
acf92741-293a-4609-9e71-9274c4b789d4,2016-12-16T08:00:00.000+08:00,3,7 Biggest Price Target Changes For Friday
517eb98a-ca2a-4275-b2c2-5764c7b1d825,2016-12-16T08:00:00.000+08:00,5,"Morgan Stanley Upgrades Eli Lilly to Overweight, Raises Target to $82.00"
eae160bb-e0b6-4783-8b04-0aae67647c17,2016-12-16T08:00:00.000+08:00,4,"Eli Lilly, Boehringer Welcome New Recommendation For Jardiance Tablets; Includes New Recommendations To consider JARDIANCE Use In People With Type 2 Diabetes and Established Cardiovascular Disease To Reduce Risk Of Cardiovascular Death"
e94cc1b4-b5a8-461f-8c50-0209cd6815f5,2016-12-16T08:00:00.000+08:00,4,"Eli Lilly Biochaperone Lispro U100 and Humalog Showed SImilar Safety Result, Well Tolerated"
03c8ba08-7430-4184-9fe7-dd22d66198b7,2016-12-16T08:00:00.000+08:00,2,"Eli Lilly's Guidance Supported By Short-Term Boosts, Not Better Fundamentals"
eeb9eebc-eb4e-4954-b9c0-719ab99d1907,2016-12-16T08:00:00.000+08:00,3,"The Market In 5 Minutes: Adobe, Oracle Take The Earnings Stage"
6ef27110-f107-4844-9b48-b427c3745081,2016-12-16T08:00:00.000+08:00,3,7 Biggest Price Target Changes For Friday
ea516c40-6c97-4cba-9da3-e56af8d322af,2016-12-16T08:00:00.000+08:00,4,"Morgan Stanley Upgrades Eli Lilly to Overweight, Raises Target to $82.00"
c960f52e-b84c-41bb-9d25-43bbc0155c76,2016-12-15T08:00:00.000+08:00,4,The Week In Guidance: 4 Companies That Gave Investors Their 2017 Outlook
59cb1a89-a25c-4ec6-b1e8-5531030bc45a,2016-12-15T08:00:00.000+08:00,4,18 Biggest Mid-Day Gainers For Thursday
7e3c21e8-9eb3-4c5a-923f-68a669e90801,2016-12-15T08:00:00.000+08:00,5,Hearing Eli Lilly Added To Conviction Buy List At Goldman
0538aeab-3e80-4df3-854d-5aef87c98acc,2016-12-15T08:00:00.000+08:00,3,Eli Lilly CFO Says They Do Not See U.S. Healthcare Reform Changes Impacting FY17 Sales
4894789c-eccf-419f-93ad-3c71c6c760f3,2016-12-15T08:00:00.000+08:00,4,"Eli Lilly Announces Guidance, U.S. Insulin Release"
42c36dbb-6f9a-45e0-83f2-ae8b5a9a92ed,2016-12-15T08:00:00.000+08:00,4,Eli Lilly Holding Guidance Call Today 10am EST
373c5744-3aa4-4811-9686-71044b43ae1f,2016-12-15T08:00:00.000+08:00,2,18 Stocks Moving In Thursday's Pre-Market Session
e43bf77c-2528-4d8e-8f58-01a93908bd2e,2016-12-15T08:00:00.000+08:00,1,A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Economic Data
a0090c60-accb-4b2f-9b9e-0c0a06c5b2c3,2016-12-15T08:00:00.000+08:00,3,Eli Lilly's Basaglar Now Available in US
422a0f31-5ad7-4bbf-a6a8-7900c8126650,2016-12-15T08:00:00.000+08:00,4,Eli Lilly and Company Common Stock Sees FY2017 EPS $4.05-4.15 vs $3.97 Est
1c39ef38-24a1-4971-9499-060b8a41d820,2016-12-15T08:00:00.000+08:00,5,Eli Lilly and Company Common Stock Sees FY2016 EPS $3.50-3.60 vs $3.52 Est
889f2ecd-ee29-43f0-9f18-d259efff3479,2016-12-15T08:00:00.000+08:00,4,The Week In Guidance: 4 Companies That Gave Investors Their 2017 Outlook
45264a5a-ccc7-428f-8f8f-ff6696a98013,2016-12-15T08:00:00.000+08:00,2,18 Biggest Mid-Day Gainers For Thursday
f8254401-eb0a-4dad-869d-9d464f9a4c8c,2016-12-15T08:00:00.000+08:00,3,Hearing Eli Lilly Added To Conviction Buy List At Goldman
8277fcfe-8827-4044-b047-22e73e674017,2016-12-15T08:00:00.000+08:00,4,Eli Lilly CFO Says They Do Not See U.S. Healthcare Reform Changes Impacting FY17 Sales
f9c8ce19-e9a3-49f3-96d2-5b95a2e91d29,2016-12-15T08:00:00.000+08:00,5,"Eli Lilly Announces Guidance, U.S. Insulin Release"
102b17f0-0f7e-4dbc-9564-3fd2d741f0ed,2016-12-15T08:00:00.000+08:00,2,Eli Lilly Holding Guidance Call Today 10am EST
7be83864-2c03-450f-b005-847dd7e485ce,2016-12-15T08:00:00.000+08:00,1,18 Stocks Moving In Thursday's Pre-Market Session
0a7cdde4-9d0f-4f32-9f30-4d003b237442,2016-12-15T08:00:00.000+08:00,2,A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Economic Data
ccff8686-c62c-4083-b291-f6461e664489,2016-12-15T08:00:00.000+08:00,4,Eli Lilly's Basaglar Now Available in US
4761a52b-dbfa-4fbd-bce2-3fc77518f80e,2016-12-15T08:00:00.000+08:00,5,Eli Lilly and Company Common Stock Sees FY2017 EPS $4.05-4.15 vs $3.97 Est
ad97c1e1-5477-4f82-8127-31861ef08133,2016-12-15T08:00:00.000+08:00,2,Eli Lilly and Company Common Stock Sees FY2016 EPS $3.50-3.60 vs $3.52 Est
d68f064f-48b0-4187-a4ed-35cf0efd5537,2016-12-13T08:00:00.000+08:00,3,Heads Up! These 4 Companies Issuing Guidance This Week
36b5d14e-de53-4997-a379-82edbde16392,2016-12-13T08:00:00.000+08:00,4,Lilly Announces Program to Provide Insulin at Discounted Prices
9a969173-9c7b-40d7-9b55-cf8aa683a220,2016-12-13T08:00:00.000+08:00,3,Heads Up! These 4 Companies Issuing Guidance This Week
104595da-1f33-4693-82d5-9e1fa0cfeb61,2016-12-13T08:00:00.000+08:00,4,Lilly Announces Program to Provide Insulin at Discounted Prices
c6b26ef6-72e1-43cc-bbf8-07ef49e0563c,2016-12-12T08:00:00.000+08:00,5,Eli Lilly Raises Qtr. Dividend from $0.51 to $0.52/Share
b4daaf6d-fffb-4c5d-af88-fd078b8cd12e,2016-12-12T08:00:00.000+08:00,4,"Eli Lilly, Boehringer Ingelheim Report FDA Approved Synjardy XR Tablets for Adults with Type-2 Diabetes"
d6d1bdfd-fdfd-4273-8ea7-1b9d758e1421,2016-12-12T08:00:00.000+08:00,3,What We Know About Trump's Potential Pick To Head The FDA
9f275c10-64c1-40c1-bf6d-b3576a4af826,2016-12-12T08:00:00.000+08:00,4,AC Immune Out Positive On Crenezumab; What Does It Mean?
b9467d2a-d687-4ecf-9425-61c374593826,2016-12-12T08:00:00.000+08:00,5,Eli Lilly Raises Qtr. Dividend from $0.51 to $0.52/Share
05c77282-a49b-4bf3-b148-978816cf0346,2016-12-12T08:00:00.000+08:00,4,"Eli Lilly, Boehringer Ingelheim Report FDA Approved Synjardy XR Tablets for Adults with Type-2 Diabetes"
918f6804-d9af-453a-aa56-68fba9d1ebc3,2016-12-12T08:00:00.000+08:00,2,What We Know About Trump's Potential Pick To Head The FDA
7a929019-c5ab-4f68-a922-2f1e18dc4789,2016-12-12T08:00:00.000+08:00,3,AC Immune Out Positive On Crenezumab; What Does It Mean?
b37ab76e-c540-4c59-a19e-b4e41762d64c,2016-12-09T08:00:00.000+08:00,4,AstraZeneca Higher Off Drug News And Upgrade
df0b8653-554b-4cdf-9684-443b88d81095,2016-12-09T08:00:00.000+08:00,5,Eli Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease
c2c33eea-54b3-43c6-9ccc-0642c5b3bcd7,2016-12-09T08:00:00.000+08:00,1,Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at CTAD 2016 Meeting; Primary Endpoint was Not Met
6de96eca-a070-4c13-a023-65b90c8e1192,2016-12-09T08:00:00.000+08:00,4,AstraZeneca Higher Off Drug News And Upgrade
d82215f7-fe10-46a6-becb-b055f506ba0e,2016-12-09T08:00:00.000+08:00,3,Eli Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease
d7f87265-b142-448a-8c37-4c226805820c,2016-12-09T08:00:00.000+08:00,1,Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at CTAD 2016 Meeting; Primary Endpoint was Not Met
f69a35ff-ada2-46d9-9242-992e0fb43e05,2016-12-08T08:00:00.000+08:00,5,UPDATE: Lilly Trial Met Primary Endpoint Of KI67 Expression Reduction After 2 Weeks Treatment
c42d3618-92d7-4911-b060-1d60d930e4b7,2016-12-08T08:00:00.000+08:00,4,Lilly Presents neoMONARCH Phase 2 Data on Abemaciclib in Early-Stage Breast Cancer
86c89a09-43fb-48a9-96e0-274d5a8795b4,2016-12-08T08:00:00.000+08:00,5,UPDATE: Lilly Trial Met Primary Endpoint Of KI67 Expression Reduction After 2 Weeks Treatment
bcf07270-c473-4869-b94c-fc5a4fda0e03,2016-12-08T08:00:00.000+08:00,4,Lilly Presents neoMONARCH Phase 2 Data on Abemaciclib in Early-Stage Breast Cancer
2a3382d3-4c54-4c74-8282-d5090413fba6,2016-12-07T08:00:00.000+08:00,2,What If Trump Keeps Badmouthing Drug Pricing?
6812f25e-06c0-43c5-899e-218905f99069,2016-12-07T08:00:00.000+08:00,1,"Pfizer, J&J, Other Big Pharma Names Dip Lower Just After the Open"
8a16e4a6-eced-491e-b1b6-9800ad9eaf89,2016-12-07T08:00:00.000+08:00,3,What If Trump Keeps Badmouthing Drug Pricing?
c8a5c0f6-eda9-4bde-84a4-3d50a332adda,2016-12-07T08:00:00.000+08:00,1,"Pfizer, J&J, Other Big Pharma Names Dip Lower Just After the Open"
2bcf876f-a101-4908-9bd3-1e89308b28a5,2016-12-05T08:00:00.000+08:00,1,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
65684183-bb5a-47ef-b7c7-18e8279c02a6,2016-12-05T08:00:00.000+08:00,4,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
7f82af48-080e-48f5-b849-e78ea5d837c7,2016-12-02T08:00:00.000+08:00,5,Eli Lilly Shares Spike Higher as FDA Has Approved Jardiance to Reduce CV Death in Adults with Type 2 Diabetes
8406deef-7eff-4374-b270-46ec55ff5919,2016-12-02T08:00:00.000+08:00,4,Lilly Pops to High of $67.45 on Volume
5347de96-6d66-47c4-9dbe-254dff1244b0,2016-12-02T08:00:00.000+08:00,5,"Eli Lilly Confirms It Will Provide Updated Guidance In Conf. Call Dec. 15, 10am EST"
1f2e7828-f107-4c78-87c1-dd17da409654,2016-12-02T08:00:00.000+08:00,3,Eli Lilly Shares Spike Higher as FDA Has Approved Jardiance to Reduce CV Death in Adults with Type 2 Diabetes
f0034592-016a-4513-acb4-7afce7b5c8c1,2016-12-02T08:00:00.000+08:00,4,Lilly Pops to High of $67.45 on Volume
a1b34d24-ec98-40c7-a755-76aeb65c8608,2016-12-02T08:00:00.000+08:00,4,"Eli Lilly Confirms It Will Provide Updated Guidance In Conf. Call Dec. 15, 10am EST"
465c1b57-029e-48d0-874e-52bf7bd3066a,2016-12-01T08:00:00.000+08:00,2,"Forbes Healthcare Summit Concludes Today; Presenters Include Express Scripts, Allergan, IBM, Bristol-Myers Squibb, Merck, Anthem, Eli Lilly, And Regeneron"
79c5aafe-2281-4e65-b79b-2b8026d056bc,2016-12-01T08:00:00.000+08:00,2,"Forbes Healthcare Summit Concludes Today; Presenters Include Express Scripts, Allergan, IBM, Bristol-Myers Squibb, Merck, Anthem, Eli Lilly, And Regeneron"
9591988b-3034-4fe8-b1ba-4f4f5be5661a,2016-11-29T08:00:00.000+08:00,3,The Difference Between Shareholders And Stakeholders
d2a330ab-06ea-439b-94ab-fcf44744678b,2016-11-29T08:00:00.000+08:00,4,The Difference Between Shareholders And Stakeholders
e1ab4ca4-3e41-4602-baa0-9cf6ff4cc87d,2016-11-25T08:00:00.000+08:00,1,"Aside From The Recent Drug Failure, What Else Is Happening With Eli Lilly?"
ef4e1c36-c538-4503-855a-de0fd24e59ef,2016-11-25T08:00:00.000+08:00,4,Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects
a733dce8-ecd8-4a5b-9876-3252773c2b2c,2016-11-25T08:00:00.000+08:00,2,Atlantic Equities Earlier Downgraded Eli Lilly to Neutral
114f7033-60de-4e8f-8207-bd612ec4c6d1,2016-11-25T08:00:00.000+08:00,3,The Market In 5 Minutes: Black Friday Closes Shortened Trading Week
e917cd0e-e525-4383-9f13-75f55eda5d05,2016-11-25T08:00:00.000+08:00,1,Benzinga's Top Downgrades
c0ff91db-0b9e-473c-ac13-4bcebafcca01,2016-11-25T08:00:00.000+08:00,2,Experts React To Concerning Alzheimer's News From Eli Lilly
3cddb046-5863-474e-ac31-1cd6744b6af0,2016-11-25T08:00:00.000+08:00,2,A Peek Into The Markets: U.S. Stock Futures Gain On Black Friday
ec99c741-3d15-4927-9a38-31368160d8e3,2016-11-25T08:00:00.000+08:00,3,"BMO Capital Downgrades Eli Lilly to Market Perform, Lowers Target to $64.00"
0ef5f06f-2234-4ca7-b5c2-6fd866640e4d,2016-11-25T08:00:00.000+08:00,3,"Must Watch Stocks for November 25, 2016"
bf838cc4-b61b-4d7e-a4f7-e1b160df4372,2016-11-25T08:00:00.000+08:00,4,"Aside From The Recent Drug Failure, What Else Is Happening With Eli Lilly?"
e4e3f77b-251d-4c6c-b8a3-59180a24baaf,2016-11-25T08:00:00.000+08:00,5,Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects
d7fa0ef0-d262-4f07-a661-5701afc16298,2016-11-25T08:00:00.000+08:00,2,Atlantic Equities Earlier Downgraded Eli Lilly to Neutral
a8898309-985e-4399-bdd2-8bdc1efec631,2016-11-25T08:00:00.000+08:00,3,The Market In 5 Minutes: Black Friday Closes Shortened Trading Week
992a63c8-f325-4cc6-860a-9fd5c2f4c032,2016-11-25T08:00:00.000+08:00,3,Benzinga's Top Downgrades
4ee41cf8-660f-48e2-b142-e63c87e2e3ed,2016-11-25T08:00:00.000+08:00,1,Experts React To Concerning Alzheimer's News From Eli Lilly
2427fd12-8908-475a-8260-16a4928cb324,2016-11-25T08:00:00.000+08:00,4,A Peek Into The Markets: U.S. Stock Futures Gain On Black Friday
e0df44ed-0b3d-40fd-8803-798e18d2e00e,2016-11-25T08:00:00.000+08:00,2,"BMO Capital Downgrades Eli Lilly to Market Perform, Lowers Target to $64.00"
96edf9af-4929-4763-9778-3e53f1529bf7,2016-11-25T08:00:00.000+08:00,3,"Must Watch Stocks for November 25, 2016"
38af399d-3fc2-473e-9493-8cec490a446f,2016-11-23T08:00:00.000+08:00,1,A Tough Day For Some Biotech Bulls
1ee91334-8ed2-4e75-94a8-5d46f25ca5ea,2016-11-23T08:00:00.000+08:00,1,Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock
b2de34f8-c514-41de-9031-0e67a4a174cd,2016-11-23T08:00:00.000+08:00,2,18 Biggest Mid-Day Losers For Wednesday
24ca7d88-090a-41e9-bddc-1a7c819fd605,2016-11-23T08:00:00.000+08:00,2,"Baird Analayst Says No Change To Axovant Sciences on Lilly's solanezumab Failure, Intepirdine Commercial Opportunity In AD Is Multiple Billions per Year"
4adafb4b-aadc-4010-ac99-1cc4293decbe,2016-11-23T08:00:00.000+08:00,3,Mid-Day Market Update: Eli Lilly Tumbles After Alzheimer's Study Fails To Meet Goals; Euroseas Shares Rise
5395ae7c-0621-473b-8eed-3d5ecd8a15b7,2016-11-23T08:00:00.000+08:00,1,Stocks Hitting 52-Week Lows
07bcd9b4-79df-4a6b-8780-38d6d8cbc9a1,2016-11-23T08:00:00.000+08:00,2,Adam Feuerstein Tweets: Check out @AF_biotech tweets laying out bear thesis on $PRTA as collateral damage from $LLY sola blowup. He knows his stuff.
76b6dbca-59cd-4629-bba4-27a62db7749e,2016-11-23T08:00:00.000+08:00,3,Mid-Morning Market Update: Markets Mostly Lower; Deere Tops Q4 Views
2ffe22b7-3219-4dbd-90ed-c02c4dfe39c6,2016-11-23T08:00:00.000+08:00,2,"Biotech Down In Early Trading: PDL BioPharma 15%, Eli Lilly 13%, Biogen, 6%, Cellectis, Insys 5.5%, Dynavax, Kite 5%"
ebd50c4c-256c-46aa-ace1-d48d50b90a88,2016-11-23T08:00:00.000+08:00,1,Neurotrope Issues Statement On Eli Lilly's Solanezumab
c7f6ece8-e110-44ae-a13d-c10f7bbb72c2,2016-11-23T08:00:00.000+08:00,3,"Credit Suisse Says Hard To Get Strong Read-Through Conclusions On Biogen From Lilly's Study Without More Details, Today's News Represents Negative Headline In A Time Where Positive Headlines Are Needed; Biotech Space Could Be Weak On This Headline News"
47233b6d-c1cc-4a22-beaa-7acf33008aca,2016-11-23T08:00:00.000+08:00,4,"JP Morgan Highlighting Downside in Biogen Shares This Morning (Down ~8%) Related to Lilly's Alzheimer Drug News; Sees Transient 5-15% Move Lower in Biogen Shares, But Sees Possibility Stock Recovers"
3435fbe4-6526-4ff1-845a-a8510e9afd07,2016-11-23T08:00:00.000+08:00,1,Eli Lilly's Solanezumab Failure Is Bad News For Biogen
42872e9d-f468-4dad-9278-2a421e374321,2016-11-23T08:00:00.000+08:00,2,"AC Immune Shares Down 20% Amid Concerning Alzheimer Drug Data from Lilly; BZ NOTE: In an Oct. 18 Note, Leerink Estimated AC Immune Shares Could Be Down 60% if Data was Not Favorable"
e97b46bd-343d-41d3-8c0c-5145d8843063,2016-11-23T08:00:00.000+08:00,3,"Morgan Stanley Calling For Biogen To End The Day Flat To Slightly Up Following Eli Lilly Data Results; Says aducanumab More Potent Than solanezumab, Believes Indication Of Activity/Trends Could Keep Amyloid Debate Alive"
66b5d122-8982-43b0-9c15-5995eb95a5e0,2016-11-23T08:00:00.000+08:00,4,Raymond James Out Saying They Would Be Buyers of Biogen On Weakness Following Eli Lilly's Failed EXPEDITION 3 Trail; May Actually Be Clearing Event With Respect To Any Takeout
d07bbc26-1481-4c8a-9e62-9c9d51823bb4,2016-11-23T08:00:00.000+08:00,1,20 Stocks Moving In Wednesday's Pre-Market Session
6f6ed2e7-2e1e-44d7-9d24-7aa7b9a94661,2016-11-23T08:00:00.000+08:00,3,"A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Economic Data, Fed Minutes"
4db63119-1ce5-4bb4-b992-c7e9ad390dba,2016-11-23T08:00:00.000+08:00,1,Eli Lilly Plunges 15% After Alzheimer's Study Fails To Meet Goals
0d3e615e-9737-4386-b8a8-cc3139e7fbc1,2016-11-23T08:00:00.000+08:00,3,Can You Guess This Chart?
ff64b6ac-c5b6-4788-9834-3e07f2836a92,2016-11-23T08:00:00.000+08:00,2,"Adam Feuerstein Tweets: Worst thing: $LLY gamed sola study to win but still failed badly, which tells you these amyloid mAbs are weak drugs. Watch out, $BIIB"
ee96ab35-aa02-4dab-aff3-2ef5df554ba5,2016-11-23T08:00:00.000+08:00,1,Lilly -15% Premarket @$64.75 Following Report that Solanezumab Did Not Meet Primary Endpoint
75968900-1ad8-40a7-bd45-3d1241e4fc14,2016-11-23T08:00:00.000+08:00,1,"Adam Feuerstein @adamfeuerstein Tweet: $LLY Alzheimer's drug fails key clinical trial thestreet.com/story/13903616… Very quick news hit, back with more perspective later."
447912bc-6294-40ff-8402-cac3097940c9,2016-11-23T08:00:00.000+08:00,2,UPDATE: Lilly EXPEDITION 3 Study Outcome Expected To Result In Q4 Charge Of ~$150M or ~$0.09
eef15cac-df76-4452-81d2-3f9840d25c71,2016-11-23T08:00:00.000+08:00,1,"Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial, Did Not Meet Primary Endpoint"
81f9abaa-ba1e-42c6-82dd-f328efd8010c,2016-11-23T08:00:00.000+08:00,3,A Tough Day For Some Biotech Bulls
c5486093-6b77-451b-9481-00153e54475b,2016-11-23T08:00:00.000+08:00,4,Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock
77ec0cec-b6a7-4365-a212-8f7ece733bb5,2016-11-23T08:00:00.000+08:00,5,18 Biggest Mid-Day Losers For Wednesday
420d4427-d73c-4a3a-88db-30af51eb5bfc,2016-11-23T08:00:00.000+08:00,2,"Baird Analayst Says No Change To Axovant Sciences on Lilly's solanezumab Failure, Intepirdine Commercial Opportunity In AD Is Multiple Billions per Year"
bbc5308b-b9d3-4950-ab98-0164422205c9,2016-11-23T08:00:00.000+08:00,3,Mid-Day Market Update: Eli Lilly Tumbles After Alzheimer's Study Fails To Meet Goals; Euroseas Shares Rise
baf896e7-2e8b-43d8-8962-9faddfb5688b,2016-11-23T08:00:00.000+08:00,1,Stocks Hitting 52-Week Lows
4249a533-6711-454f-aa52-b0f9acf38633,2016-11-23T08:00:00.000+08:00,2,Adam Feuerstein Tweets: Check out @AF_biotech tweets laying out bear thesis on $PRTA as collateral damage from $LLY sola blowup. He knows his stuff.
6ea1eb91-00bf-47a7-b5ce-a77fadb4f48d,2016-11-23T08:00:00.000+08:00,3,Mid-Morning Market Update: Markets Mostly Lower; Deere Tops Q4 Views
6f165161-a8e8-4a54-af05-db0d30890e84,2016-11-23T08:00:00.000+08:00,2,"Biotech Down In Early Trading: PDL BioPharma 15%, Eli Lilly 13%, Biogen, 6%, Cellectis, Insys 5.5%, Dynavax, Kite 5%"
7629eccb-4e7e-42d3-a397-b6f62bcd64f5,2016-11-23T08:00:00.000+08:00,1,Neurotrope Issues Statement On Eli Lilly's Solanezumab
509bfe3d-6303-4e02-b322-a4e9dc80c5fb,2016-11-23T08:00:00.000+08:00,3,"Credit Suisse Says Hard To Get Strong Read-Through Conclusions On Biogen From Lilly's Study Without More Details, Today's News Represents Negative Headline In A Time Where Positive Headlines Are Needed; Biotech Space Could Be Weak On This Headline News"
e2cd164f-4288-4444-ac2d-2a0000914964,2016-11-23T08:00:00.000+08:00,4,"JP Morgan Highlighting Downside in Biogen Shares This Morning (Down ~8%) Related to Lilly's Alzheimer Drug News; Sees Transient 5-15% Move Lower in Biogen Shares, But Sees Possibility Stock Recovers"
618c81ab-9ab6-4a89-a1cc-066797b7332e,2016-11-23T08:00:00.000+08:00,1,Eli Lilly's Solanezumab Failure Is Bad News For Biogen
9965215c-ef8f-482a-9e56-bc82cd195ea1,2016-11-23T08:00:00.000+08:00,2,"AC Immune Shares Down 20% Amid Concerning Alzheimer Drug Data from Lilly; BZ NOTE: In an Oct. 18 Note, Leerink Estimated AC Immune Shares Could Be Down 60% if Data was Not Favorable"
102f9d7c-6a53-4838-8409-1e6135175615,2016-11-23T08:00:00.000+08:00,3,"Morgan Stanley Calling For Biogen To End The Day Flat To Slightly Up Following Eli Lilly Data Results; Says aducanumab More Potent Than solanezumab, Believes Indication Of Activity/Trends Could Keep Amyloid Debate Alive"
02841949-584b-4a5b-9f19-1a8f5ddbb75a,2016-11-23T08:00:00.000+08:00,4,Raymond James Out Saying They Would Be Buyers of Biogen On Weakness Following Eli Lilly's Failed EXPEDITION 3 Trail; May Actually Be Clearing Event With Respect To Any Takeout
cd449ac9-73b0-439c-b6f1-083e8094c692,2016-11-23T08:00:00.000+08:00,1,20 Stocks Moving In Wednesday's Pre-Market Session
8e60ec5b-9716-42e8-b6d1-05d5a8ae4360,2016-11-23T08:00:00.000+08:00,3,"A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Economic Data, Fed Minutes"
f6572793-e0cd-452b-b1dd-924b1eafd5f6,2016-11-23T08:00:00.000+08:00,1,Eli Lilly Plunges 15% After Alzheimer's Study Fails To Meet Goals
c880e620-36c5-408c-817b-e376a033c88a,2016-11-23T08:00:00.000+08:00,3,Can You Guess This Chart?
68f3a823-69cf-451d-9f9f-e5ec275f76fc,2016-11-23T08:00:00.000+08:00,2,"Adam Feuerstein Tweets: Worst thing: $LLY gamed sola study to win but still failed badly, which tells you these amyloid mAbs are weak drugs. Watch out, $BIIB"
ba21ff4e-946c-4d18-a603-94c58c1e272e,2016-11-23T08:00:00.000+08:00,1,Lilly -15% Premarket @$64.75 Following Report that Solanezumab Did Not Meet Primary Endpoint
a1e829b7-db55-4b83-8668-2ba0e059955b,2016-11-23T08:00:00.000+08:00,1,"Adam Feuerstein @adamfeuerstein Tweet: $LLY Alzheimer's drug fails key clinical trial thestreet.com/story/13903616… Very quick news hit, back with more perspective later."
22bc50cf-25cd-4964-b3b4-dddbd6de477c,2016-11-23T08:00:00.000+08:00,2,UPDATE: Lilly EXPEDITION 3 Study Outcome Expected To Result In Q4 Charge Of ~$150M or ~$0.09
7cf079a4-81ae-4841-88e0-f41d023aa2bd,2016-11-23T08:00:00.000+08:00,1,"Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial, Did Not Meet Primary Endpoint"
b95189ac-d317-4c6c-a84c-a156b8db170b,2016-11-22T08:00:00.000+08:00,3,"QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to Generate Real World Insights On Usage of Anti-Cancer Therapies Across Europe"
10cd8ee6-e934-4f00-bca8-7d84b6bb9fdb,2016-11-22T08:00:00.000+08:00,4,"QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to Generate Real World Insights On Usage of Anti-Cancer Therapies Across Europe"
80c62a97-2491-4a71-a07b-bb2e8552e837,2016-11-21T08:00:00.000+08:00,5,Intelgenx Technologies Reports Signing Of Term Sheet For Eli Lilly To License Tadalafil Dosing Patent '6943
d3d43cd8-ea16-4e16-9c2e-601b869625f3,2016-11-21T08:00:00.000+08:00,4,Intelgenx Technologies Reports Signing Of Term Sheet For Eli Lilly To License Tadalafil Dosing Patent '6943
cd669fd1-9601-4142-9b08-b009857b82e5,2016-11-14T08:00:00.000+08:00,3,"Eli Lilly, Incyte Corp Report RA-BEAM and Ra-BUILD Patients Early Response To Baricitinib Show Significant Improvement Compared To Adalimummab In Patient-Reported Outcomes"
783a1d8d-82a7-4a7c-8d3f-e4b2c74d44ca,2016-11-14T08:00:00.000+08:00,3,"Eli Lilly, Incyte Corp Report RA-BEAM and Ra-BUILD Patients Early Response To Baricitinib Show Significant Improvement Compared To Adalimummab In Patient-Reported Outcomes"
ab899215-09e5-40d7-ae37-e744332fb197,2016-11-13T08:00:00.000+08:00,5,Lilly Announces Jardiance Consistently Reduced the Risk of Cardiovascular Death in Adults With Type 2 Diabetes Regardless of Type of Cardiovascular Disease at Baseline
ebed465e-cfb9-4068-8d3f-d146bae7a263,2016-11-13T08:00:00.000+08:00,5,Lilly Announces Jardiance Consistently Reduced the Risk of Cardiovascular Death in Adults With Type 2 Diabetes Regardless of Type of Cardiovascular Disease at Baseline
b6849fbf-1981-4e98-bb62-de528a10b490,2016-11-11T08:00:00.000+08:00,1,"Traders Attributing Drop In Eli Lilly To Humana Dropping Humalog Insulin From 2017 Formulary, Senator Bernie Sanders Attacked Company In Prior Week For 700% Increase In Drug Price"
35ff2019-97b3-4102-a90e-743bbd663da0,2016-11-11T08:00:00.000+08:00,1,"Traders Attributing Drop In Eli Lilly To Humana Dropping Humalog Insulin From 2017 Formulary, Senator Bernie Sanders Attacked Company In Prior Week For 700% Increase In Drug Price"
87b27e09-69c3-4da5-8eac-4019c92497bb,2016-11-10T08:00:00.000+08:00,2,"10 Notable Stocks Trading Ex-Dividend Friday, November 11"
6ed63279-81f0-492b-bf78-98e0260e6b3e,2016-11-10T08:00:00.000+08:00,4,"10 Notable Stocks Trading Ex-Dividend Friday, November 11"
dd849e68-909c-43f5-8b0c-beb2d242da62,2016-11-09T08:00:00.000+08:00,3,"Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%"
9937a6bd-bd4b-4e03-91dd-234197a40295,2016-11-09T08:00:00.000+08:00,5,Biotech Is Getting A Big Boost Following Clinton's Loss
ad9d3bd2-538b-4e51-9265-e8f29c61852a,2016-11-09T08:00:00.000+08:00,4,"Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%"
8a501260-c34b-4b6c-8301-dbf13b7c42c9,2016-11-09T08:00:00.000+08:00,3,Biotech Is Getting A Big Boost Following Clinton's Loss
5d06fa46-c690-4261-9abe-289c47a8bf10,2016-11-03T08:00:00.000+08:00,5,"Palatin's Female Arousal Drug Data Impresses, Investors React Positively"
e25dd2e2-822b-41c1-8c7a-d4bc021d5c2b,2016-11-03T08:00:00.000+08:00,5,"Palatin's Female Arousal Drug Data Impresses, Investors React Positively"
dddca0b1-7bfd-44b5-a6dd-f63d3f00ace2,2016-11-02T08:00:00.000+08:00,5,"Eli Lilly, Incyte Reports New Data from Pivotal RA-BEACON Study Showing Significant Improvement in Patient-Reported Outcomes in RA Patients Treated with Baricitinib vs Placebo"
624788a7-d6d5-4e89-903a-f1d3e7175991,2016-11-02T08:00:00.000+08:00,2,"Eli Lilly, Incyte Reports New Data from Pivotal RA-BEACON Study Showing Significant Improvement in Patient-Reported Outcomes in RA Patients Treated with Baricitinib vs Placebo"
ad2602b7-8973-49fd-a866-1775431c2447,2016-11-01T08:00:00.000+08:00,1,"Senator Bernie Sanders Tweets: People are dying or getting sicker because they can't afford their insulin, just so Eli Lilly and Novo Nordisk can make outrageous profits."
585f1802-11c7-4e93-8aa4-4ca3cde7ea2f,2016-11-01T08:00:00.000+08:00,4,"Senator Bernie Sanders Tweets: People are dying or getting sicker because they can't afford their insulin, just so Eli Lilly and Novo Nordisk can make outrageous profits."
5e9d7dab-3ebb-45b2-9cb8-7a464961c75b,2016-10-26T08:00:00.000+08:00,3,"Following Q3 Results, Here's Where Eli Lilly Investors' Focus Is Turning"
f567b996-e37c-43ca-a804-69c2eb185105,2016-10-26T08:00:00.000+08:00,2,"Following Q3 Results, Here's Where Eli Lilly Investors' Focus Is Turning"
d1c65e65-31c7-4464-b46b-0417e08f17f9,2016-10-25T08:00:00.000+08:00,3,6 Big Pharma Companies Left To Report September Quarterly Figures
b3ff93b8-6c25-4821-8a65-467eb81f0059,2016-10-25T08:00:00.000+08:00,4,Epic Earnings: Many US Companies Beating Expectations As Season Continues
bd729e9f-f3de-427e-81d7-3093898b8ed6,2016-10-25T08:00:00.000+08:00,4,"The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind"
6f0bb41a-daa3-480e-ae90-bd723f61cb07,2016-10-25T08:00:00.000+08:00,4,"A Peek Into The Markets: U.S. Stock Futures Rise; GM, Apple Earnings In Focus"
d3a4b9af-8549-46de-8724-5787fbbf43bf,2016-10-25T08:00:00.000+08:00,4,"Eli Lilly Maintains FY 2016 EPS Guidance, Raises Revenue Outlook from $20.6B - $21.1B to $20.8B - $21.2B vs $21.2B est"
0579f7e4-5d33-4664-aa22-ed8c5b925ff2,2016-10-25T08:00:00.000+08:00,2,"Eli Lilly Q3 EPS $0.88 vs $0.96 Est, Revenue $5.19B vs $5.28B Est"
d59089a6-fd60-4f74-ade9-4811f24cd975,2016-10-25T08:00:00.000+08:00,3,12 Stocks You Should Be Watching Today
6cd54128-d1d8-47be-8579-f99b6cd1e8cc,2016-10-25T08:00:00.000+08:00,3,"Earnings Scheduled For October 25, 2016"
089d9d18-613f-43d2-b536-6a1742541adb,2016-10-25T08:00:00.000+08:00,1,6 Big Pharma Companies Left To Report September Quarterly Figures
b553afec-f4bf-4ca9-a02d-0a1ab4b7c8c7,2016-10-25T08:00:00.000+08:00,4,Epic Earnings: Many US Companies Beating Expectations As Season Continues
fbadd145-f492-4f3d-ac06-64381fddbef0,2016-10-25T08:00:00.000+08:00,4,"The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind"
409cbb0b-f800-4fbe-805d-8f3b43a5562b,2016-10-25T08:00:00.000+08:00,4,"A Peek Into The Markets: U.S. Stock Futures Rise; GM, Apple Earnings In Focus"
5834847e-389c-4f58-b60e-e3f8bf22df01,2016-10-25T08:00:00.000+08:00,3,"Eli Lilly Maintains FY 2016 EPS Guidance, Raises Revenue Outlook from $20.6B - $21.1B to $20.8B - $21.2B vs $21.2B est"
e12ce3db-b0dd-4fec-b815-39801dc87cbb,2016-10-25T08:00:00.000+08:00,1,"Eli Lilly Q3 EPS $0.88 vs $0.96 Est, Revenue $5.19B vs $5.28B Est"
de9480e0-3bd3-4967-85c8-a11761a61372,2016-10-25T08:00:00.000+08:00,2,12 Stocks You Should Be Watching Today
a43b7527-19ec-4278-bc1c-fff3083ec625,2016-10-25T08:00:00.000+08:00,3,"Earnings Scheduled For October 25, 2016"
41f2c7ae-7483-4290-a123-ab70da45d929,2016-10-21T08:00:00.000+08:00,4,Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments
628d3bea-548e-45e2-b7c4-cf2e374a5c9e,2016-10-21T08:00:00.000+08:00,5,Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments
412e7ac2-1def-414d-a281-611dd205a515,2016-10-19T08:00:00.000+08:00,5,FDA Has Granted Accelerated Approval for Eli Lilly's Lartruvo with Doxorubicin for Treatment of Advanced Soft Tissue Sarcoma
5e2db847-2c55-4fc1-a42a-00f1fa59a1fd,2016-10-19T08:00:00.000+08:00,4,FDA Has Granted Accelerated Approval for Eli Lilly's Lartruvo with Doxorubicin for Treatment of Advanced Soft Tissue Sarcoma
6732e66c-84e0-46e7-b688-cbe2b3f2f963,2016-10-18T08:00:00.000+08:00,3,AC Immune Is An Alzheimer's Pure Play With A Lot On The Line
f3d0c6ec-ac57-48ac-aabf-3e7d420cb3f5,2016-10-18T08:00:00.000+08:00,3,AC Immune Is An Alzheimer's Pure Play With A Lot On The Line
a8f0eb62-5008-4c05-a14a-49293264b1ea,2016-10-17T08:00:00.000+08:00,4,Lilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative
12e9eb50-5386-4cc7-a5f1-7f141ce5d44b,2016-10-17T08:00:00.000+08:00,5,Lilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative
20a715b3-d59e-4503-9c57-61865b5c5361,2016-10-09T08:00:00.000+08:00,5,New Data on the Combination of Lilly's ALIMTA and Merck's KEYTRUDA Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic NSCLC Presented at ESMO 2016
c6743fb4-aaff-4dd2-842d-f29c07f4b267,2016-10-09T08:00:00.000+08:00,4,New Data on the Combination of Lilly's ALIMTA and Merck's KEYTRUDA Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic NSCLC Presented at ESMO 2016
147e05ac-800b-497e-bb17-ed9099a75ccc,2016-10-05T08:00:00.000+08:00,3,Anavex Life Sciences Joins The Club Of Stocks Moving Higher On News Of Alzheimer's Research
1e1c7a92-49b3-47fa-b448-dab8bc9fccb1,2016-10-05T08:00:00.000+08:00,2,"Eli Lilly Announces Elanco US Subsidiary Has Entered Deal to Buy Boehringer Ingelheim Vetmedica's US Feline, Canine, Rabies Vaccines Portfolio for $885M"
4aeb7a60-407e-4445-8aba-a3f0a4d1478b,2016-10-05T08:00:00.000+08:00,5,Anavex Life Sciences Joins The Club Of Stocks Moving Higher On News Of Alzheimer's Research
9c566b83-54a4-4796-afa5-58716ba5f211,2016-10-05T08:00:00.000+08:00,4,"Eli Lilly Announces Elanco US Subsidiary Has Entered Deal to Buy Boehringer Ingelheim Vetmedica's US Feline, Canine, Rabies Vaccines Portfolio for $885M"
c6601945-be55-4149-87d0-022fd6b3f68c,2016-10-03T08:00:00.000+08:00,5,"In One Expert's View, Eli Lilly's Alzheimer Drug Trial Has A Greater Than 60% Chance Of Success"
a2fbb4f1-2cba-417b-851f-902202f4cfe8,2016-10-03T08:00:00.000+08:00,3,A Possible Trading Opportunity Presents Itself In Biogen's Approaching Phase 3 Results
d8ea2f60-2157-4c56-a726-f84a122c4a42,2016-10-03T08:00:00.000+08:00,5,"In One Expert's View, Eli Lilly's Alzheimer Drug Trial Has A Greater Than 60% Chance Of Success"
5e27730c-f5f5-4942-85a0-aa187a4ee044,2016-10-03T08:00:00.000+08:00,4,A Possible Trading Opportunity Presents Itself In Biogen's Approaching Phase 3 Results
feac8e5c-11ff-4351-a019-866dff3ca9e9,2016-09-27T08:00:00.000+08:00,2,The Drug Price Increase Debate: Separating The Winners From The Losers
1b026c70-1395-43ec-bba6-7b990025213b,2016-09-27T08:00:00.000+08:00,1,7 Biggest Price Target Changes For Tuesday
bf715b75-3a77-48d1-8a03-5ab278c7a2ad,2016-09-27T08:00:00.000+08:00,3,Benzinga's Top Upgrades
2e8cfa32-be35-42a1-a5a5-b09a45ce8467,2016-09-27T08:00:00.000+08:00,4,"The Market In 5 Minutes: Debates, Oil Keep Stocks Mixed"
c9e251d0-c7a1-4853-bd50-4307007a75c1,2016-09-27T08:00:00.000+08:00,5,Eli Lilly Is Entering A Period Of Accelerated Growth; Goldman Upgrades Stock To Buy
d38a57c3-b996-44d9-afdd-9829131fef80,2016-09-27T08:00:00.000+08:00,4,A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Economic Data
86f9f072-2047-422d-ab85-025c946ffddb,2016-09-27T08:00:00.000+08:00,5,"Goldman Sachs Upgrades Eli Lilly to Buy, Raises PT to $95.00"
1ca7d9e6-7830-435a-ae42-af0d5f64aeb1,2016-09-27T08:00:00.000+08:00,3,The Drug Price Increase Debate: Separating The Winners From The Losers
5bb82e9c-ed30-4274-ae80-2501336bab6e,2016-09-27T08:00:00.000+08:00,4,7 Biggest Price Target Changes For Tuesday
f3e88c1f-b0ed-4e52-ab48-21c5e930b21a,2016-09-27T08:00:00.000+08:00,5,Benzinga's Top Upgrades
a7fd5dff-8c16-4259-8421-c4780942f343,2016-09-27T08:00:00.000+08:00,4,"The Market In 5 Minutes: Debates, Oil Keep Stocks Mixed"
99b7cc31-85af-4d15-9138-af34032e955c,2016-09-27T08:00:00.000+08:00,5,Eli Lilly Is Entering A Period Of Accelerated Growth; Goldman Upgrades Stock To Buy
f7fc0fb6-dfec-42f3-9b12-967f265b0011,2016-09-27T08:00:00.000+08:00,3,A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Economic Data
b9f15031-3667-4094-a901-b355ca279692,2016-09-27T08:00:00.000+08:00,5,"Goldman Sachs Upgrades Eli Lilly to Buy, Raises PT to $95.00"
d38b085f-19ac-4598-861a-b724ec961cc8,2016-09-26T08:00:00.000+08:00,5,"vTv Therapeutics Shares Initiated With Buy Rating, $13 Target"
1ac8abc7-15f5-4bd2-ade1-122e1803bf27,2016-09-26T08:00:00.000+08:00,2,Cerecor Reports Acquisition of TARP-γ8-AMPA Receptor Antagonist from Eli Lilly
6f6b1e4d-c7e3-4bdb-9b59-272faa50f378,2016-09-26T08:00:00.000+08:00,3,First Trust Gets Smart With New Sector ETFs
241d38a7-dea0-48c0-9c4d-708f11e3866d,2016-09-26T08:00:00.000+08:00,4,"vTv Therapeutics Shares Initiated With Buy Rating, $13 Target"
6460c3dc-f01e-4c55-96eb-e326066a7672,2016-09-26T08:00:00.000+08:00,2,Cerecor Reports Acquisition of TARP-γ8-AMPA Receptor Antagonist from Eli Lilly
09669f63-2fed-4088-90e2-f92b8f465801,2016-09-26T08:00:00.000+08:00,3,First Trust Gets Smart With New Sector ETFs
2ddfddd3-f6cc-4fa3-864e-c852c07076c4,2016-09-21T08:00:00.000+08:00,2,Chasing Takeover Rumors Can Be Hazardous To Your Portfolio
cc9901b2-6159-4c48-8c06-6ac053481f21,2016-09-21T08:00:00.000+08:00,1,"The Market In 5 Minutes: We're Waiting For You, Mrs. Yellen"
763f7398-d172-4c91-8ce0-a4a0a6d8b2fb,2016-09-21T08:00:00.000+08:00,4,Clovis Upgraded At Credit Suisse Following Acquisition Rumor
91af8b19-417b-4bc8-9890-3ebe2a73d558,2016-09-21T08:00:00.000+08:00,2,Chasing Takeover Rumors Can Be Hazardous To Your Portfolio
19e859d7-af23-4c4b-9243-4333950b746d,2016-09-21T08:00:00.000+08:00,1,"The Market In 5 Minutes: We're Waiting For You, Mrs. Yellen"
42daec70-4a59-4382-9ec1-6ab86b323391,2016-09-21T08:00:00.000+08:00,4,Clovis Upgraded At Credit Suisse Following Acquisition Rumor
4fb197d9-97b6-4a5e-a707-64c035b28453,2016-09-20T08:00:00.000+08:00,3,"Some Traders Attributing After-Hours Upside in Clovis to Janney Capital Analyst Comment During Bloomberg Interview There Are 'Many Suitors' for Co, Including Lilly, Roche, Merck"
79a29f2d-8090-4c75-ada9-307de80d76e3,2016-09-20T08:00:00.000+08:00,2,"Clovis Spokesperson Responds to Rumor Of Potential Acquisition By Eli Lilly, Tells Benzinga Co. Policy Is to Not Comment On Rumors"
d6b7ccf4-f8a7-476a-8319-6e75106b50d1,2016-09-20T08:00:00.000+08:00,4,Traders Attributing Spike Higher in Clovis Oncology to Unconfirmed Chatter of Lilly Interest
97984261-77b7-4ff8-a466-e5200d04e582,2016-09-20T08:00:00.000+08:00,3,"Some Traders Attributing After-Hours Upside in Clovis to Janney Capital Analyst Comment During Bloomberg Interview There Are 'Many Suitors' for Co, Including Lilly, Roche, Merck"
f5e62c9f-bffa-441a-bf0a-62bb85a97069,2016-09-20T08:00:00.000+08:00,2,"Clovis Spokesperson Responds to Rumor Of Potential Acquisition By Eli Lilly, Tells Benzinga Co. Policy Is to Not Comment On Rumors"
44ca5b63-52ad-4ad9-9bb9-f350362ddbf9,2016-09-20T08:00:00.000+08:00,4,Traders Attributing Spike Higher in Clovis Oncology to Unconfirmed Chatter of Lilly Interest
a54cb8f0-1714-4083-8c04-dab92fc28576,2016-09-16T08:00:00.000+08:00,3,3 Pharma Companies Receive Positive EU Opinions
48cd5c6a-d166-4359-a900-54ecc543d776,2016-09-16T08:00:00.000+08:00,5,Eli Lilly Reports CHMP Recommended Approval of Co.'s Olaratumab in Combo with Doxorubicin for Advanced Soft Tissue Sarcoma
baa68150-2ed9-4691-808e-ec971bd6f882,2016-09-16T08:00:00.000+08:00,3,3 Pharma Companies Receive Positive EU Opinions
ba21ba23-219b-4d29-a43d-770a4e90e2ef,2016-09-16T08:00:00.000+08:00,4,Eli Lilly Reports CHMP Recommended Approval of Co.'s Olaratumab in Combo with Doxorubicin for Advanced Soft Tissue Sarcoma
6ba83bc6-9bb0-40bb-9619-8712668ffe0b,2016-09-08T08:00:00.000+08:00,5,New Upside Potential Drives JPMorgan's Eli Lilly Upgrade
c938f7c8-521c-455c-92e0-ef382ec32110,2016-09-08T08:00:00.000+08:00,3,Benzinga's Top Upgrades
8d0ff812-d14d-40d4-85e5-36dcf685cdf7,2016-09-08T08:00:00.000+08:00,1,The Market In 5 Minutes: iPhone 7 Arrives
fb7383d9-bfd4-4502-a25c-8a7dd007e251,2016-09-08T08:00:00.000+08:00,5,JP Morgan Upgrades Eli Lilly to Overweight
525d5060-a15e-46b6-844e-e96973aae58e,2016-09-08T08:00:00.000+08:00,4,New Upside Potential Drives JPMorgan's Eli Lilly Upgrade
f9f6dfe3-00ba-40a9-85d1-60469d8f8d39,2016-09-08T08:00:00.000+08:00,4,Benzinga's Top Upgrades
f42024b9-4215-41c0-b24d-1cc1d75235e2,2016-09-08T08:00:00.000+08:00,1,The Market In 5 Minutes: iPhone 7 Arrives
05de7512-579b-4eb6-808a-b609dda9d98b,2016-09-08T08:00:00.000+08:00,4,JP Morgan Upgrades Eli Lilly to Overweight
a342e057-6fb2-4466-8798-15bb0f432dd0,2016-09-07T08:00:00.000+08:00,3,"Apple, Eli Lilly, U.S. Steel: Fast Money Picks For September 7"
2167d09a-ea0b-47fe-b49d-386bf0b43ede,2016-09-07T08:00:00.000+08:00,4,"Apple, Eli Lilly, U.S. Steel: Fast Money Picks For September 7"
9229eaa8-e566-41d5-be6a-c47b60a09401,2016-09-06T08:00:00.000+08:00,5,"Adam Feuerstein @adamfeuerstein Tweet: $LLY - Cowen analyst Steve Scala goes all in on sola, predicting 99% likelihood of hitting ph3 ADAS-Cog14 primary endpoint. 99%! Yowza."
bbdacd94-6dc9-4312-86d6-57faf2a83c31,2016-09-06T08:00:00.000+08:00,3,"Adam Feuerstein @adamfeuerstein Tweet: $LLY - Cowen analyst Steve Scala goes all in on sola, predicting 99% likelihood of hitting ph3 ADAS-Cog14 primary endpoint. 99%! Yowza."
6d348df1-cffb-4050-a09b-2a6ba1672142,2016-08-30T08:00:00.000+08:00,4,"Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64"
7b96d30f-0439-4100-96e4-d8756739156f,2016-08-30T08:00:00.000+08:00,5,"Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64"
393e4e20-d65c-4c2a-a25f-baa44d29d41b,2016-08-29T08:00:00.000+08:00,4,Novogen Names Gordon Hirsch as Chief Medical Officer
81f7f5b4-22d9-4226-8843-b346dccf6720,2016-08-29T08:00:00.000+08:00,4,Novogen Names Gordon Hirsch as Chief Medical Officer
9eaaebaa-5d17-440f-a6f6-e749bd41150c,2016-08-22T08:00:00.000+08:00,5,Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293
5982746b-47d6-49d0-9551-79f33c26ff04,2016-08-22T08:00:00.000+08:00,5,Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293
e09085c9-5e51-498f-b48c-421817f948a1,2016-08-11T08:00:00.000+08:00,5,"Lilly Announces Health Canada Approves New Indication for Jardiance Tablets for Adults With Type 2 Diabetes, Established Cardiovascular Disease"
c09b6ab1-2259-40b7-af2f-e501f562b420,2016-08-11T08:00:00.000+08:00,4,"Lilly Announces Health Canada Approves New Indication for Jardiance Tablets for Adults With Type 2 Diabetes, Established Cardiovascular Disease"
d9914005-e301-40d5-a7cf-8de159dd61ae,2016-08-10T08:00:00.000+08:00,5,Lilly Volume Spike
6a3853b7-afcd-46ae-86aa-4aef27a511ac,2016-08-10T08:00:00.000+08:00,3,Eli Lilly Update on MONARCH 2 Phase 3 Trial Recommended to Continue As Planned By Independent Committee as Interim Efficacy Criteria Not Met
c6402881-7f98-4d02-afcd-e50c04f904dc,2016-08-10T08:00:00.000+08:00,5,Lilly Volume Spike
770dad8a-6202-4166-b644-33139418cb36,2016-08-10T08:00:00.000+08:00,4,Eli Lilly Update on MONARCH 2 Phase 3 Trial Recommended to Continue As Planned By Independent Committee as Interim Efficacy Criteria Not Met
db653e03-1c49-43c2-ac97-a0ba88163acf,2016-07-28T08:00:00.000+08:00,2,UPDATE: Lilly in 10Q Says Received Civil Investigative Demand from U.S. Attorney's Office for the Southern District of New York
fd10c489-746d-43a9-a8d7-849746bc6e56,2016-07-28T08:00:00.000+08:00,2,"Eli Lilly Says DOJ Requested Documents, Information Relating to Relationships With Pharmacy-Benefit Managers - DJ"
7118e17b-e414-4833-8d6e-f8a3868cc88e,2016-07-28T08:00:00.000+08:00,3,UPDATE: Lilly in 10Q Says Received Civil Investigative Demand from U.S. Attorney's Office for the Southern District of New York
96e3ebec-882a-48c2-8965-cfab26ab5c91,2016-07-28T08:00:00.000+08:00,4,"Eli Lilly Says DOJ Requested Documents, Information Relating to Relationships With Pharmacy-Benefit Managers - DJ"
ed068157-2b19-4d0f-a627-3ca59f197154,2016-07-27T08:00:00.000+08:00,5,New Studies Suggest Relationship between Tau Pathology and Progression of Alzheimer's Disease
6b7ea6e6-1dbd-4997-9b11-54e23af44d6e,2016-07-27T08:00:00.000+08:00,4,"John Lechleiter To Step Down From Lilly CEO, David Ricks To Take Position"
95884de7-0a02-438e-a1c0-0a840073cac6,2016-07-27T08:00:00.000+08:00,5,New Studies Suggest Relationship between Tau Pathology and Progression of Alzheimer's Disease
2a25690a-6d29-4c0e-ae5f-419cfc57ce6c,2016-07-27T08:00:00.000+08:00,3,"John Lechleiter To Step Down From Lilly CEO, David Ricks To Take Position"
fb8d3370-7242-4206-b3d2-816c76530bf5,2016-07-26T08:00:00.000+08:00,2,Technical Alert: Eli Lilly Unchanged After Wild Ride Following Q2 Report
38882ab7-b938-4c9f-ae50-2e5a0c65334f,2016-07-26T08:00:00.000+08:00,4,"Lilly Sees FY 2016 EPS $3.50 to $3.60 vs $3.56 est, Revenue $20.6B to $21.1B vs $20.9B est"
7f758082-df9d-439b-a646-41aaf31d6391,2016-07-26T08:00:00.000+08:00,3,"Lilly Q2 EPS $0.86 vs $0.86 est, Revenue $5.4B vs $5.2B est"
037e6b1c-0b53-4d64-81a6-41f97e34e76d,2016-07-26T08:00:00.000+08:00,3,"Earnings Scheduled For July 26, 2016"
d1248962-2b06-4127-8018-712beb36e5b1,2016-07-26T08:00:00.000+08:00,3,Technical Alert: Eli Lilly Unchanged After Wild Ride Following Q2 Report
0eb05ae9-3371-4da1-8808-2346264dc3b2,2016-07-26T08:00:00.000+08:00,3,"Lilly Sees FY 2016 EPS $3.50 to $3.60 vs $3.56 est, Revenue $20.6B to $21.1B vs $20.9B est"
a4697687-0084-44c0-8db5-40ad6a39dc81,2016-07-26T08:00:00.000+08:00,3,"Lilly Q2 EPS $0.86 vs $0.86 est, Revenue $5.4B vs $5.2B est"
4d2c74be-5a25-423d-886c-3b058e574706,2016-07-26T08:00:00.000+08:00,2,"Earnings Scheduled For July 26, 2016"
e132b00e-fd22-402b-85f1-1984dc5081f7,2016-07-25T08:00:00.000+08:00,4,Can MCD Feed Higher Sales with More than Breakfast?
e513bf31-f470-4388-a279-a97d21cad906,2016-07-25T08:00:00.000+08:00,3,"Week Ahead: It's Not Just Earnings This Time, as GDP, Fed Also on Tap"
ccd42123-0db9-47dc-9381-541911db6ee2,2016-07-25T08:00:00.000+08:00,4,Can MCD Feed Higher Sales with More than Breakfast?
19b3a3c0-7a92-438a-81c6-a38d31fdb540,2016-07-25T08:00:00.000+08:00,3,"Week Ahead: It's Not Just Earnings This Time, as GDP, Fed Also on Tap"
40e0611b-ca92-4b57-8194-65acd4d3107b,2016-07-19T08:00:00.000+08:00,5,Eli Lilly Gets FDA Expanded Indication For Type 2 Diabetes Treatment Synjardy To Add Treatment-Naïve Adults
d714be17-b710-4da7-bed3-a10abeda37b2,2016-07-19T08:00:00.000+08:00,5,Eli Lilly Reports U.S. FDA expands indication for type 2 diabetes treatment Synjardy to include treatment-naïve adults
1b8c4d3d-1f70-4f47-8cd7-9ed818dbb657,2016-07-19T08:00:00.000+08:00,5,Eli Lilly Gets FDA Expanded Indication For Type 2 Diabetes Treatment Synjardy To Add Treatment-Naïve Adults
78f2d8fe-b3d1-481b-b86d-c1620a9eecd3,2016-07-19T08:00:00.000+08:00,4,Eli Lilly Reports U.S. FDA expands indication for type 2 diabetes treatment Synjardy to include treatment-naïve adults
bdac1867-5057-4480-9db2-3ef5cf5ea341,2016-07-18T08:00:00.000+08:00,1,BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations
58876c41-21ff-4ee7-ae93-ff7d14f9aac0,2016-07-18T08:00:00.000+08:00,2,BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations
2545ec7f-d136-4ffc-a92f-bdf1682ab3a1,2016-07-13T08:00:00.000+08:00,4,Eli Lilly Reports Clinical Trial Collaboration Deal with Ingelheim for Metastatic Breast Cancer
6db1e14c-fdff-47dd-bcb8-c092a12d7488,2016-07-13T08:00:00.000+08:00,3,Eli Lilly Reports Clinical Trial Collaboration Deal with Ingelheim for Metastatic Breast Cancer
69c0f6e5-3b59-4017-8932-02bf696e5b56,2016-07-06T08:00:00.000+08:00,1,"Watch for Near-Term Profit Taking in Lilly Shares Following Spike Higher as Traders Passing Around Vague, Unconfirmed Chatter on Co."
b8994e24-251d-4bd5-b1aa-9b03f7905cec,2016-07-06T08:00:00.000+08:00,5,Eli Lilly Shares Spiking Higher
c17dbbb5-2d86-425f-91f2-ebca499ba8ac,2016-07-06T08:00:00.000+08:00,2,"Watch for Near-Term Profit Taking in Lilly Shares Following Spike Higher as Traders Passing Around Vague, Unconfirmed Chatter on Co."
701b3195-d66b-4180-9ecf-3a9b078c89d4,2016-07-06T08:00:00.000+08:00,4,Eli Lilly Shares Spiking Higher
95a76845-3764-45a5-b7e2-0d66b9ff9abe,2016-06-30T08:00:00.000+08:00,3,"Regen BioPharma, Inc. Enters Into Open Innovation Drug Discovery Program Agreement with Eli Lilly and Company"
a1743a14-64d9-4026-a46c-df59f0a63b28,2016-06-30T08:00:00.000+08:00,4,"Regen BioPharma, Inc. Enters Into Open Innovation Drug Discovery Program Agreement with Eli Lilly and Company"
f51eeaef-0689-4ed6-81f8-44d14e7933b6,2016-06-21T08:00:00.000+08:00,5,Eli Lilly Canada Granted Approval For Taltz In Treatment Of Moderate-To-Severe Plaque Psoriasis
4f8f6af0-6713-4315-bf3a-331938fd3eaf,2016-06-21T08:00:00.000+08:00,4,Eli Lilly Canada Granted Approval For Taltz In Treatment Of Moderate-To-Severe Plaque Psoriasis
c0045965-86c0-47fa-a4c5-5407f88028ed,2016-06-14T08:00:00.000+08:00,3,German Supreme Court Grants Lilly Appeal in Alimta Vitamin Regimen Patent Lawsuit
d43b2d6e-c4d8-45bd-a0d6-0b50bbd2b4d1,2016-06-14T08:00:00.000+08:00,4,Jefferies Shares Pharma Stock Catalyst Outlook
71c4c20d-ee38-4869-93f7-a3a1dd2c099d,2016-06-14T08:00:00.000+08:00,5,Eli Lilly Says JARDIANCE Significantly Reduced Risk of Progressive Kidney Disease in Adults with Type-2 Diabetes with Established CV Disease
76eb7795-e88b-43be-8cc9-733ad33758cb,2016-06-14T08:00:00.000+08:00,3,German Supreme Court Grants Lilly Appeal in Alimta Vitamin Regimen Patent Lawsuit
8c91b6af-57de-4a16-b100-6018fee0cb01,2016-06-14T08:00:00.000+08:00,5,Jefferies Shares Pharma Stock Catalyst Outlook
5b89c8b8-b5e8-432f-84f6-2b37ede5a25d,2016-06-14T08:00:00.000+08:00,4,Eli Lilly Says JARDIANCE Significantly Reduced Risk of Progressive Kidney Disease in Adults with Type-2 Diabetes with Established CV Disease
9955812f-ac3a-4aa3-a2e7-81267984488a,2016-06-13T08:00:00.000+08:00,3,"SunTrust Highlights Upcoming Pharma Calendar, Favorite Names"
e52e8da3-957e-4c72-a734-c590afce71ce,2016-06-13T08:00:00.000+08:00,4,"SunTrust Highlights Upcoming Pharma Calendar, Favorite Names"
2bc465da-cc05-46f0-b2d9-eec083bafdf8,2016-06-12T08:00:00.000+08:00,5,Lilly Announces New Jardiance Data Show Reduced Risk for Cardiovascular Death Was Consistent Across Age Groups in Adults With Type 2 Diabetes
3a9cd873-c998-4416-abd5-a3a826b2ccb2,2016-06-12T08:00:00.000+08:00,5,Lilly Presents New Data Showing Once-Weekly Trulicity in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes at 6th American Diabetes Association Scientific Sessions
592d8c3d-076a-4088-9614-564640fe4cd5,2016-06-12T08:00:00.000+08:00,4,Lilly Announces New Study Results Show Tradjenta Reduces Blood Sugar in Adults With Type 2 Diabetes at Risk for Kidney Impairment
52c6404b-fcc7-40b7-a43b-12c42bf4960d,2016-06-12T08:00:00.000+08:00,3,Lilly Announces New Jardiance Data Show Reduced Risk for Cardiovascular Death Was Consistent Across Age Groups in Adults With Type 2 Diabetes
34d5b537-6176-4ef1-a2bc-d0e8f426e8b1,2016-06-12T08:00:00.000+08:00,5,Lilly Presents New Data Showing Once-Weekly Trulicity in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes at 6th American Diabetes Association Scientific Sessions
7d2cdb1c-2f52-48a0-8580-183ce91e3f30,2016-06-12T08:00:00.000+08:00,4,Lilly Announces New Study Results Show Tradjenta Reduces Blood Sugar in Adults With Type 2 Diabetes at Risk for Kidney Impairment
8580e154-a82b-45b1-aff5-4692589262d2,2016-06-09T08:00:00.000+08:00,5,Eli Lilly and Incyte Say Two Phase 3 Trials For Arthritis Have Positive Results
2f5f8cc8-23ff-4ad8-a97e-70b3946dbc75,2016-06-09T08:00:00.000+08:00,5,Eli Lilly and Incyte Say Two Phase 3 Trials For Arthritis Have Positive Results
ebcbef1f-b2f2-4e26-8c5b-45fb0964453a,2016-06-08T08:00:00.000+08:00,3,Studies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks
7ac4f023-5037-4184-b80e-48c62416270c,2016-06-08T08:00:00.000+08:00,4,Option Alert: LLY Fri 6/10 76.5 Calls (Wkly) Sweep: 801 @ ASK $0.13: 900 traded vs 320 OI: Earnings 7/26 Before Open $74.80 Ref
56e9c56a-0fba-41ac-a16d-1a7c29b5f819,2016-06-08T08:00:00.000+08:00,5,Studies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks
e80c1d79-e821-4229-a1aa-ad545e1619e0,2016-06-08T08:00:00.000+08:00,2,Option Alert: LLY Fri 6/10 76.5 Calls (Wkly) Sweep: 801 @ ASK $0.13: 900 traded vs 320 OI: Earnings 7/26 Before Open $74.80 Ref
11c3a7d7-cbc6-416d-a973-052bbaa21429,2016-06-07T08:00:00.000+08:00,5,"Eli Lilly Reports Results of Clinical, Patient-Reported Outcomes Data for Baricitinib in Patients with RA"
8a7006a6-b9b0-4871-9a23-cb86dc3ac0a0,2016-06-07T08:00:00.000+08:00,3,"Eli Lilly Reports Results of Clinical, Patient-Reported Outcomes Data for Baricitinib in Patients with RA"
077a7996-5f7f-4100-97ec-de16fc06bff6,2016-06-06T08:00:00.000+08:00,4,4 Key Takeaways From ASCO
2a245cd8-4bee-4eb8-ba6c-1587e8db7d25,2016-06-06T08:00:00.000+08:00,4,4 Key Takeaways From ASCO
50f015b0-93fc-4786-aa32-73406456cc84,2016-06-05T08:00:00.000+08:00,5,Lilly Announces Encouraging Data of Early-Phase Immuno-Oncology Studies of ALIMTA and CYRAMZA with Merck's KEYTRUDA in NSCLC Presented at #ASCO16
113db9c3-3abd-4e79-80c9-bd915d70d8d0,2016-06-05T08:00:00.000+08:00,5,Lilly Announces Encouraging Data of Early-Phase Immuno-Oncology Studies of ALIMTA and CYRAMZA with Merck's KEYTRUDA in NSCLC Presented at #ASCO16
a9cfea98-db28-44cd-86f9-c02ac5ee1bd8,2016-06-03T08:00:00.000+08:00,2,Negative Alimta News Disappointing For Eli Lilly
a8a89fed-7e49-42fa-9486-3263bf132139,2016-06-03T08:00:00.000+08:00,1,"Ouch! Jobs Report Miss Sends Rate Hike Odds Down, Raises Questions"
5afad9f7-9484-42aa-b532-f057762b6d63,2016-06-03T08:00:00.000+08:00,1,"Eli Lilly Shares Selling Off, Hearing Co's Patent On Alimta To be Reviewed At US Patent Office"
45b65958-4962-4fe0-9695-9f4759631204,2016-06-03T08:00:00.000+08:00,1,"Morgan Stanley Negative On Eli Lilly, Says 'Negative AlimtaIPR news disappointing since patent was upheld in District Court last year'"
8f709ee3-59e3-4136-ab9c-96095c1c878b,2016-06-03T08:00:00.000+08:00,2,Negative Alimta News Disappointing For Eli Lilly
50e44c43-9a8e-4038-a5b7-f229e9abd168,2016-06-03T08:00:00.000+08:00,3,"Ouch! Jobs Report Miss Sends Rate Hike Odds Down, Raises Questions"
eef39128-ea32-4dad-a46c-361ef7a6bd21,2016-06-03T08:00:00.000+08:00,1,"Eli Lilly Shares Selling Off, Hearing Co's Patent On Alimta To be Reviewed At US Patent Office"
965081b5-01b2-4212-a759-a046f615bd8d,2016-06-03T08:00:00.000+08:00,1,"Morgan Stanley Negative On Eli Lilly, Says 'Negative AlimtaIPR news disappointing since patent was upheld in District Court last year'"
8fb74da0-ef27-4d71-af4b-162120cfd95c,2016-05-31T08:00:00.000+08:00,5,"Adocia, Lilly Reports Positive Topline Results From Phase 1 Study Of BioChaperone Lispro U100 In Healthy Japanese Subjects, No New Or Unexpected Safety Findings Were Observed"
3a20f35a-f2a9-4e34-8429-1108862cd65e,2016-05-31T08:00:00.000+08:00,4,Eli Lilly Gets FDA Approval For Its Jentadueto XR For Adults With Type 2 Diabetes
888cbd0c-7eb2-453f-9441-ae9e32f59881,2016-05-31T08:00:00.000+08:00,3,U.S. FDA Approves Once-daily Jentadueto XR Tablets for Adults with Type 2 Diabetes
e8e9371b-7e09-4182-9838-c6a4346ba27c,2016-05-31T08:00:00.000+08:00,5,"Adocia, Lilly Reports Positive Topline Results From Phase 1 Study Of BioChaperone Lispro U100 In Healthy Japanese Subjects, No New Or Unexpected Safety Findings Were Observed"
44705527-3901-4100-9029-cb000240ab71,2016-05-31T08:00:00.000+08:00,4,Eli Lilly Gets FDA Approval For Its Jentadueto XR For Adults With Type 2 Diabetes
0d4689ed-3fff-4be0-bcc5-36347dd785a8,2016-05-31T08:00:00.000+08:00,4,U.S. FDA Approves Once-daily Jentadueto XR Tablets for Adults with Type 2 Diabetes
b414d361-0979-4035-934f-ce628bb0193e,2016-05-24T08:00:00.000+08:00,5,Eli Lilly Says It Will Launch 20 New Products Through 2023
f3394675-64e4-4010-a8a0-b5a9fe865855,2016-05-24T08:00:00.000+08:00,3,Eli Lilly Offers Outline of Potential to Launch 20 New Products in 10 Years
4e11bbd4-cc42-4ced-853d-f7b56e6a5426,2016-05-24T08:00:00.000+08:00,4,Eli Lilly Says It Will Launch 20 New Products Through 2023
b48a2c0b-9705-4e84-bbc8-46640db44325,2016-05-24T08:00:00.000+08:00,5,Eli Lilly Offers Outline of Potential to Launch 20 New Products in 10 Years
8fe0380f-2088-426b-8201-d0a4f2fe4a95,2016-05-23T08:00:00.000+08:00,4,"H.C. Wainwright Initiates Radius Health At Buy, $55 Target"
58712421-56a7-4bf3-8f42-d3f82afa5d44,2016-05-23T08:00:00.000+08:00,4,"H.C. Wainwright Initiates Radius Health At Buy, $55 Target"
6a068028-65e8-4804-af8f-24c3c42b379a,2016-05-19T08:00:00.000+08:00,3,JPMorgan's Take On Big Pharma's New ASCO Abstracts
7e691010-eacd-4233-a024-cb33072ce397,2016-05-19T08:00:00.000+08:00,4,JPMorgan's Take On Big Pharma's New ASCO Abstracts
28f3a698-d3de-426f-b0ae-2f707876cc55,2016-05-18T08:00:00.000+08:00,5,"Lilly Highlights ASCO Data Underscores Co.'s Diverse Oncology Pipeline, Portfolio"
9bfc1319-ec2c-45d5-9c07-53c9f4619604,2016-05-18T08:00:00.000+08:00,4,"Lilly Highlights ASCO Data Underscores Co.'s Diverse Oncology Pipeline, Portfolio"
bbe9c82a-e0f2-45ed-b21a-166fbda34e12,2016-05-17T08:00:00.000+08:00,4,Fitch Says Drug Approvals Are Driving Targeted Acquisitions In U.S. Pharma
70c72a35-9fef-405c-854a-ab587a6ba15d,2016-05-17T08:00:00.000+08:00,5,"Eli Lilly Now A Strong Buy, Run-Up To Continue, Vetr Top Raters Say"
a5906e94-768e-430c-a5c7-f1c04cebe9de,2016-05-17T08:00:00.000+08:00,4,Fitch Says Drug Approvals Are Driving Targeted Acquisitions In U.S. Pharma
5b0896d6-f199-4cc8-9142-33690320a5eb,2016-05-17T08:00:00.000+08:00,5,"Eli Lilly Now A Strong Buy, Run-Up To Continue, Vetr Top Raters Say"
782374af-dcb3-41d9-9abd-256c5134a834,2016-05-11T08:00:00.000+08:00,4,"Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead"
4d00ea74-80fa-48df-9620-9ba497697064,2016-05-11T08:00:00.000+08:00,3,The Market In 5 Minutes: Don't Stop Me Now
93479175-3b90-4c3f-8914-f3dd550751df,2016-05-11T08:00:00.000+08:00,4,"Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead"
5ba844ae-7abb-4695-830b-eb72627ba119,2016-05-11T08:00:00.000+08:00,2,The Market In 5 Minutes: Don't Stop Me Now
fcae79a0-3cc5-490f-814e-10cbf446eff0,2016-05-10T08:00:00.000+08:00,1,FDA Says Will Add New Warning to Labels for All Olanzapine-Containing Products; Watch Eli Lilly Shares
d715e575-3112-4cd3-b815-b708de202d28,2016-05-10T08:00:00.000+08:00,2,FDA Says Will Add New Warning to Labels for All Olanzapine-Containing Products; Watch Eli Lilly Shares
651bbb75-619f-4a91-bd08-64d93b486c85,2016-05-04T08:00:00.000+08:00,4,"FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma"
9a565e06-9711-416e-9f2d-03735d0bebab,2016-05-04T08:00:00.000+08:00,4,"FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma"
76411436-766c-4ae8-8120-188cbacbe933,2016-05-02T08:00:00.000+08:00,4,Eli Lilly's Taltz Now Available in the U.S. for the Treatment of Moderate-to-Severe Plaque Psoriasis
cbfa8ee0-3788-40ec-9716-aa7c04b5aef6,2016-05-02T08:00:00.000+08:00,1,GeoInvesting Says Anavex Life Sciences' Stock Has A Book Value Of Just $0.36
60406a61-04d4-46ef-bda8-e76a37e0c885,2016-05-02T08:00:00.000+08:00,5,Eli Lilly's Taltz Now Available in the U.S. for the Treatment of Moderate-to-Severe Plaque Psoriasis
59b24aa6-7503-405a-856a-8c6cfffb7a18,2016-05-02T08:00:00.000+08:00,3,GeoInvesting Says Anavex Life Sciences' Stock Has A Book Value Of Just $0.36
76a05edd-0156-42cc-bc39-10405986c04c,2016-04-27T08:00:00.000+08:00,4,"Adocia, Lilly ReportPositive Topline Results from a Phase 1b Study of Repeated Administration of Ultra-Rapid BioChaperone Lispro U100 in People with Type 2 Diabetes"
4bd9e2ce-5b89-4564-bb74-a86859e3efa5,2016-04-27T08:00:00.000+08:00,4,"Adocia, Lilly ReportPositive Topline Results from a Phase 1b Study of Repeated Administration of Ultra-Rapid BioChaperone Lispro U100 in People with Type 2 Diabetes"
875c751b-ad5f-4345-ae8b-35f0e31b43d9,2016-04-26T08:00:00.000+08:00,2,10 Stocks Moving In Tuesday's Pre-Market Session
42de443a-a9c5-4ca3-91e8-bae667ff02ec,2016-04-26T08:00:00.000+08:00,2,Eli Lilly's Q1 EPS Disappoints
b089155a-a0c4-44f6-a86f-e12dc20201a9,2016-04-26T08:00:00.000+08:00,3,"Eli Lilly Raises FY 2016 Guidance; Sees EPS $3.50 to $3.60 vs $3.54 est, Revenue $20.6B to $21.1B vs $20.7B est"
4afa28c9-142b-42f5-bbfb-a169dd945e52,2016-04-26T08:00:00.000+08:00,1,"Eli Lilly Q1 EPS $0.83 vs $0.85 est, Revenue $4.87B vs $4.82B est"
a157a410-7ebd-4141-9525-a1dfe5f43585,2016-04-26T08:00:00.000+08:00,4,"Keep an Eye on These 12 Stocks for April 26, 2016"
3ded0a53-c1d1-4b91-a602-9f5c03c34184,2016-04-26T08:00:00.000+08:00,3,"Earnings Scheduled For April 26, 2016"
6bc14e83-e3a3-4762-ada2-2e5c63cc6cb7,2016-04-26T08:00:00.000+08:00,2,10 Stocks Moving In Tuesday's Pre-Market Session
d06fd145-ecf7-4928-a1c9-69668c756414,2016-04-26T08:00:00.000+08:00,3,Eli Lilly's Q1 EPS Disappoints
49b0ffab-5099-417c-8758-9029c0dc0aea,2016-04-26T08:00:00.000+08:00,3,"Eli Lilly Raises FY 2016 Guidance; Sees EPS $3.50 to $3.60 vs $3.54 est, Revenue $20.6B to $21.1B vs $20.7B est"
a8f118a8-157a-42d2-9fa6-14ea91f00a6b,2016-04-26T08:00:00.000+08:00,4,"Eli Lilly Q1 EPS $0.83 vs $0.85 est, Revenue $4.87B vs $4.82B est"
8bb573d4-cec2-4493-8722-c2a3d6cc170a,2016-04-26T08:00:00.000+08:00,1,"Keep an Eye on These 12 Stocks for April 26, 2016"
f33b5ffc-93f6-40ff-b88f-2b912e864bc8,2016-04-26T08:00:00.000+08:00,4,"Earnings Scheduled For April 26, 2016"
c23d98b9-daa7-459f-9d03-e4e254825398,2016-04-25T08:00:00.000+08:00,3,"Aratana, Eli Lilly Team Create 'Watershed Contract' For Pet Biotech Sector"
6a03d6b9-402d-4c30-bbab-4d7c5c96826d,2016-04-25T08:00:00.000+08:00,5,"Aratana, Elanco Announce Global Strategic Collaboration, $45 Up Front Payment To Aratana, & Up To $83M"
b76c0944-20ef-4076-95ed-f30397a09c7c,2016-04-25T08:00:00.000+08:00,4,"Transition Therapeutics Reports Dosing of First Patient in Phase 2 Study of Drug Candidate TT701 , Will Trigger $500K Milestone Payment To Eli Lilly"
3db8926b-56df-4fc6-8516-9d03add6e9a3,2016-04-25T08:00:00.000+08:00,2,"The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers"
402ab6f0-be3f-49cb-b481-35764f9f3b86,2016-04-25T08:00:00.000+08:00,4,"The Market In 5 Minutes: Monday, April 25, 2016"
0bddd489-cfdb-4a72-bd96-ef8704ce3dff,2016-04-25T08:00:00.000+08:00,5,"Aratana, Eli Lilly Team Create 'Watershed Contract' For Pet Biotech Sector"
293e22ee-d4f0-4c74-9bf6-accf81aa6322,2016-04-25T08:00:00.000+08:00,3,"Aratana, Elanco Announce Global Strategic Collaboration, $45 Up Front Payment To Aratana, & Up To $83M"
6573896c-6bd3-4ab2-a43a-52094050b3bf,2016-04-25T08:00:00.000+08:00,4,"Transition Therapeutics Reports Dosing of First Patient in Phase 2 Study of Drug Candidate TT701 , Will Trigger $500K Milestone Payment To Eli Lilly"
45bb137e-dda6-4701-9041-500e89e7ce3c,2016-04-25T08:00:00.000+08:00,2,"The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers"
e21e64dc-9cae-48a0-a2a8-2b0b8fbbb70b,2016-04-25T08:00:00.000+08:00,4,"The Market In 5 Minutes: Monday, April 25, 2016"
42394cec-f79e-4a87-b059-88b5e63ea350,2016-04-19T08:00:00.000+08:00,5,Eli Lilly And Boehringer Reveals Study On Jardiance For Treatment Heart Failure
b82f9234-2a5f-4676-947b-875944e68097,2016-04-19T08:00:00.000+08:00,3,"Lilly, Boehringer Ingelheim Announce Jardiance to be Studied to Treat People With Chronic Heart Failure"
826ddbf0-1f8b-4bf9-9cdb-c99d5527ebf9,2016-04-19T08:00:00.000+08:00,5,Eli Lilly And Boehringer Reveals Study On Jardiance For Treatment Heart Failure
95f281c9-1f61-42ff-b1df-0b2dd770b996,2016-04-19T08:00:00.000+08:00,5,"Lilly, Boehringer Ingelheim Announce Jardiance to be Studied to Treat People With Chronic Heart Failure"
ede50b21-4ece-4f45-a378-f34913120ee4,2016-04-18T08:00:00.000+08:00,2,Mid-Afternoon Market Update: Chiasma Tumbles Following FDA Review; Cvent Shares Spike Higher
40462f2c-8722-4f4d-aea0-3f0442e07c22,2016-04-18T08:00:00.000+08:00,4,Mid-Day Market Update: US Stocks Turn Positive; Hasbro Shares Gain Following Earnings Beat
344c794d-6ba0-49d1-83b1-4b07d384376b,2016-04-18T08:00:00.000+08:00,1,Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Q1 Profit Beats Expectations
aa120915-4c02-419e-916b-be54dd0ae4bc,2016-04-18T08:00:00.000+08:00,2,Transition Therapeutics Says Partner Eli Lily Will Not Advance TT401 into Phase 3 Development
15a5b9af-8e03-4ae2-a8d1-344a71b77dc8,2016-04-18T08:00:00.000+08:00,2,Mid-Afternoon Market Update: Chiasma Tumbles Following FDA Review; Cvent Shares Spike Higher
025eab6e-ea8f-43fd-840b-df4e07f37548,2016-04-18T08:00:00.000+08:00,4,Mid-Day Market Update: US Stocks Turn Positive; Hasbro Shares Gain Following Earnings Beat
ba72d8e2-4da6-48f8-b194-06e0b0af123e,2016-04-18T08:00:00.000+08:00,2,Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Q1 Profit Beats Expectations
66b25cbc-5d61-4bc2-9386-ed1116f565ab,2016-04-18T08:00:00.000+08:00,3,Transition Therapeutics Says Partner Eli Lily Will Not Advance TT401 into Phase 3 Development
92908037-9b13-4f89-a424-524beced1468,2016-04-08T08:00:00.000+08:00,5,"Eli Lilly, AstraZeneca Report Continuation of Pivotal Trial for People with Early Alzheimer's Disease; Will Continue to Phase 3 After Positive Interim Safety Data"
9a0bd9f0-b84b-4ec0-994b-61663914f565,2016-04-08T08:00:00.000+08:00,5,"Eli Lilly, AstraZeneca Report Continuation of Pivotal Trial for People with Early Alzheimer's Disease; Will Continue to Phase 3 After Positive Interim Safety Data"
07138d6e-f4de-4140-8e4b-fce0414a14ca,2016-04-06T08:00:00.000+08:00,2,SocGen Picks New Favorites In Big Pharma
6f423db7-00c3-4bcc-a747-2b002ae063ae,2016-04-06T08:00:00.000+08:00,3,Societe Generale Initiates Coverage on Eli Lilly at Hold
96444ebf-9eb8-46e0-83a0-863ba52f4fdc,2016-04-06T08:00:00.000+08:00,3,"Incyte Acquires Rights To Devlop and Commercialize Ruxolitinib From Lilly, Will Make $35M Upfront Payment As Well As Additional Potential Payments Contingent On Certain Regulatory Milestones; Novartis Granted Right To Develop & Commercialize Ruxolitinib"
d289b040-d200-43a4-8440-f46edf22d3ac,2016-04-06T08:00:00.000+08:00,4,WHO Says Number of Adults with Diabetes has Quadrupled Since 1980 -AFP
1bea87fe-11a7-4fe1-9f96-e31e7a34864b,2016-04-06T08:00:00.000+08:00,1,SocGen Picks New Favorites In Big Pharma
5d2f2337-76ab-4541-8da4-5ca8ef2d6edd,2016-04-06T08:00:00.000+08:00,2,Societe Generale Initiates Coverage on Eli Lilly at Hold
90da7022-9bb2-44a7-840e-74861e3f8564,2016-04-06T08:00:00.000+08:00,3,"Incyte Acquires Rights To Devlop and Commercialize Ruxolitinib From Lilly, Will Make $35M Upfront Payment As Well As Additional Potential Payments Contingent On Certain Regulatory Milestones; Novartis Granted Right To Develop & Commercialize Ruxolitinib"
52514298-6ddc-4f5c-b7ca-aa3299c62775,2016-04-06T08:00:00.000+08:00,4,WHO Says Number of Adults with Diabetes has Quadrupled Since 1980 -AFP
1984ee24-1c82-4ca3-9d1a-3da6a7007b53,2016-04-04T08:00:00.000+08:00,5,This Data Signals The End For Merck's Anacetrapib
f02a5def-a0f1-4c32-9448-f3b0f8a30efd,2016-04-04T08:00:00.000+08:00,1,This Data Signals The End For Merck's Anacetrapib
09cd41a1-c16e-4c31-8a56-7d6d9ea3dc4b,2016-03-31T08:00:00.000+08:00,5,Eli Lilly's Says ACC/AHA U.S. Guideline Says It's Reasonable To Chosose Effient Over Clopidogrel For Certain ACS-PCI Patients
5f0ef0ef-d69c-4b65-936d-249572e12d29,2016-03-31T08:00:00.000+08:00,5,"Eli Lilly Phase 3 Show Baricitinib Treatment With Patients In Rheumatoid Arthritis Show Significant Improvements, Met Primary Endpoint"
d1b3da87-9efa-441f-a54b-09ad8e58d0d3,2016-03-31T08:00:00.000+08:00,4,Eli Lilly's Says ACC/AHA U.S. Guideline Says It's Reasonable To Chosose Effient Over Clopidogrel For Certain ACS-PCI Patients
b1a207d3-34ba-4665-a04f-fa3dc550e1cb,2016-03-31T08:00:00.000+08:00,5,"Eli Lilly Phase 3 Show Baricitinib Treatment With Patients In Rheumatoid Arthritis Show Significant Improvements, Met Primary Endpoint"
86929d29-bb46-46b1-9089-7ab71dabd1b0,2016-03-29T08:00:00.000+08:00,1,Citi Downgrades Novartis Following SAG Investigation
10ef6952-a251-426a-b8ee-b5fa09c7aaf8,2016-03-29T08:00:00.000+08:00,2,Citi Downgrades Novartis Following SAG Investigation
d02c8ac8-8f39-4dbf-aa03-63377746c26a,2016-03-28T08:00:00.000+08:00,4,"Biopharma Names LLY, PFE, MRK, And More Popping Higher Following Reports China FDA To Investigate Improper Vaccine Trading"
8204de16-3865-42a6-a2ba-e2cfadb1129a,2016-03-28T08:00:00.000+08:00,3,"Biopharma Names LLY, PFE, MRK, And More Popping Higher Following Reports China FDA To Investigate Improper Vaccine Trading"
bf72fccf-0550-462b-bab7-c7fed858a893,2016-03-22T08:00:00.000+08:00,5,Adam Feuerstein Tweets: '$LLY FDA approves ixekizumab to treat adults with moderate-to-severe plaque psoriasis. Brand name Taltz.'
e9dae063-bf93-40a5-abc2-d76a746a5527,2016-03-22T08:00:00.000+08:00,5,Adam Feuerstein Tweets: '$LLY FDA approves ixekizumab to treat adults with moderate-to-severe plaque psoriasis. Brand name Taltz.'
a3ace797-81dd-42c4-adbb-29ccd868effc,2016-03-17T08:00:00.000+08:00,4,Option Alert: LLY May16 70.0 Calls Sweep: 1500 @ ASK $2.76: 1500 traded vs 55 OI: Earnings 4/26 Before Open $69.58 Ref
a451d5eb-fdd0-4f3c-96da-61768f50ca20,2016-03-17T08:00:00.000+08:00,3,Option Alert: LLY May16 70.0 Calls Sweep: 1500 @ ASK $2.76: 1500 traded vs 55 OI: Earnings 4/26 Before Open $69.58 Ref
bf52247b-2eb5-4c8a-9625-1a63566f6842,2016-03-15T08:00:00.000+08:00,2,"Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study, Instead Of Co-Primary Endpoints Of Cognition & Function, The Amended Trial Will Include Single Primary Endpoint Of Cognition"
aa843042-5d12-43f1-8f73-bd047554cfac,2016-03-15T08:00:00.000+08:00,5,"Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study, Instead Of Co-Primary Endpoints Of Cognition & Function, The Amended Trial Will Include Single Primary Endpoint Of Cognition"
de22d2c0-7da8-4f91-ace3-20679325b8c0,2016-03-14T08:00:00.000+08:00,1,Adocia & Lilly Announce Topline Results: 'BioChaperone Lispro U100 demonstrated a statistically significant 31 percent reduction in blood glucose'
7c555256-00ad-46b5-bef3-80c7f3d7d05b,2016-03-14T08:00:00.000+08:00,5,Adocia And Lilly Announce Positive Topline Results From A Phase 1B Study Of Repeated Admin Of Ultra-Rapid BioChaperone Lispro In Patients With Type 1 Diabetes
e415d4e7-e7ff-4224-86dc-24b254f27a99,2016-03-14T08:00:00.000+08:00,5,Adocia & Lilly Announce Topline Results: 'BioChaperone Lispro U100 demonstrated a statistically significant 31 percent reduction in blood glucose'
52db20ce-d2bc-4545-b991-4def3409c376,2016-03-14T08:00:00.000+08:00,3,Adocia And Lilly Announce Positive Topline Results From A Phase 1B Study Of Repeated Admin Of Ultra-Rapid BioChaperone Lispro In Patients With Type 1 Diabetes
45e338ed-8a68-43f4-adea-6af3c75a5352,2016-03-07T08:00:00.000+08:00,4,Eli Lilly Studies Show Ixekizumab Improved Work Productivity for Patients W/ Moderate-to-Severe Plaque Psoriasis
7decc94c-cd07-4965-a3bf-73d47d552e96,2016-03-07T08:00:00.000+08:00,4,PeptiDream to License PDPS Technology to Lilly
985a7efd-77e4-400d-8ca0-339961706354,2016-03-07T08:00:00.000+08:00,2,Eli Lilly Studies Show Ixekizumab Improved Work Productivity for Patients W/ Moderate-to-Severe Plaque Psoriasis
8ee4b2ce-dc2e-4019-b7b2-678ca930179e,2016-03-07T08:00:00.000+08:00,3,PeptiDream to License PDPS Technology to Lilly
aa1de706-dac7-4118-9130-9ca78ddb726e,2016-03-03T08:00:00.000+08:00,3,"Bernstein Cuts LLY FY 2017 EPS From $4.23 To $4.07, Cuts NVS FY 2017 EPS From $5.21 To %5.17"
317d714d-54fc-4f24-97ac-da805146dc05,2016-03-03T08:00:00.000+08:00,4,"Bernstein Cuts LLY FY 2017 EPS From $4.23 To $4.07, Cuts NVS FY 2017 EPS From $5.21 To %5.17"
7a8db880-b745-498e-878d-3c2dd5b16c8b,2016-03-02T08:00:00.000+08:00,5,Option Alert: LLY Fri 4/8 70.0 Puts (Wkly) Sweep: 1050 @ ASK $1.15: 1050 traded vs 0 OI: $73.54 Ref
5e4c3fd6-c602-40b2-a6e1-1798afb298ec,2016-03-02T08:00:00.000+08:00,1,Option Alert: LLY Fri 4/8 70.0 Puts (Wkly) Sweep: 1050 @ ASK $1.15: 1050 traded vs 0 OI: $73.54 Ref
d0b12276-0307-4f1e-9f63-38b7cbe4478c,2016-03-01T08:00:00.000+08:00,2,Lilly To Present Phase 3 Ixekizumab Data At 74th AAD Conference Taking Place Mar. 4-8th
8db9933e-0bb1-4bdf-a7a1-d24c9f1269f6,2016-03-01T08:00:00.000+08:00,3,Lilly To Present Phase 3 Ixekizumab Data At 74th AAD Conference Taking Place Mar. 4-8th
47bd55c6-0d44-4e4d-9aa0-1c65ecd907fc,2016-02-26T08:00:00.000+08:00,4,EMA Recommends Against Approval of Eli Lilly's Psoriasis Treatment Lxekizumab ‍
50c01f54-185e-47bd-a10d-b7b35be908b6,2016-02-26T08:00:00.000+08:00,1,EMA Recommends Against Approval of Eli Lilly's Psoriasis Treatment Lxekizumab ‍
db785bce-2fc8-43a6-b55e-4d21779983c7,2016-02-22T08:00:00.000+08:00,2,"Eli Lilly Files Auto Shelf For Mixed Offering, Size Not Disclosed"
6c6b3be2-2f35-49bc-9590-7ca6e44a6875,2016-02-22T08:00:00.000+08:00,4,"Radius Health Shares Up 29% Following Data from Amgen, UCB's Romosozumab Showing Failed Achievement on One of Two Secondary Endpoints"
d4d3eacc-9f54-452c-88c3-2e15e3d05d37,2016-02-22T08:00:00.000+08:00,3,"Eli Lilly Files Auto Shelf For Mixed Offering, Size Not Disclosed"
597ed8d5-bf02-4c31-8d8a-8d11aad53d2f,2016-02-22T08:00:00.000+08:00,1,"Radius Health Shares Up 29% Following Data from Amgen, UCB's Romosozumab Showing Failed Achievement on One of Two Secondary Endpoints"
c244a49f-18a5-4b51-9544-0dd6bd999143,2016-02-16T08:00:00.000+08:00,2,Biotech Conference Suggests Tempering Expectations For Eli Lilly Drug
406504ea-7d0a-4768-bf46-f1e618cba57c,2016-02-16T08:00:00.000+08:00,2,Biotech Conference Suggests Tempering Expectations For Eli Lilly Drug
f2421d35-bfcc-483d-93fc-792990ecf283,2016-02-12T08:00:00.000+08:00,3,"13G Filing Shows Eli Lilly Holder Primecap Mgmt Co Holds Amended 5.20% Stake As Of Dec 31, Held 5.17% Stake on Sept 30 2015"
f6bfc2d4-aaed-4158-b6bd-317033bd62b3,2016-02-12T08:00:00.000+08:00,3,Eli Lilly Announces Alimta Not Infringed By Actavis Marketing Pemetrexed Trometamol
53cfcf3d-4890-49d6-b9e2-04efad337947,2016-02-12T08:00:00.000+08:00,4,"13G Filing Shows Eli Lilly Holder Primecap Mgmt Co Holds Amended 5.20% Stake As Of Dec 31, Held 5.17% Stake on Sept 30 2015"
a15991f1-dc66-41bf-bde7-0205b5c830bc,2016-02-12T08:00:00.000+08:00,3,Eli Lilly Announces Alimta Not Infringed By Actavis Marketing Pemetrexed Trometamol
cddfccf3-390a-4721-be4d-90d576a2ed5e,2016-02-08T08:00:00.000+08:00,2,Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place
934958a2-da85-471f-aa12-1e58e4fc1c91,2016-02-08T08:00:00.000+08:00,2,Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place
a0383579-be12-4068-9a8a-7e81b912d16a,2016-02-05T08:00:00.000+08:00,3,"Credit Suisse Global Focus List Update: Toyota Out, Agnico Eagle In"
0a2cc49e-e9e0-4002-913e-2162c9e54263,2016-02-05T08:00:00.000+08:00,4,"Credit Suisse Global Focus List Update: Toyota Out, Agnico Eagle In"
ccc58817-ccf6-4874-9f9a-abd83d0ee8fb,2016-01-28T08:00:00.000+08:00,1,Earnings Recap For January 28
8026646a-fc78-4be2-93b3-2258ceef6352,2016-01-28T08:00:00.000+08:00,1,Eli Lilly Punished For Inline Report
eedf4193-0cb6-4664-9479-cf623aa0b8c5,2016-01-28T08:00:00.000+08:00,2,"Eli Lilly Sees FY EPS $2.83 to $2.93 est vs $3.43 est, Revenue $20.2B to $20.7B vs $20.8B est"
60ed28b2-3d49-4152-8f11-3fcd0c44163e,2016-01-28T08:00:00.000+08:00,3,"Eli Lilly Q4 EPS $0.78 vs $0.78 est, Revenue $5.38B vs $5.32B est"
d1d2c1d6-0763-4662-9471-856b9e553c8f,2016-01-28T08:00:00.000+08:00,4,"Earnings Scheduled For January 28, 2016"
c2cad0c3-41a0-42b6-b511-854e32f69c12,2016-01-28T08:00:00.000+08:00,3,Earnings Recap For January 28
05dc6c08-7a14-4cab-bbf7-2fa53725b64c,2016-01-28T08:00:00.000+08:00,1,Eli Lilly Punished For Inline Report
1c41e7f4-8298-4cc1-accf-a911f68046aa,2016-01-28T08:00:00.000+08:00,2,"Eli Lilly Sees FY EPS $2.83 to $2.93 est vs $3.43 est, Revenue $20.2B to $20.7B vs $20.8B est"
10c1d845-6ab7-4f9f-a38d-063e1f4a6e9e,2016-01-28T08:00:00.000+08:00,3,"Eli Lilly Q4 EPS $0.78 vs $0.78 est, Revenue $5.38B vs $5.32B est"
fcf945ad-7718-4981-8bce-05f37e6fe476,2016-01-28T08:00:00.000+08:00,4,"Earnings Scheduled For January 28, 2016"
33f2c3a7-2e8f-40c2-a5a3-cc624d0ff767,2016-01-27T08:00:00.000+08:00,4,"Lilly, Roche Diagnostics to Partner on Alzheimer's Disease Adjunct Diagnostic Tool"
9185c041-92c8-4d58-97b2-36a826dce61a,2016-01-27T08:00:00.000+08:00,2,"Lilly, Roche Diagnostics to Partner on Alzheimer's Disease Adjunct Diagnostic Tool"
7ae1083b-65e9-4676-a8a8-5af24442f054,2016-01-25T08:00:00.000+08:00,3,"JNJ Kicks Off Health Care Earnings—What About Deals, Buybacks?"
0932b6d9-9ce5-450a-8594-9238d58211f6,2016-01-25T08:00:00.000+08:00,3,US Big Pharma: What To Watch For In Q4 Results
7021b7e8-233d-440c-8a67-7c264594086a,2016-01-25T08:00:00.000+08:00,4,"Stock Marquee Crowded With Oil, Apple, And The Fed"
b32a32ef-f0f1-434a-8261-c0e294a2d65e,2016-01-25T08:00:00.000+08:00,5,Eli Lilly Reports FDA Acceptance of Filing of CV Outcomes Data for Jardiance
b03e6b4a-f291-432e-ab11-0c3f8d46ae0a,2016-01-25T08:00:00.000+08:00,2,"JNJ Kicks Off Health Care Earnings—What About Deals, Buybacks?"
258892b5-86ff-473e-b52d-81257414866f,2016-01-25T08:00:00.000+08:00,3,US Big Pharma: What To Watch For In Q4 Results
0033c3a3-8001-4f1e-a221-3fda13b7179f,2016-01-25T08:00:00.000+08:00,4,"Stock Marquee Crowded With Oil, Apple, And The Fed"
4a74e22e-cbab-40f2-be79-24dd9c463944,2016-01-25T08:00:00.000+08:00,5,Eli Lilly Reports FDA Acceptance of Filing of CV Outcomes Data for Jardiance
1a86a07d-bffb-4008-adf1-72f6aae4403e,2016-01-21T08:00:00.000+08:00,1,U.S. Food and Drug Administration Approves Humulin R U-500 KwikPen
f94be1dd-b299-46ee-a233-42a58979d407,2016-01-21T08:00:00.000+08:00,2,U.S. Food and Drug Administration Approves Humulin R U-500 KwikPen
09056ca3-d6b6-4549-a0fa-241ab8973938,2016-01-19T08:00:00.000+08:00,1,Eli Lilly Reiterates FY15 Guidance Of $3.45-$3.55 vs. Est. $3.43-DJ
e7919aed-ae77-435d-b927-006436efee21,2016-01-19T08:00:00.000+08:00,3,"Eli Lilly, Incyte Report Submission of NDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe RA"
39ad26ff-f75c-4883-a7d0-5e1973a62af5,2016-01-19T08:00:00.000+08:00,1,Eli Lilly Reiterates FY15 Guidance Of $3.45-$3.55 vs. Est. $3.43-DJ
bdb3d43d-f48f-4413-8c2f-0ebdf595a14b,2016-01-19T08:00:00.000+08:00,3,"Eli Lilly, Incyte Report Submission of NDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe RA"
ee8e169f-9fbd-4e30-b661-2aeaa32d8e67,2016-01-15T08:00:00.000+08:00,4,"Argus Reiterates $93 Target On Eli Lilly, Highlights 'Strong Late-Stage Pipeline'"
d4669b94-a167-479e-9bc6-359335435cc1,2016-01-15T08:00:00.000+08:00,4,"Argus Reiterates $93 Target On Eli Lilly, Highlights 'Strong Late-Stage Pipeline'"
363a2cef-5220-4948-b9fe-7b4231a44cc4,2016-01-11T08:00:00.000+08:00,3,"Insulet Enters Agreement With Eli Lilly For OmniPod Delivery Of U200 Concentrated Insulin, Terms Not Dislcosed"
a84547e4-a329-4138-a356-5fc2ec72ac52,2016-01-11T08:00:00.000+08:00,2,"Insulet Enters Agreement With Eli Lilly For OmniPod Delivery Of U200 Concentrated Insulin, Terms Not Dislcosed"
253cb8f3-3f6d-4a60-b3b4-b231d5d17b2e,2016-01-05T08:00:00.000+08:00,1,Eli Lilly Shares Lower Following Weaker-Than-Expected 2016 Guidance
2bed30e8-2b3f-4102-9421-86f2723d6d8a,2016-01-05T08:00:00.000+08:00,1,Eli Lilly Shares Trading Down 2+% to $81 Following Weaker-Than-Expected FY16 Outlook
25f88ee4-cd54-47f4-94fd-ac5c2dcc40c7,2016-01-05T08:00:00.000+08:00,2,"UPDATE: Eli Lilly Sees FY16 Adj. EPS $3.45-$3.55 vs $3.65 Est., Sales $20.2B-$20.7B vs $21.5B Est."
da62fa52-914b-4e1e-b053-2aa061ce11bf,2016-01-05T08:00:00.000+08:00,3,UPDATE: Eli Lilly Reaffirms FY15 Adj. EPS Outlook $3.40-$3.45 vs $3.44 Est.
dc5ddcbe-012a-480b-9f50-b719f824095f,2016-01-05T08:00:00.000+08:00,4,Eli Lilly Issues Update to FY15 Outlook; Offers FY16 Guidance
938a2f79-158d-4be7-800a-d22299777bfe,2016-01-05T08:00:00.000+08:00,1,Eli Lilly Shares Lower Following Weaker-Than-Expected 2016 Guidance
e430537e-02d7-421a-8d3a-3a7de9b60248,2016-01-05T08:00:00.000+08:00,1,Eli Lilly Shares Trading Down 2+% to $81 Following Weaker-Than-Expected FY16 Outlook
f64dc85f-1a93-4beb-9529-bac07a4782f1,2016-01-05T08:00:00.000+08:00,2,"UPDATE: Eli Lilly Sees FY16 Adj. EPS $3.45-$3.55 vs $3.65 Est., Sales $20.2B-$20.7B vs $21.5B Est."
9ec2d6c6-8701-4cd1-a8f0-1b3b7a76e8b3,2016-01-05T08:00:00.000+08:00,3,UPDATE: Eli Lilly Reaffirms FY15 Adj. EPS Outlook $3.40-$3.45 vs $3.44 Est.
0d4c91f4-f889-40b1-a0c5-e9c72357f378,2016-01-05T08:00:00.000+08:00,4,Eli Lilly Issues Update to FY15 Outlook; Offers FY16 Guidance
74f229e4-16ea-4ce1-b36b-2b6699d2563e,2015-12-28T08:00:00.000+08:00,5,"Eli Lilly's 2016 Guidance Released Next Week Could Disappoint, Leerink Warns"
efa3a290-ba7b-436d-ab28-0984129c2ffc,2015-12-28T08:00:00.000+08:00,2,Leerink's Fernandez on Eli Lilly Ahead of Expected FY16 Guidance on Jan. 5: 'Much Lower Fx Benefit Makes 2016 Guidance Tough; All Eyes on Sola'
8ac68501-f835-4832-a2d2-24b1d59a55b1,2015-12-28T08:00:00.000+08:00,3,"Eli Lilly's 2016 Guidance Released Next Week Could Disappoint, Leerink Warns"
9c77c8cb-709f-40f2-83e9-dca6b5a8c0f2,2015-12-28T08:00:00.000+08:00,2,Leerink's Fernandez on Eli Lilly Ahead of Expected FY16 Guidance on Jan. 5: 'Much Lower Fx Benefit Makes 2016 Guidance Tough; All Eyes on Sola'
5a57040a-6db3-4fba-9d0d-ee5560f8bb44,2015-12-23T08:00:00.000+08:00,4,Not All Of Clinton's Policies Are Bad For Pharmaceuticals
26534f33-694c-4f20-9676-287a7a918769,2015-12-23T08:00:00.000+08:00,4,Not All Of Clinton's Policies Are Bad For Pharmaceuticals
7117613e-d55a-4fd6-ae7e-404971a245f6,2015-12-21T08:00:00.000+08:00,5,"UPDATE: Halozyme Says Will Receive Initial $25M Payment, Followed by Milestone Payments of Up to $160M for Each of Up to Five Collab Targets"
2fb86963-1a29-4709-b15f-943f80f52347,2015-12-21T08:00:00.000+08:00,4,"Halozyme Reports Entering of Global Collab, Licensing Deal with Lilly"
f2ad58b4-cc2e-4689-b9ff-13e997e8c7df,2015-12-21T08:00:00.000+08:00,3,"UPDATE: Halozyme Says Will Receive Initial $25M Payment, Followed by Milestone Payments of Up to $160M for Each of Up to Five Collab Targets"
0ce28ec8-6562-44ec-bb52-6a57e638764c,2015-12-21T08:00:00.000+08:00,4,"Halozyme Reports Entering of Global Collab, Licensing Deal with Lilly"
58f945b1-fef1-4f7d-8936-dc855b621dcf,2015-12-19T08:00:00.000+08:00,2,Credit Suisse Offers 2016 U.S. Large-Cap Pharma Outlook
33393910-4498-4b0f-8265-d0b022befc46,2015-12-19T08:00:00.000+08:00,4,Credit Suisse Offers 2016 U.S. Large-Cap Pharma Outlook
0208adad-0d44-4941-82c2-3882360e3cdb,2015-12-18T08:00:00.000+08:00,2,3 Biotechs Atlantic Equities Loves And 1 It's Avoiding
77802038-fa45-4388-a3b5-a31a13c09401,2015-12-18T08:00:00.000+08:00,5,"Atlantic Equities Initiates Coverage on Eli Lilly at Overweight, Announces $100.00 PT"
d942b3a6-af4c-4b6e-829a-c5e66d844867,2015-12-18T08:00:00.000+08:00,5,Lilly's Lung Cancer Drug Necitumumab Receives Positive Opinion from EMA
7c78ddca-5646-4102-8b84-c4b97704ff44,2015-12-18T08:00:00.000+08:00,2,3 Biotechs Atlantic Equities Loves And 1 It's Avoiding
0c5a4e62-90b5-46ab-a249-848ccd19fae3,2015-12-18T08:00:00.000+08:00,4,"Atlantic Equities Initiates Coverage on Eli Lilly at Overweight, Announces $100.00 PT"
de2fc3a9-514b-4ea4-bfa5-39aed4f8db3c,2015-12-18T08:00:00.000+08:00,5,Lilly's Lung Cancer Drug Necitumumab Receives Positive Opinion from EMA
1590826b-4dae-4509-83fd-2865a825cd5a,2015-12-17T08:00:00.000+08:00,3,Shares of Eli Lilly Up ~0.6% After Credit Suisse Adds to 'Focus List'; Shares of Bristol-Myers Down ~0.7% as Stock Removed from Same List
0c70b4f0-d334-40c4-a91b-8a3e8cdc46f4,2015-12-17T08:00:00.000+08:00,4,Shares of Eli Lilly Up ~0.6% After Credit Suisse Adds to 'Focus List'; Shares of Bristol-Myers Down ~0.7% as Stock Removed from Same List
62a3fad9-e66a-4b67-8446-cd9fef468669,2015-12-12T08:00:00.000+08:00,5,Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds
84bc68e3-60ab-44bf-ba23-2047cab583d1,2015-12-12T08:00:00.000+08:00,4,Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds
afc2b098-4642-4707-a47e-1f866cc305e5,2015-12-10T08:00:00.000+08:00,5,Eli Lilly and Merk Announces Expansion of Immuno Oncology Collaboration
c58904f3-3928-4809-a833-20a62de2c715,2015-12-10T08:00:00.000+08:00,5,Eli Lilly and Merk Announces Expansion of Immuno Oncology Collaboration
44e81583-c47a-4d01-a4bc-6481096c5ec1,2015-12-08T08:00:00.000+08:00,4,Eli Lilly Increases Dividend From $0.50 To $0.51/Share
9ea5d355-875a-4c7f-82b7-4e5bab48e820,2015-12-08T08:00:00.000+08:00,5,Eli Lilly Increases Dividend From $0.50 To $0.51/Share
61130209-21bb-4650-9b1b-264fac281806,2015-12-07T08:00:00.000+08:00,5,Eli Lilly Could Make A Lot More From Alzheimer's Drug Than Originally Thought
64e3c539-38b6-4714-90de-f125840ada00,2015-12-07T08:00:00.000+08:00,4,Benzinga's Top Upgrades
d7ae1589-4b19-4690-b67b-b1d5d42c23b7,2015-12-07T08:00:00.000+08:00,3,"Deutsche Bank Upgrades Eli Lilly to Buy, Raises to $99.00"
064178eb-c112-48cd-9ede-303c73ad5129,2015-12-07T08:00:00.000+08:00,5,Eli Lilly Could Make A Lot More From Alzheimer's Drug Than Originally Thought
459198da-aa7a-4080-8868-91d91a3270b3,2015-12-07T08:00:00.000+08:00,4,Benzinga's Top Upgrades
72fcfe27-bd7d-4d8b-b18f-acf5e8ed36bd,2015-12-07T08:00:00.000+08:00,4,"Deutsche Bank Upgrades Eli Lilly to Buy, Raises to $99.00"
484c57a6-8779-4a4a-b749-d44b85128342,2015-12-04T08:00:00.000+08:00,2,Cautious Stock Rebound as Jobs Data Delivers But Wages Still in Question
0b1218fc-ca92-42d9-bd0d-1d251a00ff5f,2015-12-04T08:00:00.000+08:00,3,Lilly Ends Basal Insulin Peglispro Development Program
f08d798c-d133-4782-942f-5257cc6705cb,2015-12-04T08:00:00.000+08:00,2,Cautious Stock Rebound as Jobs Data Delivers But Wages Still in Question
7f2005b9-2818-4160-acaa-c1427502ee8e,2015-12-04T08:00:00.000+08:00,3,Lilly Ends Basal Insulin Peglispro Development Program
5a862b8b-fc5c-4911-b85e-89bee651d407,2015-12-01T08:00:00.000+08:00,4,"New Data Show Lilly's Once-Weekly Trulicity is Effective as Add-on Treatment to Sulfonylurea, Trulicity Primary Endpoint Provided Superior A1C Rduction; Secondary Endpoint Did Not Reach Statistical Significance"
78f7017d-c49f-41bb-a5f2-5fedf2391ff6,2015-12-01T08:00:00.000+08:00,3,Barclays' Biopharmaceuticals Blueprint For 2016
82657095-f44b-42e0-b32e-420ee720f68c,2015-12-01T08:00:00.000+08:00,4,Benzinga's Top Upgrades
9e3c4b90-b728-4d7d-9150-19833ca7663d,2015-12-01T08:00:00.000+08:00,5,"Barclays Upgrades Eli Lilly to Overweight, Raises PT to $95.00"
4f6648fa-7443-4ec4-b00b-061a2a882095,2015-12-01T08:00:00.000+08:00,4,"New Data Show Lilly's Once-Weekly Trulicity is Effective as Add-on Treatment to Sulfonylurea, Trulicity Primary Endpoint Provided Superior A1C Rduction; Secondary Endpoint Did Not Reach Statistical Significance"
a9440720-2938-4a1e-a523-11a81ea31de7,2015-12-01T08:00:00.000+08:00,4,Barclays' Biopharmaceuticals Blueprint For 2016
c9d7f0ad-3e48-4574-b303-dc1e58ded058,2015-12-01T08:00:00.000+08:00,3,Benzinga's Top Upgrades
b7bbca3f-ba74-491c-9118-3be601e4ecf5,2015-12-01T08:00:00.000+08:00,5,"Barclays Upgrades Eli Lilly to Overweight, Raises PT to $95.00"
16c95ccb-9a87-4a50-a593-fd511b5d3c45,2015-11-30T08:00:00.000+08:00,5,Health Canada Approves JARDIANCE (Empagliflozin) Tablets For Adults With Type 2 Diabetes
839e3051-b68e-4f49-8415-bc6bcbbf20af,2015-11-30T08:00:00.000+08:00,5,Health Canada Approves JARDIANCE (Empagliflozin) Tablets For Adults With Type 2 Diabetes
1899eecb-bfee-47a4-8c85-f446026d1f76,2015-11-24T08:00:00.000+08:00,5,Eli Lilly Release Confirms FDA Approval If Portrazza
bc115e35-8b96-4036-9a93-75265493ada3,2015-11-24T08:00:00.000+08:00,5,FDA Approves Eli Lilly's Portrazza to Treat Advanced Squamous Non-Small Cell Lung Cancer-DJ
6a4f3807-d982-4406-8a6e-1b01aa172a9e,2015-11-24T08:00:00.000+08:00,3,Eli Lilly Release Confirms FDA Approval If Portrazza
033362ad-2c26-46dd-a7a5-c2ca301f9f11,2015-11-24T08:00:00.000+08:00,4,FDA Approves Eli Lilly's Portrazza to Treat Advanced Squamous Non-Small Cell Lung Cancer-DJ
2180ad77-60a6-497f-b459-0a21c3615d87,2015-11-19T08:00:00.000+08:00,2,US Stock Futures Edge Higher Ahead Of Jobless Claims Report
29528a08-236c-458e-9d37-957980d58a44,2015-11-19T08:00:00.000+08:00,4,Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
1f85839d-b300-4138-a1db-7f398c7059f1,2015-11-19T08:00:00.000+08:00,3,US Stock Futures Edge Higher Ahead Of Jobless Claims Report
b7e9b0b9-f7b1-475e-927e-79ee2153fa7f,2015-11-19T08:00:00.000+08:00,4,Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
182bdc63-6b8b-488f-b304-4c0216b99f61,2015-11-16T08:00:00.000+08:00,5,Benzinga's Top Upgrades
686aa08e-38f3-4b49-b0c1-26b5439def73,2015-11-16T08:00:00.000+08:00,5,"BMO Capital Upgrades Eli Lilly to Outperform, Raises PT to $100.00"
efa42152-1308-4384-9310-25af51e6156a,2015-11-16T08:00:00.000+08:00,4,Benzinga's Top Upgrades
545cb910-ef7e-4217-bb7c-c6c0e9347b3d,2015-11-16T08:00:00.000+08:00,5,"BMO Capital Upgrades Eli Lilly to Outperform, Raises PT to $100.00"
c0a7252b-597b-43b5-913f-564f9edfd115,2015-11-10T08:00:00.000+08:00,3,"WuXi, Lilly Report Strategic Collaboration to Develop Novel Therapeutic in China"
91b5838f-37f9-4acd-94e6-cdec2fa089b5,2015-11-10T08:00:00.000+08:00,4,"WuXi, Lilly Report Strategic Collaboration to Develop Novel Therapeutic in China"
e593ff59-cdce-4172-892d-c19b101c7438,2015-11-09T08:00:00.000+08:00,5,"UPDATE: Eli Lilly Release Shows New Data on JARDIANCE Showed Reduction to Risk of Rates Endpoint of Hospitalization for Heart Failure, Death from Heart Failure by 39% vs Placebo"
82f7817e-a9fc-4db4-8c2b-bb9328421568,2015-11-09T08:00:00.000+08:00,5,New Jardiance data show improved CV outcomes regardless of heart failure status at baseline
1fb23ca7-aae6-4960-a07a-caa753c2c1c7,2015-11-09T08:00:00.000+08:00,5,"UPDATE: Eli Lilly Release Shows New Data on JARDIANCE Showed Reduction to Risk of Rates Endpoint of Hospitalization for Heart Failure, Death from Heart Failure by 39% vs Placebo"
6608013e-e92d-4d8d-86ea-bfc9500d6159,2015-11-09T08:00:00.000+08:00,3,New Jardiance data show improved CV outcomes regardless of heart failure status at baseline
10b4ea4c-3f99-40d0-bb4e-21dac982f41a,2015-11-08T08:00:00.000+08:00,4,"Ignyta Acquires Exclusive Rights to Taladegib Oncology Program from Lilly for $2M, ~1.2M Ignyta Shares"
bfe79c6c-2211-44a4-b287-8b9a0f047fde,2015-11-08T08:00:00.000+08:00,4,"Ignyta Acquires Exclusive Rights to Taladegib Oncology Program from Lilly for $2M, ~1.2M Ignyta Shares"
e0334280-1b38-4f8a-be0b-5d61f2829ed7,2015-11-07T08:00:00.000+08:00,4,"Lilly, Incyte Announce Data Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of RA"
b2d8396a-e8c1-45f5-a63a-ecc69700c8d5,2015-11-07T08:00:00.000+08:00,3,"Lilly, Incyte Announce Data Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of RA"
e6867413-2b53-48f9-8fd3-5dea993b087d,2015-11-06T08:00:00.000+08:00,2,"Eli Lilly Spokesperson Confirms Disclosure of DoJ Inquiry Was In Filing A Week Ago, Notes News 'did not generate much media interest until today.'"
a62aa715-d65f-492a-83a5-30cdaf1871c7,2015-11-06T08:00:00.000+08:00,1,"Eli Lilly Moving Off DoJ Inquiry, But News Is Old"
c4aa18ca-1fb2-4005-a721-8fc15598b33d,2015-11-06T08:00:00.000+08:00,3,Eli Lilly Spokesperson Says Will Soon Be Providing Statement Related to DoJ Inquiry/Disclosure Related to Wholesalers
ecfd4321-c4cb-4db4-a12d-f7f780483495,2015-11-06T08:00:00.000+08:00,2,BZ NOTE: Eli Lilly Comments on DoJ Inquiry on Wholesalers Came from 10-Q FIled on Oct. 30; News Should Have Been Priced Into the Stock Several Days Ago
3708b659-3a8c-4329-a390-727c873fbce0,2015-11-06T08:00:00.000+08:00,3,"UPDATE: Eli Lilly Shares Plunge $1 Over Last Few Mins, Stock Now Down ~2.5% for Session"
a05f94ab-d28a-4640-906c-2d840be56c8b,2015-11-06T08:00:00.000+08:00,3,Lilly Says DoJ Conducting Inquiry Of Agreements With Wholesalers -DJ
9ac763bc-3aba-4777-9c24-b4f4dc803ddb,2015-11-06T08:00:00.000+08:00,1,Eli Lilly Shares Falling
57f7cb15-1463-4c74-b895-dd0d32c58863,2015-11-06T08:00:00.000+08:00,2,"Eli Lilly Spokesperson Confirms Disclosure of DoJ Inquiry Was In Filing A Week Ago, Notes News 'did not generate much media interest until today.'"
42d8d3a1-46d6-406f-b1aa-2bc7154cef56,2015-11-06T08:00:00.000+08:00,3,"Eli Lilly Moving Off DoJ Inquiry, But News Is Old"
c3c77d00-fe36-4a9e-a27d-1a2970d28a03,2015-11-06T08:00:00.000+08:00,4,Eli Lilly Spokesperson Says Will Soon Be Providing Statement Related to DoJ Inquiry/Disclosure Related to Wholesalers
f5d160ec-3ab2-44bc-81ab-1c6de117e41b,2015-11-06T08:00:00.000+08:00,3,BZ NOTE: Eli Lilly Comments on DoJ Inquiry on Wholesalers Came from 10-Q FIled on Oct. 30; News Should Have Been Priced Into the Stock Several Days Ago
d852ecf0-e6ad-4cf4-80fc-3eadc2d5b638,2015-11-06T08:00:00.000+08:00,1,"UPDATE: Eli Lilly Shares Plunge $1 Over Last Few Mins, Stock Now Down ~2.5% for Session"
2691cefb-f503-430f-94f4-65e0e22d433a,2015-11-06T08:00:00.000+08:00,2,Lilly Says DoJ Conducting Inquiry Of Agreements With Wholesalers -DJ
5ecebb68-33df-472d-a0d9-68aa1414a036,2015-11-06T08:00:00.000+08:00,2,Eli Lilly Shares Falling
00e92c9a-84bf-4570-8f4e-4b666fbb6a05,2015-10-27T08:00:00.000+08:00,4,Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase 3 Data
50b423a4-289b-419e-8c8c-3514482f9048,2015-10-27T08:00:00.000+08:00,4,Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase 3 Data
4d07134a-79f1-4311-8d91-a91c7c36b465,2015-10-22T08:00:00.000+08:00,1,"US Stock Futures Gain Ahead Of Earnings, Economic Data"
8084cfb1-be39-41ab-bf37-a761fb7b6cb7,2015-10-22T08:00:00.000+08:00,4,"Eli Lilly Posts Upbeat Q3 Earnings, Raises Forecast"
1c1711dc-eed8-47dc-96b3-9b5d93df1731,2015-10-22T08:00:00.000+08:00,4,"Eli Lilly Raises FY 2015 EPS $3.40-$3.45 Vs Est $3.28, Had Seen $3.20-$3.30 & Revs $19.7B-$20B Vs Est $19.93B"
281f795b-ef39-4fdf-99c1-ffa25e4b985f,2015-10-22T08:00:00.000+08:00,2,"Eli Lilly Q3 EPS $0.89 vs $0.75 est, Revenue $4.96B vs $4.99B est"
f5499b1e-0184-4886-a206-68ba918916bc,2015-10-22T08:00:00.000+08:00,3,"Earnings Scheduled For October 22, 2015"
7a0df8c3-6ec0-4004-a513-851773d81594,2015-10-22T08:00:00.000+08:00,4,"US Stock Futures Gain Ahead Of Earnings, Economic Data"
f5a6695f-03cf-4b96-bdaf-03f06c5341f6,2015-10-22T08:00:00.000+08:00,5,"Eli Lilly Posts Upbeat Q3 Earnings, Raises Forecast"
c0f97ea4-5564-48f5-8c27-000707ae8ea4,2015-10-22T08:00:00.000+08:00,4,"Eli Lilly Raises FY 2015 EPS $3.40-$3.45 Vs Est $3.28, Had Seen $3.20-$3.30 & Revs $19.7B-$20B Vs Est $19.93B"
77b617ce-84c5-4325-9daa-227e24f4ad4a,2015-10-22T08:00:00.000+08:00,3,"Eli Lilly Q3 EPS $0.89 vs $0.75 est, Revenue $4.96B vs $4.99B est"
c6dc916d-c7fc-4878-9960-2235344af4a6,2015-10-22T08:00:00.000+08:00,3,"Earnings Scheduled For October 22, 2015"
f02c4235-8bd6-404b-9210-2ecb4152d891,2015-10-21T08:00:00.000+08:00,2,"Global Growth Temperature Likely Captured In Caterpillar, McDonald's And Under Armour Earnings"
fd5c2b89-db68-46cf-ae27-cc65d3babb2d,2015-10-21T08:00:00.000+08:00,4,Lilly supports global Dementia Discovery Fund
1c665db0-121d-4800-841e-8676c13cd592,2015-10-21T08:00:00.000+08:00,4,"Global Growth Temperature Likely Captured In Caterpillar, McDonald's And Under Armour Earnings"
f5e43b2e-0578-4c1a-8b2f-db5654b93ef5,2015-10-21T08:00:00.000+08:00,5,Lilly supports global Dementia Discovery Fund
1b729c7d-96e4-4591-9bc8-b2c6e0468a01,2015-10-20T08:00:00.000+08:00,3,Yabao Pharmaceuticals Enters 2nd Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment
03ba3a7d-22b4-4787-b5fd-5c8351ab87a0,2015-10-20T08:00:00.000+08:00,5,Yabao Pharmaceuticals Enters 2nd Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment
2c7d6172-eb73-434e-9e96-911f31daee44,2015-10-18T08:00:00.000+08:00,1,Google Stands Out Amid Low Earnings Expectations
a17cbe86-16f6-44cd-b32f-dd45f789ded0,2015-10-18T08:00:00.000+08:00,4,Google Stands Out Amid Low Earnings Expectations
bef0e54e-0827-490b-ad6f-e9139ea79935,2015-10-14T08:00:00.000+08:00,5,New Type 2 Diabetes Treatment Synjardy Tablets Now Available in U.S. Pharmacies
47f25c62-53ac-4d6e-9f22-c5f72d3329de,2015-10-14T08:00:00.000+08:00,3,Incyte and Eli Lilly Announce Baricitnib Results
df3efafc-2bdd-4d22-85ce-0329c7543613,2015-10-14T08:00:00.000+08:00,5,New Type 2 Diabetes Treatment Synjardy Tablets Now Available in U.S. Pharmacies
7b4ea058-2aca-4d3f-b9ac-3db5fdd2611a,2015-10-14T08:00:00.000+08:00,4,Incyte and Eli Lilly Announce Baricitnib Results
207ef015-ede6-422b-8181-bef0c3434b59,2015-10-13T08:00:00.000+08:00,4,"JMP Analyst Says Eli Lilly's CETP Failure Positive For Esperion Therapeutics ETC-1002 Oral Candidate, States Strategic Value Of Asset Has Increased"
25e9393b-3a86-4f20-8285-9f24d1b401cd,2015-10-13T08:00:00.000+08:00,2,US Stock Futures Down; JPMorgan Earnings In Focus
f3f4f564-f8fd-4a51-ae1d-3bdb83aa2855,2015-10-13T08:00:00.000+08:00,3,"Lilly and ImaginAb Announce Preclinical Immuno-Oncology Collaboration, no terms"
1dc53561-1cc4-4f52-bd70-0bcba8a7990e,2015-10-13T08:00:00.000+08:00,4,Fast Money Traders Share Their Thoughts On Eli Lilly and And The Restaurant Sector
4dfaa0fc-7ff4-4ba4-a96b-945726968234,2015-10-13T08:00:00.000+08:00,3,Fast Money Picks For October 13
046e0d68-32d2-41b0-99fc-5f9a633c3d0c,2015-10-13T08:00:00.000+08:00,4,"JMP Analyst Says Eli Lilly's CETP Failure Positive For Esperion Therapeutics ETC-1002 Oral Candidate, States Strategic Value Of Asset Has Increased"
582650ab-7abc-49fe-8a24-2d6c20e10fab,2015-10-13T08:00:00.000+08:00,2,US Stock Futures Down; JPMorgan Earnings In Focus
04ca5649-d3ef-4108-a358-fc7bfbf020d9,2015-10-13T08:00:00.000+08:00,3,"Lilly and ImaginAb Announce Preclinical Immuno-Oncology Collaboration, no terms"
33f5eef1-4409-4d6e-b83c-554b643aad19,2015-10-13T08:00:00.000+08:00,4,Fast Money Traders Share Their Thoughts On Eli Lilly and And The Restaurant Sector
7dbeeda8-2180-4c55-ac85-3bdcf0e7333a,2015-10-13T08:00:00.000+08:00,3,Fast Money Picks For October 13
4858f3ab-c349-4c2c-9615-306e491fc7ec,2015-10-12T08:00:00.000+08:00,4,"UPDATE: Chardan's Amusa Highlights Bull vs Bear Case for Esperion, Sees the Latter as 'More Important'"
1f5da5a1-948b-4a35-a650-83e3ac18a263,2015-10-12T08:00:00.000+08:00,3,"Chardan Capital's Amusa on Esperion Following Evacetrapib Discontinuation: '...by increasing the likelihood of regulatory scrutiny on ETC-1002, the evacetrapib failure reduces the chance ETC-1002 gets there...'"
1e72f89c-6b56-4c03-b56b-2ab893409ccc,2015-10-12T08:00:00.000+08:00,3,Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives
40671ff3-2bb8-41a4-af95-8390a895b93b,2015-10-12T08:00:00.000+08:00,5,"Regeneron Trading Up To $517/Share Up 2.6% Premarket On Eli Lilly Evacetraqib Development Discontinuation, Watch Regenron Partner Sanofi"
f0145713-298f-49a9-b36c-127b422d1cdb,2015-10-12T08:00:00.000+08:00,5,UPDATE: Shares of Esperion Therapeutics Trading Up ~14% Following Discontinuation of Lilly's Evacetrapib
98a75ab5-c5ca-46a1-b2a8-be23cefda382,2015-10-12T08:00:00.000+08:00,2,"UPDATE: Shares of Eli Lilly Trading Down ~8%, Now Under $80 at $79.49"
986dd0ca-caf2-4a0a-86ac-0ef773c57d5f,2015-10-12T08:00:00.000+08:00,1,TheStreet's Adam Feuerstein Recently Tweets: 'Watch $ESPR' on the Heels of Eli Lilly Discontinuation of Evacetrapib
4dc74346-e2cb-4816-86d8-a9648c4bee85,2015-10-12T08:00:00.000+08:00,3,"Esperion Shares Trading Higher To $28.50/Share, Up 14.9% Premarket Following Eli Lilly Development Discontinuation For Evacetraqib"
89cd1cfe-d0a7-431e-87a7-c756f6eaa428,2015-10-12T08:00:00.000+08:00,2,Shares of Eli Lilly Resume; Now Trading Down ~$83
49483c4a-e5b9-4b59-91f7-c78751f7a7eb,2015-10-12T08:00:00.000+08:00,1,UPDATE: Eli Lilly Evacetraqib Devlopment Discontinuation Expected To Result In Q4 Charge Of $90M or $0.05 After-Tax
c8a1ce6e-b146-46fc-bb56-c4e3ea799f17,2015-10-12T08:00:00.000+08:00,1,"UPDATE: Eli Discontinuing Evacetraqib Development Due To Low Probability Of Study TO Achieve Primary Endpoint Based On Results To Date, Not Being Stopped Due To Safety Findings"
3042240b-f4e4-48b8-9283-7dce6df826c9,2015-10-12T08:00:00.000+08:00,2,"UPDATE: Lilly Will Terminate Phase 3 Trial of Evacetrapib, Cites Insufficient Efficacy"
7a1d957e-caf9-421b-9a28-ce33ba866e83,2015-10-12T08:00:00.000+08:00,3,Lilly Announces Will Discontinue Development of Evacetrapib
34d13f1d-4a4c-40d1-bc04-7b6b1c833f70,2015-10-12T08:00:00.000+08:00,4,Watching Volatility In Other Big Pharma Names Amid Eli Lilly Halt
d01d5d0e-7a9e-4c94-9bb3-26b2c945a561,2015-10-12T08:00:00.000+08:00,5,Eli Lilly Shares Halted News Pending
c07e8812-a5ea-4a17-b1b0-34d74656845e,2015-10-12T08:00:00.000+08:00,1,US Stock Futures Flat Ahead Of Fed Speakers
8abcba45-700a-49c3-88dc-1d1490ef472d,2015-10-12T08:00:00.000+08:00,4,"UPDATE: Chardan's Amusa Highlights Bull vs Bear Case for Esperion, Sees the Latter as 'More Important'"
15661534-902d-46af-b95e-389e25391fe7,2015-10-12T08:00:00.000+08:00,3,"Chardan Capital's Amusa on Esperion Following Evacetrapib Discontinuation: '...by increasing the likelihood of regulatory scrutiny on ETC-1002, the evacetrapib failure reduces the chance ETC-1002 gets there...'"
734b10d8-42e4-4634-b273-a66295297a73,2015-10-12T08:00:00.000+08:00,5,Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives
5e2a6c7d-2d2b-41b2-a11f-eaa4e96f9260,2015-10-12T08:00:00.000+08:00,5,"Regeneron Trading Up To $517/Share Up 2.6% Premarket On Eli Lilly Evacetraqib Development Discontinuation, Watch Regenron Partner Sanofi"
72557701-a618-4ba4-aa3c-8502fec34329,2015-10-12T08:00:00.000+08:00,4,UPDATE: Shares of Esperion Therapeutics Trading Up ~14% Following Discontinuation of Lilly's Evacetrapib
f0f8a7a0-ea4f-45ec-b8cb-15fdade1c5b5,2015-10-12T08:00:00.000+08:00,1,"UPDATE: Shares of Eli Lilly Trading Down ~8%, Now Under $80 at $79.49"
2e280626-793e-43fa-83a4-930c68249e07,2015-10-12T08:00:00.000+08:00,3,TheStreet's Adam Feuerstein Recently Tweets: 'Watch $ESPR' on the Heels of Eli Lilly Discontinuation of Evacetrapib
2d788dda-0463-4ba7-8340-4af15a401795,2015-10-12T08:00:00.000+08:00,5,"Esperion Shares Trading Higher To $28.50/Share, Up 14.9% Premarket Following Eli Lilly Development Discontinuation For Evacetraqib"
6f2dfd24-5399-4efb-8cf1-33ac8057248b,2015-10-12T08:00:00.000+08:00,2,Shares of Eli Lilly Resume; Now Trading Down ~$83
4baecf26-3847-4677-bb4f-9de64d1c5110,2015-10-12T08:00:00.000+08:00,1,UPDATE: Eli Lilly Evacetraqib Devlopment Discontinuation Expected To Result In Q4 Charge Of $90M or $0.05 After-Tax
a3aceb33-6712-405e-9c42-ae6b9a4239d8,2015-10-12T08:00:00.000+08:00,2,"UPDATE: Eli Discontinuing Evacetraqib Development Due To Low Probability Of Study TO Achieve Primary Endpoint Based On Results To Date, Not Being Stopped Due To Safety Findings"
48827e55-cf87-4517-a11a-21b34fed6656,2015-10-12T08:00:00.000+08:00,3,"UPDATE: Lilly Will Terminate Phase 3 Trial of Evacetrapib, Cites Insufficient Efficacy"
021fdfc2-5b81-4721-96f4-6b894c9ab249,2015-10-12T08:00:00.000+08:00,4,Lilly Announces Will Discontinue Development of Evacetrapib
d66286b3-0091-419a-959c-446d368f4172,2015-10-12T08:00:00.000+08:00,1,Watching Volatility In Other Big Pharma Names Amid Eli Lilly Halt
ea8668e0-917e-4ba8-879e-c01064a52657,2015-10-12T08:00:00.000+08:00,2,Eli Lilly Shares Halted News Pending
3a916f3f-bd60-4898-9e8d-00d3ad351206,2015-10-12T08:00:00.000+08:00,3,US Stock Futures Flat Ahead Of Fed Speakers
ee2f195e-9a88-4ea0-8892-5a7283b26a69,2015-10-11T08:00:00.000+08:00,4,"Lilly, Innovent Biologics Expand Their Strategic Alliance"
89f22a7a-de4d-427b-b06f-7f8dc039b009,2015-10-11T08:00:00.000+08:00,4,"Lilly, Innovent Biologics Expand Their Strategic Alliance"
00ea03f4-d0f9-45cc-8e4b-ea75ff541b69,2015-10-09T08:00:00.000+08:00,5,Lilly Acquires Phase III Intranasal Glucagon from Locemia Solutions; Terms Not Disclosed
febbae5e-cc36-4675-8e2e-5bbc76bd2284,2015-10-09T08:00:00.000+08:00,4,Benzinga's Top Upgrades
eaf96bf0-3f09-45d1-a821-fdbe9b542942,2015-10-09T08:00:00.000+08:00,5,Credit Suisse Upgrades Eli Lilly; Likes Jardiance For Short-Term And Pipeline For Long-Term
78ba0afc-7cb4-4d79-b0af-204f042d6719,2015-10-09T08:00:00.000+08:00,3,"Credit Suisse Upgrades Eli Lilly to Outperform, Raises PT to $105.00"
32b43ff8-399d-4c0e-a582-284edde9d316,2015-10-09T08:00:00.000+08:00,4,Lilly Acquires Phase III Intranasal Glucagon from Locemia Solutions; Terms Not Disclosed
25577380-7ab3-4141-a18a-41b3f49a9f07,2015-10-09T08:00:00.000+08:00,5,Benzinga's Top Upgrades
19f3e5d3-f356-4dad-b8eb-126e4bc38dc9,2015-10-09T08:00:00.000+08:00,5,Credit Suisse Upgrades Eli Lilly; Likes Jardiance For Short-Term And Pipeline For Long-Term
1bf5da50-67d1-4b59-a4be-2631f7f33274,2015-10-09T08:00:00.000+08:00,5,"Credit Suisse Upgrades Eli Lilly to Outperform, Raises PT to $105.00"
374edba8-e919-471c-b2cd-045dce974673,2015-10-08T08:00:00.000+08:00,5,Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer
3887f582-8e4e-41ed-8d33-0fa12fb16b0a,2015-10-08T08:00:00.000+08:00,3,Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer
055505d5-bc8b-4bbd-913e-9fc1de82163c,2015-10-02T08:00:00.000+08:00,2,US Insurers Cautious on Lilly's Diabetes Drug Jardiance -Reuters
3c013fb0-a655-4f78-9e12-b7c1a0cad8dd,2015-10-02T08:00:00.000+08:00,1,US Insurers Cautious on Lilly's Diabetes Drug Jardiance -Reuters
219d18c0-866a-4cbb-826a-210c949b6845,2015-10-01T08:00:00.000+08:00,3,10 Defensive Stock Ideas From Bank Of America
df57aca4-c2b7-4431-8a0b-13af7142419f,2015-10-01T08:00:00.000+08:00,3,10 Defensive Stock Ideas From Bank Of America
777d8911-01b9-4b8b-aff8-0d03a7a1405a,2015-09-29T08:00:00.000+08:00,2,Stocks Hitting 52-Week Lows
b37e4fd5-7b84-40f9-aa55-b60b26cc333f,2015-09-29T08:00:00.000+08:00,4,Morning Market Losers
c74d47ea-60bb-47b3-8148-eebcbcae39ff,2015-09-29T08:00:00.000+08:00,5,Eli Lilly and Incyte Announce Positive Top Line Phase 3 Baricitnib Results
a333f8b7-8064-47c4-8c17-701226d05e2d,2015-09-29T08:00:00.000+08:00,2,Stocks Hitting 52-Week Lows
637df5cf-fd0e-41d8-a451-9080ac4f7468,2015-09-29T08:00:00.000+08:00,3,Morning Market Losers
f3620f94-275a-497a-ab33-89c7bf89418e,2015-09-29T08:00:00.000+08:00,4,Eli Lilly and Incyte Announce Positive Top Line Phase 3 Baricitnib Results
4b2bda2c-f7fb-4bdc-bf7c-ce5ea1a4ac9c,2015-09-28T08:00:00.000+08:00,4,"Lilly, Sanofi Reach Settlement Agreement On Insulin Glargine Litigation In U.S.; Lilly To Have Ability To Launch Basaglar In 2016, Further Details Confidential"
0e5e6a1d-5eab-4327-969e-f9aab8371fea,2015-09-28T08:00:00.000+08:00,5,Lilly's CYRAMZA® (ramucirumab) Significantly Improves Progression-Free Survival in Phase II Bladder Cancer Trial
e738a357-8b69-427d-b6e9-01178fa600b6,2015-09-28T08:00:00.000+08:00,4,"Lilly, Sanofi Reach Settlement Agreement On Insulin Glargine Litigation In U.S.; Lilly To Have Ability To Launch Basaglar In 2016, Further Details Confidential"
6dab35c0-b7ee-4be7-8541-6760f75c3fbd,2015-09-28T08:00:00.000+08:00,3,Lilly's CYRAMZA® (ramucirumab) Significantly Improves Progression-Free Survival in Phase II Bladder Cancer Trial
03652f2b-61b0-4fde-9fdc-2c06e5f1a6b6,2015-09-21T08:00:00.000+08:00,4,"Forget The 2016 Election Candidates, CEOs Are Driving Change"
dba90dc8-3e82-4d5f-a289-8edc7cc44749,2015-09-21T08:00:00.000+08:00,2,"Forget The 2016 Election Candidates, CEOs Are Driving Change"
c696e410-6c98-44a4-98cf-5fb4ce289832,2015-09-18T08:00:00.000+08:00,5,Bank Of America: New Eli Lilly Data Is 'Game-Changing'
1e40ca86-0283-4506-8233-fe1fbb85cf2f,2015-09-18T08:00:00.000+08:00,5,"Eli Lilly's 'Home Run' Is Jardiance, Says Morgan Stanley"
13cd6b7a-2df0-4e46-9a60-c34f87608d23,2015-09-18T08:00:00.000+08:00,5,Bank Of America: New Eli Lilly Data Is 'Game-Changing'
28d50587-3f00-4033-8fcf-40191af617f3,2015-09-18T08:00:00.000+08:00,5,"Eli Lilly's 'Home Run' Is Jardiance, Says Morgan Stanley"
02a9f0be-f919-4e4f-b8f6-02bd80137dd7,2015-09-17T08:00:00.000+08:00,5,"Boehringer Ingelheim Pharma, Eli Lilly Announce Jardiance Significantly Reduced Risk of Combined Endpoint of CV Death, Non-Fatal Heart Attack, Stroke"
00328884-4d9e-4c54-a9f1-0222cf068d9d,2015-09-17T08:00:00.000+08:00,4,"Boehringer Ingelheim Pharma, Eli Lilly Announce Jardiance Significantly Reduced Risk of Combined Endpoint of CV Death, Non-Fatal Heart Attack, Stroke"
96dd0952-1dda-4949-a450-fdaecd176ae7,2015-09-15T08:00:00.000+08:00,3,Eli Lilly Says Abasaglar Showed Similar Safety to Lantus - Reuters
460be15a-53a3-419d-9748-e940afd484a5,2015-09-15T08:00:00.000+08:00,3,Eli Lilly Says Abasaglar Showed Similar Safety to Lantus - Reuters
8555a7e9-a3e1-4c9a-b8aa-2df8e1dd65af,2015-08-27T08:00:00.000+08:00,5,U.S. FDA approves Synjardy tablets for adults with type 2 diabetes
2cd3d91a-6079-4bc0-a227-ae831630a729,2015-08-27T08:00:00.000+08:00,4,Benzinga's Top Initiations
01ff8a2a-5844-4ad0-9b76-34ea2e895c8c,2015-08-27T08:00:00.000+08:00,5,"Berenberg Initiates Coverage on Eli Lilly at Buy, Announces $100.00 PT"
f594451b-eb01-4c7a-88e0-f3108a95893e,2015-08-27T08:00:00.000+08:00,4,U.S. FDA approves Synjardy tablets for adults with type 2 diabetes
2a1b8481-6fd9-4f91-bf99-8a048313f974,2015-08-27T08:00:00.000+08:00,3,Benzinga's Top Initiations
6bea4d8b-9ac8-4c8c-9435-3ffb0cc0e573,2015-08-27T08:00:00.000+08:00,5,"Berenberg Initiates Coverage on Eli Lilly at Buy, Announces $100.00 PT"
34a39114-aec5-4f49-887e-b8925f32d454,2015-08-25T08:00:00.000+08:00,5,U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent
913c0a2e-7f29-4303-a34b-fe90887b1da0,2015-08-25T08:00:00.000+08:00,5,U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent
bdf6ea9a-ae4b-4e41-8400-e6dc23a3e52e,2015-08-20T08:00:00.000+08:00,1,Benzinga's Volume Movers
3d1a45d3-9c73-4eab-9355-15395b0b367c,2015-08-20T08:00:00.000+08:00,4,Lily +3% on Positive Jardiance Results
1ad5276a-c1f5-407a-aa52-42580b608331,2015-08-20T08:00:00.000+08:00,4,Jardiance demonstrated cardiovascular risk reduction in people with type 2 diabetes at high risk for CV events
4c850fea-99f7-4d70-b7d4-a1925bf35c33,2015-08-20T08:00:00.000+08:00,1,Benzinga's Volume Movers
d22d6f16-a1a5-44da-8248-4e24e7c735ab,2015-08-20T08:00:00.000+08:00,4,Lily +3% on Positive Jardiance Results
57791279-1bc6-411e-b32f-70dac2a63e48,2015-08-20T08:00:00.000+08:00,5,Jardiance demonstrated cardiovascular risk reduction in people with type 2 diabetes at high risk for CV events
8f648ddc-24de-4e09-bd58-cda3b749a7c8,2015-08-16T08:00:00.000+08:00,3,Eli Lilly CEO: Recent Events In China Don't Change Much
63dfbebd-eb5f-463c-bca8-7dd965d9ac12,2015-08-16T08:00:00.000+08:00,3,Eli Lilly CEO: Recent Events In China Don't Change Much
a3da1676-08e2-49ef-8d7e-91b080cc60a2,2015-08-15T08:00:00.000+08:00,4,Here's A Look At Eli Lilly's Future Pipeline
d5ac9aec-93df-479d-bd78-e2493e3b91a1,2015-08-15T08:00:00.000+08:00,2,Here's A Look At Eli Lilly's Future Pipeline
161c1861-0a2e-4e3d-9afa-3d7d65ed0960,2015-07-27T08:00:00.000+08:00,1,Lilly Issues Update on Evacetrapib Phase 3 Trial: Last Patient Visit in ACCELERATE Expecting Jul. '16
53d91f29-4617-466b-a9d6-c069cfa13ee4,2015-07-27T08:00:00.000+08:00,3,Lilly Issues Update on Evacetrapib Phase 3 Trial: Last Patient Visit in ACCELERATE Expecting Jul. '16
e50f3132-cec3-49e5-b246-1173196f1c07,2015-07-23T08:00:00.000+08:00,4,"Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls"
5c82699d-c08d-4ed5-be90-6f662dd52017,2015-07-23T08:00:00.000+08:00,5,Eli Lilly CEO Explains The Reasons Behind The $0.16 EPS Beat
55f8ecbf-48c5-499c-ae2c-bce3342bf227,2015-07-23T08:00:00.000+08:00,2,Lilly CEO Says Bubble in Prices of Smaller Biotech Cos -Reuters
eda1b785-2baf-412e-b8f6-d323438cfa7a,2015-07-23T08:00:00.000+08:00,3,Eli Lilly Sees FY15 Adj. EPS $3.20-$3.30 vs $3.18 Est.
015b9c84-6bb2-4c88-a222-2a4bfb6c32f2,2015-07-23T08:00:00.000+08:00,3,"Eli Lilly Reports Q1 Adj. EPS $0.90 Vs Est $0.74, Sales $4.98B Vs Est $4.91B"
b94b6f38-2273-4348-9152-9726a81ff89a,2015-07-23T08:00:00.000+08:00,3,"Earnings Scheduled For July 23, 2015"
7c5d6509-c58a-4783-99ef-40daa60843df,2015-07-23T08:00:00.000+08:00,3,"Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls"
dcf468c4-aa99-40a6-916b-680cc456b124,2015-07-23T08:00:00.000+08:00,3,Eli Lilly CEO Explains The Reasons Behind The $0.16 EPS Beat
381a2287-07e5-4c9c-9d24-2174ec476533,2015-07-23T08:00:00.000+08:00,2,Lilly CEO Says Bubble in Prices of Smaller Biotech Cos -Reuters
eb9e58fd-4f0a-4373-a514-05747a07ef1c,2015-07-23T08:00:00.000+08:00,4,Eli Lilly Sees FY15 Adj. EPS $3.20-$3.30 vs $3.18 Est.
c0fd0eb9-b07a-4d07-b243-500df453d2f3,2015-07-23T08:00:00.000+08:00,4,"Eli Lilly Reports Q1 Adj. EPS $0.90 Vs Est $0.74, Sales $4.98B Vs Est $4.91B"
4411bfef-5956-482a-a9e6-ee3d34edd36b,2015-07-23T08:00:00.000+08:00,1,"Earnings Scheduled For July 23, 2015"
c35b9a74-704b-4411-b1a3-1aa762ee0372,2015-07-22T08:00:00.000+08:00,2,What's Coming For Large-Cap Pharma Stocks This Earnings Season?
e17dfac6-2996-411e-aa36-3806d07c53c2,2015-07-22T08:00:00.000+08:00,3,"Did McDonald's, Caterpillar & Amazon Lose Sizzle To Strong Dollar?"
fcf7adb2-6132-4123-8ca7-d616343f6a6a,2015-07-22T08:00:00.000+08:00,4,Evercore ISI's Mark Schoenebaum: New Eli Lilly Data 'Incrementally Positive'
091e979e-7c06-4470-b487-01c793242edb,2015-07-22T08:00:00.000+08:00,5,Data Using New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease
5758c598-eefc-449c-9bf2-ee41bf185cd1,2015-07-22T08:00:00.000+08:00,5,Data Utilizing New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease
139ab76a-3eb1-413a-b550-ff60708de547,2015-07-22T08:00:00.000+08:00,2,What's Coming For Large-Cap Pharma Stocks This Earnings Season?
7cb251f7-28ae-47f8-8c97-4accac1cae81,2015-07-22T08:00:00.000+08:00,3,"Did McDonald's, Caterpillar & Amazon Lose Sizzle To Strong Dollar?"
5af96c2d-87ca-41f6-a147-c3cef8bfa390,2015-07-22T08:00:00.000+08:00,4,Evercore ISI's Mark Schoenebaum: New Eli Lilly Data 'Incrementally Positive'
2ff9a8d3-220d-40b7-b923-5a03f87b2fd2,2015-07-22T08:00:00.000+08:00,5,Data Using New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease
94700cf3-966e-4a4e-acef-b74679c9c6c6,2015-07-22T08:00:00.000+08:00,5,Data Utilizing New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease
b135973a-012f-44ca-bfe2-95359bbab1b6,2015-07-21T08:00:00.000+08:00,5,New Alzheimer's Trials Could Produce The Most Important Drugs In History
f6ae9402-b829-43f9-bdbb-79b52fbeeaad,2015-07-21T08:00:00.000+08:00,4,Fast Money Picks For July 21
3f614129-0c81-4f7f-beaf-d05c0f9b6c09,2015-07-21T08:00:00.000+08:00,5,New Alzheimer's Trials Could Produce The Most Important Drugs In History
fbfba442-8640-4eac-9e91-e2073674e384,2015-07-21T08:00:00.000+08:00,4,Fast Money Picks For July 21
713eeef7-5a52-433e-9df7-2a9e5445f0e5,2015-07-20T08:00:00.000+08:00,5,Has Eli Lilly Found A Cure For Alzheimer's?
d6df46c1-4e65-43bc-afed-2f613e0de848,2015-07-20T08:00:00.000+08:00,2,"Stifel, JMP Securities Discuss What To Expect From AAIC Conference"
061743f9-1b38-4284-bcda-d04792f97151,2015-07-20T08:00:00.000+08:00,3,Has Eli Lilly Found A Cure For Alzheimer's?
1de3e294-37e8-45ab-bd71-87e7bc2483a0,2015-07-20T08:00:00.000+08:00,3,"Stifel, JMP Securities Discuss What To Expect From AAIC Conference"
d05492c2-cceb-42b9-8fad-7663312d8eca,2015-07-15T08:00:00.000+08:00,4,Benzinga's Top Downgrades
2eb10dbe-f816-445f-85f8-f0bc01087428,2015-07-15T08:00:00.000+08:00,1,"Morgan Stanley Cuts Eli Lilly: Says Downgraded Not Related to Negative Call on Alzheimer's Data, Sees Current Share Price Factoring 'in pipelineenthusiasm for two blockbuster candidates:' Solanezumab, Evacetrapib"
88896b71-6b97-4a96-ace3-2e6b883edc53,2015-07-15T08:00:00.000+08:00,2,Morgan Stanley Downgrades Eli Lilly to Equalweight
1fbbee20-6d49-4405-9a1b-c69342206bae,2015-07-15T08:00:00.000+08:00,1,Benzinga's Top Downgrades
b6b63c25-5bb9-42ad-9f99-b087514966cd,2015-07-15T08:00:00.000+08:00,3,"Morgan Stanley Cuts Eli Lilly: Says Downgraded Not Related to Negative Call on Alzheimer's Data, Sees Current Share Price Factoring 'in pipelineenthusiasm for two blockbuster candidates:' Solanezumab, Evacetrapib"
72116bbd-3fa6-4162-8033-3348342117f1,2015-07-15T08:00:00.000+08:00,4,Morgan Stanley Downgrades Eli Lilly to Equalweight
e6a48f64-f369-47ad-9124-83a5952aff0d,2015-07-13T08:00:00.000+08:00,5,Stocks Hitting 52-Week Highs
11039c9a-d581-4210-af4d-f9f1bca9a8a8,2015-07-13T08:00:00.000+08:00,4,Stocks Hitting 52-Week Highs
c0e49926-ca67-417c-b0c6-1e898876bb11,2015-07-09T08:00:00.000+08:00,3,"Eli Lilly Issues Statement Regarding FDA Panel Review of Necitumumab: 'Encouraged' by Committee's Constructuive Discussion, Working Closely with FDA to Continue Review"
50d89a31-132f-4643-8607-a0351821e5aa,2015-07-09T08:00:00.000+08:00,3,Fast Money Picks For July 9
b9d92e7b-6497-4735-bff0-4d1a9651d334,2015-07-09T08:00:00.000+08:00,4,"Eli Lilly Issues Statement Regarding FDA Panel Review of Necitumumab: 'Encouraged' by Committee's Constructuive Discussion, Working Closely with FDA to Continue Review"
217264df-d45d-4366-8975-f348e1373cb4,2015-07-09T08:00:00.000+08:00,4,Fast Money Picks For July 9
8827b004-7a1b-4eba-899a-b4f56fb17be1,2015-07-07T08:00:00.000+08:00,2,Fast Money Picks For July 7
78b1d103-b97f-442d-ba15-27abdca19971,2015-07-07T08:00:00.000+08:00,2,Fast Money Picks For July 7
766a4d90-526f-467e-a556-ee16fdb15582,2015-07-03T08:00:00.000+08:00,4,"AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors"
a57ae61d-e774-4d69-8d8a-974c3ef629dc,2015-07-03T08:00:00.000+08:00,4,"AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors"
c12c0ec1-69b7-4d56-9d5c-8827a7593f61,2015-06-29T08:00:00.000+08:00,3,"Lilly, Immunocore Report Immunotherapy-based Clinical Trial Collaboration in Melanoma"
080d9f66-5c56-493a-bea2-84e121ca5b20,2015-06-29T08:00:00.000+08:00,5,"Lilly, Immunocore Report Immunotherapy-based Clinical Trial Collaboration in Melanoma"
96e047f6-eea2-43e4-bc58-3fa7929b9e7a,2015-06-25T08:00:00.000+08:00,5,Eli Lilly Shares Go Parabolic
51f33bf9-1ca3-406b-9cd4-f0b986f0fa7b,2015-06-25T08:00:00.000+08:00,4,Bank of America Upgrades Eli Lilly to Buy
60f79290-308c-412f-8284-25141ea66120,2015-06-25T08:00:00.000+08:00,5,\Eli Lilly Announces UK Court Has Ruled in Favor of Co. in Alimta Vitamin Regimen Patent Suit
c52417ca-09cd-4729-ad21-b427581dcc25,2015-06-25T08:00:00.000+08:00,5,Eli Lilly Shares Go Parabolic
efa500c0-3ad5-45be-8f08-3973a43a5ddc,2015-06-25T08:00:00.000+08:00,5,Bank of America Upgrades Eli Lilly to Buy
b830c806-7913-4276-95f3-96ce286b5c68,2015-06-25T08:00:00.000+08:00,4,\Eli Lilly Announces UK Court Has Ruled in Favor of Co. in Alimta Vitamin Regimen Patent Suit
8a6d19cb-90ea-4351-afa0-98de8adb586b,2015-06-24T08:00:00.000+08:00,3,"Sales Of This Eli Lilly Drug Could Nearly Double Wall St. Consensus In 2020, SunTrust Predicts"
fd23f859-8f32-4a0c-b94c-300e9eb942c2,2015-06-24T08:00:00.000+08:00,4,"Sales Of This Eli Lilly Drug Could Nearly Double Wall St. Consensus In 2020, SunTrust Predicts"
9f52b962-18d1-4385-9eed-03823ae46e7d,2015-06-22T08:00:00.000+08:00,5,"Ken Langone's Top Stock Picks: Schlumberger, Eli Lilly And Facebook"
f10a9810-701b-4dfc-96b9-cf5e3f07a366,2015-06-22T08:00:00.000+08:00,2,"Ken Langone's Top Stock Picks: Schlumberger, Eli Lilly And Facebook"
d1bace50-ed38-4870-81a5-9b1f304f494d,2015-06-19T08:00:00.000+08:00,4,CYRAMZA Hepatocellular Carcinoma Data Published by The Lancet Oncology
a015a48b-62ce-4587-bb27-b19c9caf8c28,2015-06-19T08:00:00.000+08:00,4,CYRAMZA Hepatocellular Carcinoma Data Published by The Lancet Oncology
f0479d7e-84bd-44a8-b205-aa1a01ff6fe5,2015-06-18T08:00:00.000+08:00,4,Eli Lilly Price Target Hiked To $92 At Argus; Here's Why
45712dce-e057-450f-b76c-bca26e4c23d5,2015-06-18T08:00:00.000+08:00,5,Eli Lilly Price Target Hiked To $92 At Argus; Here's Why
78ccc54d-3238-41d6-9076-9a633ec7451c,2015-06-17T08:00:00.000+08:00,4,The Note Moving Pharma Giants Today
a500c8a5-018e-418c-8fd8-21064250bf4c,2015-06-17T08:00:00.000+08:00,5,Lilly's investigational migraine prevention medicine met primary endpoint in a Phase 2b study
cb5c0e78-50f1-4b7b-a474-7c048951a405,2015-06-17T08:00:00.000+08:00,3,Benzinga's Top Initiations
eba3de6e-cbe0-46f3-9bc0-344c5f8c01ca,2015-06-17T08:00:00.000+08:00,4,"Eli Lilly, Dana-Farber Announce Research Collaboration For New Medicines To Fight Cancer"
cb6c8ae8-9dcf-4050-971f-862514a646dd,2015-06-17T08:00:00.000+08:00,5,"Eli Lilly, Sara Cannon Research Institute Enter Collaboration To Develop Investigational Oncology Therapy"
fc71487b-efdf-4a65-943f-4bcd895ff7d4,2015-06-17T08:00:00.000+08:00,5,"Piper Jaffray Initiates Coverage on Eli Lilly at Overweight, Announces $97.00 PT"
d2043bea-ebac-4bfb-9c77-19b1a6b9667c,2015-06-17T08:00:00.000+08:00,4,The Note Moving Pharma Giants Today
d939d923-cf8a-4dfd-8693-618e6f942f27,2015-06-17T08:00:00.000+08:00,3,Lilly's investigational migraine prevention medicine met primary endpoint in a Phase 2b study
b6dbdc54-256b-43c0-9d0e-b21e51ac5526,2015-06-17T08:00:00.000+08:00,4,Benzinga's Top Initiations
44ea0898-cbca-4a68-b1b0-d1ca5ac0535b,2015-06-17T08:00:00.000+08:00,5,"Eli Lilly, Dana-Farber Announce Research Collaboration For New Medicines To Fight Cancer"
b5917c21-7c04-4676-a892-5ed1b8e6de0d,2015-06-17T08:00:00.000+08:00,4,"Eli Lilly, Sara Cannon Research Institute Enter Collaboration To Develop Investigational Oncology Therapy"
561db965-d450-476a-8df9-e7587832e6bd,2015-06-17T08:00:00.000+08:00,5,"Piper Jaffray Initiates Coverage on Eli Lilly at Overweight, Announces $97.00 PT"
5fccc51a-fe44-4947-be79-a3c811688b34,2015-06-16T08:00:00.000+08:00,3,New Report: Abbvie Is Jefferies' Top Global Pharma Stock
1be9bb10-a426-4d3a-9ffc-ef82caa64909,2015-06-16T08:00:00.000+08:00,2,New Report: Abbvie Is Jefferies' Top Global Pharma Stock
149f039c-eed3-40c4-b655-d6be7a32dcb0,2015-06-12T08:00:00.000+08:00,1,UPDATE: Alzheimers Association Says Release of Data Under Embargo to Conference Participants Might have Influenced Lily Share Price
9afe5624-0fba-40ea-ba9b-6ddfd4ff5c46,2015-06-12T08:00:00.000+08:00,2,Alzheimer's Group Says May Not Offer Early Look At Highly Sought Data On Lilly Drug -Reuters
0d2e290f-1ffe-461d-b0c1-6f6d928d61bb,2015-06-12T08:00:00.000+08:00,3,UPDATE: Alzheimers Association Says Release of Data Under Embargo to Conference Participants Might have Influenced Lily Share Price
b7fe0bcf-261f-4aa4-8c7f-34fdc440c2df,2015-06-12T08:00:00.000+08:00,3,Alzheimer's Group Says May Not Offer Early Look At Highly Sought Data On Lilly Drug -Reuters
23e58c1f-0414-43fe-a167-7551de18ec08,2015-06-10T08:00:00.000+08:00,4,"Studies Report Psoriasis Patients Achieved Significant Levels of Skin Clearance, Improved Quality of Life after 12 Weeks of Ixekizumab Treatment"
40dddda0-663c-4400-bce7-4ae772c7a8f5,2015-06-10T08:00:00.000+08:00,5,Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis
a5d9b6ee-964a-4b12-be93-c82eda3e7e8d,2015-06-10T08:00:00.000+08:00,5,Fast Money Picks For June 10
f7fdd0c9-018a-48e9-836e-de47b738bd5a,2015-06-10T08:00:00.000+08:00,5,"Studies Report Psoriasis Patients Achieved Significant Levels of Skin Clearance, Improved Quality of Life after 12 Weeks of Ixekizumab Treatment"
986e522f-b44d-4110-8d7a-ac6c6ea30c5e,2015-06-10T08:00:00.000+08:00,3,Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis
94cfb22e-2c0b-4ab6-a9e0-2269c15dc362,2015-06-10T08:00:00.000+08:00,4,Fast Money Picks For June 10
5494855e-07e2-4dc1-8f06-795f6f632767,2015-06-09T08:00:00.000+08:00,5,Lily Shares Spike to All-Time High
2b9f2b43-54ce-4206-9bef-15de8b70a0f8,2015-06-09T08:00:00.000+08:00,5,Lily Shares Spike to High; Weekly Jun 12 $79.5 Call Active
fcb53e93-8cb7-4d5a-8ae6-84dc6ae36967,2015-06-09T08:00:00.000+08:00,5,Lily Shares Spike to All-Time High
0de17005-5fab-4b95-8a51-cc60dc0b330f,2015-06-09T08:00:00.000+08:00,5,Lily Shares Spike to High; Weekly Jun 12 $79.5 Call Active
356ab812-af5e-4004-a8f6-0d685d6e8b59,2015-06-08T08:00:00.000+08:00,4,"This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says"
a2322cc2-4c5e-4b37-8e7b-71861ce5ffde,2015-06-08T08:00:00.000+08:00,4,New Data Show Enhanced Effects of Lilly's Once-Weekly Trulicity (dulaglutide) to Lantus (insulin glargine) in Patients with Type 2 Diabetes
b4fb2476-eacc-4262-981c-3f78f3020c42,2015-06-08T08:00:00.000+08:00,5,"This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says"
188bf340-1a7e-4888-a2ef-c374b3025b96,2015-06-08T08:00:00.000+08:00,4,New Data Show Enhanced Effects of Lilly's Once-Weekly Trulicity (dulaglutide) to Lantus (insulin glargine) in Patients with Type 2 Diabetes
b66adbf6-36fd-4655-9928-146e149941a7,2015-06-07T08:00:00.000+08:00,4,Lily Presents Study Indicating Once-Weekly Trulicity More Effective than Once-Daily Victoza in Japanese Patients after 52 Weeks
06a0eb2e-aad0-420f-84eb-3e550d02af92,2015-06-07T08:00:00.000+08:00,4,Lilly's Basal Insulin Peglispro Shows Superiority to Glargine in Reducing HbA1c in People with Type 2 Diabetes
7271d07e-146f-40eb-b473-0e7b7efce872,2015-06-07T08:00:00.000+08:00,5,Lilly's Basal Insulin Peglispro Studies Demonstrate Superiority to Glargine in People with Type 1 Diabetes
6fc366c6-b4e0-4fdd-b467-a09cff05c049,2015-06-07T08:00:00.000+08:00,5,Lily Presents Study Indicating Once-Weekly Trulicity More Effective than Once-Daily Victoza in Japanese Patients after 52 Weeks
248ebb60-f3b6-4fe4-bd82-4dbcdc8d3c8a,2015-06-07T08:00:00.000+08:00,5,Lilly's Basal Insulin Peglispro Shows Superiority to Glargine in Reducing HbA1c in People with Type 2 Diabetes
24ae536f-2e71-4965-b379-f034c44b5809,2015-06-07T08:00:00.000+08:00,5,Lilly's Basal Insulin Peglispro Studies Demonstrate Superiority to Glargine in People with Type 1 Diabetes
37788992-6e75-48c4-8f8e-f5be9be96eca,2015-06-04T08:00:00.000+08:00,4,Lilly to Report Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology
65f727b5-65fb-4d82-b157-025cda1ef445,2015-06-04T08:00:00.000+08:00,5,Lilly to Report Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology
aa35f841-4995-4d7f-b7cb-dce309ded7c5,2015-06-01T08:00:00.000+08:00,4,16 Biotech Stocks Moving Off The ASCO Conference
bcd23fd0-0c74-44b2-9fde-0b64f8702315,2015-06-01T08:00:00.000+08:00,4,16 Biotech Stocks Moving Off The ASCO Conference
6845b0dc-7635-4da3-ac69-c1562aa4b5f9,2015-05-29T08:00:00.000+08:00,5,"Lilly, AstraZeneca to Partner on Immuno-Oncology Combination Clinical Trial in Solid Tumors"
6bca1a0e-99f9-42ac-bb6f-a99e175bdcf6,2015-05-29T08:00:00.000+08:00,5,"Lilly, AstraZeneca to Partner on Immuno-Oncology Combination Clinical Trial in Solid Tumors"
71b0f4df-2f60-4229-898f-a1db8fe8204e,2015-05-28T08:00:00.000+08:00,5,Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data
86458945-18e1-48d8-b9a1-f8c1145007b8,2015-05-28T08:00:00.000+08:00,2,Eli Lilly Reports Results Of Cash Tender Offer
cb5f0095-bedf-43c7-9ac9-68d895902525,2015-05-28T08:00:00.000+08:00,4,Eli Lilly Reports Will Present CYRAMZA Data at ASCO Meeting: Will Submit to Japanese Regulatory Authorities
d22dcd4e-d9b0-402a-9fef-5f9ffc7af2ed,2015-05-28T08:00:00.000+08:00,3,Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data
1948532a-2994-4e65-a3ab-c2c7fef8af52,2015-05-28T08:00:00.000+08:00,2,Eli Lilly Reports Results Of Cash Tender Offer
59b60e61-32da-4fe1-bd0d-9869b943be98,2015-05-28T08:00:00.000+08:00,4,Eli Lilly Reports Will Present CYRAMZA Data at ASCO Meeting: Will Submit to Japanese Regulatory Authorities
e716fdc3-eaf9-4341-8160-516526b6a89c,2015-05-27T08:00:00.000+08:00,4,Eli Lilly Announces FDA Approves Humalog
bde3b79b-6a8c-4bc6-bc75-a8b1e3606471,2015-05-27T08:00:00.000+08:00,4,Lilly to Present New Clinical Data at 75th American Diabetes Association Scientific Sessions
b5c46841-8b23-41f6-a556-66414d64fc96,2015-05-27T08:00:00.000+08:00,4,Eli Lilly Announces FDA Approves Humalog
7c132ec6-81ec-4a61-b4dd-4c5071cfcaa9,2015-05-27T08:00:00.000+08:00,4,Lilly to Present New Clinical Data at 75th American Diabetes Association Scientific Sessions
2f7caeed-7954-470a-ae38-8c4636f0a66b,2015-05-14T08:00:00.000+08:00,3,"Lilly, Sanford-Burnham Collaborate to Investigate Immunological Therapies"
efd9d5d4-2fc9-4ef9-9917-d2145cdb3938,2015-05-14T08:00:00.000+08:00,4,"Lilly, Sanford-Burnham Collaborate to Investigate Immunological Therapies"
1a1b6a9f-87e1-4a81-94d2-199cd6ba3d78,2015-05-12T08:00:00.000+08:00,3,Lilly Announces Cash Tender Offer for Up to $1.6Aggregate Principal Amount of Its Outstanding Debt Securities and the Redemption of Its 6.57% Notes due 2016
45cda4eb-2567-44fa-8a98-4565b61979ee,2015-05-12T08:00:00.000+08:00,4,Lilly Announces Cash Tender Offer for Up to $1.6Aggregate Principal Amount of Its Outstanding Debt Securities and the Redemption of Its 6.57% Notes due 2016
c66d7147-dfc3-4b04-bf39-abf1891c0d5a,2015-05-11T08:00:00.000+08:00,4,"Lilly, BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies"
72bc89eb-b121-449f-b91d-cc1583a48445,2015-05-11T08:00:00.000+08:00,5,"Lilly, BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies"
190aa129-e9d7-416b-9195-2cea0621059f,2015-05-05T08:00:00.000+08:00,2,"Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers"
6cf1eb36-f0b7-48a2-a5f5-0eea6342ad2a,2015-05-05T08:00:00.000+08:00,2,"Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers"
e168963f-f940-4e7a-b7f1-a1d4e15e9b9b,2015-05-01T08:00:00.000+08:00,3,Shares Of Lilly Spike Lower Momentarily To $71.25 Before Rebounding To $73
d3e3ef72-4a57-4a41-924e-dd2f31dbe9cd,2015-05-01T08:00:00.000+08:00,4,Hearing Unconfirmed Market Chatter of Potential Merck Bid for Lilly
7e066ca1-18d9-44ae-a744-6d8a54fe27ae,2015-05-01T08:00:00.000+08:00,3,Shares Of Lilly Spike Lower Momentarily To $71.25 Before Rebounding To $73
01b2ba19-b413-4598-9e38-51a0bbc6224e,2015-05-01T08:00:00.000+08:00,4,Hearing Unconfirmed Market Chatter of Potential Merck Bid for Lilly
e1c54b82-5e25-4ef3-b694-1c6146d6a770,2015-04-29T08:00:00.000+08:00,3,Benzinga's Top Upgrades
fa63d368-2f58-4eb9-a8e6-e7415ad6174f,2015-04-29T08:00:00.000+08:00,5,Citigroup Upgrades Eli Lilly To Buy
576ef5bb-8252-4dc9-8f53-f5e18750c6d9,2015-04-29T08:00:00.000+08:00,4,IPO Outlook: CoLucid Offers Hope For Migraine Sufferers
cd331644-1226-4fc0-b453-1742f0fd300f,2015-04-29T08:00:00.000+08:00,5,Citigroup Upgrades Eli Lilly to Buy
bf7ddecf-da65-4ecc-a61e-f1697ff8690b,2015-04-29T08:00:00.000+08:00,5,Benzinga's Top Upgrades
13f7e630-06a5-420a-adff-7827d874d7a6,2015-04-29T08:00:00.000+08:00,5,Citigroup Upgrades Eli Lilly To Buy
3f1bb87c-95c9-476f-9843-8d96b3949ee6,2015-04-29T08:00:00.000+08:00,3,IPO Outlook: CoLucid Offers Hope For Migraine Sufferers
1f3faaa3-02ca-4073-bb59-1fc5548fc209,2015-04-29T08:00:00.000+08:00,4,Citigroup Upgrades Eli Lilly to Buy
3432622c-eea0-4fb8-8df7-6e82dd2760ba,2015-04-28T08:00:00.000+08:00,5,BofA Sees Many Catalysts On Eli Lilly's Horizon
e9806a13-ac23-43f7-b4b7-87c7b0f3d1c2,2015-04-28T08:00:00.000+08:00,4,BofA Sees Many Catalysts On Eli Lilly's Horizon
79b95145-196c-475a-8501-408e81a27690,2015-04-24T08:00:00.000+08:00,5,Lilly's CYRAMZA Receives Approval For Use With FOLFIRI In Second-Line Treatment Of Metastatic Colorectal Cancer
06754ca5-7685-446b-ad74-6cc0aa5111d2,2015-04-24T08:00:00.000+08:00,3,Eli Lilly CFO: Solid Underlying Performance Despite FX Headwind
89e562d9-321a-42ae-9ecc-d0d07a2457fc,2015-04-24T08:00:00.000+08:00,4,BMO's Updated Eli Lilly Model Following Earnings
7740ed86-64b9-45c9-96ba-2e18c0512c0b,2015-04-24T08:00:00.000+08:00,5,Lilly's CYRAMZA Receives Approval For Use With FOLFIRI In Second-Line Treatment Of Metastatic Colorectal Cancer
0add9186-0d48-4fc5-839f-f4ad3043d960,2015-04-24T08:00:00.000+08:00,3,Eli Lilly CFO: Solid Underlying Performance Despite FX Headwind
8f1878b6-8b04-4d01-b1af-2a6d9adb80a1,2015-04-24T08:00:00.000+08:00,2,BMO's Updated Eli Lilly Model Following Earnings
3c136d3a-67e8-4bcf-abf6-920d4b19fd95,2015-04-23T08:00:00.000+08:00,1,"US Stock Futures Down Ahead Of Earnings, Economic Data"
2d4efe8d-e972-4be9-8fa6-ee88eca1a65e,2015-04-23T08:00:00.000+08:00,4,Eli Lilly Tops Q1 Views
e0370c0f-5e6a-4ec3-8f47-cbcb4235763f,2015-04-23T08:00:00.000+08:00,5,Lilly Q1 EPS $4.65B vs $4.62B est
4309382e-e9b4-4fd8-8584-d749323acfc2,2015-04-23T08:00:00.000+08:00,4,Lilly Confirms FY Guidance
4dd7e2cb-5840-4f1d-9957-3081574d07c0,2015-04-23T08:00:00.000+08:00,3,Lilly Q1 EPS $0.87 vs $0.77 est
aeb877e3-d10a-4b0b-8ed4-195b54f064f3,2015-04-23T08:00:00.000+08:00,2,"Earnings Scheduled For April 23, 2015"
90e3a1af-7f1c-48ae-b26b-f984053ef19a,2015-04-23T08:00:00.000+08:00,1,"US Stock Futures Down Ahead Of Earnings, Economic Data"
afe0e0bb-21cf-4c24-9bd3-b54959543902,2015-04-23T08:00:00.000+08:00,4,Eli Lilly Tops Q1 Views
43315814-6c02-4527-9227-6cd240ef0ce9,2015-04-23T08:00:00.000+08:00,4,Lilly Q1 EPS $4.65B vs $4.62B est
5199ea13-0d71-437f-aaae-d69a799655ec,2015-04-23T08:00:00.000+08:00,3,Lilly Confirms FY Guidance
9f1e80bc-3738-4327-8d7c-8871c61a67d1,2015-04-23T08:00:00.000+08:00,2,Lilly Q1 EPS $0.87 vs $0.77 est
b55c2b4b-c43c-468a-8800-dd5a549d6292,2015-04-23T08:00:00.000+08:00,1,"Earnings Scheduled For April 23, 2015"
44691054-b0e1-4ebc-9cbf-dc589558a13c,2015-04-22T08:00:00.000+08:00,4,Eli Lilly Partner Deciphera Pharma Announces Data Highlighting Kinase Inhibitor Pipeline at AACR Meeting
04813708-9d6b-49cc-aa3d-898be058b9bb,2015-04-22T08:00:00.000+08:00,4,Eli Lilly Partner Deciphera Pharma Announces Data Highlighting Kinase Inhibitor Pipeline at AACR Meeting
47d2d60a-0c39-4d6a-a8ff-d34d96c032ca,2015-04-20T08:00:00.000+08:00,5,Lilly's Ixekizumab Meets Primary Endpoint in a Phase 3 Study Investigating Treatment of Psoriatic Arthritis
da6a2aa0-96a6-4b16-9cea-4cf60fd3359f,2015-04-20T08:00:00.000+08:00,5,Lilly's Ixekizumab Meets Primary Endpoint in a Phase 3 Study Investigating Treatment of Psoriatic Arthritis
c28e52d2-4cdf-4b04-b731-d90b85102d2a,2015-04-16T08:00:00.000+08:00,3,"Lilly, Bristol-Myers Squibb Restructure Erbitux Pact In North America; Lilly Gets Full Commercialization Rights While Bristol-Myers Gets Tiered Royalties On Product Sales"
1e5f80a7-7fa9-4cbc-8d55-f383918f62e4,2015-04-16T08:00:00.000+08:00,3,"Lilly, Bristol-Myers Squibb Restructure Erbitux Pact In North America; Lilly Gets Full Commercialization Rights While Bristol-Myers Gets Tiered Royalties On Product Sales"
e15a08d8-8100-4b5d-9f07-f62792a68ff7,2015-04-15T08:00:00.000+08:00,2,SunTrust's Latest Comments On Merck
db9dad40-b658-4a52-9274-b43bb7cd9a48,2015-04-15T08:00:00.000+08:00,2,SunTrust's Latest Comments On Merck
8f903df3-0205-4869-abfa-cdf71330dc71,2015-04-14T08:00:00.000+08:00,3,Morgan Stanley's Major Pharma Q1 Preview
6e18de90-a86f-488f-8b69-f24905021601,2015-04-14T08:00:00.000+08:00,3,Morgan Stanley's Major Pharma Q1 Preview
36c796b7-7306-4d35-854f-7b4a0f752b18,2015-04-13T08:00:00.000+08:00,4,7 Trends Drug Investors Should Know
fb75c7b7-3ed8-4509-ad67-239ce1c111c0,2015-04-13T08:00:00.000+08:00,4,7 Trends Drug Investors Should Know
9e730272-db27-4214-91a2-1de274769d0e,2015-04-01T08:00:00.000+08:00,3,8 Companies That Are Fighting Indiana's 'Religious Freedom' Law
09d73bbc-bc75-4306-ad57-85971d1119d0,2015-04-01T08:00:00.000+08:00,3,8 Companies That Are Fighting Indiana's 'Religious Freedom' Law
7eef48d8-f7df-4b53-8091-3515ad9c2b97,2015-03-27T08:00:00.000+08:00,5,"EMA Recommends Approval of Eli Lilly, Boehringer Ingelheim's Empagliflozin Plus Metformin"
42a70700-4d74-4945-bdbd-6f75878a1513,2015-03-27T08:00:00.000+08:00,5,"EMA Recommends Approval of Eli Lilly, Boehringer Ingelheim's Empagliflozin Plus Metformin"
70401384-6141-4362-be34-9c566aa9d544,2015-03-23T08:00:00.000+08:00,4,Analyst: Here's Why Eli Lilly Is Worth More Than It Used To Be
f4bab6ff-227d-4923-a6a6-8dfe679672fd,2015-03-23T08:00:00.000+08:00,2,"FDA Concludes 2 Year Zyprexa Relprevv Review Of Two Deaths Related To Schizophrenia Drug, FDA Says No New Warnings Needed"
e2a259f6-a78f-4c5c-a746-ecf197b2a1c1,2015-03-23T08:00:00.000+08:00,3,"Pfizer, Lilly To Resume Phase 3 Chronic Pain Program For Tanezumab"
1ba2a291-fd45-45b5-938b-ebee06dabbe7,2015-03-23T08:00:00.000+08:00,4,"SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms"
cd218734-6547-49f5-b6f5-e4734ae659f8,2015-03-23T08:00:00.000+08:00,5,"Pfizer, Eli Lilly Announce Preparing of Resumption for Phase 3 Chronic Pain Program for Tanezumab"
55a6e2c3-0d3b-4c33-9006-f5442fc2a140,2015-03-23T08:00:00.000+08:00,4,Analyst: Here's Why Eli Lilly Is Worth More Than It Used To Be
25eba5da-9856-4828-af87-69f2b93d23ad,2015-03-23T08:00:00.000+08:00,2,"FDA Concludes 2 Year Zyprexa Relprevv Review Of Two Deaths Related To Schizophrenia Drug, FDA Says No New Warnings Needed"
0e7f3fbe-64fe-4f74-be89-5c5899179741,2015-03-23T08:00:00.000+08:00,3,"Pfizer, Lilly To Resume Phase 3 Chronic Pain Program For Tanezumab"
e9382d66-8ed4-43a3-b81f-de52144d966e,2015-03-23T08:00:00.000+08:00,4,"SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms"
51f0cd92-5b67-41d6-8530-165a63f097c0,2015-03-23T08:00:00.000+08:00,5,"Pfizer, Eli Lilly Announce Preparing of Resumption for Phase 3 Chronic Pain Program for Tanezumab"
98abc735-e248-4d5d-9a05-1e7d8d290e8e,2015-03-20T08:00:00.000+08:00,5,Eli Lilly Just Unveiled A Major Biotech Collaboration In China
c9d433cf-e2d1-4ee4-9b6c-4fb09aaeca2a,2015-03-20T08:00:00.000+08:00,5,"UPDATE: Lilly Says Innovent Will Get Upfront Payment of $56M, Could Get Future Payments $400M+"
51cef08c-bd2d-4ece-821d-c3d4f27cf1d2,2015-03-20T08:00:00.000+08:00,3,Lilly and Innovent Biologics Announce a Strategic Alliance to Bring Potential Oncology Therapies to Patients in China and Around the World
58abcddd-2a87-414d-a294-642033b2d947,2015-03-20T08:00:00.000+08:00,5,Eli Lilly Just Unveiled A Major Biotech Collaboration In China
8d8d6877-4ded-40ad-a4a3-6219482e4d55,2015-03-20T08:00:00.000+08:00,5,"UPDATE: Lilly Says Innovent Will Get Upfront Payment of $56M, Could Get Future Payments $400M+"
0ca753a9-3c81-45c2-a5bd-a4594b48d68f,2015-03-20T08:00:00.000+08:00,4,Lilly and Innovent Biologics Announce a Strategic Alliance to Bring Potential Oncology Therapies to Patients in China and Around the World
fef05612-8dd1-4e88-84a5-96429794d041,2015-03-19T08:00:00.000+08:00,5,"Eli Lilly, Hanmi Report Exclusive License Deal for Development, Commercialization of Immunological Therapy"
e811944c-bb6c-48a7-af9e-8679848968f2,2015-03-19T08:00:00.000+08:00,5,"Eli Lilly, Hanmi Report Exclusive License Deal for Development, Commercialization of Immunological Therapy"
7e876aa3-14c6-4e3a-80c9-fcece91a9352,2015-03-10T08:00:00.000+08:00,3,8 Healthcare Names Cowen & Co Are Talking About
470bfcb9-293f-4f6e-9306-6f9c32797bcd,2015-03-10T08:00:00.000+08:00,2,8 Healthcare Names Cowen & Co Are Talking About
3f7eb351-e88f-443d-8191-dc5e55cd61d2,2015-03-06T08:00:00.000+08:00,2,German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit
4d38046b-f909-430d-b061-32efd91ddb2c,2015-03-06T08:00:00.000+08:00,2,German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit
a3cc7170-d60a-414e-831e-24bedda7bd6e,2015-03-03T08:00:00.000+08:00,3,Denovo Biopharma Announces It Has Exclusively Licensed Pomaglumetad Methionil From Eli Lily & Co.
e6576d78-0a74-49db-8208-25125051552d,2015-03-03T08:00:00.000+08:00,4,Denovo Biopharma Announces It Has Exclusively Licensed Pomaglumetad Methionil From Eli Lily & Co.
bd3bfdd8-342a-45cc-9322-e7f70ab99305,2015-02-23T08:00:00.000+08:00,1,5 'Key Pipeline Catalysts' To Watch At Eli Lilly
8c45504f-202a-4992-b3a1-b8f2960cbfd5,2015-02-23T08:00:00.000+08:00,2,Lilly Announces Delay In Submission For Basal Insulin Peglispro To Regulatory Agencies
d2f44085-ec4a-4230-a6d7-deec8b15376a,2015-02-23T08:00:00.000+08:00,1,Eli Lilly Reports Delay on Regulatory Submission Timing for Basal Insulin Peglispro
64b7c1a6-fe67-4933-928b-f1ec5ec36bbd,2015-02-23T08:00:00.000+08:00,4,Eli Lilly Reports Baricitinib Found Superior to Placebo for Reducing RA Disease Activity
6db19af8-3420-4db1-b991-4bede4c0e543,2015-02-23T08:00:00.000+08:00,4,"Lilly, Incyte Report Baricitinib Superior to Placebo in Reducing RA Disease Activity in Second Phase 3 Study"
25e2b95f-bb37-4aff-b4ac-9b25439230ff,2015-02-23T08:00:00.000+08:00,3,5 'Key Pipeline Catalysts' To Watch At Eli Lilly
7fa7ae88-0e9a-45aa-98a4-4bcfdf98ec8b,2015-02-23T08:00:00.000+08:00,2,Lilly Announces Delay In Submission For Basal Insulin Peglispro To Regulatory Agencies
53168003-c642-4648-8b36-0e8626240f83,2015-02-23T08:00:00.000+08:00,1,Eli Lilly Reports Delay on Regulatory Submission Timing for Basal Insulin Peglispro
c3ae32ea-f39f-4ab6-86d6-57122476ac4d,2015-02-23T08:00:00.000+08:00,4,Eli Lilly Reports Baricitinib Found Superior to Placebo for Reducing RA Disease Activity
58e53c15-b3fb-40cc-abbf-184df5f44bd5,2015-02-23T08:00:00.000+08:00,4,"Lilly, Incyte Report Baricitinib Superior to Placebo in Reducing RA Disease Activity in Second Phase 3 Study"
4ed98e1f-fbbf-4456-818e-c2e56bcb1f55,2015-02-19T08:00:00.000+08:00,2,Lilly Provides Phase 3 Trial Update On Evacetrapib
1ce86817-0b90-4ee9-b6d0-1042628a2dbd,2015-02-19T08:00:00.000+08:00,2,Lilly Provides Phase 3 Trial Update On Evacetrapib
aafe4816-9209-422f-a041-c27e6c947f62,2015-02-11T08:00:00.000+08:00,3,"UPDATE: Lilly Says China, Parts of Asia Most Profitable of Emerging Markets, Parts of India Subcontinent Least Profitable"
18ddd6e7-d51c-463e-97a0-6df5bcf448b6,2015-02-11T08:00:00.000+08:00,4,Lilly Says Still Room to Grow Business in China
12212fb5-569e-48cc-8c27-62df5af2145c,2015-02-11T08:00:00.000+08:00,4,Lilly Currently Presenting at Leerink Global Healthcare Conference
3d94d108-2b24-4760-baea-0fa78c9e85d6,2015-02-11T08:00:00.000+08:00,2,"UPDATE: Lilly Says China, Parts of Asia Most Profitable of Emerging Markets, Parts of India Subcontinent Least Profitable"
bd938a12-cbc2-48ea-b7e9-adb69c28d1cd,2015-02-11T08:00:00.000+08:00,3,Lilly Says Still Room to Grow Business in China
9d1a7820-879e-4718-b9f5-d18e23d5b48c,2015-02-11T08:00:00.000+08:00,2,Lilly Currently Presenting at Leerink Global Healthcare Conference
0e6fc04c-aefe-4a19-a81f-a45ccaf099c8,2015-02-06T08:00:00.000+08:00,3,"After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?"
7df2c6a7-4b4d-42fb-aa4b-2ab46308b682,2015-02-06T08:00:00.000+08:00,1,"After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?"
bb14cb63-f9e6-4149-951c-a20e4b46d6ee,2015-02-05T08:00:00.000+08:00,2,IPO Alert: Biotech Investors Should Watch Advanced Accelerator's New Drug Lineup
006d8233-0f1e-432f-b6fc-309d0172f313,2015-02-05T08:00:00.000+08:00,4,IPO Alert: Biotech Investors Should Watch Advanced Accelerator's New Drug Lineup
e5acd3e0-b434-4ce8-a783-559bd8cd22d3,2015-02-02T08:00:00.000+08:00,3,UBS: Eli Lilly's 'Outlook Continuing To Improve'
6e4c35fd-0903-4d35-bc88-ad1cc8d4399f,2015-02-02T08:00:00.000+08:00,5,Lilly Announces FDA Approves First-in-class Glyxambi Tablets for Adults With Type 2 Diabetes
1db66afd-8fc9-43e6-8d99-9faa3f6fc420,2015-02-02T08:00:00.000+08:00,4,Eli Lilly CEO Explains The Reasons Behind Not Changing 2015 Guidance On Back Of Strengthening Dollar
90b23888-baaa-4177-8313-552bdbc45957,2015-02-02T08:00:00.000+08:00,3,UBS: Eli Lilly's 'Outlook Continuing To Improve'
c4b252f1-d7cb-4f8d-9e61-492daa7208cc,2015-02-02T08:00:00.000+08:00,3,Lilly Announces FDA Approves First-in-class Glyxambi Tablets for Adults With Type 2 Diabetes
e5165247-b344-4f02-853e-9fc9a6408fe7,2015-02-02T08:00:00.000+08:00,2,Eli Lilly CEO Explains The Reasons Behind Not Changing 2015 Guidance On Back Of Strengthening Dollar
c41be22d-874c-4e50-b253-3a801af9e9d0,2015-01-30T08:00:00.000+08:00,1,"UPDATE: Eli Lilly Posts Upbeat Q4 Profit, Sales Decline"
4de1d3f9-3e6a-4ff4-a94c-3d55615ce0f5,2015-01-30T08:00:00.000+08:00,2,"Eli Lilly Guides FY 2015 Lower, Expects $19.5B to $20B"
fba00e22-cebd-4d98-9c0d-0af5b9583f2c,2015-01-30T08:00:00.000+08:00,1,"Eli Lilly Q4 EPS $0.75, $0.73 Est"
82237304-b1d0-4f52-9973-99b9c1d239b3,2015-01-30T08:00:00.000+08:00,2,"Earnings Scheduled For January 30, 2015"
382e6138-18d3-4aaa-ba05-991f09e973e6,2015-01-30T08:00:00.000+08:00,3,10 Must Watch Stocks for Today
c22e937c-9054-4ade-84c5-0c58418725b1,2015-01-30T08:00:00.000+08:00,2,"UPDATE: Eli Lilly Posts Upbeat Q4 Profit, Sales Decline"
eccf80f6-47c0-4634-837e-457eb82ea8d5,2015-01-30T08:00:00.000+08:00,1,"Eli Lilly Guides FY 2015 Lower, Expects $19.5B to $20B"
0813f934-03bc-4cba-8383-ad71d1613308,2015-01-30T08:00:00.000+08:00,3,"Eli Lilly Q4 EPS $0.75, $0.73 Est"
70d76d57-2807-48d6-8c13-adc70aa5fae3,2015-01-30T08:00:00.000+08:00,2,"Earnings Scheduled For January 30, 2015"
69d76b91-3c79-4035-965d-9e8032eea6ee,2015-01-30T08:00:00.000+08:00,4,10 Must Watch Stocks for Today
a36f4e4d-de1b-4884-9310-b36137943fa5,2015-01-15T08:00:00.000+08:00,3,A Pair Trade With Eli Lilly And Johnson & Johnson? Goldman Just Explained Why It's A Solid Idea
12ce9581-cf8e-4c52-8f97-f4533f5e472e,2015-01-15T08:00:00.000+08:00,1,10 Biotech Stories You Might've Missed This Week
ce48c30a-7bda-459f-b4f2-0d8c6b273781,2015-01-15T08:00:00.000+08:00,2,Goldman Sachs Upgrades Eli Lilly to Neutral
cd3e5d3e-7392-4ddf-bf23-21b404d0c8bc,2015-01-15T08:00:00.000+08:00,2,A Pair Trade With Eli Lilly And Johnson & Johnson? Goldman Just Explained Why It's A Solid Idea
7a2f0a60-baea-452c-971b-f7461758072c,2015-01-15T08:00:00.000+08:00,3,10 Biotech Stories You Might've Missed This Week
0075a506-4e21-4f1c-bb93-d197ab65b05d,2015-01-15T08:00:00.000+08:00,3,Goldman Sachs Upgrades Eli Lilly to Neutral
31d13736-f183-4b1d-ab4e-173c89457957,2015-01-13T08:00:00.000+08:00,4,Notes From The Street: 'FLASHBACK....Oil Going To $200/Barrel'
7719af85-6ec5-4d98-b272-1769fe6d3360,2015-01-13T08:00:00.000+08:00,4,Merck and Eli Lilly Announce Agreement For Collaboration on Cancer Clinical Trial
589e0403-629a-4818-a89e-b8e519f19bb7,2015-01-13T08:00:00.000+08:00,2,Notes From The Street: 'FLASHBACK....Oil Going To $200/Barrel'
75a06477-f7b5-45f7-9e4e-11165562dc4e,2015-01-13T08:00:00.000+08:00,4,Merck and Eli Lilly Announce Agreement For Collaboration on Cancer Clinical Trial
46fd3f81-4f74-474a-9bf4-000522864347,2015-01-12T08:00:00.000+08:00,3,'FDA stops import of Lilly's Cialis from Australia'
89cb2505-7c6f-4425-b7c8-a8f1532b64e1,2015-01-12T08:00:00.000+08:00,4,"Eil Lilly CEO Talks New Product Launches, Pricing Pressure From Other Companies"
2b1e1510-8958-4294-b507-78ed32dc7f94,2015-01-12T08:00:00.000+08:00,1,FDA Issues Import Block On Eli Lilly's Cialis
12d7ec62-d31e-4760-b20f-05bb0a2b0aa5,2015-01-12T08:00:00.000+08:00,2,FDA issues Import Block Alert On Lilly's Cialis
d99c73e1-d2cf-48ea-984a-14063a886d9a,2015-01-12T08:00:00.000+08:00,3,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2
4b705f95-eb81-4173-b1ff-ef92d6516e59,2015-01-12T08:00:00.000+08:00,4,From CNBC: Eli Lilly CEO 'Anticipates 2015 Drug Price Increases; Remains Interested In Smaller M&A Deals'
43eef1d6-fd2f-48f4-9f55-f78b0b0dcb5d,2015-01-12T08:00:00.000+08:00,1,"Fast Money Picks For January 12: Twitter, Eli Lilly, Lions Gate"
59aec797-4fa9-4c08-94f3-f0c21b3ccf82,2015-01-12T08:00:00.000+08:00,2,'FDA stops import of Lilly's Cialis from Australia'
af228b7b-bd97-4c03-95fd-f5489930714b,2015-01-12T08:00:00.000+08:00,3,"Eil Lilly CEO Talks New Product Launches, Pricing Pressure From Other Companies"
b6babf12-d3e5-4a88-930d-3605dea5e7ef,2015-01-12T08:00:00.000+08:00,1,FDA Issues Import Block On Eli Lilly's Cialis
95aee35d-ccb5-4723-8b03-8c0b30a1269d,2015-01-12T08:00:00.000+08:00,3,FDA issues Import Block Alert On Lilly's Cialis
9e8f89ac-87d0-46e0-afb8-b2babcd4d6a7,2015-01-12T08:00:00.000+08:00,4,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2
cc168eaf-56c9-47a7-88fb-5469b9e9431e,2015-01-12T08:00:00.000+08:00,2,From CNBC: Eli Lilly CEO 'Anticipates 2015 Drug Price Increases; Remains Interested In Smaller M&A Deals'
2f5a7624-82bc-4d02-ae8b-d0e1e230b3ec,2015-01-12T08:00:00.000+08:00,2,"Fast Money Picks For January 12: Twitter, Eli Lilly, Lions Gate"
4aae7a3d-84f0-457c-ad7d-44a22a70c695,2015-01-09T08:00:00.000+08:00,3,Bank of America Downgrades Eli Lilly to Neutral
8cdd9da3-afe5-4ed7-adb1-8b0f76af5ee9,2015-01-09T08:00:00.000+08:00,3,Bank of America Downgrades Eli Lilly to Neutral
cc61e7f7-d2fe-401b-9b46-ba2ce6842c59,2015-01-08T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Higher
06c0c3b2-ba24-4050-a526-04048bbe09c3,2015-01-08T08:00:00.000+08:00,3,"Deutsche Bank, Stifel Differ On Outlook For Eli Lilly"
de394c08-2faf-4d48-8873-af302a01beb7,2015-01-08T08:00:00.000+08:00,5,Benzinga's Top Upgrades
e5b8b759-6b60-483a-9aaa-50771fa97ebe,2015-01-08T08:00:00.000+08:00,5,Jefferies Upgrades Eli Lilly To Buy
dcff91fa-ad74-4223-b6a7-0771963f12c7,2015-01-08T08:00:00.000+08:00,2,"UPDATE: Deutsche Bank Downgrades Eli Lilly On Positive Outlook, Modest Upside"
f2cfb166-34fb-48b6-a1aa-66fd9c851fa2,2015-01-08T08:00:00.000+08:00,4,"Jefferies Upgrades Eli Lilly to Buy, Raises PT to $80.00"
6dbfa427-41c5-47f0-b160-e9b1f4f0a28a,2015-01-08T08:00:00.000+08:00,1,Deutsche Bank Downgrades Eli Lilly to Hold
83797931-e19b-4ee2-ba3d-2fc8812a560b,2015-01-08T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Higher
731ea827-1a0c-46ce-8bac-087f08c822d6,2015-01-08T08:00:00.000+08:00,2,"Deutsche Bank, Stifel Differ On Outlook For Eli Lilly"
2f3b5f74-847e-4553-a5fd-9681d3acc0ad,2015-01-08T08:00:00.000+08:00,5,Benzinga's Top Upgrades
98e274ce-941d-43f8-9b9b-4f9b5a512696,2015-01-08T08:00:00.000+08:00,3,Jefferies Upgrades Eli Lilly To Buy
f566e508-0bd0-4fe2-980e-8e781b0c8f3d,2015-01-08T08:00:00.000+08:00,1,"UPDATE: Deutsche Bank Downgrades Eli Lilly On Positive Outlook, Modest Upside"
fbcc4dd8-1bcc-42f6-b64a-5dcea7dba6ca,2015-01-08T08:00:00.000+08:00,3,"Jefferies Upgrades Eli Lilly to Buy, Raises PT to $80.00"
13b91966-a668-4141-bd3d-65b1bc40f124,2015-01-08T08:00:00.000+08:00,2,Deutsche Bank Downgrades Eli Lilly to Hold
9aefa52d-be43-425c-9fb5-98edc23b9ed1,2015-01-07T08:00:00.000+08:00,4,4 Stocks Trending On Social Media This Wednesday
e01fea05-a399-41f4-a2ef-72cf9fd5ca22,2015-01-07T08:00:00.000+08:00,3,Eli Lilly Moves Higher Following FY 2014 & 2015 Outlook
7536b708-71ba-462e-89b4-4994571b7c21,2015-01-07T08:00:00.000+08:00,1,"From Eli Lilly Guidance Conference Call: Mgmt Still Expecting FY14 Sales in $19.4-$19.8B Range, vs $19.7B Analyst Est."
d3118342-8098-4037-a52b-1d8ea468224b,2015-01-07T08:00:00.000+08:00,2,Benzinga's Top #PreMarket Losers
6c81a4de-513e-4360-afea-f5b4da38ee81,2015-01-07T08:00:00.000+08:00,1,Eli Lilly Sees FY2014 EPS $2.72-2.80
1a418659-2a15-4bb9-b6a5-f87d2c711f2c,2015-01-07T08:00:00.000+08:00,3,Eli Lilly Sees FY2015 EPS $3.10-3.20; Sees Sales $20.30B-20.80B
fd1ae7ea-1526-48e7-9778-a2876d7753a8,2015-01-07T08:00:00.000+08:00,4,4 Stocks Trending On Social Media This Wednesday
b21918bd-9f97-4767-8980-04ad819057dc,2015-01-07T08:00:00.000+08:00,4,Eli Lilly Moves Higher Following FY 2014 & 2015 Outlook
4ce552a5-f1ee-4802-acbc-63862aebeba6,2015-01-07T08:00:00.000+08:00,4,"From Eli Lilly Guidance Conference Call: Mgmt Still Expecting FY14 Sales in $19.4-$19.8B Range, vs $19.7B Analyst Est."
53d0ac72-ce4d-4f0c-87ae-3609ecdf2712,2015-01-07T08:00:00.000+08:00,1,Benzinga's Top #PreMarket Losers
ace20d99-b428-41f3-8c9c-596da61722ce,2015-01-07T08:00:00.000+08:00,3,Eli Lilly Sees FY2014 EPS $2.72-2.80
62813d2c-c696-4f12-b22a-f203dcf25324,2015-01-07T08:00:00.000+08:00,4,Eli Lilly Sees FY2015 EPS $3.10-3.20; Sees Sales $20.30B-20.80B
e4605716-5061-429b-86f1-e68d0e134fef,2015-01-06T08:00:00.000+08:00,2,Fast Money Halftime Report Final Trade From January 6
aef787b6-b54c-4330-a42d-2933eec46df3,2015-01-06T08:00:00.000+08:00,4,Fast Money Halftime Report Final Trade From January 6
fb7655bf-914b-4610-96d4-18858e8c4610,2015-01-02T08:00:00.000+08:00,5,#Premarket Prep Technical Update - Eli Lilly Trading Higher
379f50dd-949a-488f-a9dc-2b60abb9bcad,2015-01-02T08:00:00.000+08:00,3,US Stock Futures Surge Ahead Of Manufacturing Data
09741fb5-8b5d-4967-b16b-609c40caf668,2015-01-02T08:00:00.000+08:00,5,#Premarket Prep Technical Update - Eli Lilly Trading Higher
00971722-106f-4341-bf86-d28f54d9231b,2015-01-02T08:00:00.000+08:00,4,US Stock Futures Surge Ahead Of Manufacturing Data
f2625b96-d395-4911-8222-4949a35dd1ef,2015-01-01T08:00:00.000+08:00,2,Lilly Completes Acquisition of Novartis Animal Health
95706424-b250-4afe-87d4-47ca5e410d3e,2015-01-01T08:00:00.000+08:00,2,Lilly Completes Acquisition of Novartis Animal Health
b3d50e02-2a3d-44ff-925c-be11855b645e,2014-12-22T08:00:00.000+08:00,3,FTC Places Conditions on Lilly's Proposed Deal to Divest Sentinel to Virbac SA
a223cff4-c0c1-4b61-a300-57b13bf30b84,2014-12-22T08:00:00.000+08:00,3,FTC Places Conditions on Lilly's Proposed Deal to Divest Sentinel to Virbac SA
f1b2d21e-9dd6-44c1-aa66-edc3cb707727,2014-12-19T08:00:00.000+08:00,4,"Lilly, Adocia Announce Alliance to Co-Develop BioChaperone Lispro"
44d0d379-93cb-4363-b096-3f4f13176d4b,2014-12-19T08:00:00.000+08:00,4,"Lilly, Adocia Announce Alliance to Co-Develop BioChaperone Lispro"
aff590c2-f9b3-426f-9f63-2d63cdab667d,2014-12-16T08:00:00.000+08:00,3,7 Stocks You Should Be Watching Today
4007fd08-c94d-46ff-8687-260359960465,2014-12-16T08:00:00.000+08:00,3,7 Stocks You Should Be Watching Today
55c07f18-fcd8-4cce-96d0-e2d7e1c2dc78,2014-12-15T08:00:00.000+08:00,4,Lilly Announces Dividend Increase From $0.49 To $0.50/share
7855d7c1-39a3-4d2c-932c-b61df12bbe96,2014-12-15T08:00:00.000+08:00,5,Lilly Announces Dividend Increase From $0.49 To $0.50/share
a3f2cf59-1ff5-42dc-9f7c-2faa29cf878f,2014-12-12T08:00:00.000+08:00,4,UPDATE: FDA Expands Approval For Cyramza
6e9c5569-9b1b-4421-ae54-f5f5969c602c,2014-12-12T08:00:00.000+08:00,5,Eli Lilly's Cyramza Receives Expanded FDA Approval
4c9a69a6-be88-430f-a8e0-4cb9d71eb936,2014-12-12T08:00:00.000+08:00,3,UPDATE: FDA Expands Approval For Cyramza
6a554738-0ed5-483e-b860-11688b358db3,2014-12-12T08:00:00.000+08:00,4,Eli Lilly's Cyramza Receives Expanded FDA Approval
1763707a-de46-471e-9ad3-f4866362c22f,2014-12-11T08:00:00.000+08:00,5,"Morgan Stanley Upgrades Eli Lilly and Company to Overweight, Raises PT to $85.00"
96ffa31d-e84c-45c1-8e66-525c3c21bf5c,2014-12-11T08:00:00.000+08:00,5,"Morgan Stanley Upgrades Eli Lilly and Company to Overweight, Raises PT to $85.00"
cc1fa107-93fd-4d9d-a454-1d4ca443cedc,2014-12-09T08:00:00.000+08:00,4,"Lilly, Incyte Announce Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis Met Primary Endpoint"
9a3078b8-0b84-40a1-9e9d-f3498f109da4,2014-12-09T08:00:00.000+08:00,4,"Lilly, Incyte Announce Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis Met Primary Endpoint"
942100da-f52c-4716-982b-1ef825c6e1d5,2014-12-08T08:00:00.000+08:00,4,"Eli Lilly, Anthem, Inc. and HealthCore Create Research Collaboration"
371dfefd-a971-4b97-9c13-34059f2f5913,2014-12-08T08:00:00.000+08:00,4,"Eli Lilly, Anthem, Inc. and HealthCore Create Research Collaboration"
d0c1ca67-6844-4995-af55-cc7cd54d01b2,2014-12-04T08:00:00.000+08:00,4,"Jefferies Maintains Hold on Eli Lilly and Company, Raises PT to $5.00"
77ccaecd-f343-4ad5-be78-1dc028c4e926,2014-12-04T08:00:00.000+08:00,4,"Jefferies Maintains Hold on Eli Lilly and Company, Raises PT to $5.00"
7f084669-01c7-4371-9891-74c019d30f6b,2014-12-02T08:00:00.000+08:00,3,Zosano Pharma and Eli Lilly and Company Enter Into Exclusive Licensing Agreement for Zosano's ZP-PTH Product Candidate
cbe46c03-df5d-4a17-bf85-39deb50aec8c,2014-12-02T08:00:00.000+08:00,2,Zosano Pharma and Eli Lilly and Company Enter Into Exclusive Licensing Agreement for Zosano's ZP-PTH Product Candidate
b6f97386-869d-4beb-a3df-7f906e4c49a0,2014-12-01T08:00:00.000+08:00,1,Lilly Announces Co. AstraZeneca Report Enrollment of First Patient Into AMARANTH
c0558083-b1b2-46f1-89a9-7f13b38c1058,2014-12-01T08:00:00.000+08:00,2,Lilly Announces Co. AstraZeneca Report Enrollment of First Patient Into AMARANTH
b8d9b4ed-9c3b-444b-b714-a73b28b24566,2014-11-24T08:00:00.000+08:00,4,From 13G: Eli Lilly Company Reports 9.1% Stake In Coherus BioSciences Inc.
329baa2c-e3ee-4f92-b1cf-bc76648c9402,2014-11-24T08:00:00.000+08:00,4,From 13G: Eli Lilly Company Reports 9.1% Stake In Coherus BioSciences Inc.
912e5fd3-9718-4938-81f2-a5c6cdbaeecb,2014-11-21T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Higher
4aaf2c8e-1660-4337-98ac-8902f27998bd,2014-11-21T08:00:00.000+08:00,3,#Premarket Prep Technical Update - Eli Lilly Higher
2d6fc8c1-04c0-483d-9ce3-5a4e8713fa6e,2014-11-17T08:00:00.000+08:00,4,"Eli Lilly Reports New Retrospective Data Showed Empagliflozin Reduced A1C, Body Weight, Markers of Abdominal Fat in Adults with Type 2 Diabetes"
93292595-82f7-4d27-bc68-95e57f4c0273,2014-11-17T08:00:00.000+08:00,3,"Eli Lilly Reports New Retrospective Data Showed Empagliflozin Reduced A1C, Body Weight, Markers of Abdominal Fat in Adults with Type 2 Diabetes"
e272000d-a7e6-40ef-b65d-423e61d6dc62,2014-11-11T08:00:00.000+08:00,2,#Premarket Prep Technical Update - Eli Lilly Makes Multi-Year High And Retreats
c93bf546-0df4-41dd-9e87-dbe7760d55d6,2014-11-11T08:00:00.000+08:00,1,#Premarket Prep Technical Update - Eli Lilly Makes Multi-Year High And Retreats
3dceb702-997f-44b8-abd9-ea6a4fd259d2,2014-11-05T08:00:00.000+08:00,5,FDA Approves Ramcirumab In Combination With Paclitaxel For Gastric Cancer
fb93c1d2-d020-46dc-a9c6-b5b17a118978,2014-11-05T08:00:00.000+08:00,4,FDA Approves Ramcirumab In Combination With Paclitaxel For Gastric Cancer
4f3fcaaa-ea3c-4125-b053-94b0f173566a,2014-11-03T08:00:00.000+08:00,5,Credit Suisse Raises Eli Lilly Price Target
4483b597-9a8f-4c70-9340-e9dccfd694e2,2014-11-03T08:00:00.000+08:00,3,Credit Suisse Raises Eli Lilly Price Target
4e31362c-97cc-4149-b08d-c538b0e47cae,2014-10-29T08:00:00.000+08:00,4,"Eli Lilly Recently Filed 10-Q; Seeing FY14 EPS Expected in $2.36-$2.44 Range Amid Revisions on Boehringer Deal, Facility Closing"
17199ca1-4131-4ae4-80f6-76a81e16b07e,2014-10-29T08:00:00.000+08:00,4,"Lilly, Boehringer Ingelheim Changing Structure of Diabetes Alliance In Certain Countries"
77ae594e-7e8a-4c94-b0a2-27f0e728bab3,2014-10-29T08:00:00.000+08:00,2,"Eli Lilly Recently Filed 10-Q; Seeing FY14 EPS Expected in $2.36-$2.44 Range Amid Revisions on Boehringer Deal, Facility Closing"
41bba308-6757-4d94-973b-1324a7de7875,2014-10-29T08:00:00.000+08:00,3,"Lilly, Boehringer Ingelheim Changing Structure of Diabetes Alliance In Certain Countries"
25da7652-4d66-48b3-9014-89542343e2ea,2014-10-27T08:00:00.000+08:00,3,"Lilly Responds to Decision in Case of Terrence Allen, et al. v. Takeda"
43b972a1-2f42-4e4e-bb62-188909c0c548,2014-10-27T08:00:00.000+08:00,4,UPDATE: Judge Cut $9B Award To Eli Lilly & Takeda Pharma To $36.8M
22414316-93cd-44d2-9930-95c3eb170e38,2014-10-27T08:00:00.000+08:00,1,"Takeda, Lilly Receive $9B Actos Award To $36.8M"
32e149b8-89f9-4434-bbfe-3e405670d4b9,2014-10-27T08:00:00.000+08:00,2,Virbac to Acquire US Veterinary Assets from Eli Lilly
ee37a9a5-d09f-419c-b687-abf3457333e3,2014-10-27T08:00:00.000+08:00,3,"Lilly Responds to Decision in Case of Terrence Allen, et al. v. Takeda"
0c957e2f-d1a6-4e86-ae4c-4b0ca3c7327b,2014-10-27T08:00:00.000+08:00,1,UPDATE: Judge Cut $9B Award To Eli Lilly & Takeda Pharma To $36.8M
926e1088-a046-4f54-8f16-e1c21073d604,2014-10-27T08:00:00.000+08:00,4,"Takeda, Lilly Receive $9B Actos Award To $36.8M"
6131a0ea-ea14-4c80-a64a-e8764d28ce55,2014-10-27T08:00:00.000+08:00,5,Virbac to Acquire US Veterinary Assets from Eli Lilly
496ea68e-3e7b-4b47-8929-5de2508105ae,2014-10-24T08:00:00.000+08:00,5,#Premarket Prep Technical Update - Eli Lilly Trading Higher
1b06f890-d599-4ea3-b46e-66bad2c40ad1,2014-10-24T08:00:00.000+08:00,5,#Premarket Prep Technical Update - Eli Lilly Trading Higher
278f5215-2473-41e5-9e48-aeb4f529272a,2014-10-23T08:00:00.000+08:00,4,"US Stock Futures Rise Ahead Of Earnings, Economic Data"
d7d982c4-f46e-4b65-95ae-91cdc86f7178,2014-10-23T08:00:00.000+08:00,1,UPDATE: Eli Lilly Posts Lower Q3 Profit
932ee21b-b96f-4d3d-99ff-7bae2dc09748,2014-10-23T08:00:00.000+08:00,4,Eli Lilly and Company Sees FY2014 EPS $2.34-2.42
8ba7979b-0ae2-4043-880f-918a26dff133,2014-10-23T08:00:00.000+08:00,1,Eli Lilly and Company Reports Q3 EPS of $0.66 vs $0.69 Est; Revenue of $4.88B vs $4.83B Est
0d3dc6b4-4d38-4c75-a2d7-6379a856ec26,2014-10-23T08:00:00.000+08:00,1,"Earnings Scheduled For October 23, 2014"
536b9c42-e007-4918-9641-682222fe9ca2,2014-10-23T08:00:00.000+08:00,3,"US Stock Futures Rise Ahead Of Earnings, Economic Data"
39b752e8-6734-4293-a415-d536dc1d3a5c,2014-10-23T08:00:00.000+08:00,2,UPDATE: Eli Lilly Posts Lower Q3 Profit
0bd620f2-03e7-46cc-a16d-c377c3c0a103,2014-10-23T08:00:00.000+08:00,3,Eli Lilly and Company Sees FY2014 EPS $2.34-2.42
38b13f2d-f28d-403d-bc51-9bf99df2ce70,2014-10-23T08:00:00.000+08:00,3,Eli Lilly and Company Reports Q3 EPS of $0.66 vs $0.69 Est; Revenue of $4.88B vs $4.83B Est
81ee3636-8c31-4e46-804f-10f54d08ceaf,2014-10-23T08:00:00.000+08:00,3,"Earnings Scheduled For October 23, 2014"
53efde55-7cb7-42e8-b401-a1849736c27c,2014-10-22T08:00:00.000+08:00,4,CANDA NK-2 Files Motion To Dismiss Patent Infringement Suit
7f319ef7-6420-49b1-81b7-5a71c6e496af,2014-10-22T08:00:00.000+08:00,4,"Lilly, Zymeworks Announce Expansion Of Strategic Licensing And Collaboration Agreement"
04c4b2d3-1546-44bf-a809-4363535d6b9a,2014-10-22T08:00:00.000+08:00,1,CANDA NK-2 Files Motion To Dismiss Patent Infringement Suit
33b82866-8055-401d-b959-7efc64b42ce4,2014-10-22T08:00:00.000+08:00,4,"Lilly, Zymeworks Announce Expansion Of Strategic Licensing And Collaboration Agreement"
f3513956-f380-49c5-8440-5e3ba73257a7,2014-10-21T08:00:00.000+08:00,5,FDA Accepts Filing Of A NDA For Empagliflozin
0d643825-d8a0-4ec2-8a8f-243aef751bf6,2014-10-21T08:00:00.000+08:00,3,FDA Accepts Filing Of A NDA For Empagliflozin
f306e184-b6c5-405b-97eb-5bd9d3d9a39c,2014-10-19T08:00:00.000+08:00,2,Benzinga Weekly Preview: Earnings Season Is In Full Swing
436744dc-fbd5-46e7-907f-6122ada3f69a,2014-10-19T08:00:00.000+08:00,2,Benzinga Weekly Preview: Earnings Season Is In Full Swing
33edcff8-fa41-432f-8111-76c565458734,2014-10-16T08:00:00.000+08:00,2,UPDATE: Lilly To Initiate Efforts To Sell Guayama Site
31a407bb-5190-4f7b-818e-68ad113bba30,2014-10-16T08:00:00.000+08:00,2,Lilly Announces Plan to Realign Puerto Rico Manufacturing Operations
b83a60fd-d84d-4ba7-91e4-abe7e5df7c96,2014-10-16T08:00:00.000+08:00,2,UPDATE: Lilly To Initiate Efforts To Sell Guayama Site
d0bf3e90-bc84-4774-9d39-42d2c43bc195,2014-10-16T08:00:00.000+08:00,4,Lilly Announces Plan to Realign Puerto Rico Manufacturing Operations
2f051e8d-1d81-4795-be44-54fabba2ea6b,2014-10-13T08:00:00.000+08:00,1,"Jefferies Maintains Hold on Eli Lilly and Company, Raises PT to $70.00"
fb391a9f-ceb3-42c0-a516-edbc96abf6e1,2014-10-13T08:00:00.000+08:00,4,"Jefferies Maintains Hold on Eli Lilly and Company, Raises PT to $70.00"
96f00cfe-978a-4193-961f-7c0638e85e0e,2014-10-10T08:00:00.000+08:00,5,Eli Lilly's Olaratumab Wins FDA Orphan Drug Designation
8c823607-94f3-485c-ae20-c34ffb3238ee,2014-10-10T08:00:00.000+08:00,5,Eli Lilly's Olaratumab Wins FDA Orphan Drug Designation
6ccf8033-b08a-4edf-9787-a4136b7273e6,2014-10-03T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Trading HIgher
da9a61ef-09e0-41e0-9d36-8887cd953c81,2014-10-03T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Trading HIgher
fc383c69-7570-4720-a001-01e9438aa12f,2014-10-02T08:00:00.000+08:00,2,Markets Little Changed Ahead Of Friday's Jobs Report
d5166827-7244-4bfc-9504-6db4930a6f9c,2014-10-02T08:00:00.000+08:00,1,Eli Lilly Will Discontinue Tabalumab Development of Efficacy Data
c1778234-12d6-4a2c-ad60-32ab2f39e5f5,2014-10-02T08:00:00.000+08:00,3,"Guggenheim Securities Initiates Coverage on Eli Lilly and Company at Buy, Announces $80.00 PT"
7713daed-d787-47d5-bd0a-b4f942daa860,2014-10-02T08:00:00.000+08:00,2,Markets Little Changed Ahead Of Friday's Jobs Report
68169517-03d6-4784-b296-2c43e971c35b,2014-10-02T08:00:00.000+08:00,1,Eli Lilly Will Discontinue Tabalumab Development of Efficacy Data
e17c69b7-d959-496a-b59a-3bf2fc82f074,2014-10-02T08:00:00.000+08:00,5,"Guggenheim Securities Initiates Coverage on Eli Lilly and Company at Buy, Announces $80.00 PT"
31d49891-4119-47b4-a93a-745ac74c697d,2014-09-22T08:00:00.000+08:00,4,"Dyax Offers Highlights of Recent Progress in Licensing, Funded-Research Portfolio"
32e3af37-a413-41f0-ac65-2c0156fd64a4,2014-09-22T08:00:00.000+08:00,3,"Dyax Offers Highlights of Recent Progress in Licensing, Funded-Research Portfolio"
5fd741fb-25d7-49e2-9585-dc156363c69c,2014-09-18T08:00:00.000+08:00,4,Lilly Wins Approval From FDA For Diabetes Treatment Trulicity - Bloomberg
489976aa-1f7a-4a66-8c1b-0ac40f75fb23,2014-09-18T08:00:00.000+08:00,5,Eli Lilly Reports CYRAMZA in Combo with Paclitaxel Showed Significant Improvement in Overall Survival in Second-Line Gastric Cancer Patients
654766d5-8c03-49f5-b13c-7a25bbd66b18,2014-09-18T08:00:00.000+08:00,5,Lilly Wins Approval From FDA For Diabetes Treatment Trulicity - Bloomberg
df9f09e2-f0c9-47e7-b167-3df4063e86c1,2014-09-18T08:00:00.000+08:00,4,Eli Lilly Reports CYRAMZA in Combo with Paclitaxel Showed Significant Improvement in Overall Survival in Second-Line Gastric Cancer Patients
80d699ee-4fbf-482b-b6f1-53b5640b0f4e,2014-09-17T08:00:00.000+08:00,3,"Lipocine Inc Halted: Feds Eye Safety, Efficacy Of Testosterone"
4dcef026-9ce9-4da4-b6b0-306a9439bc3b,2014-09-17T08:00:00.000+08:00,2,"Lipocine Inc Halted: Feds Eye Safety, Efficacy Of Testosterone"
39a4bad3-4024-431a-811c-aca93eca87de,2014-09-16T08:00:00.000+08:00,1,"Denovo Biopharma Reports Purchase of Enzastaurin from Eli Lilly, Includes Rights to Develop, Manufacture, Commercialize, No Terms Disclosed"
f40b2b2d-c51d-4558-9804-5e8107fc2de8,2014-09-16T08:00:00.000+08:00,4,"Eli Lilly, AstraZeneca Report Alliance to Co-Develop Potential Treatment for Alzheimer's, Lilly to Pay Up to $500M in Milestones"
f0031524-1ce7-406a-8da8-56226e37b3c2,2014-09-16T08:00:00.000+08:00,3,"Denovo Biopharma Reports Purchase of Enzastaurin from Eli Lilly, Includes Rights to Develop, Manufacture, Commercialize, No Terms Disclosed"
5d055b59-8909-41ed-8f32-4dea2dd77403,2014-09-16T08:00:00.000+08:00,4,"Eli Lilly, AstraZeneca Report Alliance to Co-Develop Potential Treatment for Alzheimer's, Lilly to Pay Up to $500M in Milestones"
42c472d9-0e1f-45cd-b9ec-37672def15c8,2014-09-12T08:00:00.000+08:00,4,Lilly Announces CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint Of Overall Survival
5f7dd614-7810-4dcd-9862-cad347426090,2014-09-12T08:00:00.000+08:00,5,Lilly Announces CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint Of Overall Survival
7d11f0e1-fd53-42f5-8519-44378bc9462f,2014-09-08T08:00:00.000+08:00,4,What Is A High Risk Market?
25a20edb-f648-4a91-994a-40ca09562731,2014-09-08T08:00:00.000+08:00,3,What Is A High Risk Market?
222a60a8-d338-4e0a-bd3f-7b9e5c5e89af,2014-09-04T08:00:00.000+08:00,5,"Lilly's Basal Insulin Peglispro Demonstrated Hba1c Superiority Against Lantus in Phase Iii Trials In Patients With Type 1 Diabetes; Expects US, EC Submissions By End of Q1 2015"
44ed65a1-9fb0-4601-8799-857c7eafd77c,2014-09-04T08:00:00.000+08:00,2,"Lilly's Basal Insulin Peglispro Demonstrated Hba1c Superiority Against Lantus in Phase Iii Trials In Patients With Type 1 Diabetes; Expects US, EC Submissions By End of Q1 2015"
3ff543f3-f4ef-472a-a6bd-cf3a4f63ccdb,2014-08-27T08:00:00.000+08:00,1,Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend
47cf5e89-f20c-4b6f-8230-6632c01d0b48,2014-08-27T08:00:00.000+08:00,4,Deutsche Bank: Eli Lilly At 'Critical Stage' In Its Journey
6e919884-9929-4d5d-8bb7-9731014a26ce,2014-08-27T08:00:00.000+08:00,3,"Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers at Hold"
9a1b412e-a6ae-423a-a813-5be1072d4974,2014-08-27T08:00:00.000+08:00,5,"Deutsche Bank Initiates Coverage on Eli Lilly and Company at Buy, Announces $71.00 PT"
8639f81c-6f59-461d-997b-6f878a36f04c,2014-08-27T08:00:00.000+08:00,2,Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend
1530291b-7578-47dd-9c88-73f74f915582,2014-08-27T08:00:00.000+08:00,4,Deutsche Bank: Eli Lilly At 'Critical Stage' In Its Journey
10ef2dd1-7402-40e1-9af2-5f22f3e8df66,2014-08-27T08:00:00.000+08:00,5,"Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers at Hold"
b8644285-70df-45c9-a259-d98e8b3af4cd,2014-08-27T08:00:00.000+08:00,4,"Deutsche Bank Initiates Coverage on Eli Lilly and Company at Buy, Announces $71.00 PT"
67fdd62c-f4e4-476b-a584-1d8ad80d63b7,2014-08-26T08:00:00.000+08:00,3,New Type 2 Diabetes Treatment Jardiance Tablets For Adults Now Available In U.S. Pharmacies
5b0bb759-c36c-4cab-a47b-7a55371cbedd,2014-08-26T08:00:00.000+08:00,4,Eli Lilly Reports New Type 2 Diabetes Treatment Jardiance Tabs Now Available in US Pharmacies
20c82919-ef92-4402-b108-1edd66f29117,2014-08-26T08:00:00.000+08:00,5,New Type 2 Diabetes Treatment Jardiance Tablets For Adults Now Available In U.S. Pharmacies
e3876c20-7043-4709-85b0-c1719983ee2f,2014-08-26T08:00:00.000+08:00,5,Eli Lilly Reports New Type 2 Diabetes Treatment Jardiance Tabs Now Available in US Pharmacies
695d89a7-543f-4cb5-9967-e0d621490f01,2014-08-21T08:00:00.000+08:00,4,Lilly's Ixekizumab Met all Primary and Key Secondary Objectives
9d8e3a54-958e-4c52-8236-1bd6bc78145b,2014-08-21T08:00:00.000+08:00,5,"Lilly's Ixekizumab Found Superior to Etanercept, Placebo in Phase 3 Trial, Met All Primary, Key Secondary Endpoints"
7c4f0baf-20b7-4587-a03e-94b90cd4df3d,2014-08-21T08:00:00.000+08:00,5,Lilly's Ixekizumab Met all Primary and Key Secondary Objectives
a8ca540a-0799-4c5e-8a2f-fe5e0e4edb63,2014-08-21T08:00:00.000+08:00,5,"Lilly's Ixekizumab Found Superior to Etanercept, Placebo in Phase 3 Trial, Met All Primary, Key Secondary Endpoints"
7aa25f2e-3191-4b26-94f4-49c77be16cb9,2014-08-18T08:00:00.000+08:00,4,Eli Lilly reports FDA Granting of Tentative Approval for Basaglar
1152ca18-97af-42f6-97d3-1adc37448e47,2014-08-18T08:00:00.000+08:00,4,Eli Lilly reports FDA Granting of Tentative Approval for Basaglar
ab61bf26-446a-45ea-9bad-5eee5db216da,2014-08-11T08:00:00.000+08:00,3,Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments
26e6052c-6437-4f4a-963e-cc4202e785a8,2014-08-11T08:00:00.000+08:00,3,Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments
ad0871d5-293a-4070-94e6-18e8d7a4f638,2014-08-05T08:00:00.000+08:00,1,#Premarket Prep Technical Update - Eli Lilly Trading Lower
9b65fc2e-fc15-4ca0-b3a6-3c4a80c9aedb,2014-08-05T08:00:00.000+08:00,3,#Premarket Prep Technical Update - Eli Lilly Trading Lower
69fb047d-7e79-425a-a5ac-0a9a23fc5327,2014-08-02T08:00:00.000+08:00,4,FDA Approves Jardiance Rempagliflozin Tablets for Adults withType 2 Diabetes
c49e5168-f859-4442-9ecd-c4dd1c316912,2014-08-02T08:00:00.000+08:00,4,FDA Approves Jardiance Rempagliflozin Tablets for Adults withType 2 Diabetes
e607407f-ec5c-41d7-b947-8d71b9176219,2014-08-01T08:00:00.000+08:00,5,UPDATE: Tigress Initiates Coverage On Eli Lilly
58b0c5ba-4dc0-443b-92c3-c0d4cee0d27c,2014-08-01T08:00:00.000+08:00,5,Tigress Financial Initiates Coverage on Eli Lilly and Company at Buy
ffc6c6fb-5327-4343-9d89-8eea388edeb8,2014-08-01T08:00:00.000+08:00,4,UPDATE: Tigress Initiates Coverage On Eli Lilly
47b1b826-3400-42d9-8a4b-edd65ac79575,2014-08-01T08:00:00.000+08:00,5,Tigress Financial Initiates Coverage on Eli Lilly and Company at Buy
d352bbf7-450c-40e1-b339-776d38c8d5df,2014-07-31T08:00:00.000+08:00,2,Dow Suffers 300 Point Drop; S&P 500 And NASDAQ Also Tumble
842fd235-da91-4887-a54a-b3923ac1308f,2014-07-31T08:00:00.000+08:00,3,#Premarket Prep Technical Update - Eli Lilly Trading Lower
3412cfc3-2633-4f76-9f8f-89cc6c5e1f3d,2014-07-31T08:00:00.000+08:00,2,Dow Suffers 300 Point Drop; S&P 500 And NASDAQ Also Tumble
6bbedbc0-b54d-42cb-a0a6-de67f91376b4,2014-07-31T08:00:00.000+08:00,1,#Premarket Prep Technical Update - Eli Lilly Trading Lower
2063b1d9-739c-4e92-bc1b-06195f64b361,2014-07-29T08:00:00.000+08:00,1,Stocks Lower As Earnings Season Takes Back Seat To Geopolitical Uncertainties
c9eb7fa8-9e73-4ace-ac1c-d0fa4b24b1d9,2014-07-29T08:00:00.000+08:00,1,Stocks Lower As Earnings Season Takes Back Seat To Geopolitical Uncertainties
79f57d29-db13-4e55-bdfd-b5bdbb0a538b,2014-07-24T08:00:00.000+08:00,3,Thursday Morning Earnings Reports
67cbfe36-bb12-472c-b053-e893602f7f7e,2014-07-24T08:00:00.000+08:00,4,Eli Lilly and Company Reports Q2 Adjusted EPS of $0.68 vs $0.65 Est; Revenue of $4.94B vs $4.88B Est
b54da106-d8d9-41b3-8f45-f1e51fb737b3,2014-07-24T08:00:00.000+08:00,2,"Earnings Scheduled For July 24, 2014"
81169fc7-864b-46c3-b46d-74b4b3c73cb2,2014-07-24T08:00:00.000+08:00,3,Thursday Morning Earnings Reports
f85b0a27-855b-4f66-a781-03915b12c216,2014-07-24T08:00:00.000+08:00,4,Eli Lilly and Company Reports Q2 Adjusted EPS of $0.68 vs $0.65 Est; Revenue of $4.94B vs $4.88B Est
6ed891eb-9428-4bb9-862a-971e14a18694,2014-07-24T08:00:00.000+08:00,5,"Earnings Scheduled For July 24, 2014"
f7cf7727-4dfd-46f1-a319-7065ee8d5145,2014-07-18T08:00:00.000+08:00,5,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Higher
fce585bd-3940-4e23-9efc-5a73f5f65779,2014-07-18T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Higher
f3c6724c-f677-48c0-b1fb-7ab121ffa64e,2014-07-17T08:00:00.000+08:00,2,"Alzheimer's Rates Falling, But Pharma's Search For A Cure Yields No Results"
adca0c2d-b464-4e30-bc0f-90d9a8c1a1f3,2014-07-17T08:00:00.000+08:00,3,"Alzheimer's Rates Falling, But Pharma's Search For A Cure Yields No Results"
1d39d49b-f884-44e3-8b23-f15204475674,2014-07-16T08:00:00.000+08:00,4,New Study Shows Beta-Amyloid Imaging Is Associated With Altered Diagnosis And Management Of Alzheimer's Disease
9002c83b-5beb-435b-8e8f-6712a7e458cc,2014-07-16T08:00:00.000+08:00,5,Lilly And Immunocore Enter Immunotherapy Agreement To Co-Discover And Co-Develop Novel Cancer Therapies
c19c62eb-1e20-4e36-80f0-bd1917f4c969,2014-07-16T08:00:00.000+08:00,4,New Study Shows Beta-Amyloid Imaging Is Associated With Altered Diagnosis And Management Of Alzheimer's Disease
c69e8b8f-1d38-4937-bc4e-e62376817297,2014-07-16T08:00:00.000+08:00,5,Lilly And Immunocore Enter Immunotherapy Agreement To Co-Discover And Co-Develop Novel Cancer Therapies
b5acbfc6-d7c4-4575-86db-3ee9c49fb691,2014-07-15T08:00:00.000+08:00,3,Benzinga's Top #PreMarket Gainers
f6812ad5-6883-4e5b-9162-fa7d2d27a231,2014-07-15T08:00:00.000+08:00,2,US Stock Futures Mostly Higher Ahead Of Goldman Sachs Earnings
4426e183-6f51-487b-9854-49cb8cc94bae,2014-07-15T08:00:00.000+08:00,4,New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimer's Disease
99d01e6b-0193-481f-a22f-edcc7745e564,2014-07-15T08:00:00.000+08:00,4,Benzinga's Top #PreMarket Gainers
506c55cc-6b99-4366-8354-7b6a744a5552,2014-07-15T08:00:00.000+08:00,3,US Stock Futures Mostly Higher Ahead Of Goldman Sachs Earnings
05fc140d-2820-4090-a628-d881cca1004f,2014-07-15T08:00:00.000+08:00,2,New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimer's Disease
c37f2cc2-05b8-4cc5-a08a-026d5d8a6f37,2014-07-14T08:00:00.000+08:00,1,Dow Sets New Intraday High; Citigroup Impresses With Earnings
800c8dcf-92ad-4b3a-94c1-d00add8e0550,2014-07-14T08:00:00.000+08:00,3,Dow Sets New Intraday High; Citigroup Impresses With Earnings
473f9ad1-c7db-435d-a261-670a84f722a5,2014-07-07T08:00:00.000+08:00,1,#Premarket Prep Technical Update - Eli Lilly Trading Lower
2e316884-4884-4db7-9440-bafd9a41e3c4,2014-07-07T08:00:00.000+08:00,1,#Premarket Prep Technical Update - Eli Lilly Trading Lower
ffa1d82e-55c6-4983-92ca-0355b5efdb34,2014-07-02T08:00:00.000+08:00,2,Barclays Downgrades Pharmaceutical Sector
fbd0506b-6728-4299-9ece-96172b2f7b05,2014-07-02T08:00:00.000+08:00,3,UPDATE: Barclays Upgrades Eli Lilly Despite Sector Downgrade
d9aae934-31a5-4afa-ba7f-3bf8744257b8,2014-07-02T08:00:00.000+08:00,4,Benzinga's Top Upgrades
04d69dec-36f4-434d-9e8b-af3fce666af3,2014-07-02T08:00:00.000+08:00,4,"Barclays Upgrades Eli Lilly and Company to Equal-weight, Raises PT to $63.00"
3fb04b12-a321-4c82-abc3-9f7d8425dcc6,2014-07-02T08:00:00.000+08:00,2,Barclays Downgrades Pharmaceutical Sector
40b34a88-870a-43a3-971b-31d5deab41e2,2014-07-02T08:00:00.000+08:00,3,UPDATE: Barclays Upgrades Eli Lilly Despite Sector Downgrade
2baad802-9d7c-45ec-93f1-462c63ccb3a4,2014-07-02T08:00:00.000+08:00,4,Benzinga's Top Upgrades
0f3f26a8-5727-4059-b37e-1c9a22c3e670,2014-07-02T08:00:00.000+08:00,5,"Barclays Upgrades Eli Lilly and Company to Equal-weight, Raises PT to $63.00"
beee620a-8a8c-4494-8db2-df3bdc2c9a35,2014-06-27T08:00:00.000+08:00,5,CHMP Issues Positive Report For Lilly's Insulin Glargine Product
e2dc6be9-e3f0-4281-8c1a-12a9389fb7e7,2014-06-27T08:00:00.000+08:00,5,CHMP Issues Positive Report For Lilly's Insulin Glargine Product
34b3cf16-9026-4109-a5e3-fdf8226418a6,2014-06-25T08:00:00.000+08:00,3,Bernstein Analysts Say A Hostile Deal with Eli Lilly Is Unlikely Because of Indiana Law
b2b2e8b4-53dc-4a01-8fd0-0137b9d915a0,2014-06-25T08:00:00.000+08:00,4,Bernstein Analysts Say A Hostile Deal with Eli Lilly Is Unlikely Because of Indiana Law
f57c137f-6138-43d3-a756-40d19ccddd7c,2014-06-20T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Trading HIgher
fd69c2b9-0ef5-4793-919a-f17a4dcd469a,2014-06-20T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Trading HIgher
a0395211-7c67-4191-b307-51992a60f37a,2014-06-15T08:00:00.000+08:00,5,Lilly Reports Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials
18aa670a-a200-4a13-aa25-bd1d0cc3a103,2014-06-15T08:00:00.000+08:00,5,Lilly Reports Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials
e6f82077-00fa-4dbf-b761-f3e828be8805,2014-06-14T08:00:00.000+08:00,4,Lilly Announces New Data on Basal Insulin Peglispro Shows Novel Mechanism of Action
4b6a1899-6011-466d-9c02-1935928c883b,2014-06-14T08:00:00.000+08:00,3,Studies Show LY2963016 from Lilly and Boehringer Ingelheim has Similar Safety and Efficacy Profile to Lantus®
9346b920-c72e-4cb8-82e4-1e7e65ba8dc5,2014-06-14T08:00:00.000+08:00,4,Lilly Announces New Data on Basal Insulin Peglispro Shows Novel Mechanism of Action
4905d019-8185-41c2-a721-86e1768bed2e,2014-06-14T08:00:00.000+08:00,3,Studies Show LY2963016 from Lilly and Boehringer Ingelheim has Similar Safety and Efficacy Profile to Lantus®
8abace2c-fd53-4a0b-9af7-132c26be186d,2014-06-11T08:00:00.000+08:00,1,"Market Wrap For June 11: Momentum Hit, Dow Suffers Triple Digit Loss"
c6904994-cd91-48f1-873e-e6b836595bfc,2014-06-11T08:00:00.000+08:00,2,"Eli Lilly Announces Top-Line Results oh Phase III Hepatocellular Carcinoma Trial, Says Did Not Meet Primary Endpoint"
bd4564fe-384c-418a-bffe-dbdba2b15b18,2014-06-11T08:00:00.000+08:00,1,"Market Wrap For June 11: Momentum Hit, Dow Suffers Triple Digit Loss"
211b6684-f0a0-4b42-859a-a8e43d95c55a,2014-06-11T08:00:00.000+08:00,1,"Eli Lilly Announces Top-Line Results oh Phase III Hepatocellular Carcinoma Trial, Says Did Not Meet Primary Endpoint"
864d962b-943d-48d3-acf7-1ff0e3cdb38f,2014-06-04T08:00:00.000+08:00,1,ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?
0618d9b8-d9d3-478f-a97f-ac485eac2ae3,2014-06-04T08:00:00.000+08:00,3,ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica & Targeted Therapy
6d98850f-4f1f-47cc-81a2-3b61fd192cca,2014-06-04T08:00:00.000+08:00,1,ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?
e319f875-7082-45d3-b3e3-d09a4fabee3b,2014-06-04T08:00:00.000+08:00,3,ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica & Targeted Therapy
8862063b-3254-4ce6-934f-ecb1ba05db07,2014-06-02T08:00:00.000+08:00,1,#Premarket Prep Technical Update - Eli Lilly Finding Resistance At $60.00
4b7a6d00-2355-4a5a-a555-0bd9cd9eb6e4,2014-06-02T08:00:00.000+08:00,2,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower
e963479b-ed59-45bf-8ecf-2b9b726b209e,2014-06-02T08:00:00.000+08:00,2,#Premarket Prep Technical Update - Eli Lilly Trading Lower
5e21d37a-7c3e-4ada-9dec-d591e4566108,2014-06-02T08:00:00.000+08:00,1,UPDATE: Morgan Stanley Reiterates On Eli Lilly & Co. On Lackluster Survival Benefit
fc7b73a8-d21c-486c-94c1-a07d0b433931,2014-06-02T08:00:00.000+08:00,4,Lilly Reports Increased Access to Clinical Trials Data for Qualified Researchers
394ebdbd-1413-4652-9fc8-957ee3d8f0a3,2014-06-02T08:00:00.000+08:00,1,#Premarket Prep Technical Update - Eli Lilly Finding Resistance At $60.00
a8db0edf-cad8-47c6-92f7-77fb8172c6f4,2014-06-02T08:00:00.000+08:00,2,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower
e8b5fb4e-8098-46f0-a8c4-b1738bc7e8a1,2014-06-02T08:00:00.000+08:00,2,#Premarket Prep Technical Update - Eli Lilly Trading Lower
66813ffe-b23f-45c5-9f1b-42ab8144b84e,2014-06-02T08:00:00.000+08:00,1,UPDATE: Morgan Stanley Reiterates On Eli Lilly & Co. On Lackluster Survival Benefit
6e22cc3c-0ac4-4d20-9848-c59e8dbda278,2014-06-02T08:00:00.000+08:00,4,Lilly Reports Increased Access to Clinical Trials Data for Qualified Researchers
d1a4ba13-7412-4d04-bea5-7b51e38dc1b2,2014-05-30T08:00:00.000+08:00,2,US Stock Futures Edge Lower Ahead Of Consumer Spending Report
e9ae574d-dfca-4688-aea8-591410db93fb,2014-05-30T08:00:00.000+08:00,4,QIAGEN Announces Collaboration with Lilly
0ab87231-c602-4188-852d-71cf1589d004,2014-05-30T08:00:00.000+08:00,2,US Stock Futures Edge Lower Ahead Of Consumer Spending Report
ca15acbf-b3d7-4161-b0f5-ecfb71a3e34f,2014-05-30T08:00:00.000+08:00,4,QIAGEN Announces Collaboration with Lilly
537829f4-02a7-4563-a47c-a46be5ec57a5,2014-05-28T08:00:00.000+08:00,5,"Sanofi, Lilly Announce Licensing Agreement for Nonprescription Cialis"
67891855-66e2-4c2d-aa4d-dfd30e790bcf,2014-05-28T08:00:00.000+08:00,2,"Sanofi, Lilly Announce Licensing Agreement for Nonprescription Cialis"
ab8a46f2-4104-490e-93de-8848806dcc03,2014-05-27T08:00:00.000+08:00,4,Eli Lilly Announces Will Hold Investor Web Call on Jun. 16th to Discuss Phase III Data for Dulaglutide
c4c8b5e9-f105-4e0c-af0c-cd561a54fa57,2014-05-27T08:00:00.000+08:00,4,Eli Lilly Announces Will Hold Investor Web Call on Jun. 16th to Discuss Phase III Data for Dulaglutide
2cd246b5-c4cb-4ec5-9650-46e0782b2b9e,2014-05-22T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Trading HIgher
37452c67-5fa8-4ea7-861d-4ece1a767006,2014-05-22T08:00:00.000+08:00,5,#Premarket Prep Technical Update - Eli Lilly Trading HIgher
279f2c11-c6fc-40e8-bc2a-ab4364a1e95c,2014-05-15T08:00:00.000+08:00,2,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower
9d216e06-b9f5-4ca3-b679-05c4024dc337,2014-05-15T08:00:00.000+08:00,4,Eli Lilly Announces Linagliptin Positive Results
050666ff-02de-4272-9652-7c77f75e2c83,2014-05-15T08:00:00.000+08:00,2,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower
2acad809-6e87-4656-b7f6-92f82af73c20,2014-05-15T08:00:00.000+08:00,4,Eli Lilly Announces Linagliptin Positive Results
db5df026-9868-49b7-973b-b4d28579b154,2014-05-14T08:00:00.000+08:00,3,Lilly Says Abemaciclib in Phase 1 Study Demonstrated Single-Agent Activity
accd2970-8d2f-41bf-a1c3-935aa254a29c,2014-05-14T08:00:00.000+08:00,3,"Stocks To Watch For May 14, 2014"
0c245bba-b7a7-4b57-82b9-d2cb7ce4add3,2014-05-14T08:00:00.000+08:00,5,Lilly Says Abemaciclib in Phase 1 Study Demonstrated Single-Agent Activity
0b4f08b7-ed5b-4787-a5ea-6bbea9219749,2014-05-14T08:00:00.000+08:00,3,"Stocks To Watch For May 14, 2014"
6966d452-18f2-4f73-8469-874ede90fba2,2014-05-12T08:00:00.000+08:00,4,Google Celebrates Dorothy Hodgkin & Her Contributions To Chemistry
ab0272a0-9306-40f7-9180-b4f90435d543,2014-05-12T08:00:00.000+08:00,5,UPDATE: Eli Lilly Announces Peglispro Shows Superiority Compared to Insulin Glargine in HBA1C
9e5c86b2-0cc7-4629-910a-454487d997e9,2014-05-12T08:00:00.000+08:00,5,Eli Lilly Announces Peglispro Shows Superiority Compared to Insulin Glargine in HBA1C
2bcec4a4-132f-450f-9636-29d541cf0038,2014-05-12T08:00:00.000+08:00,4,Google Celebrates Dorothy Hodgkin & Her Contributions To Chemistry
a7215ece-5d70-4d8c-9206-20d5c32d1493,2014-05-12T08:00:00.000+08:00,5,UPDATE: Eli Lilly Announces Peglispro Shows Superiority Compared to Insulin Glargine in HBA1C
66a37d59-0f17-4ceb-b573-e9d4e137f212,2014-05-12T08:00:00.000+08:00,5,Eli Lilly Announces Peglispro Shows Superiority Compared to Insulin Glargine in HBA1C
7256cf7e-1997-48a7-b18e-ddd574407ea9,2014-05-09T08:00:00.000+08:00,2,Lilly Strongly Disagrees with Court's Ruling in Brazil Labor Case
7ea291ae-79e3-4a88-bc55-4fe30ffa3f82,2014-05-09T08:00:00.000+08:00,1,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower
9c2a9070-4b69-4c22-a394-0d33adc25111,2014-05-09T08:00:00.000+08:00,1,Lilly Strongly Disagrees with Court's Ruling in Brazil Labor Case
cb3238e9-555d-4310-a582-a7fc742aa1dd,2014-05-09T08:00:00.000+08:00,3,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower
6c6d62df-4eb4-4d45-a852-7d7c2dcc53c9,2014-04-29T08:00:00.000+08:00,4,Market Wrap For April 29: Dow Approaches Record Highs Despite Ongoing Ukraine Tension and Upcoming Fed Meeting
f94660a4-26c6-4dea-a24e-ee6485a56783,2014-04-29T08:00:00.000+08:00,4,Market Wrap For April 29: Dow Approaches Record Highs Despite Ongoing Ukraine Tension and Upcoming Fed Meeting
f65df124-4c60-4c31-8354-c84d46ef77cf,2014-04-24T08:00:00.000+08:00,2,Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns
e5ae8f3e-04d1-4d47-8261-94fb1404c50a,2014-04-24T08:00:00.000+08:00,3,"Eli Lilly Reports Q1 Adjusted EPS of $0.70, Inline; Revenue of $4.68B vs $4.79B Est"
379ad53e-0a2a-438a-aae2-9cea0c8b5a5b,2014-04-24T08:00:00.000+08:00,3,"Earnings Scheduled For April 24, 2014"
997ec34a-d0b2-45b2-89f3-97a7aaa2ae91,2014-04-24T08:00:00.000+08:00,2,Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns
d8757631-104b-4faf-b44f-22f3178e463c,2014-04-24T08:00:00.000+08:00,3,"Eli Lilly Reports Q1 Adjusted EPS of $0.70, Inline; Revenue of $4.68B vs $4.79B Est"
3b846dd3-12fb-4022-8ad6-df60c2686b1a,2014-04-24T08:00:00.000+08:00,2,"Earnings Scheduled For April 24, 2014"
b11f0adb-ccc5-4e9d-9df8-24e3338f5367,2014-04-23T08:00:00.000+08:00,4,"Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple Announces 7-for-1 Stock Split"
292b4119-fb21-4162-8dde-ff649a3c7171,2014-04-23T08:00:00.000+08:00,3,MKM Partners Downgrades Eli Lilly and Company to Neutral
6b737375-7e0a-4538-972e-1eab5af2a67a,2014-04-23T08:00:00.000+08:00,4,"Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple Announces 7-for-1 Stock Split"
63469885-3308-4cd4-ba4f-d472077a479b,2014-04-23T08:00:00.000+08:00,3,MKM Partners Downgrades Eli Lilly and Company to Neutral
c8205a22-4a4d-4f89-b14e-70a2083f23bd,2014-04-22T08:00:00.000+08:00,3,"Benzinga's M&A Chatter for Tuesday April 22, 2014"
bdf283a2-c1d3-4950-90a9-aecb97b80172,2014-04-22T08:00:00.000+08:00,2,US Stock Futures Edge Higher Ahead Of McDonald's Earnings
a8fb0f9b-6656-4d41-885d-c41da3d56d00,2014-04-22T08:00:00.000+08:00,5,Lilly to Acquire Novartis Animal Health for Approximately $5.4B in Cash
3cd3456d-b626-4a74-a817-0cbfbd4e123d,2014-04-22T08:00:00.000+08:00,2,"Benzinga's M&A Chatter for Tuesday April 22, 2014"
fd628e46-66f2-452c-b0ac-74d8f6a4b2cf,2014-04-22T08:00:00.000+08:00,2,US Stock Futures Edge Higher Ahead Of McDonald's Earnings
06dcaedd-bd8d-474a-95fd-c89fce3c3f38,2014-04-22T08:00:00.000+08:00,5,Lilly to Acquire Novartis Animal Health for Approximately $5.4B in Cash
9dad7743-a891-4c4d-b415-6f34d435574d,2014-04-21T08:00:00.000+08:00,4,UPDATE: Lilly's CYRAMZA is First FDA-Approved Treatment for Advanced Gastric Cancer After Prior Chemotherapy
4315e38a-69b5-430d-a2dd-1db050df6dcc,2014-04-21T08:00:00.000+08:00,3,FDA Approves Cyramza for Stomach Cancer
956254ba-b102-4257-9ebf-b25e17116c95,2014-04-21T08:00:00.000+08:00,2,"No Legwork Mondays – Takeda, Eli Lilly And Actos"
e3d1526e-e3fa-4e87-8f03-a420b6d43f2f,2014-04-21T08:00:00.000+08:00,5,UPDATE: Lilly's CYRAMZA is First FDA-Approved Treatment for Advanced Gastric Cancer After Prior Chemotherapy
72945f24-7864-444e-b9ff-5c735d12969a,2014-04-21T08:00:00.000+08:00,4,FDA Approves Cyramza for Stomach Cancer
1215116a-91b0-45f7-9f10-e5153e43b937,2014-04-21T08:00:00.000+08:00,3,"No Legwork Mondays – Takeda, Eli Lilly And Actos"
0c2a25c0-9525-408f-8d52-2791165b085e,2014-04-17T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Trading Higher
64c51107-8d89-4164-a66e-19ef02a1ca07,2014-04-17T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Trading Higher
f55c295d-810a-4528-b538-11e1fcc6bd1b,2014-04-14T08:00:00.000+08:00,5,"Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings"
842f0577-08fd-4e1c-a03a-05e215cbd88e,2014-04-14T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Trading Higher
71eb94df-beb4-4306-a5b3-3f87a1da463a,2014-04-14T08:00:00.000+08:00,5,"Jefferies Upgrades Eli Lilly and Company to Hold, Raises PT to $54.00"
ec990b97-def2-471a-ba9a-d9285689b579,2014-04-14T08:00:00.000+08:00,3,"Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings"
f1c0f0ec-2551-4648-8d56-b431f5f78234,2014-04-14T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Trading Higher
a6649451-de7a-4652-9997-7b208df821f8,2014-04-14T08:00:00.000+08:00,5,"Jefferies Upgrades Eli Lilly and Company to Hold, Raises PT to $54.00"
ca82a87b-b558-43cc-9340-81c501513724,2014-04-10T08:00:00.000+08:00,2,Eli Lilly to Report First Quarter Results April 24th Before Market Open
ea7d3aa8-07fc-4132-998e-6951e3f8c352,2014-04-10T08:00:00.000+08:00,1,Eli Lilly to Report First Quarter Results April 24th Before Market Open
899f799c-ebee-495d-af05-2fa29b0970d5,2014-04-09T08:00:00.000+08:00,3,Anne Marie Baiynd tweets: 'Careful with $LLY - looks like it is on its way to fill the gap'
ff69607e-356f-46df-9a0c-a281d4f7f3fb,2014-04-09T08:00:00.000+08:00,4,Anne Marie Baiynd tweets: 'Careful with $LLY - looks like it is on its way to fill the gap'
eee89727-899f-4dc5-a360-c32440fc1709,2014-04-08T08:00:00.000+08:00,3,Market Wrap For April 8: Markets Bounce Higher As Earnings Season Begins
f513f878-45b0-4633-a76f-79a7f971b832,2014-04-08T08:00:00.000+08:00,2,Fitch Says Lilly's Ratings Intact Following $9B Actos Jury Verdict
1aad4278-f464-4d04-b856-28ad25c197f5,2014-04-08T08:00:00.000+08:00,4,UPDATE: BMO Capital Upgrades Eli Lilly
250844c7-20c7-45f1-a288-1938f5bbbd62,2014-04-08T08:00:00.000+08:00,1,Mark Schoenebaum Tweet: '$LLY will owe nothing in this lost court case. THEY ARE INDEMNIFIED. yet stock down.
8af99583-eace-4db3-8f2d-e0bede6e3bb3,2014-04-08T08:00:00.000+08:00,3,"Lilly Issues Response to Verdict in Case of Terrence Allen, et al. v. Takeda, Says Lilly Will Be Indemnified for Expenses"
38314119-be36-4e44-8a21-e57a1e3fb45b,2014-04-08T08:00:00.000+08:00,4,Benzinga's Top Upgrades
82db7a22-bbef-4f34-9497-4602a04f18d7,2014-04-08T08:00:00.000+08:00,4,"BMO Capital Upgrades Eli Lilly and Company to Market Perform, Raises PT to $62.00"
feb6a63c-1697-49ac-b6dd-5160100c505e,2014-04-08T08:00:00.000+08:00,2,Takeda Responds to $6B Verdict in Diabetes Drug Case
e59a6625-5db7-46d0-8aa3-6949ed6fe85a,2014-04-08T08:00:00.000+08:00,3,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield
b402e675-bd55-4618-9c2c-ecc4ae82419e,2014-04-08T08:00:00.000+08:00,4,Market Wrap For April 8: Markets Bounce Higher As Earnings Season Begins
aab49983-942d-494a-93ee-02c77c7902dc,2014-04-08T08:00:00.000+08:00,1,Fitch Says Lilly's Ratings Intact Following $9B Actos Jury Verdict
23805160-adf1-471f-800a-d40b76ba3693,2014-04-08T08:00:00.000+08:00,4,UPDATE: BMO Capital Upgrades Eli Lilly
bb5cb871-163f-4543-82dd-3ee802192c48,2014-04-08T08:00:00.000+08:00,2,Mark Schoenebaum Tweet: '$LLY will owe nothing in this lost court case. THEY ARE INDEMNIFIED. yet stock down.
d8b4be7d-d0cc-4782-a276-095a809f8c19,2014-04-08T08:00:00.000+08:00,3,"Lilly Issues Response to Verdict in Case of Terrence Allen, et al. v. Takeda, Says Lilly Will Be Indemnified for Expenses"
4eb921e2-981b-4e23-b453-84bd31a7d81d,2014-04-08T08:00:00.000+08:00,4,Benzinga's Top Upgrades
bf6a834a-e961-4455-a0a7-fc3ad3d19361,2014-04-08T08:00:00.000+08:00,5,"BMO Capital Upgrades Eli Lilly and Company to Market Perform, Raises PT to $62.00"
34ba0a10-06dd-412e-af75-58ff9b0d8eca,2014-04-08T08:00:00.000+08:00,2,Takeda Responds to $6B Verdict in Diabetes Drug Case
c85326c5-58da-4484-a73b-f67952ca045d,2014-04-08T08:00:00.000+08:00,1,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield
d9aa0fc3-9516-483c-94a0-ce7f73acfa7e,2014-04-06T08:00:00.000+08:00,3,Lilly to Present Early-Stage Data Targeting Key Cancer Pathways at AACR 2014
6f0ce50b-1b1c-4d25-a842-7ed453b8ded0,2014-04-06T08:00:00.000+08:00,3,Lilly to Present Early-Stage Data Targeting Key Cancer Pathways at AACR 2014
a30c4e1a-3ca1-4c79-adb3-ac4651a29f94,2014-04-03T08:00:00.000+08:00,2,Market Wrap For April 3: Markets Winning Streak Fails To Extend To Five Days
4ff58bf0-27f2-4adf-88ca-cc4a64071daf,2014-04-03T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Makes Multi-Year High And Retreats
ee47c84a-54d2-46de-a77f-4227a23a2f84,2014-04-03T08:00:00.000+08:00,5,UPDATE: Cowen & Company Upgrades Eli Lilly
3801f96a-8bcf-4183-bd03-d3a61a6ad83d,2014-04-03T08:00:00.000+08:00,3,Benzinga's Top Upgrades
bf5b2d25-92cc-4efb-be16-b689e458405e,2014-04-03T08:00:00.000+08:00,5,"Cowen &amp; Company Upgrades Eli Lilly and Company to Outperform, Raises PT to $68.00"
da513649-f9d8-4487-a1ab-3f3ece64c749,2014-04-03T08:00:00.000+08:00,4,Market Wrap For April 3: Markets Winning Streak Fails To Extend To Five Days
c24e7390-1265-4e9e-a7ce-0b7c87e3544c,2014-04-03T08:00:00.000+08:00,4,#Premarket Prep Technical Update - Eli Lilly Makes Multi-Year High And Retreats
3b7d1dd2-bdf0-4af2-b0e6-5b8a01ab4d7d,2014-04-03T08:00:00.000+08:00,5,UPDATE: Cowen & Company Upgrades Eli Lilly
94da8a46-793d-4e3e-b2fb-784736bbddb5,2014-04-03T08:00:00.000+08:00,3,Benzinga's Top Upgrades
b455da6c-6d33-4a5b-b0c1-2917437ca982,2014-04-03T08:00:00.000+08:00,5,"Cowen &amp; Company Upgrades Eli Lilly and Company to Outperform, Raises PT to $68.00"
9b8df812-3008-4685-96cd-f5e91f529aba,2014-04-01T08:00:00.000+08:00,5,Market Wrap For April 1: S&P 500 Hitting New All-Time High Not An April Fools' Joke
80cd6423-06a2-4f82-98db-7ad28465fd1c,2014-04-01T08:00:00.000+08:00,4,Moody's Says Alimta Patent Ruling Credit Positive for Lilly
01fac9cf-d605-41da-a32f-6655bc9ef032,2014-04-01T08:00:00.000+08:00,3,"Eli Lilly Expands Authorized Generic Deals with Prasco, Will Market Authorized Generic of Evista in US"
7187ca82-8800-4ed0-8f60-d9afbb848972,2014-04-01T08:00:00.000+08:00,3,UPDATE: Bank of America Reiterates on Eli Lilly and Co. Following Alimta Case Ruling
990f06d8-059a-4469-a826-27c14f26db38,2014-04-01T08:00:00.000+08:00,5,"Bank of America Maintains Buy on Eli Lilly and Company, Raises PO to $69.00"
23c4bc3f-a883-408f-9388-8c415c2e042e,2014-04-01T08:00:00.000+08:00,2,Market Wrap For April 1: S&P 500 Hitting New All-Time High Not An April Fools' Joke
da4c8ffa-e84c-4cca-a9ed-af640fd22a79,2014-04-01T08:00:00.000+08:00,4,Moody's Says Alimta Patent Ruling Credit Positive for Lilly
3a984d49-1ac2-455e-bf53-7692e4a62b38,2014-04-01T08:00:00.000+08:00,3,"Eli Lilly Expands Authorized Generic Deals with Prasco, Will Market Authorized Generic of Evista in US"
636911c8-1c73-4084-acbf-a75f43a85dbf,2014-04-01T08:00:00.000+08:00,3,UPDATE: Bank of America Reiterates on Eli Lilly and Co. Following Alimta Case Ruling
95c86418-9bc0-43de-8a33-6ac262530307,2014-04-01T08:00:00.000+08:00,5,"Bank of America Maintains Buy on Eli Lilly and Company, Raises PO to $69.00"
54dd9bbc-3b7e-40ea-8b99-6f32ed32ab2a,2014-03-31T08:00:00.000+08:00,5,UPDATE: Court Upholds Validity of Lilly's Alimta Patent Through 2022
87584924-9125-48f3-8fd2-da66e9ebffc8,2014-03-31T08:00:00.000+08:00,5,Federal Judge Upholds Eli Lilly's Alimta Cancer Drug Patent; Had been Challenged by Generic Makers
b88197d2-e44c-44ec-833a-387e24af1238,2014-03-31T08:00:00.000+08:00,5,UPDATE: Court Upholds Validity of Lilly's Alimta Patent Through 2022
8c9429a9-a292-4a3f-9994-9b5df2408e48,2014-03-31T08:00:00.000+08:00,5,Federal Judge Upholds Eli Lilly's Alimta Cancer Drug Patent; Had been Challenged by Generic Makers
2c4747b6-62c5-4c3b-b050-cc30ca5faed3,2014-03-12T08:00:00.000+08:00,3,Eli Lilly Range Bound
67915239-5080-425b-ae9c-64146380a19e,2014-03-12T08:00:00.000+08:00,3,Eli Lilly Range Bound
e0efd12b-c82c-4f11-a680-7a266728870e,2014-03-05T08:00:00.000+08:00,2,Lilly Announces FDA Complete Response Letter for Empagliflozin
9fc80d34-ab18-4f41-8b2a-691bcacf8153,2014-03-05T08:00:00.000+08:00,2,Lilly Announces FDA Complete Response Letter for Empagliflozin
4717236e-3f7a-41b7-a9c4-0a5d783e9d19,2014-03-04T08:00:00.000+08:00,3,Biotechs vs. Pharmaceuticals: What's the Difference?
986d630b-91b8-466c-bf94-a48822a4e9d7,2014-03-04T08:00:00.000+08:00,4,Biotechs vs. Pharmaceuticals: What's the Difference?
bdc7a697-f2ac-4bea-a74d-5085b724d70a,2014-02-25T08:00:00.000+08:00,5,"Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide, Hits Primary Endpoint"
d934599e-ee9c-4c00-af6b-4b0d087af62c,2014-02-25T08:00:00.000+08:00,4,"Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide, Hits Primary Endpoint"
aa455d58-4e5c-46f8-a573-8963186ba4da,2014-02-24T08:00:00.000+08:00,2,Elanco Announces Agreement to Acquire Lohmann Animal Health; Lowers FY 2014 Earnings Guidance to $2.72-2.80 on a Non-GAAP Basis
13cb3153-1d4f-4d71-b2c7-6353a65a7e60,2014-02-24T08:00:00.000+08:00,3,Elanco Announces Agreement to Acquire Lohmann Animal Health; Lowers FY 2014 Earnings Guidance to $2.72-2.80 on a Non-GAAP Basis
c32d16e2-d2c5-4dd4-9bf1-7a9dccfa6ee1,2014-02-19T08:00:00.000+08:00,1,"Market Wrap For February 19: Stocks Close Lower, Nasdaq Ends Winning Streak"
6f74c601-e5ac-4b22-92d2-4a704c0c910d,2014-02-19T08:00:00.000+08:00,5,Eli Lilly Reports Ramucirumab Phase III Met Primary Endpoint of Overall Survival
5dd1e702-27ea-46ec-8e28-83e77b1ad585,2014-02-19T08:00:00.000+08:00,2,"Market Wrap For February 19: Stocks Close Lower, Nasdaq Ends Winning Streak"
d25f8328-4c4e-4160-886b-683ea5299507,2014-02-19T08:00:00.000+08:00,5,Eli Lilly Reports Ramucirumab Phase III Met Primary Endpoint of Overall Survival
8fafa2e1-bc55-4ea5-b2e9-1ff1fb7bb333,2014-01-31T08:00:00.000+08:00,3,Market Wrap For January 31: Markets End January On Sour Note
eec6e180-1753-4dc3-a87e-1f9877f41647,2014-01-31T08:00:00.000+08:00,4,Pfizer vs. Eli Lilly - Which Is The Better Investment?
ffb9b85e-41fd-4ccd-a0c5-a42579d125af,2014-01-31T08:00:00.000+08:00,1,"#PreMarket Primer: Friday, January 31: Emerging Market Turmoil Spills Over Into Europe"
905ce6f7-8551-4943-b7e6-1ef8b561cecf,2014-01-31T08:00:00.000+08:00,2,Market Wrap For January 31: Markets End January On Sour Note
7b65c455-8879-4d13-b4e9-4ba440517b79,2014-01-31T08:00:00.000+08:00,4,Pfizer vs. Eli Lilly - Which Is The Better Investment?
a5878d45-147a-4754-b011-d02e47276f74,2014-01-31T08:00:00.000+08:00,3,"#PreMarket Primer: Friday, January 31: Emerging Market Turmoil Spills Over Into Europe"
60e0ecf0-5ce2-4ba9-bd2e-e7efd7ec91a1,2014-01-30T08:00:00.000+08:00,1,"Sanofi Files Suit in US to Defend Lantus, Lantus SoloStar Patent Rights"
5a8cbadd-e508-4d50-b115-6e544ca0c75c,2014-01-30T08:00:00.000+08:00,2,Market Wrap For January 30: Markets Focus on Good News
66c29c92-3f57-46bb-b458-19bd071cc9cb,2014-01-30T08:00:00.000+08:00,1,Eli Lilly Declines
72a26fc8-90a0-4df6-a8cf-6c5778b63557,2014-01-30T08:00:00.000+08:00,2,UPDATE: Eli Lilly Posts Drop In Q4 Profit
d8de850e-2923-4e09-ac15-aaa4572931d9,2014-01-30T08:00:00.000+08:00,3,"#PreMarket Primer: Thursday, January 30: Fed Cut Stimulus By Further $10 Billion"
873de26d-eeb4-4a47-9891-c1ecb1b40268,2014-01-30T08:00:00.000+08:00,2,"Eli Lilly Reports Q4 Adjusted EPS of $0.74, Inline; Revenue of $5.81B vs $5.45B Est"
99134ff5-0ad3-441b-baed-f19bfa54e9a3,2014-01-30T08:00:00.000+08:00,1,"Earnings Scheduled For January 30, 2014"
cfa4f637-785f-4f29-90b6-6cd733fd7b16,2014-01-30T08:00:00.000+08:00,2,"Sanofi Files Suit in US to Defend Lantus, Lantus SoloStar Patent Rights"
2a395462-8b98-4fb9-bdc0-f372dee7c07c,2014-01-30T08:00:00.000+08:00,5,Market Wrap For January 30: Markets Focus on Good News
de1f9b9f-c606-4691-b835-d8cd6015389b,2014-01-30T08:00:00.000+08:00,1,Eli Lilly Declines
abc3b8bc-3eea-4cab-9641-3bbf4362318e,2014-01-30T08:00:00.000+08:00,3,UPDATE: Eli Lilly Posts Drop In Q4 Profit
becabf15-f6ab-4b27-bd88-5fecc2d11429,2014-01-30T08:00:00.000+08:00,2,"#PreMarket Primer: Thursday, January 30: Fed Cut Stimulus By Further $10 Billion"
5067cbb6-e475-45a7-91a0-4786fe1b4b38,2014-01-30T08:00:00.000+08:00,3,"Eli Lilly Reports Q4 Adjusted EPS of $0.74, Inline; Revenue of $5.81B vs $5.45B Est"
c455e9cc-af35-4224-806d-4e028d88cbf6,2014-01-30T08:00:00.000+08:00,2,"Earnings Scheduled For January 30, 2014"
f9006141-0254-4c3f-8025-0fa17cb6701a,2014-01-28T08:00:00.000+08:00,1,Tug Of War In Ariad Pharmaceuticals
06f03d2a-7a9e-49bf-bd91-eaacceffbfd9,2014-01-28T08:00:00.000+08:00,1,Tug Of War In Ariad Pharmaceuticals
fec14ade-26ca-4155-9b5f-7b3c80b790e7,2014-01-27T08:00:00.000+08:00,2,"Benzinga's M&A Chatter for Monday January 27, 2014"
9d054642-6e91-45d4-93d0-27983b43b762,2014-01-27T08:00:00.000+08:00,4,"Benzinga's M&A Chatter for Monday January 27, 2014"
01f09557-63e3-45b4-a1dc-9ecbd5bb80a2,2014-01-24T08:00:00.000+08:00,3,Benzinga Weekly Preview: Tech Sector To Steal The Spotlight
3b53f8b3-59ea-49ac-98db-b47783905c10,2014-01-24T08:00:00.000+08:00,5,Ariad Shares Continue to Surge Amidst Buyout Rumors
b479bf50-824a-4e63-875e-fe41d4690495,2014-01-24T08:00:00.000+08:00,3,Benzinga Weekly Preview: Tech Sector To Steal The Spotlight
6dfee9cb-520c-43ab-b4ae-12f73755c581,2014-01-24T08:00:00.000+08:00,5,Ariad Shares Continue to Surge Amidst Buyout Rumors
58f28fbc-9283-40a8-a97f-8c06a847459a,2014-01-23T08:00:00.000+08:00,2,Top Trending Tickers On StockTwits For January 23
332fbf54-7308-48b5-8aa6-d129ebcb86d3,2014-01-23T08:00:00.000+08:00,2,Top Trending Tickers On StockTwits For January 23
2148e205-4576-4ea5-a9b4-196f663d19cd,2014-01-22T08:00:00.000+08:00,4,"UK Daily Mail Reports Aria Approached by Big Pharma, Including Lilly"
6069d783-eadd-4cb8-88f2-acd311fa3dc1,2014-01-22T08:00:00.000+08:00,3,"UK Daily Mail Reports Aria Approached by Big Pharma, Including Lilly"
cee283de-9c81-4d8a-85db-3af9f421bbaf,2014-01-16T08:00:00.000+08:00,1,Is The Market On Drugs?
29526df3-d695-4209-849b-5be7a0b2071d,2014-01-16T08:00:00.000+08:00,2,Is The Market On Drugs?
ee160ac1-67fd-4695-93f2-246b04997fa3,2014-01-13T08:00:00.000+08:00,4,Lilly Acquires CGRP Antibody for Migraine Prevention from Arteaus Therapeutics
26fd2b41-2524-4b95-a58d-2eef2bf024fc,2014-01-13T08:00:00.000+08:00,3,Lilly Acquires CGRP Antibody for Migraine Prevention from Arteaus Therapeutics
27c37a4b-44fb-48ee-8d76-8d81b9c01727,2014-01-10T08:00:00.000+08:00,1,"Barclays Downgrades Eli Lilly and Company to Underweight, Lowers PT to $51.00"
48e7727f-ce9b-42ae-b968-cca2e5a03f3a,2014-01-10T08:00:00.000+08:00,1,"Barclays Downgrades Eli Lilly and Company to Underweight, Lowers PT to $51.00"
e14ef86c-d91d-446e-84e5-edf71d125344,2014-01-08T08:00:00.000+08:00,1,"BMO Capital Downgrades Eli Lilly and Company to Underperform, Maintains $50.00 PT"
e6d841ca-a789-40fc-bc7b-ac94cf3683bb,2014-01-08T08:00:00.000+08:00,1,"BMO Capital Downgrades Eli Lilly and Company to Underperform, Maintains $50.00 PT"
1ed34de9-8220-4c2a-a6df-0aff9798bc93,2014-01-07T08:00:00.000+08:00,3,Market Wrap For January 7: Markets Reverse 3-Day Slump
4b5dcdc2-ce0d-42c0-9c65-3251fd6a40eb,2014-01-07T08:00:00.000+08:00,3,Lilly Commited To Maintaining Dividend at Least at Current Level
e4956efd-7dfc-4136-b918-b53fb7289e41,2014-01-07T08:00:00.000+08:00,3,Eli Lilly Reconfirms 2013 Expectations; Sees 2014 EPS $2.77-$2.85
ffadcb02-4b30-4964-914a-bd58f2447bd7,2014-01-07T08:00:00.000+08:00,4,Market Wrap For January 7: Markets Reverse 3-Day Slump
32cb8fdf-1034-42b4-a3e7-14df71c5174b,2014-01-07T08:00:00.000+08:00,4,Lilly Commited To Maintaining Dividend at Least at Current Level
84702580-bc4a-46cf-ab9c-9724af963c87,2014-01-07T08:00:00.000+08:00,3,Eli Lilly Reconfirms 2013 Expectations; Sees 2014 EPS $2.77-$2.85
bfca4a79-ba0e-4685-9a25-21a4b51d3acd,2013-12-20T08:00:00.000+08:00,4,US Stock Futures Gain Ahead Of GDP Data
d66bb648-f6de-447b-bcc3-2a2d6c3e7747,2013-12-20T08:00:00.000+08:00,5,"PeptiDream Announces Collaboration, License Agreement with Lilly"
f937ce62-0256-46ec-ba3b-6ab5049d82e0,2013-12-20T08:00:00.000+08:00,4,US Stock Futures Gain Ahead Of GDP Data
1627b586-ce8e-4a8c-ace1-e6dcb757475a,2013-12-20T08:00:00.000+08:00,5,"PeptiDream Announces Collaboration, License Agreement with Lilly"
0858c24b-d573-41b6-a78c-8822a7ea8767,2013-12-13T08:00:00.000+08:00,3,ImmunoGen Reporting that Lilly May Extend its Pact With Added Payment
08d93bbd-ac69-4b41-a2cb-44799b6cc28d,2013-12-13T08:00:00.000+08:00,5,ImmunoGen Reporting that Lilly May Extend its Pact With Added Payment
cfa79b08-25d6-4698-a816-567a80be6d1f,2013-12-11T08:00:00.000+08:00,2,Citron Pharma Launches Generic Cymbalta Delayed Release Capsules
aa7eeccf-6bda-455d-ae72-e391076e375d,2013-12-11T08:00:00.000+08:00,2,FDA Approves First Generic Versions of Antidepressant Drug Cymbalta
030c842a-12d1-4010-8387-50998888d24b,2013-12-11T08:00:00.000+08:00,3,Citron Pharma Launches Generic Cymbalta Delayed Release Capsules
a4d7b4e2-56c8-4088-b279-bd1aa18b3ce3,2013-12-11T08:00:00.000+08:00,2,FDA Approves First Generic Versions of Antidepressant Drug Cymbalta
2639f672-3deb-43d8-a728-d7eaf3cfd4a4,2013-12-05T08:00:00.000+08:00,1,"Lilly Reports Edivoxetine Did Not Meet Primary Endpoint, Expecting Q4 Charge $0.01/Share"
65ae5038-1b0f-4b41-bb2a-d13ab55b3db3,2013-12-05T08:00:00.000+08:00,1,"Lilly Reports Edivoxetine Did Not Meet Primary Endpoint, Expecting Q4 Charge $0.01/Share"
34c959e0-01d0-409d-b0c3-ba59a07e8931,2013-12-03T08:00:00.000+08:00,2,"Bloomberg Reporting Merck, Eli Lilly Rumored to Be Interested in Novartis' Veterinary Unit"
120609e1-7208-4ba3-95f0-474f5f8ec988,2013-12-03T08:00:00.000+08:00,2,"Bloomberg Reporting Merck, Eli Lilly Rumored to Be Interested in Novartis' Veterinary Unit"
8cc324ad-1326-478b-8234-94e20cbb4925,2013-11-18T08:00:00.000+08:00,3,QIAGEN Announces Agreement to Develop Molecular Companion Diagnostic Paired with Lilly Investigational Cancer Compounds
80f84137-af17-4c5b-a558-22cc644c8e70,2013-11-18T08:00:00.000+08:00,4,QIAGEN Announces Agreement to Develop Molecular Companion Diagnostic Paired with Lilly Investigational Cancer Compounds
93eeaf1e-8287-4fb7-89a3-c5f83b5f94a4,2013-11-14T08:00:00.000+08:00,1,"Actavis Confirms Patent Challenge of Generic Axiron, Says Lilly Filed Suit"
2f1f05f1-5bae-4ded-a1c3-62ed93b7f0cb,2013-11-14T08:00:00.000+08:00,2,US Stock Futures Mixed Ahead of Economic Data
538b116c-01b3-4ba7-8689-6175dbfafd47,2013-11-14T08:00:00.000+08:00,4,Lilly to Invest $700M to Enhance Global Insulin Manufacturing Capacity
3ff5e664-aad6-479f-a8cf-c14755051367,2013-11-14T08:00:00.000+08:00,3,"Actavis Confirms Patent Challenge of Generic Axiron, Says Lilly Filed Suit"
97cdc772-6f1e-42c9-9090-6d74ce37d63f,2013-11-14T08:00:00.000+08:00,2,US Stock Futures Mixed Ahead of Economic Data
f864716e-50e0-4946-9eb3-21c1f1fa3764,2013-11-14T08:00:00.000+08:00,4,Lilly to Invest $700M to Enhance Global Insulin Manufacturing Capacity
47c84021-2968-4001-8939-5a819a75f725,2013-11-11T08:00:00.000+08:00,2,UPDATE: Goldman Sachs Downgrades Eli Lilly & Company on Relative Lack of Differentiation in Pipeline
f8600d92-7197-4e00-a783-a4b0e19a1d4f,2013-11-11T08:00:00.000+08:00,2,Benzinga's Top Downgrades
265ebf09-6dd1-442a-b084-a183e0d86d90,2013-11-11T08:00:00.000+08:00,3,US Stock Futures Mixed After Friday Rally
e159a1c5-4cbe-4420-97f3-153ee6a55efd,2013-11-11T08:00:00.000+08:00,1,"Goldman Sachs Downgrades Eli Lilly and Company to Sell, Lowers PT to $48.00"
09378f11-c62e-408d-9d40-9a2e535f326b,2013-11-11T08:00:00.000+08:00,2,UPDATE: Goldman Sachs Downgrades Eli Lilly & Company on Relative Lack of Differentiation in Pipeline
3b071437-82e9-46a3-880c-412feb9c24b4,2013-11-11T08:00:00.000+08:00,2,Benzinga's Top Downgrades
cf96a8a1-2a28-4865-8c68-194e014250b1,2013-11-11T08:00:00.000+08:00,3,US Stock Futures Mixed After Friday Rally
99ac5d96-2ce0-4722-b313-16edba1d6f53,2013-11-11T08:00:00.000+08:00,1,"Goldman Sachs Downgrades Eli Lilly and Company to Sell, Lowers PT to $48.00"
e4b967f7-d8bd-4431-a8f2-70d35d473db1,2013-10-25T08:00:00.000+08:00,4,UPDATE: FDA Approves Addition to Cialis Product Label
9997a259-7064-4217-beab-485fa5507c5f,2013-10-25T08:00:00.000+08:00,4,Elli Lilly Says FDA Approves Addition to Cialis Product Label
43976ee2-ecba-4211-85b2-1e8c13adcb77,2013-10-25T08:00:00.000+08:00,4,UPDATE: FDA Approves Addition to Cialis Product Label
df654fb1-e1ab-4478-b019-afafeebc1cf0,2013-10-25T08:00:00.000+08:00,4,Elli Lilly Says FDA Approves Addition to Cialis Product Label
28c2ec57-831b-48ee-ba78-bc820a8f64c0,2013-10-24T08:00:00.000+08:00,5,"MKM Partners Upgrades Eli Lilly and Company to Buy, Maintains $59.00 PT"
71a94d3a-b859-4ab6-a70d-9402a469f9f1,2013-10-24T08:00:00.000+08:00,5,"MKM Partners Upgrades Eli Lilly and Company to Buy, Maintains $59.00 PT"
6b01b1ab-99ae-423b-b454-a5ed267794e7,2013-10-23T08:00:00.000+08:00,3,Benzinga's Top Pre-Market Gainers
4ad178b0-82c9-4de8-818d-2d2c334a067a,2013-10-23T08:00:00.000+08:00,2,US Stock Futures Down Ahead Of Earnings
08d48795-8c01-4314-b9a0-d394bedef485,2013-10-23T08:00:00.000+08:00,1,UPDATE: Eli Lilly Q3 Profit Drops 9.3%
9a6d8074-273f-4c8a-95e0-9f322c24c423,2013-10-23T08:00:00.000+08:00,3,Eli Lilly and Company Reports Q3 EPS of $1.11 vs $1.04 Est; Revenue of $5.77B vs $5.76B Est
88debf1e-362f-4874-9fbe-125e46f7d1aa,2013-10-23T08:00:00.000+08:00,4,FDA Grants Priority Review to Lilly's Ramucirumab
ea93f439-3b7e-4b0b-a229-611a206021a5,2013-10-23T08:00:00.000+08:00,1,"Earnings Scheduled For October 23, 2013"
6a8fb7fb-81fc-4588-b79e-f8e8f0930b65,2013-10-23T08:00:00.000+08:00,2,"Stocks To Watch For October 23, 2013"
fd4029d0-080d-44a1-a10d-f6c393dedb5f,2013-10-23T08:00:00.000+08:00,4,Benzinga's Top Pre-Market Gainers
cf6a8f9a-519a-47e3-825d-8d1eb28aeea8,2013-10-23T08:00:00.000+08:00,3,US Stock Futures Down Ahead Of Earnings
9818b550-2218-4789-8066-03aea37075bc,2013-10-23T08:00:00.000+08:00,3,UPDATE: Eli Lilly Q3 Profit Drops 9.3%
5e267437-d369-4db8-bdaf-916befca3fc3,2013-10-23T08:00:00.000+08:00,4,Eli Lilly and Company Reports Q3 EPS of $1.11 vs $1.04 Est; Revenue of $5.77B vs $5.76B Est
a7d3e53c-fb2a-4124-b512-5768af053a13,2013-10-23T08:00:00.000+08:00,5,FDA Grants Priority Review to Lilly's Ramucirumab
47ed9173-5ab4-43b5-814a-7f68cebc68bd,2013-10-23T08:00:00.000+08:00,2,"Earnings Scheduled For October 23, 2013"
c2af5dad-7ecb-4470-84d1-36c084ffbffb,2013-10-23T08:00:00.000+08:00,3,"Stocks To Watch For October 23, 2013"
5cc35889-91d2-4ff0-b8e7-7430b056c113,2013-10-20T08:00:00.000+08:00,4,Earnings Expectations For The Week Of October 21: The Crunch Is On
f040c968-9786-47e7-9d02-8096b1f3d997,2013-10-20T08:00:00.000+08:00,4,Earnings Expectations For The Week Of October 21: The Crunch Is On
f7c73a2b-1022-4fae-ae12-273748ed1326,2013-10-11T08:00:00.000+08:00,2,Fitch Affirms Eli Lilly Rating; Raises Outlook from Negative to Stable
b74e3344-1952-4b45-bf5e-03298e1446b1,2013-10-11T08:00:00.000+08:00,1,"Jefferies Downgrades Eli Lilly and Company to Underperform, Lowers PT to $40.00"
3ed08a6c-44e7-4ca5-ac9c-fec30d04553c,2013-10-11T08:00:00.000+08:00,3,"Market Primer: Friday, October 11: Budget Showdown Could Be Nearing Its End"
f3a0403e-4c07-48cd-b41d-4421725d22cd,2013-10-11T08:00:00.000+08:00,2,Fitch Affirms Eli Lilly Rating; Raises Outlook from Negative to Stable
02cefb01-6c1c-4042-9652-e41c8f52c17a,2013-10-11T08:00:00.000+08:00,1,"Jefferies Downgrades Eli Lilly and Company to Underperform, Lowers PT to $40.00"
7d29ed2f-16b6-41d5-917d-67acb33f33fc,2013-10-11T08:00:00.000+08:00,2,"Market Primer: Friday, October 11: Budget Showdown Could Be Nearing Its End"
186f062c-c15e-4568-943a-e002a457e21e,2013-10-10T08:00:00.000+08:00,1,Edward Jones Upgrades Eli Lilly and Company to Sell
3fe86de1-f41a-4ede-a023-4f561362d0f2,2013-10-10T08:00:00.000+08:00,3,Edward Jones Upgrades Eli Lilly and Company to Sell
b9f22f9a-6004-46b7-9884-30ff8abea195,2013-10-08T08:00:00.000+08:00,3,"Credit Suisse Starts Pfizer, Bristol-Myers, AbbVie, Allergan at Outperform, Merck, Eli Lilly, Forest Labs at Neutral"
cadbf785-6cff-4529-ab1b-e65ab1699b7b,2013-10-08T08:00:00.000+08:00,3,"Credit Suisse Starts Pfizer, Bristol-Myers, AbbVie, Allergan at Outperform, Merck, Eli Lilly, Forest Labs at Neutral"
0b9c91e2-2138-4536-8018-6aef9dbc0532,2013-10-03T08:00:00.000+08:00,2,"PreMarket Info Recap for October 3, 2013: Quiet Markets, Range Bound"
c1ead0f4-356d-4fe4-b373-1320cf56f25b,2013-10-03T08:00:00.000+08:00,4,"Lilly Reaffirms Outlook, Will Buyback Up to $5B in Shares, Maintaining Dividend"
33882050-adc7-4c0c-ac81-51192be5b370,2013-10-03T08:00:00.000+08:00,2,"PreMarket Info Recap for October 3, 2013: Quiet Markets, Range Bound"
58167a17-7cef-4d33-b04c-fa44216890f8,2013-10-03T08:00:00.000+08:00,4,"Lilly Reaffirms Outlook, Will Buyback Up to $5B in Shares, Maintaining Dividend"
363f3694-d561-431f-bffb-4e53e64e9568,2013-10-02T08:00:00.000+08:00,3,Pharmaceutical Industry Expected To Collect Billions From Obamacare
86cd3a12-e5b6-44ba-b1d5-bc802d2166f2,2013-10-02T08:00:00.000+08:00,2,Pharmaceutical Industry Expected To Collect Billions From Obamacare
392aa655-4f8a-4d3b-9142-691dafa6989a,2013-09-30T08:00:00.000+08:00,1,Eli Lilly Says Disappointed in Medicare's Decision to Deny Patient Access to Beta-Amyloid Imaging Agents
33054926-69d4-4cdd-a6ee-818baab45552,2013-09-30T08:00:00.000+08:00,1,Eli Lilly Says Disappointed in Medicare's Decision to Deny Patient Access to Beta-Amyloid Imaging Agents
44534272-20dd-4689-98c5-789450b08ff1,2013-09-28T08:00:00.000+08:00,1,"Lilly Disappointed in Medicare Decision to Deny Appropriate Patient Access to Beta-Amyloid Imaging Agents, Including Amyvid"
df6577b6-b9e0-4c43-b598-945850557a38,2013-09-28T08:00:00.000+08:00,1,"Lilly Disappointed in Medicare Decision to Deny Appropriate Patient Access to Beta-Amyloid Imaging Agents, Including Amyvid"
6e8cd5be-c6af-4011-99a8-80b67f592515,2013-09-26T08:00:00.000+08:00,4,Lilly Shows Investigational Dulaglutide Resulted in Improved Indicators
195573a9-2bb9-45b7-b619-9e03ccfa4492,2013-09-26T08:00:00.000+08:00,3,Lilly Says RAINBOW Trial Met Primary Endpoint; Separate Phase III Trial of Ramucirumab in Women with ROSE Did Not Meet Endpoint
f50777c3-7f19-4ced-902d-c9388a7be30b,2013-09-26T08:00:00.000+08:00,3,Eli Lilly Says RAINBOW Trial Met Primary Endpoint; Separate Phase III Trial of Ramucirumab in Women with ROSE Did Not Meet Endpoint
cc0d6a23-59c3-4ccc-862c-24e80f94f13a,2013-09-26T08:00:00.000+08:00,4,Lilly Shows Investigational Dulaglutide Resulted in Improved Indicators
96acee8f-4ed7-4a19-b694-50f4a37bdc96,2013-09-26T08:00:00.000+08:00,2,Lilly Says RAINBOW Trial Met Primary Endpoint; Separate Phase III Trial of Ramucirumab in Women with ROSE Did Not Meet Endpoint
613b1267-63cc-4b26-84aa-55a23ee66bdd,2013-09-26T08:00:00.000+08:00,2,Eli Lilly Says RAINBOW Trial Met Primary Endpoint; Separate Phase III Trial of Ramucirumab in Women with ROSE Did Not Meet Endpoint
10104538-cae4-4628-8f8d-2d848720db23,2013-09-17T08:00:00.000+08:00,3,Lilly to Present Data Across Diabetes Portfolio at 49th European Association for Study of Diabetes Annual Meeting
14bc4d4d-49d4-48d6-8b6d-bfeb84ba117f,2013-09-17T08:00:00.000+08:00,3,Lilly to Present Data Across Diabetes Portfolio at 49th European Association for Study of Diabetes Annual Meeting
10e78908-f0d6-46d0-913d-80250f8730a7,2013-09-12T08:00:00.000+08:00,1,Benzinga Market Primer for September 12: Kerry and Lavrov Discuss The Terms Of Syria Resolution At Two Day Meeting
5a70c8f7-1a39-467a-a8c5-62139c51b560,2013-09-12T08:00:00.000+08:00,1,Benzinga Market Primer for September 12: Kerry and Lavrov Discuss The Terms Of Syria Resolution At Two Day Meeting
3ed52bf1-5c13-4da7-a4a6-87310e156b16,2013-08-29T08:00:00.000+08:00,4,"Humana, Lilly Collaborate on Research to Improve Health Care Outcomes"
b5ed3c06-daed-47e2-84e9-e5254e64668a,2013-08-29T08:00:00.000+08:00,4,"Humana, Lilly Collaborate on Research to Improve Health Care Outcomes"
345aa172-bfae-4746-abbc-2fb12e5a9b67,2013-08-28T08:00:00.000+08:00,5,Immunogen Shares Charge Higher Following News of Deal with Lilly for TAP Technology
e43f0280-3c9c-448c-9689-f775b7117761,2013-08-28T08:00:00.000+08:00,5,UPDATE: Immuogen May Get Up to $200.5M Under Deal with Eli Lilly
787d7df6-ac20-4968-a349-d69d2ff375ba,2013-08-28T08:00:00.000+08:00,5,Form 8-K Shows Immunogen Entered into License Deal with Eli Lilly for Targeted Antibody Payload Technology
642efb1f-0adb-4807-9954-2b6aafdb047e,2013-08-28T08:00:00.000+08:00,5,Immunogen Shares Charge Higher Following News of Deal with Lilly for TAP Technology
cd1c4efa-43a6-4fc4-a73b-901bd2dd91c5,2013-08-28T08:00:00.000+08:00,4,UPDATE: Immuogen May Get Up to $200.5M Under Deal with Eli Lilly
be9b2226-adc6-4e0b-a561-52b0ea057eb3,2013-08-28T08:00:00.000+08:00,3,Form 8-K Shows Immunogen Entered into License Deal with Eli Lilly for Targeted Antibody Payload Technology
e0d18903-8d01-4b15-ac3a-a9e8b1abf5eb,2013-08-22T08:00:00.000+08:00,1,Eli Lilly Accused of Bribing Doctors in China -WantChinaTimes
3ab6432c-3196-4bea-9d64-e7974d879993,2013-08-22T08:00:00.000+08:00,1,Eli Lilly Accused of Bribing Doctors in China -WantChinaTimes
12aabd3b-5484-4464-bc06-ae9d6bf7a9ac,2013-08-15T08:00:00.000+08:00,5,Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
c18f4ee0-3ef6-4cc6-aeeb-81830282c2d5,2013-08-15T08:00:00.000+08:00,5,Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
f240dd0e-2166-4f9e-84f3-4f113433a138,2013-08-13T08:00:00.000+08:00,4,Eli Lilly Soaring After Positive Cancer Drug Data (LLY)
3facda4a-fce9-421d-b464-6907b144b4d3,2013-08-13T08:00:00.000+08:00,3,"Notable Stocks Trading Ex-Dividend Today: DuPont, Kroger, Eli Lilly, Microsoft, TJX"
79e50fdc-cf1d-42bd-bfda-f0967efd0a3c,2013-08-13T08:00:00.000+08:00,5,Lilly Reports Phase III Necitumumab Study Met Primary Endpoint
9af508d6-86f1-4d4f-9cf0-97f14ec4d5bf,2013-08-13T08:00:00.000+08:00,5,Eli Lilly Soaring After Positive Cancer Drug Data (LLY)
99fd15c1-21c3-4088-89a9-5e8b8d76fe1f,2013-08-13T08:00:00.000+08:00,4,"Notable Stocks Trading Ex-Dividend Today: DuPont, Kroger, Eli Lilly, Microsoft, TJX"
27a6d29a-c3c4-4abd-94ea-1a043973e6fd,2013-08-13T08:00:00.000+08:00,5,Lilly Reports Phase III Necitumumab Study Met Primary Endpoint
61929c91-ead2-4751-bbc5-fcd47356d431,2013-07-25T08:00:00.000+08:00,4,"Barclays Maintains Equal-weight on Eli Lilly and Company, Raises PT to $58.00"
a9cc2a1c-8a28-448a-9bb4-5a95b255a63d,2013-07-25T08:00:00.000+08:00,2,"Benzinga Market Primer: Thursday, July 25: Futures Lower After Technical Breakdown"
9cdf4aed-58c3-46b3-abe9-faeb5f1105b3,2013-07-25T08:00:00.000+08:00,4,"Barclays Maintains Equal-weight on Eli Lilly and Company, Raises PT to $58.00"
4ff941ad-1194-4a90-b209-531b9b36ee9e,2013-07-25T08:00:00.000+08:00,1,"Benzinga Market Primer: Thursday, July 25: Futures Lower After Technical Breakdown"
4669760e-f686-4945-8708-a3cc6d98d0ff,2013-07-24T08:00:00.000+08:00,3,"Benzinga's PreMarket Info Recap for July 24, 2013: Ford and General Motors Trading at 2-Year Highs!"
504cd891-19ae-430e-8c08-46afa505395d,2013-07-24T08:00:00.000+08:00,4,Benzinga's Top Pre-Market Gainers
cc0485ce-0db6-42e4-aa17-397544563d3f,2013-07-24T08:00:00.000+08:00,3,A Peek Into The Market Before The Trading Starts
20df1f75-cb8e-4e40-97b0-3add1ec6d8e2,2013-07-24T08:00:00.000+08:00,4,Eli Lilly and Company Raises FY2013 EPS Guidance from $3.82-3.97 to $4.05-4.15 vs $3.93 Est
5d9f101d-f1c2-4273-8cb8-b4045be0d3dc,2013-07-24T08:00:00.000+08:00,4,"UPDATE: Eli Lilly Posts 31% Rise In Q2 Profit, Lifts Full-Year Outlook"
19682913-db22-4674-b3ae-216737b2ec92,2013-07-24T08:00:00.000+08:00,5,Eli Lilly and Company Reports Q2 EPS of $1.16 vs $1.01 Est; Revenue of $5.92B vs $5.82B Est
c9492cba-a4fe-47a9-b7ce-2cca475f60ee,2013-07-24T08:00:00.000+08:00,3,Eli Lilly and Company Reports Q2 EPS of $1.16 vs $1.01 Est
de89aad4-87f0-457d-959d-b8f853c5a2ef,2013-07-24T08:00:00.000+08:00,2,"Benzinga Market Primer: Wednesday, July 24: Apple Earnings Beat"
7703259c-a6a7-435e-9125-f728ec4d0718,2013-07-24T08:00:00.000+08:00,4,US Stock Futures Rise After Upbeat Apple Results
3df97930-bf04-4c17-abd7-f6ba53cd8895,2013-07-24T08:00:00.000+08:00,1,"Earnings Scheduled For July 24, 2013"
926fbf19-8e55-4e02-a813-2a4dd36f4073,2013-07-24T08:00:00.000+08:00,3,"Benzinga's PreMarket Info Recap for July 24, 2013: Ford and General Motors Trading at 2-Year Highs!"
853284f7-8baa-4f6a-a454-bec954b4adbd,2013-07-24T08:00:00.000+08:00,4,Benzinga's Top Pre-Market Gainers
16a602cf-4ce7-49de-9f4a-d8f7e4917760,2013-07-24T08:00:00.000+08:00,5,A Peek Into The Market Before The Trading Starts
1bcfd00a-2cb9-4b1a-874e-2cac890f8df6,2013-07-24T08:00:00.000+08:00,4,Eli Lilly and Company Raises FY2013 EPS Guidance from $3.82-3.97 to $4.05-4.15 vs $3.93 Est
47aed8de-5cfd-4e7f-a941-3b0074374d5f,2013-07-24T08:00:00.000+08:00,4,"UPDATE: Eli Lilly Posts 31% Rise In Q2 Profit, Lifts Full-Year Outlook"
2e9c050a-82c2-4863-a5d1-a52e07d1fb9e,2013-07-24T08:00:00.000+08:00,5,Eli Lilly and Company Reports Q2 EPS of $1.16 vs $1.01 Est; Revenue of $5.92B vs $5.82B Est
c636a825-eb85-4fa3-90a0-70c1e8b95c98,2013-07-24T08:00:00.000+08:00,3,Eli Lilly and Company Reports Q2 EPS of $1.16 vs $1.01 Est
0f69c158-9228-4d82-bbba-8efe040c0464,2013-07-24T08:00:00.000+08:00,2,"Benzinga Market Primer: Wednesday, July 24: Apple Earnings Beat"
2fc1ff15-0ca3-42f2-aa71-392810ef0e05,2013-07-24T08:00:00.000+08:00,2,US Stock Futures Rise After Upbeat Apple Results
b65ac8d9-bdde-4ff6-b58d-c98d70ec875d,2013-07-24T08:00:00.000+08:00,1,"Earnings Scheduled For July 24, 2013"
866eda4f-6b16-469f-93fb-14dadf7cb990,2013-07-23T08:00:00.000+08:00,3,Transition Therapeutics Enters Osteoarthritis License and Collaboration Agreement with Lilly
400f54b6-1d71-46db-9962-b86ec8215056,2013-07-23T08:00:00.000+08:00,4,Transition Therapeutics Enters Osteoarthritis License and Collaboration Agreement with Lilly
1e2d5e28-1762-4ea1-aaff-412237fb7072,2013-07-22T08:00:00.000+08:00,5,"Earnings Expectations for the Week of July 22 (AAPL, GM, MCD, NFLX)"
6298f0c4-1882-4720-aa5d-80da1f8a6ef7,2013-07-22T08:00:00.000+08:00,2,"Earnings Expectations for the Week of July 22 (AAPL, GM, MCD, NFLX)"
456766f7-7298-4b51-8bc0-7a6015093847,2013-07-19T08:00:00.000+08:00,3,Weekly Preview: Earnings Season Kicks Into Hyperdrive
d9ce6297-4cf7-48fd-ba7d-0e84ee283dd2,2013-07-19T08:00:00.000+08:00,3,Weekly Preview: Earnings Season Kicks Into Hyperdrive
552c7daf-5cac-417c-8f81-b48b18afeb86,2013-07-17T08:00:00.000+08:00,1,"Bloomberg Reporting Eli Lilly Spokesperson Says to Freeze Worker, Exec Pay This Year"
f9abb779-89c4-4f8f-a63a-48f1b19fa786,2013-07-17T08:00:00.000+08:00,1,"Bloomberg Reporting Eli Lilly Spokesperson Says to Freeze Worker, Exec Pay This Year"
eb3ae12f-ad39-4661-be09-fcbac2077327,2013-07-16T08:00:00.000+08:00,2,Eli Lilly Tries Again with Alzheimer's Drug as the Race for a Cure Continues (LLY)
4c3b4172-9497-4ca9-94a5-57f7d4c87e9e,2013-07-16T08:00:00.000+08:00,4,New Study Shows Men Taking Cialis® (tadalafil) Tablets Once Daily Returned to Normal Erectile Function after Incomplete Response to As-Needed PDE5 Inhibitor Therapy
de51daae-68bc-4ac1-82e7-847eeff4e5d2,2013-07-16T08:00:00.000+08:00,2,Eli Lilly Tries Again with Alzheimer's Drug as the Race for a Cure Continues (LLY)
8b2674e7-ed9f-41d7-8e23-be82153decc8,2013-07-16T08:00:00.000+08:00,4,New Study Shows Men Taking Cialis® (tadalafil) Tablets Once Daily Returned to Normal Erectile Function after Incomplete Response to As-Needed PDE5 Inhibitor Therapy
d9426ff6-2bfd-447c-83a0-8a7440fce74f,2013-07-03T08:00:00.000+08:00,1,Lilly to Host Call Discussing Trial Design of New Solanezumab Phase 3 Study
774bdf7b-8934-43d3-966f-b03b9c437a98,2013-07-03T08:00:00.000+08:00,4,Lilly to Host Call Discussing Trial Design of New Solanezumab Phase 3 Study
31a49db2-6a2a-4066-986a-bc1b52f93721,2013-06-25T08:00:00.000+08:00,4,"Boehringer, Lilly Offer Results of CV Post-Hoc Meta-Analysis Examining CV Events in Adults with Type 2 Diabetes Treated with Linagliptin"
8ede2efe-3885-44a4-954a-df1d364cdd5b,2013-06-25T08:00:00.000+08:00,4,"Boehringer, Lilly Offer Results of CV Post-Hoc Meta-Analysis Examining CV Events in Adults with Type 2 Diabetes Treated with Linagliptin"
09875ce2-cf61-4312-8596-dabc4c4e57be,2013-06-22T08:00:00.000+08:00,5,"Phase 3 Study Shows Empagliflozin Significantly Reduced Blood Glucose in Adults with Type 2 Diabetes, Impaired Kidney Function"
04aae31c-20b4-4604-99db-136c0f1949ec,2013-06-22T08:00:00.000+08:00,5,Lilly Announces Phase 3 Data Show Empagliflozin Plus Insulin Significantly Reduced HbA1c in Adults with Type 2 Diabetes
5132747e-7d80-4ba4-86a5-220ed4daa2e1,2013-06-22T08:00:00.000+08:00,5,"Phase 3 Study Shows Empagliflozin Significantly Reduced Blood Glucose in Adults with Type 2 Diabetes, Impaired Kidney Function"
abd8ecdd-98f0-4175-9dfd-0a26e06c7148,2013-06-22T08:00:00.000+08:00,5,Lilly Announces Phase 3 Data Show Empagliflozin Plus Insulin Significantly Reduced HbA1c in Adults with Type 2 Diabetes
f9dec2c0-4c91-44c2-b34e-44023db85b7b,2013-06-20T08:00:00.000+08:00,3,"Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Announce Updates to Prescribing Information for TRADJENTA® (linagliptin) Tablets and JENTADUETO® (linagliptin and metformin hydrochloride) Tablets"
34fcacc3-01e7-4410-a0b7-e194c9de4b90,2013-06-20T08:00:00.000+08:00,4,"Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Announce Updates to Prescribing Information for TRADJENTA® (linagliptin) Tablets and JENTADUETO® (linagliptin and metformin hydrochloride) Tablets"
6c096af2-815e-4a36-bd6a-bf70ff0a3442,2013-06-19T08:00:00.000+08:00,1,Eli Lilly Issues Alert for Two Illegal Scans Involving Co. Name
b85c81ff-fcd0-4022-af7e-d8c29a04f57f,2013-06-19T08:00:00.000+08:00,1,Eli Lilly Issues Alert for Two Illegal Scans Involving Co. Name
9fe4e07c-9f76-47ac-8464-64989b8d4db5,2013-06-13T08:00:00.000+08:00,3,UPDATE: Lilly Doesn't See Charge as Material
9d39ec63-2e46-4f75-9319-8513e01b9d50,2013-06-13T08:00:00.000+08:00,4,"Lilly Issues Release: Voluntarily Terminates Phase II Study of LY2886721, Says Decision Doesn't Affect Other Alzheimer's Compounds, Sees Charge"
8fd24070-ecbc-447e-a917-cf4a1debc383,2013-06-13T08:00:00.000+08:00,5,A Peek Into The Market Before The Trading Starts
ae7594d8-b1ea-4ebb-b951-295e13d80b74,2013-06-13T08:00:00.000+08:00,4,"Lilly, Incyte Announce Baricitinib Efficacy and Safety Data from Phase 2b JADA Study in Patients with Rheumatoid Arthritis"
f2c1da4c-0d44-4133-981a-e8a2f46f345d,2013-06-13T08:00:00.000+08:00,1,UPDATE: Lilly Doesn't See Charge as Material
93348cfb-e981-4548-b71f-b18c6e1c27de,2013-06-13T08:00:00.000+08:00,3,"Lilly Issues Release: Voluntarily Terminates Phase II Study of LY2886721, Says Decision Doesn't Affect Other Alzheimer's Compounds, Sees Charge"
cff27560-620e-4e1b-af85-1221bffa156c,2013-06-13T08:00:00.000+08:00,4,A Peek Into The Market Before The Trading Starts
f6509cf0-e227-49d0-a609-3139bd320117,2013-06-13T08:00:00.000+08:00,4,"Lilly, Incyte Announce Baricitinib Efficacy and Safety Data from Phase 2b JADA Study in Patients with Rheumatoid Arthritis"
034bc397-34f9-4bdb-bc0b-149f4d00f4b7,2013-06-06T08:00:00.000+08:00,2,"Drug Company Profits Set to Increase from Additions to DSM-5 (LLY, NVS, PFE)"
7a223b64-e021-4314-88be-88dd1bb6fc37,2013-06-06T08:00:00.000+08:00,2,"Drug Company Profits Set to Increase from Additions to DSM-5 (LLY, NVS, PFE)"
1ec7fa70-6e24-4264-a160-adef9b3da5ff,2013-06-03T08:00:00.000+08:00,1,Lilly Announces PRONOUNCE Trial Did Not Meet Primary Superiority Endpoint
3202ed7b-1a27-434e-996e-3b320b2a04ec,2013-06-03T08:00:00.000+08:00,1,Lilly Announces PRONOUNCE Trial Did Not Meet Primary Superiority Endpoint
dba0dd1b-348d-4133-958f-09a974754b1b,2013-06-02T08:00:00.000+08:00,4,"CVR Energy, Warner Chilcott and Other Top Performers in May"
81d44725-97fe-44b9-8570-2fa43bad1799,2013-06-02T08:00:00.000+08:00,4,"CVR Energy, Warner Chilcott and Other Top Performers in May"
f6423c63-a1ae-482c-adeb-c9a2d47dcf41,2013-05-29T08:00:00.000+08:00,5,"SunTrust Robinson Humphrey Initiates Coverage on Eli Lilly and Company at Buy, Announces $63.00 PT"
8eae2b2e-f624-46e9-9e50-5893b8ed7855,2013-05-29T08:00:00.000+08:00,4,New Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis
7de8eafb-e43d-4d4b-b241-6aa0846aa7a7,2013-05-29T08:00:00.000+08:00,3,"SunTrust Robinson Humphrey Initiates Coverage on Eli Lilly and Company at Buy, Announces $63.00 PT"
db118bd2-abe8-4da3-8a18-7422bfcc7a5c,2013-05-29T08:00:00.000+08:00,2,New Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis
b789b480-6c44-4343-9bab-dc7245322a3a,2013-05-28T08:00:00.000+08:00,1,"UPDATE: Jefferies Upgrades Eli Lilly to Hold, Raises PT Following SOTP Analysis"
c78f99a7-fff5-4e28-aeca-967edefa62fb,2013-05-28T08:00:00.000+08:00,4,"PreMarket Info Recap for May 28, 2013"
0e611350-1411-4040-92b5-dc6dcfe0b86e,2013-05-28T08:00:00.000+08:00,5,"Jefferies Upgrades Eli Lilly and Company to Hold, Raises PT to $49.00"
4cc4e69a-4444-4f63-b54d-3a491159e71e,2013-05-28T08:00:00.000+08:00,3,"UPDATE: Jefferies Upgrades Eli Lilly to Hold, Raises PT Following SOTP Analysis"
15b311a5-68ee-4768-96f9-cf88a9e8b8c6,2013-05-28T08:00:00.000+08:00,4,"PreMarket Info Recap for May 28, 2013"
8659ca82-7de0-4d76-9256-fb49ca338f2f,2013-05-28T08:00:00.000+08:00,5,"Jefferies Upgrades Eli Lilly and Company to Hold, Raises PT to $49.00"
5ed5b19e-6592-48e2-8975-a1468e0885e7,2013-05-18T08:00:00.000+08:00,2,"U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying"
8094c1dd-6876-4aca-89de-2f5370fa9a1d,2013-05-18T08:00:00.000+08:00,2,"U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying"
7f8e6e77-fa3f-4a8f-aefc-17baec856214,2013-05-14T08:00:00.000+08:00,1,"PreMarket Info Recap for May 14, 2013"
c4f0ff69-9c83-467e-9b1d-6d1a7b69f4fd,2013-05-14T08:00:00.000+08:00,4,Eli Lillly Says CEO John Lechleiter's Surgery Went as Expected
600eb6f2-8ad3-46c1-9b95-7c0822d34ee3,2013-05-14T08:00:00.000+08:00,2,"PreMarket Info Recap for May 14, 2013"
242e23b3-5039-4ddc-b4dc-140ca361c325,2013-05-14T08:00:00.000+08:00,2,Eli Lillly Says CEO John Lechleiter's Surgery Went as Expected
7ff8fc5f-fef1-4a7d-a4e1-5f416ffc1c91,2013-05-10T08:00:00.000+08:00,1,Benzinga's Top Pre-Market Losers
4bf334c0-97bd-449f-a296-3643bc2f2847,2013-05-10T08:00:00.000+08:00,3,Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
4ae9b638-765b-4ebb-9ec3-beb42a885290,2013-05-10T08:00:00.000+08:00,2,Lilly Says Enzastaurin Phase III Did Not Meet Primary Endpoint; Reaffirms Outlook
a4ea921d-b633-4838-b41c-5abe8b1b13a7,2013-05-10T08:00:00.000+08:00,1,Benzinga's Top Pre-Market Losers
ca861dae-f384-4ce3-920d-3d88f9da8c3d,2013-05-10T08:00:00.000+08:00,1,Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
ec90c190-922a-4fce-95c8-ff1a164b635f,2013-05-10T08:00:00.000+08:00,2,Lilly Says Enzastaurin Phase III Did Not Meet Primary Endpoint; Reaffirms Outlook
fc092db8-e7c2-4edb-b998-b683e4681885,2013-05-06T08:00:00.000+08:00,3,Benzinga's Top Pre-Market Losers
c66bfd4c-9bf0-4671-b433-d9927bd94700,2013-05-06T08:00:00.000+08:00,3,Benzinga's Top Pre-Market Losers
e8ed4152-01a5-4770-9ac8-39edc18b5167,2013-04-25T08:00:00.000+08:00,3,"Benzinga Market Primer: Thursday, April 25"
076f508d-a0ba-4a7f-ac94-004432c146e3,2013-04-25T08:00:00.000+08:00,2,"Benzinga Market Primer: Thursday, April 25"
0332c03a-75e4-40d6-a676-9b5c124a062b,2013-04-24T08:00:00.000+08:00,4,Eli Lilly Approaching the April 19th low of $56.37; Currently Seen as Intra-Day Support
1be08b7f-ad96-459e-a190-9d6ba91fbde2,2013-04-24T08:00:00.000+08:00,3,Eli Lilly and Company Reports Q1 EPS of $1.14 vs $1.05 Est; Revenue of $5.60B vs $5.66B Est
ce4ac753-406b-4239-a022-9eba324a21cf,2013-04-24T08:00:00.000+08:00,1,US Stock Futures Up Ahead Of Earnings
df5f2b3b-e6ba-4132-abf7-0a6c2f86f916,2013-04-24T08:00:00.000+08:00,1,"Stocks To Watch For April 24, 2013"
959b04c7-2410-4913-bfe2-3bd70e027639,2013-04-24T08:00:00.000+08:00,2,"Earnings Scheduled For April 24, 2013"
8b759eb8-6ed3-4e58-a546-4432df95b427,2013-04-24T08:00:00.000+08:00,4,Eli Lilly Approaching the April 19th low of $56.37; Currently Seen as Intra-Day Support
963abfcd-23d2-4a23-bc92-0ad03bd543c2,2013-04-24T08:00:00.000+08:00,3,Eli Lilly and Company Reports Q1 EPS of $1.14 vs $1.05 Est; Revenue of $5.60B vs $5.66B Est
6acb4a2f-ad5b-4d8a-8d49-3ee3f0a29016,2013-04-24T08:00:00.000+08:00,4,US Stock Futures Up Ahead Of Earnings
5f85488b-23ac-4c61-9928-f4813cc98fe9,2013-04-24T08:00:00.000+08:00,1,"Stocks To Watch For April 24, 2013"
c85fd82f-4e83-4035-a47c-6009710d83e4,2013-04-24T08:00:00.000+08:00,2,"Earnings Scheduled For April 24, 2013"
c93f7554-e82e-49cb-ac0c-647fa4fd1da7,2013-04-23T08:00:00.000+08:00,3,"Eli Lilly Earnings Preview: EPS, Sales Growth Expected"
6be4b321-3fa5-4b13-92e9-0039c692a295,2013-04-23T08:00:00.000+08:00,3,"Eli Lilly Earnings Preview: EPS, Sales Growth Expected"
c986a4da-a2ef-4213-800c-ec3e3d7e0925,2013-04-21T08:00:00.000+08:00,3,Earnings Expectations for the Week of April 22
4fbcc6f7-34d6-46ed-8204-6a4eecdd4297,2013-04-21T08:00:00.000+08:00,3,Earnings Expectations for the Week of April 22
24bd7c35-1bba-4ddb-9ed0-143a81b90c37,2013-04-19T08:00:00.000+08:00,4,"Weekly Preview: Earnings Season Continues, Apple In Focus"
bcb1d326-cb44-44cf-8223-2308bb9b206e,2013-04-19T08:00:00.000+08:00,4,"Weekly Preview: Earnings Season Continues, Apple In Focus"
c9d91e45-b9ec-4751-a6ea-5584e22bc1cc,2013-04-17T08:00:00.000+08:00,3,Lilly Buys Novel Tau Tangle Diagnostic Progra
d90c4a38-51a0-4ee0-8782-f813743ff344,2013-04-17T08:00:00.000+08:00,4,Lilly Buys Novel Tau Tangle Diagnostic Progra
1d8b19cc-cc9b-4c92-b39d-7ac4b79ee31a,2013-04-16T08:00:00.000+08:00,5,Lilly Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes
70d9cf2a-b98c-4467-bb2c-4971642f3c4b,2013-04-16T08:00:00.000+08:00,5,Lilly Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes
e6aa5273-3e09-4225-863e-d1eb08bd7454,2013-04-11T08:00:00.000+08:00,2,ETF Showdown: A Pharma Fight
cb1a0cfa-d986-4dd5-9299-a87cfd6f41e7,2013-04-11T08:00:00.000+08:00,3,AP Reporting Eli Lilly Planning to Cut Hundreds from US Sales Force by July 1st
5d42b140-1bdf-475a-97dd-6ee2ca875900,2013-04-11T08:00:00.000+08:00,4,ETF Showdown: A Pharma Fight
ae668cf0-f7ec-4274-a47d-4b0f4458d868,2013-04-11T08:00:00.000+08:00,4,AP Reporting Eli Lilly Planning to Cut Hundreds from US Sales Force by July 1st
1b30f816-5258-4880-b4ae-e6e1c7499645,2013-04-10T08:00:00.000+08:00,2,UPDATE: Jefferies Raises PT on Eli Lilly & Co. as Least-Preferred Name
e1654e77-53f2-460b-90b2-8040e46daa93,2013-04-10T08:00:00.000+08:00,2,"Jefferies Maintains Underperform on Eli Lilly and Company, Raises PT to $44.00"
2422486e-9ddd-4d9b-b59c-1c4da1d2e95b,2013-04-10T08:00:00.000+08:00,2,UPDATE: Jefferies Raises PT on Eli Lilly & Co. as Least-Preferred Name
eee284f6-ba63-4f23-b87e-ed4ec88f605c,2013-04-10T08:00:00.000+08:00,4,"Jefferies Maintains Underperform on Eli Lilly and Company, Raises PT to $44.00"
7d054b19-55fc-4f4d-b674-4cf808362fb9,2013-04-09T08:00:00.000+08:00,5,"Eli Lilly Rejects $57.25 Resistance, 20 EMA Support Lower At $56.04, Breakout In Play"
24bb35da-2b46-4d83-a8ba-8c0327e6ebfe,2013-04-09T08:00:00.000+08:00,2,"Eli Lilly Rejects $57.25 Resistance, 20 EMA Support Lower At $56.04, Breakout In Play"
d80ce6bf-a3c9-4660-a00c-7c43eccd239d,2013-04-03T08:00:00.000+08:00,3,"Eli Lilly Attempting To Breakout Over $57 Resistance, RSI Overbought"
1177e2d4-4298-4cfd-9f58-e1474b6cfec3,2013-04-03T08:00:00.000+08:00,3,"Eli Lilly Attempting To Breakout Over $57 Resistance, RSI Overbought"
e4f231cf-9367-447b-b17d-2a97829f53e4,2013-04-02T08:00:00.000+08:00,4,Eli Lilly Working with Indianapolis Officials for Proposal to Invest Added $180M in Insulin Manufacturing Ops
d9e217af-e840-451b-b3cd-0de86fbdcb8d,2013-04-02T08:00:00.000+08:00,5,Eli Lilly Working with Indianapolis Officials for Proposal to Invest Added $180M in Insulin Manufacturing Ops
85940ef7-f4b3-4d84-8c2a-a342cbfdcd60,2013-03-26T08:00:00.000+08:00,2,Eli Lilly Isues Statement Re Intention to Cancel Listing of Shares
e04cecfc-98ab-405c-8eb3-f169938c2ba9,2013-03-26T08:00:00.000+08:00,4,"EMA Accepts Marketing Authorization App for Boehringer, Lilly Empagliflozin"
df4e6d88-ebeb-4f74-be39-a3a0464a3524,2013-03-26T08:00:00.000+08:00,2,Eli Lilly Isues Statement Re Intention to Cancel Listing of Shares
b411b397-11f1-4828-870b-98590ef42d9a,2013-03-26T08:00:00.000+08:00,4,"EMA Accepts Marketing Authorization App for Boehringer, Lilly Empagliflozin"
a829c555-803d-4302-9e1d-fb1d283ca1b3,2013-03-25T08:00:00.000+08:00,3,This Dead Money Sector is Leading the S&P This Year
41d7681d-0a56-473b-b768-6e85f098d75d,2013-03-25T08:00:00.000+08:00,4,This Dead Money Sector is Leading the S&P This Year
12543dee-c325-4cd0-8e76-191698e974dd,2013-03-22T08:00:00.000+08:00,2,"Eli Lilly Fails At $55.75 Resistance, 20 EMA Support Lower At $54.83, Breakout Still In Play"
a24055d2-6ac8-4d00-a017-16645eee086b,2013-03-22T08:00:00.000+08:00,3,"Eli Lilly Fails At $55.75 Resistance, 20 EMA Support Lower At $54.83, Breakout Still In Play"
5b3fd49e-1c60-45db-bad0-204f6842444d,2013-03-18T08:00:00.000+08:00,4,Lilly Says New Study of Cialis Met Primary Endpoint in Men with Lower Urinary Tract Symptoms of Benign Hyperlasia
89bf83a4-737e-4014-9c1d-11d67b4ba8e1,2013-03-18T08:00:00.000+08:00,5,Lilly Says New Study of Cialis Met Primary Endpoint in Men with Lower Urinary Tract Symptoms of Benign Hyperlasia
4620b2c0-85c0-479a-b1be-2c98c0769d1d,2013-03-14T08:00:00.000+08:00,4,Magnet Trades: The Case of Eli Lilly
8552bd98-a81a-4b36-91c0-6abc7b7a56bd,2013-03-14T08:00:00.000+08:00,4,Magnet Trades: The Case of Eli Lilly
d27c8f44-dad8-4b94-ba44-a35903e1a889,2013-03-11T08:00:00.000+08:00,3,Are Scientists Edging Closer to a Cure for Alzheimer's?
02db322f-0a50-4555-8e48-ad11bbbceaf7,2013-03-11T08:00:00.000+08:00,4,Are Scientists Edging Closer to a Cure for Alzheimer's?
db7c72a2-8b2a-4632-a161-4547a1e112d6,2013-03-05T08:00:00.000+08:00,5,"Eli Lilly Breaks Out Over $55 Resistance To Continue Uptrend, MACD Attempting Bullish Crossover"
2b78b476-a4d8-4a49-825a-15acf56ab726,2013-03-05T08:00:00.000+08:00,4,Eli Lilly Sets Date for '13 Diabetes Pipeline Update
51b35a5f-a052-4abf-8650-00359844307a,2013-03-05T08:00:00.000+08:00,5,"Eli Lilly Breaks Out Over $55 Resistance To Continue Uptrend, MACD Attempting Bullish Crossover"
51b90336-2d17-4bc5-86cc-04fdc4aa4b8f,2013-03-05T08:00:00.000+08:00,4,Eli Lilly Sets Date for '13 Diabetes Pipeline Update
2a5c54fe-fa2c-4f4c-832a-2c217a832fa8,2013-03-01T08:00:00.000+08:00,3,Eli Lilly Files Automatic Mixed Securities Shelf
ae2c1682-b3b5-4e60-8b3a-19efbf50b3e2,2013-03-01T08:00:00.000+08:00,4,Eli Lilly Files Automatic Mixed Securities Shelf
f0077ede-0d98-4989-8d6f-41420f2fc22a,2013-02-28T08:00:00.000+08:00,4,"If The Market Falls, Try These Low Beta ETFs"
8ab31f49-842d-4aa1-8931-60ad97b21b08,2013-02-28T08:00:00.000+08:00,4,"If The Market Falls, Try These Low Beta ETFs"
281393dc-7652-4766-b24f-1d4e945a5ddf,2013-02-27T08:00:00.000+08:00,3,Eli Lilly Issues Statement Related to Intention to Cancel Listing of London Stock Exchange Shares
38d1a343-fd0e-4150-b404-6609957e712a,2013-02-27T08:00:00.000+08:00,5,UPDATE: Credit Suisse Raises PT to $68 on Eli Lilly on Patent Ruling Confidence
e6aa0992-95a8-4055-a253-a4d481217cb5,2013-02-27T08:00:00.000+08:00,2,Eli Lilly Issues Statement Related to Intention to Cancel Listing of London Stock Exchange Shares
483d9bc3-c0d6-4998-9d80-d3bbe17ac565,2013-02-27T08:00:00.000+08:00,4,UPDATE: Credit Suisse Raises PT to $68 on Eli Lilly on Patent Ruling Confidence
a54f4998-813e-44d6-a35d-94d12c9a42ed,2013-02-20T08:00:00.000+08:00,5,Eli Lilly Continues Advance After Breakout Over $54 Resistance
bdcb3a30-4309-4357-873d-61eab77ec869,2013-02-20T08:00:00.000+08:00,5,Eli Lilly Continues Advance After Breakout Over $54 Resistance
0b269641-d70d-47de-82c8-1b56b73bd532,2013-02-07T08:00:00.000+08:00,1,Eli Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab
d84ecdf4-97a0-46be-854d-fceea0d9921a,2013-02-07T08:00:00.000+08:00,2,Eli Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab
152f1191-6f40-4f7d-aae3-2112ad734382,2013-02-06T08:00:00.000+08:00,4,Eli Lilly Re-testing Breakout Over $53.50
9484e9e1-9279-4dd6-9751-2e233572b9dd,2013-02-06T08:00:00.000+08:00,4,Eli Lilly Re-testing Breakout Over $53.50
feb7c5fa-a9f6-4b35-a7e8-37b7158aca7f,2013-01-30T08:00:00.000+08:00,3,"UPDATE: Goldman Sachs Reiterates Neutral Rating, Raises PT on Eli Lilly & Company"
d6ad022a-0b2d-4e04-aa59-ddd7ed6bd59d,2013-01-30T08:00:00.000+08:00,4,UPDATE: Citigroup Raises Eli Lilly PT to $60 on Eli Lilly on Potential Upside
0c8a6ff4-21d7-4649-84b7-67295e953af2,2013-01-30T08:00:00.000+08:00,3,"Goldman Sachs Maintains Neutral on Eli Lilly and Company, Raises PT to $56.00"
0b565a7c-d72f-4052-95c7-56d91a8821e0,2013-01-30T08:00:00.000+08:00,5,"Citigroup Maintains Buy on Eli Lilly and Company, Raises PT to $60.00"
f1e0a53f-982a-4c81-9b1b-7b50e1479ed5,2013-01-30T08:00:00.000+08:00,2,"UPDATE: Goldman Sachs Reiterates Neutral Rating, Raises PT on Eli Lilly & Company"
a9da0fee-9a98-474d-a5d4-81d7122934eb,2013-01-30T08:00:00.000+08:00,3,UPDATE: Citigroup Raises Eli Lilly PT to $60 on Eli Lilly on Potential Upside
55cd01b4-fc56-4586-8bae-a54fe96d6f3b,2013-01-30T08:00:00.000+08:00,4,"Goldman Sachs Maintains Neutral on Eli Lilly and Company, Raises PT to $56.00"
8064f62f-7133-4d78-b828-6a641a951f0b,2013-01-30T08:00:00.000+08:00,5,"Citigroup Maintains Buy on Eli Lilly and Company, Raises PT to $60.00"
ba586187-9d0b-409e-a851-e97ffd12a962,2013-01-29T08:00:00.000+08:00,2,Novo Spokesperson Says Will Introduce Tresiba in Some EU Countries in First Half - Bloomberg
c6dbaeaa-750c-4f5e-a5fa-0ae3018db6ac,2013-01-29T08:00:00.000+08:00,3,Lilly Planning Five New Drug Regulatory Filings in 2013
fc6a5b47-0e68-4ab4-975f-4499e59eaa22,2013-01-29T08:00:00.000+08:00,3,"UPDATE: Eli Lilly Posts Upbeat Q4 Profit, Lifts FY13 Forecast"
25013bda-852a-4b73-a240-56e1d342ab0a,2013-01-29T08:00:00.000+08:00,1,Eli Lilly & Co Reports Q4 EPS of $0.85 vs $0.82 Est; Revenue $5.96B vs $5.78B Est
2053bb33-0f24-4e09-8c03-5e490221a2da,2013-01-29T08:00:00.000+08:00,2,"US Stock Futures Slightly Lower Ahead Of Ford Earnings, Consumer Confidence Data"
79e56f08-961f-4dc5-b4a9-72324e2ee385,2013-01-29T08:00:00.000+08:00,3,"Earnings Scheduled For January 29, 2013"
ec963f8c-f845-4d17-8b39-98f6a7db85ee,2013-01-29T08:00:00.000+08:00,2,Novo Spokesperson Says Will Introduce Tresiba in Some EU Countries in First Half - Bloomberg
6d122075-e466-4cd1-8eff-a74c5c419659,2013-01-29T08:00:00.000+08:00,1,Lilly Planning Five New Drug Regulatory Filings in 2013
878782a2-844d-4ff4-8b45-08cf27ae41df,2013-01-29T08:00:00.000+08:00,4,"UPDATE: Eli Lilly Posts Upbeat Q4 Profit, Lifts FY13 Forecast"
1012f832-3bb4-4b52-907a-db11cfa396fc,2013-01-29T08:00:00.000+08:00,5,Eli Lilly & Co Reports Q4 EPS of $0.85 vs $0.82 Est; Revenue $5.96B vs $5.78B Est
07f6e4de-7acc-4268-81c4-3ff1a5db7802,2013-01-29T08:00:00.000+08:00,2,"US Stock Futures Slightly Lower Ahead Of Ford Earnings, Consumer Confidence Data"
7348b022-c4cf-4fcd-9609-36d704b34968,2013-01-29T08:00:00.000+08:00,1,"Earnings Scheduled For January 29, 2013"
da80745c-169a-4c09-aa91-5d08647238dd,2013-01-26T08:00:00.000+08:00,3,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)"
ce9d481d-59a8-4cc0-8877-c065e819c66b,2013-01-26T08:00:00.000+08:00,4,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)"
9c2f0637-2a76-417e-8679-59b001c97244,2013-01-25T08:00:00.000+08:00,3,"The Week Ahead: Earnings from Facebook, Ford, Caterpillar; US Jobs Report"
7cc492df-7c46-465a-a854-f7664e96f706,2013-01-25T08:00:00.000+08:00,1,"The Week Ahead: Earnings from Facebook, Ford, Caterpillar; US Jobs Report"
270be2aa-fb83-4730-890a-26a7053b12cd,2013-01-17T08:00:00.000+08:00,1,"CLSA Initiates Coverage on Eli Lilly and Company at Sell, Announces $47.00 PT"
ec4c201f-2f45-4fa3-a6d6-7bd186d3fc5e,2013-01-17T08:00:00.000+08:00,1,"CLSA Initiates Coverage on Eli Lilly and Company at Sell, Announces $47.00 PT"
52e29b16-ab58-4243-90aa-842c968d2f46,2013-01-16T08:00:00.000+08:00,2,"UPDATE: Jefferies & Company Reiterates Underperform Rating, Raises PT on Eli Lilly & Co."
4e094a60-080c-4329-9222-f6279a5ef8d9,2013-01-16T08:00:00.000+08:00,2,"Jefferies Maintains Underperform on Eli Lilly and Company, Raises PT to $43.00"
cd93065a-1420-411e-bf41-7da4781f3ef3,2013-01-16T08:00:00.000+08:00,2,"UPDATE: Jefferies & Company Reiterates Underperform Rating, Raises PT on Eli Lilly & Co."
867a526e-227b-434e-9ee6-5bf8b2b63ae9,2013-01-16T08:00:00.000+08:00,3,"Jefferies Maintains Underperform on Eli Lilly and Company, Raises PT to $43.00"
7882fe5b-428e-431c-9ffe-07656ad21b37,2013-01-15T08:00:00.000+08:00,4,Lily's Amyvid Approved in EU for Patients with Cognitive Impairment Being Evaluated for Alzheimer's
0469a723-faef-428a-b188-1a97fe805d07,2013-01-15T08:00:00.000+08:00,5,Lily's Amyvid Approved in EU for Patients with Cognitive Impairment Being Evaluated for Alzheimer's
624522f4-14d6-42f7-ac51-4c8fe7a9775f,2013-01-09T08:00:00.000+08:00,1,"UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly & Co."
e106c76f-2ded-4c86-9581-9ee4c5b55098,2013-01-09T08:00:00.000+08:00,4,"Bank of America Maintains Buy on Eli Lilly and Company, Raises PO to $60.00"
71023d99-269c-4cc4-b3e9-57cce6e6a6d6,2013-01-09T08:00:00.000+08:00,4,"UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly & Co."
52ac248a-8acb-46f8-88ba-b36801a65f87,2013-01-09T08:00:00.000+08:00,4,"Bank of America Maintains Buy on Eli Lilly and Company, Raises PO to $60.00"
25a36310-9bb9-446c-99ed-094ab69dd991,2013-01-08T08:00:00.000+08:00,3,Goldman Sachs and Others That May Beat Earnings
a4297307-1e8a-4ab1-a543-32ea8fdda72a,2013-01-08T08:00:00.000+08:00,4,Goldman Sachs and Others That May Beat Earnings
eb6f4b55-adda-472c-a997-04663c000bbd,2013-01-07T08:00:00.000+08:00,2,"UBS Maintains Neutral on Eli Lilly and Company, Raises PT to $51.00"
7fd524c4-5bfd-4494-9e88-4b2635a6d9d8,2013-01-07T08:00:00.000+08:00,2,"UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on Eli Lilly & Co."
d357b2bf-be85-43fd-b4c8-cf9d1c21b403,2013-01-07T08:00:00.000+08:00,4,"Eli Lilly Reassumes Sole Worldwide Development, Commercialization Role for Novel Basal Insulin Analog"
f2ce6416-7098-4055-b7da-2c7b5df6f863,2013-01-07T08:00:00.000+08:00,1,"Stocks To Watch For January 7, 2013"
6e3e28d0-cb58-41d2-a1ee-0d64190a54fc,2013-01-07T08:00:00.000+08:00,2,"UBS Maintains Neutral on Eli Lilly and Company, Raises PT to $51.00"
51d70e38-9533-4c0b-ac7f-a40a238d9150,2013-01-07T08:00:00.000+08:00,2,"UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on Eli Lilly & Co."
0f9d6e04-00af-4520-876d-b7a40e6e4d68,2013-01-07T08:00:00.000+08:00,4,"Eli Lilly Reassumes Sole Worldwide Development, Commercialization Role for Novel Basal Insulin Analog"
0b748392-cc49-48a6-ab65-9bb3702ae094,2013-01-07T08:00:00.000+08:00,3,"Stocks To Watch For January 7, 2013"
ae0ea54b-e583-418b-9340-0b948bba45cb,2013-01-04T08:00:00.000+08:00,4,Eli Lilly Offers Solid FY13 EPS Outlook; Shares Slightly Higher
6783d0d1-030f-4e49-8f69-4a3d03f7c40c,2013-01-04T08:00:00.000+08:00,4,Eli Lilly Offers Solid FY13 EPS Outlook; Shares Slightly Higher
590fc43b-112f-408a-994f-8931568120a3,2012-12-20T08:00:00.000+08:00,2,Eli Lilly to Pay $29.4M to Settle SEC Foreign Bribery Case
9426b327-1ed5-4696-87dd-e74527c1f04f,2012-12-20T08:00:00.000+08:00,2,Eli Lilly to Pay $29.4M to Settle SEC Foreign Bribery Case
358be530-e432-4d4f-b8f4-a8fe87e978b6,2012-12-18T08:00:00.000+08:00,3,"Benzinga Market Primer, Tuesday, December 18"
2a8abf63-04fd-4d24-a168-fdb4d6f523d9,2012-12-18T08:00:00.000+08:00,4,"Benzinga Market Primer, Tuesday, December 18"
ade7a215-bcfb-4caf-a6ff-82df09e9ab6a,2012-12-17T08:00:00.000+08:00,4,"Eli Lilly Authorizes $1.5B Buyback Plan, Declares $0.49/Share Qtr. Dividend"
8217b12d-3202-4d8d-b9f5-659d182e0a0e,2012-12-17T08:00:00.000+08:00,4,"Eli Lilly Authorizes $1.5B Buyback Plan, Declares $0.49/Share Qtr. Dividend"
52012b7d-8fc0-483d-907e-9c1e5dbccbb5,2012-12-13T08:00:00.000+08:00,2,"Eli Lilly Reaffirms FY12 Outlook; Sees Q4 Charge of $20-35M Pretax, or ~$0.02/Share"
b424bc60-8dcc-449b-91bd-95713d6fe8d2,2012-12-13T08:00:00.000+08:00,3,"Eli Lilly Reaffirms FY12 Outlook; Sees Q4 Charge of $20-35M Pretax, or ~$0.02/Share"
e3009722-59ab-4cbb-8041-dd4e5b73adb6,2012-12-12T08:00:00.000+08:00,1,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)"
101f18d4-4dc5-4c5f-9f80-c78c76edf42c,2012-12-12T08:00:00.000+08:00,2,Benzinga's Top Pre-Market Losers
97e98324-c8af-4ede-a766-1ed45fc46505,2012-12-12T08:00:00.000+08:00,2,Eli Lilly Discusses Next Steps for Solanezumab
b38b5c66-5d42-46c0-8296-4555c46802b3,2012-12-12T08:00:00.000+08:00,3,Lilly Provides Update on Solanezumab Phase 3 Study
03c9b0bc-b61c-4030-8ec3-1d02e6f87565,2012-12-12T08:00:00.000+08:00,3,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)"
8711f122-ed98-476d-a744-de6084e5ca31,2012-12-12T08:00:00.000+08:00,1,Benzinga's Top Pre-Market Losers
7082b831-a1ae-40ea-888a-13d9fcdda5e5,2012-12-12T08:00:00.000+08:00,2,Eli Lilly Discusses Next Steps for Solanezumab
e74f11ed-f40c-4750-9906-7ded2118cd82,2012-12-12T08:00:00.000+08:00,4,Lilly Provides Update on Solanezumab Phase 3 Study
6aa7c018-165a-43d1-9443-552493a0cb4b,2012-12-10T08:00:00.000+08:00,3,"Three More Defensive Stock Picks for 2013 (LLY, PFE, VTR)"
3251ee3b-7cba-43bf-a838-fed31c4617d9,2012-12-10T08:00:00.000+08:00,3,"Three More Defensive Stock Picks for 2013 (LLY, PFE, VTR)"
7fda3e63-7dbc-4a5d-985b-daf3174d9b09,2012-11-30T08:00:00.000+08:00,5,"Citigroup Initiates Coverage on Eli Lilly and Company at Buy, Annoucnes $55.00 PT"
dbee2f6b-eee3-4bd7-8812-ff70016e23c4,2012-11-30T08:00:00.000+08:00,5,"Citigroup Initiates Coverage on Eli Lilly and Company at Buy, Annoucnes $55.00 PT"
37b8af7c-b7e1-43e5-9e1b-1d1141e8399c,2012-11-29T08:00:00.000+08:00,4,"Citi Reiterates Buy on Eli Lilly and Company, Maintains $55.00 PT"
5dcb30f5-3756-4b91-9286-2452cfa299d7,2012-11-29T08:00:00.000+08:00,4,"Citi Reiterates Buy on Eli Lilly and Company, Maintains $55.00 PT"
0288f94c-1759-4119-aafd-aa94617a961f,2012-11-21T08:00:00.000+08:00,5,Eli Lilly's Tabalumab Receives Orphan Drug Designation for Multiple Myeloma Treatment
678bc5e6-0197-4d96-a259-0fcd9691f36b,2012-11-21T08:00:00.000+08:00,5,Eli Lilly's Tabalumab Receives Orphan Drug Designation for Multiple Myeloma Treatment
2b70c852-61ea-428c-9c69-33f1d7aedcfc,2012-11-13T08:00:00.000+08:00,5,"Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Advance into Phase III Trials"
81b49430-9a2c-4eaa-a2e3-760e0284ff3d,2012-11-13T08:00:00.000+08:00,4,"Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Advance into Phase III Trials"
04a12752-3d1a-4bd0-8b44-fc3d90fcb967,2012-11-09T08:00:00.000+08:00,3,Lilly to Present Phase II Rheumatoid Arthritis and Biomarker Data at ACR For Two Investigational Medicines to Treat Autoimmune Diseases
d09a3a76-9374-4fdb-954a-127ec45f2219,2012-11-09T08:00:00.000+08:00,3,Lilly to Present Phase II Rheumatoid Arthritis and Biomarker Data at ACR For Two Investigational Medicines to Treat Autoimmune Diseases
22002868-0fb5-4882-a993-e5ea225ce15d,2012-10-30T08:00:00.000+08:00,4,Lilly to Announce Expansion of Indianapolis Insulin Manufacturing Operations
5c938aec-0f42-4934-9e83-fa6eacfc48b8,2012-10-30T08:00:00.000+08:00,5,European Commission Approves Lilly's Cialis for Benign Prostatic Hyperplasia
1c38a578-7336-4509-981e-026a1fece9ba,2012-10-30T08:00:00.000+08:00,2,Lilly to Announce Expansion of Indianapolis Insulin Manufacturing Operations
36eec4fd-ad58-4b5c-8706-39fd534d245f,2012-10-30T08:00:00.000+08:00,4,European Commission Approves Lilly's Cialis for Benign Prostatic Hyperplasia
d4491f95-596a-4ef7-9710-380dbb0a5dfb,2012-10-26T08:00:00.000+08:00,3,"BMO Capital Markets Maintains Eli Lilly & at Market Perform, Lowers PT from $50 to $47"
afda7c9e-5ef9-4a3a-9718-7e4b9fae72b7,2012-10-26T08:00:00.000+08:00,3,"BMO Capital Markets Maintains Eli Lilly & at Market Perform, Lowers PT from $50 to $47"
30ae11cc-073c-4847-92da-b63ba7fa1340,2012-10-25T08:00:00.000+08:00,1,"Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)"
accc49fc-ecd5-4b22-ade7-86360939b76a,2012-10-25T08:00:00.000+08:00,1,"Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)"
ade47abc-9556-4938-bc6d-5bbfcd79a0be,2012-10-24T08:00:00.000+08:00,2,UPDATE: Eli Lilly Posts Downbeat Q3 Profit
17568ba4-9f2c-4bfa-bb25-88567b38a4de,2012-10-24T08:00:00.000+08:00,3,Eli Lilly & Reports Q3 EPS $0.79 vs $0.83 Est; Revenues $5.62B vs $5.62B Est
9a68ff7b-34c7-450c-9389-e197be2ff105,2012-10-24T08:00:00.000+08:00,2,"Earnings Scheduled For October 24, 2012"
f2ee62dc-fa47-44ab-bb9f-334043f798b4,2012-10-24T08:00:00.000+08:00,1,UPDATE: Eli Lilly Posts Downbeat Q3 Profit
0471ea09-935c-4cd2-974d-b18734b70180,2012-10-24T08:00:00.000+08:00,2,Eli Lilly & Reports Q3 EPS $0.79 vs $0.83 Est; Revenues $5.62B vs $5.62B Est
b194330b-46cb-4e71-9340-89c7c980ad8b,2012-10-24T08:00:00.000+08:00,3,"Earnings Scheduled For October 24, 2012"
3084d3da-4408-44c1-8557-c13a97ac4533,2012-10-23T08:00:00.000+08:00,3,Eli Lilly Releases Data From Two Retrospective Studies
960d3ff0-96a2-4645-99e0-6fb6250128f8,2012-10-23T08:00:00.000+08:00,4,New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient or Plavix Presented at TCT
dd4516ff-dace-4877-9fd7-dff9e5e42471,2012-10-23T08:00:00.000+08:00,3,Eli Lilly Releases Data From Two Retrospective Studies
dac5f37f-9a9d-4c2b-988c-77f911187a45,2012-10-23T08:00:00.000+08:00,4,New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient or Plavix Presented at TCT
48cef0c7-ae42-46aa-b9d5-13fe97f0c558,2012-10-22T08:00:00.000+08:00,5,Eli Lilly Says Got Positive Data for Phase III on Type 2 Diabetes Drug
8ad64aa7-9043-45ca-b839-8157c3ba7819,2012-10-22T08:00:00.000+08:00,3,Lilly Diabetes Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes
fbd2ced0-8e88-4305-a570-3c8548733884,2012-10-22T08:00:00.000+08:00,1,Earnings Expectations for the Week of October 22
e918e5ca-55f4-4eb5-a29e-25108910fe9c,2012-10-22T08:00:00.000+08:00,5,Eli Lilly Says Got Positive Data for Phase III on Type 2 Diabetes Drug
1f1b2f48-de57-4bd7-b144-c1d5504b182f,2012-10-22T08:00:00.000+08:00,5,Lilly Diabetes Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes
390e6b6f-49c3-466d-a048-b1a9a242b258,2012-10-22T08:00:00.000+08:00,2,Earnings Expectations for the Week of October 22
f6aedb4f-52ac-4879-9a63-75c5790dc465,2012-10-19T08:00:00.000+08:00,3,Amyvid Recommended for Approval in Europe
ee24e269-f77b-4a11-a307-257a6bc28b08,2012-10-19T08:00:00.000+08:00,4,EU Recommends Approval of Lilly's Brain Plaque Test
1cd248f3-caed-4e29-ba5c-5ce06e722da3,2012-10-19T08:00:00.000+08:00,5,Amyvid Recommended for Approval in Europe
5b9b8e74-d2d8-466c-97d5-f8354598c87e,2012-10-19T08:00:00.000+08:00,4,EU Recommends Approval of Lilly's Brain Plaque Test
30895893-55ea-43f5-8b84-d32f3b52e0cc,2012-10-17T08:00:00.000+08:00,5,ALIMTA Extends Survival in Continuation Maintenance Setting for Specific Lung Cancer Patients
f29640db-fc2f-459b-b14d-f953d4603d95,2012-10-17T08:00:00.000+08:00,5,ALIMTA Extends Survival in Continuation Maintenance Setting for Specific Lung Cancer Patients
d4dd0084-720d-49af-87cb-4a3679fddf59,2012-10-15T08:00:00.000+08:00,3,Lilly Announces New Data Further Exploring Mechanistic Differences Between FORTEO and Zoledronic Acid
47dc97a7-0a14-415f-822b-bc787b51d19b,2012-10-15T08:00:00.000+08:00,5,Leerink Swan Upgrades Eli Lilly & from Market Perform to Outperform
761ff4d2-1c34-4ce9-b013-ee2be71ec44c,2012-10-15T08:00:00.000+08:00,4,Lilly Announces Ramucirumab Showed Prolonged Progression-Free Survival in Gastric Cancer Treatment
47ae3e96-4e9c-4e7a-a183-18a1384e0f33,2012-10-15T08:00:00.000+08:00,3,Lilly Announces New Data Further Exploring Mechanistic Differences Between FORTEO and Zoledronic Acid
72ba73ea-248b-468e-ac69-50d908cd41b4,2012-10-15T08:00:00.000+08:00,5,Leerink Swan Upgrades Eli Lilly & from Market Perform to Outperform
f8462099-e7e6-47dd-b986-38c193c3915e,2012-10-15T08:00:00.000+08:00,2,Lilly Announces Ramucirumab Showed Prolonged Progression-Free Survival in Gastric Cancer Treatment
65bf6fee-c0aa-4099-b352-eb6a28a60a17,2012-10-12T08:00:00.000+08:00,1,Cowen Downgrades Eli Lilly & from Neutral to Underperform
80a6313f-5de0-4b1e-bbb9-01ae85efcf90,2012-10-12T08:00:00.000+08:00,2,"Jefferies & Company Maintains Eli Lilly & at Underperform, Raises PT from $35 to $36"
23a656c1-4853-4beb-a779-49d2b27b93ca,2012-10-12T08:00:00.000+08:00,2,Cowen Downgrades Eli Lilly & from Neutral to Underperform
11cfe37a-500b-4c28-b58b-9c7447e77bad,2012-10-12T08:00:00.000+08:00,3,"Jefferies & Company Maintains Eli Lilly & at Underperform, Raises PT from $35 to $36"
098f7421-29d6-49f0-96fe-bc069cea9926,2012-10-11T08:00:00.000+08:00,4,"Bank of America Maintains Eli Lilly & at Buy, Raises PO from $52 to $57"
a8c8d885-c51e-444f-86bf-62452e5852d4,2012-10-11T08:00:00.000+08:00,4,"Bank of America Maintains Eli Lilly & at Buy, Raises PO from $52 to $57"
31ef3cc2-954c-4bcd-b58b-560a995d3c81,2012-10-09T08:00:00.000+08:00,4,Part I: Must Know ETFs For Q3 Earnings
b70c5eb3-02dd-4134-9969-fd6160d27b0b,2012-10-09T08:00:00.000+08:00,2,UPDATE: Goldman Sachs Upgrades Eli Lilly & Co. to Neutral on Sola Data
1c607aba-2312-4b9b-bf6d-68b266fce682,2012-10-09T08:00:00.000+08:00,3,"UBS Maintains Eli Lilly & at Neutral, Raises PT from $45 to $49"
bf621216-d683-4b3c-97f2-465a0c287036,2012-10-09T08:00:00.000+08:00,4,Lilly Crosses $52 on Heavy Volume
7a0caec2-37f7-4e3b-8ec2-0c3cdb4da53b,2012-10-09T08:00:00.000+08:00,5,"Lilly Hits 52-Week High Following Monday's Positive Phase 3 Results, $51.80"
cfe02024-f3fe-44f4-b009-f3add903af7b,2012-10-09T08:00:00.000+08:00,4,A Peek Into The Market Before The Trading Starts
0061012c-76ef-4d6d-acb9-6a17cd8c29d6,2012-10-09T08:00:00.000+08:00,5,Benzinga's Top Upgrades
3642c2c3-12a6-4100-a3c6-01bcd632f03b,2012-10-09T08:00:00.000+08:00,4,"Goldman Sachs Upgrades Eli Lilly & from Sell to Neutral, Raises PT from $42 to $54"
f93395bd-b2f7-425d-ba04-bc399d341942,2012-10-09T08:00:00.000+08:00,2,Part I: Must Know ETFs For Q3 Earnings
632c1e18-57be-4067-a3b7-a27aaa4dec42,2012-10-09T08:00:00.000+08:00,4,UPDATE: Goldman Sachs Upgrades Eli Lilly & Co. to Neutral on Sola Data
b02a2722-a219-4ac0-abbf-e7706b9f3ff9,2012-10-09T08:00:00.000+08:00,4,"UBS Maintains Eli Lilly & at Neutral, Raises PT from $45 to $49"
d6c4bb1d-54e9-4c61-9828-28c554ece21c,2012-10-09T08:00:00.000+08:00,5,Lilly Crosses $52 on Heavy Volume
4c21fd06-2501-4cf0-b58d-d52e3c1e986c,2012-10-09T08:00:00.000+08:00,5,"Lilly Hits 52-Week High Following Monday's Positive Phase 3 Results, $51.80"
5141d03a-0964-4eaa-bf55-ede551e98814,2012-10-09T08:00:00.000+08:00,4,A Peek Into The Market Before The Trading Starts
8d70e904-9730-44b6-83aa-522d192c7fe6,2012-10-09T08:00:00.000+08:00,4,Benzinga's Top Upgrades
85cdb03a-9dda-40d1-8448-bca05cc4ccd4,2012-10-09T08:00:00.000+08:00,4,"Goldman Sachs Upgrades Eli Lilly & from Sell to Neutral, Raises PT from $42 to $54"
3b37b1bb-0b01-404f-824b-4eb8a2727b39,2012-10-08T08:00:00.000+08:00,2,Hearing BMO Making Cautious Comments on Lilly
1ba6c00a-77e7-4804-8490-ea2020928c1a,2012-10-08T08:00:00.000+08:00,5,Lilly Hits $50 Following Positive Phase 3 Results
1d71f749-76ce-4c81-b299-63ecbd97cf0c,2012-10-08T08:00:00.000+08:00,5,"Lilly Hits 52-Week High on Phase 3 Results, $49.38"
d368cc99-737d-46d5-affe-b90810120699,2012-10-08T08:00:00.000+08:00,3,Eli Lilly Reports Phase 3 Results of Solanezumab; Decline in Expedition1 Study Not Significant
e53263bb-c669-4a0a-a02c-a2bf0d03ac26,2012-10-08T08:00:00.000+08:00,5,Lilly Spiking Higher
d730809e-71e7-4007-a161-03ea3a71b531,2012-10-08T08:00:00.000+08:00,4,Eli Lilly Says Ending Partnership with Amylin Wasn't Easy; Broad Diabetes Pipeline is Advantage; End of Amylin Deal Was Bet on Dulaglutide
2101c3e1-87f3-4096-91b8-ced154e49814,2012-10-08T08:00:00.000+08:00,3,Hearing BMO Making Cautious Comments on Lilly
5557155a-0638-45d0-adbc-8d6d2181108b,2012-10-08T08:00:00.000+08:00,4,Lilly Hits $50 Following Positive Phase 3 Results
2185a0d3-8149-4259-9f2a-18140d7aff0c,2012-10-08T08:00:00.000+08:00,5,"Lilly Hits 52-Week High on Phase 3 Results, $49.38"
e6367cc4-5d6f-4cdd-970f-7308e6c91920,2012-10-08T08:00:00.000+08:00,2,Eli Lilly Reports Phase 3 Results of Solanezumab; Decline in Expedition1 Study Not Significant
80c9ac88-c844-4660-a4ff-977072ca34d9,2012-10-08T08:00:00.000+08:00,4,Lilly Spiking Higher
b46f16b5-4a0e-41a8-94de-f09424580fd9,2012-10-08T08:00:00.000+08:00,3,Eli Lilly Says Ending Partnership with Amylin Wasn't Easy; Broad Diabetes Pipeline is Advantage; End of Amylin Deal Was Bet on Dulaglutide
da3ae2f5-8bc4-4ccb-8c6e-f5317c176554,2012-10-02T08:00:00.000+08:00,4,From Earlier: Lilly and Boehringer Say Linagliptin Treatment Shows Significance
598c58e6-b2b4-442f-8a7f-4a272c437b59,2012-10-02T08:00:00.000+08:00,1,A Peek Into The Market Before The Trading Starts
70fae4fc-d40c-4349-a58b-b1f908e0c02d,2012-10-02T08:00:00.000+08:00,4,Eli Lilly Reports on SGLT-2 Trials
b63a96a0-75ff-4650-834b-86b9511f950d,2012-10-02T08:00:00.000+08:00,5,From Earlier: Lilly and Boehringer Say Linagliptin Treatment Shows Significance
dada36dd-88ef-4550-9d7b-b039f4836fe5,2012-10-02T08:00:00.000+08:00,3,A Peek Into The Market Before The Trading Starts
261af6e9-6079-486a-98fa-19b03f309e65,2012-10-02T08:00:00.000+08:00,1,Eli Lilly Reports on SGLT-2 Trials
a4f582e5-3b74-4827-8f2f-f105f2ab2b90,2012-10-01T08:00:00.000+08:00,1,Deutsche Bank Suspends Coverage on Eli Lilly &
160ee1eb-4779-4522-a7b7-b22357abf689,2012-10-01T08:00:00.000+08:00,4,"Eli Lilly Releases Data from Phase 2 Ramucirumab Trials, Says Indicate May be Beneficial to Patients with Non-Small Cell Lung Cancer"
8244ce8d-f0f8-4310-8300-d97799e5602e,2012-10-01T08:00:00.000+08:00,2,Deutsche Bank Suspends Coverage on Eli Lilly &
e36f7a3d-85c7-4964-aa2f-95fc4d92253d,2012-10-01T08:00:00.000+08:00,3,"Eli Lilly Releases Data from Phase 2 Ramucirumab Trials, Says Indicate May be Beneficial to Patients with Non-Small Cell Lung Cancer"
362a4dd5-5733-4c60-b393-372cba30a68d,2012-09-29T08:00:00.000+08:00,3,Lilly Presents Phase II Results for Monoclonal Antibody Ramucirumab in Lung Cancer
166bbebc-b33e-4173-9e35-1765c8b9c6d5,2012-09-29T08:00:00.000+08:00,4,Lilly Presents Phase II Results for Monoclonal Antibody Ramucirumab in Lung Cancer
9df4e21f-f358-4480-bb75-d4053846d16e,2012-09-26T08:00:00.000+08:00,2,McCormick Appoints Jacques Tapiero to Board of Directors
0a104c08-537c-4a04-bcfc-a528c4693ab1,2012-09-26T08:00:00.000+08:00,3,McCormick Appoints Jacques Tapiero to Board of Directors
500d7ee5-bf01-4aec-9ab1-d7a71eaae2e0,2012-09-21T08:00:00.000+08:00,3,"UBS Maintains Eli Lilly & at Neutral, Raises PT from $42 to $45"
4d4e039f-ba29-46e7-b76c-385930fec198,2012-09-21T08:00:00.000+08:00,4,Cialis Tablets Recommended for Approval for the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia in the European Union
a165aa0d-71bc-442c-b56d-347c3b36cdc6,2012-09-21T08:00:00.000+08:00,3,"UBS Maintains Eli Lilly & at Neutral, Raises PT from $42 to $45"
5a9db520-5bd5-4ec2-b145-0cdfcd033019,2012-09-21T08:00:00.000+08:00,2,Cialis Tablets Recommended for Approval for the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia in the European Union
71fe6def-065a-452b-a7d9-62b3a2768f4f,2012-09-14T08:00:00.000+08:00,1,"UPDATE: Goldman Sachs Reiterates Sell Rating, Raises PT on Eli Lilly & Co."
e046faff-f549-404a-a79b-c7503209a1e6,2012-09-14T08:00:00.000+08:00,3,"Goldman Sachs Maintains Eli Lilly & at Sell, Raises PT from $39 to $42"
0c10d5f1-61a4-4912-809b-857ff666d481,2012-09-14T08:00:00.000+08:00,4,"UPDATE: Goldman Sachs Reiterates Sell Rating, Raises PT on Eli Lilly & Co."
1d9a92ab-5cee-43b4-a3b2-721ce87962ac,2012-09-14T08:00:00.000+08:00,4,"Goldman Sachs Maintains Eli Lilly & at Sell, Raises PT from $39 to $42"
a05acc61-1497-474c-b67a-380a3aed7a09,2012-09-06T08:00:00.000+08:00,2,Seven Cheap Large-Caps Yielding Over 4%
e17142cf-88fe-4996-b97c-dd8cea5a2cd0,2012-09-06T08:00:00.000+08:00,1,Eli Lilly Says Phase III Study on Pointbreak Did Not Meet Primary Endpoint of Improved Overall Survival
9ee74e74-db2f-4b6d-8e2e-e87c4071e3a5,2012-09-06T08:00:00.000+08:00,3,Seven Cheap Large-Caps Yielding Over 4%
0ed3c35c-5a38-44c9-a31f-8cbe5ef14320,2012-09-06T08:00:00.000+08:00,4,Eli Lilly Says Phase III Study on Pointbreak Did Not Meet Primary Endpoint of Improved Overall Survival
14b25e44-185c-485f-a4c0-b1c1f5175c44,2012-09-05T08:00:00.000+08:00,4,"Sanford C. Bernstein Upgraded Eli Lilly & from Market Perform to Outperform, Announced PT to $52"
f6b6f9ee-d5b1-422c-8b8c-1b82e9e17664,2012-09-05T08:00:00.000+08:00,5,"Sanford C. Bernstein Upgraded Eli Lilly & from Market Perform to Outperform, Announced PT to $52"
29453acb-be93-4ba2-9fe7-da711ccb2569,2012-08-29T08:00:00.000+08:00,4,"UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly"
82b34836-5841-40d6-88ba-6bbfa53da03a,2012-08-29T08:00:00.000+08:00,3,"Lilly Stops Phase 3 Development on Schizophrenia Treatment, Sees $0.02 Charge, Forecast for FY12 Unchanged"
10071df7-d13b-498a-bd49-9ae2b0b524a4,2012-08-29T08:00:00.000+08:00,4,"Bank of America Maintains Eli Lilly & at Buy, Raises PO from $46 to $52"
cad6bcbf-b3ee-4cc5-a982-351698855a22,2012-08-29T08:00:00.000+08:00,5,"UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly"
f86377af-69e1-44ff-8db0-aeed197e85b3,2012-08-29T08:00:00.000+08:00,2,"Lilly Stops Phase 3 Development on Schizophrenia Treatment, Sees $0.02 Charge, Forecast for FY12 Unchanged"
cdba07b5-8fe6-49fc-9732-ffc733abba53,2012-08-29T08:00:00.000+08:00,4,"Bank of America Maintains Eli Lilly & at Buy, Raises PO from $46 to $52"
02f9f244-11fe-45d8-9ece-5257c47737de,2012-08-28T08:00:00.000+08:00,3,"Atlantic Equities Upgrades Eli Lilly & from Underweight to Overweight, Announces PT of $49"
2782c668-15fd-4f9b-ac75-bc3f72ae6b99,2012-08-28T08:00:00.000+08:00,4,Benzinga's Top Upgrades
badf9772-293c-40b8-934b-6e614f3f7ad5,2012-08-28T08:00:00.000+08:00,1,A Peek Into The Market Before The Trading Starts
745dd96f-5dea-4762-b53f-dc575ddcacc4,2012-08-28T08:00:00.000+08:00,5,"Atlantic Equities Upgrades Eli Lilly & from Underweight to Overweight, Announces PT of $49"
55a45e21-4e63-45aa-adc7-c14f09fc0bf9,2012-08-28T08:00:00.000+08:00,4,Benzinga's Top Upgrades
88df7a2c-6481-47d3-b5b3-4ba8eaddf0d1,2012-08-28T08:00:00.000+08:00,3,A Peek Into The Market Before The Trading Starts
e2382a53-8000-4536-b73b-58776174544a,2012-08-27T08:00:00.000+08:00,4,Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure
87ac56cc-cae2-49c1-b349-4fa56955be36,2012-08-27T08:00:00.000+08:00,5,Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure
0e90c3a0-fd7a-4b41-a238-7e83754a6609,2012-08-24T08:00:00.000+08:00,2,Eli Lilly Alzheimer's Drug Misses Goals
421c3261-d900-4c2c-adf7-45f65df466e6,2012-08-24T08:00:00.000+08:00,4,U.S. Court of Appeals Upholds Validity of Lilly's Alimta Compound Patent
63e1edb6-600f-453b-a4ba-74affcbd5ae9,2012-08-24T08:00:00.000+08:00,3,Credit Suisse Upgrades Eli Lilly & Co. from Neutral to Outperform
9b96ecdd-160d-44ce-bde9-1efda245b94a,2012-08-24T08:00:00.000+08:00,1,Teva Loses Bid to Invalidate Patent on Lily's Alimata Drug -Bloomberg
184ebafb-fd28-47c8-904a-1d87109540ce,2012-08-24T08:00:00.000+08:00,2,UPDATE: Eli Lilly's Conference Call on Solanezumab Ends
87c23cd7-d2d7-45fb-93bc-75781666d951,2012-08-24T08:00:00.000+08:00,2,UPDATE: Eli Lilly Says Doesn't See Solanezumab Results Affecting Financial View
1dada193-048a-45ba-ba44-061a47eb290b,2012-08-24T08:00:00.000+08:00,1,Jefferies Maintains Underperform on Eli Lilly
9fad7b1a-3961-4582-a7ab-ebb04211a003,2012-08-24T08:00:00.000+08:00,3,"Lilly Rises 9.5% Pre-Market as Alzheimer's Drug Fails to Meet Primary Endpoints, But Slows Progression of Disease"
7f9c4100-7b5f-4430-b219-fed3e9ee2a05,2012-08-24T08:00:00.000+08:00,4,Benzinga's Top Pre-Market Gainers
d421b5dd-384a-4bf8-95f6-fff6a29b9c2a,2012-08-24T08:00:00.000+08:00,1,Eli Lilly Announces Negative Results of Solanezumab Phase 3 Trial
066c471d-ceaa-441e-ab7e-10c183d2c97a,2012-08-24T08:00:00.000+08:00,4,A Peek Into The Market Before The Trading Starts
629edd2d-5f54-46f0-82b7-bb1b38e314b1,2012-08-24T08:00:00.000+08:00,5,Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer's Disease
95d35d05-229c-414f-b13c-6f85520db1d9,2012-08-24T08:00:00.000+08:00,2,Eli Lilly Alzheimer's Drug Misses Goals
07b4875d-ecdf-4a06-94dd-108c62fb6c4b,2012-08-24T08:00:00.000+08:00,3,U.S. Court of Appeals Upholds Validity of Lilly's Alimta Compound Patent
89265846-c338-41d1-bd12-8e19d1359d3e,2012-08-24T08:00:00.000+08:00,5,Credit Suisse Upgrades Eli Lilly & Co. from Neutral to Outperform
4663a1b0-a8d7-4896-86e7-e88c7bc12ac9,2012-08-24T08:00:00.000+08:00,1,Teva Loses Bid to Invalidate Patent on Lily's Alimata Drug -Bloomberg
1340f238-4742-4227-9fc6-a2cc2c224949,2012-08-24T08:00:00.000+08:00,2,UPDATE: Eli Lilly's Conference Call on Solanezumab Ends
1dee5a81-8fe2-48db-b386-ff2d1a54c9d3,2012-08-24T08:00:00.000+08:00,3,UPDATE: Eli Lilly Says Doesn't See Solanezumab Results Affecting Financial View
5b868ff8-0084-4a8a-9a7a-31ea0c0646a7,2012-08-24T08:00:00.000+08:00,4,Jefferies Maintains Underperform on Eli Lilly
c5e64f22-ec01-4c85-a0b1-09cc7902b4e9,2012-08-24T08:00:00.000+08:00,2,"Lilly Rises 9.5% Pre-Market as Alzheimer's Drug Fails to Meet Primary Endpoints, But Slows Progression of Disease"
42cd8783-510b-48f9-ba5a-f6eb5c7e6b05,2012-08-24T08:00:00.000+08:00,2,Benzinga's Top Pre-Market Gainers
435ec150-20bd-4530-b53c-6d0cef010eeb,2012-08-24T08:00:00.000+08:00,1,Eli Lilly Announces Negative Results of Solanezumab Phase 3 Trial
bb89d610-c34f-4acd-ae1f-0496f2715899,2012-08-24T08:00:00.000+08:00,3,A Peek Into The Market Before The Trading Starts
9baa766b-e3fc-4370-acfa-41cb2500de8f,2012-08-24T08:00:00.000+08:00,4,Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer's Disease
643ccce7-8b31-4702-82e2-63c40057008e,2012-08-17T08:00:00.000+08:00,5,FDA Approves Prescribing Eli Lilly's Tradjenta Tablets
a1f50bac-3278-43bb-963c-0299f946f2dc,2012-08-17T08:00:00.000+08:00,3,FDA Approves Prescribing Eli Lilly's Tradjenta Tablets
8a05682b-eae7-4675-9520-367b8258210b,2012-08-12T08:00:00.000+08:00,2,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield
4c318d74-4344-46e4-ba3f-ff3ed2324fcf,2012-08-12T08:00:00.000+08:00,3,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield
116883a7-ecf0-40c6-9426-b8ecd2347e77,2012-08-07T08:00:00.000+08:00,1,"UPDATE: Lilly Says Fewer Forteo Patients Had Worsening Back Pain; Says had 9 Deaths in Study, 4 in Forteo Group and 5 in Risedronate Group"
ec8183fd-c023-412b-96a7-ec5afad88f75,2012-08-07T08:00:00.000+08:00,4,Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
c18c74e4-3b0a-4fc9-bb9c-a1abebabd8c8,2012-08-07T08:00:00.000+08:00,1,Benzinga's Top Pre-Market Losers
e48d2cc6-26f4-48aa-9f08-532c631b2fd5,2012-08-07T08:00:00.000+08:00,3,"UPDATE: Lilly Says Fewer Forteo Patients Had Worsening Back Pain; Says had 9 Deaths in Study, 4 in Forteo Group and 5 in Risedronate Group"
581b003b-8452-4914-9a06-1452fdf1f39e,2012-08-07T08:00:00.000+08:00,4,Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
d5e4bc4e-fbdf-40d9-82e2-9ca5715820a5,2012-08-07T08:00:00.000+08:00,1,Benzinga's Top Pre-Market Losers
7a7413bf-85ad-4e03-ae61-224c1db1f613,2012-07-30T08:00:00.000+08:00,1,"Financial Breakfast: Morning News Summary for July 30, 2012"
32eb7732-43a4-4cb4-92e6-5a164fe8016b,2012-07-30T08:00:00.000+08:00,1,Benzinga's Top Downgrades
1508d176-43d5-47ca-9ce1-2015af4986f6,2012-07-30T08:00:00.000+08:00,1,"Jefferies & Company Downgrades Eli Lilly & from Hold to Underperform, Lowers PT from $37 to $35"
c9063d98-421b-4bb3-b3ae-f5209d7adbec,2012-07-30T08:00:00.000+08:00,3,"Financial Breakfast: Morning News Summary for July 30, 2012"
ab65cad0-440f-4172-be95-014470617505,2012-07-30T08:00:00.000+08:00,1,Benzinga's Top Downgrades
26f2acd2-eb57-42a4-bb33-61a94c2f9ad7,2012-07-30T08:00:00.000+08:00,1,"Jefferies & Company Downgrades Eli Lilly & from Hold to Underperform, Lowers PT from $37 to $35"
af738640-6996-4031-8b3a-83dfd2264331,2012-07-27T08:00:00.000+08:00,4,UPDATE: Morgan Stanley Raises PT on Eli Lily & Co. from $39 to $41
d7a667c2-efc8-4229-83a1-74c0d6b083c9,2012-07-27T08:00:00.000+08:00,4,"Morgan Stanley Maintains Eli Lilly & at Underweight, Raises PT from $39 to $41"
18fe3da0-11a8-4d16-a4b2-aa81748e68ba,2012-07-27T08:00:00.000+08:00,4,UPDATE: Morgan Stanley Raises PT on Eli Lily & Co. from $39 to $41
695e5aea-5ff2-4391-acbb-105f2bb7246e,2012-07-27T08:00:00.000+08:00,4,"Morgan Stanley Maintains Eli Lilly & at Underweight, Raises PT from $39 to $41"
55508ba0-cde7-4892-8455-bf4b8a25531e,2012-07-25T08:00:00.000+08:00,5,Boehringer Ingelheim and Eli Lilly and Company Announced Jentadueto tablets Receive Approval for the Treatment of Adults with Type 2 Diabetes in Europe
0819cfae-951f-4187-bea8-f5920e2086bc,2012-07-25T08:00:00.000+08:00,3,UPDATE: Eli Lilly Sees $250M Generics Effect on Emerging Market Sales
7b9832ee-890c-428d-984d-e7fa2dd4f896,2012-07-25T08:00:00.000+08:00,4,Eli Lilly Says Will Buy Back 420M Shares By the End of the Year
db27feff-4004-42d0-87c7-1c56ccaccbb4,2012-07-25T08:00:00.000+08:00,3,"Financial Breakfast: Morning News Summary for July 25, 2012"
2c2f326f-86c6-41f4-91be-804f5ebf3ff8,2012-07-25T08:00:00.000+08:00,4,"Benzinga Market Primer, Wednesday July 25"
2ef2dffa-84b3-4ba7-a60c-ab0232a6b62d,2012-07-25T08:00:00.000+08:00,4,Eli Lilly & Reports Q2 EPS $0.83 vs $0.77 Est; Revenues $5.6B vs $5.59B Est
11c26c7c-1e33-4341-8d75-6d883e3c28fd,2012-07-25T08:00:00.000+08:00,3,US Stock Futures Mixed; Apple Shares Drop In Pre-Market Trading
2414590b-8822-4159-a20e-13866d862b3d,2012-07-25T08:00:00.000+08:00,1,Earnings Scheduled For July 25
669c1d70-118f-48ff-9add-775e03bcf9c1,2012-07-25T08:00:00.000+08:00,4,Boehringer Ingelheim and Eli Lilly and Company Announced Jentadueto tablets Receive Approval for the Treatment of Adults with Type 2 Diabetes in Europe
699f854d-6ffa-4e2e-8e3c-0372a0c2c628,2012-07-25T08:00:00.000+08:00,2,UPDATE: Eli Lilly Sees $250M Generics Effect on Emerging Market Sales
f255d962-5a90-49b9-bfdf-840a78170597,2012-07-25T08:00:00.000+08:00,4,Eli Lilly Says Will Buy Back 420M Shares By the End of the Year
3234135d-56e3-4913-b696-e2129036868a,2012-07-25T08:00:00.000+08:00,2,"Financial Breakfast: Morning News Summary for July 25, 2012"
76edebe9-68ad-4ac9-8274-6d4055a8e67e,2012-07-25T08:00:00.000+08:00,3,"Benzinga Market Primer, Wednesday July 25"
47af71de-4ba3-432e-ac63-16adb2ce75b3,2012-07-25T08:00:00.000+08:00,4,Eli Lilly & Reports Q2 EPS $0.83 vs $0.77 Est; Revenues $5.6B vs $5.59B Est
85613045-8eee-471d-b538-656fdeb09d1a,2012-07-25T08:00:00.000+08:00,1,US Stock Futures Mixed; Apple Shares Drop In Pre-Market Trading
fbb2a401-7903-4e26-92dc-626e4fb0c4b4,2012-07-25T08:00:00.000+08:00,3,Earnings Scheduled For July 25
043e941d-6cd8-46d7-a403-ec5ac6d4ec18,2012-07-24T08:00:00.000+08:00,2,What You Need in Order to Retire Before Age 60
16a57233-3ca1-443d-9c5f-9a392424d03b,2012-07-24T08:00:00.000+08:00,2,What You Need in Order to Retire Before Age 60
394ca6d0-a203-41fd-90bc-83a9ba4cdf35,2012-07-23T08:00:00.000+08:00,3,From Earlier: Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO and Protease Inhibitor Combination in Healthy Volunteers
229cc6c9-2f73-4b96-8b7f-b5156b29bc53,2012-07-23T08:00:00.000+08:00,1,Earnings Expectations for the Week of July 23
78114a2a-943c-474d-a1b2-fc089e7b50e3,2012-07-23T08:00:00.000+08:00,2,From Earlier: Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO and Protease Inhibitor Combination in Healthy Volunteers
81d08aab-5fec-4e07-8963-ce0327380a30,2012-07-23T08:00:00.000+08:00,2,Earnings Expectations for the Week of July 23
1e21120b-95a2-4296-931d-4855709bc900,2012-07-22T08:00:00.000+08:00,3,Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO and Protease Inhibitor Combination in Healthy Volunteers
65eb651d-8283-4825-ae3c-1b4199567d7f,2012-07-22T08:00:00.000+08:00,3,Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO and Protease Inhibitor Combination in Healthy Volunteers
92598e6e-d692-437c-94bb-bf483ab608d2,2012-07-18T08:00:00.000+08:00,4,"Morgan Stanley Maintains Eli Lilly & at Underweight, Raises PT from $35 to $39"
dfa339ca-7f70-4039-b0e7-2539dbad5f45,2012-07-18T08:00:00.000+08:00,4,"Morgan Stanley Maintains Eli Lilly & at Underweight, Raises PT from $35 to $39"
35726b85-9b40-4944-84e5-4228e4eebc62,2012-07-13T08:00:00.000+08:00,2,3 New Bets by a Biotech Hedge Fund
05e36599-3ee9-4928-b81c-9189af4a220b,2012-07-13T08:00:00.000+08:00,3,"Jefferies & Company Maintains Eli Lilly & at Hold, Raises PT from $36 to $37"
f373dd8d-e4aa-4f6d-a932-e40200c8109d,2012-07-13T08:00:00.000+08:00,3,3 New Bets by a Biotech Hedge Fund
6ad6978a-5309-4c34-b600-577089885bc0,2012-07-13T08:00:00.000+08:00,3,"Jefferies & Company Maintains Eli Lilly & at Hold, Raises PT from $36 to $37"
1302b217-6e61-45d2-b8b2-bd266af54203,2012-07-11T08:00:00.000+08:00,1,Lilly's Schizophrenia Drug as Effective as Placebo -IBD
71d13597-456c-4f15-8586-feade11a836c,2012-07-11T08:00:00.000+08:00,1,Eli Lilly Announces Negative Clinical Trial Results From Schizophrenia Study
d56fbf6c-c5f8-4b28-aabd-9236dd88592b,2012-07-11T08:00:00.000+08:00,1,Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
2c70f42d-93d6-4e9a-a32c-c96223d45893,2012-07-11T08:00:00.000+08:00,2,Lilly's Schizophrenia Drug as Effective as Placebo -IBD
c01113ff-0906-4e7d-9296-68a78ffdf277,2012-07-11T08:00:00.000+08:00,1,Eli Lilly Announces Negative Clinical Trial Results From Schizophrenia Study
9ecb8ed9-3656-4e01-b94d-4333e2e3c017,2012-07-11T08:00:00.000+08:00,1,Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
c2ed00e5-3b2b-473d-bb7f-1929c1a6c39e,2012-07-10T08:00:00.000+08:00,2,"Immigrants: Restless Dreamers, Economic Pillars"
87334562-96ff-4c2c-ba52-19bc5971e627,2012-07-10T08:00:00.000+08:00,2,"Immigrants: Restless Dreamers, Economic Pillars"
5e26c9c0-5b18-4356-85a4-168cb963c9bc,2012-07-06T08:00:00.000+08:00,4,Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta (duloxetine HCl)
110eb3a7-b2cd-4736-b9d2-a3468b33f57d,2012-07-06T08:00:00.000+08:00,4,Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta (duloxetine HCl)
6c4c4952-ad49-4996-93a4-012d52b8e374,2012-07-06T08:00:00.000+08:00,4,Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta (duloxetine HCl)
f6bba038-a747-404d-9324-fa5e9e41bf5d,2012-07-06T08:00:00.000+08:00,2,Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta (duloxetine HCl)
d0ea7e9a-35ea-4b77-b931-daa86cff7faa,2012-07-02T08:00:00.000+08:00,1,Bristol-Myers to Acquire Amylin
62292901-d333-4c33-832d-cdee655369c4,2012-07-02T08:00:00.000+08:00,1,Bristol-Myers to Acquire Amylin
cd511660-f90b-454c-acb4-c8bc43599f79,2012-06-28T08:00:00.000+08:00,1,Lilly Statement on Affordable Care Act Ruling by Supreme Court
6e9ec1d7-4b81-4487-945c-63250f6e1c6f,2012-06-28T08:00:00.000+08:00,1,Lilly Statement on Affordable Care Act Ruling by Supreme Court
d666528e-a7b6-406e-9c8e-41fa64f1bf5a,2012-06-27T08:00:00.000+08:00,4,UPDATE: Goldman Sachs Raises PT on Eli Lily & Company to $38
161b0da3-9488-4902-847f-9ad35b4cc10a,2012-06-27T08:00:00.000+08:00,1,"Goldman Sachs Maintains Eli Lilly & Company at Sell, Raises PT from $35 to $38"
e5bf1e18-ccbf-4f6e-ae24-9d327ce12f22,2012-06-27T08:00:00.000+08:00,3,UPDATE: Goldman Sachs Raises PT on Eli Lily & Company to $38
ba91e535-9c92-4d88-b9d5-3cfa7f934f92,2012-06-27T08:00:00.000+08:00,1,"Goldman Sachs Maintains Eli Lilly & Company at Sell, Raises PT from $35 to $38"
723eae31-e946-44cf-9395-c970f5df5073,2012-06-26T08:00:00.000+08:00,2,Lilly Puts Statement Out on Pdufa Vote
f1a11e32-0cbd-4b7b-85eb-a1ebf1d43ae4,2012-06-26T08:00:00.000+08:00,2,Lilly Puts Statement Out on Pdufa Vote
6491e868-caeb-4257-af29-2bb2a01381a4,2012-06-19T08:00:00.000+08:00,3,"Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program"
1be344fc-508a-4885-9e2b-82c720379b41,2012-06-19T08:00:00.000+08:00,3,"Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program"
c65c69d3-63bc-4eb4-947f-2e0096f61867,2012-06-11T08:00:00.000+08:00,4,"Lilly Releases Data on Diabetes Drug, Patients Lost Weight on Lilly's Drug, Gained on Sanofi's"
75e0c3f3-5f6c-46e4-bab1-c0b4004f6df2,2012-06-11T08:00:00.000+08:00,4,"Lilly Releases Data on Diabetes Drug, Patients Lost Weight on Lilly's Drug, Gained on Sanofi's"
e5b4e7a3-b4f8-4e99-aa69-14064aa87ce2,2012-06-08T08:00:00.000+08:00,4,"UPDATE: Lilly Says 1 Serious Adverse Event in 8 MG Group, 4 Serious Adverse Events in 2 MG Group, No Deaths or Opportunistic Infection in Active Treatment Group"
95af3855-9c47-43cc-b7b0-ab050e596f83,2012-06-08T08:00:00.000+08:00,5,"Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis"
96ee5106-50a2-495f-8a97-a1682cedb640,2012-06-08T08:00:00.000+08:00,3,"UPDATE: Lilly Says 1 Serious Adverse Event in 8 MG Group, 4 Serious Adverse Events in 2 MG Group, No Deaths or Opportunistic Infection in Active Treatment Group"
30172664-2326-4f1a-9e93-b2707065291a,2012-06-08T08:00:00.000+08:00,5,"Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis"
78a28691-e1fc-4e97-860a-328b8749b81b,2012-06-06T08:00:00.000+08:00,2,Eli Lilly's CEO Says No Large Pharma Deals Coming -WSJ
47fe515e-c975-4fe1-b16d-b2f1a9ed9703,2012-06-06T08:00:00.000+08:00,4,Eli Lilly's CEO Says No Large Pharma Deals Coming -WSJ
6a4244a4-e293-4771-8acb-94285f790c3b,2012-06-04T08:00:00.000+08:00,5,Eli Lilly Announces Lung Cancer Study Showed Encouraging Results For ALIMTA-based Regimens And Full-dose Radiation
87005e0c-9fd8-45fe-973e-e927a9895f77,2012-06-04T08:00:00.000+08:00,3,Eli Lilly Announces Patients With Most Common Type Of Lung Cancer Lived Longer With ALIMTA-Based Continuation Maintenance Therapy
03c635ef-4989-4025-92bb-cd43b220b3de,2012-06-04T08:00:00.000+08:00,5,Eli Lilly Announces Lung Cancer Study Showed Encouraging Results For ALIMTA-based Regimens And Full-dose Radiation
eda3b40b-0540-43df-83d8-03859db58917,2012-06-04T08:00:00.000+08:00,5,Eli Lilly Announces Patients With Most Common Type Of Lung Cancer Lived Longer With ALIMTA-Based Continuation Maintenance Therapy
3b167577-1614-457e-a09c-82d67a4a05b4,2012-06-01T08:00:00.000+08:00,4,Eli Lilly Says Amyvid Now Available in Select US Markets
ec8f331d-25f5-40c0-ad08-4a27d8d82303,2012-06-01T08:00:00.000+08:00,4,"Cardinal Health to Manufacture, Distribute Eli Lilly and Company's Brain Imaging Agent Amyvid"
23b3830b-8e63-4266-bdbb-a661a17634dd,2012-06-01T08:00:00.000+08:00,4,Eli Lilly Says Amyvid Now Available in Select US Markets
23546718-773f-47b0-9e54-8db8ce26fcbf,2012-06-01T08:00:00.000+08:00,3,"Cardinal Health to Manufacture, Distribute Eli Lilly and Company's Brain Imaging Agent Amyvid"
43da27a8-9a25-4e80-b786-a1e0586fe71f,2012-05-31T08:00:00.000+08:00,2,15 Great Stocks with Great Yield
f1ad4e3c-0c99-4073-8947-127dde934711,2012-05-31T08:00:00.000+08:00,2,Vivus' Qnexa Is Not Guaranteed Approval. Remember Provenge?
bdadc30f-df41-45d1-9b04-90d0397de432,2012-05-31T08:00:00.000+08:00,4,Lily: New Data Showed LIVALO Met Primary Endpoint of LDL-C Reduction When Compared with Pravastatin
717c2358-edff-4f4e-a21c-d3c47d39b1aa,2012-05-31T08:00:00.000+08:00,3,15 Great Stocks with Great Yield
38ab2c5e-1d1e-4ec9-a90c-72a740172773,2012-05-31T08:00:00.000+08:00,2,Vivus' Qnexa Is Not Guaranteed Approval. Remember Provenge?
c95849d6-dc69-4ff1-86fa-3ec85c3f33b8,2012-05-31T08:00:00.000+08:00,4,Lily: New Data Showed LIVALO Met Primary Endpoint of LDL-C Reduction When Compared with Pravastatin
88a20336-44b2-4a19-abac-f321eca069c7,2012-05-29T08:00:00.000+08:00,4,Eli Lilly Announces Jentadueto Tablets Recommended for Approval in Treatment of Adults with Type 2 Diabetes in Europe
a3cc43f7-12ec-44b5-ab99-24c98b663bb9,2012-05-29T08:00:00.000+08:00,4,Eli Lilly Announces Jentadueto Tablets Recommended for Approval in Treatment of Adults with Type 2 Diabetes in Europe
f7f71730-4913-4b25-9b76-11da0d3d4c3b,2012-05-24T08:00:00.000+08:00,2,FDA Fee Bill Gets Enough Support for Passage as Vote Continues -Bloomberg
eeda4c50-3599-459a-a38e-481fede2eb85,2012-05-24T08:00:00.000+08:00,5,New Phase 3 data for Tradjenta
dca3ba72-b8ed-47b6-a467-b4899dda0d78,2012-05-24T08:00:00.000+08:00,4,FDA Fee Bill Gets Enough Support for Passage as Vote Continues -Bloomberg
9e13345a-c464-4043-9340-4a88c469c10a,2012-05-24T08:00:00.000+08:00,4,New Phase 3 data for Tradjenta
d1a16a3e-4e12-48af-aeb7-7aac82588f31,2012-05-18T08:00:00.000+08:00,3,"BMO Capital Markets Initiates Coverage on Eli Lilly & at Market Perform, Announces PT of $38"
fc23668d-f83e-4d77-bd26-c030e1d65f4f,2012-05-18T08:00:00.000+08:00,3,"BMO Capital Markets Initiates Coverage on Eli Lilly & at Market Perform, Announces PT of $38"
2083346e-17f4-48a3-b08d-03c775987912,2012-05-17T08:00:00.000+08:00,4,Eli Lilly Receives Positive Mad Money/Jim Cramer Mention -CNBC
6b62beed-ac12-40f1-a73e-0c8ba27f91ba,2012-05-17T08:00:00.000+08:00,5,Eli Lilly Receives Positive Mad Money/Jim Cramer Mention -CNBC
28c28f07-0fa5-4299-89ac-654413ecbcf1,2012-05-10T08:00:00.000+08:00,4,Option Alert: Heavy Volume in Lilly Calls
fdc591b3-9dbe-494c-92a2-c7b9ff48c05f,2012-05-10T08:00:00.000+08:00,4,Option Alert: Heavy Volume in Lilly Calls
f268d8fc-06cd-417e-b256-dccec2cd0483,2012-05-07T08:00:00.000+08:00,5,UPDATE: Bank of America Increases PO on Eli Lilly & Co to $46
cc62d243-8749-4441-a3d1-35dbcb036f26,2012-05-07T08:00:00.000+08:00,5,"Bank of America Maintains Eli Lilly at Buy, Raises PO from $43 to $46"
5a83041b-4a57-4684-aed9-d02b07f7d4f8,2012-05-07T08:00:00.000+08:00,5,UPDATE: Bank of America Increases PO on Eli Lilly & Co to $46
e8012807-64b4-4266-bcff-88091ce3fb0d,2012-05-07T08:00:00.000+08:00,4,"Bank of America Maintains Eli Lilly at Buy, Raises PO from $43 to $46"
ee9ae926-2666-4be0-b444-32053f029c35,2012-05-04T08:00:00.000+08:00,3,"Option Alert: Eli Lilly July 42 Call; Block Trade: 6,000 Contracts; Currently $41.20"
a5d8cab4-9f00-4d6e-ab09-90a2361e72da,2012-05-04T08:00:00.000+08:00,3,"Option Alert: Eli Lilly July 42 Call; Block Trade: 6,000 Contracts; Currently $41.20"
ee8ca5f8-9666-448d-a180-0d47ecbf4c92,2012-04-30T08:00:00.000+08:00,5,FDA Considering Letting Patients Purchase Drugs Without Prescriptions
fb268ea3-0c68-4d63-aa74-15e9ad9ff89f,2012-04-30T08:00:00.000+08:00,5,FDA Considering Letting Patients Purchase Drugs Without Prescriptions
0cf37ea4-3d54-46b6-ae64-b8f711ca811f,2012-04-25T08:00:00.000+08:00,4,"Financial Breakfast: Morning News Summary for April 25, 2012"
9e046e71-90c4-4c39-8cd4-0d6ca975d0ce,2012-04-25T08:00:00.000+08:00,4,Eli Lilly &amp; Reports Q1 EPS $0.92 vs $0.79 Est; Revenues $5.6B vs $5.35B Est
d11f9b79-2a0b-4c2d-acf7-26e861ae4a26,2012-04-25T08:00:00.000+08:00,3,Earnings Scheduled For April 25
cc85d15c-612c-4f30-be92-906ffb94be42,2012-04-25T08:00:00.000+08:00,4,"Financial Breakfast: Morning News Summary for April 25, 2012"
b990c6a6-8a29-4605-9453-9743b2ac971d,2012-04-25T08:00:00.000+08:00,4,Eli Lilly &amp; Reports Q1 EPS $0.92 vs $0.79 Est; Revenues $5.6B vs $5.35B Est
fd01f95f-f30b-426d-9a19-1054371dd64c,2012-04-25T08:00:00.000+08:00,2,Earnings Scheduled For April 25
953d7bf9-f191-4f69-add8-458f28c525e0,2012-04-22T08:00:00.000+08:00,3,"Earnings Expectations for the Week of April 23 (AAPL, XOM, UPS)"
63b2e93d-cd54-4e49-b490-659fbcd1133d,2012-04-22T08:00:00.000+08:00,3,"Earnings Expectations for the Week of April 23 (AAPL, XOM, UPS)"
34b88db0-9bdd-4e11-b318-ae08279749b9,2012-04-18T08:00:00.000+08:00,1,Why our portfolio is John Deere green
68c958a7-f521-4c80-b893-1ddaf325c73e,2012-04-18T08:00:00.000+08:00,1,Why our portfolio is John Deere green
d543a803-0ca6-4b90-b12b-5d0fa36d7368,2012-04-16T08:00:00.000+08:00,4,How I approach biotech investing
12333a2f-e9c4-4b5d-8e7f-50dea67be42a,2012-04-16T08:00:00.000+08:00,4,How I approach biotech investing
f69b09b8-0cae-4b5c-9c72-0e3b4bfe0c81,2012-04-12T08:00:00.000+08:00,5,Why we added biotech stock Sequenom to the lineup
ea1a6926-7d1a-4834-a1d3-74c9e833e049,2012-04-12T08:00:00.000+08:00,3,Lilly's CEO on CNBC Says Hopes to Offset Decline Due to Patent Expiration
46b1f3c8-5972-4200-b345-4dd25c3fc344,2012-04-12T08:00:00.000+08:00,5,Why we added biotech stock Sequenom to the lineup
ed608343-ed80-41be-ae5f-021788e6edb0,2012-04-12T08:00:00.000+08:00,2,Lilly's CEO on CNBC Says Hopes to Offset Decline Due to Patent Expiration
b34ce3ba-ceb5-466c-a15f-946ec763ebbb,2012-04-10T08:00:00.000+08:00,4,Safeguard Scientifics Will Realize Additional Proceeds from Eli Lilly's Acquisition of Avid Radiopharma
0e4d4d20-dfe7-4563-a29f-fcd6716c0e51,2012-04-10T08:00:00.000+08:00,3,Safeguard Scientifics to Realize Additional Proceeds from Eli Lilly's Acquisition of Avid Radiopharmaceuticals
d9d16853-51dc-493b-b657-4451363a196b,2012-04-10T08:00:00.000+08:00,4,Safeguard Scientifics Will Realize Additional Proceeds from Eli Lilly's Acquisition of Avid Radiopharma
8d0fb746-7ad1-4811-bc92-3b8c67994064,2012-04-10T08:00:00.000+08:00,4,Safeguard Scientifics to Realize Additional Proceeds from Eli Lilly's Acquisition of Avid Radiopharmaceuticals
df8f12ea-2c77-4c9f-9414-707a7630ae85,2012-04-09T08:00:00.000+08:00,4,Benzinga's Top Pre-Market Gainers
11a89d28-0246-45db-9eb3-e99742d8b6ab,2012-04-09T08:00:00.000+08:00,5,Eli Lilly Announces FDA Approves Amyvid for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline
31f1478d-4fb5-4e56-85a6-6dd2764515e1,2012-04-09T08:00:00.000+08:00,3,Benzinga's Top Pre-Market Gainers
20a3fb50-cbad-4820-bcbf-bd93897de8d4,2012-04-09T08:00:00.000+08:00,5,Eli Lilly Announces FDA Approves Amyvid for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline
12c9cb07-6c30-4cc9-852b-f3ea07507987,2012-04-03T08:00:00.000+08:00,2,Where the Rubber Meets the Road for Obamacare
68924c2c-6da5-40db-b607-e5aac98aa098,2012-04-03T08:00:00.000+08:00,4,Benzinga's Top Pre-Market Gainers
15403ec3-c0f0-4cba-aa89-c863dd6da596,2012-04-03T08:00:00.000+08:00,3,Where the Rubber Meets the Road for Obamacare
c1baaa61-bdb9-43e7-a9a4-2960a03e4ebd,2012-04-03T08:00:00.000+08:00,3,Benzinga's Top Pre-Market Gainers
ad653867-7ac8-4a6c-8c5f-70ed109dcf70,2012-03-28T08:00:00.000+08:00,4,ImmunoCellular's Intellectual Property Steadily Increases
eb3871cd-8cc4-4b1e-887a-a8c23847209e,2012-03-28T08:00:00.000+08:00,5,"Lilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint in Phase II Study in Patients With Chronic Plaque Psoriasis"
93eaf3a4-935b-421d-b871-91c90c7b9680,2012-03-28T08:00:00.000+08:00,4,Amylin Rejected $3.5 Billion Offer; Stock Soars
a36ed5db-220e-483f-a579-cafa2e959f7c,2012-03-28T08:00:00.000+08:00,4,ImmunoCellular's Intellectual Property Steadily Increases
75628d14-43d2-4abd-af1d-79f14b783cc1,2012-03-28T08:00:00.000+08:00,4,"Lilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint in Phase II Study in Patients With Chronic Plaque Psoriasis"
0f459824-72ac-4438-9d53-f03c83d955d7,2012-03-28T08:00:00.000+08:00,4,Amylin Rejected $3.5 Billion Offer; Stock Soars
812d7cfe-9bdc-4a8a-b323-11a070eb7f2f,2012-03-23T08:00:00.000+08:00,5,Amylin Pharmaceuticals Announces BYETTA Approved for Use with Basal Insulin in Europe
5d1279ab-35d7-428b-958e-52adf11edcef,2012-03-23T08:00:00.000+08:00,4,Amylin Pharmaceuticals Announces BYETTA Approved for Use with Basal Insulin in Europe
198d2ba1-9e34-4375-8fb1-81b968544577,2012-03-21T08:00:00.000+08:00,1,"Benzinga's M&A Chatter for Wednesday March 21, 2012"
0ea061c3-bcfd-46e9-a446-4cd63609f75c,2012-03-21T08:00:00.000+08:00,3,"Forest Labs Spiking Higher on Takeover Chatter, Lilly Rumored Buyer"
ce99f103-2a2e-42c5-85a5-a4ed2368f000,2012-03-21T08:00:00.000+08:00,1,"St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now"
a3870b61-4448-4655-b2e2-eeb3e3578c5c,2012-03-21T08:00:00.000+08:00,1,"Benzinga's M&A Chatter for Wednesday March 21, 2012"
2718f79a-6e86-4d5f-97d7-260107f62c11,2012-03-21T08:00:00.000+08:00,2,"Forest Labs Spiking Higher on Takeover Chatter, Lilly Rumored Buyer"
a570249c-0109-47d4-bb0e-a326f2f3be59,2012-03-21T08:00:00.000+08:00,3,"St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now"
aaf7f038-4797-4d3d-9848-a93dc62276bb,2012-03-15T08:00:00.000+08:00,3,"A Look At The New Russell High Yield ETF (HDIV, ABT, KFT)"
2727d322-da0c-42c5-9581-04bb355dda6c,2012-03-15T08:00:00.000+08:00,3,"A Look At The New Russell High Yield ETF (HDIV, ABT, KFT)"
6b025fce-0eeb-4ce1-b4f1-6fe961cd4a8f,2012-03-09T08:00:00.000+08:00,1,S&P Indices Announces Changes to U.S. Index
946f78b9-9fbc-4e6b-b22b-fa8fe36b173d,2012-03-09T08:00:00.000+08:00,4,S&P Indices Announces Changes to U.S. Index
0eb3737a-cb19-4ef3-bc35-95d266e947cd,2012-03-08T08:00:00.000+08:00,3,"Fresh Del Monte, BlackRock and Other Stocks Insiders Are Buying"
b1968189-ff4b-477f-876b-ba49a231bd57,2012-03-08T08:00:00.000+08:00,3,"Fresh Del Monte, BlackRock and Other Stocks Insiders Are Buying"
383d52cf-a99e-444b-8290-d2072c14adc4,2012-03-07T08:00:00.000+08:00,4,"Boehringer Ingelheim and Lilly's new oral type 2 diabetes treatment for adults, Jentadueto tablets, now available in U.S. pharmacies"
d6c7deb1-8f9d-4dc7-88d5-312a58c18c06,2012-03-07T08:00:00.000+08:00,5,"Boehringer Ingelheim and Lilly's new oral type 2 diabetes treatment for adults, Jentadueto tablets, now available in U.S. pharmacies"
5f0518f1-0316-416c-9fc7-ccd93a33a8d6,2012-03-02T08:00:00.000+08:00,3,UPDATE: JP Morgan Upgrades Eli Lilly to Neutral
47ffccbe-7abe-4590-a0b8-42c707469c3c,2012-03-02T08:00:00.000+08:00,3,"Financial Breakfast: Morning News Summary for March 2, 2012"
fc83c13c-c24d-4d91-90d8-fe88fbe16477,2012-03-02T08:00:00.000+08:00,3,"JP Morgan Upgrades Eli Lilly from Underweight to Neutral, Maintains PT at $40"
498db961-6a3e-4dcc-93de-3ac0f58deb60,2012-03-02T08:00:00.000+08:00,3,UPDATE: JP Morgan Upgrades Eli Lilly to Neutral
9c297de3-376d-4383-97a6-8cad48db23a0,2012-03-02T08:00:00.000+08:00,3,"Financial Breakfast: Morning News Summary for March 2, 2012"
30566151-033e-48a3-8e94-a472b04ab38d,2012-03-02T08:00:00.000+08:00,3,"JP Morgan Upgrades Eli Lilly from Underweight to Neutral, Maintains PT at $40"
e1d7b352-cf9b-49b7-92c2-bbddd8a08ae8,2012-02-17T08:00:00.000+08:00,4,CHMP Recommends Approval of BYETTA for Use With Basal Insulin
c731562e-0daf-4ba4-bf21-a174696d168d,2012-02-17T08:00:00.000+08:00,4,CHMP Recommends Approval of BYETTA for Use With Basal Insulin
3c4b7289-dcab-43c3-bdfa-3d435ca65207,2012-02-07T08:00:00.000+08:00,1,Stocks Going Ex-Dividend the Third Week of February 2012
d7e6b170-b271-4831-a1fa-40c71024c2ed,2012-02-07T08:00:00.000+08:00,2,New Study Evaluates Cialis in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia
f87c1087-746c-47dd-be23-dbfd707478c4,2012-02-07T08:00:00.000+08:00,5,Eli Lilly Says Cialis Data Met Primary Endpoint
87456a55-c75c-47e7-aa64-19370087bc44,2012-02-07T08:00:00.000+08:00,4,Stocks Going Ex-Dividend the Third Week of February 2012
242f31b7-feda-4d30-8bbe-e72589e6e683,2012-02-07T08:00:00.000+08:00,3,New Study Evaluates Cialis in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia
74283e7f-57ef-49fe-94f2-cc0d1838464e,2012-02-07T08:00:00.000+08:00,5,Eli Lilly Says Cialis Data Met Primary Endpoint
6946858d-0402-4bf8-aaf6-f740856757ef,2012-02-02T08:00:00.000+08:00,5,Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon Approval
a32e2474-f0cc-492a-bc42-76a89b94e61d,2012-02-02T08:00:00.000+08:00,5,Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon Approval
ead9f2ee-b423-49bb-9df2-450f4d7fc6ae,2012-01-31T08:00:00.000+08:00,3,Earnings Roundup
213e4e2b-9430-4e98-920b-7f7615e330f6,2012-01-31T08:00:00.000+08:00,4,FDA Approves Lilly & Co's Jentadueto Tablets
15e829db-44e5-4b29-94f3-a7f681923e63,2012-01-31T08:00:00.000+08:00,1,"Financial Breakfast: Morning News Summary for January 31, 2012"
25170517-296b-4d9e-a14e-c6b224752df3,2012-01-31T08:00:00.000+08:00,1,UPDATE: Eli Lilly Reports 27% Decline In Q4 Profit
9c046780-a3ea-4291-9437-88b7e7712761,2012-01-31T08:00:00.000+08:00,4,From Earlier: FDA Approves Lilly's Jentadueto Tablets for the Treatment of Adult Patients with Type 2 Diabetes
954511cf-342d-41dd-b4ef-2d0761d0e533,2012-01-31T08:00:00.000+08:00,3,Eli Lilly & Reports Q4 EPS $0.87 vs $0.81 Est; Revenues $6.05B vs $5.90B Est
b8b99f6b-4e2c-4f3e-8cbc-f24578b7eb07,2012-01-31T08:00:00.000+08:00,2,US Stock Futures Signal Higher Start On Wall Street
56d7c880-cc35-41f6-948f-489df31d0355,2012-01-31T08:00:00.000+08:00,1,Earnings Scheduled For January 31
12069d75-31e8-4deb-8165-0d4ecf1e78cf,2012-01-31T08:00:00.000+08:00,3,Earnings Roundup
ea92047d-05d6-4ede-a779-ca2c07df06b6,2012-01-31T08:00:00.000+08:00,3,FDA Approves Lilly & Co's Jentadueto Tablets
f22c33d8-fb4c-4e12-a02e-99aac000bcd1,2012-01-31T08:00:00.000+08:00,1,"Financial Breakfast: Morning News Summary for January 31, 2012"
c22ba776-349d-483a-abea-886d7021e482,2012-01-31T08:00:00.000+08:00,2,UPDATE: Eli Lilly Reports 27% Decline In Q4 Profit
d4c6d6d4-4bc3-43c3-b4ca-88c05d7e0ce1,2012-01-31T08:00:00.000+08:00,4,From Earlier: FDA Approves Lilly's Jentadueto Tablets for the Treatment of Adult Patients with Type 2 Diabetes
ca1aa75f-eb4d-4278-9049-f04479068b34,2012-01-31T08:00:00.000+08:00,4,Eli Lilly & Reports Q4 EPS $0.87 vs $0.81 Est; Revenues $6.05B vs $5.90B Est
438b4c9c-a87f-41cb-b286-3454ff0f58a0,2012-01-31T08:00:00.000+08:00,2,US Stock Futures Signal Higher Start On Wall Street
a3971b3b-bdc0-4e68-b766-55bcaf43b56d,2012-01-31T08:00:00.000+08:00,3,Earnings Scheduled For January 31
81ed52d4-2f1f-43b2-9612-53746fca2da1,2012-01-29T08:00:00.000+08:00,3,Earnings Expectations for the Week of January 30
a9a9e748-8f4f-454f-a3a6-36a71981bc01,2012-01-29T08:00:00.000+08:00,4,Earnings Expectations for the Week of January 30
56a20c6f-1f6c-4002-9090-6666f42885dd,2012-01-24T08:00:00.000+08:00,5,Elanco Animal Health Announces Lilly's Agreement to Acquire ChemGen Corp; Terms Not Disclosed
bb518d88-6eb9-4f37-9e6e-aaf56b5b05a9,2012-01-24T08:00:00.000+08:00,1,Elanco Animal Health Announces Lilly's Agreement to Acquire ChemGen Corp; Terms Not Disclosed
1fe0b318-122c-4b1c-be1b-d137f1cf3a8a,2012-01-17T08:00:00.000+08:00,3,"Benzinga's M&A Chatter for Tuesday January 17, 2012"
f8b58a1b-d104-43f3-8b42-af4e9507fe61,2012-01-17T08:00:00.000+08:00,4,"UPDATE: Deutsche Bank Raises PT to $40, Maintains Hold on Eli Lilly"
2d36e7de-75df-4ede-b1df-ba5299ac18de,2012-01-17T08:00:00.000+08:00,4,"Benzinga's M&A Chatter for Tuesday January 17, 2012"
e7664c0c-0bf7-4e45-94f2-31ee8f2fc3c1,2012-01-17T08:00:00.000+08:00,4,"UPDATE: Deutsche Bank Raises PT to $40, Maintains Hold on Eli Lilly"
ac20d4a2-f70d-47f1-8deb-fc4f9592d193,2012-01-10T08:00:00.000+08:00,1,ShangPharma Announces Opening of New Facility to Support Lilly's Pipeline
d5947714-733f-4c32-8e8d-ffada682376b,2012-01-10T08:00:00.000+08:00,1,ShangPharma Announces Opening of New Facility to Support Lilly's Pipeline
d4940f6f-1f40-4dec-bb05-2277292a1305,2012-01-05T08:00:00.000+08:00,2,UPDATE: Eli Lilly Says Decline in 2012 Guidance Reflects Zyprexa Patent Expiration
459ac75d-df9d-44fb-82a9-d4f9629dc5cb,2012-01-05T08:00:00.000+08:00,2,Eli Lilly Guides 2012 EPS $3.10-3.20 vs $3.67 Est
62e91c4e-63d9-4a01-a63c-a021dd5b95e2,2012-01-05T08:00:00.000+08:00,1,UPDATE: Eli Lilly Says Decline in 2012 Guidance Reflects Zyprexa Patent Expiration
5f412400-26cb-4c09-a785-a4f40b8edff6,2012-01-05T08:00:00.000+08:00,2,Eli Lilly Guides 2012 EPS $3.10-3.20 vs $3.67 Est
c4194380-0faf-4b71-9ef4-e233e555b511,2012-01-03T08:00:00.000+08:00,5,Eli Lilly & Hits 52-Week High of $41.97
4068a1b1-0224-42c2-9a40-6a9db4957ddf,2012-01-03T08:00:00.000+08:00,3,Eli Lilly & Hits 52-Week High of $41.97
56925b43-af63-47ca-b0d1-b19d64a753f2,2011-12-30T08:00:00.000+08:00,4,ETF Showdown: Fun With Pharma
a3088115-46d2-46bb-8d57-61b8ea6194f5,2011-12-30T08:00:00.000+08:00,4,ETF Showdown: Fun With Pharma
af6d9c82-bff3-4ff5-b286-7ef02fcf87bc,2011-12-27T08:00:00.000+08:00,5,Eli Lilly & Hits 52-Week High of $41.87
ec18cb38-67e4-44ff-a4e8-c27caca5d78e,2011-12-27T08:00:00.000+08:00,5,Best Biotech Stocks of 2011
229b6267-4c8b-4bc4-b2ed-144871130ba7,2011-12-27T08:00:00.000+08:00,5,Eli Lilly & Hits 52-Week High of $41.87
63243168-74db-4ca7-9f34-de5a2c15ab1a,2011-12-27T08:00:00.000+08:00,5,Best Biotech Stocks of 2011
4bcd0c48-72ab-46e6-ad43-f535eae8dafa,2011-12-22T08:00:00.000+08:00,4,Eli Lilly & Hits 52-Week High of $41.85
c40ca866-6109-4b60-8d0a-9a0f999e7efb,2011-12-22T08:00:00.000+08:00,4,Eli Lilly & Hits 52-Week High of $41.85
08c8dd85-bb79-411a-b35f-2a9c456d3c72,2011-12-21T08:00:00.000+08:00,3,Eli Lilly & Hits 52-Week High of $41.44
975ff892-c9cc-4ac8-afae-4e8e7f6fa4e4,2011-12-21T08:00:00.000+08:00,3,Ligand Enters into Platform Captisol License and Supply Agreements with Lilly; Terms Not Disclosed
36d90f36-cbc4-4603-8f9a-77b683340450,2011-12-21T08:00:00.000+08:00,4,Eli Lilly & Hits 52-Week High of $41.44
d1a407a0-9a30-42ec-80d0-7fde01811baf,2011-12-21T08:00:00.000+08:00,4,Ligand Enters into Platform Captisol License and Supply Agreements with Lilly; Terms Not Disclosed
8ea56e43-b5f2-4fc4-9b94-9964c75709a8,2011-12-20T08:00:00.000+08:00,2,"Financial Breakfast: Morning News Summary for December 20, 2011"
a9c6de75-1eb3-46ce-8ca4-165af333402b,2011-12-20T08:00:00.000+08:00,4,"ImmunoGen, Inc. Announces Antibody-Drug Conjugate Collaboration With Lilly"
a2ece0fb-3b01-4a7d-8d1f-fb1898415b44,2011-12-20T08:00:00.000+08:00,2,"Financial Breakfast: Morning News Summary for December 20, 2011"
98fc06d1-9280-4272-9574-ebf6a7713f9f,2011-12-20T08:00:00.000+08:00,4,"ImmunoGen, Inc. Announces Antibody-Drug Conjugate Collaboration With Lilly"
83535e4c-4cad-45f7-9724-3fd8f8ab15d5,2011-12-15T08:00:00.000+08:00,3,"Fast Money Picks For December 16th (AET, M, MANT, ETR, COV, LLY, ADBE)"
6001e4b6-8bd2-4db9-b519-46ec2f1d2629,2011-12-15T08:00:00.000+08:00,4,Eli Lilly & Hits 52-Week High of $40.49
f92a9145-8690-4475-ac15-3c3b5d00b64a,2011-12-15T08:00:00.000+08:00,3,"Fast Money Picks For December 16th (AET, M, MANT, ETR, COV, LLY, ADBE)"
0d35c025-e2cd-4fd3-aaf6-128d9ef360f5,2011-12-15T08:00:00.000+08:00,4,Eli Lilly & Hits 52-Week High of $40.49
1442e4a6-cd66-4ea0-a923-5cfef0017f3f,2011-12-14T08:00:00.000+08:00,4,Eli Lilly & Hits 52-Week High of $40.25
7a1539ff-55be-4c12-89d1-eda57bd8837a,2011-12-14T08:00:00.000+08:00,4,Eli Lilly & Hits 52-Week High of $40.25
d17a6940-f184-4590-9a66-84cdcf1a17f5,2011-12-13T08:00:00.000+08:00,5,Eli Lilly & Hits 52-Week High of $40.13
25b5daa1-a03b-4f8f-8590-9ee30e604953,2011-12-13T08:00:00.000+08:00,5,Eli Lilly & Hits 52-Week High of $40.13
2a599523-45a1-48d1-9f01-469404fe23f0,2011-12-12T08:00:00.000+08:00,4,Katherine Baicker Elected to Lilly Board of Directors
ef57bc94-b0ef-40a2-859b-5abe97097a03,2011-12-12T08:00:00.000+08:00,4,"From Earlier, Lilly Oncology Reveals Findings From Study of JAK2 Inhibitor for Blood Cancers at ASH Meeting"
cb4fe2cd-eb13-40ee-a165-c4ec4c1bd105,2011-12-12T08:00:00.000+08:00,5,Katherine Baicker Elected to Lilly Board of Directors
823a404b-104c-4eba-b7ff-1db846f8a9e6,2011-12-12T08:00:00.000+08:00,4,"From Earlier, Lilly Oncology Reveals Findings From Study of JAK2 Inhibitor for Blood Cancers at ASH Meeting"
6e068843-694a-4c4e-989e-cd6218cfede9,2011-12-07T08:00:00.000+08:00,5,Eli Lilly & Hits 52-Week High of $39.79
ade9e613-8316-4fb1-b06d-f690c1d2b66e,2011-12-07T08:00:00.000+08:00,3,Eli Lilly & Hits 52-Week High of $39.79
24a9fa87-6a3f-475c-b311-83d933377b56,2011-12-06T08:00:00.000+08:00,4,"3M, Eli Lily, General Electric Receive Positive Mad Money/Jim Cramer Mention -CNBC"
39d6a976-f3c6-4db1-89a5-5dd292d0e4dd,2011-12-06T08:00:00.000+08:00,5,"3M, Eli Lily, General Electric Receive Positive Mad Money/Jim Cramer Mention -CNBC"
8895c889-243f-41da-bc81-a944f24383a6,2011-12-01T08:00:00.000+08:00,2,"Lilly Announces First and Only International, Prospective Observational Study Designed to Understand Barriers to Progression of Insulin Treatment"
4efe2d84-505b-47d7-bcc3-d3f3bba91de6,2011-12-01T08:00:00.000+08:00,3,"Lilly Announces First and Only International, Prospective Observational Study Designed to Understand Barriers to Progression of Insulin Treatment"
d77ff148-6f9c-4ad1-b287-7768d60200e3,2011-11-22T08:00:00.000+08:00,1,Eli Lilly Spokesperson Says the Company does Not Comment on Rumors; Response to Chatter Lilly is Pursuing Acquisition of Forest Laboratories
bb4ae2a6-78e2-47a0-9558-3ad426c6cfee,2011-11-22T08:00:00.000+08:00,4,Forest Laboratories Moving Higher; May be Attributed to Takeover Chatter
92fecf33-01a7-4de0-82ea-c1a3e958b5f1,2011-11-22T08:00:00.000+08:00,2,Eli Lilly Spokesperson Says the Company does Not Comment on Rumors; Response to Chatter Lilly is Pursuing Acquisition of Forest Laboratories
b8353448-a595-4ae4-9c63-7b6a6da0b931,2011-11-22T08:00:00.000+08:00,4,Forest Laboratories Moving Higher; May be Attributed to Takeover Chatter
60172fd9-e740-4490-9997-18b56edb0117,2011-11-16T08:00:00.000+08:00,3,New Analysis of Data Presented at AHA Regarding Effect of Effient on Cardiovascular Events in STEMI Patients According to Timing of PCI
853f7026-cfa7-47f0-b7c6-fad06c3d00e8,2011-11-16T08:00:00.000+08:00,3,Kenexa Announces Partnership With Eli Lilly and Company
1bfdbac5-52b8-4aee-9d31-d3b568c6a8d8,2011-11-16T08:00:00.000+08:00,4,New Analysis of Data Presented at AHA Regarding Effect of Effient on Cardiovascular Events in STEMI Patients According to Timing of PCI
84b5156b-1a62-4290-8c98-a80d131076de,2011-11-16T08:00:00.000+08:00,4,Kenexa Announces Partnership With Eli Lilly and Company
811ccbc9-d550-4e44-8300-c7ec21fee028,2011-11-10T08:00:00.000+08:00,4,Lilly CEO Lechleiter Outlines Opportunities for Improved Health and Economic Growth in Asia-Pacific Region
61ca0f90-85c7-4740-898f-bd56bdc5656c,2011-11-10T08:00:00.000+08:00,4,Lilly CEO Lechleiter Outlines Opportunities for Improved Health and Economic Growth in Asia-Pacific Region
811012b0-1eb9-4676-a908-a3431cc40c6c,2011-11-08T08:00:00.000+08:00,2,From Earlier: Amylin to End Diabetes Drug Deal with Lilly
c8b71f4c-706f-4340-bdd1-479e9fd6628f,2011-11-08T08:00:00.000+08:00,1,A Peek Into The Market Before The Trading Starts
6d804d0d-39dd-4753-b56d-fe02f0b87d17,2011-11-08T08:00:00.000+08:00,3,Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
8fe1a7f6-b3cf-4c63-a0b0-19cc70a2f256,2011-11-08T08:00:00.000+08:00,2,From Earlier: Amylin to End Diabetes Drug Deal with Lilly
d3497013-3ced-416a-a828-a76d64ce4de2,2011-11-08T08:00:00.000+08:00,3,A Peek Into The Market Before The Trading Starts
724de0ab-8ace-4638-9766-04ddafe075f2,2011-11-08T08:00:00.000+08:00,3,Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
004f202f-4823-4363-bb62-ac016f299aa6,2011-11-07T08:00:00.000+08:00,4,Siemens PETNET Solutions Signs Nationwide Commercial Agreement to Manufacture and Distribute Lilly's Molecular Imaging Agent
11a890d4-f64d-4ad0-86f4-0101bb828552,2011-11-07T08:00:00.000+08:00,3,Siemens PETNET Solutions Signs Nationwide Commercial Agreement to Manufacture and Distribute Lilly's Molecular Imaging Agent
13d4a8a8-63a6-4462-8557-f0329691e081,2011-11-03T08:00:00.000+08:00,2,Fitch Downgrades Eli Lilly's Bank Loan Rating To 'A' From 'A+'
71e4d243-a9f6-4c6e-ab46-74894bc7288e,2011-11-03T08:00:00.000+08:00,2,Fitch Downgrades Eli Lilly's Bank Loan Rating To 'A' From 'A+'
ce7efc76-11ba-4f65-87d5-6174a36c8013,2011-10-31T08:00:00.000+08:00,4,Watch for YM BioSciences' Upcoming Clinical Data Catalyst
58b48797-7eb5-45d2-8bf6-749bd6b35b99,2011-10-31T08:00:00.000+08:00,4,Watch for YM BioSciences' Upcoming Clinical Data Catalyst
9dddf00a-8c07-4872-8210-0a553f3b97b1,2011-10-28T08:00:00.000+08:00,3,UPDATE: First Global Upgrades Eli Lilly to Moderate Outperform
7a3159a9-78ce-479b-be1c-785c013323c6,2011-10-28T08:00:00.000+08:00,4,Lilly's ALIMTA Receives EC Approval
953761c8-3218-41c2-bc4b-7da9f5a79051,2011-10-28T08:00:00.000+08:00,3,"Financial Breakfast: Morning News Summary for October 28, 2011"
d5489744-7660-4ee3-a482-44b786e39fae,2011-10-28T08:00:00.000+08:00,5,Eli Lilly Announces ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer
c1991880-8223-4063-8a38-2cef66bec466,2011-10-28T08:00:00.000+08:00,4,First Global Upgrades Eli Lilly from Market Perform to Market Outperform
232bdef9-6afc-4bb5-be31-3f8647057245,2011-10-28T08:00:00.000+08:00,5,UPDATE: First Global Upgrades Eli Lilly to Moderate Outperform
b5fcd5ff-3783-4a82-bc51-418dc2dffcd9,2011-10-28T08:00:00.000+08:00,5,Lilly's ALIMTA Receives EC Approval
329fe49e-c3f2-4206-b9cc-8ac3f990fed6,2011-10-28T08:00:00.000+08:00,2,"Financial Breakfast: Morning News Summary for October 28, 2011"
a7c984b7-4dfb-4d28-a9c2-3c0a87b13f96,2011-10-28T08:00:00.000+08:00,3,Eli Lilly Announces ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer
33cfdc17-7b98-487c-87fa-05c95e21faf5,2011-10-28T08:00:00.000+08:00,4,First Global Upgrades Eli Lilly from Market Perform to Market Outperform
9628081e-79ee-40b1-8c2c-d1095b7b4af5,2011-10-25T08:00:00.000+08:00,1,Lilly Cuts 2011 Financial Guidance Due to Xigris Withdrawal; Expects $3.84-$3.89 vs $4.33 Est and $4.30-$4.35 Prior
fbbef948-cd8d-4efe-8db1-1a851c085333,2011-10-25T08:00:00.000+08:00,2,UPDATE: Lilly Sees Charge $0.75-0.95 Pretax; Reaffirms Forecast Adj EPS 2011
30034680-46dc-4c2d-adde-f9b0fffa1700,2011-10-25T08:00:00.000+08:00,3,Lilly Announces Withdrawal of Xigris® Following Recent Clinical Trial Results
580dd3ab-2725-4cb0-8425-88487695e906,2011-10-25T08:00:00.000+08:00,3,Lilly Cuts 2011 Financial Guidance Due to Xigris Withdrawal; Expects $3.84-$3.89 vs $4.33 Est and $4.30-$4.35 Prior
463f1183-a25c-4064-8804-7f100a38b36c,2011-10-25T08:00:00.000+08:00,2,UPDATE: Lilly Sees Charge $0.75-0.95 Pretax; Reaffirms Forecast Adj EPS 2011
01db6188-265b-419f-b71b-09d14fe9d5ea,2011-10-25T08:00:00.000+08:00,2,Lilly Announces Withdrawal of Xigris® Following Recent Clinical Trial Results
4536dbc5-2adc-453a-8787-19a7e10d7667,2011-10-24T08:00:00.000+08:00,2,"Eli Lilly: FDA Approves First Generic Olanzapine To Treat Schizophrenia, Bipolar Disorder"
6074af13-6e5d-494e-bf4d-6e820d97331c,2011-10-24T08:00:00.000+08:00,1,UPDATE: Jefferies Lowers PT on Eli LIlly to $33
5ac81a12-845d-47a5-8dd8-b44b5d747783,2011-10-24T08:00:00.000+08:00,3,Jefferies Lowers PT on Eli Lilly to $33
fcf5ac0e-d2ed-4054-8786-029e9eaccc8f,2011-10-24T08:00:00.000+08:00,4,"Eli Lilly: FDA Approves First Generic Olanzapine To Treat Schizophrenia, Bipolar Disorder"
06ce42bb-c707-44c8-9b5b-c3917ef49beb,2011-10-24T08:00:00.000+08:00,2,UPDATE: Jefferies Lowers PT on Eli LIlly to $33
de6337b2-099b-4514-ba62-36862963484f,2011-10-24T08:00:00.000+08:00,2,Jefferies Lowers PT on Eli Lilly to $33
b98d2e33-27a2-4d22-bc82-c7fbc5b9ce95,2011-10-20T08:00:00.000+08:00,4,Earnings Roundup
88d0a18e-5c09-4584-b76d-f56b10ff4cc0,2011-10-20T08:00:00.000+08:00,1,Eli Lilly Sees Zyprexa Expiration to Significantly Hurt Sales
e6164e19-9153-4e9e-9aba-2330df0cf6d9,2011-10-20T08:00:00.000+08:00,2,UPDATE: Eli Lilly Reports Decline In Q3 Net Profit
98ac2ad0-7da3-4f8c-830b-03dc458cfd6e,2011-10-20T08:00:00.000+08:00,4,Eli Lilly Reports Q3 EPS $1.13 vs $1.13 Est; Revenues $6.15B vs $6.06B Est
65523c18-a2c1-4453-a5c6-83f54b2fe3ab,2011-10-20T08:00:00.000+08:00,1,Eli Lilly and Company's Profit Falls
3c054bf4-d0c9-4c6a-b46d-78b54a31fc9e,2011-10-20T08:00:00.000+08:00,2,Earnings Scheduled For October 20
1ad2b079-9f4e-46d3-83ff-a289ea6b2703,2011-10-20T08:00:00.000+08:00,3,Earnings Roundup
25ab4c0b-3434-48e9-94ed-10f8c01e5627,2011-10-20T08:00:00.000+08:00,2,Eli Lilly Sees Zyprexa Expiration to Significantly Hurt Sales
73add187-2049-474a-9a61-3dafb69212b0,2011-10-20T08:00:00.000+08:00,1,UPDATE: Eli Lilly Reports Decline In Q3 Net Profit
cbbedaab-f90d-40a7-8fb7-7bd31d4b5833,2011-10-20T08:00:00.000+08:00,4,Eli Lilly Reports Q3 EPS $1.13 vs $1.13 Est; Revenues $6.15B vs $6.06B Est
efa595a7-daab-422f-be2e-726cda7486a6,2011-10-20T08:00:00.000+08:00,2,Eli Lilly and Company's Profit Falls
d06aa84a-3a6a-43da-83da-93e5ae4dc6fb,2011-10-20T08:00:00.000+08:00,3,Earnings Scheduled For October 20
b3371b87-ab6a-414d-948e-cbbc3c7cc63d,2011-10-17T08:00:00.000+08:00,3,"Eli Lilly Earnings Preview: Analysts Expect Rising Revenue, Falling EPS"
3cf9d5a1-1d37-4547-9609-c487cb03682c,2011-10-17T08:00:00.000+08:00,3,"Eli Lilly Earnings Preview: Analysts Expect Rising Revenue, Falling EPS"
a7f8f05b-fcb7-4ae6-a1e8-89354e8ed663,2011-10-14T08:00:00.000+08:00,2,Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield
79f9b8e3-1f99-41eb-8820-47867e778eb8,2011-10-14T08:00:00.000+08:00,2,Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield
c4d61ebb-af06-4340-9a12-52f03e4a0d5b,2011-10-12T08:00:00.000+08:00,4,New Study Shows Cialis Significantly Improved Study Endpoints in Men
49cee712-f821-45f2-ac92-4cb4e00d6fa3,2011-10-12T08:00:00.000+08:00,4,New Study Shows Cialis Significantly Improved Study Endpoints in Men
3d4bb188-17d8-4016-b51c-6fa86a7ffe02,2011-10-07T08:00:00.000+08:00,3,Will Earnings Be a Catalyst?
35b573e6-c9ea-41a5-a472-fded63c74ed1,2011-10-07T08:00:00.000+08:00,4,Notable Call Options Activity in Eli Lilly
f286228e-f5fa-489a-be1a-1b906f90fd47,2011-10-07T08:00:00.000+08:00,2,Resistance 10-07-2011
fe615f6b-ccdb-4340-9f4d-8ca8c63d24fa,2011-10-07T08:00:00.000+08:00,3,"Financial Breakfast: Morning News Summary for October 7, 2011"
11bc7f2a-ca2f-453e-b46e-75c5b987bb6b,2011-10-07T08:00:00.000+08:00,4,Cialis for Once Daily Use Now FDA-Approved to Treat Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Men With Both Erectile Dysfunction and Signs and Symptoms of BPH
1792d71e-c018-404f-91be-b0d1e6ca3c34,2011-10-07T08:00:00.000+08:00,5,Will Earnings Be a Catalyst?
41156ff1-82fb-4345-8ae7-e897ca6df309,2011-10-07T08:00:00.000+08:00,4,Notable Call Options Activity in Eli Lilly
8e51883f-730b-4802-8757-6e0df3d605bd,2011-10-07T08:00:00.000+08:00,2,Resistance 10-07-2011
3aca217c-f1f2-4af8-8bb5-203f2c91ff1f,2011-10-07T08:00:00.000+08:00,3,"Financial Breakfast: Morning News Summary for October 7, 2011"
84018b9c-a353-451e-976f-35e1e3809341,2011-10-07T08:00:00.000+08:00,5,Cialis for Once Daily Use Now FDA-Approved to Treat Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Men With Both Erectile Dysfunction and Signs and Symptoms of BPH
56f906b0-91ea-4941-87c1-9f48ab49e6d6,2011-10-06T08:00:00.000+08:00,5,Lilly's Cialis is Approved for Treatment of Enlarged Prostates
f3b5d76e-8bdc-4e6f-a968-a08a0c6299d6,2011-10-06T08:00:00.000+08:00,4,Lilly's Cialis is Approved for Treatment of Enlarged Prostates
23a5adf2-e6cf-487b-9ed4-872204a54c49,2011-10-05T08:00:00.000+08:00,1,Lilly CEO Says Not Interested in Pfizer Nutrition Business
37276a02-259b-449e-9f20-290df5014ce9,2011-10-05T08:00:00.000+08:00,3,Lilly CEO Wants Better Chance to Win Worker Green Cards
310685a7-2082-4fd0-9aed-6341ddfe3e0a,2011-10-05T08:00:00.000+08:00,1,Lilly CEO Says Not Interested in Pfizer Nutrition Business
24052a68-83e9-425c-ad6c-fffa16477e23,2011-10-05T08:00:00.000+08:00,3,Lilly CEO Wants Better Chance to Win Worker Green Cards
c22baf3d-f584-4c63-bd68-b593bc1a5e52,2011-09-26T08:00:00.000+08:00,5,Eli Lilly Announces ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients
9aa18f3e-2e88-4f4b-9b96-77f01e73aba2,2011-09-26T08:00:00.000+08:00,5,ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer
00d4efde-3d10-4659-8edc-32a0a197d1af,2011-09-26T08:00:00.000+08:00,3,Eli Lilly Announces ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients
6ddf041b-b2e7-4585-b613-d0c6332ab74d,2011-09-26T08:00:00.000+08:00,4,ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer
981e0cc3-b853-437c-8243-fde23c18da14,2011-09-13T08:00:00.000+08:00,4,Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases
610f799d-4bfe-4749-baa4-2b7b134a0c5e,2011-09-13T08:00:00.000+08:00,4,Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases
58d39c3a-e649-4ab2-87d1-db6bfc8dbc7e,2011-09-12T08:00:00.000+08:00,3,A Peek Into The Market Before The Trading Starts
a8736828-55da-4187-bc21-15dffc349fa7,2011-09-12T08:00:00.000+08:00,5,"Amylin Pharmaceuticals, Eli Lilly, and Alkermes Announce Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors"
82e909bd-5667-4f60-8994-eebc6a272808,2011-09-12T08:00:00.000+08:00,3,A Peek Into The Market Before The Trading Starts
7220cd20-0d4e-4476-8d6b-fb2c152889cc,2011-09-12T08:00:00.000+08:00,5,"Amylin Pharmaceuticals, Eli Lilly, and Alkermes Announce Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors"
391f7db1-e182-4a12-87a4-c941afd03210,2011-09-07T08:00:00.000+08:00,4,Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations
94341f2c-20fe-41fa-8945-c114257bd371,2011-09-07T08:00:00.000+08:00,4,Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations
82304abd-ecf2-4fbe-aad0-ca01c6784297,2011-09-01T08:00:00.000+08:00,3,"Mustafa Nevzat Could Attract Other Suitors, Ultimately Be Sold For About $1B - WSJ"
e0173294-9f4c-4f58-ba1f-ce9dfe106fe8,2011-09-01T08:00:00.000+08:00,5,"Mustafa Nevzat Could Attract Other Suitors, Ultimately Be Sold For About $1B - WSJ"
cdd2327d-6ec1-4ee2-bd14-99c0e8f17870,2011-08-25T08:00:00.000+08:00,4,Eli Lilly Announces Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
9dbe3699-7e65-49be-8130-6befeb2bbe0c,2011-08-25T08:00:00.000+08:00,5,Eli Lilly Announces Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
2f356a1a-e529-4390-bea6-7d0dd40bc8d0,2011-08-15T08:00:00.000+08:00,5,Effient Showed Significant 26% Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study
d0649f72-859c-46ab-8ce2-6f32ff024441,2011-08-15T08:00:00.000+08:00,5,Effient Showed Significant 26% Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study
b75042fa-005b-4097-8808-49320deab5f5,2011-08-10T08:00:00.000+08:00,1,"Bydureon FDA Action Date Set For January 28, 2012"
6bd38bd5-dd1c-4040-9901-dc11e56147d8,2011-08-10T08:00:00.000+08:00,1,"Bydureon FDA Action Date Set For January 28, 2012"
09f224fc-ee3c-4a39-870e-e449f75c9255,2011-08-09T08:00:00.000+08:00,2,Eli Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
dc2f9eb3-d5ba-4886-b280-7adff452e0f6,2011-08-09T08:00:00.000+08:00,2,Eli Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
f9507692-3088-4257-8a0b-3331b76ee1c1,2011-08-01T08:00:00.000+08:00,3,Leerink Swann Upgrades Eli Lilly to Market Perform
61333933-d468-4682-b014-f541f2b5f5e1,2011-08-01T08:00:00.000+08:00,3,Leerink Swann Upgrades Eli Lilly to Market Perform
4c748252-ceb3-4c48-9669-11145207621c,2011-07-29T08:00:00.000+08:00,1,U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent
95bff5c7-c39b-4026-b364-421af60e4093,2011-07-29T08:00:00.000+08:00,2,Bank of America Comments on Eli Lilly
b289bfe9-3b32-4b62-a263-f5ae1d08899a,2011-07-29T08:00:00.000+08:00,3,U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent
65391195-a527-43ed-9172-d605f3b7bc0f,2011-07-29T08:00:00.000+08:00,2,Bank of America Comments on Eli Lilly
9d5608a0-e55c-46b8-9c77-666b29978e33,2011-07-28T08:00:00.000+08:00,4,Stocks Going Ex Dividend the Second Week of August
00d697f3-e89d-4af6-b709-3b5684257157,2011-07-28T08:00:00.000+08:00,5,BYDUREON™ Reply Submitted to FDA
673bc9e2-e4f1-438f-a99d-c22b86b62dce,2011-07-28T08:00:00.000+08:00,2,Stocks Going Ex Dividend the Second Week of August
efe8a0c3-c297-4217-b0d1-bf6928a29d90,2011-07-28T08:00:00.000+08:00,4,BYDUREON™ Reply Submitted to FDA
6a4a90d7-ccdf-4fc1-b40c-ce98c731eb35,2011-07-27T08:00:00.000+08:00,1,Hearing Supreme Court Asked to Overturn Obama's Health Care Reform
0e254a75-5007-4847-a12f-8e35aba7bb05,2011-07-27T08:00:00.000+08:00,1,Hearing Supreme Court Asked to Overturn Obama's Health Care Reform
35a16b2b-4078-4fb1-8d18-000c99652bea,2011-07-22T08:00:00.000+08:00,3,"EMA Gives Negative Opinion on Ariclaim, Cymbalta, Xeristar Extensions"
47d0343f-8bee-4a53-8195-1c6e4732b27f,2011-07-22T08:00:00.000+08:00,2,"EMA Gives Negative Opinion on Ariclaim, Cymbalta, Xeristar Extensions"
11862d76-fa38-4309-9ed5-28d6c853848d,2011-07-21T08:00:00.000+08:00,3,"Deutsche Bank Maintains Eli Lilly Hold, $38.50 PT"
43598080-06e4-46e6-9b92-3d2fd56a212b,2011-07-21T08:00:00.000+08:00,4,Fifteen Health Care ETFs Trading Near 52-Week Highs
a972eec3-4ca0-4313-ae1d-cd5a396d4a2c,2011-07-21T08:00:00.000+08:00,2,Earnings Roundup For July 21
62d3fc6a-309f-4faf-8f95-3776a1307818,2011-07-21T08:00:00.000+08:00,1,"News Summary for July 20, 2011"
ab57d30f-c65d-44a0-af4e-83f5a0e900b6,2011-07-21T08:00:00.000+08:00,3,A Peek Into The Market Before The Trading Starts
f14c8631-a6f7-46cb-a34b-44f55467f55c,2011-07-21T08:00:00.000+08:00,1,"Lilly Sees Year EPS $4.25-4.35, Had Seen $4.15-4.30"
fbb97410-94f6-4da0-8a2f-fd5c365e380e,2011-07-21T08:00:00.000+08:00,2,UPDATE: Eli Lilly Reports 11% Drop In Q2 Earnings
b985da86-7834-4cea-842b-2b97a0a2d4a8,2011-07-21T08:00:00.000+08:00,2,US Stock Futures Down As Investors Await Earnings Reports
e954d628-9eee-4939-ad65-78741c5605d1,2011-07-21T08:00:00.000+08:00,4,Earnings Scheduled For July 21
13886f5c-7299-44c1-b0fa-633ff6b4cfc8,2011-07-21T08:00:00.000+08:00,2,"Deutsche Bank Maintains Eli Lilly Hold, $38.50 PT"
02764493-fa79-46d9-8159-4a28ef92d874,2011-07-21T08:00:00.000+08:00,4,Fifteen Health Care ETFs Trading Near 52-Week Highs
4d1cdb43-3d29-4424-802e-55e6f4ed363c,2011-07-21T08:00:00.000+08:00,3,Earnings Roundup For July 21
aaa7400f-c001-4a51-a606-01ac96418eb1,2011-07-21T08:00:00.000+08:00,1,"News Summary for July 20, 2011"
f617c13f-dc58-4db5-92a6-1add3820fb21,2011-07-21T08:00:00.000+08:00,2,A Peek Into The Market Before The Trading Starts
88005c32-bae3-4674-8086-43e19c17be68,2011-07-21T08:00:00.000+08:00,3,"Lilly Sees Year EPS $4.25-4.35, Had Seen $4.15-4.30"
ea211c11-361e-44b2-9633-acf048e66c0b,2011-07-21T08:00:00.000+08:00,2,UPDATE: Eli Lilly Reports 11% Drop In Q2 Earnings
a1724389-03e5-4aac-ad26-fb7a9f80fe91,2011-07-21T08:00:00.000+08:00,1,US Stock Futures Down As Investors Await Earnings Reports
2a56682f-4393-4d28-859f-2aa4c5f57650,2011-07-21T08:00:00.000+08:00,4,Earnings Scheduled For July 21
ccfa15ba-b5a4-4a50-bc58-e6e1154bcd9d,2011-07-18T08:00:00.000+08:00,4,Eli Lilly & Earnings Preview: Analysts Predict Higher Earnings Over Prior Quarter
1378e49c-5d6c-4da6-98f6-7a3214f4e7d3,2011-07-18T08:00:00.000+08:00,2,Citi Comments on Eli Lilly
4c9ad402-ca67-44be-b17d-3c1100b8f209,2011-07-18T08:00:00.000+08:00,4,Eli Lilly Announces New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO and a Common Antiretroviral Therapy
9ef4fada-c146-47f9-b5c2-0d1159692cc5,2011-07-18T08:00:00.000+08:00,3,Jefferies Raises PT On Eli Lilly To $34
31647030-b4d6-4a12-bda4-0a6f66398009,2011-07-18T08:00:00.000+08:00,4,Jefferies Raises PT On Eli Lilly To $34
1a75ea1c-f2dc-4dc7-8a6e-9390d3ea5664,2011-07-18T08:00:00.000+08:00,5,Eli Lilly & Earnings Preview: Analysts Predict Higher Earnings Over Prior Quarter
1893356a-4c2b-41c5-842a-e65e7ec7d122,2011-07-18T08:00:00.000+08:00,2,Citi Comments on Eli Lilly
b3529dab-1077-4910-b206-68dd2664caa0,2011-07-18T08:00:00.000+08:00,4,Eli Lilly Announces New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO and a Common Antiretroviral Therapy
b0ccd353-26ae-4656-a3bd-7c96f3dd3ea9,2011-07-18T08:00:00.000+08:00,5,Jefferies Raises PT On Eli Lilly To $34
a3c6386f-7a52-48bb-a745-9b74a010bffe,2011-07-18T08:00:00.000+08:00,4,Jefferies Raises PT On Eli Lilly To $34
e9858130-ae30-4abd-987a-04a400fa8f08,2011-07-17T08:00:00.000+08:00,3,Earnings Expectations for the Week of July 18
2cf04e07-4b60-49ab-a713-fd47bdff8b62,2011-07-17T08:00:00.000+08:00,4,Earnings Expectations for the Week of July 18
235d7b52-41b3-4dd5-8841-7535ef40f788,2011-07-13T08:00:00.000+08:00,4,Twelve Health Care ETFs Trading Near 52-Week Highs
5f2113bc-75f7-40b4-a61a-b9ff1951801e,2011-07-13T08:00:00.000+08:00,4,Twelve Health Care ETFs Trading Near 52-Week Highs
c6ad26b2-105e-48d1-a088-228c4adba631,2011-07-08T08:00:00.000+08:00,4,Citi Reiterates Hold and PT of $38 on Eli Lilly
4ca3d117-6904-4243-8fc8-8819f5e0f115,2011-07-08T08:00:00.000+08:00,4,Citi Reiterates Hold and PT of $38 on Eli Lilly
1b20b701-7206-4408-8a98-9da8f6b8957a,2011-07-01T08:00:00.000+08:00,2,Sideline Money Flows In 07-01-2011
bac171c0-6b9e-4cb6-ae30-65a50338685f,2011-07-01T08:00:00.000+08:00,3,Wells Fargo Maintains Market Perform on Eli Lilly
c5440196-56c0-4bf8-9257-89f8804799cc,2011-07-01T08:00:00.000+08:00,3,J.P. Morgan Comments On Eli Lilly Investor Day
56ef3b98-3e49-46ee-b5ec-f6990e88f3c5,2011-07-01T08:00:00.000+08:00,3,Deutsche Bank Discusses Eli Lilly Investor Meeting
aee51511-c62f-4b8b-816c-244bcf90f203,2011-07-01T08:00:00.000+08:00,2,Sideline Money Flows In 07-01-2011
e42dae7d-5234-47e1-b5b7-77389cc3ae43,2011-07-01T08:00:00.000+08:00,2,Wells Fargo Maintains Market Perform on Eli Lilly
a66fbd10-5b30-4633-a87a-61ff3c5618f1,2011-07-01T08:00:00.000+08:00,2,J.P. Morgan Comments On Eli Lilly Investor Day
5fae1109-80c1-4068-a32a-3164eda9b290,2011-07-01T08:00:00.000+08:00,2,Deutsche Bank Discusses Eli Lilly Investor Meeting
4acdfe06-672b-48f0-9c51-af9027e0e902,2011-06-29T08:00:00.000+08:00,2,Citi Maintains Hold Rating On Eli Lilly
04a34b45-9e0a-4966-9e27-ae0916c7223f,2011-06-29T08:00:00.000+08:00,2,Citi Maintains Hold Rating On Eli Lilly
8eb37b18-cf2b-4787-922e-3a8ed64671b4,2011-06-28T08:00:00.000+08:00,4,"Fast Money Picks For June 29th (LULU, XHB, BAC, LLY)"
0a04c488-c903-4606-98e9-401b64694825,2011-06-28T08:00:00.000+08:00,5,Eli Lilly: Newly Published Study Showed Axiron Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men
370d0009-c3e9-4892-a93f-cc6e827dd556,2011-06-28T08:00:00.000+08:00,3,Eli Lilly Announces New Investment to Boost Its Biotechnology Capabilities
81e27e3f-4dfa-41f4-a97f-f76b8a12a1cc,2011-06-28T08:00:00.000+08:00,4,"Fast Money Picks For June 29th (LULU, XHB, BAC, LLY)"
3943d8a7-adbc-454d-a946-e0751d0e0a0a,2011-06-28T08:00:00.000+08:00,5,Eli Lilly: Newly Published Study Showed Axiron Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men
70d4bfd0-3c57-4b2c-8ffa-e9cac1016d0c,2011-06-28T08:00:00.000+08:00,2,Eli Lilly Announces New Investment to Boost Its Biotechnology Capabilities
1131f512-962d-49cd-a714-f7d8e4a05e93,2011-06-27T08:00:00.000+08:00,3,Citi Maintains Hold Rating on Eli Lilly
ac2f5ca3-cb76-4011-a6bb-ec448612acd5,2011-06-27T08:00:00.000+08:00,5,Jefferies Maintains Buy on Amylin Pharmaceuticals
d2a4df23-21d8-4a79-8814-382a89531623,2011-06-27T08:00:00.000+08:00,3,Citi Maintains Hold Rating on Eli Lilly
a709a062-a44d-4e07-aaa5-52cd84dfc4ae,2011-06-27T08:00:00.000+08:00,5,Jefferies Maintains Buy on Amylin Pharmaceuticals
7fae05b0-07bf-4946-8f04-a724cb6d2317,2011-06-24T08:00:00.000+08:00,4,Eli Lilly: Linagliptin Recommended For Approval In The Treatment Of Type 2 Diabetes In Europe
bd523611-e754-4bfa-a069-05b33eb28114,2011-06-24T08:00:00.000+08:00,4,Eli Lilly: Linagliptin Recommended For Approval In The Treatment Of Type 2 Diabetes In Europe
22ee85bf-358f-4f7c-8b71-d839e75ce8f0,2011-06-23T08:00:00.000+08:00,3,Forest Labs and Watson Pharma to Open Near 52-Week Highs
3311b298-649a-4f25-9c6a-e497c2e882fe,2011-06-23T08:00:00.000+08:00,1,Deutsche Bank Sees No Catalyst At Eli Lilly Investor Meeting
b67d6adb-b386-4bf4-b331-00966a26481c,2011-06-23T08:00:00.000+08:00,4,Forest Labs and Watson Pharma to Open Near 52-Week Highs
35325a0a-74e9-406e-99c7-2fd67c6a07dd,2011-06-23T08:00:00.000+08:00,2,Deutsche Bank Sees No Catalyst At Eli Lilly Investor Meeting
5bf19f59-751b-479a-923e-4f2546bde5a9,2011-06-22T08:00:00.000+08:00,4,Goldman Sachs Suggests Buying Put Spreads on Eli Lilly and Company
96fa252f-4e6a-4894-b1ab-41c612eab41e,2011-06-22T08:00:00.000+08:00,3,Goldman Sachs Suggests Buying Put Spreads on Eli Lilly and Company
ff311acc-a029-4581-851e-b4d77df8ad37,2011-06-21T08:00:00.000+08:00,5,Colgate and Forest Labs to Open Near 52-Week Highs
5ab2943b-db71-4f39-a071-a750632cfc19,2011-06-21T08:00:00.000+08:00,1,"News Summary for June 21, 2011"
94de3548-2bf4-4e3e-9c18-67822d355413,2011-06-21T08:00:00.000+08:00,4,A Peek Into The Market Before The Trading Starts
e32cb447-b136-4576-8a32-0f7fe801337d,2011-06-21T08:00:00.000+08:00,5,Eli Lilly and Amylin Pharmaceuticals Announces BYDUREON Receives Marketing Authorization in Europe
d40be36c-4cea-4f76-9ddd-c685b8741b8a,2011-06-21T08:00:00.000+08:00,3,Colgate and Forest Labs to Open Near 52-Week Highs
ce608c3b-0b15-48ae-be6e-cf4a49925b0b,2011-06-21T08:00:00.000+08:00,2,"News Summary for June 21, 2011"
2ba50911-e8e0-4406-a292-10d332567bf6,2011-06-21T08:00:00.000+08:00,4,A Peek Into The Market Before The Trading Starts
827a2006-996e-47e1-a6cc-01b0bad7e321,2011-06-21T08:00:00.000+08:00,4,Eli Lilly and Amylin Pharmaceuticals Announces BYDUREON Receives Marketing Authorization in Europe
d5586d2f-f77b-4f49-b8bb-a7301c764ab3,2011-06-20T08:00:00.000+08:00,4,Lilly Declares Third-Quarter 2011 Dividend of $0.49/Share
c3b09b32-e24e-4ebd-a542-f01981cd35b2,2011-06-20T08:00:00.000+08:00,4,Lilly Declares Third-Quarter 2011 Dividend of $0.49/Share
8408a8ae-53fa-4c85-8cdc-cd3587f36aa4,2011-06-15T08:00:00.000+08:00,3,Options Brief: Eli Lilly and Company
8d4b0575-a12b-4a86-8312-665a9ea873ef,2011-06-15T08:00:00.000+08:00,5,Boehringer Ingelheim and Eli Lilly's New Type 2 Diabetes Treatment Tradjenta Tablets for Adults Now Available in U.S. Pharmacies
82cfd78a-4b7e-443e-9c5d-a2ace1a5b322,2011-06-15T08:00:00.000+08:00,4,Options Brief: Eli Lilly and Company
33c04d55-1b1a-4135-b619-e18d5339f11a,2011-06-15T08:00:00.000+08:00,5,Boehringer Ingelheim and Eli Lilly's New Type 2 Diabetes Treatment Tradjenta Tablets for Adults Now Available in U.S. Pharmacies
83e0f59a-83c7-4e92-b852-efcb2b0e228e,2011-06-10T08:00:00.000+08:00,3,CIGNA and Forest Laboratories Open Near 52-Week Highs
526b1a4d-f6ce-4f23-85b2-739a5a41668d,2011-06-10T08:00:00.000+08:00,3,CIGNA and Forest Laboratories Open Near 52-Week Highs
0ce15e6a-4b3f-49e6-afc0-bfff036a9a20,2011-06-09T08:00:00.000+08:00,2,Synthes and Eli Lilly Sign Development and Collaboration Agreement
1483c2b9-9da3-427b-9b5c-834b17bade96,2011-06-09T08:00:00.000+08:00,4,Synthes and Eli Lilly Sign Development and Collaboration Agreement
334775c3-1d8f-4454-942f-5c1afb2870c3,2011-06-08T08:00:00.000+08:00,2,UPDATE: Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
3fc558af-468f-46d9-bab7-cffa79188643,2011-06-08T08:00:00.000+08:00,3,U.S. District Court Rules in Favor of Eli Lilly in Amylin Litigation
56a59337-507e-44ab-8bb3-1d601f61e6ab,2011-06-08T08:00:00.000+08:00,4,FDA Approves Updates to Lilly's HumalogLabel
c78838a0-0537-46e5-95da-ce2901a77e08,2011-06-08T08:00:00.000+08:00,1,UPDATE: Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
112ebd98-ec94-4afe-ba51-af5b7d6bcddb,2011-06-08T08:00:00.000+08:00,4,U.S. District Court Rules in Favor of Eli Lilly in Amylin Litigation
a7f83732-4c7c-4fbd-bd76-ebf73437f070,2011-06-08T08:00:00.000+08:00,5,FDA Approves Updates to Lilly's HumalogLabel
871b2937-fdd4-4c30-944e-79db2de2f2fd,2011-06-06T08:00:00.000+08:00,2,Will Prozac Murder Trial Doom Eli Lilly Stock?
dd9d3028-d85f-4822-a72e-b379ce5c6732,2011-06-06T08:00:00.000+08:00,2,Will Prozac Murder Trial Doom Eli Lilly Stock?
18361888-96eb-4427-8984-c8123f8304b1,2011-06-02T08:00:00.000+08:00,3,Options Brief: Eli Lilly and Company
5c8daf9e-2ff8-4bec-bea2-40c553db3cc8,2011-06-02T08:00:00.000+08:00,2,Options Brief: Eli Lilly and Company
9cdbc608-31b5-45a1-852a-48a0e94f43d0,2011-06-01T08:00:00.000+08:00,3,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer"
fc8fa1fd-6bdb-4359-9827-d37b6d96bae6,2011-06-01T08:00:00.000+08:00,3,Hapoalim Cutting Ocverage On Multitude Of Names
cf1cad8d-0857-4eba-a7ae-5c8caba7cae1,2011-06-01T08:00:00.000+08:00,1,Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest ROE
29aa2547-8932-4f9b-94e8-08b4ee44635f,2011-06-01T08:00:00.000+08:00,2,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer"
12f86c48-40a2-4d62-a3f2-e84af8dbd836,2011-06-01T08:00:00.000+08:00,2,Hapoalim Cutting Ocverage On Multitude Of Names
04c68f4d-5e27-4b8b-a0bc-c4dd6a2473ee,2011-06-01T08:00:00.000+08:00,3,Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest ROE
1a671e4b-10dd-4bf6-b840-773789e42708,2011-05-24T08:00:00.000+08:00,4,Diabetes Device Market to Reach $24 Billion by 2017
23357637-cb1a-401f-a285-5ce60e52b132,2011-05-24T08:00:00.000+08:00,5,Diabetes Device Market to Reach $24 Billion by 2017
9425bd03-0c95-46fc-9d77-12949458d4a6,2011-05-23T08:00:00.000+08:00,4,"Eli Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement"
df49c0f2-e8cf-4a96-9261-32c88e328349,2011-05-23T08:00:00.000+08:00,4,"Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement"
e5e574b3-0e32-44db-8d79-db3768122425,2011-05-23T08:00:00.000+08:00,4,"Eli Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement"
bc13f9a2-1fc1-42c8-97c4-ca6c341f8bb4,2011-05-23T08:00:00.000+08:00,4,"Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement"
e1696b83-a4a6-4cac-9f9f-d9c97c2aac58,2011-05-22T08:00:00.000+08:00,2,Top Healthcare and Major Drugs stocks to watch- Sector Performance
8126e1ff-51da-4c1b-a47e-1bcd9c1c1a46,2011-05-22T08:00:00.000+08:00,3,Top Healthcare and Major Drugs stocks to watch- Sector Performance
49d5345f-aa53-4f4b-b33b-fff185254d9e,2011-05-19T08:00:00.000+08:00,4,A Mega Cap ETF Joins the First Trust AlphaDEX Lineup
6bc7737d-6b18-4259-82b7-3dca1bd6677a,2011-05-19T08:00:00.000+08:00,5,Eli Lilly Announces Study Determined Best Dose and Showed 55% Response Rate With Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients
db5c8515-4394-4dad-a81d-d3b6fb82fb3e,2011-05-19T08:00:00.000+08:00,3,ELi Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma
5f0b058e-bfd9-4230-b0a6-ed3b19b2bd63,2011-05-19T08:00:00.000+08:00,4,A Mega Cap ETF Joins the First Trust AlphaDEX Lineup
f6885304-fb18-4c58-a813-e74fff76f802,2011-05-19T08:00:00.000+08:00,5,Eli Lilly Announces Study Determined Best Dose and Showed 55% Response Rate With Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients
7dc978f2-c033-4e66-b60d-f6192f102e20,2011-05-19T08:00:00.000+08:00,4,ELi Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma
063a0c3a-7bad-4bb1-86ae-c1aeecb0e548,2011-05-18T08:00:00.000+08:00,3,GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term
ddc45d47-c324-4c6d-ae68-044d465c0c6c,2011-05-18T08:00:00.000+08:00,3,GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term
ecfea770-aae0-4efe-aff1-91f9b9d44167,2011-05-16T08:00:00.000+08:00,2,Eli Lilly Provides Its Perspective in Response to Amylin Lawsuit
c652cf52-cc5c-410e-9922-93025761cb56,2011-05-16T08:00:00.000+08:00,1,"Lilly Says Suit Is Without Merit, Will Vigorously Defend Position"
2ee1f110-4566-4f86-a730-95ba4d05ee40,2011-05-16T08:00:00.000+08:00,2,Lilly Rejected By U.S. Supreme Court On Gemzar Patent -Bloomberg
73fcb16d-fffe-4819-9b5b-dde4ee7ff67f,2011-05-16T08:00:00.000+08:00,3,Lilly Provides Statement in Response to Amylin Lawsuit
2277e93a-a297-4ed7-8262-c64aa0d62640,2011-05-16T08:00:00.000+08:00,4,Bank Of America Raising PT On LLY To $43
707a4460-03f4-490d-b4cd-d215e27596ae,2011-05-16T08:00:00.000+08:00,1,Amylin Pharmaceuticals Files Suit Against Eli Lilly
a1e04253-e375-4549-a409-241d30a49b8c,2011-05-16T08:00:00.000+08:00,2,Eli Lilly Provides Its Perspective in Response to Amylin Lawsuit
ba8ba440-0386-4a1d-b75c-e988e6ea19ea,2011-05-16T08:00:00.000+08:00,2,"Lilly Says Suit Is Without Merit, Will Vigorously Defend Position"
413356e9-f0a0-4f58-a4ce-78d5a09266d8,2011-05-16T08:00:00.000+08:00,3,Lilly Rejected By U.S. Supreme Court On Gemzar Patent -Bloomberg
def601d1-2b0a-43b7-8184-daac4cbf5540,2011-05-16T08:00:00.000+08:00,3,Lilly Provides Statement in Response to Amylin Lawsuit
8e0cc536-3aa4-4da2-a96e-4df76689908d,2011-05-16T08:00:00.000+08:00,4,Bank Of America Raising PT On LLY To $43
73d18857-348c-4548-9c92-89407833e168,2011-05-16T08:00:00.000+08:00,1,Amylin Pharmaceuticals Files Suit Against Eli Lilly
bb58be46-8c48-43c6-93e5-d3b65a9aca55,2011-05-12T08:00:00.000+08:00,2,Going Large: First Trust Introduces Mega-Cap ETF
af4bb4d3-357b-4a39-83c8-35018a59f765,2011-05-12T08:00:00.000+08:00,2,Going Large: First Trust Introduces Mega-Cap ETF
13938c49-a488-49d4-918b-05109717f12f,2011-05-10T08:00:00.000+08:00,3,Using the Euro as a Barometer 05-10-2011
334fb437-ca67-4fc5-b96e-011772c2b310,2011-05-10T08:00:00.000+08:00,3,Using the Euro as a Barometer 05-10-2011
a0ca5118-00d2-4672-8a05-9dc057a3f923,2011-05-03T08:00:00.000+08:00,2,"Defense, Defense 05-03-2011"
ce3f2ca7-5b07-48fc-858c-dbbb7b0e0d7a,2011-05-03T08:00:00.000+08:00,4,"Defense, Defense 05-03-2011"
73660ab6-460c-4e8e-adb3-af46cbb05a0a,2011-05-02T08:00:00.000+08:00,5,UPDATE: FDA Approves Tradjenta™ Tablets for the Treatment of Type 2 Diabetes (LLY)
4124a700-da2b-44b0-b301-965d53ff05d5,2011-05-02T08:00:00.000+08:00,3,UPDATE: FDA Approves New Treatment for Type 2 Diabetes; Marketed by Eli Lilly
1588afdf-de93-4123-96d6-5c3b7b35303b,2011-05-02T08:00:00.000+08:00,5,"Lilly, Boehringer Win FDA Approval For Diabetes Drug, Bloomberg (LLY)"
24d2cc1a-b9cc-4da4-a1af-4f6ec9ba8c5c,2011-05-02T08:00:00.000+08:00,5,UPDATE: FDA Approves Tradjenta™ Tablets for the Treatment of Type 2 Diabetes (LLY)
5ed56c12-86cc-4a51-acc0-541424937d8b,2011-05-02T08:00:00.000+08:00,5,UPDATE: FDA Approves New Treatment for Type 2 Diabetes; Marketed by Eli Lilly
42ca3929-4c47-4409-8f58-dc2c483a4ac0,2011-05-02T08:00:00.000+08:00,5,"Lilly, Boehringer Win FDA Approval For Diabetes Drug, Bloomberg (LLY)"
0595a36f-ad3d-405d-8172-08751e5f9b82,2011-04-30T08:00:00.000+08:00,3,Stocks Going Ex Dividend the Second Week of May
b1a21e88-e79c-4e3d-8531-e1440cce436f,2011-04-30T08:00:00.000+08:00,4,Stocks Going Ex Dividend the Second Week of May
22aa4963-6e91-4724-82d8-74d6dd5fedd9,2011-04-29T08:00:00.000+08:00,2,Lilly In Advanced Talks To Resolve SEC Foreign Bribery Probe -DJ (LLY)
85a3fb84-2c08-40ae-b3db-f351eddc8b8e,2011-04-29T08:00:00.000+08:00,4,New Treatment For Chronic Low Back Pain Approved by Health Canada (LLY)
13e2a205-ac90-4d41-a79f-898becfc7eac,2011-04-29T08:00:00.000+08:00,2,Lilly In Advanced Talks To Resolve SEC Foreign Bribery Probe -DJ (LLY)
ff3199fc-b857-4d1c-9dfd-d95e9d3d3bf9,2011-04-29T08:00:00.000+08:00,4,New Treatment For Chronic Low Back Pain Approved by Health Canada (LLY)
615dc4a9-25cc-4089-9c45-7d212452e17d,2011-04-27T08:00:00.000+08:00,3,U.S. District Court Order Maintains Patent Exclusivity for Lilly's Cymbalta (LLY)
f0769728-4afc-4dfa-860b-806fbc8575cc,2011-04-27T08:00:00.000+08:00,5,"Biotech /Pharma Stocks Snapshot; Technology and Medical Devices on the Rise Within Healthcare; Aethlon Medical, ELI Lilly (LLY), Medtronic (MDT), Pfizer (PFE), Apple (AAPL)"
3d8baff9-d19b-4e21-89e4-2200c494eb5f,2011-04-27T08:00:00.000+08:00,4,U.S. District Court Order Maintains Patent Exclusivity for Lilly's Cymbalta (LLY)
9d2027cc-e0db-44ef-91c2-a9696fbf0d80,2011-04-27T08:00:00.000+08:00,3,"Biotech /Pharma Stocks Snapshot; Technology and Medical Devices on the Rise Within Healthcare; Aethlon Medical, ELI Lilly (LLY), Medtronic (MDT), Pfizer (PFE), Apple (AAPL)"
e9ade7b5-83df-4209-91a8-a52e81908274,2011-04-26T08:00:00.000+08:00,5,Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease
dc5d76bd-5cc1-43a9-b44f-90bd57e6abf5,2011-04-26T08:00:00.000+08:00,5,Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease
912328fd-b287-4c90-a476-1fb8309296ae,2011-04-20T08:00:00.000+08:00,2,"Five Stocks that May End Up, umm, Higher, if Marijuana is Legalized"
2ba43a18-19c2-47e0-900f-b4aac19520ce,2011-04-20T08:00:00.000+08:00,4,"Five Stocks that May End Up, umm, Higher, if Marijuana is Legalized"
a75299d5-d0a9-4997-8fd6-a56b48d14ada,2011-04-19T08:00:00.000+08:00,5,"Hapoalim Upgrades LLY From Hold To Buy, Raises PT To $39"
20e64444-7256-4fde-bff4-27a538cefb71,2011-04-19T08:00:00.000+08:00,3,Deutsche Bank Maintains Hold on Eli Lilly (LLY)
c1144184-0bd4-4375-8848-34db13386d3e,2011-04-19T08:00:00.000+08:00,4,"CEOWORLD Daily Business Roundup- BP, GS, GM, RIMM, YHOO, TXN, IBM, YHOO, C, INTC, WMT, AAPL…"
a710942e-f146-42ce-8e0e-b15f3027bb30,2011-04-19T08:00:00.000+08:00,5,"Hapoalim Upgrades LLY From Hold To Buy, Raises PT To $39"
753083ea-9d5b-4bb1-a67c-7dba45057121,2011-04-19T08:00:00.000+08:00,2,Deutsche Bank Maintains Hold on Eli Lilly (LLY)
b6adec99-f415-4aa4-a7f0-34327e2dbbeb,2011-04-19T08:00:00.000+08:00,3,"CEOWORLD Daily Business Roundup- BP, GS, GM, RIMM, YHOO, TXN, IBM, YHOO, C, INTC, WMT, AAPL…"
7bf895e5-f634-4cd3-a105-5a46d0098c92,2011-04-18T08:00:00.000+08:00,3,Jefferies Maintains Hold on Eli Lilly (LLY)
9196aab2-9e56-4780-9363-d553a79345d5,2011-04-18T08:00:00.000+08:00,4,A Peek Into The Market Before The Trading Starts
10a4d9fe-99ee-4b68-a8d2-93c4d2626f08,2011-04-18T08:00:00.000+08:00,5,Eli Lilly Reports Upbeat Q1 Earnings
ddbaccaa-6a66-4a88-a1c2-56388758c58a,2011-04-18T08:00:00.000+08:00,2,US Stock Futures Down As Investors Await Citigroup Earnings
e8a1aeea-41d7-4519-83eb-e9b8029855c4,2011-04-18T08:00:00.000+08:00,3,Jefferies Maintains Hold on Eli Lilly (LLY)
c875edd0-c792-4cde-b759-688b645c4fd1,2011-04-18T08:00:00.000+08:00,3,A Peek Into The Market Before The Trading Starts
1caa2d3d-6ee8-4c89-9796-a399217cb314,2011-04-18T08:00:00.000+08:00,4,Eli Lilly Reports Upbeat Q1 Earnings
7ecf32d9-507c-4b56-8d9d-6a255362637c,2011-04-18T08:00:00.000+08:00,2,US Stock Futures Down As Investors Await Citigroup Earnings
5da71c2a-cef2-4551-8838-fca5c5354d6c,2011-04-17T08:00:00.000+08:00,2,"Earnings Scheduled For April 18 (AMTD, TXN, KEY, C, LLY, GCI, HAL, MTB, BRO, AMLN, ZION, CR)"
4d0a75ec-7e10-468a-b7ea-b0134f87ae6c,2011-04-17T08:00:00.000+08:00,3,"Stocks To Watch For April 18 (C, TXN, JNJ, HAL, LLY)"
75ddd197-9d0c-472d-b77c-748dc488260b,2011-04-17T08:00:00.000+08:00,3,Monday's Economic and Earnings Schedule
bd19da5d-3012-44bd-8699-3efab25a111c,2011-04-17T08:00:00.000+08:00,2,"Earnings Scheduled For April 18 (AMTD, TXN, KEY, C, LLY, GCI, HAL, MTB, BRO, AMLN, ZION, CR)"
aa0435a4-7140-4873-a8d1-853bfc4280b8,2011-04-17T08:00:00.000+08:00,2,"Stocks To Watch For April 18 (C, TXN, JNJ, HAL, LLY)"
f6c18726-3e51-418a-ad81-aa2694ef41a0,2011-04-17T08:00:00.000+08:00,2,Monday's Economic and Earnings Schedule
b285d271-f959-4fea-a846-618cf0832eed,2011-04-16T08:00:00.000+08:00,3,"CEOWORLD Daily Business Roundup- JNJ, CHK, AMD, T, AXP, AAPL, INTC, JPM, GOOG, LLY, CSCO…"
539c95a3-c4fe-483c-9771-99ecd9743735,2011-04-16T08:00:00.000+08:00,3,"CEOWORLD Daily Business Roundup- JNJ, CHK, AMD, T, AXP, AAPL, INTC, JPM, GOOG, LLY, CSCO…"
437a1e11-564a-4f55-8873-3ff469d2e075,2011-04-15T08:00:00.000+08:00,4,"Top Percentage Gainers and Losers as of 10am 4/15/11 (AGO, OPXA, MBI, AMLN, ABMD, CTCT, CRUS, GGC, OTIV, SFG, BAC, LLY, ALKS)"
53276bd1-0cfc-430c-8579-c2a34c51e6f2,2011-04-15T08:00:00.000+08:00,5,"BYDUREON Recommended For Approval In Europe (LLY, ALKS)"
f4fd4cda-0854-456a-afff-fe9bf8b87904,2011-04-15T08:00:00.000+08:00,4,"Eli Lilly, Amylin Pharmaceuticals, and Alkermes Announce BYDUREON Recommended for Approval in Europe"
101e4794-c97b-4d13-aeab-e4b644b74588,2011-04-15T08:00:00.000+08:00,3,"Top Percentage Gainers and Losers as of 10am 4/15/11 (AGO, OPXA, MBI, AMLN, ABMD, CTCT, CRUS, GGC, OTIV, SFG, BAC, LLY, ALKS)"
fd9d6144-cc13-40b7-a3ca-aec1defd13b8,2011-04-15T08:00:00.000+08:00,5,"BYDUREON Recommended For Approval In Europe (LLY, ALKS)"
51a52261-9533-4769-a6ac-8687f252b195,2011-04-15T08:00:00.000+08:00,2,"Eli Lilly, Amylin Pharmaceuticals, and Alkermes Announce BYDUREON Recommended for Approval in Europe"
d78d68be-914d-43c9-a95f-219ddf80418b,2011-04-14T08:00:00.000+08:00,1,Jefferies: LLY Q1 Earnings Could Be Under Pressure
dc471e57-456c-4cce-aac9-6135274908a3,2011-04-14T08:00:00.000+08:00,2,Jefferies: LLY Q1 Earnings Could Be Under Pressure
e5f245ee-b041-4836-83cb-95f2d1ce396c,2011-04-07T08:00:00.000+08:00,3,Market Holds Its Ground 04-07-2011
f699d663-e340-4a9e-befa-9f1ac61f646b,2011-04-07T08:00:00.000+08:00,3,Market Holds Its Ground 04-07-2011
94edb26d-65c3-4667-838c-cae601f1f4e6,2011-04-04T08:00:00.000+08:00,4,Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer
07115aae-7e2a-4483-b90e-798cf7f6a115,2011-04-04T08:00:00.000+08:00,4,Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer
3aa6ece0-ac87-4fb2-8614-9e91d7a42b22,2011-04-01T08:00:00.000+08:00,4,Axiron Topical Solution CIII Now Available in Pharmacies
87ef6355-72c0-4125-8f79-ce366cdbeed5,2011-04-01T08:00:00.000+08:00,4,Axiron Topical Solution CIII Now Available in Pharmacies
9ab114f8-5382-44fe-9d20-24c924f33010,2011-03-29T08:00:00.000+08:00,3,"Mad Money Lightning Round: Cramer Likes Gentex, Micron Technology (AES, CHS, ASNA, BTU, WLT, LLY, LYG, GNTX, MSFT, INTC, CSCO, MU)"
2a256a12-be27-4bed-9127-5026cbba29a9,2011-03-29T08:00:00.000+08:00,2,"Mad Money Lightning Round: Cramer Likes Gentex, Micron Technology (AES, CHS, ASNA, BTU, WLT, LLY, LYG, GNTX, MSFT, INTC, CSCO, MU)"
709c5653-1d86-415f-a396-41fca42de359,2011-03-18T08:00:00.000+08:00,1,Lilly and Avid Receive Complete Response Letter from FDA for Amyvid
90ab3757-eddc-4ee8-bbad-2f1cefaef364,2011-03-18T08:00:00.000+08:00,2,Jefferies Comments On Eli Lilly Strattera Appeal
78162fb1-efea-4550-a9f0-b2b7110b4b52,2011-03-18T08:00:00.000+08:00,3,Lilly and Avid Receive Complete Response Letter from FDA for Amyvid
00c83d65-3df0-4bfd-aebe-0542efd6dbf8,2011-03-18T08:00:00.000+08:00,2,Jefferies Comments On Eli Lilly Strattera Appeal
81976c21-dce2-4563-8ebe-1e5a7acc3056,2011-03-17T08:00:00.000+08:00,2,Lilly Announces Important Action Regarding Recall of Alcohol Prep Pads Made by Triad Group
f7913e40-c62f-44d2-9b56-b4bbd66f20bc,2011-03-17T08:00:00.000+08:00,1,Lilly Announces Important Action Regarding Recall of Alcohol Prep Pads Made by Triad Group
ca1c6626-5bb3-4118-94d1-8d05b8a2b690,2011-03-15T08:00:00.000+08:00,2,Citi Maintains Hold Rating On LLY
917c99ef-b2c5-4bfc-8327-2f3e54efd640,2011-03-15T08:00:00.000+08:00,2,Citi Maintains Hold Rating On LLY
3cdae2a1-b4f5-41b4-a962-147cd8cab302,2011-03-14T08:00:00.000+08:00,3,A Peek Into The Market Before The Trading Starts
df114c64-6a10-4266-8552-ad9ef25fcf45,2011-03-14T08:00:00.000+08:00,4,Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health
91545508-ec55-4dad-bce6-70e1aa23ee49,2011-03-14T08:00:00.000+08:00,3,A Peek Into The Market Before The Trading Starts
2d1efdc7-43ce-44c9-b3cd-2677c609a92f,2011-03-14T08:00:00.000+08:00,4,Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health
675f9b89-fba7-44cd-89bf-912b4fff3eef,2011-03-10T08:00:00.000+08:00,3,Health Insurers Triple S&P 500 Returns
05de6e95-8bb5-493b-870b-b16066061b5a,2011-03-10T08:00:00.000+08:00,3,Health Insurers Triple S&P 500 Returns
7de3ef15-4d24-4c2b-950b-675104526ac2,2011-03-09T08:00:00.000+08:00,2,"Stocks To Watch When Human Genome Sciences Reopens After Benlysta Approval (HGSI, GSK, LJPC, ANTH, CEPH)"
fa5c35f7-f08f-4a43-b2cc-34cbefe1713d,2011-03-09T08:00:00.000+08:00,2,"Stocks To Watch When Human Genome Sciences Reopens After Benlysta Approval (HGSI, GSK, LJPC, ANTH, CEPH)"
08e79dd8-e61a-4f92-9365-39fb05b63f3a,2011-03-08T08:00:00.000+08:00,4,Citi Comments On LLY 10-K
455af009-a8f3-46fc-b651-0fbd10b54e66,2011-03-08T08:00:00.000+08:00,4,Citi Comments On LLY 10-K
942ade62-b629-4b75-a565-d5009432e3b6,2011-03-03T08:00:00.000+08:00,5,"Amylin Pharmaceuticals, Eli Lilly and Alkermes Announce Top-line Results from DURATION-6 Study"
0b7cbc0a-a243-4ba2-9fe3-5e9a9c7e2e9f,2011-03-03T08:00:00.000+08:00,4,"Amylin Pharmaceuticals, Eli Lilly and Alkermes Announce Top-line Results from DURATION-6 Study"
c56d6f48-e38d-4bfc-a634-d7ada2ca9ac3,2011-02-11T08:00:00.000+08:00,3,Two ETFs for the Recovery in Big Pharma
b50cef2b-47bc-454e-bbd8-1d576b9d207e,2011-02-11T08:00:00.000+08:00,2,A Peek Into The Market Before The Trading Starts
efe986ac-858b-4021-b934-efc40dd57c86,2011-02-11T08:00:00.000+08:00,3,Eli Lilly Announces Senior Leadership Changes
b1293fbd-08eb-444e-99bc-e0354f8b2ac8,2011-02-11T08:00:00.000+08:00,3,Two ETFs for the Recovery in Big Pharma
206eb332-bbad-494b-b0c1-03f805c77171,2011-02-11T08:00:00.000+08:00,2,A Peek Into The Market Before The Trading Starts
ab303359-8e21-4847-b31f-a1fd106fbe68,2011-02-11T08:00:00.000+08:00,2,Eli Lilly Announces Senior Leadership Changes
bdd76c9a-4a01-4194-aef9-82dcd5bfee08,2011-02-04T08:00:00.000+08:00,2,Jefferies Updates Estimates on Eli Lilly (LLY)
c8fa8d93-7f67-4abe-b369-d703543f2ffa,2011-02-04T08:00:00.000+08:00,2,Jefferies Updates Estimates on Eli Lilly (LLY)
508a7b5e-cd02-4b61-a03b-a413fb8345df,2011-02-03T08:00:00.000+08:00,1,Roche Misses on Tamiflu Decline - Analyst Blog
e074aca4-a548-4b2a-8f5c-f821feedf069,2011-02-03T08:00:00.000+08:00,1,Roche Misses on Tamiflu Decline - Analyst Blog
08f97c10-6c0b-4525-bcd3-fc1af8d409ed,2011-02-03T08:00:00.000+08:00,1,Roche Misses on Tamiflu Decline - Analyst Blog
14a825bb-43c9-4886-bbf9-97b788dbbe40,2011-02-03T08:00:00.000+08:00,2,Roche Misses on Tamiflu Decline - Analyst Blog
09f67ba0-cebd-42a6-a2f7-d772f6482b69,2011-02-02T08:00:00.000+08:00,3,Stocks Going Ex Dividend the Second Week of February
68e9e5fc-90ea-4971-9bb2-8e2be116977b,2011-02-02T08:00:00.000+08:00,2,Hospira Misses; 2011 View Weak - Analyst Blog
5fd77d20-f6b2-4950-84ad-47d242a0703e,2011-02-02T08:00:00.000+08:00,2,Hospira Misses; 2011 View Weak - Analyst Blog
944a20e4-3a26-470a-b421-55c1348c946f,2011-02-02T08:00:00.000+08:00,1,"Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab"
f269291b-61b3-4e12-9c9e-3d628450bd40,2011-02-02T08:00:00.000+08:00,2,Stocks Going Ex Dividend the Second Week of February
2d17cd20-2a45-4558-99f0-6fe8e8dded1d,2011-02-02T08:00:00.000+08:00,1,Hospira Misses; 2011 View Weak - Analyst Blog
fcabf239-9e40-4e3b-b797-c0e3f8fb61aa,2011-02-02T08:00:00.000+08:00,3,Hospira Misses; 2011 View Weak - Analyst Blog
c2ba7c4f-e2f6-4f19-a877-1961da081d45,2011-02-02T08:00:00.000+08:00,4,"Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab"
b106bfd8-8e4a-4d84-8d11-c8e917a8d33e,2011-01-31T08:00:00.000+08:00,2,Earnings Preview: Alkermes - Analyst Blog
68050d22-b954-4072-bbab-f2568822cb0f,2011-01-31T08:00:00.000+08:00,2,Earnings Preview: Alkermes - Analyst Blog
c821b861-d84a-496e-a8e8-1f4282f9235f,2011-01-31T08:00:00.000+08:00,2,Earnings Preview: Alkermes - Analyst Blog
2845c797-dab2-4b09-a79c-35c9055cf4ad,2011-01-31T08:00:00.000+08:00,2,Earnings Preview: Alkermes - Analyst Blog
07964d24-32c5-4836-b1a4-52733f2c5241,2011-01-28T08:00:00.000+08:00,3,"Company News for January 28, 2011 - Corporate Summary"
05055056-3c4d-4576-9b81-b539ce83f0e4,2011-01-28T08:00:00.000+08:00,2,Hapoalim Reiterates Hold on Eli Lilly (LLY)
2bd722d7-1eb4-484b-a0ae-0507d3f8e3ef,2011-01-28T08:00:00.000+08:00,2,"Company News for January 28, 2011 - Corporate Summary"
a17575d0-ac05-4599-b51b-28bcc897f855,2011-01-28T08:00:00.000+08:00,3,"Company News for January 28, 2011 - Corporate Summary"
1478448d-8d7a-45f5-9eed-470659a29672,2011-01-28T08:00:00.000+08:00,3,Hapoalim Reiterates Hold on Eli Lilly (LLY)
61cba38a-2104-4b52-a46f-29e84771d4a1,2011-01-28T08:00:00.000+08:00,3,"Company News for January 28, 2011 - Corporate Summary"
fe3af635-c8f4-4e18-9578-5839f4ef6e17,2011-01-27T08:00:00.000+08:00,2,Jefferies Comments on Eli Lilly's FY 2010 Earnings (LLY)
c2858db2-b131-43b9-9383-c47f6e2a9293,2011-01-27T08:00:00.000+08:00,4,Eli Lilly Tops Ests; Guides In Line - Analyst Blog
6e4d1f25-7a4c-4176-b8f4-d73940a0ad29,2011-01-27T08:00:00.000+08:00,3,Cost Control Helps Amylin Cut Loss - Analyst Blog
36e6ed0b-e71d-4616-bebb-bbd72b3643cc,2011-01-27T08:00:00.000+08:00,3,Cost Control Helps Amylin Cut Loss - Analyst Blog
87bb8af7-9bdf-492a-a2ac-ab087c9e2270,2011-01-27T08:00:00.000+08:00,4,Eli Lilly Tops Ests; Guides In Line - Analyst Blog
9aab8e37-b531-4358-b3fb-41e300d6623d,2011-01-27T08:00:00.000+08:00,5,"Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance"
eca59971-ac4d-4661-a0cc-3c5cfb7c2a42,2011-01-27T08:00:00.000+08:00,4,A Peek Into The Market Before The Trading Starts
65444f47-11dd-4a2c-beb6-5796f32faa52,2011-01-27T08:00:00.000+08:00,5,Eli Lilly Beats EPS Estimates By 1 Cent (LLY)
9fde00b3-ac08-4c86-b823-59a7210c001a,2011-01-27T08:00:00.000+08:00,3,"Earnings Scheduled For January 27 (CAT, MSFT, PG, T, BMY, LLY, AMZN, AZN, TWC, SNDK, NOK, CB, JBLU, VRSN, PMCS, CL, MSI, KLAC)"
6d1f4225-e092-4d5d-a019-2623a9c577c5,2011-01-27T08:00:00.000+08:00,4,Jefferies Comments on Eli Lilly's FY 2010 Earnings (LLY)
e9f35c0f-909b-440b-ad75-1e440cdab153,2011-01-27T08:00:00.000+08:00,5,Eli Lilly Tops Ests; Guides In Line - Analyst Blog
701569a5-de6a-4513-9e10-4647ecbdcfd3,2011-01-27T08:00:00.000+08:00,4,Cost Control Helps Amylin Cut Loss - Analyst Blog
2580b846-3d5c-4107-8854-9e06407d0d85,2011-01-27T08:00:00.000+08:00,4,Cost Control Helps Amylin Cut Loss - Analyst Blog
9776c199-52a6-40ff-b10e-442c34f08405,2011-01-27T08:00:00.000+08:00,3,Eli Lilly Tops Ests; Guides In Line - Analyst Blog
06e0cbcb-6163-4f3c-aa74-7c2def26b958,2011-01-27T08:00:00.000+08:00,2,"Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance"
86512ceb-0bb9-4145-8d2d-ca979b5bdeef,2011-01-27T08:00:00.000+08:00,1,A Peek Into The Market Before The Trading Starts
b9e080cc-19a2-4915-a9ca-14449e52ba56,2011-01-27T08:00:00.000+08:00,2,Eli Lilly Beats EPS Estimates By 1 Cent (LLY)
7af484d3-3dc3-4d5f-99d7-d67218d50a6a,2011-01-27T08:00:00.000+08:00,3,"Earnings Scheduled For January 27 (CAT, MSFT, PG, T, BMY, LLY, AMZN, AZN, TWC, SNDK, NOK, CB, JBLU, VRSN, PMCS, CL, MSI, KLAC)"
9a7e6b7b-4339-4afa-b34b-cef8f9ce1d8c,2011-01-26T08:00:00.000+08:00,1,Teva and APP Announce Launch of Generic Gemzar
f8bd21b2-fb42-4288-bb42-67bad5e1cea2,2011-01-26T08:00:00.000+08:00,4,Teva and APP Announce Launch of Generic Gemzar
eb41460b-c876-44c0-9f84-cdf6ea1fd940,2011-01-25T08:00:00.000+08:00,5,Earnings Preview: Eli Lilly - Analyst Blog
95e44d1a-b893-4e78-960a-2418a202a458,2011-01-25T08:00:00.000+08:00,4,Earnings Preview: Eli Lilly - Analyst Blog
4b5af187-bc12-4d7e-b223-ac7d575f995f,2011-01-25T08:00:00.000+08:00,4,Earnings Preview: Eli Lilly - Analyst Blog
2232a7f7-f6d2-4a26-8e08-5c14d891b07b,2011-01-25T08:00:00.000+08:00,4,Earnings Preview: Eli Lilly - Analyst Blog
934bd0da-b214-496f-8bcd-0993c32c4601,2011-01-24T08:00:00.000+08:00,5,Citi Increases EPS Estimate on Eli Lilly (LLY)
d4bfcfc6-8953-4d81-b55a-4856360bb68c,2011-01-24T08:00:00.000+08:00,5,Citi Increases EPS Estimate on Eli Lilly (LLY)
264e6e76-5930-4aab-9bdd-02948d4300c0,2011-01-21T08:00:00.000+08:00,2,FDA Panel Reviews Lilly Drug - Analyst Blog
13c3340f-17c3-4910-8412-9d3fd0879ab0,2011-01-21T08:00:00.000+08:00,2,FDA Panel Reviews Lilly Drug - Analyst Blog
1a50abb1-852f-4ead-a08c-e760e947146a,2011-01-21T08:00:00.000+08:00,2,FDA Panel Reviews Lilly Drug - Analyst Blog
b18a5e93-bc5c-459e-90c2-dd2c02927166,2011-01-21T08:00:00.000+08:00,2,FDA Panel Reviews Lilly Drug - Analyst Blog
372e22bf-55e7-49d5-afc4-babe3095caf8,2011-01-20T08:00:00.000+08:00,1,Bleeding Risk with MRK's Candidate - Analyst Blog
b1388698-f6a7-423f-a2cc-40a430c1e123,2011-01-20T08:00:00.000+08:00,1,Bleeding Risk with MRK's Candidate - Analyst Blog
e6785ef7-adb8-49fe-96fb-84e92b0fd1d8,2011-01-20T08:00:00.000+08:00,1,MannKind in Jeopardy - Analyst Blog
8dca515c-a700-4e25-9885-ed97de7273bc,2011-01-20T08:00:00.000+08:00,1,MannKind in Jeopardy - Analyst Blog
07dfce0a-7283-4ba4-b9b9-e179593b9a7b,2011-01-20T08:00:00.000+08:00,1,Bleeding Risk with MRK's Candidate - Analyst Blog
156d4be8-d076-4381-a4cb-160d9d188b33,2011-01-20T08:00:00.000+08:00,1,Bleeding Risk with MRK's Candidate - Analyst Blog
71c9a624-4449-4c69-9e0e-f14af41e18de,2011-01-20T08:00:00.000+08:00,2,MannKind in Jeopardy - Analyst Blog
cc3e9362-a18f-4b04-bda2-5326d6c65075,2011-01-20T08:00:00.000+08:00,2,MannKind in Jeopardy - Analyst Blog
5d767f5b-c3d1-4545-a4b9-7ddc9db22078,2011-01-19T08:00:00.000+08:00,4,FDA To Review Alzheimer's Brain Scan (LLY)
f3466663-5c36-4a90-ac77-9127ca14c3d7,2011-01-19T08:00:00.000+08:00,4,FDA To Review Alzheimer's Brain Scan (LLY)
47bf1a0d-3c6d-4609-a35b-f2217d287118,2011-01-17T08:00:00.000+08:00,1,Community to put Directors in Tenet - Analyst Blog
af2055a2-66fd-4179-911e-1743ec6dba39,2011-01-17T08:00:00.000+08:00,2,Community to put Directors in Tenet - Analyst Blog
c9008eb3-d5a8-4bd8-9359-29b60a1f812a,2011-01-17T08:00:00.000+08:00,2,Community to put Directors in Tenet - Analyst Blog
055ff6cd-cbea-4199-84e0-fe97f4482416,2011-01-17T08:00:00.000+08:00,2,Community to put Directors in Tenet - Analyst Blog
48ec3987-303f-418a-8cf7-4a4096871aff,2011-01-14T08:00:00.000+08:00,1,Merck's Blood Thinner in Trouble - Analyst Blog
45419733-6ca7-40e9-a7ce-1fa5c8db8ee9,2011-01-14T08:00:00.000+08:00,1,Merck's Blood Thinner in Trouble - Analyst Blog
e2208033-510f-49e7-9afe-d48abe946723,2011-01-14T08:00:00.000+08:00,1,Merck's Blood Thinner in Trouble - Analyst Blog
40c8c282-6c6e-46e9-aee8-45382f0d9a06,2011-01-14T08:00:00.000+08:00,1,Merck's Blood Thinner in Trouble - Analyst Blog
fedaf4b4-dc0d-4515-a064-5fcf8e6e8651,2011-01-13T08:00:00.000+08:00,1,FDA Panel Rejects LLY's candidate - Analyst Blog
d9849054-5922-4701-b0f9-81f3c55bee15,2011-01-13T08:00:00.000+08:00,1,FDA Panel Rejects LLY's candidate - Analyst Blog
31122583-2fe5-4b4d-8025-9613b28fc063,2011-01-13T08:00:00.000+08:00,1,FDA Panel Rejects LLY's candidate - Analyst Blog
fe7757c0-6f78-4f7f-adea-2b28fb1cee7f,2011-01-13T08:00:00.000+08:00,2,FDA Panel Rejects LLY's candidate - Analyst Blog
56223e74-54c7-4fcb-8aef-36cc517a23bc,2011-01-12T08:00:00.000+08:00,3,Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application
158964ce-3a87-4546-8bc5-139d6ad3959b,2011-01-12T08:00:00.000+08:00,4,"Benzinga's Top Upgrades (LLY, CPNO, VZ, SLE)"
b7d0177e-65b5-4a04-a052-e2bfe7a8caa0,2011-01-12T08:00:00.000+08:00,4,Hapoalim Upgrades Eli Lilly To Hold (LLY)
51fc4589-5bb2-43ed-b15a-aa18899ea405,2011-01-12T08:00:00.000+08:00,1,Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application
ef5a3e14-45a8-4425-bb46-8f33d41e6eca,2011-01-12T08:00:00.000+08:00,4,"Benzinga's Top Upgrades (LLY, CPNO, VZ, SLE)"
68ef8eb2-3360-49a8-9d7e-9860255193f2,2011-01-12T08:00:00.000+08:00,3,Hapoalim Upgrades Eli Lilly To Hold (LLY)
7b4008ed-d4d2-4c65-b85d-8b1db899bc28,2011-01-07T08:00:00.000+08:00,3,Data on Sanofi Cancer Candidate - Analyst Blog
67501fc4-7693-40a5-a61b-564c7690832c,2011-01-07T08:00:00.000+08:00,3,Data on Sanofi Cancer Candidate - Analyst Blog
648338ad-fd5c-45c8-b0e5-0ad0ec8e6b01,2011-01-07T08:00:00.000+08:00,4,Data on Sanofi Cancer Candidate - Analyst Blog
9f17159d-ff39-439e-a468-df5b8f33e73b,2011-01-07T08:00:00.000+08:00,4,Data on Sanofi Cancer Candidate - Analyst Blog
187c2df9-d49f-4b2d-8b44-ebb5779d32b7,2011-01-06T08:00:00.000+08:00,3,Label Expansion for Roche's Actemra - Analyst Blog
4df03362-cf9c-4d02-98e0-bdcd02b29026,2011-01-06T08:00:00.000+08:00,3,Label Expansion for Roche's Actemra - Analyst Blog
adb9ccea-431c-4b54-aa4c-80b155434026,2011-01-06T08:00:00.000+08:00,3,Label Expansion for Roche's Actemra - Analyst Blog
f54e8619-cddf-467d-94ad-ae1a3b95f31c,2011-01-06T08:00:00.000+08:00,5,Label Expansion for Roche's Actemra - Analyst Blog
718967f0-7fa0-4618-a1bf-0a92d1981d19,2011-01-04T08:00:00.000+08:00,2,Bristol-Myers Outlook Mixed - Analyst Blog
56745776-2bdd-4b9d-9efe-3fe00a5ef525,2011-01-04T08:00:00.000+08:00,2,Bristol-Myers Outlook Mixed - Analyst Blog
de21a7f6-a1bb-4dba-a041-f850808aa817,2011-01-04T08:00:00.000+08:00,3,Citi Comments On Eli Lilly Product Trends
b02139cf-c1ab-40ca-9f6d-0334952ecaea,2011-01-04T08:00:00.000+08:00,4,"Mad Money Lightning Round: Cramer Advises Investors To Buy Baidu (AXL, F, GM, LLY, BIDU, DEO)"
c70480e8-f6f4-417f-9c06-f12f93e09215,2011-01-04T08:00:00.000+08:00,2,Bristol-Myers Outlook Mixed - Analyst Blog
e277f486-8bfc-43ca-9e25-60e328d7aad0,2011-01-04T08:00:00.000+08:00,2,Bristol-Myers Outlook Mixed - Analyst Blog
ef474ab2-6717-4be6-bcc1-33d3532840c0,2011-01-04T08:00:00.000+08:00,3,Citi Comments On Eli Lilly Product Trends
610411d2-27f4-46a7-b79a-ce4a3d60da0d,2011-01-04T08:00:00.000+08:00,4,"Mad Money Lightning Round: Cramer Advises Investors To Buy Baidu (AXL, F, GM, LLY, BIDU, DEO)"
9fcf773f-a84b-464e-8293-1ee2a5c3e6d6,2011-01-03T08:00:00.000+08:00,1,'Mad Money Lightning Round': Baidu's Terrific
e3fb292e-627d-4148-b370-4cde11cadea5,2011-01-03T08:00:00.000+08:00,2,Xoma: Key Diabetes Drug Study Preview
10efa721-8d69-40c5-a476-1659227dd728,2011-01-03T08:00:00.000+08:00,2,'Mad Money Lightning Round': Baidu's Terrific
1e770801-c9af-46ba-aa7d-6a21f46006fe,2011-01-03T08:00:00.000+08:00,4,Xoma: Key Diabetes Drug Study Preview
6f43d708-3376-405f-8372-6c1d4736aa68,2010-12-23T08:00:00.000+08:00,3,Label Expansion Sought for Byetta - Analyst Blog
98eec4dd-62bb-4e12-828d-253dad7026c7,2010-12-23T08:00:00.000+08:00,3,Label Expansion Sought for Byetta - Analyst Blog
43233bdd-c13e-4521-9b59-5ae36c62bc2a,2010-12-23T08:00:00.000+08:00,3,Label Expansion Sought for Byetta - Analyst Blog
d45d8a32-29ed-47c5-b04a-ee04d75bc220,2010-12-23T08:00:00.000+08:00,2,Label Expansion Sought for Byetta - Analyst Blog
e36fcd8f-1782-49c6-aaf9-01f688a32b8d,2010-12-22T08:00:00.000+08:00,4,Amylin and Lilly Seek Expanded Use of BYETTA
bab9679b-3bc4-4772-8275-8db0374ff5ed,2010-12-22T08:00:00.000+08:00,3,INCY's INC424 Meets Goal - Analyst Blog
d5986d83-aaca-494d-aed6-b56a13f0e9b8,2010-12-22T08:00:00.000+08:00,3,INCY's INC424 Meets Goal - Analyst Blog
7a52bbc2-2f73-4e5e-9e48-6ee94ff5c0a1,2010-12-22T08:00:00.000+08:00,1,Unconfirmed Rumors Circulate that Neurocrine Biosciences Inc. (NBIX) will be taken out by Eli Lilly & Co. (LLY) at $17.00 a share
1535fe3f-20f5-4337-8d98-368b5e03e0ba,2010-12-22T08:00:00.000+08:00,4,Eli Lilly Acquires Avid - Analyst Blog
fe7f0d47-7629-4119-938d-1078c5104e2f,2010-12-22T08:00:00.000+08:00,4,Eli Lilly Acquires Avid - Analyst Blog
43c10f8b-0133-4b10-8fda-d946fe5be42e,2010-12-22T08:00:00.000+08:00,3,Amylin and Lilly Seek Expanded Use of BYETTA
184022ee-e535-448d-8aad-56f65d35ecb7,2010-12-22T08:00:00.000+08:00,4,INCY's INC424 Meets Goal - Analyst Blog
ba350f0c-775e-44de-bcaa-036266bf1242,2010-12-22T08:00:00.000+08:00,4,INCY's INC424 Meets Goal - Analyst Blog
55b4c13c-8c94-4d87-927f-49aed9e7f9e6,2010-12-22T08:00:00.000+08:00,2,Unconfirmed Rumors Circulate that Neurocrine Biosciences Inc. (NBIX) will be taken out by Eli Lilly & Co. (LLY) at $17.00 a share
5ea82d43-dbff-40be-afd9-e3533f712033,2010-12-22T08:00:00.000+08:00,4,Eli Lilly Acquires Avid - Analyst Blog
0df1aec6-772c-4ba9-9e58-7268381dbce9,2010-12-22T08:00:00.000+08:00,3,Eli Lilly Acquires Avid - Analyst Blog
738b2d45-22fa-44e9-90e3-43cb9fa9af83,2010-12-21T08:00:00.000+08:00,3,Rolling BLA for AMLN's Metreleptin - Analyst Blog
f769a4aa-f8e5-41ff-80e8-e9d8ce687ebd,2010-12-21T08:00:00.000+08:00,4,Rolling BLA for AMLN's Metreleptin - Analyst Blog
44951e26-ab32-487e-b373-fc63b6dc27de,2010-12-21T08:00:00.000+08:00,2,Rolling BLA for AMLN's Metreleptin - Analyst Blog
3a24ab0c-3088-41b8-a338-cf5f5dc752f1,2010-12-21T08:00:00.000+08:00,2,Rolling BLA for AMLN's Metreleptin - Analyst Blog
24e6aa62-6552-441a-a8e5-afd2552c431f,2010-12-20T08:00:00.000+08:00,3,Safeguard Scientifics to Realize at Least $36M in Initial Sale Proceeds from Eli Lilly's Acquisition of Avid Radiopharmaceuticals
2fecb972-2284-402e-a4c7-173832a3de90,2010-12-20T08:00:00.000+08:00,4,Safeguard Scientifics to Realize at Least $36M in Initial Sale Proceeds from Eli Lilly's Acquisition of Avid Radiopharmaceuticals
45b2bc30-c7df-4ac0-994d-172aab82df5d,2010-12-17T08:00:00.000+08:00,1,"Friday's Put/Call Ratio Leaders (PSUN, LO, COCO, LLY, MCHP)"
55418036-7bbf-491f-a6de-da710de2a5d1,2010-12-17T08:00:00.000+08:00,1,"Friday's Put/Call Ratio Leaders (PSUN, LO, COCO, LLY, MCHP)"
84cde54c-48b9-4eb7-bbf2-f477901c1c3a,2010-12-14T08:00:00.000+08:00,2,Lilly Study Stopped on Safety Concerns - Analyst Blog
6bccd053-78e8-46fc-b867-8d77ef31838b,2010-12-14T08:00:00.000+08:00,3,Lilly Study Stopped on Safety Concerns - Analyst Blog
044abf67-c9fe-4794-818a-54b8e14158fc,2010-12-14T08:00:00.000+08:00,4,Lilly Study Stopped on Safety Concerns - Analyst Blog
0760ddb6-4a28-4093-8ca8-f2c2c721d5ab,2010-12-14T08:00:00.000+08:00,5,Lilly Study Stopped on Safety Concerns - Analyst Blog
0803b83d-e87f-442c-8e55-e886a1254f00,2010-12-13T08:00:00.000+08:00,2,Loss at BIOD Narrower than Expected - Analyst Blog
8a675caa-7ae8-4e9d-bc0a-982de7268f60,2010-12-13T08:00:00.000+08:00,2,Loss at BIOD Narrower than Expected - Analyst Blog
87cb67f5-26d7-4acf-b43b-998729e398c0,2010-12-13T08:00:00.000+08:00,2,Loss at BIOD Narrower than Expected - Analyst Blog
20af4196-8e72-4af7-a140-249879cf7765,2010-12-13T08:00:00.000+08:00,4,Loss at BIOD Narrower than Expected - Analyst Blog
6e54125e-c371-4391-9b91-5592c80cd0b6,2010-12-10T08:00:00.000+08:00,5,"Mad Money Lightning Round: Cramer Advises Investors To Buy BlackRock (LLY, DECK, CMI, OXPS, AXP, V, MRK, ABT, BLK)"
23872963-4751-458e-8954-eb40e958467a,2010-12-10T08:00:00.000+08:00,5,"Mad Money Lightning Round: Cramer Advises Investors To Buy BlackRock (LLY, DECK, CMI, OXPS, AXP, V, MRK, ABT, BLK)"
cd5bee0d-7442-406f-befd-7a6420eded96,2010-12-09T08:00:00.000+08:00,5,'Mad Money Lightning Round': Go for BlackRock
38fabae2-3d1d-41d9-b31d-bde58455536b,2010-12-09T08:00:00.000+08:00,4,Best Stocks For Creating A Passive Income Stream
acd15742-c2e6-4a54-89b9-5e291ed91281,2010-12-09T08:00:00.000+08:00,5,'Mad Money Lightning Round': Go for BlackRock
d323f4eb-d7ea-4596-9fb8-86c2c1f13308,2010-12-09T08:00:00.000+08:00,5,Best Stocks For Creating A Passive Income Stream
65000ce7-70a2-4763-9d44-96d44f7a615e,2010-12-03T08:00:00.000+08:00,2,Neutral on Incyte - Analyst Blog
9e904eed-88a5-44e1-a92f-ef69d381a3e8,2010-12-03T08:00:00.000+08:00,2,Neutral on Incyte - Analyst Blog
d02b522f-2846-4407-840a-709bac1db9a6,2010-12-03T08:00:00.000+08:00,3,CBST's Fast-Injection Cubicin OK'd - Analyst Blog
b31d1d33-bb68-410f-b30c-e31da8246238,2010-12-03T08:00:00.000+08:00,3,CBST's Fast-Injection Cubicin OK'd - Analyst Blog
995bf256-1562-4eb4-99ca-53414e6c2311,2010-12-03T08:00:00.000+08:00,4,Merck Strikes Deal with SmartCells - Analyst Blog
731cdc98-d8ca-4c24-9b3d-c17d7fb8ea80,2010-12-03T08:00:00.000+08:00,2,Merck Strikes Deal with SmartCells - Analyst Blog
12f1324d-8192-4d29-a409-0f6521840bf1,2010-12-03T08:00:00.000+08:00,2,Neutral on Incyte - Analyst Blog
f25405ac-feaa-4644-bd31-3ce413a3c9fb,2010-12-03T08:00:00.000+08:00,2,Neutral on Incyte - Analyst Blog
59d86959-3718-4607-b470-191ff2fda7ac,2010-12-03T08:00:00.000+08:00,2,CBST's Fast-Injection Cubicin OK'd - Analyst Blog
1da3714c-6cf2-4894-b78f-46401816c642,2010-12-03T08:00:00.000+08:00,2,CBST's Fast-Injection Cubicin OK'd - Analyst Blog
cbde9235-0a80-453e-9ce7-fb049a3173fc,2010-12-03T08:00:00.000+08:00,4,Merck Strikes Deal with SmartCells - Analyst Blog
2f002d19-cf39-4ea7-bfce-bcc273d32344,2010-12-03T08:00:00.000+08:00,4,Merck Strikes Deal with SmartCells - Analyst Blog
b696af0a-b14f-4bc3-b9ea-1b1077ed3c57,2010-11-29T08:00:00.000+08:00,5,Acrux and Eli Lilly Receive FDA Approval for Testosterone Drug
891025fe-a318-48fc-abc6-314d7417ed40,2010-11-29T08:00:00.000+08:00,5,Acrux and Eli Lilly Receive FDA Approval for Testosterone Drug
7bc37a4c-0c13-42de-b43b-831a7513fd60,2010-11-24T08:00:00.000+08:00,2,Amylin Stays Neutral - Analyst Blog
23c2640e-1639-4bc0-9700-12da5f1bb325,2010-11-24T08:00:00.000+08:00,2,"Company News for November 24, 2010 - Corporate Summary"
a97922a4-e26b-478b-ac0a-1b23a0797a23,2010-11-24T08:00:00.000+08:00,5,FDA Approves Axiron - Analyst Blog
66d387a1-f8f0-4295-aa4a-086c0e9cbd54,2010-11-24T08:00:00.000+08:00,3,Amylin Stays Neutral - Analyst Blog
5518156b-64f3-479a-9722-949fa36e890d,2010-11-24T08:00:00.000+08:00,2,"Company News for November 24, 2010 - Corporate Summary"
64925cd0-358e-4322-902d-cd555d5a0c5d,2010-11-24T08:00:00.000+08:00,5,FDA Approves Axiron - Analyst Blog
66ee5b35-ff3c-416f-84d0-c79c9224bd58,2010-11-24T08:00:00.000+08:00,2,Amylin Stays Neutral - Analyst Blog
5c598bc5-037e-4a27-8d60-9a8b40352de2,2010-11-24T08:00:00.000+08:00,3,"Company News for November 24, 2010 - Corporate Summary"
2f7e6e07-198c-44ed-8032-5595405db7aa,2010-11-24T08:00:00.000+08:00,4,FDA Approves Axiron - Analyst Blog
81e0589a-5566-4655-bfde-fa6c52940884,2010-11-24T08:00:00.000+08:00,2,Amylin Stays Neutral - Analyst Blog
8065eaec-bd1b-4719-b056-4f4bb6aae6fc,2010-11-24T08:00:00.000+08:00,3,"Company News for November 24, 2010 - Corporate Summary"
72994b30-9b60-4ef2-bb7f-65d1dd016f02,2010-11-24T08:00:00.000+08:00,2,FDA Approves Axiron - Analyst Blog
dfa597e0-455d-4f48-9166-8291b7cc8783,2010-11-22T08:00:00.000+08:00,3,Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta
d9e038e6-75ec-4a13-a46e-28910590442d,2010-11-22T08:00:00.000+08:00,3,Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta
4991dfce-6b8e-4e2f-b696-0081658b25a9,2010-11-19T08:00:00.000+08:00,4,"Zings Of The Day (GOOG, LLY)"
b977ac52-bb35-4486-8296-016284bcb4c3,2010-11-19T08:00:00.000+08:00,4,"Zings Of The Day (GOOG, LLY)"
268d1663-674d-4f4a-a6a8-a91428ee4351,2010-11-16T08:00:00.000+08:00,2,Citi Gives Valuation Update On Eli Lilly
5d68f43a-c90b-412f-86d3-9a197cad7f67,2010-11-16T08:00:00.000+08:00,2,Citi Gives Valuation Update On Eli Lilly
9ccc7abb-d8f7-4d24-9b87-06baaabbbd7f,2010-11-15T08:00:00.000+08:00,3,Hospira Launches Gemcitabine HCL
f29d168f-4147-4b54-9d29-01660bd2fa1f,2010-11-15T08:00:00.000+08:00,3,Hospira Launches Gemcitabine HCL
5897ac13-23d3-4578-b588-bc7b913943a0,2010-11-12T08:00:00.000+08:00,4,"Zacks Analyst Blog Highlights: Lions Gate Entertainment, Amylin Pharmaceuticals, Amylin Pharmaceuticals, Eli Lilly, Alkermes and Novo Nordisk - Press Releases"
da886334-9245-473a-81c6-9b4649c60939,2010-11-12T08:00:00.000+08:00,2,Eli Lilly's Dividend Security Threatened
93582972-081e-4a7b-83bb-c1af31e09fe4,2010-11-12T08:00:00.000+08:00,3,"Zacks Analyst Blog Highlights: Lions Gate Entertainment, Amylin Pharmaceuticals, Amylin Pharmaceuticals, Eli Lilly, Alkermes and Novo Nordisk - Press Releases"
c603c63f-d373-4df7-8ac4-efc35fd65772,2010-11-12T08:00:00.000+08:00,1,Eli Lilly's Dividend Security Threatened
9b385829-e288-4e81-8d06-78efb5a07bad,2010-11-11T08:00:00.000+08:00,1,J.P. Morgan Reiterates Incyte Corporation Rating
327e9f8a-d290-440b-9ff1-690c034b29ec,2010-11-11T08:00:00.000+08:00,3,J.P. Morgan Reiterates Incyte Corporation Rating
1f4c8aaa-c928-4e05-9d65-43d24b101569,2010-11-09T08:00:00.000+08:00,2,Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews
8c27fe79-da65-4ae3-8ff8-e9de5a51c64a,2010-11-09T08:00:00.000+08:00,3,Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook
9a220e03-693d-4d50-a5b8-680bcf28afc1,2010-11-09T08:00:00.000+08:00,3,Pharma and Biotech Industry Outlook - Nov. 2010 - Industry Outlook
ffa7ac31-5f1f-4fed-ba07-65c0cdfb25f6,2010-11-09T08:00:00.000+08:00,4,LLY's Avid Interest in Alzheimer's - Analyst Blog
f6a54ae1-5a3d-4b4c-9a8c-8f7c8a6bfaf8,2010-11-09T08:00:00.000+08:00,3,Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews
d148987c-c665-4574-86aa-8204a2c00c81,2010-11-09T08:00:00.000+08:00,4,Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook
747ebea0-eee7-48a8-abb8-2641994d4bd9,2010-11-09T08:00:00.000+08:00,3,Pharma and Biotech Industry Outlook - Nov. 2010 - Industry Outlook
d95f2023-9def-4b7f-93ed-b539ce70c45e,2010-11-09T08:00:00.000+08:00,5,LLY's Avid Interest in Alzheimer's - Analyst Blog
6cffb85a-8a52-4105-8bec-744afadd7ead,2010-11-08T08:00:00.000+08:00,4,"Eli Lilly Buying Alzheimer's Drug Maker, Is It A Buy? (LLY)"
f97c1c20-7b30-4343-b929-5d557f461065,2010-11-08T08:00:00.000+08:00,5,Lilly to Acquire Avid Radiopharmaceuticals for up to $550M
f8e13d72-ad6b-4824-ad02-381ac1785d99,2010-11-08T08:00:00.000+08:00,2,"Eli Lilly Buying Alzheimer's Drug Maker, Is It A Buy? (LLY)"
dc0801ed-c6b3-413e-8982-189bdc9b5f73,2010-11-08T08:00:00.000+08:00,4,Lilly to Acquire Avid Radiopharmaceuticals for up to $550M
0cf23a29-0925-407c-a9a1-eb454b0ebb93,2010-10-21T08:00:00.000+08:00,1,Hapoalim Securities Reiterates Sell Rating on Eli Lilly (LLY)
6ef5cc11-9e98-4367-ba40-4ac1c3a4ad62,2010-10-21T08:00:00.000+08:00,3,Lilly Beats by a Penny; Ups View - Analyst Blog
5f937ddc-ead1-47ba-ab61-cc98b44c29ae,2010-10-21T08:00:00.000+08:00,1,"Stock Market News for October 21, 2010 - Market News"
794c2960-a8b0-4157-a197-74f299504fa1,2010-10-21T08:00:00.000+08:00,2,"Company News for October 21, 2010 - Corporate Summary"
0f53fa58-59f1-430d-b7e0-6d8558dd2d82,2010-10-21T08:00:00.000+08:00,1,"Trading Plan for October 21, 2010"
60246e67-1946-46f0-b465-da5affdbc53f,2010-10-21T08:00:00.000+08:00,3,"Earnings Scheduled For October 21 (MCD, CAT, T, LLY, CS, UAL, BAX, NVS, UNP, UPS, BBT, PM, RAI, CTXS, SNDK, JBLU, AXP, TRV, LUV, AMZN, STI, HSY, XRX, CB)"
21a7b92c-594b-4a59-8a04-c949aa461a5c,2010-10-21T08:00:00.000+08:00,4,Hapoalim Securities Reiterates Sell Rating on Eli Lilly (LLY)
ab0d0a2d-860c-4900-9759-c6134d7795fe,2010-10-21T08:00:00.000+08:00,5,Lilly Beats by a Penny; Ups View - Analyst Blog
bd695980-f43c-4916-aa0f-48328249300d,2010-10-21T08:00:00.000+08:00,2,"Stock Market News for October 21, 2010 - Market News"
bdd1be76-503a-4801-bfa8-7549d9cdb09f,2010-10-21T08:00:00.000+08:00,3,"Company News for October 21, 2010 - Corporate Summary"
faab49f7-e353-45f0-952a-26a37d74026a,2010-10-21T08:00:00.000+08:00,3,"Trading Plan for October 21, 2010"
706a7a59-890a-4057-9830-6c37da85b3b7,2010-10-21T08:00:00.000+08:00,4,"Earnings Scheduled For October 21 (MCD, CAT, T, LLY, CS, UAL, BAX, NVS, UNP, UPS, BBT, PM, RAI, CTXS, SNDK, JBLU, AXP, TRV, LUV, AMZN, STI, HSY, XRX, CB)"
ab6f8d41-4425-4508-8ca3-0fae0532e397,2010-10-20T08:00:00.000+08:00,5,Viagra Treatment for Muscular Dystrophy
941ea5c9-4bff-4ca0-b8b5-252f3e01bcc0,2010-10-20T08:00:00.000+08:00,2,"\"\"\"Change Of Heart\"\" By FDA For LLY\""
979ac4b9-c3a0-49bc-a95a-fb0e3ddb9ec8,2010-10-20T08:00:00.000+08:00,3,"Benzinga's Top Downgrades (KOF, LLY, ITW, AMLN)"
e99a82a9-a2b4-4cbd-a9c5-a6edbf32ab88,2010-10-20T08:00:00.000+08:00,4,Amylin Pharmaceuticals Crushed In Pre-Market (AMLN)
7a340f19-87d5-4497-b879-6cdd443b834c,2010-10-20T08:00:00.000+08:00,1,Citigroup Downgrades LLY To Hold
69f1a334-9be5-467f-bc86-d70278d41f03,2010-10-20T08:00:00.000+08:00,4,Viagra Treatment for Muscular Dystrophy
90c5e53b-f4d4-4b30-8f4a-58b083906bdc,2010-10-20T08:00:00.000+08:00,2,"\"\"\"Change Of Heart\"\" By FDA For LLY\""
56dc4f93-5105-458f-b84e-4501e65235bf,2010-10-20T08:00:00.000+08:00,3,"Benzinga's Top Downgrades (KOF, LLY, ITW, AMLN)"
d4462ad4-a6c9-423a-890c-0f8543e337dd,2010-10-20T08:00:00.000+08:00,1,Amylin Pharmaceuticals Crushed In Pre-Market (AMLN)
57afe229-399d-40ab-bdf9-6b28e8519d34,2010-10-20T08:00:00.000+08:00,2,Citigroup Downgrades LLY To Hold
eec7008c-289d-49f2-ba6e-7b25fd8cbcef,2010-10-19T08:00:00.000+08:00,4,"In Core Product Trends Report, Citigroup Rates Eli Lilly High Risk"
aad699dd-b209-42fd-a7d3-0c6e74202803,2010-10-19T08:00:00.000+08:00,2,"In Core Product Trends Report, Citigroup Rates Eli Lilly High Risk"
6dfc99e5-0a9e-4186-af73-29c31ce6e8bb,2010-10-18T08:00:00.000+08:00,3,Lilly Declares Fourth-Quarter 2010 Dividend of $.49
60eb09cd-9cfb-425f-89b6-28280843a152,2010-10-18T08:00:00.000+08:00,3,Lilly Declares Fourth-Quarter 2010 Dividend of $.49
3dc20531-237d-4072-a673-6babf81bdd9f,2010-10-12T08:00:00.000+08:00,4,Eli Lilly Product Trends: Increases Across The Board
6773033d-6d3d-4cff-ac8a-d7fa9bce0b59,2010-10-12T08:00:00.000+08:00,1,"Top 4 NYSE Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)"
b850b7ae-242b-440e-b513-692e75c11931,2010-10-12T08:00:00.000+08:00,4,Eli Lilly Product Trends: Increases Across The Board
9be82f0f-3814-4de9-9b78-38e98cd509c2,2010-10-12T08:00:00.000+08:00,2,"Top 4 NYSE Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)"
d2ab527c-4808-4b3e-966d-076d420dc185,2010-10-11T08:00:00.000+08:00,1,Eli Lilly Drug Fails Phase 3 Trial (LLY)
eab0b3bf-f0ee-4f64-8d08-e7b467546c83,2010-10-11T08:00:00.000+08:00,1,Eli Lilly Drug Fails Phase 3 Trial (LLY)
c06b319c-0558-4d0b-82a8-29f051238d06,2010-10-07T08:00:00.000+08:00,3,5 Most Undervalued Stocks in the S&P 500
5c4f700d-78d5-4839-9ccd-1cae37ff62e7,2010-10-07T08:00:00.000+08:00,2,5 Most Undervalued Stocks in the S&P 500
6d82fc2f-2684-4732-b4a8-f59422f61b2e,2010-10-06T08:00:00.000+08:00,4,"Unconfirmed rumor that Amylin Pharmaceuticals, Inc. (AMLN) is in talks with Eli Lilly & Co. (LLY) to be acquired in the mid $30s"
aef87efd-3281-4831-8a08-14c4d747222b,2010-10-06T08:00:00.000+08:00,3,Eli Lilly's Core Product Trends For The Week Ending 9/24
0502d97b-6da5-4dda-b7ef-0237f02c2ef9,2010-10-06T08:00:00.000+08:00,4,"Unconfirmed rumor that Amylin Pharmaceuticals, Inc. (AMLN) is in talks with Eli Lilly & Co. (LLY) to be acquired in the mid $30s"
a73a88a7-3de1-409d-a8ef-46aee558ffd1,2010-10-06T08:00:00.000+08:00,3,Eli Lilly's Core Product Trends For The Week Ending 9/24
8ac39ebe-ee9b-478c-99d7-89b5ce9ef9b0,2010-10-04T08:00:00.000+08:00,2,J&J-Galapagos in Anti-Cancer Deal - Analyst Blog
ef868aac-bf69-4698-b47d-eb70dff3f357,2010-10-04T08:00:00.000+08:00,3,Bristol Myers at Neutral - Analyst Blog
d218e805-3c59-4339-88c0-8b7edc69b8b3,2010-10-04T08:00:00.000+08:00,3,Male Menopause: Another Treatment for Pharmaceutical Companies
2aa6087c-5500-475e-ab7d-e6cf5278eb0d,2010-10-04T08:00:00.000+08:00,2,J&J-Galapagos in Anti-Cancer Deal - Analyst Blog
8cf46352-46c4-42ee-bcb5-a726f98b3a0d,2010-10-04T08:00:00.000+08:00,3,Bristol Myers at Neutral - Analyst Blog
073bd3d9-b4c7-43e8-938f-a7b909727685,2010-10-04T08:00:00.000+08:00,2,Male Menopause: Another Treatment for Pharmaceutical Companies
92956388-016d-4a9a-be47-2b110db33428,2010-09-30T08:00:00.000+08:00,3,"Benzinga's Top Pre-Market NASDAQ Gainers (SNTS, LLNW, APWR, MNKD)"
c1b866d9-d07e-4c4a-a2f2-2dbaead9f8b7,2010-09-30T08:00:00.000+08:00,3,"Benzinga's Top Pre-Market NASDAQ Gainers (SNTS, LLNW, APWR, MNKD)"
ac931b41-5ffc-4f81-8de5-163c92d0f84d,2010-09-29T08:00:00.000+08:00,4,Unconfirmed Rumor that Eli Lilly & Co. (LLY) is readying bid for MannKind Corp. (MNKD) at $12.50 a share
1d5ec0e7-368b-4750-b253-bf1ec394c99b,2010-09-29T08:00:00.000+08:00,5,Unconfirmed Rumor that Eli Lilly & Co. (LLY) is readying bid for MannKind Corp. (MNKD) at $12.50 a share
30b54ae4-9e22-4b58-904f-6884ea20907b,2010-09-28T08:00:00.000+08:00,2,"Mad Money Lightning Round: Cramer Considers Apple As One Of The Best Stocks Ever, Advises Investors To Buy AT&T And Verizon, Sell A-Power Energy (AAPL, LLY, T, VZ, GOOG, APWR, LDK, ARUN)"
a698b28e-d1c4-4246-ab4f-3f266d347fb3,2010-09-28T08:00:00.000+08:00,2,"Mad Money Lightning Round: Cramer Considers Apple As One Of The Best Stocks Ever, Advises Investors To Buy AT&T And Verizon, Sell A-Power Energy (AAPL, LLY, T, VZ, GOOG, APWR, LDK, ARUN)"
a8abd285-33a8-446b-ab1d-c688a7e70512,2010-09-23T08:00:00.000+08:00,3,Lilly CEO Says Regional Innovation Important to the Nation's Economy (LLY)
22947b8e-0299-42ac-96fa-302f4b18cac6,2010-09-23T08:00:00.000+08:00,4,Yield Versus Yield
6ba97673-ecee-4b7d-91fc-70ce9b3c62fb,2010-09-23T08:00:00.000+08:00,3,Lilly CEO Says Regional Innovation Important to the Nation's Economy (LLY)
aefd7cf9-db61-40c5-8861-d8ffaf1cd784,2010-09-23T08:00:00.000+08:00,2,Yield Versus Yield
bd07ac6d-2160-4db3-adaa-419e63200064,2010-09-22T08:00:00.000+08:00,4,"Unconfirmed rumor that Amylin Pharmaceuticals, Inc. (AMLN) will be taken out by Eli Lilly & Co. (LLY) at $32.00"
b5e78bb2-ebe8-44a8-bd6e-d5921115f25f,2010-09-22T08:00:00.000+08:00,3,"Unconfirmed rumor that Amylin Pharmaceuticals, Inc. (AMLN) will be taken out by Eli Lilly & Co. (LLY) at $32.00"
b26b0f46-ccf6-4d1d-801c-af50bd4d7038,2010-09-21T08:00:00.000+08:00,1,Jeffrey A. Winton Named VP At Eli Lilly And Company (LLY)
404c6fd5-65bd-4a1d-854b-59fcd65a06ca,2010-09-21T08:00:00.000+08:00,2,J.P. Morgan Has Underweight Rating On Eli Lilly (LLY)
b09369b3-751b-463c-9f8c-503f9eae0123,2010-09-21T08:00:00.000+08:00,2,Jeffrey A. Winton Named VP At Eli Lilly And Company (LLY)
c1c1a833-8632-4f5e-93bd-a065c3d30bbd,2010-09-21T08:00:00.000+08:00,3,J.P. Morgan Has Underweight Rating On Eli Lilly (LLY)
15e6a019-2eb7-4ee5-ad72-67a7f04f3332,2010-09-20T08:00:00.000+08:00,1,Pipeline Setback for TTHI - Analyst Blog
25ad6e4b-e11c-42fd-9cb6-e1315e96217b,2010-09-20T08:00:00.000+08:00,1,Pipeline Setback for TTHI - Analyst Blog
2eff8e4c-d2fc-4d8a-b8c4-dbc2fcc21438,2010-09-17T08:00:00.000+08:00,4,Thumbs Up for ALKS Drug - Analyst Blog
10bfabfc-89c4-4034-86f3-0e2813a1262d,2010-09-17T08:00:00.000+08:00,4,Thumbs Up for ALKS Drug - Analyst Blog
b8456e4d-452e-4220-9fab-7c5f81a6d30b,2010-09-15T08:00:00.000+08:00,4,Pharmaceutical Stocks Worth Owning For The Dividend Alone
063da7b3-57a8-45db-b73f-1626b1a110bb,2010-09-15T08:00:00.000+08:00,4,Pharmaceutical Stocks Worth Owning For The Dividend Alone
eb360189-4b3b-4fcc-9dc9-3946e0e3ea83,2010-09-15T08:00:00.000+08:00,4,Pharmaceutical Stocks Worth Owning For The Dividend Alone
f4be8dcb-adcc-466d-a22b-7fb2a98dc28b,2010-09-15T08:00:00.000+08:00,5,Pharmaceutical Stocks Worth Owning For The Dividend Alone
122e8bd0-52a6-4e0c-ac88-57ea8bb755e1,2010-09-10T08:00:00.000+08:00,2,More Unconfirmed Chatter On Vivus Takeover (VVUS)
60041edb-2f2c-4081-8d27-7154309cfe18,2010-09-10T08:00:00.000+08:00,2,More Unconfirmed Chatter On Vivus Takeover (VVUS)
f6e1b60a-7cd1-408a-8c71-b4beffccab3c,2010-09-03T08:00:00.000+08:00,3,PDLI Gives Third-Quarter Outlook - Analyst Blog
7417ba45-579f-4725-ac87-ce44d657e976,2010-09-03T08:00:00.000+08:00,3,PDLI Gives Third-Quarter Outlook - Analyst Blog
dfaee4db-5f32-45dd-afb6-da18c297b9f6,2010-09-01T08:00:00.000+08:00,1,U.S. Court of Appeals Upholds Validity of Lilly's Evista Patents (LLY)
ee4412b5-8c42-472c-bf79-1da0ccbf04cd,2010-09-01T08:00:00.000+08:00,4,U.S. Court of Appeals Upholds Validity of Lilly's Evista Patents (LLY)
0c826c13-f492-48f4-839e-bebccb9d9ac9,2010-08-30T08:00:00.000+08:00,3,Incyte Evenly Poised - Analyst Blog
ce1dd121-df3d-486b-8e15-78deecf0289b,2010-08-30T08:00:00.000+08:00,3,Goldman Sachs Introduces And Adjusts Estimates For Major Pharmaceuticals
66ddd79e-5899-477c-ba44-964fec5ede98,2010-08-30T08:00:00.000+08:00,3,Incyte Evenly Poised - Analyst Blog
915ae903-ce77-4c98-8d77-3482c90ede5c,2010-08-30T08:00:00.000+08:00,4,Goldman Sachs Introduces And Adjusts Estimates For Major Pharmaceuticals
26f03ae3-0a0c-43c1-a384-ea10fe5ec730,2010-08-26T08:00:00.000+08:00,2,Repros Schedules Meeting with FDA - Analyst Blog
f0c0ceaa-3801-41a9-bac6-561a563f9bf8,2010-08-26T08:00:00.000+08:00,1,VVUS) Unconfirmed rumor that (LLY) will buy the company for $9.00 Cash
b90469dd-f3b1-45e5-9989-fa8e720c74ca,2010-08-26T08:00:00.000+08:00,3,Repros Schedules Meeting with FDA - Analyst Blog
02e7bbfa-36f9-43d9-8cdd-7d2db70a8de7,2010-08-26T08:00:00.000+08:00,4,VVUS) Unconfirmed rumor that (LLY) will buy the company for $9.00 Cash
05afaed2-30c8-40d2-8302-bde41c7f59e7,2010-08-20T08:00:00.000+08:00,3,Jefferies Reiterates Hold Rating on Eli Lilly (LLY)
c746bb6b-1cb1-4dd1-93ed-c0249c8e6599,2010-08-20T08:00:00.000+08:00,2,Jefferies Reiterates Hold Rating on Eli Lilly (LLY)
656517f4-bbc1-4ac7-8154-40f0974fed1b,2010-08-18T08:00:00.000+08:00,3,FDA Panel to Review Eli Lilly's Cymbalta - Analyst Blog
5206b2e6-bd3f-4e13-b002-c0c7917b2b41,2010-08-18T08:00:00.000+08:00,3,FDA Panel to Review Eli Lilly's Cymbalta - Analyst Blog
7319c888-9c99-4784-bd11-f41f5bb55cea,2010-08-17T08:00:00.000+08:00,1,Eli Lilly Halts Development Of Alzheimer Drug (LLY)
23d8c164-1ad7-43cb-8906-5db4953bf977,2010-08-17T08:00:00.000+08:00,2,"Top 4 Large-Cap Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)"
718524cf-7fdc-4467-a13b-f9e329d1befe,2010-08-17T08:00:00.000+08:00,1,Eli Lilly Halts Development Of Alzheimer Drug (LLY)
74750494-3fc0-4fd8-84db-f1029d79f39e,2010-08-17T08:00:00.000+08:00,3,"Top 4 Large-Cap Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)"
1e3ff86b-fa65-413f-ae05-3a4ab8f2e53f,2010-08-13T08:00:00.000+08:00,2,All Is Not Well In The Pharmaceutical Industry
0735e8a9-d46e-47f6-9da1-d7e200a1008f,2010-08-13T08:00:00.000+08:00,1,Eli Lilly Cuts Revenue Guidance - Analyst Blog
741dcf6d-025f-47c9-8139-85d7f8dfcf9c,2010-08-13T08:00:00.000+08:00,1,Eli Lilly Loses Strattera Patent Case; Hapoalim Securities Reiterates Sell Rating (LLY)
51ea9516-299d-4f92-b92b-6f1174771b9b,2010-08-13T08:00:00.000+08:00,2,"U.S. Probing Pharmaceutical Corruption (GSK, PFE, BMY, LLY)"
404dfd7b-1288-43d4-8a42-fc6f6c70cda0,2010-08-13T08:00:00.000+08:00,3,All Is Not Well In The Pharmaceutical Industry
faed4075-a659-47db-9bd8-40f4054bf277,2010-08-13T08:00:00.000+08:00,1,Eli Lilly Cuts Revenue Guidance - Analyst Blog
5f76de24-97aa-4a7e-9c18-db56ffd6bead,2010-08-13T08:00:00.000+08:00,2,Eli Lilly Loses Strattera Patent Case; Hapoalim Securities Reiterates Sell Rating (LLY)
e03cec7f-da02-44ba-8bdc-ce93d39dff96,2010-08-13T08:00:00.000+08:00,2,"U.S. Probing Pharmaceutical Corruption (GSK, PFE, BMY, LLY)"
86e44641-6cfd-4f22-9ece-94d77522a5a0,2010-08-12T08:00:00.000+08:00,1,Amgen's Vectibix Disappoints - Analyst Blog
d61a4d15-3010-4247-911d-90cb2d19cf89,2010-08-12T08:00:00.000+08:00,1,Amgen's Vectibix Disappoints - Analyst Blog
3ea312a6-8c75-4dba-a5fa-057bfaaef721,2010-08-11T08:00:00.000+08:00,3,"Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (LLY, GSK, BMY, PFE)"
60c4cd2b-c9b2-439a-8e79-c09b93fbead4,2010-08-11T08:00:00.000+08:00,2,"Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (LLY, GSK, BMY, PFE)"
b5955f79-38f1-4bcd-80ea-568fb78d374d,2010-08-09T08:00:00.000+08:00,1,Revenues Dip at Alkermes - Analyst Blog
3902b328-ddcd-40d1-be85-a2086ea09e2c,2010-08-09T08:00:00.000+08:00,5,Finally There Is A Cure For Tobacco Addiction (CIGX)
9230028a-113e-4068-9a46-84a6164853a4,2010-08-09T08:00:00.000+08:00,2,Revenues Dip at Alkermes - Analyst Blog
e0d6a3b5-7907-412d-99ca-af4dff07fe92,2010-08-09T08:00:00.000+08:00,5,Finally There Is A Cure For Tobacco Addiction (CIGX)
922708ec-52de-4f50-86cb-8ed6d8ca9907,2010-08-03T08:00:00.000+08:00,4,Stocks Going Ex Dividend the Second Week of August 2010
24fcf7e7-8a26-4b8c-a0c0-e229a68d9e06,2010-08-03T08:00:00.000+08:00,4,Stocks Going Ex Dividend the Second Week of August 2010
c7da8f5e-10bb-4bef-9ab9-ae3d8cbee2c3,2010-08-02T08:00:00.000+08:00,2,"Top 4 NYSE Stocks In The Healthcare Sector With The Highest Free Cash Flow (PFE, JNJ, MRK, LLY)"
7826e95b-9604-4e35-97a6-0b29dc454a10,2010-08-02T08:00:00.000+08:00,2,"Top 4 NYSE Stocks In The Healthcare Sector With The Highest Free Cash Flow (PFE, JNJ, MRK, LLY)"
44ea00ea-e0ca-4e05-a877-ff18780d60b4,2010-07-30T08:00:00.000+08:00,1,July Impressive -- S&Ps Up 6.9% 07-30-2010
c78a0bd4-af56-4c83-943b-348b43b87005,2010-07-30T08:00:00.000+08:00,3,July Impressive -- S&Ps Up 6.9% 07-30-2010
04c999e7-91fd-4d45-8d84-850a39aacfdf,2010-07-26T08:00:00.000+08:00,4,Corporate Catalysts For The Week Starting July 26
518b8a7b-df17-4eea-9dcb-13230048da12,2010-07-26T08:00:00.000+08:00,5,Corporate Catalysts For The Week Starting July 26
9f3ab463-ead8-404b-9764-aff893b85db3,2010-07-22T08:00:00.000+08:00,4,Markets Surge on Strong Corporate Earnings (SPY)
57d1b093-5dc2-4d25-b5c2-fd5313098ece,2010-07-22T08:00:00.000+08:00,5,"Eli Lilly Beats Estimates, Raises Forecast (LLY)"
4f3dca7c-ac14-4fa3-b04d-22ffa0f2b3e6,2010-07-22T08:00:00.000+08:00,5,"Eli Lilly Reports Strong Sales, Beats on Profit (LLY)"
1f2084cb-a2b4-4019-8282-3a92dfb023ed,2010-07-22T08:00:00.000+08:00,5,"Eli Lilly Posts Better-Than-Expected Q2 Results, Raises 2010 EPS Guidance"
59aea553-62e2-45e0-9476-edf6760c2d05,2010-07-22T08:00:00.000+08:00,5,Markets Surge on Strong Corporate Earnings (SPY)
e4a0f5d8-3713-4526-9088-74f708cf7ead,2010-07-22T08:00:00.000+08:00,5,"Eli Lilly Beats Estimates, Raises Forecast (LLY)"
49966763-bdaa-42a7-9a85-d56725a5fcee,2010-07-22T08:00:00.000+08:00,4,"Eli Lilly Reports Strong Sales, Beats on Profit (LLY)"
1d5cdba6-b18d-41d7-9520-ab0a3fbccee4,2010-07-22T08:00:00.000+08:00,5,"Eli Lilly Posts Better-Than-Expected Q2 Results, Raises 2010 EPS Guidance"
115c3584-b198-43e4-905b-a6167f3b348b,2010-07-06T08:00:00.000+08:00,5,Lechleiter Says LLY Has The Most Exciting Pipeline
da8ffda4-d6cc-41a8-a704-1df88cd9021b,2010-07-06T08:00:00.000+08:00,5,"News Summary (LLY, TM)"
07c5b7d1-53bc-4e12-bc90-11b5f406dd25,2010-07-06T08:00:00.000+08:00,5,Lechleiter Says LLY Has The Most Exciting Pipeline
fbaea16c-0e7a-41a1-a3c0-a0ede37df75c,2010-07-06T08:00:00.000+08:00,3,"News Summary (LLY, TM)"
87f45571-983c-43c3-a08b-0cfc89a0f20f,2010-07-02T08:00:00.000+08:00,4,Calls Purchased on Eli Lilly & Co. (LLY)
5f95461b-7e96-4319-8e39-81bef6ffbca0,2010-07-02T08:00:00.000+08:00,4,Calls Purchased on Eli Lilly & Co. (LLY)
8c0c8342-9217-4c21-bae6-0ae5f5a1dd21,2010-06-30T08:00:00.000+08:00,2,"Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (AZN, LLY, GSK, BMY)"
e85daf53-b50c-4a27-be4d-f443fc82f671,2010-06-30T08:00:00.000+08:00,2,"Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (AZN, LLY, GSK, BMY)"
a2bda991-264e-401c-8d8c-8485ffee5c31,2010-06-28T08:00:00.000+08:00,4,Hapoalim Securities Expects Eli Lilly To Acquire Amylin Pharmaceuticals Post Approval Of AMLN’s Bydureon
92569842-628c-48b1-83a2-464299e0c999,2010-06-28T08:00:00.000+08:00,1,Hapoalim Securities Expects Eli Lilly To Acquire Amylin Pharmaceuticals Post Approval Of AMLN’s Bydureon
c763155e-b4db-448d-8247-7e38f01f633f,2010-06-10T08:00:00.000+08:00,3,MannKind Corp. Glosses Over FDA Meeting; Hapoalim Balks (MNKD)
2ae23abd-d90e-4d8a-8b3b-71cb86167eeb,2010-06-10T08:00:00.000+08:00,2,News Summary
3713c1eb-9efd-4f20-aac6-a48c714b00f5,2010-06-10T08:00:00.000+08:00,1,MannKind Corp. Glosses Over FDA Meeting; Hapoalim Balks (MNKD)
93eed736-9b23-4d90-aabe-d5b14baee313,2010-06-10T08:00:00.000+08:00,3,News Summary
7e56a28b-164d-4974-8837-b7e8bc679433,2010-06-07T08:00:00.000+08:00,4,"Top 5 Large-Cap NYSE Stocks In The Healthcare Sector With The Highest Return On Equity (GSK, LLY, AZN, ACL, NVO)"
3c2272ed-c8ba-4327-92a5-2346dcd9b57d,2010-06-07T08:00:00.000+08:00,3,"Top 5 Large-Cap NYSE Stocks In The Healthcare Sector With The Highest Return On Equity (GSK, LLY, AZN, ACL, NVO)"
506e4f0f-6fab-433d-ac57-e499f9f3b712,2010-05-27T08:00:00.000+08:00,2,"With Interest Rates this low, Should Investors Look to Equity Dividend Yields?"
d57aa554-7653-4af5-a347-dc13ef034197,2010-05-27T08:00:00.000+08:00,2,"With Interest Rates this low, Should Investors Look to Equity Dividend Yields?"
72abb59c-98c1-4ce0-b0c3-62039938be39,2010-05-13T08:00:00.000+08:00,1,Companies Dodge $60 Billion in Taxes
947755b1-ea2d-4ebe-9729-c35fe2cbd5c9,2010-05-13T08:00:00.000+08:00,1,Companies Dodge $60 Billion in Taxes
f6bd05a5-ea5a-491d-a370-8759eb7195fa,2010-05-03T08:00:00.000+08:00,4,Stocks Going Ex Dividend the Second Week of May
b8ec41a1-4a2b-4929-9257-ce7373dc516e,2010-05-03T08:00:00.000+08:00,2,Stocks Going Ex Dividend the Second Week of May
91543285-9f4d-4f93-b96f-b7e1bcf3bfba,2010-04-28T08:00:00.000+08:00,5,"Whistleblower Gets Rewarded In AstraZeneca Case (AZN, LLY)"
99f22812-ccc0-4be4-81c1-7914b9965bb0,2010-04-28T08:00:00.000+08:00,3,"Whistleblower Gets Rewarded In AstraZeneca Case (AZN, LLY)"
3bb3c559-e06e-47ed-94fe-f0fa8b8447a8,2010-04-21T08:00:00.000+08:00,4,"Afternoon-Market Update Abbott Labs (NYSE: ABT), Boeing (NYSE: BA), Tempur-Pedic (NYSE: TPX)"
dd9edff7-252b-4f02-8068-f032480a3e16,2010-04-21T08:00:00.000+08:00,3,"Afternoon-Market Update Abbott Labs (NYSE: ABT), Boeing (NYSE: BA), Tempur-Pedic (NYSE: TPX)"
fa89c31e-c449-4730-9458-875a6099d22e,2010-04-19T08:00:00.000+08:00,2,"Company News for April 19, 2010 - Corporate Summary"
4103fea3-e99b-4f4d-8543-4660adf607c4,2010-04-19T08:00:00.000+08:00,4,Eli Lilly Slashes Earnings Guidance (LLY)
d789e0d0-815b-47cc-9052-f448aef4010a,2010-04-19T08:00:00.000+08:00,3,Bulls Bet on Eli Lilly
d44d3d88-bb3e-4887-9c90-136fd17ff5a4,2010-04-19T08:00:00.000+08:00,1,US Stock Futures Point To A Weak Opening; Investors Eyeing Citigroup Results
0561e87e-8e93-4ef1-b081-3ea189fd8aa8,2010-04-19T08:00:00.000+08:00,2,Eli Lilly & Co. (LLY) Reports A 5% Drop In First-Quarter Profit
2c33be98-67f6-49b3-8e8d-485bb5afcc4d,2010-04-19T08:00:00.000+08:00,2,"Stocks To Watch On April 19 (C, HAL, LLY, IBM, ZION)"
b30a5fb6-cb1c-4c76-8516-d96092d8dce8,2010-04-19T08:00:00.000+08:00,1,"Eli Lilly and Co. (LLY) Profit Falls 5%, As Revenues Climb"
98586998-9ae8-4429-aec8-f464016b641b,2010-04-19T08:00:00.000+08:00,3,"Company News for April 19, 2010 - Corporate Summary"
016d9cd1-a207-485c-b485-8ca59f431f86,2010-04-19T08:00:00.000+08:00,4,Eli Lilly Slashes Earnings Guidance (LLY)
beae43fa-1e65-4f6c-87fb-fb73db439a8c,2010-04-19T08:00:00.000+08:00,5,Bulls Bet on Eli Lilly
e6416617-f162-49a1-9acb-974e674124ad,2010-04-19T08:00:00.000+08:00,1,US Stock Futures Point To A Weak Opening; Investors Eyeing Citigroup Results
cd0ab9c6-4975-49b8-ac54-2b9d6690aec2,2010-04-19T08:00:00.000+08:00,2,Eli Lilly & Co. (LLY) Reports A 5% Drop In First-Quarter Profit
31a19820-b905-4869-a796-1df3304ad25d,2010-04-19T08:00:00.000+08:00,3,"Stocks To Watch On April 19 (C, HAL, LLY, IBM, ZION)"
58902234-7eb4-4bb4-8ed3-9b0d6cd55cd6,2010-04-19T08:00:00.000+08:00,4,"Eli Lilly and Co. (LLY) Profit Falls 5%, As Revenues Climb"
d11ca51b-bc18-45f1-8c04-d57cb8b9bc68,2010-04-01T08:00:00.000+08:00,5,Citigroup Rates Teva Pharmaceutical Industries (TEVA) A Buy After Court Ruling
af754ff8-9eb8-4c47-9fec-f1bb9d167929,2010-04-01T08:00:00.000+08:00,2,Citigroup Rates Teva Pharmaceutical Industries (TEVA) A Buy After Court Ruling
51855640-0c67-4e6c-99d4-ebcd49135162,2010-03-29T08:00:00.000+08:00,2,"There Are Still Some Bargains In The Market; Barron’s (LLY, PFE, GS, MS, CVX)"
0cd7a1e2-abf3-4af4-b713-95ce642b674d,2010-03-29T08:00:00.000+08:00,2,"There Are Still Some Bargains In The Market; Barron’s (LLY, PFE, GS, MS, CVX)"
792719f7-644b-490b-9325-9c5bbe451cac,2010-03-24T08:00:00.000+08:00,1,Investors Need To Pay More Attention To Dividend ETFs In 2010
e052e5a1-7e64-4268-b52c-6cac5f996313,2010-03-24T08:00:00.000+08:00,1,Investors Need To Pay More Attention To Dividend ETFs In 2010
ba5b24ba-dccd-4588-ae44-052622138ce0,2010-03-23T08:00:00.000+08:00,4,Before Jumping Into A Single Health Care Stock Consider This ETF
a15ff6aa-06f1-44d8-a782-ba3949affb05,2010-03-23T08:00:00.000+08:00,4,Before Jumping Into A Single Health Care Stock Consider This ETF
39225b1d-dda5-487c-8c4e-f44d048404c7,2010-03-22T08:00:00.000+08:00,5,Investors Flock To Healthcare ETFs On Historic Reform
3d834897-8b21-4836-8aa5-5024d1706667,2010-03-22T08:00:00.000+08:00,5,Investors Flock To Healthcare ETFs On Historic Reform
993a103b-12c1-4771-9fe6-d4bc95d4bb45,2010-03-21T08:00:00.000+08:00,4,How Will Obama-Care Play Into The Markets And ETFs?
64a1270e-0bb8-4d83-b209-d892a5faef8f,2010-03-21T08:00:00.000+08:00,2,How Will Obama-Care Play Into The Markets And ETFs?
cc7db17a-c07e-477a-9ff1-96e41eb8dcf3,2010-03-17T08:00:00.000+08:00,4,This Healthcare ETF (XLV) Is Seeing Above Average Call Buying
92d40732-b485-4b17-9f6b-6889c11efd5d,2010-03-17T08:00:00.000+08:00,4,This Healthcare ETF (XLV) Is Seeing Above Average Call Buying
687b608b-d54e-40be-89cc-c92f7fb7cc62,2010-03-15T08:00:00.000+08:00,3,"Benzinga’s News Roundup (PEP, ALKS, MRK)"
062ccb32-116d-47dc-ad40-291be3fb2d08,2010-03-15T08:00:00.000+08:00,1,"Benzinga’s Top Pre-Market Gainers (PVH, AMLN, CHRD, ISIS, NVAX)"
8d3a4a82-69af-4bd3-8df5-29eb07f8e538,2010-03-15T08:00:00.000+08:00,2,"Benzinga’s News Roundup (PEP, ALKS, MRK)"
b76e8398-a4f7-4c7e-8e92-72659a10db60,2010-03-15T08:00:00.000+08:00,3,"Benzinga’s Top Pre-Market Gainers (PVH, AMLN, CHRD, ISIS, NVAX)"
3e3e4980-69e3-43f7-abc3-b2f7a1bab8d9,2010-03-08T08:00:00.000+08:00,1,AMLN Is Waiting For A Decision On Byetta
88af9e2f-982b-4432-bb74-5277b759d88c,2010-03-08T08:00:00.000+08:00,1,AMLN Is Waiting For A Decision On Byetta
086225a8-7381-4537-a008-538eab78e76e,2010-03-03T08:00:00.000+08:00,4,Transition (TTHI) Secures Licensing Deal With Eli Lilly (LLY)
2b0c3ea7-5746-4472-9ac1-77bb23442c91,2010-03-03T08:00:00.000+08:00,2,Transition (TTHI) Secures Licensing Deal With Eli Lilly (LLY)
e8f5702b-8c01-4a4e-842f-62f49ab2e080,2010-02-25T08:00:00.000+08:00,3,Eli Lilly Banks On Its Restructured Development Process To Offset Sales Loss (LLY)
e3c38be7-16b9-4e81-acbd-a85a376126bb,2010-02-25T08:00:00.000+08:00,3,Eli Lilly Banks On Its Restructured Development Process To Offset Sales Loss (LLY)
9fe2c2dc-a3a2-44d1-9873-580fafb4a86b,2010-02-23T08:00:00.000+08:00,4,"Market Roundup (BAC, JPM, DELL, WAG, LLY)"
be8891b7-1c62-435c-8dfa-cf8daf3b072b,2010-02-23T08:00:00.000+08:00,4,"Market Roundup (BAC, JPM, DELL, WAG, LLY)"
9f380006-1953-4bc5-b5ff-d2a2d200bc50,2010-02-18T08:00:00.000+08:00,2,"Carl Icahn On CNBC (AMLN, GELG, LGM)"
96db6e93-5e24-4e2e-bd3c-967885be523d,2010-02-18T08:00:00.000+08:00,2,"Carl Icahn On CNBC (AMLN, GELG, LGM)"
0746efe1-bc92-4296-acda-d230f90257f5,2010-02-05T08:00:00.000+08:00,3,"Market Round-up (UBS, GOOG¸ AAPL, MOT¸ PG, PFE, MRK, LLY, CVS, WAG)"
807bf57f-344f-4b44-8551-28cbf0231d24,2010-02-05T08:00:00.000+08:00,2,"Market Round-up (UBS, GOOG¸ AAPL, MOT¸ PG, PFE, MRK, LLY, CVS, WAG)"
a1859ec0-5a26-4a22-ae2d-0f7da67c9d4d,2010-02-03T08:00:00.000+08:00,1,Pharma Stocks Dive On Missed Expectations
4362a492-4f5c-4ab2-8bd8-0147829eca34,2010-02-03T08:00:00.000+08:00,2,Pharma Stocks Dive On Missed Expectations
cc24ff38-f9b5-47d7-9050-71c2f9f1c28b,2010-02-01T08:00:00.000+08:00,4,"Five Stocks To Buy Since Analysts Hate Them (LLY, CAN, EEP, LXK, PCX)"
a0e14dd4-d89a-40ae-81dd-63975f9f83fb,2010-02-01T08:00:00.000+08:00,3,"Five Stocks To Buy Since Analysts Hate Them (LLY, CAN, EEP, LXK, PCX)"
3e9fcc55-0f84-4d7f-ab0b-d12f3ab45ae9,2010-01-29T08:00:00.000+08:00,4,Eli Lilly (LLY) Has A Healthy Pipeline : CEO Tells CNBC
36df1dff-3974-4867-b5b4-36b14a29f124,2010-01-29T08:00:00.000+08:00,1,Eli Lilly (LLY) Has A Healthy Pipeline : CEO Tells CNBC
607d7b0b-bd2f-4394-8a15-029c7f4ddbf7,2010-01-28T08:00:00.000+08:00,2,"Eli Lilly & Co. (LLY) Profits Are Up, But Concerns Remain"
8e89ce2c-b797-499e-a89f-c4685041f267,2010-01-28T08:00:00.000+08:00,4,"Bristol (BMY), Lilly (LLY) Up Sales And Settle Dispute"
88e01ef7-c218-42d5-9ae5-5b8f9f2678e9,2010-01-28T08:00:00.000+08:00,3,"Benzinga’s Earnings Roundup (TYC, BDX, TWC, BLL, LLY)"
d86dcaea-26ad-4222-9a00-3b1b7cda7918,2010-01-28T08:00:00.000+08:00,2,"Eli Lilly & Co. (LLY) Profits Are Up, But Concerns Remain"
5734a698-595f-4c51-9972-3838b5b09dfa,2010-01-28T08:00:00.000+08:00,4,"Bristol (BMY), Lilly (LLY) Up Sales And Settle Dispute"
317d9e8f-15ef-425f-989b-d34436ec4645,2010-01-28T08:00:00.000+08:00,2,"Benzinga’s Earnings Roundup (TYC, BDX, TWC, BLL, LLY)"
e9d5c622-1b12-4d65-8fb6-2561e2b097fb,2010-01-26T08:00:00.000+08:00,5,"FDA Approval For Diabetes Drug Lifts Novo Shares (NVO, AMLN, LLY)"
e653321e-b28f-4822-997e-e23869d32061,2010-01-26T08:00:00.000+08:00,3,"FDA Approval For Diabetes Drug Lifts Novo Shares (NVO, AMLN, LLY)"
ec7c27fe-fb10-44d9-83f3-ba54f9ff2801,2010-01-05T08:00:00.000+08:00,1,Eli Lilly (LLY) To Outsource Drug Testing
c757fe1d-7b8c-4978-a589-223d037836c3,2010-01-05T08:00:00.000+08:00,1,Eli Lilly (LLY) To Outsource Drug Testing
d9eb3250-ecdc-47cf-9498-44d99ac2791f,2009-12-22T08:00:00.000+08:00,1,Eli Lilly (LLY) Lacks Near Term Upside Drivers
18de47f7-5f41-4a33-ae78-bf4d11eb2ef4,2009-12-22T08:00:00.000+08:00,1,Eli Lilly (LLY) Lacks Near Term Upside Drivers
cc0b5634-cb7e-48fc-b7b9-62d663c28573,2009-12-21T08:00:00.000+08:00,3,Play Biotech M&A With This ETF (XBI)
df8435d4-6178-4c0a-91f2-120788fe18ef,2009-12-21T08:00:00.000+08:00,4,"Top Gainers in NASDAQ (CHTT, BUCY, INCY, SBLK, MAIL)"
0cec0fb6-5a95-453f-8732-1c033ba97c13,2009-12-21T08:00:00.000+08:00,3,Play Biotech M&A With This ETF (XBI)
abfa9811-2a4d-4a44-9b66-d2e3b1feae58,2009-12-21T08:00:00.000+08:00,5,"Top Gainers in NASDAQ (CHTT, BUCY, INCY, SBLK, MAIL)"
4b10ae8a-b3cc-489a-afb8-3901c4a9f58d,2009-12-11T08:00:00.000+08:00,4,Eli Lilly’s EPS Guidance Exceeds Estimates (LLY)
7a272491-9ac1-4f34-a10f-f5bc68088174,2009-12-11T08:00:00.000+08:00,4,LLY Has Strong Product Pipeline
dfdbdc30-14c5-496a-a3bb-86e77dc3393c,2009-12-11T08:00:00.000+08:00,2,LLY Issues Disappointing Long Term Guidance
92a247b4-fd42-422c-95c1-2c5698066130,2009-12-11T08:00:00.000+08:00,4,Eli Lilly’s EPS Guidance Exceeds Estimates (LLY)
adced9a0-91b6-4d0f-b483-efdae575b9fa,2009-12-11T08:00:00.000+08:00,4,LLY Has Strong Product Pipeline
e2bee8c1-3d4e-49ad-9e2e-a47bf21314be,2009-12-11T08:00:00.000+08:00,2,LLY Issues Disappointing Long Term Guidance
838f602c-9a6b-4106-a66d-efb86f714ef5,2009-12-10T08:00:00.000+08:00,3,Eli Lilly (LLY) Is Facing Big Challenges
eb5165f3-fb15-456c-a1d1-edb8b751ca24,2009-12-10T08:00:00.000+08:00,2,LLY Issues Disappointing Long-term Guidance
f6e023d0-d52e-4d21-9286-d6281dd53a4c,2009-12-10T08:00:00.000+08:00,5,SEC On Trail Of Insider Trading Transactions
eaf5f6aa-5ec3-4698-a4e3-4d02914a79c3,2009-12-10T08:00:00.000+08:00,2,"Benzinga’s Top Pre- Market Losers (CIEN, LLY, OSIP, PROV, CYTK, AOL, SIGA)"
47d75e0c-ca81-40ce-b8ab-0865524c7e29,2009-12-10T08:00:00.000+08:00,3,"Benzinga’s Earnings Roundup (GIL, LLY, COST, UNFI, ROK)"
dfd78a79-4f43-4a5b-88af-215c85156e11,2009-12-10T08:00:00.000+08:00,4,"Lilly (LLY) Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines"
206de2b1-c3d4-46b7-ac7c-0b00b48addb6,2009-12-10T08:00:00.000+08:00,1,Eli Lilly (LLY) Is Facing Big Challenges
dce6205f-9878-4f0b-9552-826145528e83,2009-12-10T08:00:00.000+08:00,1,LLY Issues Disappointing Long-term Guidance
12cdc6af-bd5b-48e0-bc36-be59468e7049,2009-12-10T08:00:00.000+08:00,2,SEC On Trail Of Insider Trading Transactions
26ae8d71-98f9-40a9-899c-1c07d056b42c,2009-12-10T08:00:00.000+08:00,3,"Benzinga’s Top Pre- Market Losers (CIEN, LLY, OSIP, PROV, CYTK, AOL, SIGA)"
312cf023-8d04-4a22-b95b-c110805ddb00,2009-12-10T08:00:00.000+08:00,3,"Benzinga’s Earnings Roundup (GIL, LLY, COST, UNFI, ROK)"
a4de084c-9fe1-48ea-84d7-3cfcd0c287a2,2009-12-10T08:00:00.000+08:00,4,"Lilly (LLY) Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines"
e46d499d-7cd8-47fd-916a-313cf5c7a708,2009-12-08T08:00:00.000+08:00,1,"10 Stocks To Shine In 2010 (C, NYT, LVLT, KBH, LLY)"
43c2270f-dbc1-438d-8cd7-93e0f6c7e36b,2009-12-08T08:00:00.000+08:00,2,"10 Stocks To Shine In 2010 (C, NYT, LVLT, KBH, LLY)"
63ac9900-93c0-4bae-b3de-399a9c7d962e,2009-12-01T08:00:00.000+08:00,3,"Company News for December 01, 2009 - Corporate Summary"
dbf12af8-79a1-4dee-8732-aaf4c7283045,2009-12-01T08:00:00.000+08:00,3,"Company News for December 01, 2009 - Corporate Summary"
aad8df97-aca3-4f25-9c71-f2406d6b1ece,2009-11-13T08:00:00.000+08:00,4,Eli Lilly Calls Active (NYSE: LLY)
954f921a-f0e2-45c5-8f79-e5e10b3dff1e,2009-11-13T08:00:00.000+08:00,5,Eli Lilly Calls Active (NYSE: LLY)
e30e3a12-445a-49af-bdea-62533b1a7bea,2009-11-02T08:00:00.000+08:00,4,"Stocks Running Early (HGSI, VRTX, DNDN, JWN)"
4a00d996-6a72-4c8a-9eaa-4db15eecc915,2009-11-02T08:00:00.000+08:00,3,"Stocks Running Early (HGSI, VRTX, DNDN, JWN)"
dd83eba7-9ca3-4652-b69b-6def9e8580b5,2009-10-21T08:00:00.000+08:00,5,Eli Lilly Posts Higher Returns than Expected Behind Increased Sales Volumes (NYSE: LLY)
7894eefa-e080-45b5-be07-43684db2e4a3,2009-10-21T08:00:00.000+08:00,2,"Today’s Earnings Preview (BA, MS, WFC, EBAY, LLY, MO)"
0bebe78f-8a25-4c92-96c1-8f116355c479,2009-10-21T08:00:00.000+08:00,5,Eli Lilly Posts Higher Returns than Expected Behind Increased Sales Volumes (NYSE: LLY)
5b6e0b88-b62a-487e-865c-2bbf51f1ebb7,2009-10-21T08:00:00.000+08:00,2,"Today’s Earnings Preview (BA, MS, WFC, EBAY, LLY, MO)"
a977b18f-decd-4555-afbb-f14a1449b623,2009-10-19T08:00:00.000+08:00,2,The Week’s Must-Haves and Have-nots According to Jim Cramer
901077e0-5c7f-4977-b9f4-46c94713f032,2009-10-19T08:00:00.000+08:00,2,The Week’s Must-Haves and Have-nots According to Jim Cramer
a5f12df9-87de-476a-9acb-20f99bdd0930,2009-09-29T08:00:00.000+08:00,1,Eli Lilly (LLY) trading in a congestion zone
e33cc51a-37bd-4206-91d9-96941f4309a6,2009-09-29T08:00:00.000+08:00,2,Eli Lilly (LLY) trading in a congestion zone
c2f6fda8-8b23-4ca1-a3ec-da9ffdf766b2,2009-09-24T08:00:00.000+08:00,4,Eli Lilly and Company (LLY) Wins Evista Patent Till 2014
576318bb-78af-405d-a127-f26120f16911,2009-09-24T08:00:00.000+08:00,4,Eli Lilly and Company (LLY) Wins Evista Patent Till 2014
1668d9ee-f6a0-430d-b224-12b43f5d873f,2009-09-09T08:00:00.000+08:00,3,Zignals Stock Charts: 7 Divided Elites from TheStockAdvisors
ab49d759-2f05-43da-8edc-2b39225c0b29,2009-09-09T08:00:00.000+08:00,2,Zignals Stock Charts: 7 Divided Elites from TheStockAdvisors
58a821c0-8411-48aa-b805-70bca742c2fc,2009-08-31T08:00:00.000+08:00,1,"Negative Implications for Eli Lilly's (LLY) Efficient, Says Leerink"
0257f9af-9fab-4885-a161-a776c0f3899d,2009-08-31T08:00:00.000+08:00,2,"Negative Implications for Eli Lilly's (LLY) Efficient, Says Leerink"
